BCG

1. Starke J.R.: Bacille Calmette-Guérin vaccine. Semin Pediatr Infect Dis 1991; 2:153-158.
2. Lugosi L.: Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology: a review. Tuber Lung Dis 1992; 73:252-261.
3. Dye C.: Global epidemiology of tuberculosis. Lancet 2006; 367:938-940.
4. World Health Organization : Global tuberculosis control 2010. Geneva, WHO, 2010.
5. Raviglione M.C., Snider Jr. D.E., Kochi A.: Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273:220-226.
6. Kochi A.: The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72:1-6.
7. Comstock G.W.: The International Tuberculosis Campaign: a pioneering venture in mass vaccination and research. Clin Infect Dis 1994; 19:528-540.
8. Fine P.E.M.: Bacille Calmette-Guérin vaccines: a rough guide. Clin Infect Dis 1995; 20:11-14.
9. Smith D.W.: Protective effect of BCG in experimental tuberculosis. Adv Tuberc Res 1985; 22:1-97.
10. Dheda K., Schwander S.K., Zhu B., et al: The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15:433-450.
11. Stevens J.P., Daniel T.M.: Bacille Calmette-Guérin immunization of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis. Tuber Lung Dis 1996; 77:315-321.
12. Brewer T.F., Colditz G.A.: Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in healthcare workers. Clin Infect Dis 1995; 20:136-142.
13. Selwyn P.A., Hartel D., Lewis V.A., et al: A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-550.
14. Hesseling A.C., Rabie H., Marais B.J., et al: Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006; 42:559-561.
15. Hesseling A.C., Marais B.J., Gie R.P., et al: The risk of disseminated bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-18.
16. Zignol M., Hosseini M.S., Wright A., et al: Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194:479-485.
17. Shah N.S., Wright A., Bai G.H., et al: Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13:380-387.
18. Centers for Disease Control and Prevention : Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—Worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-305.
19. Dooley S.W., Villarino M.E., Lawrence M., et al: Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients. JAMA 1992; 267:2632-2635.
20. Pearson M.L., Jereb J.A., Frieden T.R., et al: Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and healthcare workers. Ann Intern Med 1992; 117:191-196.
21. Centers for Disease Control and Prevention : The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45(RR-4):1-18.
22. Bloom B.R., Murray C.J.L.: Tuberculosis: commentary on a reemergent killer. Science 1992; 257:1055-1064.

23. Morse D., Brothwell D.R., Ucko P.J.: Tuberculosis in ancient Egypt. Am Rev Respir Dis 1964; 90:524-541.
24. Starke J.R., Smith M.H.D.: Tuberculosis. In: Feigin R.D., Cherry J.D., ed. Textbook of Pediatric Infectious Diseases, 4th ed. Philadelphia, PA: WB Saunders; 1998:1196-1239.
25. Cruz A.T., Starke J.R.: Childhood tuberculosis. Pediatr Rev 2010; 31:13-25.
26. Marais B.J., Gie R.P., Schaaf H.S., et al: The natural history of childhood intra-thoracic tuberculosis: a critical review of the pre-chemotherapy literature. Int J Tuberc Lung Dis 2004; 8:392-402.
27. Nemir R.L.: Perspectives in adolescent tuberculosis: three decades of experience. Pediatrics 1986; 78:399-404.
28. Vallejo J.G., Ong L.T., Starke J.R.: Clinical features, diagnosis and treatment of tuberculosis in infants. Pediatrics 1994; 94:1-7.
29. Perry S., Starke J.R.: Adherence to prescribed treatment and public health aspects of tuberculosis in children. Semin Pediatr Infect Dis 1993; 4:291-298.
30. Krieder M.E., Rossman M.D.: Pulmonary tuberculosis. In: Schlossberg D., ed. Tuberculosis and Nontuberculous Mycobacterial Infections, Washington, DC: ASM Press; 2011:245-256.
31. Khan M.A., Kovnat D.M., Bachus B., et al: Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977; 62:31-38.
32. Alvarez S., Shell C., Berk S.L.: Pulmonary tuberculosis in elderly men. Am J Med 1987; 82:602-606.
33. Gordin F.M., Slutkin G., Schecter G., et al: Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings. Am Rev Respir Dis 1989; 139:1090-1093.
34. Palmer P.E.S.: Pulmonary tuberculosis: usual and unusual radiographic presentations. Semin Roentgenol 1979; 14:204-242.
35. Chang S.C., Lee P.Y., Perng R.P.: Lower lung field tuberculosis. Chest 1987; 91:230-232.
36. Barnes P.F., Bloch A.B., Davidson P.T., et al: Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324:1644-1650.
37. Jones B.E., Young S.M.M., Antoniskis D., et al: Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148:1292-1297.
38. Kwan C.K., Ernst J.D.: HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011; 24:351-376.
39. El-Sadr W.M., Tsiouris S.J.: HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med 2008; 29:525-531.
40. Pitchenik A.E., Rubinson H.A.: The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis 1985; 131:393-396.
41. Long R., Maycher B., Scalcini M., et al: The chest roentgenogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. Chest 1991; 99:123-127.
42. Wasser L.S., Shaw G.W., Talvera W.: Endobronchial tuberculosis in the acquired immunodeficiency syndrome. Chest 1988; 94:1240-1244.
43. Aaron L., Saadoun D., Calatroni I., et al: Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004; 10:388-398.
44. Rieder H.L., Snider Jr. D.E., Cauthen G.M.: Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990; 141:347-351.

45. Marais B.J., Wright C.A., Schaaf H.S., et al: Tuberculous lymphadenitis as a cause of persistent cervical lymphadenopathy in children from a tuberculous endemic area. Pediatr Infect Dis J 2006; 25:142-146.
46. Sharma S.K., Mohan A., Sharma A., et al: Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005; 5:415-530.
47. Doerr C.A., Starke Jr , Ong L.T.: Clinical and public health aspects of tuberculous meningitis in children. J Pediatr 1995; 127:27-33.
48. Saitoh A., Pong A., Waecker Jr. N.J., et al: Prediction of neurologic sequelae in childhood tuberculosis meningitis: a review of 20 cases and proposal of a novel scoring system. Pediatr Infect Dis J 2005; 24:207-212.
49. Floyd M.M., Silcox V.A., Jones Jr. W.D., et al: Separation of Mycobacterium bovis BCG from Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids. J Clin Microbiol 1992; 30:1327-1330.
50. Good M., Duignan A.: Perspectives on the history of bovine TB and the role of tuberculin in bovine TB eradication. Vet Med Int 2011; 2011:410-470.
51. Feldman W.H., Davis R., Moses H.E., et al: An unusual mycobacterium isolated from sputum of a man suffering from pulmonary disease of long duration. Am Rev Tuberc 1943; 48:82-93.
52. Wagner D., Young L.S.: Nontuberculous mycobacterial infections: a clinical review. Infection 2004; 32:257-270.
53. Brown-Elliott B.A., Griffith D.E., Wallace Jr. R.J.: Newly described or emerging human species of nontuberculous mycobacteria. Infect Dis Clin North Am 2002; 16:187-220.
54. Asiedu K., Scherpbier R., Raviglione M.: Buruli ulcer—Mycobacterium ulcerans infection. Global Buruli Ulcer Initiative. Geneva, World Health Organization, 2000.
55. Musher D.M.: How contagious are common respiratory tract infections?. N Engl J Med 2003; 348:1256-1266.
56. Riley R.L., The J.: Burns Amberson lecture: aerial dissemination of pulmonary tuberculosis. Am Rev Tuberc Pulm Dis 1957; 76:931-941.
57. Orme I.M.: The immunopathogenesis of tuberculosis: a new working hypothesis. Trends Microbiol 1998; 6:94-97.
58. Lasco T.M., Turner O.C., Cassone L., et al: Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect Immun 2004; 72:1147-1149.
59. Turner O.C., Basaraba R.J., Orme I.M.: Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 2003; 71:864-871.
60. Stead W.W.: Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residual of the primary infection or exogenous reinfection?. Am Rev Respir Dis 1967; 95:729-745.
61. Raleigh J.W., Weichelhausen R.: Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing. Am Rev Respir Dis 1973; 108:639-642.
62. Nardell E., McInnis B., Thomas B., et al: Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986; 315:1570-1575.
63. Chiang C.Y., Riley L.W.: Exogenous reinfection in tuberculosis. Lancet Infect Dis 2005; 5:629-636.
64. Cooper A.M.: Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27:393-422.
65. North R.J., Jung Y.L.: Immunity to tuberculosis. Annu Rev Immunol 2004; 22:599-623.

66. Cooper A.M., D'Souza C., Frank A.A.: The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms. Infect Immun 1997; 65:1317-1320.
67. Grange J.M.: Vaccination against tuberculosis: past problems and future hopes. Semin Respir Crit Care Med 1997; 18:459-470.
68. Orme I.M., Flynn J.L., Bloom B.R.: The role of CD8+ T cells in immunity to tuberculosis. Trends Microbiol 1995; 1:77-78.
69. Molloy A., Laochumroonvorapong P., Kaplan G.: Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin. J Exp Med 1995; 180:1499-1509.
70. Park J.S., Tamayo M.H., Gonzalez-Juarrero M., et al: Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J Leukoc Biol 2006; 79:80-86.
71. Orme I.M., Anderson P., Boom W.H.: T cell response to Mycobacterium tuberculosis. J Infect Dis 1993; 167:1481-1497.
72. Mosmann T.R.: Regulation of immune response by T cells with different cytokine secretor phenotypes: role of a new cytokine, cytokine synthesis inhibitory factor (IL-10). Int Arch Allergy Appl Immunol 1991; 94:110-115.
73. Bretscher P.A.: A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol Today 1992; 13:342-345.
74. Khader S.A., Pearl J.E., Sakamoto K., et al: IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005; 175:788-795.
75. Surcel H.M., Troyer-Blomberg M., Paulie S., et al: Th1/Th2 profiles in tuberculosis based on proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994; 81:171-176.
76. Schauf V., Rom W.N., Smith K.A., et al: Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis 1993; 168:1056-1059.
77. Rook G.A.W., Hernandez-Pando R.: The pathogenesis of tuberculosis. Am Rev Microbiol 1996; 50:259-284.
78. Hernandez-Pando R., Rook G.A.W.: The role of TNF in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994; 82:591-595.
79. Brandt L., Cunha J.F., Olsen A.W., et al: Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block mulitplication of BCG and induction of protective immunity with tuberculosis. Infect Immun 2002; 70:672-678.
80. Springett V.H., Sutherland I.: A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials. Tuber Lung Dis 1994; 75:227-233.
81. Fine P.E.: BCG: the challenge continues. Scand J Infect Dis 2001; 33:243-245.
82. Hsu K.H.K.: Tuberculin reaction in children treated with isoniazid. Am J Dis Child 1983; 137:1090-1092.
83. Hardy J.B.: Persistence of hypersensitivity to old tuberculin following primary tuberculosis in childhood: a long-term study. Am J Public Health 1946; 36:1417-1426.
84. Howard T.P., Soloman D.A.: Reading the tuberculin skin test: who, when and how?. Arch Intern Med 1988; 148:2457-2459.
85. Steiner P., Rao M., Victoria M.S., et al: Persistently negative tuberculin reactions: their presence among children culture-positive for Mycobacterium tuberculosis. Am J Dis Child 1980; 134:747-750.

86. Kent D.C., Schwartz R.: Active pulmonary tuberculosis with negative tuberculin skin reactions. Am Rev Respir Dis 1967; 95:411-418.
87. American Thoracic Society , Centers for Disease Control and Prevention , Infectious Diseases Society of America : Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172:1169-1227.
88. Pediatric Tuberculosis Collaborative Group : Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics 2004; 114:1175-1201.
89. O'Brien R.J., Geiter L.J., Snider Jr. D.E., et al: The epidemiology of nontuberculous mycobacterial diseases in the United States. Am Rev Respir Dis 1987; 135:1007-1014.
90. Edwards L.B., Acquaviva F.A., Livesay V.T., et al: An atlas of sensitivity to tuberculin. PPD-B and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:1-99.
91. American Thoracic Society and the Centers for Disease Control and Prevention : Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161:1376-1395.
92. Nemir R.L., Teichner A.: Management of tuberculin reactions in children and adolescents previously vaccinated with BCG. Pediatr Infect Dis J 1983; 2:446-451.
93. Menzies R., Vissandjee B.: Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145:621-625.
94. Lifschitz M.: The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Pediatrics 1965; 36:624-627.
95. Horwitz O., Bunch-Christensen K.: Correlation between tuberculin sensitivity after 2 months and 5 years among BCG-vaccinated subjects. Bull World Health Organ 1972; 47:49-58.
96. Comstock G.W., Edwards L.B., Nabangxang H.: Tuberculin sensitivity eight to fifteen years after BCG vaccination. Am Rev Respir Dis 1971; 103:572-575.
97. Margus J.H., Khassis Y.: The tuberculin sensitivity in BCG vaccinated infants and children in Israel. Acta Tuberc Pneumol Scand 1965; 46:113-122.
98. Landi S., Ashley M.J., Grzybowski S.: Tuberculin sensitivity following the intradermal and multiple puncture methods of BCG vaccination. Can Med Assoc J 1967; 97:222-225.
99. Ashley M.J., Siebenmann C.O.: Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts. Can Med Assoc J 1967; 97:1335-1338.
100. Kemp E.B., Belshe R.B., Hoft D.F.: Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis 1996; 174:113-119.
101. Joncas J.H., Robitaille R., Gauthier T.: Interpretation of the PPD skin test in BCG-vaccinated children. Can Med Assoc J 1975; 113:127-128.
102. Magnus K., Edwards L.B.: The effect of repeated tuberculin testing on post-vaccination allergy. Lancet 1955; 1:643-644.
103. Ildirim I., Hacimustafaoglu M., Ediz B.: Correlation of tuberculin induration with the number of bacillus Calmette-Guérin vaccines. Pediatr Infect Dis J 1995; 14:1060-1063.
104. Young T.K., Mirdad S.: Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. Tuber Lung Dis 1992; 73:94-100.
105. Sepulveda R.L., Heiba I.M., Naverrete C., et al: Tuberculin reactivity after newborn BCG immunization in mono- and dizygotic twins. Tuber Lung Dis 1994; 75:138-143.
106. Sepulveda R.L., Heiba I.M., King A., et al: Evaluation of tuberculin reactivity in BCG-immunized siblings. Am J Respir Crit Care Med 1994; 149:620-624.
107. Garly M.L., Bale C., Martins C.L., et al: BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria-tetanus antigens. Vaccine 2002; 20:468-474.

108. Karalliede S., Katugha L.P., Uragoda C.G.: The tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987; 68:33-38.
109. Thompson N.J., Glassroth J.L., Snider D.E., et al: The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587-597.
110. Bass Jr. J.B., Serio R.A.: The use of repeat skin tests to eliminate the booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1982; 123:394-396.
111. Sepulveda R.L., Burr C., Ferrer X., et al: Booster effect of tuberculin testing in healthy 6-year-old school children vaccinated with bacillus Calmette-Guérin at birth in Santiago, Chile. Pediatr Infect Dis J 1988; 7:578-581.
112. Sepulveda R.L., Ferrer X., Latrach C., et al: The influence of Calmette-Guérin bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis 1990; 142:24-28.
113. Horowitz H.W., Luciano B.B., Kadel J.R., et al: Tuberculin skin test conversion in hospital employees vaccinated with bacille Calmette-Guérin: recent Mycobacterium tuberculosis infection or booster effect?. Am J Infect Control 1995; 23:181-187.
114. Julian E., Cama M., Martinez P., et al: An ELISA for five glycolipids from the cell wall of Mycobacterium tuberculosis: Tween 20 interference in the assay. J Immunol Methods 2001; 252:21-30.
115. Singh K.K., Zhang X., Patibandla A.S., et al: Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences. Infect Immun 2001; 69:4185-4191.
116. Tessema T.A., Hamasur B., Bjune G., et al: Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis center. Scand J Infect Dis 2001; 33:279-284.
117. Hamasur B., Bruchfeld J., Haile M., et al: Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J Microbiol Methods 2001; 45:41-52.
118. Pottumarthy S., Wells V.C., Morris A.J.: A comparison of seven tests for serological diagnosis of tuberculosis. J Clin Microbiol 2000; 38:2227-2231.
119. Ferrara G., Losi M., D'Amico R., et al: Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367:1328-1334.
120. Al Zahrani K., Al Jahdali H., Poirier L., et al: Accuracy and utility of commercially available amplification and serologic tests for the diagnosis of minimal pulmonary tuberculosis. Am J Respir Crit Care Med 2000; 162:1323-1329.
121. Pai M., Kalantri S., Dheda K.: New tools and emerging technologies for the diagnosis of tuberculosis, pt 1: latent tuberculosis. Expert Rev Mol Diagn 2006; 6:413-422.
122. Centers for Disease Control and Prevention : Updated guidelines for using interferon-gamma release assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep 2010; 59(RR-5):1-28.
123. Pai M., Zwerling A., Menzies D.: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:1-8.
124. Eriksen J., Chow J.Y., Mellis V., et al: Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold?. Thorax 2010; 65:1067-1071.
125. Eisenhut M., Paranjothy S., Abubakar I., et al: BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 2009; 27:6116-6120.
126. Nicol M.P., Zar H.J.: New specimens and laboratory diagnostics for childhood pulmonary tuberculosis: progress and prospects. Paediatr Respir Rev 2011; 12:9-15.
127. Abadco D.L., Steiner P.: Gastric lavage is better than bronchoalveolar lavage for isolation of Mycobacterium tuberculosis in childhood pulmonary tuberculosis. Pediatr Infect Dis J 1992; 11:735-738.

128. Urbanczik R.: Laboratory tests focusing on sputum. Int J Tuberc Lung Dis 2010; 14:1087-1093.
129. Horne D.J., Royce S.E., Gooze L., et al: Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010; 10:387-394.
130. Gordin F., Slutkin G.: The validity of acid-fast smears in the diagnosis of pulmonary tuberculosis. Arch Pathol Lab Med 1990; 114:1025-1027.
131. Eisenach K.D., Sifford M.D., Cane M.D., et al: Detection of Mycobacterium tuberculosis in sputum samples using a polymerase chain reaction. Am Rev Respir Dis 1991; 144:1160-1163.
132. Noordhock A., Kolk A., Bjune G., et al: Sensitivity and specificity of polymerase chain reaction for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol 1994; 32:277-284.
133. Pierre C., Oliver C., Lecoissier D., et al: Diagnosis of primary tuberculosis in children by amplification and detection of mycobacterial DNA. Am Rev Respir Dis 1993; 147:420-424.
134. Smith K.C., Starke J.R., Eisenach K., et al: Detection of Mycobacterium tuberculosis in clinical specimens from children using a polymerase chain reaction. Pediatrics 1996; 97:155-160.
135. Gomez-Pastrana D., Torronteras R., Caro P., et al: Comparison of Amplicor, in-house polymerase chain reaction, and conventional culture for the diagnosis of tuberculosis in children. Clin Infect Dis 2001; 32:17-22.
136. Migliori A.B., Borghesi A., Rossnigo P., et al: Proposal for an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. Tuber Lung Dis 1992; 73:145-149.
137. Marais B.J., Gie R.P., Schaaf H.S., et al: Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006; 173:1078-1090.
138. American Thoracic Society and the Centers for Disease Control and Prevention , Infectious Disease Society of America : Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662.
139. American Thoracic Society and the Centers for Disease Control and Prevention : Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161(suppl):S221-S247.
140. American Academy of Pediatrics : Tuberculosis. In: Pekering L.K., et al ed. Red Book: Report of the Committee on Infectious Diseases, Elk Grove Village, IL: American Academy of Pediatrics; 2009:680-701.
141. Centers for Disease Control and Prevention : Core Curriculum on Tuberculosis: What a Clinician Should Know. 4th ed. Atlanta, GA, CDC, 2000.
142. Joint Tuberculosis Committee of the British Thoracic Society : Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53:536-548.
143. World Health Organization : Treatment of tuberculosis: guidelines. WHO Report (WHO/HTM/TB 2009.420), Geneva: WHO; 2010.
144. World Health Organization : Global tuberculosis control: WHO report 2001. (WHO/CDS/TB/2001.287)Geneva, WHO, 2001.
145. Corbett E.I., Watt C.J., Walker N., et al: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-1021.
146. World Health Organization : Global tuberculosis control: surveillance, planning, financing. Geneva, WHO, 2006. 242

147. Dye C., Watt C.J., Bleed D.M., et al: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293:2767-2775.
148. Estpinal M.A., Laszlo A., Simonsen L., et al: Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344:1294-1303.
149. World Health Organization , International Union against Tuberculosis and Lung Disease (IUATALD : Anti-tuberculosis drug resistance in the world: third global report. Geneva, WHO, 2004. 299
150. Dye C., Espinal M.A., Watt C.J., et al: Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185:1197-1202.
151. Kochi A.: The global tuberculosis situation and the new control strategy of the World Health Organization 1991. Bull World Health Organ 2001; 79:71-75.
152. Cantwell M.F., Snider Jr. D.E., Cauthen G.M., et al: Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 272:535-539.
153. Centers for Disease Control and Prevention : Reported tuberculosis in the United States. Atlanta, GA, US Department of Health and Human Services, 2010.
154. Centers for Disease Control and Prevention : Trends in tuberculosis incidence—United States, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:245-250.
155. Rose A.M.C., Watson J.M., Graham C., et al: Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001; 56:173-179.
156. McKenna M.T., McCray E., Onorato I.M.: The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med 1995; 332:1071-1076.
157. Nelson L.J., Schneider E., Wells C.D., et al: Epidemiology of childhood tuberculosis in the United States, 1993–2001: the need for continued vigilance. Pediatrics 2004; 114:333-341.
158. Parslow R., El-Shimy N.A., Cundall B.C., et al: Tuberculosis, deprivation, and ethnicity in Leeds, UK, 1982–1997. Arch Dis Child 2001; 84:109-113.
159. Centers for Disease Control and Prevention : Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons: Florida and New York, 1988–1991. MMWR Morb Mortal Wkly Rep 1991.585-591.
160. World Bank : World Development Report: 1993. Washington, DC, World Bank, 1993.
161. Centers for Disease Control and Prevention : Extensively drug-resistant tuberculosis—United States, 1993–2006. MMWR Morb Mortal Wkly Rep 2007; 56:250-253.
162. Wells C.S., Flahiff E.W., Smith H.H.: Results obtained in man with the use of a vaccine of heat-killed tubercle bacilli. Am J Hyg 1944; 40:116-126.
163. Great Britain Medical Research Council : BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early life. Br Med J 1959; 2:379-396.
164. Weill-Halle B.: Oral vaccination. In: Rosenthal S.R., ed. BCG Vaccination against Tuberculosis, Boston: Little, Brown; 1957:175-182.
165. Luelmo F.: BCG vaccination. Am Rev Respir Dis 1982; 125(suppl):70-72.
166. International Union against Tuberculosis : Phenotypes of BCG vaccines seed lot strains: results of an international cooperative study. Tubercle 1978; 59:139-142.
167. Lewis K.N., Liao R., Guinn K.M., et al: Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J Infect Dis 2003; 187:117-123.
168. Milstien J.B., Gibson J.J.: Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990; 68:93-108.
169. Osborn T.W.: Changes in BCG strains. Tubercle 1983; 64:1-13.
170. Jensen K.A.: Practice of the Calmette vaccination. Acta Tuberc Scand 1946; 20:1-45.

171. Jacox R.F., Meade G.M.: Variation in the duration of tuberculin skin sensitivity produced by two strains of BCG. Am Rev Tuberc 1949; 60:541-546.
172. Dubos R.J., Pierce C.H., Schaefer W.B.: Antituberculous immunity induced in mice by vaccination with living cultures of attenuated tubercle bacilli. J Exp Med 1953; 9:207-220.
173. Dubos R.J., Pierce C.H.: Differential characteristics in and in of several substrains of BCG. I. Multiplication and survival in. Am Rev Tuberc Pulm Dis 1956; 74:655-666.
174. Pierce C.H., Dubos R.J.: Differential characteristics in vitro and in vivo of several substrains of BCG, II: morphologic characteristics in vitro and in vivo. Am Rev Tuberc Pulm Dis 1956; 74:667-682.
175. Pierce C.H., Dubos R.J., Schaefer W.B.: Differential characteristics in vitro and in vivo of several substrains of BCG, III: multiplication and survival in vivo. Am Rev Tuberc Pulm Dis 1956; 74:683-698.
176. Dubos R.J., Pierce C.H.: Differential characteristics in and in of several substrains of BCG, IV: immunizing effectiveness. Am Rev Tuberc Pulm Dis 1956; 74:699-717.
177. Zhang Y., Wallace Jr. R.J., Mazurek G.H.: Genetic differences between BCG substrains. Tuber Lung Dis 1995; 76:43-50.
178. Gheorghiu M.: The present and future role of BCG vaccine in tuberculosis control. Biologicals 1990; 18:135-141.
179. Sekuis V.M., Freudenstein H., Sirks J.L.: Report on results of a collaborative assay of BCG vaccines organized by the International Association of Biological Standardization. J Biol Stand 1977; 5:85-109.
180. Gheorghiu M., Lagrange P.H.: Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains. Ann Immunol (Paris) 1983; 134C:124-147.
181. Formukong N.G., Dale J.N., Osborn T.W., et al: Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains. J Appl Bacteriol 1992; 72:126-133.
182. Behr M.A.: BCG: different strains, different vaccines?. Lancet Infect Dis 2002; 2:86-92.
183. Smith D., Harding C., Chan J., et al: Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pigs. J Biol Stand 1979; 7:179-197.
184. Behr M.A.: Correlation between BCG genomics and protective efficacy. Scand J Infect Dis 2001; 33:249-252.
185. Brosch R., Gordon S.V., Garnier T., et al: Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 2007; 104:5596-5601.
186. Seki M., Honda I., Fujita I., et al: Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains. Vaccine 2009; 27:1710-1716.
187. Comstock G.W.: Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 1988; 138:479-480.
188. Tuberculosis Control Program and Expanded Programme on Immunization : Efficacy of infant BCG immunization. Wkly Epidemiol Rec 1986; 28:216-218.
189. Pollock T.M.: BCG vaccination in man. Tubercle 1959; 40:339-412.
190. Lehman H.G., Englehardt H., Freudenstein H., et al: BCG vaccination of neonates, infants, school children and adolescents, II: safety of vaccine with strain 1331 Copenhagen. Dev Biol Stand 1979; 43:133-136.
191. Expanded Programme on Immunization, Biologicals Unit : Lymphadenitis associated with BCG immunization. Wkly Epidemiol Rec 1988; 63:381-388.
192. Expanded Programme on Immunization, Biologicals Unit : BCG-associated lymphadenitis in infants. Wkly Epidemiol Rec 1989; 30:231-232.

193. Kroger L., Brander E., Korppi M., et al: Osteitis after newborn vaccination with three different bacillus Calmette-Guérin vaccines: twenty-nine years of experience. Pediatr Infect Dis J 1994; 12:113-116.
194. Behr M.A., Small P.M.: Declining efficacy of BCG strains over time? A new hypothesis for an old controversy. Am J Respir Crit Care Med 1997; 155:A222.
195. Harboe M., Nagel S.: MPB70, a unique antigen of Mycobacterium bovis BCG. Am Rev Respir Dis 1984; 129:444-452.
196. Abou-Zeid C., Rook G.A.W., Mannikin D.E., et al: Effect of the method of preparation of bacille Calmette-Guérin vaccine on the properties of four daughter strains. J Appl Bacteriol 1987; 63:449-453.
197. TICE BCG: BCG live. www.pdr.net . Accessed June 3, 2002.
198. Devadoss P.O., Klegerman M.E., Groves M.J.: A scanning electron microscope study of mycobacterial developmental stages in commercial BCG vaccines. Curr Microbiol 1991; 22:247-252.
199. Gheorghiu M.: The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J Biol Stand 1988; 15:15-26.
200. Fine P.E.M., Carneiro I.A.M., Milstien J.B., et al: Issues relating to the use of BCG in immunization programmes: a discussion document. Geneva, World Health Organization, Department of Vaccines and Biologicals, 1999.
201. World Health Organization, Immunization Standards. UN prequalified vaccines: BCG as of August 2006. www.who.int/immunization-standards/vaccine_quality/bcg/en/index.html/ . Accessed August 6, 2006.
202. Ho M.M., Southern J., Kang H.N., et al: WHO informal consultation on standardization and evaluation of BCG vaccines. Geneva, Switzerland; 22–23 September 2009. Vaccine 2010; 28:6945-6950.
203. Gheorghiu M., Augier J., Lagrange P.H.: Maintenance and control of the French BCG strain 1173P2 (primary and secondary seed lots). Bull Inst Pasteur 1983; 81:281-288.
204. Gorak-Stolinska P., Weir R.E., Floyd S., et al: Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. Vaccine 2006; 24:5726-5733.
205. ten Dam H.G.: Research on BCG vaccination. Adv Tuberc Res 1984; 21:79-106.
206. ten Dam H.G., Fillastre C., Conge C., et al: The use of jet injectors in BCG vaccination. Bull World Health Organ 1970; 43:707-720.
207. Darmanger A.M., Nekzad S.M., Kuis M., et al: BCG vaccination by bifurcated needle in a pilot BCG vaccination programme. Bull World Health Organ 1977; 55:49-61.
208. Birkhaug K.: An experimental and clinical investigation of a percutaneous (Rosenthal) method of BCG vaccination. Nord Med 1941; 10:1224-1231.
209. Briggs I.L., Smith C.: BCG vaccination by the multiple puncture method in northern Rhodesia. Tubercle 1957; 38:107-111.
210. Griffith A.H.: BCG vaccination by multiple puncture. Lancet 1959; 1:1170-1172.
211. ten Dam H.G., Hitze K.L.: Does BCG vaccination protect the newborn and young infants?. Bull World Health Organ 1980; 58:37-41.
212. World Health Organization : BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004; 79:27-38.
213. Kagina B.M.N., Abel B., Bowmaker M., et al: Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009; 27:5488-5495.
214. Ferreira A.A., Bunn-Moreno M.M., Sant'Anna C.C., et al: BCG vaccination in low birth weight newborns: analysis of lymphocyte proliferation, IL-2 generation and intradermal reaction to PPD. Tuber Lung Dis 1996; 77:476-481.

215. Thayyil-Sudhan S., Kumar A., Singh M., et al: Safety and effectiveness of BCG vaccination in preterm babies. Arch Dis Child Fetal Neonatal Ed 1999; 81:F64-F66.
216. Dantas O.M., Ximenes R.A., Albuquerque MdeF de, et al: A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. Int J Tuberc Lung Dis 2006; 10:536-541.
217. Bedwell J., Kairo S.K., Behr M.A., et al: Identification of substrains of BCG vaccine using multiplex PCR. Vaccine 2001; 19:2146-2151.
218. Markey K., Ho M.M., Choudhury B., et al: Report of an international collaborative study to evaluate the suitability of multiplex PCR as an identity assay for different sub-strains of BCG vaccine. Vaccine 2010; 28:6964-6969.
219. Jensen S.E., Hubrechts P., Klein B.M., et al: Development and validation of an ATP method for rapid estimation of viable units in lyophilized BCG Danish 1331 vaccine. Biologicals 2008; 36:308-314.
220. Ho M.M., Markey K., Rigsby P., et al: Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine 2008; 26:4754-4757.
221. Smith P.G.: Case-control studies of the efficacy of BCG against tuberculosis. Singapore, Japan: Professional Postgraduate Services International; 1987:73-79.
222. Filho V.W., de Castilho E.A., Rodrigues L.C., et al: Effectiveness of BCG vaccination against tuberculous meningitis: a case-control study in Sao Paulo, Brazil. Bull World Health Organ 1990; 68:69-74.
223. Trunz B.B., Fine P.E.M., Dye C.: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-1180.
224. Sutherland I., Lindgren I.: The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 1979; 60:225-231.
225. Jensen K.A., Bindsleu G., Holm J.: Experimental studies on the development of tuberculous infection in allergic and non-allergic animals, I: development of tuberculous infection in the lungs after inhalation of virulent tubercle bacilli. Acta Tuberc Scand 1935; 9:27-46.
226. Levy F.M., Conge G.A., Pasquier J.F., et al: The effect of BCG-vaccination on the fate of virulent tubercle bacilli in mice. Am Rev Respir Dis 1961; 84:28-36.
227. Smith D.W., McMurray D.N., Wiegeshaus E.H., et al: Host-parasite relationship in experimental airborne tuberculosis, IV: early events in the course of infection in vaccinated and nonvaccinated guinea pigs. Am Rev Respir Dis 1970; 102:937-949.
228. Ordway D., Henao-Tamayo M., Orme I.M., et al: Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. J Immunol 2005; 175:3873-3881.
229. Duffy D, Dawoodji A, Agger EM, et al. Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection. PLoS One Dec 14;4(12):e8272, 2009.
230. Browne J.A.K., Stone M.M., Sutherland I.: BCG vaccination of children against leprosy in Uganda: first results. Br Med J 1966; 1:7-14.
231. Pönnighaus J.M., Fine P.E., Sterne J.A.C., et al: Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339:636-639.
232. Karonga Prevention Trial Group : Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis. Lancet 1996; 348:17-24.

233. Trnka L., Dankova D., Svandova E.: Six years' experience with the discontinuation of BCG vaccine, 4: protective effect of BCG against Mycobacterium avium-intracellulare complex. Tuber Lung Dis 1994; 75:348-352.
234. Romanus V., Svensson A., Hollander H.O.: The impact of changing BCG coverage on tuberculosis in Swedish children between 1969 and 1989. Tuber Lung Dis 1992; 73:150-161.
235. Ota M.O., Vekemans J., Schlegel-Haueter S.E., et al: Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168:919-925.
236. Covert B.A., Spencer J.S., Orme I.M., et al: The application of proteomics in defining the T cell antigens of Mycobacterium tuberculosis. Proteomics 2001; 1:574-586.
237. Fine P.E.M., The B.C.G.: story: lessons from the past and implications for the future. Rev Infect Dis 1989; 11(suppl 2):S353-S359.
238. Fine P.E.M., Pönnighaus J.M., Maine N.P.: The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Lepr Rev 1986; 57(suppl 12):S274-S283.
239. Fine P.E.M., Sterne J.A.C., Pönnighaus J.M., et al: Delayed type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994; 344:1245-1249.
240. Tuberculosis Prevention Trial : Trial of BCG vaccines in South India for tuberculosis prevention: first report. Bull World Health Organ 1979; 57:819-827.
241. Tripathy S.P.: Fifteen-year follow-up of the Indian BCG prevention trial. Bull Int Union Tuberc Lung Dis 1987; 62:69-73.
242. al-Kassimi F.A., al-Hajjaj M.S., al-Orainey I.O., et al: Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?. Am J Respir Crit Care Med 1995; 152:1575-1578.
243. Grange J.M.: Environmental mycobacteria and BCG vaccination. Tubercle 1986; 67:1-4.
244. Pithie A.D., Rahelu M., Kumararatne D.S., et al: Generation of cytolytic T cells in individuals infected with Mycobacterium tuberculosis and vaccinated with BCG. Thorax 1992; 47:695-701.
245. Fine P.E.M.: Leprosy and tuberculosis: an epidemiological comparison. Tubercle 1984; 65:137-153.
246. Ota M.O., Goetghebuer T., Vekemans J., et al: Dissociation between tuberculin skin test and in IFN-γ: responses following neonatal BCG vaccination. J Trop Pediatr 2006; 52:136-140.
247. Schluger N.W., Rom W.N.: The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157:679-691.
248. Klunner T., Bartels T., Vordermeier M., et al: Immune reactions of CD4-and CD8-positive T cell subpopulations in spleen and lymph nodes of guinea pigs after vaccination with bacillus Calmette-Guérin. Vaccine 2001; 19:1968-1977.
249. Serbina N.V., Liu C-C, Scanga C.A., et al: CD8+ CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in and lyse infected macrophages. J Immunol 2000; 165:353-363.
250. Stenger S., Modlin R.L.: Cytotoxic T cell responses to intracellular pathogens. Curr Opin Immunol 1998; 10:471-477.
251. Andersen P., Munk M.E., Pollock J.M., et al: Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-1104.
252. Mazurek G.H., LoBue P.A., Daley C.L., et al: Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286:1740-1747.

253. Hill P.C., Brookes R.H., Adetifa I.M., et al: Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 2006; 117:1542-1548.
254. Clemens J.D., Chuong J.J.H., Feinstein A.R.: The BCG controversy: a methodological and statistical reappraisal. JAMA 1983; 249:2362-2369.
255. Fine P.E.M., Rodrigues L.C.: Modern vaccines: mycobacterial diseases. Lancet 1990; 335:1016-1020.
256. Wilson M.E., Fineberg H.V., Colditz G.A.: Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin Infect Dis 1995; 20:982-991.
257. Brewer T.F., Colditz G.A.: Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 1995; 20:126-135.
258. Fine P.E.M.: Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-1345.
259. Miceli I., de Kantor I.N., Colaiacovo D., et al: Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 1988; 17:629-634.
260. Camargos P.A.M., Guimaraes M.D.C., Antunes C.M.F.: Risk assessment for acquiring meningitis tuberculosis among children not vaccinated with BCG: a case control study. Int J Epidemiol 1988; 17:193-197.
261. Bonifachich E., Chort M., Astigarraga A., et al: Protective effect of bacillus Calmette-Guérin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease: a case-control study in Rosario, Argentina. Vaccine 2006; 24:2894-2899.
262. Bagshawe A., Scott G.C., Russell D.A., et al: BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea. Bull World Health Organ 1989; 67:389-399.
263. Stanley S.J., Howland C., Stone M.M., et al: BCG vaccination of children against leprosy in Uganda: final results. J Hyg (Camb) 1981; 87:235-248.
264. Bertolli J., Pangi C., Frerichs R., et al: A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol 1997; 26:888-895.
265. Lwin K., Sundaresan T., Gyi M.M., et al: BCG vaccination of children against leprosy: fourteen year findings of the trial in Burma. Bull World Health Organ 1985; 63:1069-1078.
266. Thuc N.V., Abel L., Lap V.C., et al: Protective effect of BCG against leprosy and its subtypes: a case control study in Southern Viet Nam. Int J Lepr 1994; 62:532-538.
267. Tripathy S.P.: The case for BCG. Ann Natl Acad Med Sci 1983; 19:11-21.
268. Orege P.A., Fine P.E.M., Lucas S.B., et al: Case control study of BCG vaccination as a risk factor for leprosy and tuberculosis in Western Kenya. Int J Lepr 1993; 61:542-549.
269. Comstock G.W.: Field trials of tuberculosis vaccines: how could we have done them better?. Control Clin Trials 1994; 15:247-276.
270. Starke J.R., Connelly K.K.: Bacille Calmette-Guérin (BCG) vaccine. Vaccines, 2nd ed. Philadelphia, PA: WB Saunders; 1994:439-473.
271. Smith K.C., Starke J.R.: Bacille Calmette-Guérin (BCG) vaccine. Vaccines, 3rd ed. Philadelphia, PA: WB Saunders; 1999:111-139.
272. Smith K.C., Starke J.R.: Bacille Calmette-Guérin (BCG) vaccine. Vaccines, 4th ed. Philadelphia, PA: WB Saunders; 2004:179-209.
273. Stein S.C., Aronson J.D.: The occurrence of pulmonary lesions in BCG-vaccinated and unvaccinated persons. Am Rev Tuberc 1953; 68:695-712.
274. Rosenthal S.R., Loewinsohn E., Graham M.L., et al: BCG vaccination against tuberculosis in Chicago: a twenty-year study statistically analyzed. Pediatrics 1961; 28:622-641.

275. Hart P.D., Sutherland I.: BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Final report to the Medical Research Council. Br Med J 1977; 2:293-295.
276. Aronson N.E., Santosham M., Comstock G.W., et al: Long-term efficacy of BCG vaccine in American Indians and Alaska Natives. JAMA 2004; 291:2086-2091.
277. Palmer C.E., Shaw L.W., Comstock G.W.: Community trials of BCG vaccination. Am Rev Tuberc Pulm Dis 1958; 77:877-907.
278. Frimodt-Moller J., Thomas J., Parthasanathy R.: Observations on the protective effect of BCG vaccination in a south Indian rural population. Bull World Health Organ 1964; 30:545-574.
279. Frimodt-Moller J., Acharyulu G., Pillai K.: Observations on the protective effect of BCG vaccination in a south Indian rural population: fourth report. Bull Int Union Tuberc 1973; 48:40-52.
280. Comstock G., Shaw L.: Controlled trial of BCG vaccination in a school population. Public Health Rep 1960; 75:583-594.
281. Comstock G., Webster R.: Tuberculosis studies in Muscogee County, Georgia, VII: a 20 year evaluation of BCG vaccination in a school population. Am Rev Respir Dis 1969; 100:839-845.
282. Comstock G., Palmer C.: Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis 1966; 93:171-183.
283. Stanford J.L., Shield M.J., Rook G.A.W.: How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 1981; 62:55-62.
284. Rook G.A.W., Bahr G.M., Stanford J.L.: The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle 1981; 62:63-68.
285. Fine P.E., Floyd S., Stanford J.L., et al: Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect 2001; 126:379-387.
286. Edwards L.B., Palmer C.E.: Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci 1968; 154:140-148.
287. Palmer C.E., Hopwood L.: Effect of previous infection with unclassified mycobacteria on survival of guinea pigs challenged with virulent tubercle bacilli. Bull Int Union Tuberc 1962; 32:389-391.
288. Edwards M.L., Goodrich J.M., Muller D., et al: Infection with Mycobacterium avium-intracellulare and the protective effects of bacilli Calmette-Guérin. J Infect Dis 1982; 145:733-741.
289. Brandt L., Feino Cunha J., Weinreich Olsen A., et al: Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tubercusis. Infect Immun 2002; 70:672-678.
290. Tuberculosis Research Centre (ICMR), Chennai, India : Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in south India. Indian J Med Res 2006; 123:119-124.
291. Fine P.E.M.: Immunogenetics of susceptibility to leprosy, tuberculosis and leishmaniasis: an epidemiological perspective. Int J Lepr 1981; 49:437-454.
292. Di Pietrantonio T., Schurr E.: Mouse models for the genetic study of tuberculosis susceptibility. Brief Funct Genomic Proteomic 2005; 4:277-292.
293. Skamene E.: Genetic control of susceptibility to mycobacterial infections. Rev Infect Dis 1989; 11(suppl 2):S394-S399.
294. Vidal S.M., Malo D., Vogan K., et al: Natural resistance to infection with intracellular parasites: isolation of a candidate for BCG. Cell 1993; 73:469-485.

295. Bulat-Kardum L., Etokebe G.E., Knezevic J., et al: Interferon-gamma receptor-1 gene promoter polymorphisms (G-611A, T-56C) and susceptibility to tuberculosis. Scand J Immunol 2006; 63:142-150.
296. Mansouri D., Adimi P., Mirsaeidi M., et al: Inherited disorders of the IL-12-IFN-gamma axis in patients with disseminated BCG infection. Eur J Pediatr 2005; 164:753-757.
297. Hsu Y.H., Chen C.W., Sun H.S., et al: Association of NRAMP 1 gene polymorphism with susceptibility to tuberculosis in Taiwanese aboriginals. J Formos Med Assoc 2006; 105:363-369.
298. Pan H., Yan B.S., Rojas M.: Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005; 434:767-772.
299. Li H., Zhang T.T., Zhou Y.Q., et al: SLC11A1 (formerly NRAMP1) gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis 2006; 10:2-12.
300. Dubos R.: Acquired immunity to tuberculosis. Am Rev Respir Dis 1964; 90:505-515.
301. Cohen M.K., Bartow R.A., Mintzer C.L., et al: Effect of diet and genetics on Mycobacterium bovis BCG vaccine efficacy in inbred guinea pigs. Infect Immun 1987; 55:314-319.
302. McMurray D.N., Kimball M.S., Tetzlaff C.L., et al: Effects of protein deprivation and BCG vaccination on alveolar macrophage function in pulmonary tuberculosis. Am Rev Respir Dis 1986; 133:1081-1085.
303. Dai G., Phalen S., McMurray D.N.: Nutritional modulation of host responses to mycobacteria. Front Biosci 1998; 3:e110-e122.
304. Padungchan S., Konjanart S., Kasiratta S., et al: The effectiveness of BCG vaccination of the newborn against childhood tuberculosis in Bangkok. Bull World Health Organ 1986; 64:247-258.
305. Jason J., Archibald L.K., Nwanyanwu O.C., et al: Vitamin A levels and immunity in humans. Clin Diagn Lab Immunol 2002; 9:616-621.
306. Malhotra I., Mungai P., Wamachi A., et al: Helminth- and bacillus Calmette-Guérin–induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 1999; 162:6843-6848.
307. Hank J.A., Chan J.K., Edwards M.L., et al: Influence of the virulence of Mycobacterium tuberculosis on protection induced by bacilli Calmette-Guérin in guinea pigs. J Infect Dis 1981; 143:734-738.
308. Ziegler J.E., Edwards M.L., Smith D.W.: Exogenous reinfection in experimental airborne tuberculosis. Tubercle 1985; 66:121-128.
309. Stead W.W.: The pathogenesis of pulmonary tuberculosis among older persons. Am Rev Respir Dis 1965; 91:811-822.
310. Styblo K.: Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 1980; 20:1-63.
311. Eisenach K.D., Crawford J.T., Bates J.H.: Genetic relatedness among strains of the Mycobacterium tuberculosis complex. Am Rev Respir Dis 1986; 133:1065-1068.
312. Daley C.L., Small P.M., Schecter G.F., et al: An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231-235.
313. Smith P.G.: Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method. Tubercle 1982; 62:23-35.
314. Fine P.E.M.: BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988; 44:693-703.
315. Murtagh K.: Efficacy of BCG [letter]. Lancet 1980; 1:423.

316. Chavalittamrong B., Chearskul S., Tuchinda M.: Protective value of BCG vaccination in children in Bangkok, Thailand. Pediatr Pulmonol 1986; 2:202-205.
317. Micheli I., de Kantor I.N., Colaiacovo D., et al: Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 1988; 17:629-634.
318. Sirinavin S., Chotpitayasunondh T., Suwanjutha S., et al: Protective efficacy of neonatal bacillus Calmette-Guérin vaccination against tuberculosis. Pediatr Infect Dis J 1991; 10:359-365.
319. Effectiveness of BCG vaccination in Great Britain in 1978: a report from the research committee of the British Thoracic Association. Br J Dis Chest 1980; 74(3):215-227.
320. Ferguson R.G., Simes A.B.: BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949; 30:5-11.
321. Curtis H.M., Leck I., Bamford F.N.: Incidence of childhood tuberculosis after neonatal BCG vaccination. Lancet 1984; 1:145-148.
322. Shannon A., Kelly P., Lucey M., et al: Isoniazid resistant tuberculosis in a school outbreak: the protective effect of BCG. Eur Respir J 1991; 4:778-782.
323. Rodriques L.C., Gill O.N., Smith P.G.: BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. J Epidemiol Community Health 1991; 45:78-80.
324. Packe G.E., Innes J.A.: Protective effect of BCG vaccination in infant Asians: a case-control study. Arch Dis Child 1988; 63:277-281.
325. Houston S., Fanning A., Soskolne C.L., et al: The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis: a case-control study in treaty Indians, Alberta, Canada. Am J Epidemiol 1990; 131:340-347.
326. Young T.K., Hershfield E.S.: A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians. Am J Public Health 1986; 76:783-786.
327. Blin P., Delolme H.G., Heyraud J.D., et al: Evaluation of the protective effect of BCG vaccination by a case-control study in Yaounde, Cameroon. Tubercle 1986; 67:283-288.
328. Tidjani O., Amendome A., ten Dam H.G.: The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community. Tubercle 1986; 67:269-281.
329. Putrali J., Sutrisna B., Rahayoe N., et al: A case-control study of effectiveness of BCG vaccination in children in Jakarta, Indonesia. Jakarta, Indonesia; November 20–251983:194-200.
330. Patel A., Schofield F., Siskind V., et al: Case-control evaluation of a school-age BCG vaccination programme in subtropical Australia. Bull World Health Organ 1991; 69:425-433.
331. Shapiro C., Cook N., Evans D., et al: A case-control study of BCG and childhood tuberculosis in Cali, Colombia. Int J Epidemiol 1985; 14:441-446.
332. Smith P.G.: Evaluating interventions against tropical diseases. Int J Epidemiol 1987; 16:159-166.
333. Sepulveda R.L., Parcha C., Sorensen R.U.: Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber Lung Dis 1992; 73:372-377.
334. Stainer D.W., Landi S.: Stability of BCG vaccines. Dev Biol Stand 1986; 58:119-125.
335. Thilothammal N., Kirshnamurthy P.V., Runyan D.K., et al: Does BCG vaccine prevent tuberculous meningitis?. Arch Dis Child 1996; 74:144-147.
336. Rodriques L.C., Diwan V.K., Wheeler J.G.: Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154-1158.

337. Colditz G.A., Berkey C.S., Mosteller F., et al: The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96:29-35.
338. Colditz G.A., Brewer T.F., Berkey C.S., et al: Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271:698-702.
339. Sterne J.A.C., Rodrigues L.C., Guedes I.N.: Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis 1998; 2:200-207.
340. Henao-Tamayo M.I., Ordway D.J., Irwin S.M., et al: Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol 2010; 17:618-625.
341. Orme I.M.: The Achilles heel of BCG. Tuberculosis (Edinb) 2010; 90:329-332.
342. Joint Tuberculosis Committee of the British Thoracic Society : Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000; 55:887-901.
343. Lotte A., Wasz-Hockert O., Poisson N., et al: BCG complications: estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984; 21:107-193.
344. Victoria M.S., Shah B.R.: Bacillus Calmette-Guérin lymphadenitis: a case report and review of the literature. Pediatr Infect Dis J 1985; 4:295-296.
345. Turnbull F.M., McIntyre P.B., Achat H.M., et al: National study of adverse reactions after vaccination with bacille Calmette-Guérin. Clin Infect Dis 2002; 34:447-453.
346. Brewer M.A., Edwards K.M., Palmer P.S., et al: Bacille Calmette-Guérin immunization in normal healthy adults. J Infect Dis 1994; 170:476-479.
347. Fine P.E.M., Ponnighaus J.M., Maine N.: The distribution and implications of BCG scars, with particular reference to a population in Northern Malawi. Bull World Health Organ 1989; 67:35-42.
348. Lotte A., Wasz-Hockert O., Poisson N., et al: Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc 1988; 63:47-59.
349. Reynes J., Perez C., Lamaury I., et al: Bacille Calmette-Guérin adenitis 30 years after immunization in a patient with AIDS [letter]. J Infect Dis 1989; 160:727.
350. Gheorghiu M.: Potency and suppurative adenitis in BCG vaccination. Dev Biol Stand 1978; 41:79-84.
351. Muzy de Souza G.R., Sant'Anna C.C., Lapane Silva J.R., et al: Intradermal BCG vaccination complications-analysis of 51 cases. Tubercle 1983; 64:23-27.
352. Helmick C.G., D'Souza A.J., Goddard N.: An outbreak of severe BCG axillary lymphadenitis in Saint Lucia, 1982–83. West Indian Med J 1986; 35:12-17.
353. Praveen K.N., Smikle M.F., Prabhakar P., et al: Outbreak of bacillus Calmette-Guérin-associated lymphadenitis and abscesses in Jamaican children. Pediatr Infect Dis J 1990; 9:890-893.
354. O'Brien K.L., Ruff A.J., Louis M.A., et al: Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995; 95:414-418.
355. Caglayan S., Yegin O., Kayean K., et al: Is medical therapy effective for regional lymphadenitis following BCG vaccination?. Am J Dis Child 1987; 141:1213-1214.
356. Oguz F., Mujgan S., Alper G., et al: Treatment of bacillus Calmette-Guérin-associated lymphadenitis. Pediatr Infect Dis J 1992; 11:887-888.
357. Hanley S.P., Gumb J., MacFarlane J.T.: Comparison of erythromycin and isoniazid in treatment of adverse reactions to BCG vaccination. Br Med J (Clin Res Ed) 1985; 290:970.
358. Murphy P.M., Mayers D.L., Brock N.F., et al: Cure of bacille Calmette-Guérin vaccination abscess with erythromycin. Rev Infect Dis 1989; 11:335-337.

359. Power J.T., Stewart I.C., Ross J.D.: Erythromycin in the management of troublesome BCG lesions. Br J Dis Chest 1984; 78:192-193.
360. Goraya J.S., Virdi V.S.: Treatment of Calmette-Guérin bacillus adenitis: a metaanalysis. Pediatr Infect Dis J 2001; 20:632-634.
361. Kroger L., Korppi M., Brander E., et al: Osteitis caused by bacillus Calmette-Guérin vaccination: a retrospective analysis of 222 cases. J Infect Dis 1995; 172:574-576.
362. Bergdahl S., Fellander M., Robertson B.: BCG osteomyelitis: experience in the Stockholm region over the years 1961–1974. J Bone Joint Surg Br 1976; 58:212-216.
363. Vanicek H.: Complications after initial BCG vaccination in a 5-year period in the East Bohemia region. Cesk Pediatr 1988; 43:23-26.
364. Bottiger M.: Osteitis and other complications caused by generalized BCGitis. Acta Paediatr Scand 1982; 71:471-478.
365. Rouillon A., Waaler H.: BCG vaccination and epidemiological situation: a decision making approach to the use of BCG. Adv Tuberc Res 1976; 19:64-126.
366. Pedersen F.K., Engbaek H.C., Hertz H., et al: Fatal BCG infection in an immunocompetent girl. Acta Paediatr Scand 1978; 67:519-523.
367. Trevenen C.L., Pagtakhan R.D.: Disseminated tuberculoid lesions in infants following BCG. Can Med J 1982; 15:502-504.
368. Lachaux A., Descos B., Mertani A., et al: Infection generalisée a BCG d'evolution favorable chez un nourrisson de 3 mois sans deficit immunitaire reconnu. Arch Fr Pediatr 1986; 43:807-809.
369. Tardieu M., Truffot-Pernot C., Carriere J.P., et al: Tuberculosis meningitis due to BCG in two previously healthy children. Lancet 1988; 1:440-441.
370. Gormsen H.: On the occurrence of epithelioid cell granulomas in the organs of BCG vaccinated human beings. Acta Pathol Microbiol Scand 1956; 39(suppl 111):117-120.
371. Casanova J.L., Blanche S., Emile J.F., et al: Idiopathic disseminated bacille Calmette-Guérin infection: a French national retrospective study. Pediatrics 1996; 98:774-778.
372. Thamthitiwat S., Marin N., Baggett H.C., et al: Mycobacterium bovis (bacille Calmette-Guerin) bacteremia in immunocompetent neonates following vaccination. Vaccine 2011; 29:1727-1730.
373. Konno K., Feldmann F.M., McDermott W.: Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 1967; 95:461-469.
374. Von Kries R., Grunert V.P., Kaletsch U., et al: Prevention of childhood leukemia by BCG vaccination in newborns? a population-based case-control study in Lower Saxony, Germany. Pediatr Hematol Oncol 2000; 17:541-550.
375. Kolmel K.F., Grange J.M., Krone B., et al: Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival: an European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 2005; 41:118-125.
376. Villumsen M., Sorup S., Jess T., et al: Risk of lymphoma and leukaemia after bacilli Calmette-Guerin and smallpox vaccination: a Danish case-cohort study. Vaccine 2009; 27:6950-6958.
377. Farez M.F., Correale J.: Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258:1197-1206.
378. Gonzalez B., Moreno S., Burdach R., et al: Clinical presentation of bacillus Calmette-Guérin infections in patients with immunodeficiency syndromes. Pediatr Infect Dis J 1989; 8:201-206.
379. Kobayashi Y., Komazawa Y., Kobayshi M., et al: Presumed BCG infection in a boy with chronic granulomatous disease. Clin Pediatr 1984; 23:586-589.

380. Houde C., Dery P.: Mycobacterium bovis sepsis in an infant with human immunodeficiency virus infection. Pediatr Infect Dis J 1988; 11:810-811.
381. Sicevic S.: Generalized B.C.G. tuberculosis with fatal course in two sisters. Acta Paediatr Scand 1972; 61:178-184.
382. Talbot E.A., Perkins M.D., Silva S.F.M., et al: Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis 1997; 24:1139-1146.
383. Jouanguy E., Altare F., Lamhamedi S., et al: Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 1996; 335:1956-1961.
384. Elloumi-Zghal H., Barbouche M.R., Chemli J., et al: Clinical and genetic heterogeneity of inherited autosomal recessive susceptibility to disseminated Mycobacterium bovis bacilli Calmette-Guérin infection. J Infect Dis 2002; 185:1468-1475.
385. Hesseling A.C., Johnson L.S., Jaspan H., et al: Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87:505-511.
386. Fallo A., Torrado L., Sanchez A., et al: Delayed complications of bacille Calmette-Guerin (BCG) vaccination in HIV infected children. July 2005.Rio de Janeiro, Brazil Abstract WeOa0104Accessed March 15, 2011 www.iasociety.org/AbstractSearch.aspx
387. Besnard M., Sauvion S., Offredo C., et al: Bacillus Calmette-Guérin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993; 12:993-997.
388. Azzopardi P., Bennett C.M., Graham S.M., et al: Bacille Calmette-Guerin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis 2009; 13:1331-1334.
389. Ninane J., Grymonprez A., Burtonboy G., et al: Disseminated BCG in HIV infection. Arch Dis Child 1988; 63:1268-1269.
390. Centers for Disease Control and Prevention : Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985; 34:227-228.
391. Edwards K., Kernodle D.S.: Possible hazards of routine bacillus Calmette-Guérin immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:836-838.
392. Nuttall J.J., Davies M.A., Hussey G.D., et al: Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 2008; 12:e99-e105.
393. Armbruster C., Junker W., Vetter N., et al: Disseminated bacille Calmette-Guérin infection in an AIDS patient 30 years after BCG vaccination [letter]. J Infect Dis 1990; 162:1216.
394. Colebunders R.L., Izaley L., Musampu M., et al: BCG vaccine abscesses are unrelated to HIV infection [letter]. JAMA 1988; 259:352.
395. Carswell M.: BCG immunization in the children of HIV-positive mothers. AIDS 1987; 1:258.
396. Dabis F., Lepage P., Nsengumuremyi F., et al: Infection par le virus V1HI et vaccination de routine de l'enfant: une etude cohorte à Kigali, Rwanda: surveillance des effets indésirables de la vaccination. 1989.Paris Abstract C29
397. Lallemant-Le Coeur S., Cheynier D., Lallemant M., et al: Complications loco-régionales de la vaccination par le BCG chez des enfants nés de mères positive pour anti-HIV1: etude cas-témoins à Brazzaville. Ottawa, Canada: International Development Research Center; 1989:982.Abstract WG03
398. Thaithumyanon P., Thisyakorn U., Punnahitananda S., et al: Safety and immunogenicity of bacillus Calmette-Guérin vaccine in children born to HIV-1 infected women. Southeast Asian J Trop Med Public Health 2000; 31:482-486.

399. Van Rie A., Madhi S.A., Heera J.R., et al: Gamma interferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virus–infected mothers. Clin Vaccine Immunol 2006; 13:246-252.
400. Fernandes R.D., de Araujo L.C., Medina-Acosta E.: Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and in HIV-infected children from an endemic setting in Brazil. Eur J Pediatr 2009; 168:691-696.
401. World Health Organization : Use of BCG vaccine in HIV-infected infants. Wkly Epidemiol Rec 2010; 85:29-33.
402. Palme I.B., Gudetta B., Degefu H., et al: Risk factors for human immunodeficiency virus infection in Ethiopian children with tuberculosis. Pediatr Infect Dis J 2001; 20:1066-1072.
403. World Health Organization : Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82:193-196.
404. Puthanakit T., Oberdorfer P., Punjaisee S., et al: Immune reconstitution syndrome due to bacillus Calmette-Guerin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41:1049-1052.
405. Siberry G.K., Tessema S.: Immune reconstitution syndrome precipitated by bacille Calmette-Guerin after initiation of antiretroviral therapy. Pediatr Infect Dis J 2006; 25:249-648.
406. Hoft D.F., Leonardi C., Milligan T., et al: Clinical reactogenicity of intradermal bacilli Calmette-Guérin vaccination. Clin Infect Dis 1999; 28:785-790.
407. Hart P.D.: Efficacy and applicability of mass BCG vaccination in tuberculosis control. Br Med J 1967; 1:587-592.
408. Sutherland I., Springett V.H.: The effects of the scheme for BCG vaccination of school children in England and Wales and the consequences of discontinuing the scheme at various dates. J Epidemiol Community Health 1989; 43:15-24.
409. Springett V.H., Sutherland I.: BCG vaccination of school children in England and Wales. Thorax 1990; 45:83-88.
410. United Kingdom Health Departments : Immunisation against Infectious Diseases. London, HM Stationery Office, 1996. 1–290
411. Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceudical Officer. Changes to the BCG vaccination program. http.//www.dh.gov.uk/assetRoot/04/11/81/35/04118135.pdf . Accessed June 19, 2006.
412. Teo S.S.S., Shingadia D.V.: Does BCG have a role in tuberculosis control and prevention in the United Kingdom?. Arch Dis Child 2006; 91:529-531.
413. Gordon M., Roberts H., Odeka E.: Knowledge and attitudes of parents and professionals to neonatal BCG vaccination in light of recent UK policy changes: a questionnaire study. BMC Infect Dis 2007; 7:82.doi:10.1186/1471-2334-7-82
414. Romanus V., Svensson A., Hallander H.O.: The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989. Tuber Lung Dis 1992; 73:150-161.
415. Trnka L., Dankova D., Svandova E.: Six years' experience with the discontinuation of BCG vaccination, 1: risk of tuberculosis infection and disease. Tuber Lung Dis 1993; 74:167-172.
416. International Union Against Tuberculosis and Lung Disease : Criteria for discontinuation of vaccination programmes using bacille Calmette Guérin (BCG) in countries with a low prevalence of tuberculosis. Tuber Lung Dis 1994; 75:179-181.
417. WHO Expert Committee on Leprosy Seventh Report : 1998. WHO Tech Rep Ser No 874,
418. World Health Organization : BCG in immunization programmes. Wkly Epidemiol Rec 2001; 76:33-40.

419. Noeske J., Kuaban C., Rondini S., et al: Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 2004; 70:520-526.
420. Portaels F., Aguiar J., Debacker M., et al: Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62-65.
421. Brandau S., Suttmann H.: Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007; 61:299-305.
422. Williams S.K., Hoenig D.M., Ghavamian R., et al: Intravesical therapy for bladder cancer. Expert Opin Pharmacother 2010; 11:947-958.
423. Brewer T.F., Heymann S.J., Krumplitsch S.M., et al: Strategies to decrease tuberculosis in US homeless populations: a computer simulation model. JAMA 2001; 286:834-842.
424. Global Advisory Committee on Vaccine Safety : Meeting of the Global Advisory Committee on Vaccine Safety, 29–30 November 2006. Wkly Epidemiol Rec 2007; 82:18-24.
425. Hesseling A.C., Caldwell J., Cotton M.F., et al: BCG vaccination in South African HIV-exposed infants: risks and benefits. S Afr Med J 2009; 99:88-91.
426. Hesseling A.C., Cotton M.F., Fordham von Reyn C.: Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12:1376-1379.
427. Briggs B., Illingworth R.S., Lorber J.: The human source of tuberculous infection in children. Lancet 1956; 1:263-266.
428. Andrews R.H., Devadatta S., Fox W., et al: Prevalence of tuberculosis among close family contacts of tuberculous patients in south India, and influence of segregation of the patient on the early attack rate. Bull World Health Organ 1963; 23:463-510.
429. Ramakrishnan C.V., Andrews R.H., Devadatta S., et al: Prevalence and early attack rate of tuberculosis among close family contacts of tuberculous patients in South India under domiciliary treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1964; 25:361-407.
430. Romanus V.: Tuberculosis in bacillus Calmette-Guérin-immunized and unimmunized children in Sweden: a ten year evaluation following the cessation of general bacillus Calmette-Guérin immunization of the newborn in 1975. Pediatr Infect Dis J 1987; 6:272-280.
431. Walker K.B., Brennan M.J., Ho M.M., et al: The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010; 28:2259-2270.
432. Orme I.M.: Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 2006; 24:2-19.
433. Skeiky Y.A.W., Sadoff J.C.: Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006; 4:469-476.
434. Kaufmann S.H., Hussey G., Lambert P.H.: New vaccines for tuberculosis. Lancet 2010; 375:2110-2119.
435. Barker L.F., Leadman A.E., Clagett B.: The challenges of developing new tuberculosis vaccines. Health Aff 2011; 30:1073-1079.
436. Brandt L., Elhay M., Rosenkrands I., et al: ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68:791-795.
437. Andersen P.: Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62:2536-2544.
438. Baldwin S.L., D'Souza C., Roberts A.D., et al: Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998; 66:2951-2959.

439. Horwitz M.A., Lee B.W., Dillon B.J., et al: Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 1995; 92:1530-1534.
440. Skeiky Y.A., Alderson M.R., Ovendale P.J., et al: Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172:7618-7628.
441. Olsen A.W., Williams A., Okkels L.M., et al: Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004; 72:6148-6150.
442. Dietrich J., Aagaard C., Leah R., et al: Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174:6332-6339.
443. Bertholet S., Ireton G.C., Ordway D.J., et al: A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2:53-74.
444. Coler R.N., Bertholet S., Moutaftsi M., et al: Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011; 6:e16333.
445. Huygen K., Plasmid D.N.A.: vaccination. Microbes Infect 2005; 7:932-938.
446. Cebere I., Dorrell L., McShane H., et al: Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24:417-425.
447. McShane H., Pathan A.A., Sander C.R., et al: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-1244.
448. McShane H., Pathan A.A., Sander C.R., et al: Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005; 85:47-52.
449. Lang T., Hill A.V., McShane H., et al: New TB vaccine granted orphan drug status. BMJ 2005; 331:1476.
450. Scriba T.J., Tameris M., Mansoor N., et al: Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4 + T cells. Eur J Immunol 2010; 40:279-290.
451. Hondalus M.K., Bardarov S., Russell R., et al: Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 2000; 68:2888-2898.
452. Sampson S.L., Dascher C.C., Sambandamurthy V.K., et al: Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 2004; 72:3031.3017
453. Hinchey J., Lee S., Jeon B.Y., et al: Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 2007; 117:2279-2288.
454. Cardona P.J., Asensio J.G., Arbues A., et al: Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine 2010; 27:2499-2505.
455. Orme I.M.: Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol 2011; 6:161-177.
456. Palanisamy G.S., DuTeau N., Eisenach K.D., et al: Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb) 2009; 89:203-209.

457. Ordway D., Henao-Tamayo M., Harton M., et al: The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 2007; 179:522-531.
458. Sharpe S.A., McShane H., Dennis M.J., et al: Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol 2010; 17:1170-1182.
459. Comas I., Chakravartti J., Small P.M., et al: Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42:498-503.

DIFTERIJA:

1. Zink A., Reischl U., Wolf H., et al: Corynebacterium in ancient Egypt. Med Hist 2001; 45:267-272.
2. Holmes W.H.: Diphtheria: history. Bacillary and Rickettsial Infections Acute and Chronic, New York: Macmillan; 1940:291-305.
3. Andrewes F.W., Bulloch W., Douglas S.R., et al: Diphtheria: Its Bacteriology, Pathology and Immunology. London, His Majesty's Stationery Office, 1923.
4. English P.C.: Diphtheria and theories of infectious disease. Pediatrics 1985; 76:1-9.
5. Caulfield E.: A true history of the terrible epidemic vulgarly called the throat distemper: which occurred in His Majesty's New England colonies between the years 1735 and 1740. Yale J Biol Med 1939; 11:226-272.
6. Ramon G.: Sur le pouvoir floculant et sur les proprietes immunisantes d'une toxin diphterique rendue anatoxique (anatoxine). C R Acad Sci 1923; 177:1338-1340.
7. Belsey M.A., Sinclair M., Roder M.R., et al: Corynebacterium diphtheriae skin infections in Alabama and Louisiana: a factor in the epidemiology of diphtheria. N Engl J Med 1969; 280:135-141.
8. Höfler W.: Cutaneous diphtheria. Int J Dermatol 1991; 30:845-847.
9. Afghani B., Stutman H.R.: Bacterial arthritis caused by Corynebacterium diphtheriae. Pediatr Infect Dis J 1993; 12:881-882.
10. Zuber P.L.F., Gruner E., Altwegg M., et al: Invasive infection with nontoxigenic Corynebacterium diphtheriae among drug users [letter]. Lancet 1992; 339:1359.
11. Poilane I., Fawaz F., Nathanson M., et al: Corynebacterium diphtheriae osteomyelitis in an immunocompetent child: a case report. Eur J Pediatr 1995; 154:381-383.
12. Patey O., Bimet F., Riegal P.for the Coryne Study Group: Clinical and molecular study of Corynebacterium diphtheriae systemic infections in France. J Clin Microbiol 1997; 35:441-445.
13. Reacher M., Ramsay M., White J., et al: Nontoxigenic Corynebacterium diphtheriae: an emerging pathogen in England and Wales?. Emerg Infect Dis 2000; 6:640-645.
14. Romney M.G., Roscoe D.L., Bernard K., et al: Emergence of an invasive clone of nontoxigenic Corynebacterium diphtheriae in the urban poor population of Vancouver, Canada. J Clin Microbiol 2006; 44:1625-1629.
15. Holthouse D., Power B., Kermode A., et al: Non-toxigenic Corynebacterium diphtheriae: two cases and review of the literature. J Infect 1998; 37:62-66.
16. Anderson J.S., Happold F.C., McLeod J.W., et al: On the existence of two forms of diphtheria bacillus-B. diphtheriae gravis and B. diphtheriae mitis-and a new medium for their differentiation and for the bacteriological diagnosis of diphtheria. J Pathol Bacteriol 1931; 34:667-681.
17. Robinson D.T., Marshall F.N.: Investigations on the gravis, mitis, and intermediate types of C. diphtheriae and their clinical significance. J Pathol Bacteriol 1934; 38:73-89.

18. Diphtheria. In: Top F.H., ed. Communicable and Infectious Diseases, 4th ed. St. Louis: CV Mosby; 1960:198-213.
19. Leete H.M.: The heart in diphtheria. Lancet 1938; 1:136-139.
20. Wesselhoeft C.: Communicable diseases: cardiovascular disease in diphtheria. N Engl J Med 1940; 223:57-66.
21. Bethell D.B., Dung N.M., Loan H.T., et al: Prognostic value of electrocardiographic monitoring of patients with severe diphtheria. Clin Infect Dis 1995; 20:1259-1265.
22. Stockins B.A., Lanas F.T., Saavedra J.G., et al: Prognosis in patients with diphtheritic myocarditis and bradyarrhythmias: assessment of results of ventricular pacing. Br Heart J 1994; 72:190-191.
23. Jayashree M., Shruthi N., Singhi S.: Predictors of outcome in patients with diphtheria receiving intensive care. Indian Pediatr 2006; 43:155-160.
24. Loukoushkina E.F., Bobko P.V., Kolbasova E.V., et al: The clinical picture and diagnosis of diphtheritic carditis in children. Eur J Pediatr 1998; 145:528-533.
25. Ordian A.M., Iushchuk N.D., Karetkina G.N., et al: Clinical and prognostic significance of disturbed global and regional contractility of left ventricle in diphtheria myocarditis [in Russian]. Klin Med 2000; 78:20-23.
26. Celik T., Selimov N., Vekilova A., et al: Prognostic significance of electrocardiographic abnormalities in diphtheritic myocarditis after hospital discharge: a long-term follow-up study. Ann Noninvasive Electrocardiol 2006; 11:28-33.
27. Ford F.R.: Diseases of the Nervous System in Infancy, Childhood and Adolescence. 6th ed. Springfield, IL, Charles C Thomas, 1973.
28. Longina I., Donaghy M.: Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1999; 67:433-438.
29. Piradov M.A., Pirogov V.N., Popova L.M., et al: Diphtheritic polyneuropathy: clinical analysis of severe forms. Arch Neurol 2001; 58:1438-1442.
30. Schubert C.R., Cruickshanks K.J., Wiley T.I., et al: Diphtheria and hearing loss. Public Health Rep 2001; 116:362-368.
31. Funke G., von Graevenitz A., Clarridge J.E., et al: Clinical microbiology of coryneform bacteria. Clin Microbiol Rev 1997; 10:125-159.
32. Collier R.J.: Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon 2001; 39:1793-1803.
33. Holmes R.K.: Biology and molecular epidemiology of diphtheria toxin and the tox gene. J Infect Dis 2000; 181(Suppl. 1):S156-S167.
34. Pappenheimer A.M., Gill D.M.: Diphtheria. Science 1973; 182:353-358.
35. Collier R.J.: Diphtheria toxin: mode of action and structure. Bacteriol Rev 1975; 39:54-85.
36. Nakao H., Mazurova I.K., Glushkevich T., et al: Analysis of heterogeneity of Corynebacterium diphtheriae toxin gene, tox, and its regulatory element, dtxR, by direct sequencing. Res Microbiol 1997; 148:45-54.
37. Schmitt M.P.: Utilization of host iron sources by Corynebacterium diphtheriae: identification of a gene whose product is homologous to eukaryotic heme oxygenases and is required for the acquisition of iron from heme and hemoglobin. J Bacteriol 1997; 179:838-845.
38. Tao X., Schiering N., Zeng H., et al: Iron, DtxR, and the regulation of diphtheria toxin expression. Mol Microbiol 1994; 14:191-197.
39. Naglich J.G., Metherall J.E., Russell D.W., et al: Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 1992; 69:1051-1061.

40. Cha J-H, Brooke J.S., Ivey K.N., et al: Cell surface monkey CD9 antigen is a coreceptor that increases diphtheria toxin sensitivity and diphtheria toxin receptor affinity. J Biol Chem 2000; 275:6901-6907.
41. Morris R.E., Gerstein A.S., Bonventre P.F., et al: Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infect Immun 1985; 50:721-727.
42. Vaughan T.J., Pascall J.C., Brown K.D.: Tissue distribution of mRNA for heparin binding epidermal growth factor. Biochem J 1992; 287:681-684.
43. Nakamura Y., Handa K., Iwamoto R., et al: Immunohistochemical distribution of CD9, heparin binding epidermal growth factor-like growth factor, and integrin α3β1 in normal human tissues. J Histochem Cytochem 2001; 49:439-444.
44. Pappenheimer Jr A.M., Murphy J.R.: Studies on the molecular epidemiology of diphtheria. Lancet 1983; 2:923-926.
45. Lautrop H.: Studies on the antigenic structure of Corynebacterium diphtheriae. Acta Pathol Microbiol Scand 1950; 27:443-447.
46. Edward D.G.F., Allison V.D.: Diphtheria in the immunized with observations on a diphtheria-like disease associated with non-toxigenic strains of Corynebacterium diphtheriae. J Hyg 1951; 49:205-219.
47. Kato M.: Action of a toxic glycolipid of Corynebacterium diphtheriae on mitochondrial structure and function. J Bacteriol 1970; 101:709-716.
48. Wong T.P., Groman N.: Production of diphtheria toxin by selected isolates of Corynebacterium ulcerans and Corynebacterium pseudotuberculosis. Infect Immun 1984; 43:1114-1116.
49. Maximescu P., Oprisan A., Pop A.: Further studies on Corynebacterium species capable of producing diphtheria toxin (C. diphtheriaeC. ulceransC. ovis. J Gen Microbiol 1974; 82:49-56.
50. Sing A., Hogardt A.M., Bierschenk S., et al: Detection of differences in the nucleotide and amino acid sequences of diphtheria toxin from Corynebacterium diphtheriae and Corynebacterium ulcerans causing extrapharyngeal infections. J Clin Microbiol 2003; 41:4848-4851.
51. Meers P.D.: A case of classical diphtheria, and other infections due to Corynebacterium ulcerans. J Infect 1979; 1:139-142.
52. Hust M.H., Metzler B., Schubert U., et al: Toxische Diphtherie durch Corynebacterium ulcerans. Dtsch Med Wochenschr 1994; 119:548-553.
53. Centers for Disease Control and Prevention : Respiratory diphtheria caused by Corynebacterium ulcerans: Terre Haute, Indiana, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:330-332.
54. Bonmarin I., Guiso N., Le Flèche-Matéos A., et al: Diphtheria: a zoonotic disease in France?. Vaccine 2009; 27:4196-4200.
55. Efstratiou A., Engler K.H., Mazurova I.K., et al: Current approaches to the laboratory diagnosis of diphtheria. J Infect Dis 2000; 181(Suppl. 1):S138-S145.
56. Engler K.H., Glushkevich T., Mazurova I.K., et al: A modified Elek test for detection of toxigenic corynebacteria in the diagnostic laboratory. J Clin Microbiol 1997; 35:495-498.
57. Pallen M.J.: Rapid screening for toxigenic Corynebacterium diphtheriae by the polymerase chain reaction. J Clin Pathol 1991; 44:1025-1026.
58. Hauser D., Popoff M.R., Kiredjian M., et al: Polymerase chain reaction assay for diagnosis of potentially toxigenic Corynebacterium diphtheriae strains: correlation with ADP-ribosylation activity assay. J Clin Microbiol 1993; 31:2720-2723.
59. Aravena-Romaán M., Bowman R., O'Neill G.: Polymerase chain reaction for detection of toxigenic Corynebacterium diphtheriae. Pathology 1995; 27:71-73.

60. Mikhailovich V.M., Melnikov V.G., Mazurova I.K., et al: Application of PCR for detection of toxigenic Corynebacterium diphtheriae strains isolated during the Russian diphtheria epidemic, 1990 through 1994. J Clin Microbiol 1995; 33:3061-3063.
61. Efstratiou A., Engler K.H., Dawes C.S., et al: Comparison of phenotypic and genotypic methods for detection of diphtheria toxin among isolates of pathogenic corynebacteria. J Clin Microbiol 1998; 36:3173-3177.
62. Nakao H., Popovic T.: Development of a direct PCR assay for detection of the diphtheria toxin gene. J Clin Microbiol 1997; 35:1651-1655.
63. Schuhegger R., Lindermayer M., Kugler R., et al: Detection of toxigenic Corynebacterium diphtheriae and Corynebacterium ulcerans by a novel real-time PCR. J Clin Microbiol 2008; 46:2822-2823.
64. Sing A, Berger A, Schneider-Brachert W, et al. Rapid detection and molecular differentiation of toxigenic Corynebacterium diphtheriae and Corynebacterium ulcerans strains by LightCycler PCR. J Clin Microbiol 49:2485–9.
65. Saragea A., Maximescu P.: Phage typing of Corynebacterium diphtheriae. Bull World Health Organ 1966; 35:681-689.
66. Rappuoli R., Perugini M., Falsen E.: Molecular epidemiology of the 1984–1986 outbreak of diphtheria in Sweden. N Engl J Med 1988; 318:12-14.
67. Coyle M.B., Groman N.B., Russell J.Q., et al: The molecular epidemiology of three biotypes of Corynebacterium diphtheriae in the Seattle outbreak, 1972–1982. J Infect Dis 1989; 159:670-679.
68. De Zoysa A., Efstratiou A., George R.C., et al: Molecular epidemiology of Corynebacterium diphtheriae from northwestern Russia and surrounding countries studied by using ribotyping and pulsed-field gel electrophoresis. J Clin Microbiol 1995; 33:1080-1083.
69. Popovic T., Kombarova S.Y., Reeves M.W., et al: Molecular epidemiology of diphtheria in Russia, 1985–1994. J Infect Dis 1996; 174:1064-1072.
70. Nakao H., Pruckler J.M., Mazurova I.K., et al: Heterogeneity of diphtheria toxin gene, tox, and its regulatory element, dxtR, in Corynebacterium diphtheriae strains causing epidemic diphtheria in Russia and Ukraine. J Clin Microbiol 1996; 34:1711-1716.
71. Nakao H., Popovic T.: Development of a rapid ribotyping method for Corynebacterium diphtheriae by using PCR single-strand conformation polymorphism: comparison with standard ribotyping. J Microbiol Methods 1998; 31:127-134.
72. Grimont P.A.D., Grimont F., Efstratiou A., et al: International nomenclature for Corynebacterium diphtheriae ribotypes. Res Microbiol 2004; 155:162-166.
73. Popovic T., Mazurova I.K., Efstratiou A., et al: Molecular epidemiology of diphtheria. J Infect Dis 2000; 181(Suppl. 1):S168-S177.
74. Popovic T., Kim C., Reiss J., et al: Use of molecular subtyping to document long-term persistence of Corynebacterium diphtheriae in South Dakota. J Clin Microbiol 1999; 37:1092-1099.
75. Marston C.K., Jamieson F., Cahoon F., et al: Persistence of a distinct Corynebacterium diphtheriae clonal group within two communities in the United States and Canada where diphtheria is endemic. J Clin Microbiol 2001; 39:1586-1590.
76. Farizo K.M., Strebel P.M., Chen R.T., et al: Fatal respiratory disease due to Corynebacterium diphtheriae: case report and review of guidelines for management, investigation, and control. Clin Infect Dis 1993; 16:59-68.
77. Weaver G.H.: Diphtheria carriers. JAMA 1921; 76:831-835.
78. Galazka A.M., Robertson S.E.: Diphtheria: changing patterns in the developing world and the industrialized world. Eur J Epidemiol 1995; 11:107-117.

79. Murakami H., Phuong N.M., Thang H.V., et al: Endemic diphtheria in Ho Chi Minh City, Vietnam: a matched case-control study to identify risk factors of incidence. Vaccine 2010; 28:8141-8146.
80. Bisgard K.M., Hardy I.R.B., Popovic T., et al: Respiratory diphtheria in the United States, 1980–1995. Am J Public Health 1998; 88:787-791.
81. Centers for Disease Control and Prevention : Summary of notifiable diseases: United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 48:33.
82. Centers for Disease Control and Prevention : Summary of notifiable diseases: United States, 2000. MMWR Morb Mortal Wkly Rep 2002; 49:5.
83. Centers for Disease Control and Prevention : Summary of notifiable diseases: United States, 2001. MMWR Morb Mortal Wkly Rep 2003; 50:5.
84. Groseclose S.L., Brathwaite W.S., Hall P.A., et al: Summary of notifiable diseases: United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 51:19.
85. Hopkins R.S., Jajosky R.A., Hall P.A., et al: Summary of notifiable diseases: United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:19.
86. Centers for Disease Control and Prevention , Jajosky R.A., Hall P.A., Adams D.A., et al: Summary of notifiable diseases: United States, 2004. MMWR Morb Mortal Wkly Rep 2006; 53:18.
87. Centers for Disease Control and Prevention : Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:64.
88. Centers for Disease Control and Prevention : Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep 2011; 60:1136.
89. Centers for Disease Control and Prevention : Toxigenic Corynebacterium diphtheriae: Northern Plains Indian Community, August-October 1996. MMWR Morb Mortal Wkly Rep 1997; 46:506-510.
90. Young T.K.: Endemicity of diphtheria in an Indian population in northwestern Ontario. Can J Public Health 1984; 75:310-313.
91. Wilson C.R., Casson R.I., Wherrett B., et al: Toxigenic diphtheria in two isolated northern communities. Arctic Med Res 1991.346-347.
92. Cahoon F.E., Brown S., Jamieson F.: Corynebacterium diphtheriae-toxigenic isolations from northeastern Ontario. Toronto, Ontario, Canada; September 28-October 11997.Abstract K-171
93. Patel M., Morey F., Butcher A., et al: The frequent isolation of toxigenic and non-toxigenic Corynebacterium diphtheriae at Alice Springs Hospital. Commun Dis Intell 1994; 18:310-311.
94. Mortensen V.: Occurrence of diphtheria in recent years, with a special view to the influence of the antidiphtheric vaccination. Acta Med Scand 1946; 125:283-293.
95. Walker J.V.: Age and sex distribution of diphtheria in Oldenburg, Germany. Lancet 1947; 1:422-423.
96. Madsen S.: Diphtheria in Denmark; from 23, 695 to 1 case-: post or propter? II: diphtheria immunization. Dan Med Bull 1956; 3:116-121.
97. Vitek C.R., Brisgalov S.P., Bragina V.Y., et al: Epidemiology of epidemic diphtheria in three regions, Russia, 1994–1996. Eur J Epidemiol 1999; 15:75-83.
98. Dittmann S., Wharton M., Vitek C., et al: Successful control of epidemic diphtheria in the states of the former Union of Soviet Socialist Republics: lessons learned. J Infect Dis 2000; 181(Suppl. 1):S10-S22.
98a. Wagner K.S., White J.M., Lucenko I., et al: Diphtheria in the postepidemic period, Europe, 2000–2009. Emerg Infect Dis 2012; 18:217-225.
99. Wright H.D., Shone H.R., Tucker J.R.: Cross infection in diphtheria wards. J Pathol Bacteriol 1941; 52:111-128.

100. Crosbie W.E., Wright H.D.: Diphtheria bacilli in floor dust. Lancet 1941; 1:656-659.
101. Belsey M.A.: Isolation of Corynebacterium diphtheriae in the environment of skin carriers. Am J Epidemiol 1970; 91:294-299.
102. Larsson P., Brinkhoff B., Larsson L.: Corynebacterium diphtheriae in the environment of carriers and patients. J Hosp Infect 1987; 10:282-286.
103. Jones E.E., Kim-Farley R.J., Algunaid M., et al: Diphtheria: a possible foodborne outbreak in Hodeida, Yemen Arab Republic. Bull World Health Organ 1985; 63:287-293.
104. Burnet M., White D.O.: Natural History of Infectious Disease. 4th ed. London, Cambridge University Press, 1972.
105. US Bureau of the Census : Historical Statistics of the United States, Colonial Times to 1970, Bicentennial Edition, Part 1. Washington, DC, US Department of Congress, 1975.
106. Metaxas Quiroga V.A.: Diphtheria and medical therapy in late 19th century New York City. N Y State J Med 1990; 90:256-262.
107. Hammonds E.M.: Childhood's Deadly Scourge: The Campaign to Control Diphtheria in New York City, 1880–1930. Baltimore, MD, Johns Hopkins University Press, 1999.
108. Salisbury G., Salisbury L.: The Cruelest Miles: The Heroic Story of Dogs and Men in a Race Against an Epidemic. New York, WW Norton, 2003.
109. McKinnon N.E.: Diphtheria prevented. In: Cruickshank R., ed. Control of the Common Fevers, London: Lancet; 1942:41-56.
110. Lewis J.: The prevention of diphtheria in Canada and Britain 1914–1945. J Social Hist 1986; 20:163-176.
111. Mortimer P.P.: The diphtheria vaccine debacle of 1940 that ushered in comprehensive childhood immunization in the United Kingdom. Epidemiol Infect 2011; 139:487-493.
112. Stowman K.: Diphtheria pandemic recedes. UN World Health Organ 1947; 1:60-67.
113. Stuart G.: A note on diphtheria incidence in certain countries. Br Med J 1945; 2:613-615.
114. Wheeler S.M., Morton A.R.: Epidemiological observations in the Halifax epidemic. Am J Public Health 1942; 32:947-956.
115. Fleck S., Kellam J.W., Klippen A.J.: Diphtheria among German prisoners of war. Bull US Army Med Dept 1944; 74:80-89.
116. Brooks G.F., Bennett J.V., Feldman R.A.: Diphtheria in the United States, 1959–1970. J Infect Dis 1974; 129:172-178.
117. Chen R.T., Broome C.V., Weinstein R.A., et al: Diphtheria in the United States, 1971–1981. Am J Public Health 1985; 75:1393-1397.
118. Harnisch J.P., Tronca E., Nolan C.M., et al: Diphtheria among urban alcoholic adults: a decade of experience in Seattle. Ann Intern Med 1989; 111:71-82.
119. McCloskey R.V., Saragea A., Maximescu P.: Phage typing in diphtheria outbreaks in the southwestern United States, 1968–1971. J Infect Dis 1972; 126:196-199.
120. Wharton M., Dittmann S., Strebel P.M., et al: Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned. J Infect Dis 2000; 181(Suppl. 1):S1-22.
121. Skogen V., Cherkasova V.V., Maksimova N., et al: Molecular characterization of Corynebacterium diphtheriae isolates, Russia, 1957–1987. Emerg Infect Dis 2002; 8:516-518.
122. Wharton M., Hardy I.R.B., Vitek C., et al: Epidemic diphtheria in the newly independent states of the former Soviet Union. In: Scheld W.M., Armstrong D., Hughes J.M., ed. Emerging Infections, vol. I. Washington, DC: ASM Press; 1998:165-176.
123. Tharmaphornpilas P., Yoocharoan P., Prempree P., et al: Diphtheria in Thailand in the 1990s. J Infect Dis 2001; 184:1035-1040.

124. Singh J., Ichhpujani R.L., Prabha S., et al: Immunity to diphtheria in women of childbearing age in Delhi in 1994: evidence of continued Corynebacterium diphtheriae circulation. Southeast Asian J Trop Med Public Health 1996; 27:274-278.
125. Lodha R., Dash N.R., Kapil A., et al: Diphtheria in urban slums in north India. Lancet 2000; 355:204.
126. Bitragunta S., Murhekar M.V., Hutin Y.J., et al: Persistence of diphtheria, Hyderabad, India, 2003–2006. Emerg Infect Dis 2008; 14:1144-1146.
127. Walsh J.A., Warren K.S.: Selective primary health care: an interim strategy for disease control in developing countries [special article]. N Engl J Med 1979; 301:967-974.
128. World Health Organization, Department of Immunization, Vaccines and Biologicals : WHO Vaccine-Preventable Diseases: Monitoring System. 2010 Global Summary. Geneva, World Health Organization, 2010.
129. World Health Organization, Department of Vaccines and Biologicals : Vaccine-Preventable Diseases: Monitoring System. 2001 Global Summary. Geneva, World Health Organization, 2001.
130. Roux E., Yersin A.: Contribution à l'étude de la diphthérie. Ann Inst Pasteur 1888; 2:629-664.
131. Behring E.: Untersuchungen über das Zustandekommen der Diphtherie-Immunität bei Thieren. Dtsch Med Wochenschr 1890; 16:1145.
132. Kondratas R.A.: Death helped write the biologics law. FDA Consum 1982; 16:23-25.
133. US Food and Drug Administration : Biological products; bacterial vaccines and toxoids; implementation of efficacy review: diphtheria antitoxin. Fed Reg 1985; 50:51079-51082.
134. Wagner K.S., Stickings P., White J.M., et al: A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use. Vaccine 2009; 28:14-20.
135. Centers for Disease Control and Prevention : Notice to Readers. Availability of diphtheria antitoxin through an investigational new drug protocol. MMWR Morb Mortal Wkly Rep 2004; 53:413.
136. Kakita M., Takahashi T., Komiya T., et al: Isolation of a human monoclonal antibody with strong neutralizing activity against diphtheria toxin. Infect Immun 2006; 74:3682-3683.
137. Cha J-H, Brooke J.S., Chang M.Y., et al: Receptor-based antidote for diphtheria. Infect Immun 2002; 70:2344-2350.
138. Dowling H.F.: Diphtheria as a model. JAMA 1973; 226:550-553.
139. Ker C.B.: Infectious Diseases: A Practical Textbook. 3rd ed. London, Oxford University Press, 1929.
140. Fibiger J.: Om Serumbehandling af Difteri [On treatment of diphtheria with serum]. Hospitalstidende 1898; 6:309-325.
141. Hróbjartsson A., Gøtzche P.C., Gluud C.: The controlled clinical trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. BMJ 1998; 317:1243-1245.
142. Tasman A., Minkenhof J.E., Vink H.H., et al: Importance of intravenous injection of diphtheria antiserum. Lancet 1958; 1:1299-1304.
143. Smith T.: Active immunity produced by so-called balanced or neutral mixtures of diphtheria toxin and antitoxin. J Exp Med 1909; 11:241-256.
144. von Behring E.: Über ein neues Diphtheries Schutzmittel. Dtsch Med Wochenschr 1913; 39:873-876.
145. Park W.H.: Duration of immunity against diphtheria achieved by various methods. JAMA 1937; 109:1681-1684.
146. Glenny A.T., Pope C.G., Waddington H., et al: Immunological notes, XIII: the antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29:38-39.

147. Greenberg L., Fleming D.S.: The immunizing efficacy of diphtheria toxoid when combined with various antigens. Can J Public Health 1948; 39:131-135.
148. Spiller V., Barnes J.M., Holt L.B., et al: Immunization against whooping-cough: combined v. separate inoculations. Br Med J 1955; 2:639-642.
149. Aprile M.A., Wardlaw A.C.: Aluminum compounds as adjuvants for vaccines and toxoids in man: a review. Can J Public Health 1966; 57:343-354.
150. Edwards K.M., Decker M.D.: Combination vaccines consisting of acellular pertussis vaccines. Pediatr Infect Dis J 1997; 16(Suppl.):S97-102.
151. US Food and Drug Administration. Thimerosal in vaccines. www.fda.gov/cber/vaccine/thimerosal.htm
152. World Health Organization : Requirements for diphtheria, tetanus, pertussis and combined vaccines. World Health Organ Tech Rep Ser 1990.800.Annex 2
153. World Health Organization : Recommendations for diphtheria, tetanus, pertussis and combined vaccines (Amendments 2003). World Health Organ Tech Rep Ser 2005.927.Annex 5
154. Milstien J.B., Gellin B.G., Kane M., et al: Global DTP manufacturing capacity and capability: status report: January 1995. Vaccine 1996; 14:313-320.
155. Edwards K.M., Meade B.D., Decker M.D., et al: Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96:548-557.
156. Miller E., Waight P., Laurichesse H., et al: Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster: effect of simultaneous administration of MMR. Vaccine 2001; 19:3904-3911.
157. Centers for Disease Control and Prevention : Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-13):1-8.
158. Centers for Disease Control and Prevention : Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-7):1-25.
159. Centers for Disease Control and Prevention : Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-3):1-43.
160. Centers for Disease Control and Prevention : Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13-15.
161. Miyamura K., Nishio S., Ito A., et al: Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells, I: studies on factors affecting the toxin and antitoxin titration. J Biol Stand 1974; 2:189-201.
162. Melville-Smith M., Balfour A.: Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralization test. J Med Microbiol 1988; 25:279-283.
163. Walory J., Grzesiowski P., Hryniewicz W.: Comparison of four serological methods for the detection of diphtheria antitoxin. J Immunol Methods 2000; 245:55-65.
164. von Hunolstein C., Aggerbeck H., Andrews N., et al: European sero-epidemiology network: standardization of the results of diphtheria antitoxin assays. Vaccine 2000; 18:3287-3296.
165. Barr M., Glenny A.T., Randall K.J.: Diphtheria immunization in young babies: a study of some factors involved. Lancet 1950; 1:6-10.

166. Vahlquist B.: Response of infants to diphtheria immunization. Lancet 1949; 1:16-18.
167. Bjorkholm B., Granström M., Taranger J., et al: Influence of high titers of maternal antibody on the serologic response of infants to diphtheria vaccination at three, five, and twelve months of age. Pediatr Infect Dis J 1995; 14:846-850.
168. Galazka A.M.: The immunological basis for immunization: diphtheria. Expanded Programme on ImmunizationWorld Health Organization, 1993.
169. Anderson E.L., Belshe R.B., Bartram J.: Differences and reactogenicity and antigenicty of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J Infect Dis 1988; 157:731-737.
170. Orenstein W.A., Weisfeld J.S., Halsey N.A.: Diphtheria and tetanus toxoids and pertussis vaccine, combined. In: Halsey N.A., de Quadros C.A., ed. Recent Advances in Immunization: A Bibliographic Review, Washington, DC: Pan-American Health Organization; 1983:30-51.
171. Myers M.G., Beckman C.W., Vosdingh R.A., et al: Primary immunization with tetanus and diphtheria toxoids: reaction rates and immunogenicity in older children and adults. JAMA 1982; 248:2478-2480.
172. Olander R-M, Wuorimaa T., Käyhty H., et al: Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers. Vaccine 2002; 20:336-341.
173. US Food and Drug Administration : Aventis Pasteur. Menactra briefing document. Bethesda, MD, US Department of Health and Human Services, Center for Biologic Evaluation and Research, 2004. September 22[accessed 12.03.12] www.fda.gov/ohrms/dockets/ac/04/briefing/4072B1_1.pdf
174. McVernon J., MacLennan J., Clutterbuck E., et al: Effect of infant immunization with meningococcus serogroup C-CRM197 conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children. Vaccine 2003; 21:2573-2579.
175. MacLennan J.M., Shackley F., Heath P.T., et al: Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized control trial. JAMA 2000; 283:2795-2801.
176. Shelly M.A., Pichichero M.E., Treanor J.J.: Low baseline antibody level of diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults. Scand J Infect Dis 2001; 33:542-544.
177. Insel R.A.: Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 1995; 754:35-47.
178. Dagan R., Eskola J., LeClerc C., et al: Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998; 66:2093-2098.
179. Fattom A., Cho Y.H., Chu C., et al: Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 1999; 17:126-133.
180. Ipsen J.: Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol 1946; 54:325-347.
181. Björkholm B., Böttiger M., Christensen B., et al: Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis 1986; 18:235-239.
182. Danilova E., Jenum P.A., Skogen V., et al: Antidiphtheria antibody responses in patients and carriers of Corynebacterium diphtheriae in the Arkangelsk region of Russia. Clin Vaccine Immunol 2006; 13:627-632.

183. Ohuabunwo C., Perevoscikovs J., Griskevica A., et al: Respiratory diphtheria among highly vaccinated military trainees in Latvia: improved protection from DT compared with Td booster vaccination. Scand J Infect Dis 2005; 37:813-820.
184. Pappenheimer A.M.: The Schick test, 1913–1958. Int Arch Allergy Appl Immunol 1958; 12:35-41.
185. Efstratiou A., Maple P.A.C.: Laboratory Diagnosis of Diphtheria. Copenhagen, World Health Organization, 1994. Expanded Programme on Immunization in the European Region
186. Miller L.W., Older J.J., Drake J., et al: Diphtheria immunization: effect on carriers and the control of outbreaks. Am J Dis Child 1972; 123:197-199.
187. Marcuse E.K., Grand M.G.: Epidemiology of diphtheria in San Antonio, Texas, 1970. JAMA 1973; 224:305-310.
188. Chen R.T., Hardy I.R.B., Rhodes P.H., et al: Ukraine, 1992: first assessment of diphtheria vaccine effectiveness during the recent resurgence of diphtheria in the former Soviet Union. J Infect Dis 2000; 181(Suppl. 1):S178-S183.
189. Bisgard K.M., Rhodes P., Hardy I.R.B., et al: Diphtheria toxoid vaccine effectiveness: a case-control study in Russia. J Infect Dis 2000; 181(Suppl. 1):S184-S187.
190. Vitek C., Brennan M., Gotway C., et al: Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination. Lancet 1999; 353:355-358.
191. Brennan M., Vitek C., Strebel P., et al: How many doses of diphtheria toxoid are required for protection of adults? results of a case-control study among 40- to 49-year-old adults in the Russian Federation. J Infect Dis 2000; 181(Suppl. 1):S193-S196.
192. Tsu V., Tyshchenko D.K.: Case-control evaluation of an adult diphtheria immunization program. J Infect Dis 2000; 181(Suppl. 1):S188-S192.
193. Naiditch M.J., Bower A.G.: Diphtheria: a study of 1,433 cases observed during a ten-year period at Los Angeles County Hospital. Am J Med 1954; 17:229-245.
194. Narkevich M.I., Tymchakovskaia L.M.: Specific features of the spread of diphtheria in Russia in the presence of mass immunization of children. Zh Mikrobiol Epidemiol Immunobiol 1996; 2:25-29.
195. Quick M.L., Sutter R.W., Kobaidze K., et al: Risk factors for diphtheria: a prospective case-control study in the Republic of Georgia, 1995–1996. J Infect Dis 2000; 181(Suppl. 1):S121-S129.
196. Fox J.P., Elveback L., Scott W., et al: Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 1971; 94:179-189.
197. Galazka A.M., Robertson S.E.: Immunization against diphtheria with special emphasis on immunization of adults. Vaccine 1996; 14:845-857.
198. Scheibel I., Bentzon M.W., Christensen P.E., et al: Duration of immunity to diphtheria and tetanus after active immunization. Acta Path Microbiol Scand 1966; 67:380-392.
199. Tiru M., Hallander H.O., Custafsson L., et al: Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 2000; 18:2295-2306.
200. Taranger J., Trollfors B., Knutsson N., et al: Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 2000; 18:884-891.
201. Booy R., Aitken S.J., Taylor S., et al: Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 1992; 339:507-510.
202. Ramsey M.E., Rao M., Begg N.T., et al: Antibody response to accelerated immunization with diphtheria, tetanus, pertussis vaccine. Lancet 1993; 342:203-205.
203. Ramsey M.E., Corbel M.J., Redhead K., et al: Persistence of antibody after accelerated immunization with diphtheria/tetanus/pertussis vaccine. BMJ 1991; 302:1489-1491.

204. Edmunds W.J., Pebody R.G., Aggerback H., et al: The sero-epidemiology of diphtheria in Western Europe. Epidemiol Infect 2000; 125:113-125.
205. Trollfors B., Knutsson N., Taranger J., et al: Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for timing of a booster dose. Eur J Pediatr 2006; 165:14-18.
206. Golaz A., Hardy I.B., Glushkevich T.G., et al: Evaluation of a single dose of diphtheria-tetanus toxoids among adults in Odessa, Ukraine, 1995: immunogenicity and adverse reactions. J Infect Dis 2000; 181(Suppl. 1):S203-S207.
207. Sutter R.W., Hardy I.R., Kozlova I.A., et al: Immunogenicity of tetanus-diphtheria toxoids (Td) among Ukrainian adults: implications for diphtheria control in the newly independent states of the former Soviet Union. J Infect Dis 2000; 181(Suppl. 1):S197-S202.
208. Rønne T., Valentelis R., Tarum S., et al: Immune response to diphtheria booster vaccine in the Baltic States. J Infect Dis 2000; 181(Suppl. 1):S213-S219.
209. Khetsuriani N., Music S., Deforest A., et al: Evaluation of a single dose of diphtheria toxoid among adults in the Republic of Georgia, 1995: immunogenicity and adverse reactions. J Infect Dis 2000; 181(Suppl. 1):S208-S212.
210. World Health Organization : Diphtheria vaccine: WHO position paper. Wkly Epidemiol Rec 2006; 81:24-32.
211. Greco D., Salmaso S., Mastrantonio P.for the Progetto Pertosse Working Group: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-348.
212. Gustafsson L., Hallander H.O., Olin P., et al: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-355.
213. Trollfors B., Taranger J., Lagergard T., et al: A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333:1045-1050.
214. Schmitt-Grohé S., Stehr K., Cherry J.D.Pertussis Vaccine Study Group, et al: Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. Dev Biol Stand 1997; 89:113-118.for the
215. Tozzi A.E., Olin P.: Common side effects in the Italian and Stockholm I trials. Dev Biol Stand 1997; 89:105-108.
216. Macko M.B., Powell C.E.: Comparison of the morbidity of tetanus toxoid boosters with tetanus-diphtheria toxoid boosters. Ann Emerg Med 1985; 14:33-35.
217. Björkholm B., Wahl F.Y.I., Granström M., et al: Immune status and booster effects of low doses of diphtheria toxoid in Swedish medical personnel. Scand J Infect Dis 1989; 21:429-434.
218. Wassilak S.G.F., Orenstein W.A., Sutter R.W.: Tetanus toxoid. In: Plotkin S.A., Mortimer E.A., ed. Vaccines, 2nd ed. Philadelphia: WB Saunders; 1994:76.
219. Nathum E., Lerman Y., Cohen D., et al: The immune response to booster vaccination against diphtheria toxin at age 18–21 years. Isr J Med Sci 1994; 30:600-603.
220. Mortimer J., Melville-Smith M., Sheffield F.: Diphtheria vaccine for adults. Lancet 1986; 2:1182-1183.
221. Simonsen O., Kjeldsen K., Vendborg H-A, et al: Revaccination of adults against diphtheria, I: responses and reactions to different doses of diphtheria toxoid in 30–70-year-old persons with low serum antitoxin levels. Acta Pathol Microbiol Immunol Scand [C] 1986; 94:213-218.
222. Simonsen O., Klaerke M., Klaerke A., et al: Revaccination of adults against diphtheria, II: combined diphtheria and tetanus revaccination with different doses of diphtheria toxoid 20

years after primary vaccination. Acta Pathol Microbiol Immunol Scand [C] 1986; 94:219-225.
223. Bartels I., Jüngert J., Lugauer S., et al: Immunogenicity and reactogenicity of a single dose of a diphtheria-tetanus-acellular pertussis component vaccine (DTaP) compared to a diphtheria-tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults. Vaccine 2001; 19:3137-3145.
224. Knuf M., Habermehl P., Faber J., et al: Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Vaccine 2006; 24:5627-5636.
225. Langley J.M., Predy G., Guasparina R., et al: An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4–6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 2007; 25:1121-1125.
226. Collins C.L., Salt P., McCarthy N., et al: Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 2004; 22:4262-4269.
227. Blennow M., Granström M., Strandell A.: Adverse reactions after diphtheria-tetanus booster in 10-year-old schoolchildren in relation to the type of vaccine given for the primary vaccination. Vaccine 1994; 12:427-430.
228. Mark A., Granström M.: The role of aluminum for adverse reactions and immunogenicity of diphtheria-tetanus booster vaccine. Acta Paediatr 1994; 83:159-163.
229. Mark A., Granström B., Granström M.: Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminum-absorbed and fluid DT-vaccines. Vaccine 1995; 13:669-673.
230. Jackson L.A., Yu O., Belongia E.A., et al: Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink Study. BMC Infect Dis 2009; 9:165.
231. Jackson L.A., Yu O., Nelson J., et al: Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink Study. Vaccine 2009; 27:4912-4916.
232. Arguedas A., Soley C., Loaiza C., et al: Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010; 28:3171-3179.
233. Kattan J.D., Konstantinou G.N., Cox A.L., et al: Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. J Allergy Clin Immunol 2011; 128:215-217.
234. Alderslade R., Bellman M.H., Rawson N.S.B., et al: The National Childhood Encephalopathy Study. Whooping Cough: Reports from the Committee on the Safety of Medicines and the Joint Committee on Vaccination and Immunisation, London: Department of Health and Social Security, Her Majesty's Stationery Office; 1981:79-154.
235. Bellman M.H., Ross E.M., Miller D.L.: Infantile spasms and pertussis immunisation. Lancet 1983; 1:1031-1034.
236. Berkovic S.F., Harkin L., McMahon J.M., et al: De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006; 5:488-492.
237. McIntosh A.M., McMahon J., Dibbens L.M., et al: Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. Lancet Neurol 2010; 9:562-568.

238. Institute of Medicine : Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, DC, National Academy Press, 1994.
239. Institute of Medicine : Adverse Effects of Vaccines: Evidence and Causality. Washington, DC, National Academy Press, 2011.
240. Centers for Disease Control and Prevention : Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1120-1124.
241. Dengrove J., Lee E.J., Heiner D.C., et al: IgG and IgG subclass specific antibody responses to diphtheria and tetanus toxoids in newborns and infants given DTP immunization. Pediatr Res 1986; 20:735-739.
242. Bernbaum J.C., Daft A., Anolik R., et al: Response of preterm infants to diphtheria-tetanus-pertussis immunization. J Pediatr 1985; 107:184-188.
243. Koblin B.A., Townsend T.R., Munoz A., et al: Response of preterm infants to diphtheria-tetanus-pertussis vaccine. Pediatr Infect Dis J 1988; 7:704-711.
244. Ramsey M.E., Miller E., Ashworth L.A.E., et al: Adverse events and antibody response to accelerated immunization in term and preterm infants. Arch Dis Child 1995; 72:230-232.
245. Faldella G., Alessandroni R., Magini G.M.: The preterm infant's antibody response to a combined diphtheria, tetanus, acellular pertussis and hepatitis B vaccine 1998; 16:1646-1649.
246. Kirmani K.I., Lofthus G., Pichichero M.E., et al: Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics 2002; 109:498-504.
247. Barkin A.M., Pichichero M.E., Samuelson J.S., et al: Pediatric diphtheria and tetanus toxoids vaccine: clinical and immunologic response when administered as the primary series. J Pediatr 1985; 106:779-781.
248. Pichichero M.E., Barkin R.M., Samuelson J.S.: Pediatric diphtheria and tetanus toxoids-adsorbed vaccine: immune response to the first booster following the diphtheria and tetanus toxoids vaccine primary series. Pediatr Infect Dis 1986; 5:428-430.
249. Centers for Disease Control and Prevention : Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40(RR-10):1-28.
250. Feery B.J., Benenson A.S., Forsyth J.R.L., et al: Diphtheria immunization in adolescents and adults with reduced doses of adsorbed diphtheria toxoid. Med J Aust 1981; 1:128-130.
251. King G.E., Hadler S.C.: Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1994; 13:394-407.
252. Centers for Disease Control and Prevention : General recommendations on immunization: recommendations of the Advisory Committee Immunization Practices (ACIP) and the American Academy of Family Physicians. MMWR Recomm Rep 2002; 51(RR-2):1-35.
253. Howard P., Riley H.D.: An outbreak of diphtheria in eastern Oklahoma. J Okla State Med Assoc 1966; 59:520-527.
254. Anderson R.M.: The concept of herd immunity and the design of community-based immunization programmes. Vaccine 1992; 10:928-935.
255. Marlovits S., Stocker R., Efstratiou A., et al: Seroprevalence of diphtheria immunity among injured adults in Austria. Vaccine 2001; 19:1061-1067.
256. Maple P.A., Efstratiou A., George R.C., et al: Diphtheria immunity in UK blood donors. Lancet 1995; 345:963-965.
257. Rappuoli R., Podda A., Giovannoni F., et al: Absence of protective immunity against diphtheria in a large proportion of young adults. Vaccine 1993; 11:576-577.

258. Walory J., Grzesiowski J., Hryniewicz W.: The seroprevalence of diphtheria immunity in healthy population in Poland. Epidemiol Infect 2001; 126:225-230.
259. Maple P.A.C., Jones C.S., Wall E.C., et al: Immunity to diphtheria and tetanus in England and Wales. Vaccine 2001; 19:167-173.
260. McQuillan G.M., Kruszon-Moran D., Deforest A., et al: Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136:660-666.
261. Christenson B., Hellström U., Sylvan S.P.E., et al: Impact of a vaccination campaign on adult immunity to diphtheria. Vaccine 2001; 19:1133-1140.
262. Hardy I.R.B., Dittmann S., Sutter R.W.: Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union. Lancet 1996; 347:1739-1744.
263. Maksimova N.M., Sukhorukova N.L., Kostiuchenko G.I., et al: Specific prophylaxis of diphtheria in adults in the focus of diphtheria infection. Zh Mikrobiol Epidemiol Immunobiol 1987; 8:36-40.
264. Tatochenko V., Mitjushin I.L.: Contraindications to vaccination in the Russian Federation. J Infect Dis 2000; 181(Suppl. 1):S228-S231.
265. Galazka A.M., Robertson S.E., Oblapenko G.P.: Resurgence of diphtheria. Eur J Epidemiol 1995; 11:95-105.
266. Centers for Disease Control and Prevention : Update on adult immunization: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40(RR-12):1-94.
267. Levin P.L.: Diphtheria immunization: desirability of combined tetanus and diphtheria injection in wound management. Postgrad Med 1986; 79:139-140.
268. Golaz A., Hardy I.R., Strebel P., et al: Epidemic diphtheria in the newly independent states of the former Soviet Union: implication for diphtheria control in the United States. J Infect Dis 2000; 181(Suppl. 1):S237-S243.
269. Ekwueme D.U., Strebel P.M., Hadler S.C., et al: Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 2000; 154:797-803.
270. Zhou F., Santoli J., Messonnier M.L., et al: Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med 2005; 159:1136-1144.
271. Groman N., Schiller J., Russell J.: Corynebacterium ulcerans and Corynebacterium pseudotuberculosis responses to DNA probes derived from corynephage and Corynebacterium diphtheriae. Infect Immun 1984; 45:511-517.
272. Hart R.J.C.: Corynebacterium ulcerans in humans and cattle in North Devon. J Hyg (Camb) 1984; 92:161-164.
273. Bostock A.D., Gilbert F.R., Lewis D., et al: Corynebacterium ulcerans infection associated with untreated milk. J Infect 1984; 9:286-288.
274. Kitchin N.R.E.: Review of diphtheria, tetanus and pertussis vaccines in clinical development. Exp Rev Vaccines 2011; 10:605-615.
275. Mirchamsy H., Hamedi M., Fateh G., et al: Oral immunization against diphtheria and tetanus infections by fluid diphtheria and tetanus toxoids. Vaccine 1994; 12:1167-1172.
276. Rydell N., Stertman L., Stålenheim G., et al: Use of an oral diphtheria vaccine in human. Vaccine 2006; 24:5928-5930.
277. Aggerbeck H., Gizurarson S., Wantizin J., et al: Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 1997; 15:307-316.
278. Robbins F.C., Robbins J.B.: Current status and prospects for some improved and new bacterial vaccines. Annu Rev Public Health 1986; 7:105-125.

279. Frech C., Hilbert A.K., Hartmann G., et al: Physicochemical analysis of purified diphtheria toxoids: is toxoided then purified the same as purified then toxoided?. Dev Biol 2000; 103:205-215.
280. Diwan M., Misra A., Khar R.K., et al: Long-term high immune response to diphtheria toxoid in rodents with diphtheria toxoid conjugated to dextran as a single contact point delivery system. Vaccine 1997; 15:1867-1871.
281. Higaki M., Azechi Y., Takase T., et al: Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid. Vaccine 2001; 19:3091-3096.

TETANUS

1. Bleck T.P., Brauner J.S.: Tetanus. In: Scheld W.M., Whitley R.J., Marra C.M., ed. Infections of the Central Nervous System, 3 rd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:625-648.
2. Nunn J.F., Trap E.: Tropical diseases in ancient Egypt. Trans R Soc Trop Med Hyg 2000; 94:147-153.
3. Carle A., Rattone G.: Studio esperimentale sull'etiologia del tetano. G Accad Med Torrino 1884; 32:174.
4. Nicolaier A.: Über infektiösen Tetanus. Dtsch Med Wochenschr 1884; 10:842-844.
5. Rosenbach : Zur Ätiologie des Wundstarrkrampfes beim Menschen. Arch Klin Chir 1886; 34:306-317.
6. Kitasato S.: Über den Tetanusbazillus. Z Hyg 1889; 7:225-234.
7. von Behring E., Kitasato S.: Über das Zustandekommen der Diphtherie-Immunität bei Tieren. Dtsch Med Wochenschr 1890; 16:1113-1114.
8. Descombey P.: L'anatoxine tetanique. Can R Soc Biol 1924; 91:239-241.
9. Srivastava P., Brown K., Chen J., et al: Trends in tetanus epidemiology in the United States, 1972–2001. DC: Washington; 2005.March 21–24accessed April 5, 2012 http://cdc.confex.com/cdc/nic2005/techprogram/paper_7813.htm
10. Weinstein L.: Tetanus. N Engl J Med 1973; 289:1293-1296.
11. Kryzhanovsky G.N.: Pathophysiology. In: Veronesi R., ed. Tetanus: Important New Concepts, Amsterdam: Excerpta Medica; 1981:109-182.
12. Bruce D.: Tetanus. J Hyg (Camb) 1920; 19:1-32.
13. Garcia-Palmieri M.R., Ramirez R.: Generalized tetanus: analysis of 202 cases. Ann Intern Med 1957; 47:721-730.
14. Adams E.B.: The prognosis and prevention of tetanus. S Afr Med J 1968; 42:739-743.
15. Patel J.C., Mehta B.C., Modi K.N.: Prognosis in tetanus. In: Patel J.C., ed. Proceedings of the International Conference on Tetanus, 1963, Bombay: PH Ramans; 1965:181.
16. LaForce F.M., Young L.S., Bennett J.V.: Tetanus in the United States (1965–1966). N Engl J Med 1969; 280:569-574.
17. Buchanan T.M., Brooks G.F., Martin S., et al: Tetanus in the United States, 1968 and 1969. J Infect Dis 1970; 122:564-567.
18. Blake P.A., Feldman R.A.: Tetanus in the United States 1970–1971. J Infect Dis 1975; 131:745-748.
19. Armitage P., Clifford R.: Prognosis in tetanus: use of data from therapeutic trials. J Infect Dis 1978; 138:1-8.
20. Brauner J.S., Viera S.R., Bleck T.P.: Changes in severe accidental tetanus mortality in the ICU during two decades in Brazil. Intensive Care Med 2002; 28:930-935.
21. Millard A.H.: Local tetanus. Lancet 1954; 2:844-846.
22. Roistacher K., Griffin J.W.: Local tetanus. Johns Hopkins Med J 1981; 149:84-88.

23. Pratt E.L.: Clinical tetanus: a study of fifty-six cases with special reference to methods of prevention and a plan for evaluating treatment. JAMA 1945; 129:1243-1247.
24. Newton-John H.F.: Tetanus in Victoria, 1957–1980: review of 106 patients managed in one hospital. Med J Aust 1984; 140:194-200.
25. Kasanzew M., Browne B., Dawes P.: Tetanus presenting as dysphagia. J Laryngol Otol 1989; 103:229-230.
26. Rauch A., Droz S., Zimmerli S., et al: Dysphagia in elderly women: consider tetanus. Infection 2006; 34:35-38.
27. Farrar J.J., Yen L.M., Cook T., et al: Tetanus. J Neurol Neurosurg Psychiatry 2000; 69:292-301.
28. Trujillo M.J., Castillo A., Espana J.V., et al: Tetanus in the adult: intensive care and management experience with 233 cases. Crit Care Med 1980; 8:419-423.
29. Kerr J.H., Corbett J.L., Prys-Roberts C., et al: Involvement of the sympathetic nervous system in tetanus: studies on 82 cases. Lancet 1968; 2:236-241.
30. Kanarek D.J., Kaufman B., Zwi S.: Severe sympathetic hyperactivity associated with tetanus. Arch Intern Med 1973; 132:602-604.
31. Hollow V.M., Clarke G.M.: Autonomic manifestations of tetanus. Anaesth Intensive Care 1975; 3:142-147.
32. Buchanan N., Cane G.W., DeAndrade M.: Autonomic dysfunction in tetanus: the effects of a variety of therapeutic agents, with special reference to morphine. Intensive Care Med 1979; 5:65-68.
33. Udwadia F.E., Lall A., Udwadia Z.F., et al: Tetanus and its complications: intensive care and management experience in 150 Indian patients. Epidemiol Infect 1987; 99:675-684.
34. Wasay M., Khealani B.A., Talati N., et al: Autonomic nervous system dysfunction predicts poor prognosis in patients with mild to moderate tetanus. BMC Neurol 2005; 5:2.
35. Luisto M.: Outcome and neurological sequelae of patients after tetanus. Acta Neurol Scand 1989; 80:504-511.
36. Luisto M., Seppalainen A.M.: Electroencephalopathy in tetanus. Acta Neurol Scand 1989; 80:157-161.
37. Luisto M., Zitting A., Tallroth K.: Hyperostosis and osteoarthritis in patients surviving after tetanus. Skeletal Radiol 1994; 23:31-35.
38. Flowers M.W., Edmondson R.S.: Long-term recovery from tetanus: a study of 50 survivors. Br Med J 1980; 280:303-305.
39. Roper M.H., Vandelaer J.H., Gasse F.L.: Maternal and neonatal tetanus. Lancet 2007; 370:1947-1959.
40. Veronesi R., Focaccia R.: The clinical picture. In: Veronesi R., ed. Tetanus: Important New Concepts, Amsterdam: Excerpta Medica; 1981:459-463.
41. Galazka A.M., Stroh G.: Neonatal tetanus: guidelines on the community-based survey on neonatal tetanus mortality, Geneva, World Health Organization, 1986. (WHO/EPI/GEN/86/8)accessed April 5, 2012 http://whqlibdoc.who.int/hq/1985-86/WHO_EPI_GEN_86_8.pdf
42. Teknetzi P., Manios S., Katsouyanopoulos V.: Neonatal tetanus: long-term residual handicaps. Arch Dis Child 1983; 58:68-69.
43. Anlar B., Yalaz K., Dizmen R.: Long-term prognosis after neonatal tetanus. Dev Med Child Neurol 1989; 31:76-80.
44. Okan M., Hacimustafaoglu M., Ildirim I., et al: Long-term neurologic and psychomotor sequelae after neonatal tetanus. J Child Neurol 1997; 12:270-272.
45. Barlow J.L., Mung'Ala-Odera V., Gona J., et al: Brain damage after neonatal tetanus in a rural Kenyan hospital. Trop Med Int Health 2001; 6:305-308.

46. Galazka A., Birmingham M., Kurian M., et al: Tetanus. In: Murray C.JL., Lopez A.D., Mathers C.D., ed. The Global Epidemiology of Infectious Diseases, [elactronic resource,], Geneva: World Health Organization; 2004:151-199.accessed April 5, 2012 http://whqlibdoc.who.int/publications/2004/9241592303_chap6.pdf
47. Garnier M.J.: Tetanus in patients 3 years of age and up. Am J Surg 1975; 129:459-463.
48. Edmondson R.S., Flowers M.W.: Intensive care in tetanus: management, complications and mortality in 100 cases. Br Med J 1979; 1:1401-1404.
49. Humbert G., Fillastre J.P., Dordain M., et al: One hundred cases of tetanus. Scand J Infect Dis 1972; 4:129-131.
50. Peetermans W.E., Schepens D.: Tetanus: still a topic of present interest: a report of 27 cases from a Belgian referral hospital. J Intern Med 1996; 239:249-252.
51. Sow P.S., Diop B.M., Barry H.L., et al: Tetanos et pratiques traditionnelles a Dakar (a propos de 141 cas). Dakar Med 1993; 38:55-59.
52. Cook T.M., Protheroe R.T., Handel J.M.: Tetanus: a review of the literature. Br J Anaesth 2001; 87:477-487.
53. Thwaites C.L., Yen L.M., Nga N.T., et al: Impact of improved vaccination programme and intensive care facilities on incidence and outcome of tetanus in southern Vietnam, 1993–2002. Trans R Soc Trop Med Hyg 2004; 98:671-677.
54. Saltigeral Simental P., Macias Parra M., Mejia Valdez J., et al: Neonatal tetanus experience at the National Institute of Pediatrics in Mexico City. Pediatr Infect Dis J 1993; 12:722-725.
55. Ojini F.I., Danesi M.A.: Mortality of tetanus at the Lagos University Teaching Hospital, Nigeria. Trop Doctor 2005; 35:178-181.
56. Hesse I.F., Mensah A., Asante D.K., et al: Adult tetanus in Accra: why the high mortality? an audit of clinical management of tetanus. West Afr J Med 2005; 24:157-161.
57. Arogundade F.A., Bello I.S., Kuteyi E.A., et al: Patterns of presentation and mortality in tetanus: a 10-year retrospective review. Niger Postgrad Med 2004; 11:58-63.
58. Basu S., Paul D.K., Ganguly S., et al: Risk factors for mortality from neonatal tetanus: 7 years experience in North Bengal, India. Ann Trop Paediatr 2006; 26:233-239.
59. Prevots R., Sutter R.W., Strebel P.M., et al: Tetanus surveillance: United States, 1989–1990. MMWR CDC Surveill Summ 1992; 41(SS-8):1-9.
60. Izurieta H.S., Sutter R.W., Strebel P.M., et al: Tetanus surveillance: United States, 1991–1994. MMWR CDC Surveill Summ 1996; 46(SS-2):16-24.
61. Bardenheier B., Prevots D.R., Khetsuriani N., et al: Tetanus surveillance: United States, 1995–1997. MMWR CDC Surveill Summ 1998; 47(SS-2):1-13.
62. Pascual F.B., McGinley E., Zanardi L., et al: Tetanus surveillance: United States, 1998–2000. MMWR CDC Surveill Summ 2003; 52(SS-3):1-8.
63. Yen L.M., Dao L.M., Day N.PJ., et al: Role of quinine in the high mortality of intramuscular injection tetanus. Lancet 1994; 344:786-787.
64. Vakil B.J.: Tetanus. Q Med Rev 1974; 24–25:1-44.
65. Bytchenko B.: Geographical distribution of tetanus in the world, 1951–60. Bull World Health Organ 1966; 34:71-104.
66. Oyelami O.A., Aladekomo T.A., Ononye F.O.: A 10-year retrospective evaluation of cases of post neonatal tetanus seen in a paediatric unit of a university teaching hospital in southwestern Nigeria (1985 to 1994). Cent Afr J Med 1996; 42:73-75.
67. Jagoda A., Riggio S., Burguieres T.: Cephalic tetanus: a case report and review of the literature. Am J Emerg Med 1988; 6:128-130.
68. Bytchenko B.: Microbiology of tetanus. In: Veronesi R., ed. Tetanus: Important New Concepts, Amsterdam: Excerpta Medica; 1981:28-39.

69. Bizzini B.: Tetanus. In: Germanier R., ed. Bacterial Vaccines, Orlando, FL: Academic Press; 1984:38-68.
70. Hatheway C.L., Johnson E.A.: Clostridium: the spore-bearing anaerobes. In: Collier L., Balows A., Sussman M., ed. Topley & Wilson's Microbiology and Microbial Infections, 2. London: Arnold; 1998:731-782.Vol. 2. 9th ed
71. Tulloch W.J.: Report of bacteriological investigation of tetanus carried out on behalf of the War Office Committee for the Study of Tetanus. J Hyg (Camb) 1919; 18:103-202.
72. Sanada I., Nishida S.: Isolation of Clostridium tetani from soil. J Bacteriol 1965; 89:626-629.
73. Finegold S.M.: Tetanus. In: Collier L., Balows A., Susman M., ed. Topley and Wilson's Microbiology and Microbial Infections, Vol. 3. London: Hodder Arnold; 1998:693-722.9th ed
74. Dubovsky J., Meyer K.: The occurrence of C. tetani in soil and in vegetables. J Infect Dis 1922; 31:614-616.
75. Smith L.D.: The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States. Health Lab Sci 1978; 15:74-80.
76. Kerrin J.C.: The distribution of C. tetani in the intestines of animals. Br J Pathol 1929; 10:370-373.
77. TenBroeck C., Bauer J.H.: The tetanus bacillus as an intestinal saprophyte in man. J Exp Med 1922; 36:261-271.
78. TenBroeck C., Bauer J.H.: Studies on the relation of tetanus bacilli in the digestive tract to tetanus antitoxin in the blood. J Exp Med 1923; 37:479-489.
79. Coleman G.E., Meyer K.F.: Study of tetanus agglutinins and antitoxin in human serums. J Infect Dis 1926; 39:332-336.
80. Bauer J.H., Meyer K.F.: Human intestinal carriers of tetanus spores in California. J Infect Dis 1926; 38:295-305.
81. Kerrin J.C.: The incidence of C. tetani in human feces. Br J Pathol 1928; 9:69-71.
82. Bandmann F.: Zum Nachweis von Tetanusbacillen im Darm von Ulcus- und Carcinomträgern. Z Hyg 1953; 136:559-567.
83. Lowbury E.JL., Lilly H.A.: Contamination of operating-theatre air with Cl. tetani. Br Med J 1958; 2:1334-1336.
84. Gilles E.C.: The isolation of tetanus bacilli from street dust. JAMA 1937; 109:484-486.
85. Smith J.WG.: Tetanus and its prevention. Prog Drug Res 1975; 19:391-401.
86. Laird W.J., Aaronson W., Silver R.P., et al: Plasmid-associated toxigenicity in Clostridium tetani. J Infect Dis 1980; 142:623.
87. Finn Jr. LW,., Silver R.P., Habig H.W., et al: The structural gene for tetanus neurotoxin is on a plasmid. Science 1984; 224:881-884.
88. Marvaud J.C., Eisel U., Binz T., et al: TetR is a positive regulator of the tetanus toxin gene in Clostridium tetani and is homologous to BotR. Infect Immun 1998; 66:5698-5702.
89. Plourde-Owobi L., Seguin D., Baudin M.A., et al: Molecular characterization of Clostridium tetani strains by pulsed-field electrophoresis and colony PCR. Appl Exp Microbiol 2005; 71:5604-5606.
90. Matsuda M., Yoneda M.: Isolation and purification of two antigenically active, “complementary” polypeptide fragments of tetanus neurotoxin. Infect Immun 1975; 12:1147-1153.
91. Schiavo G., Papini E., Genna G., et al: An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin. Infect Immun 1990; 58:4136-4141.
92. Pellizzari R., Roesstto O., Schiavo G., et al: Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Phil Trans R Soc Lond 1999; 354:259-268.
93. Halpern J.L., Loftus A.: Characterization of the receptor-binding domain of tetanus toxin. J Biol Chem 1993; 268:11188-11192.

94. Ahnert-Hilger G., Dauzenroth M.W., Habermann E., et al: Chains and fragments of tetanus toxin, and their contribution to toxicity. J Physiol 1990; 84:229-236.
95. Parton R.G., Critchley D.R., Ockleford C.D.: Tetanus toxin binding to mouse spinal cord cells: an evaluation of the role of gangliosides in toxin internalization. Brain Res 1988; 475:118-127.
96. Schiavo G., Matteoli M., Montecucco C.: Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80:717-766.
97. Gill D.M.: Bacterial toxins: a table of lethal amount. Microbiol Rev 1982; 46:86-94.
98. Humeau Y., Doussau F., Grant N., et al: How botulinum and tetanus neurotoxin block neurotransmitter release. Biochemie 2000; 82:427-446.
99. Bulloch W.E., Cramer W.: On a new factor in the mechanism of bacterial infection. Proc R Soc B 1919; 90:513-528.
100. Abel J.J., Firor W.M., Chalain W.: Researches on tetanus, IX: further evidence to show that tetanus toxin is not carried to central nervous system by way of the axis cylinders of motor nerves. Bull Johns Hopkins Hosp 1938; 63:373-403.
101. Montecucco C.: How do tetanus and botulinum toxins bind to neuronal membranes?. Trends Biochem Sci 1986; 11:314-317.
102. Lalli G., Bohnert S., Deinhardt K., et al: The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol 2003; 11:431-437.
103. Herreros J., Schiavo G.: Lipid microdomains are involved in neurospecific binding and internalisation of clostridial neurotoxins. Int J Med Microbiol 2002; 291:447-453.
104. Deinhardt K., Berninghausen O., Willison H.J., et al: Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J Cell Biol 2006; 174:459-471.
105. Chen C., Fu Z., Kim J.J., et al: Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem 2009; 284:26569-26577.
106. Caleo M., Schiavo G.: Central effects of tetanus and botulinum neurotoxins. Toxicon 2009; 54:593-599.
107. Binz T., Rummel A.: Cell entry strategy of clostridial neurotoxins. J Neurochem 2009; 109:1584-1595.
108. Price D.L., Griffin J.W., Young A., et al: Tetanus toxin: direct evidence for retrograde axonal transport. Science 1975; 188:945-957.
109. Manning K.A., Erichsen J.T., Evinger C.: Retrograde transneuronal transport properties of fragment C of tetanus toxin. Neuroscience 1990; 34:251-263.
110. Lalli G., Schiavo G.: Analysis of retrograde transport in motor neurons reveals common endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. J Cell Biol 2002; 156:233-239.
111. Bohnert S., Schiavo G.: Tetanus toxin is transported in a novel neuronal compartment characterized by a specialized pH regulation. J Biol Chem 2005; 280:42336-42344.
112. González-Forero D., Morcuende S., Alvarez F.J., et al: Transynaptic effects of tetanus neurotoxin in the oculomotor system. Brain 2005; 128:2175-2188.
113. Yeh F.L., Dong M., Yao J., et al: SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog 2010; 6:e1001207.
114. Bergey G.K., Nelson P.G., Bigalke H.: Differential effects of tetanus toxin on inhibitory and excitatory synaptic transmission in mammalian spinal cord neurons in culture: a presynaptic locus of action for tetanus toxin. J Neurophysiol 1987; 57:121-131.
115. Schiavo G., Benfenati R., Poulain B., et al: Tetanus and botulism-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832-835.

116. Cornille F., Fournie-Zaluski M.C., Roques B.P., et al: Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain. J Biol Chem 1997; 272:3459-3464.
117. Bleck T.P.: Tetanus: pathophysiology, management, and prophylaxis. Dis Mon 1991; 37:545-603.
118. Brooks V.B., Curtis D.R., Eccles J.C.: Mode of action of tetanus toxin. Nature 1955; 175:120-121.
119. Brooks V.B., Asanuma H.: Action of tetanus toxin in the cerebral cortex. Science 1962; 137:674-676.
120. Bizzini B.: Tetanus toxin. Microbiol Rev 1979; 43:224-240.
121. Green J., Erdmann J.G., Wellhoner H.H.: Is there retrograde axonal transport of tetanus toxin in both alpha and beta fibres?. Nature 1977; 265:370.
122. Schwab M.E., Thoenen H.: Selective binding, uptake and retrograde transport of tetanus toxin by nerve terminals in the rat iris. J Cell Biol 1978; 77:1-13.
123. Sanford J.P.: Tetanus: forgotten but not gone [editorial]. N Engl J Med 1995; 332:812-813.
124. Habig W.H., Nelson P.G., Hardegree M.C., et al: Tetanus toxin in dissociated spinal cord cultures: long-term characterization of form and action. J Neurochem 1986; 47:930-937.
125. Empson R.M., Gutnick M.J., Jefferys J.G., et al: Injection of tetanus toxin into the neocortex elicits persistent epileptiform activity but only transient impairment of GABA release. Neuroscience 1993; 57:235-239.
126. Takano K., Kirchner T., Teibert B., et al: Presynaptic inhibition of the monosynaptic reflex during local tetanus in the cat. Toxicon 1989; 27:431-438.
127. Boyd R.E., Brennan P.T., Denj J-F., et al: Strychnine poisoning. Am J Med 1983; 74:507-512.
128. Brunger A.T., Rummel A.: Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009; 54:550-560.
129. Alfery D.D., Rauscher L.A.: Tetanus: a review. Crit Care Med 1979; 7:176-181.
130. Goulon M., Girard O., Grosbuis S., et al: Les anticorps antitetaniques. Nouv Presse Med 1972; 1:3049-3050.
131. Berger S.A., Cherubin L.E., Nelson S., et al: Tetanus despite preexisting antitetanus antibody. JAMA 1978; 240:769-770.
132. Passen E.L., Andersen B.R.: Clinical tetanus despite a “protective” level of toxin-neutralizing antibody. JAMA 1986; 255:1171-1173.
133. Maselle S.Y., Matre R., Mbise R., et al: Neonatal tetanus despite protective serum antitoxin concentration. FEMS Microbiol Immunol 1991; 3:171-175.
134. Crone N.E., Reder A.T.: Severe tetanus in immunized patients with high anti-tetanus titers. Neurology 1992; 42:761-764.
135. de Moraes-Pinto M.I.: Neonatal tetanus despite immunization and protective antitoxin antibody. J Infect Dis 1995; 171:1076-1077.
136. Pryor T., Onarecker C., Coniglione T.: Elevated antitoxin titers in a man with generalized tetanus. J Fam Pract 1997; 44:299-303.
137. Abrahamian F.M., Pollack C.V., LoVecchio F., et al: Fatal tetanus in a drug abuser with “protective” antitetanus antibodies. J Emerg Med 2000; 18:189-193.
138. Turner T.B., Velasco-Joven E.A., Prudovsky S.: Studies on the prophylaxis and treatment of tetanus, II: studies pertaining to treatment. Bull Johns Hopkins Hosp 1958; 102:71-84.
139. Steinegger T., Wiederkehr M., Ludin H.P., et al: Elektromyogramm als diagnostische Hilfe beim Tetanus. Schweiz Med Wochenschr 1996; 126:379-385.
140. Apte N.M., Karnad D.R.: Short report: the spatula test: a simple bedside test to diagnose tetanus. Am J Trop Med Hyg 1995; 53:386-387.

141. Smith W.D., Tobias M.A.: Tetany, tetanus or drug reaction?. Br J Anaesth 1976; 48:703-705.
142. Barnes V., Ware M.R.: Tetanus, pseudotetanus, or conversion disorder: a diagnostic dilemma?. South Med J 1993; 86:591-592.
143. Anker M., Black R.E., Kalter H.D., et al: A standard verbal autopsy method for investigating causes of death in infants and children, Geneva, World Health Organization, 1999. (WHO/CDS/CSR/ISR/99.4).accessed April 5, 2012 http://whqlibdoc.who.int/hq/1999/WHO_CDS_CSR_ISR_99.4.pdf
144. World Health Organization : WHO-recommended standards for surveillance of selected vaccine-preventable diseases, Geneva, World Health Organization, 2003. accessed April 5, 2012 http://www.who.int/immunization_monitoring/diseases/NT_surveillance/en/index.html
145. Ernst M.E., Klepser M.E., Fouts M., et al: Tetanus: pathophysiology and management. Ann Pharmacother 1997; 31:1507-1513.
146. Bleck T.P.: Clostridium tetani (tetanus). In: Mandell G.L., Bennet J.E., Dolin R., ed. Principles and Practice of Infectious Diseases, 7th ed. New York: Churchill Livingstone; 2010:3091-3096.
147. Bassin S.L.: Tetanus. Curr Treat Options Neurol 2004; 6:25-34.
148. World Health Organization : Current recommendations for treatment of tetanus during humanitarian emergencies: WHO technical note, Geneva, World Health Organization, 2010. (WHO/HSE/GAR/DCE/2010.2).accessed April 5, 2012 http://whqlibdoc.who.int/hq/2010/WHO_HSE_GAR_DCE_2010.2_eng.pdf
149. Afshar M., Raju M., Ansell D., et al: Narrative review: tetanus: a health threat after natural disasters in developing countries. Ann Intern Med 2011; 154:329-335.
150. Phillips L.A.: A classification of tetanus. Lancet 1967; 1:1216-1217.
151. Thwaites C.L., Yen L.M., Glover C., et al: Predicting the clinical outcome of tetanus: the tetanus severity score. Trop Med Int Health 2006; 11:279-287.
152. Nation N.S., Pierce N.F., Adler S.J., et al: Tetanus: the use of human hyperimmune globulin in treatment. Calif Med 1963; 98:305-307.
153. Blake P.A., Feldman R.A., Buchanan T.M., et al: Serologic therapy of tetanus in the United States, 1965–1971. JAMA 1976; 235:42-44.
154. Attygalle D., Rodrigo N.: New trends in the management of tetanus. Expert Rev Anti Infect Ther 2004; 2:73-84.
155. Tetanus (lockjaw). In: Pickering L.K., Baker C.J., Kimberlin D.W., et al ed. 2009 Red Book: Report of the Committee on Infectious Diseases, 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:655-660.
156. Thwaites C.L.: Tetanus. Practical Neurol 2002; 2:130-137.
157. Abrutyn E. T.etanus.: In: Braunwald E., Fauci A.S., Kasper D.L., et al ed. Harrison's Principles of Internal Medicine, 15th ed. New York: McGraw-Hill; 2001:918-920.
158. Moynihan N.H.: Serum-sickness and local reactions in tetanus prophylaxis. Lancet 1955; 2:264-266.
159. Merson M.H., Hughs J.M., Dowell V.R., et al: Current trends in botulism in the United States. JAMA 1974; 229:1305-1308.
160. Rubenstein H.M.: Studies on human tetanus antitoxin. Am J Hyg 1962; 76:276-292.
161. Lee D.C., Lederman H.M.: Anti-tetanus toxoid antibodies in intravenous gamma globulin: an alternative to tetanus immune globulin. J Infect Dis 1992; 166:642-645.
162. McCracken Jr G.H., Dowell D.L., Marschall F.N.: Double-blind trial of equine antitoxin and human immune globulin in tetanus neonatorum. Lancet 1971; 1:1146-1149.
163. Bleck T.P.: Intravenous immune globulin for passive tetanus prophylaxis. J Infect Dis 1993; 167:498-499.

164. Krause I., Wu R., Sherer Y., et al: In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations: a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfusion Med 2002; 12:133-139.
165. Lejtenyi D., Mazer B.: Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol 2007; 121:254-255.
166. Rey M., Diop-Mar I., Robert D.: Treatment of tetanus. In: Veronesi R., ed. Tetanus: Important New Concepts, Amsterdam: Excerpta Medica; 1981:207-237.
167. Abrutyn E., Berlin J.A.: Intrathecal therapy in tetanus: a meta-analysis. JAMA 1991; 266:2262-2267.
168. Gupta P.S., Kapoor R.: Intrathecal tetanus immunoglobulin (human). Indian J Pediatr 1982; 49:15-17.
169. Chugh K., Sehgal H.: Evaluation of intrathecal human tetanus immunoglobulin in tetanus neonatorum. Indian Pediatr 1985; 22:153-158.
170. Vakil B.J., Armitage P.: Therapeutic trial of intracisternal human tetanus immunoglobulin in clinical tetanus. Trans R Soc Trop Med Hyg 1979; 73:579-583.
171. Neequaye J., Nkrumah F.R.: Failure of intrathecal antitetanus serum to improve survival in neonatal tetanus. Arch Dis Child 1983; 58:276-278.
172. Begue R.E., Lindo-Soriano I.: Failure of intrathecal tetanus antitoxin in the treatment of tetanus neonatorum. J Infect Dis 1991; 164:419-420.
173. Mongi P.S., Mbise R.L., Msengi A.E., et al: Tetanus neonatorum: experience with intrathecal therapy at Muhimbili Medical Centre, Dar es Salaam. Tanzania. Ann Trop Paediatr 1987; 7:27-31.
174. Singh A.K., Bansal A., Goel S.P., et al: Intrathecal antitetanus serum (horse) with steroid in the treatment of neonatal tetanus. Arch Dis Child 1980; 55:527-531.
175. Sanders R.KM., Joseph R., Martyn B., et al: Intrathecal antitetanus serum (horse) in the treatment of tetanus. Lancet 1977; 1:974-977.
176. Gupta P.S., Kapoor R., Goyal S., et al: Intrathecal human tetanus immunoglobulin in early tetanus. Lancet 1980; 2:439-440.
177. Keswani N.K., Singh A.K., Upadhyanaya K.D.: Intrathecal tetanus antitoxin in moderate and severe tetanus. J Indian Med Assoc 1980; 75:67-69.
178. Chopra K., Gupta A., Mhatre K.: Intrathecal tetanus hyperimmune human gamma globulin in the treatment of tetanus. Indian Pediatr 1986; 23:775-778.
179. Agarwal M., Thomas K., Peter J.V., et al: A randomized double-blind sham-controlled study of intrathecal human anti-tetanus immunoglobulin in the management of tetanus. Nat Med J India 1998; 11:209-212.
180. Miranda-Filjho D.B., Ximenes R.AA., Barone A.A., et al: Randomised controlled clinical trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. BMJ 2004; 328:615-618.
181. Kabura L., Ilibagiza D., Menten J., et al: Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health 2006; 11:1075-1081.
182. Geeta M.G., Krishnakumar P., Mathews L.: Intrathecal tetanus immunoglobulins in the management of tetanus. Ind J Pediatr 2007; 74:43-45.
183. Wateba M.I., Diop S.A., Nichols S., et al: Intrathecal therapy with 1,500 IU antitetanic serum and 1.5 g of intravenous metronidazole: prognosis of tetanus in hospitalized patients in Togo. Sante 2008; 18:125-129.
184. Spenney J.G., Lamb R.N., Cobbs C.G.: Recurrent tetanus. South Med J 1971; 64:859-862.

185. Bhatt A.D., Dastur F.D.: Relapsing tetanus: a case report. J Postgrad Med 1981; 27:184-186.
186. Cain H.D., Falco F.G.: Recurrent tetanus. Calif Med 1962; 97:31-33.
187. Lindley-Jones M., Lewis D., Southgate J.L.: Recurrent tetanus. Lancet 2004; 363:2048.
188. Sharma A., Kapoor S.: Relapse in a child with otogenic tetanus. Trop Doct 2006; 36:56-57.
189. Naranyanan K., Gupta P.S., Kumar N., et al: Antitoxin response in tetanus. Indian J Med Res 1981; 74:482-485.
190. Yeni P., Carbon C., Tremolieres F., et al: Serum levels of antibody to toxoid during tetanus and after specific immunization of patients with tetanus. J Infect Dis 1982; 145:278.
191. Campbell J.I., Lam T.M., Huynh T.L., et al: Microbiologic characterization and antimicrobial susceptibility of Clostridium tetani isolated from wounds of patients with clinically diagnosed tetanus. Am J Trop Med Hyg 2009; 80:827-831.
192. Ahmadsyah I., Salim A.: Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J (Clin Res Ed) 1985; 291:648-650.
193. Ganesh Kumar A.V., Kothari V.M., Krishnan A., et al: Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial. Ann Trop Med Parasitol 2004; 98:59-63.
194. Okoromah C.AN., Lesi A.FE.: Diazepam for treating tetanus. Cochrane Database of Systematic Reviews; Issue 1, Art. 2004. CD003954accessed April 2012. (DOI: 10.1002/14651858.CD003954.pub2.)
http://www.who.int/immunization_monitoring/diseases/NT_surveillance/en/index.htm
195. Tallman J.F., Gallager D.W.: The GABA-ergic system: a locus of benzodiazepine action. Annu Rev Neurosci 1985; 8:21-44.
196. Davidoff R.A.: Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17:107-116.
197. Joseph A., Pulimood B.M.: Use of diazepam in tetanus: a comparative study. Indian J Med Res 1978; 68:489-491.
198. Dasta J.F., Brier K.L., Kidwell G.A., et al: Diazepam infusion in tetanus: correlation of drug levels with effect. South Med J 1981; 74:278-280.
199. Tekur U., Gupta A., Tayal G., et al: Blood concentrations of diazepam and its metabolites in children and neonates with tetanus. J Pediatr 1983; 102:145-147.
200. Vassa T., Yajnik V.H., Joshi K.R., et al: Comparative clinical trial of diazepam with other conventional drugs in tetanus. Postgrad Med J 1974; 50:755-758.
201. Checketts M.R., White R.J.: Avoidance of intermittent positive pressure ventilation in tetanus with dantrolene therapy. Anaesthesia 1993; 48:969-971.
202. Cabrerizo Garcia J.L., Homs Gimeno C.A., Pacheco Aracibia G., et al: Treatment of tetanus with intrathecal baclofen (in Spanish). An Med Interna 2008; 25:372-373.
203. Borgeat A., Popovic V., Schwander D.: Efficiency of a continuous infusion of propofol in a patient with tetanus. Crit Care Med 1991; 19:295-297.
204. Attygalle D., Rodrigo N.: Magnesium sulphate for control of spasms in severe tetanus: can we avoid sedation and artificial ventilation?. Anaesthesia 1997; 52:956-962.
205. Attygalle D., Rodrigo N.: Magnesium as first line therapy in the management of tetanus: a prospective study of 40 patients. Anaesthesia 2002; 57:778-817.
206. Thwaites C.L., Yen L.M., Loan H.T., et al: Magnesium sulphate for treatment of severe tetanus: a randomized controlled trial. Lancet 2006; 368:1436-1443.
207. Puliyel M.M., Pillai R., Korula S.: Intravenous magnesium sulphate infusion in the management of very severe tetanus in a child: a descriptive case report. J Trop Pediatr 2009; 55:58-59.

208. Mathew P.J., Samra T., Wig J.: Magnesium sulphate for treatment of tetanus in adults. Anaesth Intensive Care 2010; 38:185-189.
209. Thomas R.M., Bellamy M.C.: Tetanus in a subcutaneous drug abuser: ineffectiveness of intrathecal baclofen. Anaesth Intensive Care 2006; 34:811-815.
210. Domenighetti G.M., Savary G., Stricker H.: Hyperadrenergic syndrome in severe tetanus: extreme rise in catecholamines responsive to labetalol. Br Med J (Clin Res Ed) 1984; 288:1483-1484.
211. Rie M., Wilson R.S.: Morphine therapy controls autonomic hyperactivity in tetanus. Ann Intern Med 1978; 88:653-654.
212. Wright D.K., Lalloo U.G., Nayiager S., et al: Autonomic nervous system dysfunction in severe tetanus: current perspectives. Crit Care Med 1989; 17:371-375.
213. Sutton D.N., Tremlett M.R., Woodcock T.E., et al: Management of autonomic dysfunction in severe tetanus: the use of magnesium sulfate and clonidine. Intensive Care Med 1990; 16:75-80.
214. Moughabghab A.V., Prevost G., Socolovsky C.: Fentanyl therapy controls autonomic hyperactivity in tetanus. Br J Clin Pract 1996; 50:477-478.
215. Mukherjee D.R.: Tetanus and tracheostomy. Ann Otol Rhinol Laryngol 1977; 86:67-72.
216. O'Keefe S.JD., Wesley A., Jialal I., et al: The metabolic response and problems with nutritional support in acute tetanus. Metabolism 1984; 33:482-487.
217. Hiraide A., Katayama M., Sugimoto H., et al: Metabolic changes in patients severely affected by tetanus. Ann Surg 1991; 213:66-69.
218. Tateno I., Suzuki S., Kitamoto O.: Epidemiology of tetanus in Japan. Japan J Exp Med 1961; 31:365-380.
219. Bytchenko B.D., Causse G., Grab B., et al: Tetanus: recent trends of world distribution. In: Mérieux C., ed. Proceedings of the Sixth International Conference on Tetanus, Lyon: Collection Foundation Mérieux; 1981:97-111.Lyon, France; December 3–5, 1981
220. Suleman O.: Mortality from tetanus neonatorum in Punjab (Pakistan). Pakistan Pediatr J 1982; 6:152-183.
221. Stanfield J.P., Galazka A.: Neonatal tetanus in the world today. Bull World Health Organ 1984; 62:647-669.
222. Expanded Programme on Immunization : Prevention of neonatal tetanus. Wkly Epidemiol Rec 1993; 68:337-341.
223. Expanded Programme on Immunization : Global Advisory Group Part II. Wkly Epidemiol Rec 1982; 57:137-142.
224. Galazka A., Cook R.: Neonatal tetanus today and tomorrow. In: Nistico G., Mastroeni P., Pitzurra M., ed. Proceedings of the Seventh International Conference on Tetanus, Rome: Gangeni; 1985:350-363.Copanello, Italy; September 10–15, 1984
225. Rey M., Tikhomirov E.: Non neonatal tetanus over the world. In: Nistico G., Bizzini B., Bytchenko M., et al ed. Proceedings of the Eighth International Conference on Tetanus, Rome: Pythagora Press; 1989:506-518.Leningrad; August 25–28, 1987
226. Department Immunization, Vaccines and Biologicals : WHO vaccine-preventable diseases: monitoring system: 2010 global summary, Geneva, WHO, 2010. accessed April 5, 2012 http://www.who.int/immunization/documents/who_ivb_2010/en/index.html
227. Galazka A., Gasse F.: The present status of tetanus and tetanus vaccination. Curr Top Microbiol Immunol 1995; 195:31-53.
228. Deaths by cause, sex and age in the world, 2001. Table 3B.9. In: Mathers C.D., Lopez A.D., Murray C.JL., ed. Global Burden of Disease and Risk Factors, New York: Oxford University Press; 2006:174-175.
229. World Health Organization : Annex A; Table A1. Global Burden of Disease, 2004 update, Geneva, WHO, 2008.

230. World Health Organization Regional Office for Europe. Health for All database. http://data.euro.who.int/hfadb , accessed April 5, 2012.
231. Centers for Disease Control and Prevention : Tetanus surveillance: United States, 2001–2008. MMWR 2011; 60:365-369.
232. Lau L.G., Kong K.O., Chew P.H.: A ten-year retrospective study of tetanus at a general hospital in Malaysia. Singapore Med J 2001; 42:346-350.
233. Lubbad E.H., Khazindar A.M., Ayyub M.: Tetanus experience in a public hospital in Western Saudi Arabia. Saudi Med J 2003; 24:1325-1328.
234. Sun K.O., Chan Y.W., Cheung R.TF., et al: Management of tetanus: a review of 18 cases. J R Soc Med 1994; 87:135-137.
235. Chatchatee P., Chatproedprai S., Warinsathien P., et al: Seroprevalence of tetanus antibody in the Thai population: a national survey. Asian Pac J Allergy Immunol 2007; 25:219-223.
236. Gouveia P.A., Silva C.E., Miranda Filho Dde B., et al: Tendência temporal do tétano acidental no período de 1981 a 2004 em Pernambuco com avaliação do impacto da assistência em unidade de terapia intensiva sobre a letalidade. Mortality trend due to accidental tetanus from 1981 to 2004 in Pernambuco and analysis of the impact on intensive care unit attendance. Rev Soc Bras Med Trop 2009; 42:54-57.
237. Seydi M., Soumaré M., Gbangba-ngai E., et al: Apects actuels du tétanos de l'enfant et de l'adulte à Dakar. Current aspects of pediatric and adult tetanus in Dakar. Med Mal Infect 2005; 35:28-32.
238. Chapp-Jumbo E.N.: Neurologic infections in a Nigerian university teaching hospital. Afr Health Sci 2006; 6:55-58.
239. Melaku Z., Alemayehu M., Oli K., et al: Pattern of admissions to the medical intensive care unit of Addis Ababa University Teaching Hospital. Ethiop Med J 2006; 44:33-42.
240. Black R.E., Cousens S., Johnson H.L., et al: Global, regional and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375:1969-1987.
241. Singh J., Datta K.K., Foster S.O.: Sensitivity of neonatal tetanus surveillance system in India. Indian Pediatr 1997; 34:398-401.
242. Idema C.D., Harris B.N., Ogunbanjo G.A., et al: Neonatal tetanus elimination in Mpumalanga Province, South Africa. Trop Med Int Health 2002; 7:622-624.
243. Gilbert N.L., N'doutabé M.: Sous-déclaration du tétanos néonatal dans la région de Kayes au Mali. Under-reporting of neonatal tetanus in the Kayes Region of Mali. Sante 2007; 17:193-194.
244. Sutter R.W., Cochi S.L., Brink E.W., et al: Assessment of vital statistics and surveillance data for monitoring tetanus mortality, 1979–1984. Am J Epidemiol 1990; 131:132-142.
245. Rushdy A.A., White J.M., Ramsay M.E., et al: Tetanus in England and Wales, 1984–2000. Epidemiol Infect 2003; 130:71-77.
246. Antona D. L.e.: tetanos en France en 2000 et 2001. Bull Epidemiol Hebdomadaire 2002; 40:197-199.
247. Zuber P.L., Schierz A., Aréstegui G., et al: Tetanus in Switzerland 1980–1989. Eur J Epidemiol 1993; 9:617-624.
248. Quinn H.E., McIntyre P.B.: Tetanus in the elderly: an important preventable disease in Australia. Vaccine 2007; 25:1304-1309.
249. Moore R.M., Singleton A.O.: Tetanus at the John Sealy Hospital. Surg Gynecol Obstet 1939; 69:146-154.
250. Christensen N.A., Thurber D.L.: Clinical experience with tetanus: 91 cases. Proc Mayo Clin 1957; 32:146-158.
251. Faust R.A., Vickers O.R., Cohn I.: Tetanus: 2,449 cases in 68 years at Charity Hospital. J Trauma 1976; 16:704-712.

252. Bowen V., Johnson J., Boyle J., et al: Tetanus: a continuing problem in minor injuries. Can J Surg 1988; 31:7-9.
253. Patel J.C., Mehta B.C.: Tetanus: study of 8,697 cases. Indian J Med Sci 1999; 53:393-401.
254. Boyd J.SK.: Tetanus in the African and European theatres of war 1939–1945. Lancet 1946; 1:113-119.
255. Glenn F.: Tetanus: a preventable disease, including an experience with civilian casualties in the battle for Manila (1945). Ann Surg 1946; 124:1030-1040.
256. Aceh Epidemiology Group : Outbreak of tetanus cases following the tsunami in Aceh province, Indonesia. Glob Public Health 2006; 1:173-177.
257. Jeremijenko A., McLaws M.L., Kosasih H.: A tsunami related tetanus epidemic in Aceh, Indonesia. Asia Pac J Public Health 2007; 19:40-44.
258. World Health Organisation : South Asia earthquake situation report no. 19, Geneva, WHO, 2005. accessed April 5, 2012 http://www.who.int/hac/crises/international/pakistan_earthquake/sitrep/earthquakesituationreport19.pdf
259. Yasin M.A., Malik S.A., Nasreen G., et al: Experience with mass casualties in a subcontinent earthquake. Turk J Trauma Emerg Surg 2009; 15:487-492.
260. Sutiono A.B., Qiantori A., Suwa H., et al: Characteristic tetanus infection in disaster-affected areas: case study of the Yogyakarta earthquakes in Indonesia. BMC Res Notes 2009; 2:34.
261. Greco J.B., Sacramento E., Tavares-Neto J.: Chronic ulcers and myasis as ports of entry for Clostridium tetani. Braz J Infect Dis 2001; 5:319-523.
262. Greco J.B., Tavares-Neto J., Greco Júnior J.B.: Accidental tetanus: prognosis evaluation in a historical series at a hospital in Salvador, Bahia, Brazil. Rev Inst Med Trop Sao Paulo 2003; 45:35-40.
263. Fischer G.W., Sunakorn P., Duangman C.: Otogenous tetanus: a sequelae of chronic ear infections. Am J Dis Child 1977; 131:445-446.
264. Tullu M.S., Deshmukh C.T., Kamat J.R.: Experience of pediatric tetanus cases from Mumbai. Indian Pediatr 2000; 37:765-771.
265. Ramos J.M., Reyes F., Tesfamariam A.: Tetanus in a rural Ethiopian hospital. Trop Doct 2008; 38:104-105.
266. Amsalu S., Lulseged S.: Tetanus in a children's hospital in Addis Ababa: review of 113 cases. Ethiop Med J 2005; 43:233-240.
267. Joseph J.K., Bazile J., Mutter J., et al: Tungiasis in rural Haiti: a community-based response. Trans R Soc Trop Med Hyg 2006; 100:970-974.
268. Postoperative tetanus [editorial]. Lancet 1984; 2:964-965.
269. Federmann M., Kotzerke M.: Postoperativ tetanus. Dtsch Med Wochenschr 1989; 114:1833-1836.
270. Tanon A.K., Eholie S.P., Coulibaly-Dacoury C., et al: Morbidité et mortalité du tétanos dans le service des maladies infectieuses et tropicales d'Abidjan (1985–1998). Morbidity and mortality of tetanus in the infectious and tropical diseases department in Abidjan 1985–1998. Bull Soc Pathol Exot 2004; 97:283-287.
271. Boumandouki P., Kounkou R.Y., Teke-Bagamboula J.N., et al: Injections de quinine et tétanos au CHU de Brazzaville, Congo. Intramuscular injections of quinine and tetanus at the Centre Hospitalier Universitaire of Brazzaville, Congo. Bull Soc Pathol Exot 2008; 101:298-300.
272. Faveau V., Mamdani M., Steinglass R., et al: Maternal tetanus: magnitude, epidemiology and potential control measures. Int J Gynecol Obstet 1993; 40:3-12.

273. Rochat R., Akhter H.H.: Tetanus and pregnancy-related mortality in Bangladesh. Lancet 1999; 354:565.
274. O'Malley C.D., Smith N., Braun R., et al: Tetanus associated with body piercing [letter]. Clin Infect Dis 1998; 27:1343-1344.
275. Dyce O., Bruno J.R., Hong D., et al: Tongue piercing: the new “rusty nail”?. Head Neck 2000; 22:728-732.
276. Levinson A.K., Marske R.L., Shein M.D.: Tetanus in heroin addicts. JAMA 1955; 157:658-660.
277. Cherubin C.E.: Urban tetanus: the epidemiologic aspects of tetanus in narcotic addicts in New York City. Arch Environ Health 1967; 14:802-808.
278. Cherubin C.E., Millian S.J., Palusci E., et al: Investigations in tetanus in narcotics addicts in New York City. Am J Epidemiol 1968; 88:215-223.
279. Cherubin C.E.: Epidemiology of tetanus in narcotic addicts. N Y State J Med 1970; 70:267-271.
280. Rezza G., Pizzuti R., De Campora E., et al: Tetanus and injection drug use: rediscovery of a neglected problem?. Eur J Epidemiol 1996; 12:665-666.
281. Hahné S.JM., White J.M., Crowcroft N.S., et al: Tetanus in injecting drug users, United Kingdom. Emerg Infect Dis 2006; 12:709-710.
282. Hahné S., Crowcroft N., White J., et al: Ongoing outbreak of tetanus in injecting drug users in the UK. Eurosurv Wkly 2004; 8:4.
283. Centers for Disease Control and Prevention : Tetanus among injecting drug users: California, 1997. MMWR 1998; 47:149-151.
284. Axnick N.W., Alexander E.R.: Tetanus in the United States: a review of the problem. Am J Public Health 1957; 47:1493-1501.
285. Heath C.W., Zusman J., Sherman I.L.: Tetanus in the United States, 1950–1960. Am J Public Health 1964; 54:769-779.
286. Conybeare E.T., Logan W.PD.: The incidence and prevention of tetanus among civilians. Br Med J 1951; 1:504-508.
287. Berginer V.M., Alkan M.: Acquisition of tetanus in the desert. Eur J Clin Microbiol 1987; 6:318.
288. Ball K., Norboo T., Gupta U., et al: Is tetanus rare at high altitudes? [letter]. Trop Doct 1994; 24:78-80.
289. Ipsen J.: Immunization of adults against diphtheria and tetanus. N Engl J Med 1954; 251:459-466.
290. de Baker W.C.: A note on the epidemiology of tetanus in Kenya. East Afr Med J 1963; 40:127-131.
291. Fraser D.W.: Tetanus in the United States, 1900–1969: analysis by cohorts. Am J Epidemiol 1972; 96:306-312.
292. Luisto M.: Epidemiology of tetanus in Finland from 1969 to 1985. Scand J Infect Dis 1989; 21:655-663.
293. Galazka A., Kardymowicz B.: Tetanus incidence and immunity in Poland. Eur J Epidemiol 1989; 5:474-480.
294. Pedalino B., Cotter B., Ciofi degli Atti M., et al: Epidemiology of tetanus in Italy in years 1971–2000. Euro Surveill 2002; 7:103-110.
295. Castro L., Gonçalves G., Catarino J.: Caracterização epidemiológica dos casos declarados de tetano: oportunidades perdidas de vacinação. Acta Med Port 2004; 17:225-230.
296. Fair E., Murphy T.V., Golaz A., et al: Philosophic objection to vaccination as a risk for tetanus among children younger than 15 years. Pediatrics 2002; 109:E2.
297. de Melker H.E., van den Hof S., Berbers G.A., et al: A population-based study on tetanus antitoxin levels in The Netherlands. Vaccine 1999; 18:100-108.

298. Maple P.A., Jones C.S., Wall E.C., et al: Immunity to diphtheria and tetanus in England and Wales. Vaccine 2000; 19:167-173.
299. Wu C.J., Ko H.C., Lee H.C., et al: Decline of tetanus antitoxin level with age in Taiwan. J Formos Med Assoc 2009; 108:395-401.
300. Theeten H., Hutse V., Hens N., et al: Are we hitting immunity targets? the 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. Epidemiol Infect 2011; 139:494-504.
301. Stark K., Schönfeld C., Barg J., et al: Seroprevalence and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin. Germany. Vaccine 1999; 17:844-850.
302. McQuillan G.M., Kruszon-Moran D., Deforest A., et al: Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136:660-666.
303. Gidding H.F., Backhouse J.L., Burgess M.A., et al: Immunity to diphtheria and tetanus in Australia: a national serosurvey. Med J Aust 2005; 183:301-304.
304. Manga N.M., Dia N.M., Ndour C.T., et al: Tétanos néonatal et de la femme en âge de procréer à la clinique des maladies infectieuses de Dakar. Tetanus in neonates and women of child-bearing age in the Dakar hospital infectious diseases unit. Med Mal Infect 2009; 39:901-905.
305. Marshall F.N.: Tetanus of the newborn: with special reference to experiences in Haiti, W. I. Adv Pediatr 1968; 15:65-110.
306. Adams J.M., Kenny J.D., Rudolph A.J.: Modern management of tetanus neonatorum. Pediatrics 1979; 64:472-477.
307. Hinman A.R., Foster S.O., Wassilak S.GF.: Neonatal tetanus: potential for elimination in the USA and the world. Pediatr Infect Dis 1987; 6:813-816.
308. Stride P.: St Kilda, the neonatal tetanus tragedy of the nineteenth century and some twenty-first century answers. J R Coll Physicians Edinb 2008; 38:70-77.
309. Berggren W.L.: Administration and evaluation of rural health services, I: a tetanus control program in Haiti. Am J Trop Med Hyg 1974; 23:936-949.
310. Schofield F.D., Tucker V.M., Westbrook G.R.: Neonatal tetanus in New Guinea: effect of active immunization in pregnancy. Br Med J 1961; 5255:785-789.
311. Newell K.W., Dueñas Lehman A., LeBlanc D.R., et al: The use of toxoid for the prevention of tetanus neonatorum: final report of a double-blind controlled field trial. Bull World Health Organ 1966; 35:863-871.
312. Christensen P.E.: Comments on epidemiology and immunology of tetanus in Denmark. Third International Conference on Tetanus, 1970:27-30.Sao Paulo, Brazil;
313. World Health Organization : Validation of elimination of neonatal tetanus in Turkey by lot quality assurance cluster sampling. Wkly Epidemiol Rec 2009; 84:141-146.
314. Leroy O., Garenne M.: Risk factors of neonatal tetanus in Senegal. Int J Epidemiol 1991; 20:521-526.
315. Hlady W.G., Bennett J.V., Samadi A.R., et al: Neonatal tetanus in rural Bangladesh: risk factors and toxoid efficacy. Am J Public Health 1992; 82:1365-1369.
316. Quddus A., Luby S., Rahbar M., et al: Neonatal tetanus: mortality rate and risk factors in Loralai District, Pakistan. Int J Epidemiol 2002; 31:648-653.
317. Jagetiya P., Bhandari B.: Analysis of tetanus neonatorum cases admitted in a hospital during 1976–1977. Indian J Public Health 1979; 23:103-105.
318. Hamid E.D., Daulay A.P., Lubis C.P., et al: Tetanus neonatorum in babies delivered by traditional birth attendants in Medan, Indonesia. Paediatr Indones 1985; 25:167-174.
319. Cliff J.: Neonatal tetanus in Maputo, Mozambique, I: hospital incidence and childbirth practices. Cent Afr J Med 1985; 31:9-12.

320. Traverso H.D., Bennett J.V., Kahn A.J., et al: Ghee application to the umbilical cord: a risk factor for tetanus. Lancet 1989; 1:486-488.
321. Bennett J., Azhar , Rahim F., et al: Further observations on ghee as a risk factor for tetanus. Int J Epidemiol 1995; 24:643-647.
322. Bennett J., Schooley M., Traverso H., et al: Bundling, a newly identified risk factor for neonatal tetanus: implications for global control. Int J Epidemiol 1996; 25:879-884.
323. Roison A.J., Prazuch T., Tall F., et al: Risk factor for neonatal tetanus in west Burkina Faso: a case-control study. Eur J Epidemiol 1996; 12:535-537.
324. Eregie C.O.: Epidemiological factors associated with neonatal tetanus mortality: observations from a cluster survey in Nigeria. East Afr Med J 1993; 70:434-437.
325. Melgaard B., Mutie D.M., Kimani G.: A cluster survey of mortality due to neonatal tetanus in Kenya. Int J Epidemiol 1988; 17:174-177.
326. Meegan M.E., Conroy R.M., Lengeny S.O., et al: Effect on neonatal tetanus mortality after a culturally based health promotion programme. Lancet 2001; 358:640-641.
327. Mull D.S., Anderson J.W., Mull J.D.: Cow dung, rock salt, and medical innovation in the Hindu Kush of Pakistan: the cultural transformation of neonatal tetanus and iodine deficiency. Soc Sci Med 1990; 30:675-691.
328. Smucker C.M., Simmons G.B., Bernstein S., et al: Neo-natal mortality in South Asia: the special role of tetanus. Popul Stud (Camb) 1980; 34:321-335.
329. Asekun-Olarinmoye E.O., Lawoyin T.O., Onadeko M.O.: Risk factors for neonatal tetanus in Ibadan. Nigeria. Eur J Pediatr 2003; 162:526-527.
330. Bennett J., Ma C., Traverso H., et al: Neonatal tetanus associated with topical umbilical ghee: covert role of cow dung. Int J Epidemiol 1999; 28:1172-1175.
331. Baltazar J.C., Sarol J.N.: Prenatal tetanus immunization and other practices associated with neonatal tetanus. Southeast Asian J Trop Med Public Health 1994; 25:132-138.
332. Eregie C.O.: Uvulectomy as an epidemiological factor in neonatal tetanus mortality: observations from a cluster survey. West Afr J Med 1994; 13:56-58.
333. Bennett J., Breen C., Traverso H., et al: Circumcision and neonatal tetanus: disclosure of risk and its reduction by topical antibiotics. Int J Epidemiol 1999; 28:263-266.
334. Rahman S.: The effect of traditional birth attendants and tetanus toxoid in reduction of neonatal mortality. J Trop Pediatr 1982; 28:163-165.
335. Berggren G.G., Verly A., Garnier N., et al: Traditional midwives, tetanus immunization, and infant mortality in rural Haiti. Trop Doct 1983; 13:79-87.
336. Kessel E.: Strategies for the control of neonatal tetanus. J Trop Pediatr 1984; 30:145-149.
337. Stroh G., Kyu U.A., Thaung U., et al: Measurement of mortality from neonatal tetanus in Burma. Bull World Health Organ 1988; 66:141.Bull World Health Organ 65:309–316, 1987. Erratum:
338. Traverso H., Kamil S., Rahim H., et al: A reassessment of risk factors for neonatal tetanus. Bull World Health Organ 1991; 69:573-579.
339. Parashar U.D., Bennett J., Boring J.R., et al: Topical antimicrobials applied to the umbilical cord stump: a new intervention against neonatal tetanus. Int J Epidemiol 1998; 27:904-908.
340. Bennett J., Macia J., Traverso H., et al: Protective effects of topical antimicrobials against neonatal tetanus. Int J Epidemiol 1997; 26:897-903.
341. Mullany L.C., Darmstadt G.L., Khatry S.K., et al: Topical applications of chlorhexidine to the umbilical cord for prevention of omphalitis and neonatal mortality in southern Nepal: a community-based, cluster-randomised trial. Lancet 2006; 367:910-918.

342. Blencowe H., Cousens S., Mullany L.C., et al: Clean birth and postnatal care practices to reduce neonatal deaths from sepsis and tetanus: a systematic review and Delphi estimation of mortality effect. BMC Public Health 2011; 1(suppl 3):S11.
343. Chahnazarian A.: Determinants of the sex ratio at birth: review of recent literature. Soc Biol 1988; 35:214-235.
344. Chai F., Prevots D.R., Wang X., et al: Neonatal tetanus incidence in China, 1996–2001, and risk factors for neonatal tetanus, Guangxi Province. China. Int J Epidemiol 2004; 33:551-557.
345. Oudesluys-Murphy A.M.: Umbilical cord care and neonatal tetanus [letter]. Lancet 1989; 1:843.
346. Ruben F.L., Nagel J., Fireman P.: Antitoxin responses in the elderly to tetanus-diphtheria (Td) immunization. Am J Epidemiol 1978; 108:145-149.
347. Crossley K., Irvine P., Warren B., et al: Tetanus and diphtheria immunity in urban Minnesota adults. JAMA 1979; 242:2298-2300.
348. Weiss B.P., Strassburg M.A., Feeley J.C.: Tetanus and diphtheria immunity in an elderly population in Los Angeles County. Am J Public Health 1983; 73:802-804.
349. Stair T.O., Lippe M.A., Russell H., et al: Tetanus immunity in emergency department patients. Am J Emerg Med 1989; 7:563-566.
350. Gergen P.J., McQuillan G.M., Kiely M., et al: A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332:761-766.
351. Koblin B.A., Townsend T.R.: Immunity to diphtheria and tetanus in inner-city women of childbearing age. Am J Public Health 1989; 79:1297-1298.
352. Talan D.A., Abrahamian F.M., Moran G.J., et al: Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. Ann Emerg Med 2004; 43:305-314.
353. Jacobs D.H., Tovar J.M., Hung O.L., et al: Behavioral risk factor and preventive health care practice survey of immigrants in the emergency department. Acad Emerg Med 2002; 9:599-608.
354. Henderson S.O., Mody T., Growth D.E., et al: The presentation of tetanus in an emergency department. J Emerg Med 1998; 16:705-708.
355. Alagappan K., McGowan J., DeClaro D., et al: Tetanus antibody protection among HIV-infected US-born patients and immigrants. Int J Emerg Med 2008; 1:123-126.
356. Alagappan K., Park R., Naderi S., et al: Evaluation for tetanus antibodies in Korean-Americans living in the New York area: a pilot study. J Immigr Minor Health 2009; 11:105-107.
357. National Center for Health Statistics. National Health Interview Survey, 1998, 1999, and 2000. http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm , accessed April 2012.
358. Can modified tetanus occur? [editorial]. N Engl J Med 1962; 266:1117-1118.
359. McComb J.A.: Tetanus in a previously immunized person [letter]. N Engl J Med 1965; 273:452-453.
360. Luisto M., Iivananinen M.: Tetanus in immunized children. Dev Med Child Neurol 1993; 35:351-355.
361. Centers for Disease Control and Prevention : Tetanus: Puerto Rico, 2002. MMWR 2002; 51:613-615.
362. Kumar S., Malecki J.M.: A case of neonatal tetanus. South Med J 1991; 84:396-398.
363. Craig A.S., Reed G.W., Mohon R.T., et al: Neonatal tetanus in the United States: a sentinel event in the foreign-born. Pediatr Infect Dis J 1997; 16:955-959.
364. Centers for Disease Control and Prevention : Neonatal tetanus: Montana, 1998. MMWR 1998; 47:928-930.

365. Borrow R., Balmer P., Roper M.H.: The immunologic basis for immunization: module 3: tetanus, Geneva, World Health Organization, 2007. (update 2006; revision of Galazka's 1st ed). (WHO/EPI/GEN/93.13).
366. Ray S.N., Ray K., Grover S.S.: Sero-survey of diphtheria and tetanus antitoxin. Indian J Med Res 1978; 68:901-904.
367. Dastur F.D., Awatramani V.P., Dixit S.K.: Response to single dose of tetanus vaccine in subjects with naturally acquired tetanus antitoxin. Lancet 1981; 2:219-222.
368. Veronesi R., Bizzini B., Focaccia R., et al: Naturally acquired antibodies to tetanus toxin in humans and animals from the Galapagos Islands. J Infect Dis 1983; 147:308-311.
369. Matzkin H., Regev S.: Naturally acquired immunity to tetanus toxin in an isolated community. Infect Immun 1985; 48:267-268.
370. Veronesi R.: Naturally acquired tetanus immunity: still a controversial theme?. In: Nistico G., Mastroeni P., Pitzurra M., ed. Proceedings of the Seventh International Conference on Tetanus, Rome: Gangeni; 1985:365-372.Copanello, Italy; September 10–15, 1984
371. Leshem Y., Herman J.: Tetanus immunity in kibbutz women. Isr J Med Sci 1989; 25:127-130.
372. Newell K.W., LeBlank D.R., Edsall G., et al: The serological assessment of a tetanus toxoid field trial. Bull World Health Organ 1971; 45:773-785.
373. Smith J.WG.: Tetanus. In: Wilson G., Miles A., Parker M.T., ed. Topley and Wilson's Principles of Bacteriology, Virology and Immunity, Vol. 3. Baltimore: Williams & Wilkins; 1984:345-368.7th ed
374. Rubbo S.D., Suri J.C.: Passive immunization against tetanus with human immune globulin. Br Med J 1962; 2:79-81.
375. Pope C.G.: Development of knowledge of antitoxins. Br Med Bull 1963; 19:230-234.
376. Lang J., Kamga-Fotso L., Peyrieux J.C., et al: Safety and immunogenicity of a new equine tetanus immunoglobulin associated with tetanus-diphtheria vaccine. Am J Trop Med Hyg 2000; 63:298-305.
377. Reisman R.E., Rose N.R., Witebsky E., et al: Serum sickness, II: demonstration and characteristics of antibodies. J Allergy 1961; 32:531-543.
378. Suri J.C., Rubbo S.D.: Immunization against tetanus. J Hyg (Camb) 1961; 59:29-48.
379. McComb J.A.: The prophylactic dose of homologous tetanus antitoxin. N Engl J Med 1964; 270:175-178.
380. Wilde H., Thipkong P., Sitprija V., et al: Heterologous antisera and antivenoms are essential biologicals: perspectives on a worldwide crisis. Ann Intern Med 1996; 125:233-236.
381. Smith J.WG., Evans D.G., Jones D.A., et al: Simultaneous active and passive immunization against tetanus. Br Med J 1963; 1:237-238.
382. Eckmann L.: Active and passive immunization. N Engl J Med 1964; 271:1087-1091.
383. Smith J.WG.: Simultaneous active and passive immunization of guinea-pigs against tetanus. J Hyg (Camb) 1964; 62:379-388.
384. Levine L., McComb J.A., Dwyer R.C., et al: Active-passive tetanus immunization. N Engl J Med 1966; 274:186-190.
385. Sesardic D., Wong M.Y., Gaines Das R.E., et al: The first international standard for Antitetanus Immunoglobulin, Human: pharmaceutical evaluation and international collaborative study. Biologicals 1993; 21:67-75.
386. Ramon G., Zoeller C.: L'anatoxine tetanique et l'immunisation active de l'homme vis-à-vis du tetanos. Ann Inst Pasteur 1927; 41:808-825.
387. De Luca M.M., Basualdo J.A., Bernagozzi J.A., et al: Nitrogen-gas bubbling during the cultivation of Clostridium tetani produces a higher yield of tetanus toxin for the preparation of its toxoid. Microbiol Immunol 1997; 41:161-163.

387a. WHO : Production and control of tetanus vaccine: Module 3, principles of tetanus vaccine production. (WHO/VSQ/94.4). Geneva; World Health Organization. accessed April 6, 2012 http://whqlibdoc.who.int/hq/1994/WHO_VSQ_GEN_94.4.pdf 1994
388. WHO Expert Committee on Biological Standardization : International Standards for Tetanus Vaccine (Adsorbed), Geneva, World Health Organization, 1965. (WHO/BS/66.839)
389. Pitman M., Kolb R.W., Barile M.F., et al: Immunization against neonatal tetanus in New Guinea, 5: laboratory assayed potency of tetanus toxoids and relationship to human antitoxin response. Bull World Health Organ 1970; 43:469-478.
390. Hardegree M.C., Pittman M., Maloney C.J.: Influence of mouse strain on the assayed potency (unitage) of tetanus toxoid. Appl Microbiol 1972; 24:120-126.
391. Lyng J., Nyerges G.: The second international standard for Tetanus Toxoid (Adsorbed). J Biol Stand 1984; 12:121-130.
392. Hardegree M.C., Fornwald R.E., Farber J., et al: Titration of tetanus toxoids in international units: relationship to antitoxin responses of rhesus monkeys. In: Mérieux C., ed. Proceedings of the Sixth International Conference on Tetanus, Lyon: Collection Foundation Mérieux; 1981:409-424.Lyon, France; December 3–5, 1981
393. Sasardic D., Winsness R., Rigsby P., et al: Calibration of replacement international standard and European Pharmacopoeia Biological Reference preparation for Tetanus Toxoid. Adsorbed. Biologicals 2002; 30:49-68.
394. Rob Tierney R., Hockley J., Rigsby P., et al: 2010.(WHO/BS/10.2150.)accessed April 5, 2012 http://whqlibdoc.who.int/hq/2010/WHO_BS_10.2150_eng.pdf
395. Manahilov R., Solomonova K.: Evaluation of the quality of tetanus toxoid preparations. In: Nistico G., Bizzini B., Bytchenko M., et al ed. Eighth International Conference on Tetanus, Rome: Pythagora Press; 19871989:235-237.Leningrad, USSR; August 25–28
396. World Health Organization : Requirements for diphtheria, tetanus, pertussis and combined vaccines, Geneva, WHO, 1990. WHO Technical Report Series, no. 800, annex 2
397. World Health Organization : Recommendations for diphtheria, tetanus, pertussis and combined vaccines (amendments 2003), Geneva, WHO, 2005. WHO Technical Report Series, no. 927, annex 5.
398. World Health Organization : Tetanus Vaccine: WHO position paper. Wkly Epidemiol Rec 2006; 81:198-208.
399. Bizzini B.: The chemistry of tetanus toxin as a basis for understanding its immunological and biological activities. In: Nistico G., Mastroeni P., Pitzurra M., ed. Proceedings of the Seventh International Conference on Tetanus, Rome: Gangeni; 1985:11-28.Copanello, Italy; September 10–15,1984
400. Dietz V., Milstien J.B., van Loon F., et al: Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. Bull World Health Organ 1996; 74:619-628.
401. World Health Assembly : Resolution 45.17: Immunization and vaccine quality, 1992. Handbook of Resolutions and Decisions of the World Health Assembly and the Executive Board (1985–1992), Vol. 3. 3 rd ed. Geneva: WHO; 1993.
402. Hardegree M.C., Barile M.F., Pittman M., et al: Immunization against neonatal tetanus in New Guinea, 2: duration of primary antitoxin responses to adjuvant tetanus toxoids and comparison of booster responses to adjuvant and plain toxoids. Bull World Health Organ 1970; 43:439-451.
403. Dhillon H., Menon P.S.: Active immunization of women in pregnancy with two injections of absorbed tetanus toxoid for prevention of tetanus neonatorum in Punjab India. Indian J Med Res 1975; 63:583-589.
404. Black R.E., Huber D.H., Curlin G.T.: Reduction of neonatal tetanus by mass immunization of non-pregnant women: duration of protection provided by one or two doses of aluminum-adsorbed tetanus toxoid. Bull World Health Organ 1980; 58:927-930.

405. Rahman M., Chen L.C., Chakraborty J., et al: Use of tetanus toxoid for the prevention of neonatal tetanus, 1: reduction of neonatal mortality by immunization of non-pregnant and pregnant women in rural Bangladesh. Bull World Health Organ 1982; 60:261-267.
406. Chen S.T., Edsall G., Peel M.M., et al: Timing of antenatal tetanus immunization for effective protection of the neonate. Bull World Health Organ 1983; 61:159-163.
407. Owa J.A., Makinde O.O.: Neonatal tetanus in babies of women immunized with tetanus toxoid during pregnancy. Trop Doct 1990; 20:156-157.
408. Ghosh J.B.: Prevention of tetanus neonatorum [letter]. Indian Pediatr 1990; 27:210.
409. Deivanayagam N., Nedunchelian K., Kamala K.G.: Neonatal tetanus: observations on antenatal immunization, natal and immediate post-natal factors. Indian J Pediatr 1991; 58:119-122.
410. Bjerregaard P., Steinglass R., Mutie D.M., et al: Neonatal tetanus mortality in coastal Kenya: a community survey. Int J Epidemiol 1993; 22:163-169.
411. World Health Organization. Immunizations standards: vaccine quality: WHO prequalified vaccines. http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html , accessed April 5, 2012.
412. McCarroll J.R., Abrahams I., Skudder P.A.: Antibody response to tetanus toxoid 15 years after initial immunization. Am J Public Health 1962; 52:1669-1675.
413. Centers for Disease Control and Prevention. Diphtheria, tetanus and pertussis: guidelines for vaccine prophylaxis and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40(RR-10):1-28.
414. Centers for Disease Control and Prevention : Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-7):1-25.
415. Centers for Disease Control and Prevention : Preventing tetanus, diphtheria and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-3):1-43.
416. Centers for Disease Control and Prevention : FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR 2009; 58:374-375.
417. Centers for Disease Control and Prevention : Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR 2011; 60:13-15.
418. Jones F.G., Moss J.M.: Studies on tetanus toxoid, I: the antitoxic titer of human subjects following immunization with tetanus toxoid and tetanus alum precipitated toxoid. J Immunol 1936; 30:115-125.
419. MacLennan R., Schofield F.D., Pittman M., et al: Immunization against neonatal tetanus in New Guinea: antitoxin response of pregnant women to adjuvant and plain toxoids. Bull World Health Organ 1965; 32:683-697.
420. MacLennan R., Levine L., Newell K.W., et al: The early primary immune response to absorbed tetanus toxoid in man: a study of the influence of antigen concentration, carrier concentration, and sequence of dosage on the rate, extent, and persistence of the immune response to one and to two doses of toxoid. Bull World Health Organ 1973; 49:615-626.
421. Gottlieb S., McLaughlin F.X., Levine L., et al: Long-term immunity to tetanus: a statistical evaluation and its clinical implications. Am J Public Health 1964; 54:961-971.
422. Mahoney L.J., Aprile M.A., Moloney P.J.: Combined active-passive immunization against tetanus in man. Can Med Assoc J 1967; 96:1401-1404.

423. Relyveld E., Bengounia A., Huet M., et al: Antibody response of pregnant women to two different adsorbed tetanus toxoids. Vaccine 1991; 9:369-372.
424. Vassilev T.L.: Aluminum phosphate but not calcium phosphate stimulates the specific IgE response in guinea-pigs to tetanus toxoid. Allergy 1978; 33:155-159.
425. Kielmam A.A., Vohra S.R.: Control of tetanus neonatorum in rural communities: immunization effects of high-dose calcium phosphate-adsorbed tetanus toxoid. Indian J Med Res 1977; 66:906-916.
426. Relyveld E.H., Bizzini B., Gupta R.K.: Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998; 16:1016-1023.
427. Kumar V., Sahai G., Kumar A.: Studies on the stability of tetanus and pertussis components of DTP vaccine on exposure to different temperatures. Indian J Pathol Microbiol 1982; 23:50-54.
428. Expanded Programme on Immunisation : The effects of freezing on the appearance, potency and toxicity of adsorbed and unadsorbed DPT vaccines. Wkly Epidemiol Rec 1980; 55:385-390.
429. Expanded Programme on Immunisation : The effects of freezing on the appearance, potency and toxicity of adsorbed and unadsorbed DPT vaccines. Wkly Epidemiol Rec 1980; 55:396-398.
430. Menon P.S., Sahai G., Joshi V.B., et al: Field trial on frozen and thawed tetanus toxoid. Indian J Med Res 1976; 64:25-32.
431. Dietz V., Galazka A., van Loon F., et al: Factors affecting the immunogenicity and potency of tetanus toxoid: implications for the elimination of neonatal and non-neonatal tetanus as public health problems. Bull World Health Organ 1997; 75:81-93.
432. Galazka A., Milstien J., Zaffran M.: Thermostability of vaccines, Geneva, World Health Organization, 1998. (WHO/GPV/98.07)
433. Milstein J.B.: Temperature sensitivity of vaccines, Geneva, World Health Organization, 2006. (WHO/IVB/06.10).accessed April 5, 2012
http://whqlibdoc.who.int/hq/2006/WHO_IVB_06.10_eng.pdf
434. Schatz D., Ellis T., Ottendorfer E., et al: Aging and the immune response to tetanus toxoid: diminished frequency and level of cellular immune reactivity to antigenic stimulation. Clin Diagn Lab Immunol 1998; 5:894-896.
435. Borut T.C., Ank B.J., Gard S.E., et al: Tetanus toxoid skin test in children: correlation with in vitro lymphocyte stimulation and monocyte chemotaxis. J Pediatr 1980; 97:567-573.
436. Johnson C., Walls R.S., Ruwoldt A.: Delayed hypersensitivity to tetanus toxoid in man: in vivo and in vitro studies. Pathology 1983; 15:369-372.
437. Delafuente J.C., Eisenberg J.D., Hoelzer D.R., et al: Tetanus toxoid as an antigen for delayed cutaneous hypersensitivity. JAMA 1983; 249:3209-3211.
438. Kaufman D.B., deMendonca W.C., Newton J.: Diphtheria-tetanus skin testing. Am J Dis Child 1980; 134:479-483.
439. Edsall G.: Problems in the immunology and control of tetanus. Med J Aust 1976; 2:216-220.
440. Barile M.F., Hardegree M.C., Pittman M.: Immunization against neonatal tetanus in New Guinea, 3: the toxin-neutralization test and the response of guinea-pigs to the toxoids as used in the immunization schedules in New Guinea. Bull World Health Organ 1970; 43:453-459.
441. Christiansen G.: Quantification of tetanus antitoxin by toxin neutralization test in mice: a comparison between lethal and paralytic techniques. J Biol Stand 1981; 9:453-460.
442. Marconi P., Pitzurra M., Bistoni F.: Passive hemagglutination as the reference method for evaluation of tetanus immunity. In: Nistico G., Mastroeni P., Pitzurra M., ed. Proceedings of the Seventh International Conference on Tetanus, Rome: Gangeni; 1985:259-273.Copanello, Italy; September 10–15, 1984.

443. Hardegree M.C., Barile M.F., Pittman M., et al: Immunization against neonatal tetanus in New Guinea, 4: comparison of tetanus antitoxin titers obtained by haemagglutination and toxin neutralization in mice. Bull World Health Organ 1970; 43:461-468.
444. Winsnes R., Christiansen G.: Quantification of tetanus antitoxin in human sera, II: comparison of counter-immunoelectrophoresis and passive haemagglutination with toxin neutralisation in mice. Acta Pathol Microbiol Scand B 1979; 87:197-200.
445. Peel M.M.: Measurement of tetanus antitoxin, I: indirect haemagglutination. J Biol Stand 1980; 8:177-189.
446. Pitzurra L., Bistoni M., Pitzurra L., et al: Comparison of passive haemagglutination with turkey erythrocyte assay, enzyme-linked immunosorbent assay and counter immunoelectrophoresis assay for serological evaluation of tetanus immunity. J Clin Microbiol 1983; 17:432-435.
447. Gupta R.K., Maheshwari S.C., Singh H.: The titration of tetanus antitoxin, I: factors affecting the sensitivity of the indirect haemagglutination test. J Biol Stand 1984; 12:11-17.
448. Gupta R.K., Maheshwari S.C., Singh H.: The titration of tetanus antitoxin, II: a comparative evaluation of the indirect haemagglutination and toxin neutralization tests. J Biol Stand 1984; 12:137-143.
449. Ourth P.P., MacDonald A.B.: Neutralization of tetanus toxin by human and rabbit immunoglobulin classes and subunits. Immunology 1977; 3:807-815.
450. Melville-Smith M.E., Seagroatt V.A., Watkins J.T.: A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137-144.
451. Cox J.C., Permier R.R., Finger W., et al: A comparison of enzyme immunoassay and bioassay for the quantitative determination of antibodies to tetanus toxin. J Biol Stand 1983; 11:123-128.
452. Sedgwick A.K., Ballow M., Sparks K., et al: Rapid quantitative micro-enzyme-linked immunosorbent assay for tetanus antibodies. J Clin Microbiol 1983; 18:104-109.
453. Hagenaars A.M., van Delft R.W., Nagel J.: Comparison of ELISA and toxin neutralization for the determination of tetanus antibodies. J Immunoassay 1984; 5:1-11.
454. Simonsen O., Bentzon M.W., Heron I.: ELISA for the routine determination of antitoxic immunity to tetanus. J Biol Stand 1986; 14:231-239.
455. Virella G., Hyman B.: Quantitation of anti-tetanus and anti-diphtheria antibodies by enzymoimmunoassay: methodology and applications. J Clin Lab Anal 1991; 5:43-48.
456. Dokmetjian J., Della Valle C., Lavigne V., et al: A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin. Vaccine 2000; 18:2698-2703.
457. Simonsen O., Schou C., Heron I.: Modification of the ELISA for the estimation of tetanus antitoxin in human sera. J Biol Stand 1987; 15:143-157.
458. US Food and Drug Administration : Biological products: bacterial vaccines and toxoids: implementation of efficacy review. Fed Reg 1985; 50:51002-51117.
459. Vernacchio L., Madico G., Verastegui M., et al: Neonatal tetanus in Peru: risk assessment with modified enzyme-linked immunosorbent assay and toxoid skin test. Am J Public Health 1993; 83:1754-1756.
460. Hendriksen C.FM., van der Gun J.W., Kreeftenberg J.G.: The toxin-binding inhibition test as a reliable in vitro alternative to the toxin neutralization test in mice for the estimation of tetanus antitoxin in human sera. J Biol Stand 1988; 16:287-297.
461. Hendriksen C.FM., van der Gun J.W., Kreeftenberg J.G.: Combined estimation of tetanus and diphtheria antitoxin in human sera by the in vitro toxin-binding inhibition (ToBi) test. J Biol Stand 1989; 17:191-200.

462. Hong H.A., Ke N.T., Nhon T.N., et al: Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Vietnam. Bull World Health Organ 1996; 74:275-282.
463. Kristiansen M., Aggerbeck H., Heron I.: Improved ELISA for determination of anti-diphtheria and/or anti-tetanus antitoxin antibodies in sera. APMIS 1997.843-853.
464. Caglar K., Karakus R., Aybay C.: Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups. Eur J Clin Microbiol Infect Dis 2005; 24:523-528.
465. Olander R.M., Auranen K., Härkänen T., et al: High tetanus and diphtheria antitoxin concentrations in Finnish adults: time for new booster recommendations?. Vaccine 2009; 27:5295-5298.
466. Deming M.S., Roungou J-B., Kristiansen M., et al: Tetanus toxoid coverage as an indicator of serological protection against neonatal tetanus. Bull World Health Organ 2002; 80:696-703.
467. Bonetti T.C., Succi R.C., Weckx L.Y., et al: Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004; 22:3707-3712.
468. Viana P.O., Ono E., Miyamoto M., et al: Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen. J Clin Immunol 2010; 30:574-582.
468a. Tapia M.D., Pasetti M.F., Cuberos L., et al: Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys. Pediatr Infect Dis J 2006; 25:819-825.
469. Yuan L., Lau W., Thipphawong J., et al: Diphtheria and tetanus immunity among blood donors in Toronto. CMAJ 1997; 156:985-990.
470. Smith J.WG.: Diphtheria and tetanus toxoids. Br Med Bull 1969; 25:177-182.
471. Sneath P.AT., Kerlake E.G., Sruby F.: Tetanus immunity: resistance of guinea pigs to lethal spore doses induced by active and passive immunization. Am J Hyg 1937; 25:464-476.
472. Looney J.M., Edsall G., Ipsen J., et al: Persistence of antitoxin levels after tetanus-toxoid inoculation in adults, and effect of a booster dose after various intervals. N Engl J Med 1956; 254:6-12.
473. Wolters K.L., Dehmel H.: Abschliessende Untersuchungen über die Tetanusprophylaxe durch aktive Immunisierung. Z Hyg 1942; 124:326-332.
474. Long A.P., Sartwell P.E.: Tetanus in the U.S. Army in World War II. Bull US Army Med Dept 1947; 7:371-385.
475. Kumar V., Kumar R., Mathur V.N., et al: Neonatal tetanus mortality in a rural community of Haryana. Indian Pediatr 1986; 25:167-169.
476. Maru M., Geahun A., Hosana S.: A house-to-house survey on neonatal tetanus in urban and rural areas in the Gondar region Ethiopia. Trop Geogr Med 1986; 40:233-236.
477. Expanded Programme on Immunization : Neonatal tetanus mortality surveys, Egypt. Wkly Epidemiol Rec 1987; 62:332-335.
478. Cardenas Ayala V.M., Nunez Urquiza R.M., Brogan D.R., et al: Neonatal tetanus mortality in Veracruz, Mexico, 1989. Bull Pan Am Health Organ 1995; 29:116-128.
479. Yusuf B., Solter S., Bertsch D., et al: Impact of a tetanus toxoid immunization mass campaign on neonatal tetanus mortality in Aceh Province. Indonesia. Southeast Asian J Trop Med Public Health 1991; 22:351-356.
480. Arnold R.B., Soewarso T.I., Karyadi A.: Mortality from neonatal tetanus in Indonesia: results of two surveys. Bull World Health Organ 1986; 64:259-262.
481. Blencowe H., Lawn J., Vandelaer J., et al: Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol 2010; 39:1102-1109.
482. Gendrel D., Richard-Lenoble D., Massamba M.B., et al: Placental transfer of tetanus antibodies and protection of the newborn. J Trop Pediatr 1990; 36:279-282.

483. Madico G., Salazar G., McDonald J., et al: Rates of tetanus protection and transplacental tetanus antibody transfer in pregnant women from different socioeconomic groups in Peru. Clin Diagn Lab Immunol 1996; 3:753-755.
484. de Moraes-Pinto M.I., Almeida A.C., Kenj G., et al: Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis 1996; 173:1077-1084.
485. Brair M.E., Brabin B.J., Milligan P., et al: Reduced transfer of tetanus antibodies with placental malaria. Lancet 1994; 343:208-209.
486. Okoko J.B., Wesumperuma H.L., Hart C.A.: The influence of prematurity and low birthweight on transplacental antibody transfer in a rural West African population. Trop Med Int Health 2001; 6:529-534.
487. Cumberland P., Shulman C.E., Maple P.A., et al: Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis 2007; 196:550-557.
488. Jones C.E., Naidoo S., De Beer C., et al: Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA 2011; 305:576-584.
489. van den Berg J.P., Westerbeek E.A., Berbers G.A., et al: Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, Haemophilus influenzae type b, and Neisseria meningitides serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J 2011; 29:801-805.
490. Press E.: Desirability of the routine use of tetanus toxoid. N Engl J Med 1948; 239:50-56.
491. Centers for Disease Control. Immunization schedules. http://www.cdc.gov/vaccines/recs/schedules/default.htm , accessed April 5, 2012.
492. Centers for Disease Control and Prevention : General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002; 51(RR-2):1-36.
493. World Health Organization. Recommendations for routine immunization: summary tables. http://www.who.int/immunization/policy/immunization_tables/en/index.html , accessed April 5, 2012.
494. Ramsay M.E., Corbel M.J., Redhead K., et al: Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine. BMJ 1991; 302:1489-1491.
495. World Health Organization. WHO Vaccine Preventable Diseases Monitoring System: immunization schedules by antigen. http://apps.who.int/immunization_monitoring/en/globalsummary/scheduleselect.cfm , accessed April 5, 2012.
496. Expanded Programme on Immunization : Global Advisory Group. Wkly Epidemiol Rec 1985; 60:13-16.
497. Cooke J.V., Holowach J., Atkins J.E., et al: Antibody formation in early infancy against diphtheria and tetanus toxoids. J Pediatr 1948; 33:141-146.
498. Barrett C.D., McLeon I.W., Molner J.G., et al: Multiple antigen immunization of infants against poliomyelitis, diphtheria, pertussis and tetanus: an evaluation of antibody responses of infants one day old to seven months of age at start of inoculations. Pediatrics 1962; 30:720-736.
499. Di Sant'Agnese P.A.: Combined immunization against diphtheria, tetanus, and pertussis in newborn infants, I: production of antibodies in early infancy. Pediatrics 1949; 3:20-33.
500. Di Sant'Agnese P.A.: Combined immunization against diphtheria, tetanus, and pertussis in newborn infants, III: relationship of age to antibody production. Pediatrics 1949; 3:333-344.

501. Di Sant'Agnese P.A.: Simultaneous immunization of newborn infants against diphtheria, tetanus, and pertussis: production of antibodies and duration of antibody levels in an eastern metropolitan area. Am J Public Health 1950; 40:674-680.
502. Bernbaum J.C., Daft A., Anolik R., et al: Response of preterm infants to diphtheria-tetanus-pertussis immunizations. J Pediatr 1985; 107:184-188.
503. Barr M., Glenny A.T., Butler N.R.: Immunization of babies with diphtheria-tetanus-pertussis prophylactic. Br Med J 1955; 2:635-639.
504. Di Sant'Agnese P.A.: Combined immunization against diphtheria, tetanus, and pertussis in newborn infants, II: duration of antibody levels; antibody titers after booster dose; effect of passive immunity to diphtheria on active immunization with diphtheria toxoid. Pediatrics 1949; 13:181-194.
505. Peterson J.C., Christie A.: Immunization in the young infant: response to combined vaccines, VI: tetanus. Am J Dis Child 1951; 81:518-529.
506. Halsey N.A., Galazka A.: The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull World Health Organ 1985; 63:1151-1169.
507. Barkin R.M., Samuelson J.S., Gotlin L.P.: DTP reactions and serologic response with a reduced dose schedule. J Pediatr 1984; 105:189-194.
508. Barkin R.M., Pichichero M.E., Samuelson J.S., et al: Pediatric diphtheria and tetanus toxoids vaccine: clinical and immunologic response when administered as the primary series. J Pediatr 1985; 106:779-781.
509. Edwards K.M., Meade B.D., Decker M.D., et al: Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96:548-557.
510. Kutukculer N., Kurugol Z., Egemen A., et al: The effect of immunization against tetanus during pregnancy for protective antibody titres and specific antibody responses of infants. J Trop Pediatr 1996; 42:308-309.
511. Habig W.H., Tankersley D.L.: Tetanus. In: Cryz S.J., ed. Vaccines and Immunotherapy, New York: Pergamon Press; 1991:13-19.
512. Booy R., Aitken S.JM., Taylor S., et al: Immunogenicity of combined diphtheria, tetanus, pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 1992; 339:505-510.
513. Nohynek H., Gustafsson L., Capeding M.R., et al: Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b–tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Pediatr Infect Dis J 1999; 18:25-30.
514. Ramsay M.EB., Rao M., Begg N.T., et al: Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine. Lancet 1993; 342:203-205.
515. Brown G.C., Volk V.K., Gottshall R.Y., et al: Responses of infants to DTP-P vaccine used in nine injection schedules. Public Health Rep 1964; 79:585-602.
516. Breman J.G., Wright G.G., Levine L., et al: The primary serologic response to a single dose of adsorbed tetanus toxoid, high concentration type. Bull World Health Organ 1981; 59:745-752.
517. Stanfield J.P., Gall D., Bracken P.M.: Single-dose antinatal tetanus immunisation. Lancet 1973; 1:215-219.
518. Agarwal K., Pandit K., Kannan A.T.: Single dose tetanus toxoid: a review of trials in India with special reference to control of tetanus neonatorum. Indian J Pediatr 1984; 81:283-285.
519. Dick G.: Combined vaccines. Can J Public Health 1966; 57:435-446.
520. Someya S., Mizuhara H., Murata R., et al: Studies on the adequate composition of diphtheria and tetanus toxoids with reference to the amounts of toxoids and aluminum adjuvant. Jpn J Med Sci Biol 1981; 34:21-35.

521. Ruben F.L., Smith E.A., Foster S.O., et al: Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children. Bull World Health Organ 1973; 48:175-181.
522. Miller J.J., Saito T.M.: Concurrent immunization against tetanus, diphtheria and pertussis: a comparison of fluid and alum-precipitated toxoids. J Pediatr 1942; 21:31-44.
523. Orenstein W.A., Weisfeld J.S., Halsey N.A.: Diphtheria and tetanus toxoids and pertussis vaccine, combined. Recent Advances in Immunization: A Bibliographic Review, Washington, DC: Pan American Health Organization (no. 451); 1983:30-51.
524. Volk V.K.: Safety and effectiveness of multiple antigen preparations in a group of free-living children. Am J Public Health 1949; 39:1299-1313.
525. Barrett C.D., Timm E.A., Molner J.G., et al: Multiple antigen immunization of infants against poliomyelitis, diphtheria, pertussis and tetanus, II: response of infants and young children to primary immunization and eighteen-month booster. Am J Public Health 1959; 49:644-655.
526. Pichichero M.E., Barkin R.M., Samuelson J.S.: Pediatric diphtheria and tetanus toxoids-adsorbed vaccine: immune response to the first booster following the diphtheria and tetanus toxoids primary series. Pediatr Infect Dis 1986; 5:428-430.
527. Scheibel I., Bentzon M.W., Christensen P.E., et al: Duration of immunity to diphtheria and tetanus after active immunization. Acta Pathol Microbiol Scand 1966; 67:380-392.
528. Simonsen O., Kjeldsen K., Heron I.: Immunity against tetanus and effect of revaccination 25–30 years after primary vaccination. Lancet 1984; 2:1240-1242.
529. Peebles T.C., Levine L., Eldred M.L., et al: Tetanus-toxoid emergency boosters: a reappraisal. N Engl J Med 1969; 280:575-581.
530. World Health Organization : Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 40:385-400.
531. Joint Committee on Vaccination and Immunisation : In: Salisbury D., Begg N., ed. Immunisation against Infectious Disease, London: Department of Health; 1996:205-214.
532. United Kingdom Department of Health : The Green Book: tetanus: immunisation against infectious disease, 2006. London;accessed April 5, 2012 http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_079917
533. Myers M.G., Beckman C.W., Vosdingh R.A., et al: Primary immunization with tetanus and diphtheria toxoids: reaction rate and immunogenicity in older children and adults. JAMA 1982; 248:2478-2480.
534. Task Force on Immunization of the American College of Physicians : Guide for Adult Immunization, 4th ed. Philadelphia, PA, American College of Physicians, 1997.
535. Centers for Disease Control and Prevention : Recommended adult immunization schedule: United States, 2012. MMWR 2012; 61:37-43.
536. Ruben F.L., Fireman P.: Follow-up study: protective immunization in the elderly [letter]. Am J Public Health 1983; 73:1330.
537. Solomonova K., Vizev S.: Secondary response to boostering by purified aluminum-hydroxide-adsorbed tetanus antitoxin in aging and in aged adults. Immunobiology 1981; 158:312-319.
538. Kishimoto S., Tomino S., Mitsuya H., et al: Age-related decline in the in vitro and in vivo syntheses of anti-tetanus toxoid antibody in humans. J Immunol 1980; 125:2347-2352.
539. Simonsen O., Block A.V., Klaerke A., et al: Immunity against tetanus and response to revaccination in surgical patients more that 50 years of age. Surg Gynecol Obstet 1987; 164:329-334.
540. Murphy S.M., Hegarty D.M., Feighery C.S., et al: Tetanus immunity in elderly people. Age Ageing 1995; 24:99-102.

541. Masar I., Kamienicka L., Novakova I.: Immune response of elderly to booster of tetanus. In: Nistico G., Bizzini B., Bytchenko M., et al ed. Proceedings of the Eighth International Conference on Tetanus, Rome: Pythagora Press; 1989:251-253.Leningrad; Aug 25–28, 1987
542. Hainz U., Jenewein B., Asch E., et al: Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005; 23:3232-3235.
543. Koenig M.A., Roy N.C., McElrath T., et al: Duration of protective immunity conferred by maternal tetanus toxoid immunization: further evidence from Matlab, Bangladesh. Am J Public Health 1998; 88:903-907.
544. Expanded Programme on Immunization : Prevention of neonatal tetanus through immunization, Geneva, World Health Organization, 1986. (WHO/EPI/GEN/86/9).
545. Centers for Disease Control and Prevention : General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(RR-2):3-60.
546. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP). MMWR2011. 60, 1424–1426
547. Evans D.G.: Persistence of antitoxin in man following active immunisation. Lancet 1943; 2:316-317.
548. Simonsen O., Badsberg J.H., Kjeldsen K., et al: The fall-off in serum concentration of tetanus antitoxin after primary and booster vaccination. Acta Pathol Microbiol Scand C 1986; 94:77-82.
549. Simonsen O.: Vaccination against tetanus and diphtheria. Danish Med Bull 1989; 36:24-47.
550. Simonsen O., Klærke M., Jensen J.EB., et al: Revaccination against tetanus 17 to 20 years after primary vaccination: kinetics of antibody response. J Trauma 1987; 27:1358-1361.
551. Simonsen O., Bentzon M.W., Kjeldsen J., et al: Evaluation of vaccination requirements to secure continuous antitoxin immunity to tetanus. Vaccine 1987; 5:115-122.
552. Kaiser G.C., King R.D., Lempe R.E., et al: Delayed recall of active tetanus immunization. JAMA 1961; 178:914-916.
553. Christenson B., Böttiger M.: Immunity and immunization of children against tetanus in Sweden. Scand J Infect Dis 1991; 23:643-647.
554. Volk V.K., Gottshall R.Y., Anderson H.D., et al: Antigenic response to booster dose of diphtheria and tetanus toxoids, seven to thirteen years after primary inoculation of noninstitutionalized children. Public Health Rep 1962; 77:185-194.
555. Gonçalves G., Santos M.A., Frade J.G., et al: Levels of diphtheria and tetanus specific IgG of Portuguese adult women, before and after vaccination with adult type Td: duration of immunity following vaccination. BMC Public Health 2007; 7:109.
556. Mathias R.G., Schechter M.T.: Booster immunization for diphtheria and tetanus: no evidence for need in adults. Lancet 1985; 1:1089-1091.
557. Gardner P., LaForce F.M.: Protection against tetanus [letter]. N Engl J Med 1995; 333:599.
558. Bowie C.: Tetanus toxoid for adults: too much of a good thing [editorial]. Lancet 1996; 348:1185-1186.
559. Balestra D.J., Littenberg B.: Should adult tetanus immunization be given as a single vaccination at age 65?. J Gen Intern Med 1993; 8:405-412.
560. Gardner P.: Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults. Infect Dis Clin North Am 2001; 15:143-153.

561. Bracebridge S., Crowcroft N., White J.: Tetanus immunisation policy in England and Wales: an overview of the literature. Commun Dis Public Health 2004; 7:283-286.
562. Singleton J.A., Greby S.M., Wooten K.G., et al: Influenza, pneumococcal, and tetanus toxoid vaccination of adults: United States, 1993–1997. MMWR CDC Surveill Summ 2000; 49(SS-9):39-52.
563. Roper M.H.: Tetanus prophylaxis in the emergency department. Ann Emerg Med 2004; 43:315-317.
564. Murphy K.J.: Fatal tetanus with brain-stem involvement and myocarditis in an ex-serviceman. Med J Aust 1970; 57(SS-9):542-544.
566. Weckx L.Y., Divino-Goes K., Lihama D.M., et al: Effect of a single tetanus-diphtheria vaccine dose on the immunity of elderly people in São Paulo. Brazil. Braz J Med Biol Res 2006; 39:519-523.
567. Sutter R.W., Hadler S.C., McQuillan G., et al: Protection against tetanus [letter reply]. N Engl J Med 1995; 333:600.
568. Centers for Disease Control and Prevention : Update on adult immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1991; 40(RR-12):1-52.
569. World Health Organization : Field manual for neonatal tetanus elimination, Geneva, World Health Organization, 1999. (WHO/V&B/99.14)
570. Centers for Disease Control and Prevention : Use of vaccines and immune globulins in persons with altered immunocompetence: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42(RR-4):1-18.
571. Moss W.J., Clements C.J., Halsey N.A.: Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81:61-70.
572. Webster A.DB., Latif A.AA., Brenner M.K., et al: Evaluation of test immunization in the assessment of antibody deficiency syndromes. Br Med J (Clin Res Ed) 1984; 288:1864-1866.
573. Kroon F.P., Van Dissel J.T., Labadie J., et al: Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1197-1203.
574. Dieye T.N., Sow P.S., Simonart T., et al: Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. Vaccine 2002; 20:905-913.
575. Von Reyn C.F., Clements C.J., Mann J.M.: Human immunodeficiency virus infection and routine childhood immunisation. Lancet 1987; 1:669-672.
576. Ryder R.W., Oxtoby M.J., Mvula M., et al: Safety and immunogenicity of bacille Calmette-Guerin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 1993; 122:697-702.
577. Tejiokem M.C., Gouandjika I., Béniguel L., et al: HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS One 2007; 2:e1260.
578. Hammarstrom V., Pauksen K., Svensson H., et al: Tetanus immunity in patients with hematological malignancies. Support Care Cancer 1998; 6:469-472.
579. Molrine D.C., Hibberd P.L.: Vaccines for transplant recipients. Infect Dis Clin North Am 2001; 15:273-305.
580. Girndt M., Pietsch M., Kohler H.: Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995; 26:454-460.
581. Kruger S., Seyfarth M., Sack K., et al: Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. Vaccine 1999; 17:1145-1150.

582. Kruger S., Muller Steinhardt M., Kirchner H., et al: A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis 2001; 38:1264-1270.
583. Guerin A., Buisson Y., Nutini M.T., et al: Response to vaccination against tetanus in chronic haemodialysed patients. Nephrol Dial Transplant 1992; 7:323-326.
584. Duchini A., Goss J.A., Karpen S., et al: Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003; 16:357-364.
585. Ek T., Mellander L., Hahn-Zoric M., et al: Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b. J Pediatr Hematol Oncol 2004; 26:727-734.
586. Zignol M., Peracchi M., Tridello G., et al: Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004; 101:635-641.
587. Robinson M.J., Heal C., Gardener E., et al: Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease. Pediatrics 2004; 113:733-737.
588. Ercan T.E., Soycan L.Y., Apak H., et al: Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005; 27:273-277.
589. Patel S.R., Ortin M., Cohen B.J., et al: Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis 2007; 44:635-642.
590. Paulides M., Stöhr W., Laws H.J., et al: Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: a report from the Late Effects Surveillance System. Vaccine 2011; 29:1565-1568.
591. Kurtzhals J.AL., Kjeldsen K., Heron I., et al: Immunity against diphtheria and tetanus in human immunodeficiency virus-infected Danish men born 1950–59. APMIS 1992; 100:803-808.
592. World Health Organization : HIV infection and immunization. 1996, . Immunization Policy, Geneva: World Health Organization; 1996:36-39.(WHOGPV/GEN/95.03 Rev.1).
593. Talesnik E., Vial P.A., Labarca J., et al: Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV. J Acquir Immune Defic Syndr 1998; 19:471-477.
594. Ching N., Deville J.G., Nielsen K.A., et al: Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART). Euro J Pediatr 2007; 166:51-56.
595. Sutcliffe C.G., Moss W.J.: Do children infected with HIV receiving HAART need to be revaccinated?. Lancet Infect Dis 2010; 10:630-642.
596. Andrade R.M., Andrade A.F., Lazaro M.A., et al: Failure of highly active antiretroviral therapy in reconstituting immune response to Clostridium tetani vaccine in aged AIDS patients. J Acquir Immune Defic Syndr 2010; 54:10-17.
597. Centers for Disease Control and Prevention : Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Recomm Rep 2000; 49(RR-10):1-125.
598. Patel S.R., Ortin M., Cohen B.J., et al: Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007; 44:625-634.
599. Balloni A., Assael B.M., Ghio L., et al: Immunity to poliomyelitis, diphtheria and tetanus in pediatric patients before and after renal or liver transplantation. Vaccine 1999; 17:2507-2511.

600. Enke B.U., Bokenkamp A., Offner G., et al: Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997; 64:237-241.
601. Beaman M., Michael J., MacLennan I.CM., et al: T-cell-independent and T-cell-dependent antibody responses in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4:216-221.
602. Kleinknecht C., Margolis A., Bonnissol C., et al: Serum antibodies before and after immunisation in haemodialysed children. Proc Eur Dial Transplant Assoc 1977; 14:209-214.
603. Neu A.M., Warady B.A., Furth S.L., et al: Antibody levels to diphtheria, tetanus and rubella in infants vaccinated while on PD: a study of the Pediatric Peritoneal Dialysis Study Consortium. Adv Perit Dial 1997; 13:297-299.
604. Relihan M.: Reactions to tetanus toxoid. J Irish Med Assoc 1969; 62:430-434.
605. White W.G., Barnes G.M., Barker E., et al: Reactions to tetanus toxoid. J Hyg (Camb) 1973; 71:283-297.
606. Williams J.J., Ellingson H.V.: Field trial of commercially prepared diphtheria-tetanus toxoid: immunization reactions among recruits, 1954. Unpublished report to the Armed Forces Epidemiologic Board,
607. Collier L.H., Polakoff S., Mortimer J.: Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet 1979; 1:1364-1368.
608. Jones A.E., Melville-Smith M., Watkins J., et al: Adverse reactions in adolescents to reinforcing doses of plain and adsorbed tetanus vaccines. Community Med 1985; 7:99-106.
609. Macko M.B.: Comparison of the morbidity of tetanus toxoid boosters with tetanus-diphtheria toxoid boosters. Ann Emerg Med 1985; 14:33-35.
610. Deacon S.P., Langford D.T., Shepard W.M., et al: A comparative clinical study of adsorbed tetanus vaccine and adult-type tetanus-diphtheria vaccine. J Hyg (Camb) 1982; 89:513-519.
611. Zurrer G., Steffen R.: Side effects in tetanus vs. diphtheria tetanus vaccination in travellers. 1988.Zurich, Switzerland; April 5–8, Abstract WPO3.3
612. Sisk C.W., Lewis C.E.: Reactions to tetanus-diphtheria toxoid (adult). Arch Environ Health 1965; 11:34-36.
613. McComb J.A., Levine L.: Adult immunization, II: dosage reduction as a solution to increasing reactions to tetanus toxoid. N Engl J Med 1961; 265:1152-1153.
614. White W.G., Gall D., Barnes G.M., et al: Duration of immunity after active immunisation against tetanus. Lancet 1969; 2:95-96.
615. Levine L., Ipsen J., McComb J.A.: Adult immunization: preparation and evaluation of combined fluid tetanus and diphtheria toxoids for adult use. Am J Hyg 1961; 73:20-35.
616. Holden J.M., Strang D.U.: Reactions to tetanus toxoid: comparison of fluid and adsorbed toxoids. N Z Med J 1965; 64:574-577.
617. Eisen A.H., Cohen J.J., Rose B.: Reaction to tetanus toxoid: report of a case with immunologic studies. N Engl J Med 1963; 269:1408-1411.
618. Schneider C.H.: Reactions to tetanus toxoid: a report of five cases. Med J Aust 1964; 1:303-305.
619. Edsall G., Elliot M.W., Peebles T.C., et al: Excessive use of tetanus toxoid boosters. JAMA 1967; 202:17-19.
620. Levine L., Edsall G.: Tetanus toxoid: what determines reaction proneness?. J Infect Dis 1981; 144:376.
621. Jacobs R.L., Lowe R.S., Lanier B.Q.: Adverse reactions to tetanus toxoid. JAMA 1982; 247:40-42.
622. Griffith A.H.: Clinical reactions to tetanus toxoid. In: Eckmann L., ed. Principles of Tetanus, Bern: Hans Huber; 1967:299.
623. Edelman R.: Vaccine adjuvants. Rev Infect Dis 1980; 2:370-383.

624. Gherardi R.K., Coquet M., Cherin P., et al: Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001; 124:1821-1831.
625. World Health Organization : [Macrophagic myofasciitis and aluminum-containing vaccines]. Wkly Epidemiol Rec 1999; 74:337-340.
626. World Health Organization : Wkly Epidemiol Rec 1999; 74:354.Corrigendum to no. 41, pp 338–339: vaccine safety.
627. Jefferson T., Rudin M., Di Pietrantonj C.: Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004; 4:84-90.
628. Expanded Programme on Immunization : Reactions to tetanus toxoid. Wkly Epidemiol Rec 1982; 57:193-194.
629. Middaugh J.P.: Side effects of diphtheria-tetanus toxoid in adults. Am J Public Health 1979; 69:246-249.
630. Ullberg-Olsson K.: Vaccinationsreaktioner efter injektion: av tetanustoxoid med och utan tillsats av difteritoxoid. Lakartidningen 1979; 76:2976.
631. Rennels M.B., Deloria M.A., Pichichero M.E., et al: Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000; 105:E12.
632. Centers for Disease Control and Prevention : Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-13):1-8.
633. Scot L.J.: Tdap5 Vaccine (Covaxis): a review of its use as a single booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged > 4 years), adolescents, and adults. Biodrugs 2010; 24:387-406.
634. Plosker G.L.: Combined, reduced-antigen content tetanus, diphtheria, and acellular vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10 –64 years in the US. Biodrugs 2009; 23:254-267.
635. Reisman R.E.: Delayed hypersensitivity to merthiolate preservative. J Allergy 1969; 43:245-248.
636. Gold H.: Sensitization induced by tetanus toxoid, alum precipitated. J Lab Clin Med 1941; 27:26-36.
637. Church J.A., Richards W.: Recurrent abscess formation following DTP immunizations: association with hypersensitivity to tetanus toxoid. Pediatrics 1985; 75:899-900.
638. Osawa J., Kitamura K., Ikezawa Z., et al: A probable role for vaccines containing thimerosal in thimerosal hypersensitivity. Contact Dermatitis 1991; 24:178-182.
639. In: Stratton K.R., Gable A., McCormick M.C., ed. Institute of Medicine Immunization Safety Review Committee. In: Thimerosal-containing vaccines and neurodevelopmental disorders, Washington, DC: National Academy Press; 2001.
640. European Agency for the Evaluation of Medicinal Products : Public Statement on Thimerosal in vaccines for human use-recent evidence supports safety of thimerosal-containing vaccines. London, 2004, 2004. London, (EMEA/CPMP/VEG/1194/04/Adopted)accessed April 6, 2012 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003904.pdf
641. Centers for Disease Control and Prevention : Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR 1999; 48:563-565.
642. World Health Organization : Thiomersal as a vaccine preservative. Wkly Epidemiol Rec 2000; 75:12-16.

643. Zhou W., Pool V., Iskander J.K., et al: Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS): United States, 1991–2001. MMWR CDC Surveill Summ 2003; 52(SS-1):1-24.
644. Quast U., Hennessen W., Widmark R.M.: Mono- and polyneuritis after tetanus vaccination (1970–1977). Dev Biol Stand 1979; 43:25-32.
645. Pollard J.D., Selby G.: Relapsing neuropathy due to tetanus toxoid: report of a case. J Neurol Sci 1978; 37:113-125.
646. Holliday P.L., Bauer R.B.: Polyradiculoneuritis secondary to immunization with tetanus and diphtheria toxoids. Arch Neurol 1983; 40:56-57.
647. Newton N., Janati A.: Guillain-Barré syndrome after vaccination with purified tetanus toxoid. South Med J 1987; 80:1053-1054.
648. Kiwit J.CW.: Neuralgic amyotrophy after administration of tetanus toxoid [letter]. J Neurol Neurosurg Psychiatry 1984; 47:320.
649. Tsairis P., Dyck P.J., Mulder D.W.: Natural history of brachial plexus neuropathy: report on 99 patients. Arch Neurol 1965; 2:116-120.
650. Beghi E., Kurland L.T., Mulder D.W., et al: Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970–1981. Ann Neurol 1985; 18:320-323.
651. Dittman S.: Tetanusschutzimpfung. Beitr Hyg Epidemiol 1981; 25:239-240.
652. Rutledge S.L., Snead O.C.: Neurologic complications of immunizations. J Pediatr 1986; 109:917-923.
653. Institute of Medicine Vaccine Safety Committee : Diphtheria and tetanus toxoids. In: Adverse events associated with childhood vaccines: evidence bearing on causality. In: Stratton K.R., Howe C.J., Johnston R.B., ed. Washington, DC: National Academy Press; 1994:67-117.
654. Garvey J.L.: Serum neuritis: 20 cases following use of antitetanic serum. Postgrad Med 1953; 13:210-213.
655. Zhou W., Pool V., Chen R.: Reports of brachial neuritis in the Vaccine Adverse Event Reporting System (VAERS), United States, 1991–2003. Bordeaux, France; Aug 22–25,2004.Abstract 557
656. Rantala J., Cherry J.D., Shields W.D., et al: Epidemiology of Guillain-Barré syndrome in children: relationship of oral polio vaccine occurrence. J Pediatr 1994; 124:220-223.
657. Tuttle J., Chen R.T., Rantala H., et al: The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health 1997; 87:2045-2048.
658. Schlenska G.K.: Unusual neurologic complications following tetanus toxoid administration. J Neurol 1977; 215:299-302.
659. Schwarz G., Lanzer G., List W.F.: Acute midbrain syndrome as an adverse reaction to tetanus toxoid. Intensive Care Med 1988; 15:53-54.
660. Hernán M.A., Alonso A., Hernández-Díaz S.: Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006; 67:212-215.
661. Verstraeten T., Davis R., DeStefano F,.Vaccine Safety Datalink Team: Decreased risk of demyelinating disease following tetanus immunization. Am J Epidemiol 2002; 155:S52.
662. Confavreux C., Suissa S., Saddier P., et al: Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001; 344:319-326.
663. Verstraeten T., Davis R., DeStefano F.: Immunity to tetanus is protective against the development of multiple sclerosis. Med Hypotheses 2005; 65:966-969.
664. Nagel J., Svec D., Waters T., et al: IgE synthesis in man, I: development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids. J Immunol 1977; 118:334-341.

665. Matuhasi T., Ikegami H.: Elevation of levels of IgE antibody to tetanus toxin in individuals vaccinated with diphtheria-pertussis-tetanus vaccine. J Infect Dis 1982; 146:290.
666. Cogne M., Ballet J.J., Schmitt C., et al: Total and IgE antibody levels following booster immunization with aluminum adsorbed and nonadsorbed tetanus toxoid in humans. Ann Allergy 1985; 54:148-151.
667. Zalogna G.P., Chernow B.: Life-threatening anaphylactic reactions to tetanus toxoid. Ann Allergy 1982; 49:107-108.
668. Ratliff D.A., Burns-Cox C.J.: Anaphylaxis to tetanus toxoid (unreviewed reports). Br Med J (Clin Res Ed) 1983; 288:114.
669. Engler R.JM., Zalogna G.: Anaphylaxis to tetanus toxoid: IgE mediated disease. Forty-first annual meeting of the American Academy of Allergy and Immunology, March 16-20 1985, New York. J Allergy Clin Immunol 1985; 75(pt 2):314 (Abstract 422)
670. Cooke R.A., Hampton S., Sherman W.B., et al: Allergy induced by immunization with tetanus toxoid. JAMA 1940; 114:1854-1858.
671. Whittingham H.E.: Anaphylaxis following administration of tetanus toxoid. Br Med J 1940; 1:292-293.
672. Parrish H.J., Oakley C.L.: Anaphylaxis after injection of tetanus toxoid: report of a case. Br Med J 1940; 1:294-295.
673. Miller H.G., Stanton J.B.: Neurologic sequelae of prophylactic inoculation. Q J Med 1954; 23:1-27.
674. Smith R.E., Wolnisty C.: Allergic reactions to tetanus, diphtheria, influenza and poliomyelitis immunization. Ann Allergy 1962; 20:809-813.
675. Mansfield L.E., Ting S., Rawls D.O., et al: Systemic reactions during cutaneous testing for tetanus toxoid hypersensitivity. Ann Allergy 1986; 57:135-137.
676. Facktor M.A., Bernstein R.A., Fireman P.: Hypersensitivity to tetanus toxoid. J Allergy Clin Immunol 1973; 52:1-12.
677. Gupte S.C., Bhatia H.M.: Anti-A and anti-B titre response after tetanus toxoid injections in normal adults and pregnant women. Indian J Med Res 1979; 70:221-228.
678. Gupte S.C., Bhatia H.M.: Increased incidence of haemolytic disease of the newborn caused by ABO-incompatibility when tetanus toxoid is given during pregnancy. Vox Sang 1980; 38:22-28.
679. Kurikka S., Olander R.M., Eskola J., et al: Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy. Pediatr Infect Dis J 1996; 15:530-535.
680. Carlsson R.M., Claesson B.A., Iwarson S., et al: Antibodies against Haemophilus influenzae type b and tetanus in infants after subcutaneous vaccination with PRP-T/diphtheria, or PRP-OMP/diphtheria-tetanus vaccines. Pediatr Infect Dis J 1994; 13:27-33.
681. Holmes S.J., Fritzell B., Guito K.P., et al: Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants. Am J Dis Child 1993; 147:832-836.
682. Avendano A., Ferreccio C., Lagos R., et al: Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993; 12:638-643.
683. Kaplan S.L., Lauer B.A., Ward M.A., et al: Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr 1994; 124:323-327.

684. da Silveira C.M., Caceres V.M., Dutra M.G., et al: Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. Bull World Health Organ 1995; 73:605-608.
685. Catindig N., Abad-Viola G., Magboo F.: Tetanus toxoid and spontaneous abortions: is there epidemiological evidence of an association? [letter]. Lancet 1996; 348:1098-1099.
685a. Czeizel A.E., Rockenbauer M.: Tetanus toxoid and congenital abnormalities. Int J Gynaecol Obstet 1999; 64:253.28,
686. Smith J.WG., Laurence D.R., Evans D.G.: Prevention of tetanus in the wounded. Br Med J 1975; 3:453-455.
687. Percy A.S., Kukora J.S.: The continuing problem of tetanus. Surg Gynecol Obstet 1985; 160:307-312.
688. Furste W.: Four keys to 100 per cent success in tetanus prophylaxis. Am J Surg 1974; 128:616-623.
689. Committee on Trauma, American College of Surgeons : Prophylaxis against tetanus in wound management (revised 1995). accessed April 5 http://www.facs.org/trauma/publications/tetanus.pdf 2012
690. Gindi M., Oravitz P., Sexton R., et al: Unreliability of reported tetanus vaccination histories. Am J Emerg Med 2005; 23:120-122.
691. Fishbein D.B., Willis B.C., Cassidy W.M., et al: Determining indications for adult vaccination: patient self-assessment, medical record, or both?. Vaccine 2006; 24:803-818.
692. Colombet I., Saguez C., Sanson-Le Pors M.J., et al: Diagnosis of tetanus immunization status: multicenter assessment of a rapid biological test. Clin Diagn Lab Immunol 2005; 12:1057-1062.
693. Stubbe M., Swinnen R., Crusiaux A., et al: Seroprotection against tetanus in patients attending an emergency department in Belgium and evaluation of a bedside immunotest. Eur J Emerg Med 2007; 14:14-24.
694. Hatamabadi H.R., Abdalvand A., Safari S., et al: Tetanus Quick Stick as an applicable and cost-effective test in assessment of immunity status. Am J Emerg Med 2011; 29:717-720.
695. Hoel T., Wolter J.M., Schuermann L.M.: Combined diphtheria-tetanus-pertussis vaccine for tetanus-prone wound management in adults. Eur J Emerg Med 2006; 13:67-71.
696. Halperin S.A., Sweet L., Baxendale D., et al: How soon after prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. Pediatr Infect Dis J 2006; 25:195-200.
697. Banton H.J., Miller P.A.: An observation of antitoxin titers after booster doses of tetanus toxoid. N Engl J Med 1949; 240:13-14.
698. Trinca J.C.: Active immunization against tetanus: the need for a single all-purpose toxoid. Med J Aust 1945; 2:116-120.
699. McComb J.A., Dwyer R.C.: Passive-active immunization with tetanus immune globulin. N Engl J Med 1963; 268:857-862.
700. Moloney P.J.: Active-passive immunization against tetanus. In: Eckmann L., ed. Principles of Tetanus, Bern: Hans Huber; 1967:393-396.
701. Rubbo S.D.: New approaches to tetanus prophylaxis. Lancet 1966; 2:449-453.
702. Cohen H., Leussink A.B.: Passive-active immunization with human tetanus immunoglobulin and adsorbed toxoid. J Biol Stand 1973; 1:313-320.
703. Wahlbert T., Leibl H., Brauner A., et al: Tetanus antibody levels of female volunteers after injection with solvent/detergent-treated human tetanus immunoglobulin (Tetabulin S/D). Vox Sanguinis 2001; 80:159-161.
704. Lindsey D.: Tetanus prophylaxis: do our guidelines assure protection? [editorial]. J Trauma 1984; 24:1063-1064.

705. Johnson D.M.: Fatal tetanus after prophylaxis with human tetanus immune globulin [letter]. JAMA 1969; 207:1519.
706. Pontecorvo M.: The prophylactic dose of TIG. In: Nistico G., Mastroeni P., Pitzurra M., ed. Proceedings of the Seventh International Conference on Tetanus, Rome: Gangeni; 1985:375-379.Copanello, Italy; September 10–15, 1984
707. Forrat R., Dumas R., Seiberling M., et al: Evaluation of the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin administered as sham, postexposure prophylaxis of tetanus. Antimicrob Agents Chemother 1998; 42:298-305.
708. Smith J.WG., MacIver A.G.: Studies in experimental tetanus infection. J Med Microbiol 1969; 2:385-393.
709. Smith J.WG.: Penicillin in prevention of tetanus. Br Med J 1964; 2:1293-1296.
710. Lucas A.O., Willis A.JP.: Prevention of tetanus. Br Med J 1965; 2:1333-1336.
711. Lowbury E.JL., Kidson A., Lilly H.A., et al: Prophylaxis against tetanus in non-immune patients with wounds: the role of antibiotics and of human antitetanus globulin. J Hyg (Camb) 1978; 80:267-274.
712. Brand D.A., Acampora D., Gottlieg L., et al: Adequacy of antitetanus prophylaxis in six hospital emergency rooms. N Engl J Med 1983; 309:636-640.
713. Giangrosso J., Smith R.K.: Misuse of tetanus immunoprophylaxis in wound care. Ann Emerg Med 1985; 14:573-579.
714. Ribero M.L., Gastaldi G., Fara G.M.: Ongoing tetanus prophylaxis of injured patients in five hospital emergency rooms. Boll Ist Sieroter Milan 1985; 64:70-76.
715. Elkharrat D., Chammard A.B., Raskine L., et al: Impact of guidelines to alter antitetanus prophylaxis practices and reduce costs in the emergency department. Am J Therapeutics 1999; 6:203-209.
716. Savage E.J., Nash S., McGuinness A., et al: Audit of tetanus prevention knowledge and practices in accident and emergency departments in England. Emerg Med J 2007; 24:417-421.
717. Abbate R., Di Giuseppe G., Marinelli P., et al: Appropriate tetanus prophylaxis practices in patients attending emergency departments in Italy. Vaccine 2008; 26:3634-3639.
718. Stubbe M., Mortelmans L.J., Desruelles D., et al: Improving tetanus prophylaxis in the emergency department: a prospective, double-blind cost-effectiveness study. Emerg Med J 2007; 24:648-653.
719. Lu B., Craven M., Morgan S., et al: Evidence review: rapid tests for tetanus immunity. Nottingham, England, Nottingham CEP Partnership, 2010. accessed April 6 http://nhscep.useconnect.co.uk/ShowDocument.ashx?id=451&i=true
720. George A.O., Ogunbiyi A.O., Amanor-Boadu S., et al: Tetanus in Nigeria: the economic burden. Trop Doct 2005; 35:126-127.
721. Gareau A.B., Eby R.J., McLellan B.A., et al: Tetanus immunization status and immunologic response to a booster in an emergency department geriatric population. Ann Emerg Med 1990; 19:1377-1382.
722. Böttiger M., Gustavsson O., Svensson A.: Immunity to tetanus, diphtheria and poliomyelitis in the adult population of Sweden in 1991. Int J Epidemiol 1998; 27:916-925.
723. World Health Assembly : Resolution 42.32: Expanded Programme on Immunization, 1989. Handbook of Resolutions and Decisions of the World Health Assembly and the Executive Board (1985–1992), Vol. 3. 3rd ed. Geneva: World Health Organization; 1993.
724. Expanded Programme on Immunization : Global Advisory Group. Pt I. Wkly Epidemiol Rec 1990; 65:5-11.
725. Expanded programme on immunization : The global elimination of neonatal tetanus: progress to date. Wkly Epidemiol Rec 1993; 68:277-282.

726. Expanded programme on immunization : Tetanus control. Wkly Epidemiol Rec 1987; 50:380-383.
727. WHO Expanded Programme on Immunization : Eliminating neonatal tetanus: how near, how far?, Geneva, World Health Organization, 1996. (WHO/EPI/GEN/96.01).accessed April 6, 2012 http://whqlibdoc.who.int/hq/1996/WHO_EPI_GEN_96.01.pdf
728. United Nations Children's Fund World Health Organization and United Nations Population Fund: Maternal and neonatal tetanus elimination by 2005: strategies for achieving and maintaining elimination, Nov 2000, Geneva, World Health Organization, 2002. (WHO/V&B/02.09)accessed April 6, 2012 http://www.who.int/vaccines-documents/DocsPDF02/www692.pdf
729. Vandelaer J., Birmingham M., Gasse F., et al: Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 2003; 21:3442-3445.
730. da Silveira C.M., de Quadros C.A.: Neonatal tetanus: countdown to 1995. World Health Forum 1991; 12:289-296.
731. Expanded Programme on Immunization : Reassessment of the neonatal tetanus problem, China. Wkly Epidemiol Rec 1993; 68:201-204.
732. Expanded Programme on Immunization : Elimination of neonatal tetanus, Thailand. Wkly Epidemiol Rec 1993; 68:337-341.
733. Bennett J., Seward J., Sakai S., et al: Identifying areas at high-risk for neonatal tetanus [letter]. Lancet 1995; 346:1628-1629.
734. Aylward R.B., Mansour E., Aly Oon E.S., et al: The role of surveillance in “high risk” approach to the elimination of neonatal tetanus in Egypt. Int J Epidemiol 1996; 25:1286-1291.
735. Expanded programme on immunization : The "high risk" approach: the WHO-recommended strategy to accelerate elimination of neonatal tetanus. Wkly Epidemiol Rec 1996; 71:33-36.
736. Ekanem E.E., Asindi A.A., Antia-Obong O.E.: Factors influencing tetanus toxoid immunization among pregnant women in Cross Rivers State Nigeria. Nigerian Med Pract 1994; 27:3-5.
737. Brabin L., Kemp J., Maxwell S., et al: Protecting adolescent girls against tetanus. Br Med J 1995; 311:73-74.
738. Aylward R.B., Mansour E., Cummings F.: Surveillance for neonatal tetanus in high-risk areas [letter]. Lancet 1996; 347:690-691.
739. Expanded Programme on Immunization : Estimating tetanus protection of women by serosurvey, Burundi. Wkly Epidemiol Rec 1997; 71:117-124.
740. World Health Organization : Protection-at-birth (PAB) method, Tunisia. Wkly Epidemiol Rec 2000; 75:203-206.
741. Expanded Programme on Immunization : Training for Mid-Level Managers: EPI Coverage Survey, Geneva, World Health Organization, 1991. (WHO/EPI/MLM/91.10).
742. Perez-Trallero E., Urbieta M., Diaz-de-Tuesta J.L., et al: Anti-tetanus toxin titers in sera of the women who gave birth in 1985 and 1989 in Gipuzkoa (Basque Country, Spain). Eur J Epidemiol 1995; 11:231-234.
743. De Francisco A., Chakraborty J.: Maternal recall of tetanus toxoid vaccination. Ann Trop Paediatr 1996; 16:49-54.
744. World Health Organization : Progress towards the global elimination of neonatal tetanus, 1990–1998. Wkly Epidemiol Rec 1999; 74:73-80.
745. The United Nations Children's Fund : The state of the world's children 2006. New York, UNCF, 2005.

746. World Health Organization. Maternal and Neonatal Tetanus (MNT) elimination website. http://www.who.int/immunization_monitoring/diseases/MNTE_initiative/en/index.html , accessed April 5, 2012.
747. Stroh G., Birmingham M.: Protocol for assessing neonatal tetanus mortality in the community using a combination of cluster and lot quality assurance sampling, Geneva, World Health Organization, 2002. (WHO/V&B/02.05)
748. van Geldermalsen A.A.: Misguided advice on vaccines, Cameroon. Lancet 1991; 338:1528.
749. Milstien J., Griffin P.D., Lee J-W.: Damage to immunisation programmes from misinformation on contraceptive vaccines. Reprod Health Matters 1995; 6:24-28.
750. Tan M.L.: All in the name of life. Reprod Health Matters 1995; 6:29-30.
751. Rey M., Guillaumont P., Majnoni d'Intignano B.: Benefits of immunization versus risk factors in tetanus. Dev Biol Stand 1979; 43:15-23.
752. Carducci A., Avio C.M., Bendinelli M.: Cost-benefit analysis of tetanus prophylaxis by a mathematical model. Epidemiol Infect 1989; 102:473-483.
753. Cvjetanovic B., Grab B., Uemura K., et al: Epidemiologic model of tetanus and its use in the planning of immunization programmes. Int J Epidemiol 1972; 1:125-137.
754. Smucker C.M., Swint J.M., Simmons G.B.: Prevention of neonatal tetanus in India: a prospective cost-effectiveness analysis. J Trop Pediatr 1984; 30:227-236.
755. Griffiths U.K., Wolfson L.J., Quddus A., et al: Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan. Bull World Health Organ 2004; 82:643-651.
756. Adam T., Lim S.S., Mehta S., et al: Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. BMJ 2005; 331:1107-1112.
757. Berman P., Quinley J., Yusef B., et al: Maternal immunization in Aceh Province. Sumatra: the cost effectiveness of alternative strategies. Soc Sci Med 1991; 33:185-192.
758. United Nations Children's Fund. Immunization Summary 2008 (2010 ed). http://www.childinfo.org/files/Immunization_Summary_2008_r6.pdf , accessed April 6, 2012.

HRIPAVAC

1. Holmes W.H.: Bacillary and Rickettsial Infections, Acute and Chronic: A Textbook: Black Death to White Plague. New York, Macmillan, 1940.
2. Hardy A.: Whooping cough. In: Kiple K.F., ed. The Cambridge World History of Human Disease, New York: Cambridge University Press; 1993:1094-1096.
3. Bordet J., Gengou O.: Le microbe de la coqueluche. Ann Inst Pasteur (Paris) 1906; 20:731-741.
4. Cherry J., Brunnel P., Golden G.: Report of the Task Force on Pertussis and Pertussis Immunization, 1988. Pediatrics 1988; 81:933-984.(Suppl.)
5. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-7):1-25.
6. Centers for Disease Control and Prevention : Pertussis: United States, 1997–2000. MMWR Morb Mortal Wkly Rep 2002; 51:73-76.
7. Broder K.R., Cortese M.M., Iskander J.K., et al: Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-3):1-34.
8. Cortese M.M., Baughman A.L., Brown K., et al: A “new age” in pertussis prevention: new opportunities through adult vaccination. Am J Prev Med 2007; 32:177-185.

9. Centers for Disease Control and Prevention : Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13-15.
10. World Health Organization. Immunization, Vaccines and Biologicals: Pertussis. www.who.int/immunization/topics/pertussis/en/index.html [accessed 07.04.11].
11. Zackrisson G., Taranger J., Trollfors B.: History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr 1990; 116:190-194.
12. Heininger U., Klich K., Stehr K., et al: Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 1997; 100:E10.
13. Nuolivirta K., Koponen P., He Q., et al: Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. Pediatr Infect Dis J 2010; 29:1013-1015.
14. Lapin J.H.: Whooping Cough. Springfield, IL, CC Thomas, 1943.
15. Paddock C.D., Sanden G.N., Cherry J.D., et al: Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008; 47:328-338.
16. Halasa N.B., Barr F.E., Johnson J.E., et al: Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role?. Pediatrics 2003; 112(6 pt 1):1274-1278.
17. Williams G.D., Numa A., Sokol J., et al: ECLS in pertussis: does it have a role?. Intensive Care Med 1998; 24:1089-1092.
18. Wortis N., Strebel P.M., Wharton M., et al: Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 1996; 97:607-612.
19. Sreenan C.D., Osiovich H.: Neonatal pertussis requiring extracorporeal membrane oxygenation. Pediatr Surg Int 2001; 17:201-203.
20. Chan L.: Cough and respiratory distress in a two-month-old infant. Pediatr Infect Dis J 1997; 16:631-635.
21. Gillis J., Grattan-Smith T., Kilham H.: Artificial ventilation in severe pertussis. Arch Dis Child 1988; 63:364-367.
22. Goulin G.D., Kaya K.M., Bradley J.S.: Severe pulmonary hypertension associated with shock and death in infants infected with Bordetella pertussis. Crit Care Med 1993; 21:1791-1794.
23. Pierce C., Klein N., Peters M.: Is leukocytosis a predictor of mortality in severe pertussis infection?. Intensive Care Med 2000; 26:1512-1514.
24. Centers for Disease Control and Prevention : Pertussis deaths: United States 2000. MMWR Morb Mortal Wkly Rep 2002; 51:616-618.
25. Grzeszczak M.J., Churchwell K.B., Edwards K.M., et al: Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure. Pediatr Crit Care Med 2006; 7:580-582.
26. Donoso A.F., Cruces P.I., Camacho J.F., et al: Exchange transfusion to reverse severe pertussis-induced cardiogenic shock. Pediatr Infect Dis J 2006; 25:846-848.
27. Rowlands H.E., Goldman A.P., Harrington K., et al: Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010; 126:e816-e827.
28. Johnston I.D., Bland J.M., Ingram D., et al: Effect of whooping cough in infancy on subsequent lung function and bronchial reactivity. Am Rev Respir Dis 1986; 134:270-275.
29. Grant C.C., McKay E.J., Simpson A., et al: Pertussis encephalopathy with high cerebrospinal fluid antibody titers to pertussis toxin and filamentous hemagglutinin. Pediatrics 1998; 102(4 pt 1):986-990.

30. Mikelova L.K., Halperin S.A., Scheifele D., et al: Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003; 143:576-581.
31. Litvak A., Gibel H., Rosenthal S.: Cerebral complications in pertussis. J Pediatr 1948; 32:357-379.
32. Department of Health and Social Security , Great Britain : Whooping cough: reports from the Committee on Safety of Medicines and the Joint Committee on Vaccination and Immunisation. London, HMSO, 1981.
33. Zellweger H.: Pertussis encephalopathy. Arch Pediatr 1959; 76:381-386.
34. Nelson J.D.: The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child 1978; 132:371-373.
35. De Serres G., Shadmani R., Duval B., et al: Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182:174-179.
36. Bisgard K.M., Pascual F.B., Ehresmann K.R., et al: Infant pertussis: who was the source?. Pediatr Infect Dis J 2004; 23:985-989.
37. Wendelboe A.M., Njamkepo E., Bourillon A.Infant Pertussis Study Group: Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293-299.
38. de Greeff S.C., Mooi F.R., Westerhof A., et al: Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010; 50:1339-1345.
39. Senzilet L.D., Halperin S.A., Spika J.S., et al: Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001; 32:1691-1697.
40. Schmitt-Grohe S., Cherry J.D., Heininger U., et al: Pertussis in German adults. Clin Infect Dis 1995; 21:860-866.
41. Postels-Multani S., Schmitt H.J., Wirsing von Konig C.H., et al: Symptoms and complications of pertussis in adults. Infection 1995; 23:139-142.
42. Long S.S., Lischner H.W., Deforest A., et al: Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J 1990; 9:700-705.
43. Cromer B.A., Goydos J., Hackell J., et al: Unrecognized pertussis infection in adolescents. Am J Dis Child 1993; 147:575-577.
44. Long S.S., Welkon C.J., Clark J.L.: Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990; 161:480-486.
45. Eidlitz-Markus T., Zeharia A.: Bordetella pertussis as a trigger of migraine without aura. Pediatr Neurol 2005; 33:283-284.
46. Skowronski D.M., Buxton J.A., Hestrin M., et al: Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. Clin Infect Dis 2003; 36:e1-e4.
47. Jenkins P., Clarke S.W.: Cough syncope: a complication of adult whooping cough. Br J Dis Chest 1981; 75:311-313.
48. Halperin S.A., Marrie T.J.: Pertussis encephalopathy in an adult: case report and review. Rev Infect Dis 1991; 13:1043-1047.
49. MacLean D.W.: Adults with pertussis. J R Coll Gen Pract 1982; 32:298-300.
50. Fatal case of unsuspected pertussis diagnosed from a blood culture: Minnesota, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:131-132.
51. Mertens P.L., Borsboom G.J., Richardus J.H.: A pertussis outbreak associated with social isolation among elderly nuns in a convent. Clin Infect Dis 2007; 44:266-268.
52. Manclark C.R., Cowell J.L.: Pertussis. In: Germanier R., ed. Bacterial Vaccines, Orlando: Academic Press; 1984:69-106.
53. Kloos W., Mohapatra N., Dobrogosz W.: Deoxyribonucleotide sequence relationship among Bordetella species. Int J Syst Bacteriol 1981; 31:173-176.

54. Bjornstad O.N., Harvill E.T.: Evolution and emergence of Bordetella in humans. Trends Microbiol 2005; 13:355-359.
55. Arico B., Rappuoli R.: Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J Bacteriol 1987; 169:2847-2853.
56. Mattoo S., Foreman-Wykert A.K., Cotter P.A., et al: Mechanisms of Bordetella pathogenesis. Front Biosci 2001; 6:E168-E186.
57. Diavatopoulos D.A., Cummings C.A., Schouls L.M., et al: Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog 2005; 1:e45..doi:10.1371/journal.ppat.0010045
58. Tang Y.W., Hopkins M.K., Kolbert C.P., et al: Bordetella holmesii–like organisms associated with septicemia, endocarditis, and respiratory failure. Clin Infect Dis 1998; 26:389-392.
59. Yih W.K., Silva E.A., Ida J., et al: Bordetella holmesii–like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg Infect Dis 1999; 5:441-443.
60. Lindquist S.W., Weber D.J., Mangum M.E., et al: Bordetella holmesii sepsis in an asplenic adolescent. Pediatr Infect Dis J 1995; 14:813-815.
61. Shepard C.W., Daneshvar M.I., Kaiser R.M., et al: Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients. Clin Infect Dis 2004; 38:799-804.
62. Guthrie J.L., Robertson A.V., Tang P., et al: Novel duplex real-time detects Bordetella holmesii in specimens from patients with pertussis-like symptoms in Ontario, Canada. J Clin Microbiol 2010; 48:1435-1437.
63. Panagopoulos M.I., Saint Jean M., Brun D., et al: Bordetella holmesii bacteremia in asplenic children: report of four cases initially misidentified as Acinetobacter ewoffi. J Clin Microbiol 2010; 48:3762-3764.
64. Cookson B.T., Vandamme P., Carlson L.C., et al: Bacteremia caused by a novel Bordetella species, “B. hinzii”. J Clin Microbiol 1994; 32:2569-2571.
65. Funke G., Hess T., von Graevenitz A., et al: Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period. J Clin Microbiol 1996; 34:966-969.
66. Spilker T., Liwienski A.A., LiPuma J.J.: Identification of Bordetella spp. with cystic fibrosis. Clin Microbiol Infect 2008; 14:504-506.
67. Tuomanen E.: Bordetella pertussis adhesins. In: Wardlaw A.C., Parton R., ed. Pathogenesis and Immunity in Pertussis, New York: John Wiley & Sons; 1988:75-94.
68. Weiss A.: Mucosal immune defenses and the response of Bordetella pertussis. ASM News 1997; 63:22-28.
69. Sato H., Sato Y.: Relationship between structure and biological and protective activities of pertussis toxin. Dev Biol Stand 1991; 73:121-132.
70. Farizo K.M., Huang T., Burns D.L.: Importance of holotoxin assembly in PT-mediated secretion of pertussis toxin from Bordetella pertussis. Infect Immun 2000; 68:4049-4054.
71. Tamura M., Nogimori K., Murai S., et al: Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982; 21:5516-5522.
72. Halperin S.A., Issekutz T.B., Kasina A.: Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin. J Infect Dis 1991; 163:355-361.
73. Nencioni L., Pizza M.G., Volpini G., et al: Properties of the B oligomer of pertussis toxin. Infect Immun 1991; 59:4732-4734.
74. Watanabe M.: Biological activities of pertussigen from Bordetella pertussis strains of various agglutinogen types. Microbiol Immunol 1984; 28:509-515.
75. Hausman S.Z., Cherry J.D., Heininger U., et al: Analysis of proteins encoded by the ptx and ptl genes of Bordetella bronchiseptica and Bordetella parapertussis. Infect Immun 1996; 64:4020-4026.

76. Meade B.D., Kind P.D., Manclark C.R.: Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infect Immun 1984; 46:733-739.
77. Kirimanjeswara G.S., Agosto L.M., Kennett M.J., et al: Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 2005; 115:3594-3601.
78. Carbonetti N.H., Artamonova G.V., Mays R.M., et al: Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect Immun 2003; 71:6358-6366.
79. Carbonetti N.H., Artamonova G.V., Andreasen C., et al: Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract. Infect Immun 2005; 73:2698-2703.
80. Toyota T., Kai Y., Kakizaki M., et al: Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies). Tohoku J Exp Med 1980; 130:105-116.
81. Pittman M.: The concept of pertussis as a toxin-mediated disease. Pediatr Infect Dis 1984; 3:467-486.
82. Sato H., Sato Y.: Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun 1984; 46:415-421.
83. Arciniega J.L., Shahin R.D., Burnette W.N., et al: Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin. Infect Immun 1991; 59:3407-3410.
84. Sutherland J.N., Chang C., Yoder S.M., et al: Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization. Clin Vaccine Immunol 2011; 18:954-962.
85. McGuirk P., McCann C., Mills K.H.: Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002; 195:221-231.
86. Abramson T., Kedem H., Relman D.A.: Proinflammatory and proapoptotic activities associated with Bordetella pertussis filamentous hemagglutinin. Infect Immun 2001; 69:2650-2658.
87. Tuomanen E., Weiss A., Rich R., et al: Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia. Dev Biol Stand 1985; 61:197-204.
88. Tuomanen E., Weiss A.: Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J Infect Dis 1985; 152:118-125.
89. Oda M., Cowell J.L., Burstyn D.G., et al: Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis 1984; 150:823-833.
90. He Q., Viljanen M.K., Olander R.M., et al: Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren. J Infect Dis 1994; 170:705-708.
91. Meade B.D., Lynn F., Reed G.F., et al: Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines. Pediatrics 1995; 96:595-600.
92. Tsang R.S., Sill M.L., Advani A., et al: Use of monoclonal antibodies to serotype Bordetella pertussis isolates: comparison of results obtained by indirect whole-cell enzyme-linked immunosorbent assay and bacterial microagglutination methods. J Clin Microbiol 2005; 43:2449-2451.

93. Geuijen C.A., Willems R.J., Bongaerts M., et al: Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. Infect Immun 1997; 65:4222-4228.
94. Cotter P.A., Yuk M.H., Mattoo S., et al: Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Infect Immun 1998; 66:5921-5929.
95. Stanbridge T.N., Preston N.W.: Variation of serotype in strains of Bordetella pertussis. J Hyg (Lond) 1974; 73:305-310.
96. Preston N.W., Stanbridge T.N.: Efficacy of pertussis vaccines: a brighter horizon. Br Med J 1972; 3:448-451.
97. Bronne-Shanbury C., Miller D., Standfast A.F.: The serotypes of Bordetella pertussis isolated in Great Britain between 1941 and 1968 and a comparison with the serotypes observed in other countries over this period. J Hyg (Lond) 1976; 76:265-275.
98. Efficacy of whooping-cough vaccines used in the United Kingdom before 1968. Br Med J 1973; 1:259-262.
99. Preston N.W.: Prevalent serotypes of Bordetella pertussis in non-vaccinated communities. J Hyg (Lond) 1976; 77:85-91.
100. Storsaeter J., Hallander H.O., Gustafsson L., et al: Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-1916.
101. Willems R.J., Kamerbeek J., Geuijen C.A., et al: The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model. Vaccine 1998; 16:410-416.
102. Rodriguez M.E., Hellwig S.M., Perez Vidakovics M.L., et al: Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol Med Microbiol 2006; 46:39-47.
103. WHO Expert Committee on Biological Standardization : 1990. Paper presented at World Health Organ Tech Rep SerAnnex 2: Requirements for Diphtheria, Tetanus, Pertussis, and Combined Vaccines () or at this specific link: http://www.who.int/biologicals/technical_report_series/en/ Paper presented at World Health Organ Tech Rep SerAnnex 2: Requirements for Diphtheria, Tetanus, Pertussis, and Combined Vaccines () or at this specific link: http://whqlibdoc.who.int/trs/WHO_TRS_800_(part2).pdf
104. Li Z.M., Brennan M.J., David J.L., et al: Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies. Infect Immun 1988; 56:3184-3188.
105. Brennan M.J., Li Z.M., Cowell J.L., et al: Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun 1988; 56:3189-3195.
106. Novotny P., Chubb A.P., Cownley K., et al: Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine. J Infect Dis 1991; 164:114-122.
107. Emsley P., McDermott G., Charles I.G., et al: Crystallographic characterization of pertactin, a membrane-associated protein from Bordetella pertussis. J Mol Biol 1994; 235:772-773.
108. Leininger E., Kenimer J.G., Brennan M.J.: Surface proteins of Bordetella pertussis: role in adherence. Proceedings of the Sixth International Symposium on Pertussis (DHHS no. FDA 90-1164), Bethesda, MD: US Public Health Service; 1990:100-104.
109. Ewanowich CA E.L.: Mechanisms of Bordetella pertussis invasion of HeLa 229 cells. Proceedings of the Sixth International Symposium on Pertussis (DHHS no. FDA 90-1164), Bethesda, MD: US Public Health Service; 1990:106-113.

110. Trollfors B., Zackrisson G., Taranger J., et al: Serum antibodies against a 69-kilodalton outer-membrane protein, pertactin, from Bordetella pertussis in nonvaccinated children with and without a history of clinical pertussis. J Pediatr 1992; 120:924-926.
111. Thomas M.G., Redhead K., Lambert H.P.: Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination. J Infect Dis 1989; 159:211-218.
112. Shahin R.D., Brennan M.J., Li Z.M., et al: Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 1990; 171:63-73.
113. Mooi F.R., van Oirschot H., Heuvelman K., et al: Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998; 66:670-675.
114. Njamkepo E., Rimlinger F., Thiberge S., et al: Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002; 20:1290-1294.
115. Weber C., Boursaux-Eude C., Coralie G., et al: Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 2001; 39:4396-4403.
116. King A.J., Berbers G., van Oirschot H.F., et al: Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 2001; 147(pt 11):2885-2895.
117. Mooi F.R., van Loo I.H., King A.J.: Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?. Emerg Infect Dis 2001; 7(3 Suppl.):526-528.
118. Hallander H.O., Advani A., Donnelly D., et al: Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 2005; 43:2856-2865.
119. Bouchez V., Brun D., Cantinelli T., et al: First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009; 27:6034-6041.
119a. Octavia S., Sintchenko V., Gilbert G.L., et al: Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis 2012 Ap; 205(8):1220-1224.Epub 2012 Mar 13.
122. Poolman J.: Efficacy of Infanrix in promoting lung cancer clearance of B. pertussis strains expressing pertactin antigenic variants in a mouse respiratory model. San Francisco, CA; September 26–29Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999:356.Abstract 234
124. Hewlett E.L., Gordon V.M.: Adenylate cyclase toxin of Bordetella pertussis. In: Wardlaw A.C., Parton R., ed. Pathogenesis and Immunity in Pertussis, New York: John Wiley; 1998:193-209.
125. Hewlett E.L., Donato G.M., Gray M.C.: Macrophage cytotoxicity produced by adenylate cyclase toxin from Bordetella pertussis: more than just making cyclic AMP!. Mol Microbiol 2006; 59:447-459.
126. Weiss A., Roper M.G., Halsey N.A.: Investigation of the role of Bordetella pertussis virulence factors in disease. Proceedings of the Sixth International Symposium on Pertussis (DHHS no. FDA 90-1164), Bethesda, MD: US Public Health Service; 1990:202-205.
127. Arciniega J.L., Hewlett E.L., Johnson F.D., et al: Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis. J Infect Dis 1991; 163:135-142.
128. Guiso N., Szatanik M., Rocancourt M.: Bordetella pertussis adenylate cyclase: a protective antigen against lethality and bacterial colonizations in murine respiratory and intracerebral models. Proceedings of the Sixth International Symposium on Pertussis (DHHS no. FDA 90-1164), Bethesda, MD: US Public Health Service; 1990:207-231.

129. Dunne A., Ross P.J., Pospisilova E., et al: Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol 2010; 185:1711-1719.
130. Cookson B.T., Cho H.L., Herwaldt L.A., et al: Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis. Infect Immun 1989; 57:2223-2229.
131. Goldman W.E.: Tracheal cytotoxin of Bordetella pertussis. In: Wardlaw A.C., Parton R., ed. Pathogenesis and Immunity in Pertussis, New York: John Wiley; 1988:231-246.
132. Nakase Y., Endoh M.: Heat-labile toxin of Bordetella pertussis endotoxin. In: Wardlaw A.C., Parton R., ed. Pathogenesis and Immunity in Pertussis, New York: John Wiley; 1988:211-229.
133. Endoh M., Nagai M., Burns D.L., et al: Effects of exogenous agents on the action of Bordetella parapertussis heat-labile toxin on guinea pig skin. Infect Immun 1990; 58:1456-1460.
134. Fernandez R.C., Weiss A.A.: Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect Immun 1994; 62:4727-4738.
135. Elder K.D., Harvill E.T.: Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect Immun 2004; 72:5919-5924.
136. Oliver D.C., Fernandez R.C.: Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine 2001; 20:235-241.
137. Barnes M.G., Weiss A.A.: Growth phase influences complement resistance of Bordetella pertussis. Infect Immun 2002; 70:403-406.
138. Marr N., Oliver D.C., Laurent V., et al: Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 2008; 26:4306-4311.
139. Chaby R., Croff M.: Lipopolysaccharides of Bordetella pertussis endotoxin. In: Wardlaw A.C., Parton R., ed. Pathogenesis and Immunity in Pertussis, New York: John Wiley; 1988:247-271.
140. Harvill E.T., Preston A., Cotter P.A., et al: Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect Immun 2000; 68:6720-6728.
141. Li Z.M., Cowell J.L., Brennan M.J., et al: Agglutinating monoclonal antibodies that specifically recognize lipooligosaccharide A of Bordetella pertussis. Infect Immun 1988; 56:699-702.
142. Baraff L.J., Manclark C.R., Cherry J.D., et al: Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 1989; 8:502-507.
143. Weiss A.A., Hewlett E.L.: Virulence factors of Bordetella pertussis. Annu Rev Microbiol 1986; 40:661-686.
144. Hewlett E.L.: Pertussis: current concepts of pathogenesis and prevention. Pediatr Infect Dis J 1997; 16(4 Suppl.):S78-S84.
145. Zhang J.M., Cowell J.L., Steven A.C., et al: Purification of serotype 2 fimbriae of Bordetella pertussis and their identification as a mouse protective antigen. Dev Biol Stand 1985; 61:173-185.
146. Confer D.L., Eaton J.W.: Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 1982; 217:948-950.
147. de Gouw D., Diavatopoulos D.A., Bootsma H.J., et al: Pertussis: a matter of immune modulation. FEMS Microbiol Rev 2011; 35:441-474.doi:10.1111/j.1574-6976.2010.00257.x
148. Olson L.C.: Pertussis. Medicine (Baltimore) 1975; 54:427-469.

149. Muller F.M., Hoppe J.E., Wirsing von Konig C.H.: Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol 1997; 35:2435-2443.
150. Hallander H.O.: Microbiological and serological diagnosis of pertussis. Clin Infect Dis 1999; 28(Suppl. 2):S99-106.
151. Broome C.V., Fraser D.W., English W.J.: Pertussis: diagnostic methods and surveillance. In: Manclark C.R., Hill J.C., ed. International Symposium on Pertussis, Bethesda, MD: US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health; 1979.DHEW publication no. (NIH)79-1830:19–22
152. Strebel P.M., Cochi S.L., Farizo K.M., et al: Pertussis in Missouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis. Clin Infect Dis 1993; 16:276-285.
153. Onorato I.M., Wassilak S.G.: Laboratory diagnosis of pertussis: the state of the art. Pediatr Infect Dis J 1987; 6:145-151.
154. Halperin S.A., Bortolussi R., Wort A.J.: Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. J Clin Microbiol 1989; 27:752-757.
155. Hallander H.O., Reizenstein E., Renemar B., et al: Comparison of nasopharyngeal aspirates with swabs for culture of Bordetella pertussis. J Clin Microbiol 1993; 31:50-52.
156. Granstrom G., Wretlind B., Granstrom M.: Diagnostic value of clinical and bacteriological findings in pertussis. J Infect 1991; 22:17-26.
157. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1988; 1:955-960.
158. Heininger U., Schmidt-Schlapfer G., Cherry J.D., et al: Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial. Pediatrics 2000; 105:E31.
159. Stadel A.J.: Use of monoclonal fluorescent antibodies for the detection of B. pertussis and B. parapertussis. Am Clin Lab 2000; 19:14.
160. Ewanowich C.A., Chui L.W., Paranchych M.G., et al: Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology. J Clin Microbiol 1993; 31:1715-1725.
161. He Q., Mertsola J., Soini H., et al: Sensitive and specific polymerase chain reaction assays for detection of Bordetella pertussis in nasopharyngeal specimens. J Pediatr 1994; 124:421-426.
162. Schlapfer G., Cherry J.D., Heininger U., et al: Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis J 1995; 14:209-214.
163. Olcen P., Backman A., Johansson B., et al: Amplification of DNA by the polymerase chain reaction for the efficient diagnosis of pertussis. Scand J Infect Dis 1992; 24:339-345.
164. Reizenstein E., Lofdahl S., Granstrom M., et al: Evaluation of an improved DNA probe for diagnosis of pertussis. Diagn Microbiol Infect Dis 1992; 15:569-573.
165. Glare E.M., Paton J.C., Premier R.R., et al: Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. J Clin Microbiol 1990; 28:1982-1987.
166. Edelman K., Nikkari S., Ruuskanen O., et al: Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr Infect Dis J 1996; 15:54-57.
167. He Q., Schmidt-Schlapfer G., Just M., et al: Impact of polymerase chain reaction on clinical pertussis research: Finnish and Swiss experiences. J Infect Dis 1996; 174:1288-1295.

168. Knorr L., Fox J.D., Tilley P.A., et al: Evaluation of real-time PCR for diagnosis of Bordetella pertussis infection. BMC Infect Dis 2006; 6:62.
169. Schmidt-Schlapfer G., Liese J.G., Porter F., et al: Polymerase chain reaction (PCR) compared with conventional identification in culture for detection of Bordetella pertussis in 7153 children. Clin Microbiol Infect 1997; 3:462-467.
170. Sloan L.M., Hopkins M.K., Mitchell P.S., et al: Multiplex LightCycler PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis in nasopharyngeal specimens. J Clin Microbiol 2002; 40:96-100.
171. Kosters K., Riffelmann M., Wirsing von Konig C.H.: Evaluation of a real-time PCR assay for detection of Bordetella pertussis and B. parapertussis in clinical samples. J Med Microbiol 2001; 50:436-440.
172. Reischl U., Lehn N., Sanden G.N., et al: Real-time PCR assay targeting IS481 of Bordetella pertussis and molecular basis for detecting Bordetella holmesii. J Clin Microbiol 2001; 39:1963-1966.
173. Tilley P.A., Kanchana M.V., Knight I., et al: Detection of Bordetella pertussis in a clinical laboratory by culture, polymerase chain reaction, and direct fluorescent antibody staining: accuracy, and cost. Diagn Microbiol Infect Dis 2000; 37:17-23.
174. Loeffelholz M.J., Thompson C.J., Long K.S., et al: Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol 1999; 37:2872-2876.
175. Templeton K.E., Scheltinga S.A., van der Zee A., et al: Evaluation of real-time PCR for detection of and discrimination between Bordetella pertussisBordetella parapertussis, and Bordetella holmesii for clinical diagnosis. J Clin Microbiol 2003; 41:4121-4126.
176. Muyldermans G., Soetens O., Antoine M., et al: External quality assessment for molecular detection of Bordetella pertussis in European laboratories. J Clin Microbiol 2005; 43:30-35.
177. Lievano F.A., Reynolds M.A., Waring A.L., et al: Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol 2002; 40:2801-2805.
178. Centers for Disease Control and Prevention : Outbreaks of respiratory illness mistakenly attributed to pertussis: New Hampshire, Massachusetts, and Tennessee, 2004–2006. MMWR Morb Mortal Wkly Rep 2007; 56:837-842.
179. Waters V., Jamieson F., Richardson S.E., et al: Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. Pediatr Infect Dis J 2009; 28:582-587.
180. Tatti K.M., Slade B., Patel M., et al: Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines. Pediatr Infect Dis J 2008; 27:73-74.
181. Klement E., Uliel L., Engel I., et al: An outbreak of pertussis among young Israeli soldiers. Epidemiol Infect 2003; 131:1049-1054.
182. Srugo I., Benilevi D., Madeb R., et al: Pertussis infection in fully vaccinated children in day-care centers, Israel. Emerg Infect Dis 2000; 6:526-529.
183. Fisher M.C., Long S.S., McGowan K.L., et al: Outbreak of pertussis in a residential facility for handicapped people. J Pediatr 1989; 114:934-939.
184. Meade B., Mink C., Manclark C.R.: Serodiagnosis of pertussis. In: Manclark C.R., ed. Proceedings of the 6th International Symposium on Pertussis. DHHS no. (FDA) 90-1164, Washington, DC: Food and Drug Administration; 1990:322-329.
185. Wirsing von Konig C.H., Gounis D., Laukamp S., et al: Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis 1999; 18:341-345.

186. Simondon F., Iteman I., Preziosi M.P., et al: Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diagn Lab Immunol 1998; 5:130-134.
187. Steketee R.W., Burstyn D.G., Wassilak S.G., et al: A comparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled. J Infect Dis 1988; 157:441-449.
188. Mink C.M., Cherry J.D., Christenson P., et al: A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14:464-471.
189. Addiss D.G., Davis J.P., Meade B.D., et al: A pertussis outbreak in a Wisconsin nursing home. J Infect Dis 1991; 164:704-710.
190. Cattaneo L.A., Reed G.W., Haase D.H., et al: The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. J Infect Dis 1996; 173:1256-1259.
191. Giammanco A., Chiarini A., Stroffolini T., et al: Seroepidemiology of pertussis in Italy. Rev Infect Dis 1991; 13:1216-1220.
192. Cherry J.D., Chang S.J., Klein D., et al: Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis 2004; 39:1715-1718.
193. Baughman A.L., Bisgard K.M., Edwards K.M., et al: Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 2004; 11:1045-1053.
194. de Greeff S.C., de Melker H.E., van Gageldonk P.G., et al: Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One 2010; 5:e14183.doi:10.1371/journal.pone.0014183
195. Halperin S.A., Bortolussi R., MacLean D., et al: Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 1989; 115(5 pt 1):686-693.
196. Edwards K.M.: Is pertussis a frequent cause of cough in adolescents and adults? should routine pertussis immunization be recommended?. Clin Infect Dis 2001; 32:1698-1699.
197. Ward J.I., Cherry J.D., Chang S.J., et al: Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555-1563.
198. Meade B.D., Deforest A., Edwards K.M., et al: Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 1995; 96(3 pt 2):570-575.
199. Lynn F., Reed G.F., Meade B.D.: A comparison of enzyme immunoassays used to measure serum antibodies to components of Bordetella pertussis. Dev Biol Stand 1997; 89:197-204.
200. Lynn F., Reed G.F., Meade B.D.: Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol 1996; 3:689-700.
201. Reizenstein E., Hallander H.O., Blackwelder W.C., et al: Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995; 183:279-290.
202. Menzies S.L., Kadwad V., Pawloski L.C.Pertussis Assay Working Group: Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection. Clin Vaccine Immunol 2009; 16:1781-1788.
203. Tondella M.L., Carlone G.M., Messonnier N.Centers for Disease Control and Prevention: International Bordetella pertussis assay standardization and harmonization meeting report. Vaccine 2009; 27:803-814.

204. Marchant C.D., Loughlin A.M., Lett S.M., et al: Pertussis in Massachusetts, 1981–1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 1994; 169:1297-1305.
205. Yih W.K., Lett S.M., des Vignes F.N., et al: The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989–1998. J Infect Dis 2000; 182:1409-1416.
206. Strebel P., Nordin J., Edwards K., et al: Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. J Infect Dis 2001; 183:1353-1359.
207. de Melker H.E., Versteegh F.G., Conyn-Van Spaendonck M.A., et al: Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000; 38:800-806.
208. Hallander H.O.: Diagnostic pertussis serology in the recent clinical efficacy studies of acellular vaccines. Dev Biol Stand 1997; 89:205-212.
209. Tiwari T., Murphy T.V., Moran J.: Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54(RR-14):1-16.
210. Halperin S.A., Bortolussi R., Langley J.M., et al: Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 1997; 100:65-71.
211. Bass J.W., Klenk E.L., Kotheimer J.B., et al: Antimicrobial treatment of pertussis. J Pediatr 1969; 75:768-781.
212. Hewlett E.L.: Bordetella species. In: Mandell G., ed. Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th ed. New York: Churchill Livingstone; 1995.
213. Mortimer Jr E.A., Jones P.K.: An evaluation of pertussis vaccine. Rev Infect Dis 1979; 1:927-934.
214. In: Peter G., Hall C.B., Halsey N.A., et al ed. Red book: report of the Committee on Infectious Diseases, 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997.
215. Kawai H., Aoyama T., Goto A., et al: Evaluation of pertussis treatment with erythromycin ethylsuccinate and stearate according to age. Kansenshogaku Zasshi 1994; 68:1324-1329.
216. Aoyama T., Sunakawa K., Iwata S., et al: Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996; 129:761-764.
217. Halperin S.A., Bortolussi R., Langley J.M., et al: A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 1999; 104:e42.
218. Bortolussi R., Miller B., Ledwith M., et al: Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870-874.
219. Kwantes W., Joynson D.H., Williams W.O.: Bordetella pertussis isolation in general practice: 1977–79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 1983; 90:149-158.
220. Henry R., Dorman D., Skinner J., et al: Limitations of erythromycin in whooping cough. Med J Aust 1981; 2:108-109.
221. Hoppe J.E., Rahimi-Galougahi E., Seibert G.: In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem. Antimicrob Agents Chemother 1996; 40:807-808.
222. Hoppe J.E., Bryskier A.: In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother 1998; 42:965-966.

223. Langley J.M., Halperin S.A., Boucher F.D., et al: Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:e96-101.
224. Centers for Disease Control and Prevention : Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin: Knoxville, Tennessee, 1999. JAMA 2000; 283:471-472.
225. Honein M.A., Paulozzi L.J., Himelright I.M., et al: Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999; 354:2101-2105.
226. Centers for Disease Control and Prevention : Erythromycin-resistant Bordetella pertussis: Yuma County, Arizona, May-October, 1994. JAMA 1995; 273:13-14.
227. Gordon K.A., Fusco J., Biedenbach D.J., et al: Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2001; 45:3599-3600.
228. Korgenski E.K., Daly J.A.: Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States. J Clin Microbiol 1997; 35:2989-2991.
229. Bartkus J.M., Juni B.A., Ehresmann K., et al: Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance. J Clin Microbiol 2003; 41:1167-1172.
230. Fry N.K., Duncan J., Vaghji L., et al: Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the E-test method. Eur J Clin Microbiol Infect Dis 2010; 29:1183-1185.
231. Altunaiji S., Kukuruzovic R., Curtis N., et al: Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007; 3:CD004404
232. Beneson A.S.: Control of Communicable Disease Manual. 16th ed. Washington, DC, American Public Health Association, 1995.
233. Weber D.J., Rutala W.A.: Management of healthcare workers exposed to pertussis. Infect Control Hosp Epidemiol 1994; 15:411-415.
234. Decker M.D., Schaffner W.: Nosocomial diseases of health care workers spread by airborne or contact route (other than tuberculosis). In: Mayhall C.G., ed. Hospital Epidemiology and Infection Control, Baltimore: Williams & Wilkins; 1996:725-730.
235. Wirsing von Konig C.H., Schmitt H.J., Bogaerts H., et al: Factors influencing the analysis of secondary prevention of pertussis. Dev Biol Stand 1997; 89:175-179.
236. De Serres G., Boulianne N., Duval B.: Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995; 14:969-975.
237. Fine P.E., Clarkson J.A.: The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1982; 1:666-669.
238. Farizo K.M., Cochi S.L., Zell E.R., et al: Epidemiological features of pertussis in the United States, 1980–1989. Clin Infect Dis 1992; 14:708-719.
239. Guris D., Strebel P.M., Bardenheier B., et al: Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin Infect Dis 1999; 28:1230-1237.
240. Cherry J.D.: The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 1984; 14:1-78.
241. Kanai K.: Japan's experience in pertussis epidemiology and vaccination in the past thirty years. Jpn J Med Sci Biol 1980; 33:107-143.
242. Cherry J.D., Baraff L.J., Hewlett E.: The past, present, and future of pertussis: the role of adults in epidemiology and future control. West J Med 1989; 150:319-328.
243. Cherry J.D.: Pertussis in adults. Ann Intern Med 1998; 128:64-66.

244. Luttinger P.: The epidemiology of pertussis. Am J Dis Child 1916; 12:290-315.
245. Friedlander A.: Whooping cough. Pediatrics 1925; 11:128-147.
246. Pertussis: United States, 2001–2003. MMWR Morb Mortal Wkly Rep 2005; 54:1283-1286.
247. Lambert H.J.: Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep 1965; 80:365-369.
248. Cherry J.D., Beer T., Chartrand S.A., et al: Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin Infect Dis 1995; 20:1271-1274.
249. Linnemann Jr C.C., Bass J.W., Smith M.H.: The carrier state in pertussis. Am J Epidemiol 1968; 88:422-427.
250. Lambert H.P.: The carrier state: Bordetella pertussis. J Antimicrob Chemother 1986; 18(Suppl. A):13-16.
251. Kretsinger K., Broder K.R., Cortese M.M.Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (ACIP), Healthcare Infection Control Practices Advisory Committee (HICPAC): Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; recommendations of ACIP, supported by HICPAC, for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55(RR-17):1-37.
251a. http://www.cdc.gov/pertussis/surv-reporting.html
252. Rosenthal S., Strebel P., Cassiday P., et al: Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis 1995; 171:1650-1652.
253. Christie C.D., Marx M.L., Marchant C.D., et al: The 1993 epidemic of pertussis in Cincinnati: resurgence of disease in a highly immunized population of children. N Engl J Med 1994; 331:16-21.
254. Resurgence of pertussis: United States, 1993. MMWR Morb Mortal Wkly Rep 1993; 42:952-960.
255. Pertussis outbreak: Vermont, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:822-826.
256. Edwards K.M., Decker M.D., Halsey N.A., et al: Differences in antibody response to whole-cell pertussis vaccines. Pediatrics 1991; 88:1019-1023.
257. Edwards K.M., Decker M.D.: Acellular pertussis vaccines for infants. N Engl J Med 1996; 334:391-392.
258. Stehr K., Cherry J.D., Heininger U., et al: A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101(1 pt 1):1-11.
259. Gustafsson L., Hallander H.O., Olin P., et al: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-355.
260. Greco D., Salmaso S., Mastrantonio P., et al: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334:341-348.
261. Pertussis: United States, January 1992-June 1995. MMWR Morb Mortal Wkly Rep 1995; 44:525-529.
262. California Department of Public Health. Pertussis report: July 12, 2011. http://www.cdph.ca.gov/programs/immunize/Documents/PertussisReport2011–07–12.pdf . (Accessed 15 June 2012)
263. Roehr B.: Whooping cough outbreak hits several US states. BMJ 2010; 341:c4627.doi:10.1136/bmj.c4627
263a. http://www.doh.wa.gov/Portals/1/Documents/Pubs/348-254-PertussisUpdate.pdf

263b. http://www.cdc.gov/pertussis/outbreaks.html
264. Davis S.F., Strebel P.M., Cochi S.L., et al: Pertussis surveillance: United States, 1989–1991. MMWR CDC Surveill Summ 1992; 41:11-19.
265. He Q., Viljanen M.K., Nikkari S., et al: Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 1994; 170:873-877.
266. Biellik R.J., Patriarca P.A., Mullen J.R., et al: Risk factors for community- and household-acquired pertussis during a large-scale outbreak in central Wisconsin. J Infect Dis 1988; 157:1134-1141.
267. Mink C.A., Sirota N.M., Nugent S.: Outbreak of pertussis in a fully immunized adolescent and adult population. Arch Pediatr Adolesc Med 1994; 148:153-157.
268. School-associated pertussis outbreak: Yavapai County, Arizona, September 2002-February 2003. MMWR Morb Mortal Wkly Rep 2004; 53:216-219.
269. Davis J.P.: Clinical and economic effects of pertussis outbreaks. Pediatr Infect Dis J 2005; 24(6 Suppl.):S109-S116.
270. Centers for Disease Control and Prevention : Use of Mass Tdap vaccination to control an outbreak of pertussis in a high school: Cook County, Illinois, September 2006-January 2007. MMWR Morb Mortal Wkly Rep 2008; 57:796-799.
271. Elliott E., McIntyre P., Ridley G., et al: National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004; 23:246-252.
272. Robertson P.W., Goldberg H., Jarvie B.H., et al: Bordetella pertussis infection: a cause of persistent cough in adults. Med J Aust 1987; 146:522-525.
273. Wright S.W., Edwards K.M., Decker M.D., et al: Pertussis infection in adults with persistent cough. JAMA 1995; 273:1044-1046.
274. Nennig M.E., Shinefield H.R., Edwards K.M., et al: Prevalence and incidence of adult pertussis in an urban population. JAMA 1996; 275:1672-1674.
275. Campins-Marti M., Cheng H.K., Forsyth K., et al: Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001; 20:641-646.
276. Lee G.M., Lett S., Schauer S., et al: Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004; 39:1572-1580.
277. Purdy K.W., Hay J.W., Botteman M.F., et al: Evaluation of strategies for use of acellular 719966 pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004; 39:20-28.
278. Van Rie A., Hethcote H.W.: Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004; 22:3154-3165.
279. Centers for Disease Control and Prevention : National, state, and local area vaccination coverage among adolescents aged 13-17 years: United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1018-1023.
280. Wei S.C., Tatti K., Cushing K., et al: Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010; 51:315-321.
281. World Health Organization : Global Programme on Vaccines. New York, World Health Organization, 1996. Presented at State of the World's Vaccines and Immunization http://www.who.int/vaccines-documents/DocsPDF/www9532.pdf
282. Crowcroft N.S., Stein C., Duclos P., et al: How best to estimate the global burden of pertussis?. Lancet Infect Dis 2003; 3:413-418.
283. Van Savage J., Decker M.D., Edwards K.M., et al: Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990; 161:487-492.
284. Shakib J.H., Ralston S., Raissy H.H., et al: Pertussis antibodies in postpartum women and their newborns. J Perinatol 2010; 30:93-97.

285. Healy C.M., Munoz F.M., Rench M.A., et al: Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190:335-340.
286. Lichty J.A., Slavin B., Bradford W.L.: An attempt to increase resistance to pertussis in newborn infants by immunizing their mothers during pregnancy. J Clin Invest 1938; 17:613-621.
287. Pertussis antibodies in pregnant women : protective, agglutinating and complement fixing antibodies before and after vaccination. Am J Dis Child 1942; 64:608-617.
288. Cohen P., Scadron S.: The placental transmission of protective antibodies against whooping cough by inoculation of the pregnant mother. JAMA 1943; 121:656-662.
289. Kendrick P., Thompson M., Eldering G.: Immunity response of mothers and babies to injections of pertussis vaccine during pregnancy. Am J Dis Child 1946; 70:25-28.
290. Englund J.A., Anderson E.L., Reed G.F., et al: The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995; 96(3 pt 2):580-584.
291. Elahi S., Buchanan R.M., Babiuk L.A., et al: Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun 2006; 74:2619-2627.
292. Leuridan E., Hens N., Peeters N., et al: Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011; 30:608-610.
293. Centers for Disease Control and Prevention : Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged < 12 months: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1424-1426.
293a. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011 Oct 21;60
294. Bradford W.: Use of convalescent blood in whooping cough. Am J Dis Child 1935; 50:918-928.
295. Balagtas R.C., Nelson K.E., Levin S., et al: Treatment of pertussis with pertussis immune globulin. J Pediatr 1971; 79:203-208.
296. Morris D., McDonald J.C.: Failure of hyperimmune gamma globulin to prevent whooping cough. Arch Dis Child 1957; 32:236-239.
297. Granstrom M., Olinder-Nielsen A.M., Holmblad P., et al: Specific immunoglobulin for treatment of whooping cough. Lancet 1991; 338:1230-1233.
298. Halperin S.A., Vaudry W., Boucher F.D., et al: Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? no answer yet. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 2007; 26:79-81.
299. Madsen T.: Vaccination against whooping cough. JAMA 1933; 101:187-188.
300. Kendrick P., Eldering G., Dixon M.: Mouse protection tests in the study of pertussis vaccine: a comparative series using intercerebral route for challenge. Am J Public Health 1947; 37:803-810.
301. Eldering G.: Symposium on pertussis immunization, in honor of Dr. Pearl L. Kendrick in her eightieth year: historical notes on pertussis immunization. Health Lab Sci 1971; 8:200-205.
302. Vaccination against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton,

Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley. Br Med J 1956; 2:454-462.
303. Sato Y., Kimura M., Fukumi H.: Development of a pertussis component vaccine in Japan. Lancet 1984; 1:122-126.
304. Kimura M., Hikino N.: Results with a new DTP vaccine in Japan. Dev Biol Stand 1985; 61:545-561.
305. Noble G.R., Bernier R.H., Esber E.C., et al: Acellular and whole-cell pertussis vaccines in Japan: report of a visit by US scientists. JAMA 1987; 257:1351-1356.
306. Aoyama T., Murase Y., Gonda T., et al: Type-specific efficacy of acellular pertussis vaccine. Am J Dis Child 1988; 142:40-42.
307. Kimura M., Kuno-Sakai H.: Current epidemiology of pertussis in Japan. Pediatr Infect Dis J 1990; 9:705-709.
308. Kimura M.: Japanese clinical experiences with acellular pertussis vaccines. Dev Biol Stand 1991; 73:5-9.
309. Kuno-Sakai H., Kimura M.: Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int 2004; 46:650-655.
310. Okada K., Ohashi Y., Matsuo F., et al: Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study. Epidemiol Infect 2009; 137:124-130.
311. Edwards K.M., Meade B.D., Decker M.D., et al: Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96(3 pt 2):548-557.
312. Guiso N., Capiau C., Carletti G., et al: Intranasal murine model of Bordetella pertussis infection, I: prediction of protection in human infants by acellular vaccines. Vaccine 1999; 17:2366-2376.
313. Edwards K., Decker M., Mortimer E.A.: Pertussis vaccine. In: Plotkin S., Mortimer Jr E.A., Orenstein W.A., ed. Vaccines, 3rd ed. Philadelphia: WB Saunders; 1999:293-344.
314. Greenberg D.P., Pickering L.K., Senders S.D., et al: Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. Pediatrics 2002; 109:666-672.
315. Hinman A.R., Koplan J.P.: Pertussis and pertussis vaccine: reanalysis of benefits, risks, and costs. JAMA 1984; 251:3109-3113.
316. Miller D.L., Alderslade R., Ross E.M.: Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol Rev 1982; 4:1-24.
317. Kendrick P., Eldering G.: Progress report on pertussis immunization. Am J Public Health 1936; 26:8-12.
318. Sauer L.: Whooping cough: new phases of the work of immunizations and prophylaxis. JAMA 1939; 112:305-308.
319. Baker J.D., Halperin S.A., Edwards K., et al: Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 1992; 121:523-527.
320. Steinhoff M.C., Reed G.F., Decker M.D., et al: A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 1995; 96(3 pt 2):567-570.
321. Doull J., Shibley G., McClelland J.: Active immunization against whooping cough: interim report of the Cleveland experience. Am J Public Health 1936; 26:1097-1105.
322. Sako W.: Studies on pertussis immunization. J Pediatr 1947; 30:29-40.
323. Vaccination against whooping-cough; the final report to the Whooping-Cough Immunization Committee of the Medical Research Council and to the medical officers of health for Battersea and Wandsworth, Bradford, Liverpool, and Newcastle. Br Med J 1959; 46:994-1000.

324. Schmitt H.J., von Konig C.H., Neiss A., et al: Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41.
325. Liese J.G., Meschievitz C.K., Harzer E., et al: Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997; 16:1038-1044.
326. Lederle Laboratories : ACEL-MUNE product labeling. Montvale, NJ, Medical Economics Company, 1997.
327. Simondon F., Preziosi M.P., Yam A., et al: A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15:1606-1612.
328. Ramsay M.E., Farrington C.P., Miller E.: Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect 1993; 111:41-48.
329. White J.M., Fairley C.K., Owen D., et al: The effect of an accelerated immunisation schedule on pertussis in England and Wales. Commun Dis Rep CDR Rev 1996; 6:R86-R91.
330. Miller E., Ashworth L.A., Redhead K., et al: Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 1997; 15:51-60.
331. Lautrop H., Mikkelsen O.S.: The effect of prophylactic whooping-cough vaccination. An attempt at an evaluation based on experiences in Denmark. Ugeskr Laeger 1969; 131:735-741.
332. Sutter R.W., Cochi S.L.: Pertussis hospitalizations and mortality in the United States, 1985–1988. Evaluation of the completeness of national reporting. JAMA 1992; 267:386-391.
333. Dauer C.: Reported whooping cough morbidity and mortality in the United States. Public Health Rep 1943; 58:661-676.
334. Kimura M., Kuno-Sakai H.: Immunization system in Japan: its history and present situation. Acta Paediatr Jpn 1988; 30:109-126.
335. Stuart-Harris C.H.: Experiences of pertussis in the United Kingdom. In: Manclark C.R., Hill J.C., ed. International Symposium on Pertussis, Washington, DC: US Department of Health; 1979.Education, and Welfare publication no. (NIH) 79-1830
336. Romanus V., Jonsell R., Bergquist S.O.: Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6:364-371.
337. Storsaeter J., Olin P.: Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 1992; 10:142-144.
338. Taranger J., Trollfors B., Bergfors E., et al: Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics 2001; 108:E115.
339. Trollfors B., Dotevall L., Sundh V., et al: Pertussis after end of a mass vaccination project: end of the “vaccination honey-moon”. Vaccine 2011; 29:2444-2450.
340. Gustafsson L., Hessel L., Storsaeter J., et al: Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006; 118:978-984.
341. Baron S., Njamkepo E., Grimprel E., et al: Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998; 17:412-418.
342. Pollard R.: Relation between vaccination and notification rates for whooping cough in England and Wales. Lancet 1980; 1:1180-1182.
343. Onorato I.M., Wassilak S.G., Meade B.: Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 1992; 267:2745-2749.
344. Vesselinova-Jenkins C.K., Newcombe R.G., Gray O.P., et al: The effects of immunisation upon the natural history of pertussis: a family study in the Cardiff area. J Epidemiol Community Health 1978; 32:194-199.

345. Grob P.R., Crowder M.J., Robbins J.F.: Effect of vaccination on severity and dissemination of whooping cough. Br Med J (Clin Res Ed) 1981; 282:1925-1928.
346. Preziosi M.P., Halloran M.E.: Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis 2003; 37:772-779.
347. Preziosi M.P., Halloran M.E.: Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 2003; 21:1853-1861.
348. Cvjetanovic B., Grab B., Uemura K.: Diphtheria and whooping cough: diseases affecting a particular age group. Bull World Health Organ 1978; 56(Suppl. 1):103-133.
349. Fox J.P., Elveback L., Scott W., et al: Herd immunity: basic concept and relevance to public health immunization practices: 1971. Am J Epidemiol 1995; 141:185-197.
350. Feikin D.R., Lezotte D.C., Hamman R.F., et al: Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 2000; 284:3145-3150.
351. Jenkinson D.: Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988; 296:612-614.
352. Fine P.E., Clarkson J.A.: Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9:866-883.
353. Weiss E., Kendrick P.: The effectiveness of pertussis vaccine: an application of Sargent and Merrell's method of measurement. Am J Hyg 1943; 38:306-309.
354. Howson C.P., Fineberg H.V.: Adverse events following pertussis and rubella vaccines: summary of a report of the Institute of Medicine. JAMA 1992; 267:392-396.
355. In: Stratton K.R., Howe C.J., Johnston R.B., ed. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis, Washington, DC: National Academy Press; 1994.
356. In: Howson C.P., Howe B.J., Fineberg H.V., ed. Adverse Effects of Pertussis and Rubella Vaccines: Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines, Washington, DC: National Academy Press; 1991.Institute of Medicine
357. Mortimer E.: Pertussis. In: Plotkin S., Mortimer E., ed. Vaccines, 2nd ed. Philadelphia, PA: WB Saunders; 1994.
358. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40(RR-10):1-28.
359. Cadoz M., Arminjon F., Quentin-Millet M.J.: Safety and immunogenicity of Merieux acellular pertussis in adult volunteers. Transcript of the Workshop on Acellular Pertussis Vaccines, Washington, DC: US Department of Health and Human Services; 1986:131-134.
360. Cody C.L., Baraff L.J., Cherry J.D., et al: Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68:650-660.
361. Decker M.D., Edwards K.M., Steinhoff M.C., et al: Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96(3 pt 2):557-566.
362. Baraff L.J., Cody C.L., Cherry J.D.: DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 1984; 73:31-36.
363. Pichichero M.E., Christy C., Decker M.D., et al: Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics 1995; 96(3 pt 2):588-592.
364. Deloria M.A., Blackwelder W.C., Decker M.D., et al: Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 1995; 96(3 pt 2):592-594.
365. Hirtz D.G., Nelson K.B., Ellenberg J.H.: Seizures following childhood immunizations. J Pediatr 1983; 102:14-18.

366. Walker A.M., Jick H., Perera D.R., et al: Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 1988; 81:345-349.
367. Griffin M.R., Ray W.A., Mortimer E.A., et al: Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA 1990; 263:1641-1645.
368. Stetler H.C., Orenstein W.A., Bart K.J., et al: History of convulsions and use of pertussis vaccine. J Pediatr 1985; 107:175-179.
369. Bellman M., Ross E.: Pertussis immunizations and fits. In: Ross E., Reynolds E., ed. Paediatric Perspectives on Epilepsy, New York: John Wiley; 1985.
370. Livengood J.R., Mullen J.R., White J.W., et al: Family history of convulsions and use of pertussis vaccine. J Pediatr 1989; 115:527-531.
371. Center for Biologics Evaluation and Research : Proceedings of the Sixth International Symposium on Pertussis, National Institutes of Health, Bethesda, MD: Dept. of Health and Human Services, US Public Health Service, Food and Drug Administration; 1990.Sept 26–28
372. Ellenberg J.H., Hirtz D.G., Nelson K.B.: Do seizures in children cause intellectual deterioration?. N Engl J Med 1986; 314:1085-1088.
373. Shields W.D., Nielsen C., Buch D., et al: Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. J Pediatr 1988; 113:801-805.
374. Braun M.M., Terracciano G., Salive M.E., et al: Report of a US public health service workshop on hypotonic-hyporesponsive episode (HHE) after pertussis immunization. Pediatrics 1998; 102:E52.
375. Miller D.C., Wadsworth M.J., Ross E.M.: Pertussis vaccine and severe acute neurological illnesses: response to a recent review by members of the NCES team. Vaccine 1989; 7:487-489.
376. Bellman M.H., Ross E.M., Miller D.L.: Infantile spasms and pertussis immunisation. Lancet 1983; 1:1031-1034.
377. Safety of pertussis vaccine. Lancet 1990; 335:655-656.
378. Miller D., Madge N., Diamond J., et al: Pertussis immunisation and serious acute neurological illnesses in children. BMJ 1993; 307:1171-1176.
379. Griffith A.H.: Pertussis vaccines and permanent brain damage. Vaccine 1989; 7:489-490.
380. Bowie C.: Lessons from the pertussis vaccine court trial. Lancet 1990; 335:397-399.
381. Stephenson J.B.: A neurologist looks at neurological disease temporally related to DTP immunization. Tokai J Exp Clin Med 1988; 13:157-164.(Suppl.)
382. Leviton A.: Neurologic sequelae of pertussis immunization: 1989. J Child Neurol 1989; 4:311-314.
383. MacRae K.D.: Epidemiology, encephalopathy, and pertussis vaccine. In: Mebel S., Stompe H., Drescher M., et al ed. FEMS Symposium: Pertussis: Proceedings of the Conference Organized by the Society of Microbiology and Epidemiology of the GDR, 1988.Berlin; April 20–22
384. Riikonen R., Donner M.: Incidence and aetiology of infantile spasms from 1960 to 1976: a population study in Finland. Dev Med Child Neurol 1979; 21:333-343.
385. Millichap J.G.: Etiology and treatment of infantile spasms: current concepts, including the role of DPT immunization. Acta Paediatr Jpn 1987; 29:54-60.
386. Melchior J.C.: Infantile spasms and early immunization against whooping cough: Danish survey from 1970 to 1975. Arch Dis Child 1977; 52:134-137.
387. Fukuyama Y., Tomori N., Sugitate M.: Critical evaluation of the role of immunization as an etiological factor of infantile spasms. Neuropadiatrie 1977; 8:224-237.
388. Lombroso C.T.: A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983; 24:135-158.

389. Guyer B., Martin J.A., MacDorman M.F., et al: Annual summary of vital statistics: 1996. Pediatrics 1997; 100:905-918.
390. Bernier R.H., Frank Jr J.A., Dondero Jr T.J., et al: Diphtheria-tetanus toxoids-pertussis vaccination and sudden infant deaths in Tennessee. J Pediatr 1982; 101:419-421.
391. Baraff L.J., Ablon W.J., Weiss R.C.: Possible temporal association between diphtheria-tetanus toxoid-pertussis vaccination and sudden infant death syndrome. Pediatr Infect Dis 1983; 2:7-11.
392. Torch W.: Diphtheria-pertussis-tetanus (DPT) immunization: a potential cause of sudden infant death syndrome (SIDS). J Pediatr 1982; 101:169-170.
393. Torch W.: Characteristics of diphtheria-pertussis-tetanus (DPT) postvaccinal deaths and DPT-caused sudden infant death syndrome (SIDS): a review. Neurology 1986; 36(Suppl. 1):148.
394. Nickerson B., Robison B.: How many sudden infant death syndrome victims were recently immunized?. Western Soc Pediatr Res Clin Res 1985; 33:121A.
395. Taylor E.M., Emergy J.L.: Immunization and cot deaths. Lancet 1982; 2:721.
396. Hoffman H.J., Hunter J.C., Damus K., et al: Diphtheria-tetanus-pertussis immunization and sudden infant death: results of the National Institute of Child Health and Human Development Cooperative Epidemiological Study of Sudden Infant Death Syndrome risk factors. Pediatrics 1987; 79:598-611.
397. Bouvier-Colle M.H., Flahaut A., Messiah A., et al: Sudden infant death and immunization: an extensive epidemiological approach to the problem in France: winter 1986. Int J Epidemiol 1989; 18:121-126.
398. Griffin M.R., Ray W.A., Livengood J.R., et al: Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl J Med 1988; 319:618-623.
399. Geraghty K.: 1985.
400. Walker A.M., Jick H., Perera D.R., et al: Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health 1987; 77:945-951.
401. Solberg L.K.: DTP immunization, visit to child health center and sudden infant death syndrome (SIDS). Report to the Oslo Health Council, Norway1985.
402. Wennergren G., Milerad J., Lagercrantz H., et al: The epidemiology of sudden infant death syndrome and attacks of lifelessness in Sweden. Acta Paediatr Scand 1987; 76:898-906.
403. Howson C.P., Fineberg H.V.: The ricochet of magic bullets: summary of the Institute of Medicine Report, Adverse Effects of Pertussis and Rubella Vaccines. Pediatrics 1992; 89:318-324.
404. Skowronski D.M., De Serres G., MacDonald D., et al: The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002; 185:1448-1453.
405. Ridgway D.: Disputed claims for pertussis vaccine injuries under the National Vaccine Injury Compensation Program. J Investig Med 1998; 46:168-174.
406. Mills K.H., Barnard A., Watkins J., et al: Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993; 61:399-410.
407. Petersen J.W., Andersen P., Ibsen P.H., et al: Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine. Vaccine 1993; 11:463-472.
408. Petersen J.W., Ibsen P.H., Haslov K., et al: Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis. Infect Immun 1992; 60:4563-4570.

409. Redhead K., Watkins J., Barnard A., et al: Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 1993; 61:3190-3198.
410. Adamson P.C., Wu T.C., Meade B.D., et al: Pertussis in a previously immunized child with human immunodeficiency virus infection. J Pediatr 1989; 115:589-592.
411. Bromberg K., Tannis G., Steiner P.: Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect Immun 1991; 59:4715-4719.
412. Mills K.H., Ryan M., Ryan E., et al: A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998; 66:594-602.
413. Gearing A.J., Bird C.R., Redhead K., et al: Human cellular immune responses to Bordetella pertussis infection. FEMS Microbiol Immunol 1989; 1:205-211.
414. De Magistris M.T., Romano M., Nuti S., et al: Dissecting human T cell responses against Bordetella species. J Exp Med 1988; 168:1351-1362.
415. Peppoloni S., Nencioni L., Di Tommaso A., et al: Lymphokine secretion and cytotoxic activity of human T-cell clones against CD4 Bordetella pertussis. Infect Immun 1991; 59:3768-3773.
416. Petersen J.W., Ibsen P.H., Bentzon M.W., et al: The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans. FEMS Microbiol Immunol 1991; 3:279-287.
417. Podda A., Nencioni L., De Magistris M.T., et al: Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med 1990; 172:861-868.
418. Meyer C.U., Zepp F., Decker M., et al: Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Clin Vaccine Immunol 2007; 14:288-292.
419. Zepp F., Knuf M., Habermehl P., et al: Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 1996; 64:4078-4084.
420. Guiso N., Njamkepo E., Vié le Sage F., et al: Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25:1390-1397.
421. Ausiello C.M., Lande R., Urbani F., et al: Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 2000; 181:1989-1995.
422. Ausiello C.M., Lande R., Urbani F., et al: Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 1999; 67:4064-4071.
423. Cassone A., Ausiello C.M., Urbani F.: Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussi vaccines. Arch Pediatr Adolesc Med 1997; 151:282-289.
424. Cassone A., Mastrantonio P., Ausiello C.M.: Are only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients?. J Infect Dis 2000; 182:1575-1577.
425. Tran Minh N.N., He Q., Edelman K., et al: Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatr Infect Dis J 1999; 18:366-370.

426. Edelman K.J., He Q., Makinen J.P., et al: Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 2004; 39:179-185.
427. Scheifele D.W., Ochnio J.J., Halperin S.A.: Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. Pediatr Infect Dis J 2009; 28:985-989.
428. Rieber N., Graf A., Hartl D., et al: Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response. PLoS One 2011; 6:e17271.doi:10.1371/journal.pone.0017271
429. Miller J.J., Silverberg R., Saito T.M., et al: An agglutinative reaction for Haemophilus pertussis, II: its relations to clinical immunity. J Pediatr 1943; 22:644-651.
430. Olin P., Hallander H.O., Gustafsson L., et al: How to make sense of pertussis immunogenicity data. Clin Infect Dis 2001; 33(Suppl. 4):S288-S291.
431. Cherry J.D., Gornbein J., Heininger U., et al: A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-1906.
432. Hewlett E.L., Halperin S.A.: Serological correlates of immunity to Bordetella pertussis. Vaccine 1998; 16:1899-1900.
433. Poland G.A.: Still more questions on pertussis vaccines. Lancet 1997; 350:1564-1565.
434. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use: supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1992; 41(RR-1):1-10.
435. Storsaeter J., Olin P., Renemar B., et al: Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect Dis J 1988; 7:637-645.
436. Isomura S.: License application for pertussis vaccine withdrawn in Sweden. Lancet 1989; 1:114.
437. Samore M.H., Siber G.R.: Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b. J Infect Dis 1992; 165:945-948.
438. Black S.B., Cherry J.D., Shinefield H.R., et al: Apparent decreased risk of invasive bacterial disease after heterologous childhood immunization. Am J Dis Child 1991; 145:746-749.
439. Davidson M., Letson G.W., Ward J.I., et al: DTP immunization and susceptibility to infectious diseases: is there a relationship?. Am J Dis Child 1991; 145:750-754.
440. Joffe L.S., Glode M.P., Gutierrez M.K., et al: Diphtheria-tetanus toxoids-pertussis vaccination does not increase the risk of hospitalization with an infectious illness. Pediatr Infect Dis J 1992; 11:730-735.
441. Kimura M., Kuno-Sakai H.: Acellular pertussis vaccines and fatal infections. Lancet 1988; 1:881-882.
442. Blackwelder W.C., Storsaeter J., Olin P., et al: Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am J Dis Child 1991; 145:1285-1289.
443. Storsaeter J., Hallander H., Farrington C.P., et al: Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990; 8:457-461.
444. Olin P., Storsaeter J.: Vaccine efficacy in a clinical trial of acellular pertussis vaccines in Sweden: technical report. Paper presented at Stockholm, Sweden, National Bacteriological Laboratory, 1988.
445. World Health Organization : Paper presented at WHO Meeting on Case Definition of Pertussis. Geneva; January 10–111991. p. 4–5
446. Gustafsson L., Hallander H., Olin P.: Efficacy Trial of acellular pertussis vaccines: technical report trial I, with results of preplanned analysis of safety, efficacy and

immunogenicity. Paper presented at Swedish Institute for Infectious Diseases Control. Stockholm, Sweden1995.
447. Hallander H.O., Storsaeter J., Mollby R.: Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial. J Infect Dis 1991; 163:1046-1054.
448. Taranger J., Trollfors B., Lagergard T., et al: Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997; 16:180-184.
449. Heininger U., Cherry J.D., Eckhardt T., et al: Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr Infect Dis J 1993; 12:504-509.
450. Edwards K.M., Decker M.D.: Comparison of serological results in the NIAID Multicenter Acellular Pertussis Trial with recent efficacy trials. Dev Biol Stand 1997; 89:265-273.
451. Salmaso S., Anemona A., Mastrantonio P., et al: Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Dev Biol Stand 1998; 95:189-194.
452. Salmaso S., Mastrantonio P., Tozzi A.E., et al: Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108:E81.
453. Olin P., Rasmussen F., Gustafsson L., et al: Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350:1569-1577.
454. Plotkin S.A., Cadoz M.: Acellular vaccine efficacy trials. Pediatr Infect Dis J 1997; 16:913-914.
455. Trollfors B., Taranger J., Lagergard T., et al: A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333:1045-1050.
456. Trollfors B., Taranger J., Lagergard T., et al: Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. J Pediatr 1997; 130:532-536.
457. Taranger J., Trollfors B., Bergfors E., et al: Mass vaccination of children with pertussis toxoid-decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001; 33:1004-1010.
458. Nilsson L, Rydevik G. Twelve year report: pertussis in Göteborg study area. http://www.smittskyddsinstitutet.se/upload/Publikationer/smirapport-02–2010.pdf . (Accessed on 15 June 2012)
459. Heininger U., Cherry J.D., Stehr K., et al: Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics 1998; 102(3 pt 1):546-553.
460. Cherry J.D., Heininger U., Stehr K., et al: The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics 1998; 102(4 pt 1):909-912.
461. Lugauer S., Heininger U., Cherry J.D., et al: Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002; 161:142-146.
462. Simondon F.: Senegal pertussis trial. Dev Biol Stand 1997; 89:63-66.
463. Plotkin S.A., Cadoz M.: The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 1997; 16:508-519.
464. Cherry J.D.: Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997; 16(4 Suppl.):S90-S96.

465. Gustafsson L., Hallander H., Olin P.: Pertussis surveillance in Sweden: progress report Oct 1997-Sept 2004 with executive summary: seven year report. Swedish Institute for Infectious Disease Control (SMI), 2005. June 16
466. Olin P., Gustafsson L., Rasmussen F.: Efficacy trial of acellular pertussis vaccines: technical report trial II, with results of preplanned analysis of efficacy and immunogenicity and safety. Stockholm, Sweden, 1997. Published by Swedish Institute for Infectious Disease Control
467. Kimura M., Kuno-Sakai H.: Pertussis vaccines in Japan. Acta Paediatr Jpn 1988; 30:143-153.
468. Kimura M., Kuno-Sakai H.: Epidemiology of pertussis in Japan. Tokai J Exp Clin Med 1988; 13:1-7.(Suppl.)
469. Sato Y., Sato H.: Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J Exp Clin Med 1988; 13:79-88.(Suppl.)
470. Ginnaga A., Morokuma K., Aihara K., et al: Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin. Tokai J Exp Clin Med 1988; 13:59-69.(Suppl.)
471. Kimura M., Kuno-Sakai H.: Developments in pertussis immunisation in Japan. Lancet 1990; 336:30-32.
472. Pittman M.: History of the development of pertussis vaccine. Dev Biol Stand 1991; 73:13-29.
473. Aoyama T., Murase Y., Kato M., et al: Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am J Dis Child 1989; 143:655-659.
474. Isomura S., Suzuki S., Sato Y.: Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients. Dev Biol Stand 1985; 61:531-537.
475. Mortimer Jr E.A., Kimura M., Cherry J.D., et al: Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child 1990; 144:899-904.
476. Cherry J.D., Mortimer E.A., Hackell J.G., et al: Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Dev Biol Stand 1991; 73:51-58.
477. Kuno-Sakai H., Kimura M., Ozaki K., et al: Japanese clinical trials with Takeda acellular pertussis vaccine. Tokai J Exp Clin Med 1988; 13:15-19.(Suppl.)
478. Morgan C.M., Blumberg D.A., Cherry J.D., et al: Comparison of acellular and whole-cell pertussis-component DTP vaccines: a multicenter double-blind study in 4- to 6-year-old children. Am J Dis Child 1990; 144:41-45.
479. Glode M., Joffe L., Reisinger K., et al: Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. Pediatr Infect Dis J 1992; 11:530-535.
480. Blumberg D.A., Mink C.M., Cherry J.D., et al: Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. J Pediatr 1990; 117(1 pt 1):46-51.
481. Kamiya H., Nii R., Matsuda T., et al: Immunogenicity and reactogenicity of Takeda acellular pertussis-component diphtheria-tetanus-pertussis vaccine in 2- and 3-month-old children in Japan. Am J Dis Child 1992; 146:1141-1147.
482. Blumberg D.A., Mink C.M., Cherry J.D., et al: Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group. J Pediatr 1991; 119:194-204.

483. Watson B., Cawein A., McKee B.L., et al: Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four- and six-month-old infants. Pediatr Infect Dis J 1992; 11:930-935.
484. Pertussis vaccination: acellular pertussis vaccine for the forth and fifth doses of the DTP series: update to supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1992; 41(RR-15):1-5.
485. Juretzko P., von Kries R., Hermann M., et al: Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002; 35:162-167.
486. Watanabe M., Nagai M.: Acellular pertussis vaccines in Japan: past, present and future. Expert Rev Vaccines 2005; 4:173-184.
487. Han H-J., Kamachi K., Okada K., et al: Antigenic variation in Bordetella pertussis isolates recovered from adults and children in Japan. Vaccine 2008; 26:1530-1534.
488. Okada K., Komiya T., Yamamoto A., et al: Safe and effective booster immunization using DTaP in teenagers. Vaccine 2010; 28:7626-7633.
489. Wiese-Posselt M., Hellenbrand W.: Changes to the varicella and pertussis immunisation schedule in Germany 2009: background, rationale and implementation. Euro Surveill 2010; 15:pii19548.
490. Edwards K.M., Karzon D.T.: Pertussis vaccines. Pediatr Clin North Am 1990; 37:549-566.
491. Lewis K., Cherry J.D., Holroyd H.J., et al: A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children. Am J Dis Child 1986; 140:872-876.
492. Edwards K.M., Lawrence E., Wright P.F.: Diphtheria, tetanus, and pertussis vaccine: a comparison of the immune response and adverse reactions to conventional and acellular pertussis components. Am J Dis Child 1986; 140:867-871.
493. Edwards K.M., Bradley R.B., Decker M.D., et al: Evaluation of a new highly purified pertussis vaccine in infants and children. J Infect Dis 1989; 160:832-837.
494. Pichichero M.E., Badgett J.T., Rodgers Jr G.C., et al: Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month-old children. Pediatr Infect Dis J 1987; 6:352-363.
495. Anderson E.L., Belshe R.B., Bartram J.: Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J Infect Dis 1988; 157:731-737.
496. Edwards K., Decker M.D.: Pertussis vaccine. In: Plotkin S.A., Orenstein W.A., ed. Vaccines, 4th ed. Philadelphia, PA: WB Saunders; 2004:471-528.
497. Ciofi degli Atti M.L., Olin P.: Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Dev Biol Stand 1997; 89:77-81.
498. Kuno-Sakai H., Kimura M.: Epidemiology of pertussis and use of acellular pertussis vaccines in Japan. Dev Biol Stand 1997; 89:331-332.
499. McDermott C., Grimsrud K., Waters J.: A cellular pertussis vaccine and whole cell pertussis vaccine: a comparison of reported selected adverse events. Calgary (Alberta), Canada; DecemberAbstracts of the Third Canadian National Conference on Immunization, 1988.Abstract P41
500. Scheifele D., Halperin S.: Marked reduction in febrile seizures and hypotonic-hyporesponsive episodes with acellular pertussis-based vaccines: results of Canada-wide surveillance. Philadelphia, PA; NovemberAbstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, 1999.Abstract 31

501. Chen R.T., Rastogi S.C., Mullen J.R., et al: The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994; 12:542-550.
502. Rosenthal S., Chen R., Hadler S.: The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine: a postmarketing assessment. Arch Pediatr Adolesc Med 1996; 150:457-460.
503. Braun M.M., Mootrey G.T., Salive M.E., et al: Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000; 106:E51.
504. Huang W.T., Gargiullo P.M., Broder K.R.Vaccine Safety Datalink Team: Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics 2010; 126:263-269.
505. Pichichero M.E., Deloria M.A., Rennels M.B., et al: A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100:772-788.
506. Schmitt H.J., Beutel K., Schuind A., et al: Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997; 130:616-623.
507. Rennels M.B., Deloria M.A., Pichichero M.E., et al: Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000; 105:e12.
508. Liese J.G., Stojanov S., Zink T.H., et al: Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J 2001; 20:981-988.
509. Pichichero M.E., Edwards K.M., Anderson E.L., et al: Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000; 105:e11.
510. Rennels M.B., Deloria M.A., Pichichero M.E., et al: Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine 2002; 20(Suppl. 3):S44-S47.
511. Isomura S.: Efficacy and safety of acellular pertussis vaccine in Aichi Prefecture, Japan. Pediatr Infect Dis J 1988; 7:258-262.
512. Blennow M., Granstrom M.: Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. Pediatrics 1989; 84:62-67.
513. Diggle L., Deeks J.: Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ 2000; 321:931-933.
514. Nagel J., Svec D., Waters T., et al: IgE synthesis in man, I: development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids. J Immunol 1977; 118:334-341.
515. Mark A., Bjorksten B., Granstrom M.: Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 1995; 13:669-673.
516. Hedenskog S., Bjorksten B., Blennow M., et al: Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine. Int Arch Allergy Appl Immunol 1989; 89:156-161.
517. Ausiello C.M., Urbani F., la Sala A., et al: Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997; 65:2168-2174.
518. Scheifele D.W., Halperin S.A., Ferguson A.C.: Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine 2001; 19:4720-4726.

519. Scheifele D.W., Halperin S.A., Ochnio J.J., et al: A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 2005; 24:1059-1066.
520. Knuf M., Habermehl P., Faber J., et al: Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Vaccine 2006; 24:5627-5636.
521. Keitel W.A., Muenz L.R., Decker M.D., et al: A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 1999; 180:397-403.
522. Decker M.D., Cates K.L., Maida A.: Safety and immunogenicity in adults and adolescents of Biocine acellular pertussis (aP) vaccine. Hong Kong; JuneAbstracts of the 7th International Congress for Infectious Diseases, 1996.Abstract 123.002
523. Edwards K.M., Decker M.D., Graham B.S., et al: Adult immunization with acellular pertussis vaccine. JAMA 1993; 269:53-56.
524. Sekura R.D., Zhang Y.L., Roberson R., et al: Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J Pediatr 1988; 113:806-813.
525. Stehr K., Lugauer S., Heninger U.: Immunogenicity and reactogenicity of Lederle/Takeda acellular pertussis vaccine in 185 German adults. Pediatr Res 1995; 37:189A.
526. Keitel W.: Adult pertussis study results using five acellular vaccines. Acellular pertussis vaccine trials: results and impact on US public health. 1996.Washington, DC; June 3–5
527. Forsyth K.D., Campins-Marti M., Caro J., et al: New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39:1802-1809.
528. Forsyth K., Nagai M., Lepetic A., et al: Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24(5 Suppl.):S93-S97.
529. Wirsing von Konig C.H., Campins-Marti M., Finn A., et al: Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24(5 Suppl):S87-S92.
530. Tan T., Halperin S., Cherry J., et al: Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis 2005; 24(5 Suppl.):S83-S86.
531. Caro J.J., Getsios D., El-Hadi W., et al: Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis 2005; 24(5 Suppl.):S75-S82.
532. Plotkin S.: The global pertussis initiative: process overview. Pediatr Infect Dis 2005; 24(5 Suppl.):S7-S9.
533. Forsyth K., Tan T., von König C.H., et al: Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis 2005; 24(5 Suppl.):S69-S74.
534. Plotkin S.: Aims, scope and findings of the global pertussis initiative. Pediatr Infect Dis 2005; 24(5 Suppl.):S5-S6.
535. Caro J., Getsios D., Payne K., et al: Economic burden of pertussis and the impact of immunization. Pediatr Infect Dis 2005; 24(Suppl. 5):S48-S54.
536. Greenberg D., von Konig C.H., Heininger U.: Health burden of pertussis in infants and children. Pediatr Infect Dis 2005; 24(5 Suppl.):S39-S43.
537. Lu C., Michaud C.M., Gakidou E., et al: Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment. Lancet 2006; 368:1088-1095.

538. Forsyth K.D., Wirsing von Konig C.H., et al: Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007; 25:2634-2642.
539. Ulloa-Gutierrez R., Hozbor D., Avila-Aguero M.L., et al: The global pertussis initiative: meeting report from the Regional Latin America Meeting, Costa Rica, 5–6 December, 2008. Hum Vaccin 2010; 6:876-880.
540. Guiso N., von König CH W.irsing., et al: The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11–12 January 2010. Vaccine 2011; 29:1115-1121.
541. Guiso N., Liese J., Plotkin S.: The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14–15, 2010. Hum Vaccin 2011; 7:481-488.
542. Reid S., Wilson E.: New Zealand pertussis epidemiology and the Global Pertussis Initiative immunisation strategies. N Z Med J 2011; 124:63-64.
543. Centers for Disease Control and Prevention : Tetanus and pertussis vaccination coverage among adults aged ⩾ 18 years: United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1302-1306.
544. Pichichero M.E., DeTora L.M., Johnson D.: An adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine. Vaccine 2006; 5:175-187.
545. Pichichero M.E., Blatter M., Kennedy W.A., et al: Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006; 117:1084-1093.
546. Pichichero M.E., Rennels M.B., Edwards K.M., et al: Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003-3011.
547. Zepp F., Knuf M., Habermehl P., et al: Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 2006; 149:603-610.
548. Halperin S.: How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. Pediatr Infect Dis 2006; 25:195-200.
549. Talbot E.A., Brown K.H., Kirkland K.B., et al: The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010; 28:8001-8007.
550. Klein N.P., Hansen J., Lewis E., et al: Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J 2010; 29:613-617.
551. Yih W.K., Nordin J.D., Kulldorff M., et al: An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009; 27:4257-4262.
552. Halperin S.A.: The control of pertussis: 2007 and beyond. N Engl J Med 2007; 356:110-113.
553. Halperin S.A.: Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future. J Pediatr 2006; 149:589-591.
554. National Institute of Allergy and Infectious Diseases. Pertussis vaccine in healthy pregnant women.

http://www.clinicaltrials.gov/ct2/show/NCT00707148?term=NCT00707148&rank=1 . (Accessed on 18 June 2012).
555. Dalhousie University. Pertussis maternal immunization study. http://www.clinicaltrials.gov/ct2/show/NCT00553228?term=NCT00553228&rank=1 . (Accessed on 18 June 2012).
556. Gall S.A., Myers J., Pichichero M.: Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011; 204:334.e1-334.e5.
557. Population and Public Health Branch , Centre for Infectious Disease Prevention and Control : Canada Immunization Guide. 6th ed. Ottawa (Ontario), Canada, National Advisory Committee on Immunization, 2002.
558. World Health Organization. WHO vaccine preventable diseases monitoring system. http://apps.who.int/immunization_monitoring/en/globalsummary/scheduleselect.cfm . (Accessed on 18 June 2012).
559. Shefer A., Dales L., Nelson M., et al: Use and safety of acellular pertussis vaccine among adult hospital staff during an outbreak of pertussis. J Infect Dis 1995; 171:1053-1056.
560. Christie C.D., Garrison K.M., Kiely L., et al: A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993. Clin Infect Dis 2001; 33:997-1003.
561. Kirkland K.B., Talbot E.A., Decker M.D., et al: Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control. Clin Infect Dis 2009; 49:584-587.

DJEČJA PARALIZA

1. Poliomyelitis Vaccine Evaluation Center : Evaluation of 1954 field trials of poliomyelitis vaccine. Introduction. Am J Public Health Nations Health 1955; 45:xii-xiv.
2. Poliomyelitis Vaccine Evaluation Center : Evaluation of 1954 field trials of poliomyelitis vaccine, I: plan of study. Am J Public Health Nations Health 1955; 45:1-14.
3. Poliomyelitis Vaccine Evaluation Center : Evaluation of 1954 field trials of poliomyelitis vaccine, II: results. Am J Public Health Nations Health 1955; 45:15-48.
4. Poliomyelitis Vaccine Evaluation Center : Evaluation of 1954 field trials of poliomyelitis vaccine, III: summary of estimates of effectiveness of vaccine. Am J Public Health Nations Health 1955; 45:49-51.
5. Lambert S.M., Markel H.: Making history: Thomas Francis, Jr, MD, and the 1954 Salk poliomyelitis vaccine field trial. Arch Pediatr Adolesc Med 2000; 154:512-517.
6. Plotkin S.A.: An end to Manicheism. Public Health Rev 1993; 21:135-138.
7. Landsteiner K., Popper E.: Ueberstragung der poliomyelitis acuta auf affen. Z Immunitatsforsch 1909; 2:377-390.
8. Bodian D., Morgan I., Howe H.: Differentiation of types of poliomyelitis viruses; the grouping of fourteen strains into three basic immunologic types. Am J Hyg 1949; 49:234-245.
9. Horstman D.M., McCollum R., Mascola A.: Viremia in human poliomyelitis. J Exp Med 1954; 99:355-369.
10. Hammon W., Coriell L.L., Wehrle P.F., et al: Evaluation of red cross γ-globulin as a prophylactic agent for poliomyelitis. J Am Med Assoc 1953; 151:1272-1285.
11. Enders J., Weller T., Robbins F.: Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949; 109:85-87.
12. Burke D.S.: Lessons learned from the 1954 field trial of poliomyelitis vaccine. Clin Trials 2004; 1:3-5.

13. Beale J.: The Development of IPV. Paris, Elsevier, 1996.
14. Lépine P.: Prophylaxie de la poliomyélite Present et avenir. Bull Org Mond Santé 1955; 13:447-472.
15. van Wezel A.L.: Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 1967; 216:64-65.
16. Montagnon B.: Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1988; 70:27-47.
17. Paul J.R., Melnick P.J., Barnett V., et al: A survey of neutralizing antibodies to poliomyelitis in Cairo, Egypt. Am J Hyg 1952; 55:402-413.
18. Lebrun A., Cerf J., Gelfand H., et al: Vaccination with the CHAT strain of type I attenuated poliomyelitis virus in Leopoldville, Belgian Congo, I: description of the city, its history of poliomyelitis, and the plan of vaccination campaign. Bull World Health Organ 1960; 22:203-213.
19. Minor P.D.: Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 1990; 161:121-154.
20. Plotkin S., Koprowski H., Stokes Jr. J.: Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics 1960; 23:1041-1062.
21. Brodie M., Park W.: Active immunization against poliomyelitis. Am J Public Health 1936; 26:119-125.
22. Kolmer J.: Vaccination against acute anterior poliomyelitis. Am J Public Health 1936; 26:126-135.
23. Lepine P., Sautter V.: Inactivation of viruses by the combined action of two inactivating drugs employed in controlled doses. C R Hedb Seance Acad Sci 1957; 244:2200-2201.
24. Murray R.: Standardization licensing and availability of live polio virus vaccine. J Am Med Assoc 1961; 175:843-846.
25. Berkovich S., Pickering J., Kibrick S.: Paralytic poliomyelitis in Massachusetts. N Engl J Med 1959; 264:1325-1329.
26. Montagnon B.J., Fanget B., Vincent-Falquet J.C.: Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 1984; 6(Suppl. 2):S341-S344.
27. Montagnon B.J., Fanget B., Nicolas A.J.: The large-scale cultivation of Vero cells in micro-carrier culture for virus production: preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981; 47:55-64.
28. Montagon B.J., Nicolas A.J., Fanget B., et al: Comparison of sensitivity of Vero cell line versus primary monkey kidney cells in the detection of residual live polio virus during and after inactivation. Dev Biol Stand 1981; 47:151-155.
29. Montagon B.J., Vincent-Falquet J.C., Fanget B.: Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine.Promising results. Dev Biol Stand 1984; 55:37-42.
30. Duchene M., Peetermans J., D'Hont E., et al: Production of poliovirus vaccines: past, present, and future. Viral Immunol 1990; 3:243-272.
31. Montagnon B.J., Vincent-Falquet J.C., Saluzzo J.F.: Experience with Vero cells at Pasteur Merieux Connaught. Dev Biol Stand 1999; 98:137-140.
32. Thomassen Y.E., van Sprang E.N., van der Pol L.A., et al: Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol Bioeng 2010; 107:96-104.
33. Horaud F.: Viral vaccines and residual cellular DNA. Biologicals 1995; 23:225-228.
34. Melnick J.L.: Virus inactivation: lessons from the past. Dev Biol Stand 1990; 75:29-36.
35. Meignier B.: Industrial experience with live polio vaccine prepared on the Vero continuous cell line. Dev Biol (Basel) 2001; 106:341-342.

36. Wood D.J., Heath A.B.: A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Biologicals 1995; 23:301-311.
37. Wood D.J., Heath A.B., Kersten G.F., et al: A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine. Biologicals 1997; 25:59-64.
38. Rezapkin G., Dragunsky E., Chumakov K.: Improved ELISA test for determination of potency of inactivated poliovirus vaccine (IPV). Biologicals 2005; 33:17-27.
39. Westdijk J., Brugmans D., Martin J., et al: Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011; 29:3390-3397.
40. Racaniello V.R.: One hundred years of poliovirus pathogenesis. Virology 2006; 344:9-16.
41. Martin J., Crossland G., Wood D.J., et al: Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003; 84:1781-1788.
42. Dragunsky E.M., Ivanov A.P., Wells V.R., et al: Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004; 190:1404-1412.
43. Global Polio Eradication Initiative. http://www.polioeradication.org/Research/PolioPipeline/No1Summer2008/ImprovingIPV.aspx Accessed on June 1st, 2012
44. Kreeftenberg H., van der Velden T., Kersten G., et al: Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006; 34(2):155-158.
45. Ferguson M., Wood D.J., Minor P.D.: Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 1993; 74:685-690.
46. Rezapkin G., Martin J., Chumakov K.: Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 2005; 33:29-39.
47. Dragunsky E., Chernokhvostova Y., Taffs R., et al: Tg PVR21 mice for testing type-3 oral poliovirus vaccines: role of clinical observation and histological examination vaccine. 151997. 1863–6
48. Kersten G., Hazendonk T., Beuvery C.: Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 1999; 17:2059-2066.
49. Herremans T., Reimerink J.H.J., Kimman T.G., et al: Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure. Clin Diag Lab Immunol 2000; 7:40-44.
50. Rezapkin G., Neverov A., Cherkasova E., et al: Repertoire of antibodies against type 1 poliovirus in human sera. J Virol Methods 2010; 169:322-331.
51. Abe S., Tano Y., Ohta Y., et al: Development and clinical evaluation on the enhanced-potency inactivated poliovirus vaccine made from the Sabin strains. Clin Virol 1999; 27:9-28.
52. Tano Y., Shimizu H., Martin J., et al: Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007; 25:7041-7046.
53. Bian C.X., Jiang S.D., Yang J.Y., et al: Effect of 2-phenoxy-ethanol on potency on Sabin inactivated poliomyelitis vaccine and its safety. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007; 21:44-46.
54. Che Y.C., Jiang L., Shao C.W.: Feasibility study of using Sabin-IPV immunization in post-eradication era in China. Zhongguo Ji Hua Mian Yi 2010; 16:72-75.
55. Verdijk P., Rots N.Y., Bakker W.A.M.: Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011; 10:635-644.

56. Bakker W.A.M., Thomassen Y.E., van't Oever A.G., et al: Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011; 29:7188-7196.
57. Sawyer L.A., Wood D., Ferguson M., et al: Potency of wild-type or Sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site. Biologicals 1997; 25:299-306.
58. Wood D.J., Heath A.B., Sawyer L.A.: A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals 1995; 23:83-94.
59. Murph J.R., Grose C., McAndrew P., et al: Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 1988; 7:760-765.
60. Doi Y., Abe S., Yamamoto H., et al: Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001; 105:163-169.
61. Eighth WHO/UNICEF consultation with OPV/IPV manufacturers and NRAs in Geneva WHO/HQ. (Accessed November 2011) http://www.who.int/immunization_standards/vaccine_quality/ipvopv_summary3dec09.pdf 2009.
62. Liao G., Li R., Li C., et al: Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial. Journal of Infectious Diseases 2012; 205:237-243.
63. Horie H., Yoshida H., Matsuura K., et al: Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 2002; 68:445-451.
64. Ehrenfeld E., Modlin J., Chumakov K.: Future of polio vaccines. Expert Rev Vaccines 2009; 8:899-905.
65. Global Post-eradication IPV Supply and Demand Assessment: Integrated Findings, 2009. (Accessed November 2011) www.polioeradication.org/content/general/March%202009%20OW%20IPV%20Effort%20Report.pdf
66. The supply landscape and economics of ipv-containing combination vaccines: key findings, 2010. (Accessed November 2011) www.polioeradication.org/Portals/0/Document/Resources/SupplyLandscapeEconomics.09.06.2010.pdfs
67. Salk J.: One-dose immunization against paralytic poliomyelitis using a non infectious vaccine. Rev Infect Dis 1984; 6(Suppl. 2):S444-S450.
68. Salk J., Cohen H., Fillastre C., et al: Killed poliovirus antigen titration in humans. Dev Biol Stand 1978; 41:119-132.
69. Salk J., van Wezel A.L., Stoeckel P., et al: Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev Biol Stand 1981; 43:181-198.
70. Salk J., Stoeckel P., van Wezel A.L., et al: Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. Ann Clin Res 1982; 14:204-212.
71. Mellander L., Bottiger M., Hanson L.A., et al: Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content. Acta Paediatr 1993; 82:552-556.
72. Knuf M., Vetter V., Celzo F., et al: Repeated administration of a reduced-antigen content dipththeria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix IPV). Hum Vaccin 2010; 6:554-561.
73. Larnaudie S., Guiso N., Baptiste C., et al: Humoral immunity of dTap-IPV vaccine (Repevax) administered one month after dT-IPV vaccine (Revaxis) in adults with unknown vaccination history. Hum Vaccin 2010; 6:829-834.

74. Beytout J., Launay O., Guiso N., et al: Safety of Tadp-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009; 5:315-321.
75. Hässelbarth A.: Effect of polymyxin B on the replication of poliovirus in cell cultures. Med Microbiol Immunol 1972; 157:239-243.
76. McBean A.M., Thoms M.L., Albrecht P., et al: Field staff and coordinating committee. Am J Epidemiol 1988; 128:615-628.
77. Cutler J.C., Lesesne L., Lit M., et al: Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered. J Allergy 1962; 33:193-209.
78. Henneberg G., Drescher J., Godgluck G., et al: Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macata mulata. Am J Hyg 1962; 75:44-55.
79. Relyveld E., Martin R., Raynaud M., et al: Le phosphate de calcium comme adjuvant dans les vaccinations chez l'homme. Ann Inst Pasteur 1969; 116:300-326.
80. Ivanov A.P., Dragunsky E.M., Chumakov K.M.: 1,25-dihydroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006; 193:598-600.
81. Yang C., Shi H., Zhou J., et al: CpG oligooxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 2009; 27:6558-6563.
82. Ghendon Y., Markushin S., Koptiaeva I., et al: Chitosan as an adjuvant for poliovaccine. J Med Virol 2011; 83:847-852.
83. Sawyer L.A., McInnis J., Patel A., et al: Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine 1994; 12:851-856.
84. Sutter R.W., Pallansch M.A., Sawyer L.A., et al: Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995; 754:289-299.
85. WHO : WHO/EPI/GEN 93.9Guidelines for WHO/EPI collaborative studies on poliomyelitis. Standard procedure for determining immunity to poliovirus using the microneutralization test, Geneva, Switzerland, WHO, 1993.
86. Boone E.J., Albrecht P.: Conventional and enhanced plaque neutralization assay for polio antibody. J Virol Methods 1983; 6:193-202.
87. Albrecht P., Enterline J.C., Boone E.J., et al: Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J Biol Stand 1983; 11:91-97.
88. Albrecht P., van Sleenis G., van Wezel A.L., et al: Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984; 6(S2):S540-S544.
89. Wood D.J., Heath A.B.: Comparability of poliovirus neutralizing antibody tests. Biologicals 1992; 20:293-300.
90. Wood D.J., Heath A.B.: The second international standard for anti-poliovirus sera types 1, 2 and 3. Biologicals 1992; 20:203-211.
91. Vidor E., Caudrelier P., Plotkin S.A.: The place of DTP/eIPV vaccine in routine paediatric vaccination. Rev Med Virol 1994; 4:261-277.
92. Vidor E., Meschievitz C., Plotkin S.A.: Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997; 16:312-322.
93. Poliovirus vaccine inactivated IPOL, https://www.vaccineshoppe.com/image.cfm?doc_id=5984&image_type=product_pdf . (Accessed in November 2011)
94. Bonnet M.C., Dutta A.: World wide experience with inactivated poliovirus vaccine. Vaccine 2008; 26:4978-4983.
95. Juhela S., Hyoty H., Lonnrot M., et al: Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol 1998; 54:226-232.

96. Glezen W.P.: Effect of maternal antibodies on the infant immune response. Vaccine 2003; 21:3389-3392.
97. Sormunen H., Stenvik M., Eskola J., et al: Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol 2001; 63:305-310.
98. Hovi T.: Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 2001; 19:2268-2272.
99. Singh J., Ravi R.N., Dutta A.K., et al: Immunogenicity of enhanced potency inactivated polio vaccine. Indian Pediatr 1992; 29:1353-1356.
100. Kok P.W., Leeuwenburg J., Tukei P., et al: Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ 1992; 70:93-103.
101. Linder N., Handsher R., German B., et al: Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed 2000; 83:F24-F27.
102. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines : Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. Bull World Health Organ 1996; 74:253-268.
103. Sutter R.W., Suleiman A.J., Malankar P.G., et al: Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. J Infect Dis 1997; 175(Suppl. 1):S235-S240.
104. Simoes E.A., Padmini B., Steinhoff M.C., et al: Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 1985; 139:977-980.
105. Simoes E.A., John T.J.: The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J Biol Stand 1986; 14:127-131.
106. Swartz T.A., Handsher R., Stoeckel P., et al: Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989; 5:143-145.
107. Hovi T., Stenvik M., Agboatwalla M.: Effect of administering oral and inactivated polio vaccines immediately after birth. Eur J Clin Microbiol Infect Dis 1999; 18:526-528.
108. Jain P.K., Dutta A.K., Nangia S., et al: Seroconversion following killed polio vaccine in neonates. Indian J Pediatr 1997; 64:511-515.
109. Ruuskanen O., Viljanen M., Salmi T.T., et al: DTP and DTP-inactivated polio vaccines: comparison of adverse reactions and IgG, IgM and IgA antibody responses to DTP. Acta Paediatr Scand 1980; 69:177-182.
110. White C., Halperin S., Scheifele D.: Pediatric combined formulation DTaP-IPV/Hib vaccine. Expert Rev Vaccines 2009; 8:831-840.
111. Mallet E., Belohradsky B., Lagos R., et al: A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 2004; 22:1343-1357.
112. Dhillon S.: DTaP-HBV-IPV/Hib vaccine (Infanrix hexa): a review of its use as primary series and booster vaccination. Drugs 2010; 70:1021-1058.
113. Plotkin S.A., Liese L., Madhi S.A., et al: A DTaP-IPV//PRP T vaccine (Pentaxim™): a review of 16 years' clinical experience. Expert Rev Vaccines 2011; 10:981-1005.
113a. Quiambao B., Meeren van der O., Kolhe D., et al: A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. Human Vaccine 2012; 8:1-8.co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.

114. Black S., Greenberg D.P.: A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 2005; 4:793-805.
115. Zepp F., Knuf M., Heininger U., et al: Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004; 22:2226-2233.
116. Lee S.Y., Hwang H.S., Kim J.H., et al: Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea. Vaccine 2011; 29:1551-1557.
117. Lagos R., Kotloff K., Hoffenbach A., et al: Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis ad Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 1998; 17:294-304.
118. Yeh S., Ward J.I., Partridge S., et al: Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Ped Infect Dis J 2001; 20:973-980.
119. Pichichero M., Bernstein H., Blatter M.M., et al: Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. J Pediatr 2007; 151:43-49.
120. Meriste S., Lutsar I., Tamm E., et al: Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. Scand J Infect Dis 2006; 38:350-356.
121. Grimprel E., von Sonnenburg F., Sanger R., et al: Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005; 23:3657-3667.
122. Southern J., Andrews N., Burrage M., et al: Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as booster to UK teenagers. Vaccine 2005; 23:3829-3835.
123. Laroche P., Barrand M., Wood S., et al: The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV). Infection 1999; 27:49-60.
124. Jacquet J.M., Begue P., Grimprel E., et al: Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 2006; 24:2400-2448.
125. Kaml M., Weiskirchner I., Keller M., et al: Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006; 24:6808-6811.
126. Salk J.: Studies in human subjects on active immunization against poliomyelitis, I. a preliminary report of experiments in progress. J Am Med Assoc 1953; 151:1081-1098.
127. Salk J.: Recent studies on in immunization against poliomyelitis. Pediatrics 1953; 12:471-482.
128. von Magnus H., von Magnus P., Petersen I., et al: Polio vaccination in Denmark in April-June 1955, I: the production of formalinized poliovaccine and preliminary results. Dan Med Bull 1955; 2:226-233.
129. Sigurdsson B., Gudnadottir M., Petursson G.: Response to poliomyelitis vaccination. Lancet 1958.370-371.

130. Connolly J.H., Dick G.W.: Antibody responses following intradermal or oral administration of formalinised poliomyelitis vaccine. Lancet 1958.333-336.
131. Slonim D., Svandova E., Strand P., et al: History of poliomyelitis in the Czech Republic—Part III. Cent Eur J Public Health 1995; 3:124-126.
132. Skovranek V., Radkovsky J., Roudny J., et al: Vaccination against poliomyelitis in Czechoslovakia in 1957, II. evaluation of morbidity following vaccination. J Hyg Epidemiol Microb Immunol 1958; 2:469-477.
133. Lipson M.J., Carver D.H., Eleff M.G., et al: Antibody response to poliomyelitis vaccine administered by jet injection. Am J Public Health Nations Health 1958; 48:599-603.
134. Hingson R.A., Davis H.S., Bloomfield R.A., et al: Mass inoculation of the Salk polio vaccine with the multiple dose jet injector. GP 1957; 15:94-96.
135. Samuel B., Cherian T., Sridharan G., et al: Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991; 338:343-344.
136. Samuel B., Cherian T., Rajasingh J., et al: Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 1992; 10:135.
137. Nirmal S., Cherian T., Samuel B.U., et al: Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998; 16:928-931.
138. Resik S., Tejeda A., Lago P.M., et al: Randomised controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010; 201:1344-1352.
139. Mohammed A.J., AlAwaidy S., Bawikar S., et al: Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010; 362:2351-2359.
140. Carlos J., Vidor E., Bonnet M.C.: Immunogenicity and safety profile of inactivated polio vaccine (Imovax Polio™) administered at a fractional dose intradermally in comparison with inactivated polio vaccine (Imovax Polio™) administered at a full dose intramuscularly in the Philippines using the epi schedule. Int J Infect Dis 2012; 116:e110-e116.
141. Estivariz C., Jafari H., Sutter R.W., et al: Immunogenicity of supplemental doses of poliovirus vaccine for children age 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012; 12:128-135.
142. Sutter R. Personal communication.
142a. Nelson K.S., Janssen J.M., Troy S.B., et al: Intradermal fractional dose inactivated polio vaccine: A review of literature. Vaccine 2012; 30:121-125.
143. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines : Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. J Infect Dis 1997; 175(Suppl. 1):S215-S227.
144. Krishnan R., Jadhav M., John T.J.: Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 1983; 61:689-692.
145. Gylca R., Gylca V., Benes O., et al: A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 2000; 19:825-833.
146. Hussey G., Malan H., Hughes J., et al: Aventis Pasteur Study HIT40498. Data in file1998.
147. Capeding M.R.: Aventis Pasteur study EUV07199/HE9810. Data in File1999.
148. Cuba IPV Study Collaborative Group : Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007; 356:1536-1544.
149. Hussey G.: Sanofi Pasteur Study A3R25 and A3R38. Data in file.2005.
150. Capeding R.M., Cadorna-Carlos J., Book-Montellano M., et al: Immunogenicity and safety of a DTaP-IPV//PRP-T combination vaccine given with hepatitis B vaccine; a randomized open-label trial. Bull World Health Organ 2008; 86:443-451.

151. Dayan G.H., Thorley M., Yamamura Y., et al: Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007; 195:12-20.
152. Madhi S.A., Cutland C., Jones S., et al: Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 months of age in infants in South Africa. S Afr Med J 2011; 101:126-131.
153. Dutta A.K., Verghese V.P., Pemde H.K., et al: Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate combination vaccine (Pentaxim™) with hepatitis B vaccine. Indian Pediatr 2009; 46:975-982.
154. Madhi S., Mitha I., Santos Lima E.: Immunogenicity and safety of an investigational fully liquid hexavalent DTaP IPV Hep B PRP-T combined vaccine versus DTwP//Hib, Hepatitis B and OPV licensed vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J 2011; 30:458-465.
155. Centers for Disease Control, Prevention : Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(RR-3):
156. Halsey N., Blatter M., Bader G., et al: Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatr Infect Dis J 1997; 16:675-679.
157. Modlin J.F., Halsey N., Thoms M.L., et al: The Baltimore Area Polio Vaccine Study Group. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine—live attenuated oral poliovirus vaccine immunization schedules. J Infect Dis 1997; 175(Suppl. 1):S228-S234.
158. Asturias E.J., Dueger E.L., Omer S.B., et al: Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 2007; 196:692-698.
159. Lasch E.E., Abed Y., Gerichter C.B., et al: Results of a program successfully combining live and killed polio vaccines. Isr J Med Sci 1983; 19:1021-1023.
160. Ramsay M.E., Begg N.T., Gandhi J., et al: Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 1994; 13:1117-1121.
161. Strebel P., Ion-Nedelcu N., Baughman A.L., et al: Intramuscular injections within 30 days of immunization with oral poliovirus vaccine-a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med 1995; 332:500-506.
162. Ion-Nedelcu N., Strebel P., Toma F., et al: Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992–1994. J Infect Dis 1997; 175:S241-S246.
163. Moriniere B.J., van Loon F.P., Rhodes P.H., et al: Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993; 341:1545-1550.[see comments]
164. Parent du Chatelet I., Merchant A.T., Fisher-Hoch S., et al: Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003; 21:1710-1718.
165. Sutter R., Suleiman A.J.S., Malankar P., et al: Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000; 343:767-773.

166. Herremans T.M.P.T., Reimerink J.H.J., Buisman A.M., et al: Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999; 162:5011-5018.
167. Adenyi-Jones S.C.A., Faden H., Ferdon M.B., et al: Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992; 120:686-689.
168. Linder N., Yaron M., Handsher R., et al: Early immunization with inactivated poliovirus vaccine in premature infants. J Pediatr 1995; 127:128-130.
169. Sikora J.P., Chlebna-Sokol D.: Seroconversion after vaccination against pertussis, Haemophilus influenzae type b and poliomyelitis in preterm infants. Przegl Lek 2003; 60:699-703.
170. Klein N.P., Gans H.A., Sung P., et al: Preterm infants' T cell responses to inactivated poliovirus vaccine. J Infect Dis 2010; 201:214-222.
171. Vasquez L., Garcia F., Ruttimann R., et al: Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination on low-birth-weight premature infants. Acta Paediatr 2008; 97:1243-1249.
172. Slack M.H., Cade S., Schapira D., et al: DT5aP-Hib-IPV and MCC vaccines: preterm infants' responses to accelerated immunization. Arch Dis Child 2005; 90:338-341.
173. O'Shea T.M., Dillard R.G., Gillis D.C., et al: Low rate of response to enhanced inactivated polio vaccine in preterm infants with chronic illness. Clin Res Reg Aff 1993; 10:49-57.
174. Barbi M., Bardare M., Luraschi C., et al: Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers. Eur J Epidemiol 1992; 8:211-216.
175. Varon D., Handsher R., Dardik R., et al: Response of hemophilic patients to poliovirus vaccination: correlation with HIV serology and with immunological parameters. J Med Virol 1993; 40:91-95.
176. Sipila R., Hortling L., Hovi T.: Good seroresponse to enhanced-potency inactivated poliovirus vaccine in patients on chronic dialysis. Nephrol Dial Transplant 1990; 5:352-355.
177. Engelhard D., Handsher R., Naparstek E., et al: Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8:295-300.
178. Ljungman P., Duraj V., Magnius L.: Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7:89-93.
179. Ljungman P., Aschan J., Gustafsson B., et al: Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 2004; 34:1067-1069.
180. Ogra P.L., Karzon D., Righthand F., et al: Immunoglobulin response in serum and secretions after immunization with live and inactivated polio vaccine and natural infection. N Engl J Med 1968; 279:893-900.
181. Zhaori G., Sun M., Faden H.S., et al: Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 1989; 159:1018-1024.
182. Faden H., Duffy L.: Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. Am J Dis Child 1992; 146:1320-1323.
183. Faden H., Modlin J., Thoms M.L., et al: Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990; 162:1291-1297.
184. Onorato I.M., Modlin J.F., McBean A.M., et al: Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163:1-6.

185. Hanson L.A., Carlsson B., Jalil F., et al: Different secretory IgA antibody responses after immunization with inactivated and live poliovirus vaccines. Rev Infect Dis 1984; 6(Suppl. 2):S356-S360.
186. Fox J.P., Gelfand H.M., LeBlanc D.R., et al: The influence of natural and artificially induced immunity on alimentary infections with poliovirus. Am J Public Health 1958; 48:1181-1192.
187. Horstman D.M., Paul J.R., Melnick J.L., et al: Infection induced by oral administration of attenuated poliovirus to persons possessing homotypic antibody. J Exp Med 1957; 105:159-177.
188. David D., Lipson M., Carver D., et al: The degree and duration of poliomyelitis virus excretion among vaccinated household contacts of clinical cases of poliomyelitis. Pediatrics 1958; 22:33-40.
189. Gelfand H.M., LeBlanc D.R., Potash L., et al: Studies on the development of natural immunity to poliomyelitis in Louisiana, IV: natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg 1959; 70:312-327.
190. Howe H.A., O'Leary W., Bender W., et al: Day-by-day response of vaccinated chimpanzees to poliomyelitis infection. Am J Public Health 1956; 47:871-875.
191. Craig D.E., Brown G.C.: The relationship between poliomyelitis antibody and virus excretion from the pharynx and anus of orally infected monkeys. Am J Hyg 1959; 69:1-12.
192. Selvakumar R., John T.J.: Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine 1987; 5:141.
193. Marine W.M., Chin T.D.Y., Gravelle C.R.: Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. Am J Hyg 1962; 76:173-195.
194. Swartz T.A., Green M.S., Handscher R., et al: Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. Vaccine 2008; 26:1083-1090.
195. Ghendon Y., Robertson S.E.: Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 1994; 72:973-983.
196. Samoilovich E., Roivainen M., Titov L.P., et al: Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol 2003; 71:274-280.
197. Laassri M., Lottenbach K., Belshe R., et al: Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 2005; 192:2092-2098.
198. Minor P.D.: The molecular biology of poliovaccines. J Gen Virol 1992; 73:3065-3077.
199. Macadam A.J., Arnold C., Howlett J., et al: Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 1989; 172:408-414.
200. Chumakov K.M., Powers L.B., Noonan K.E., et al: Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci U S A 1991; 88:199-203.
201. Abraham R., Minor P., Dunn G., et al: Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 1993; 168:1105-1109.
202. Ogra P.L., Faden H.S., Abraham R., et al: Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 1991; 164:191-194.
203. Murdin A.D., Barreto L., Plotkin S.A.: Inactivated poliovirus vaccine: past and present experience. Vaccine 1996; 14:735-746.
204. Minor P.D., Dunn G., Ramsay M.E., et al: Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 2005; 75:153-160.

205. Laassri M., Lottenbach K., Belshe R., et al: Analysis of reversions in the 5′ -untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis 2006; 193:1344-1349.
206. Francis T., Korns R., Voight R., et al: Am J Public Health Nations Health 1955; 45(5 pt2):1-63.
207. Melnick J.L., Benyeh-Melnick M., Peña R., et al: Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis. J Am Med Assoc 1961; 175:1159-1162.
208. Stoeckel P., Schlumberger M., Parent G., et al: Use of killed poliovirus vaccine in a routine immunization program in West Africa. Rev Infect Dis 1984; 6(S2):S463-S466.
209. Sanofi Pasteur, Kolda area intervention study. Data in file.
210. CDC : Paralytic poliomyelitis-Senegal, 1986–1987: update on the N-IPV efficacy study. MMWR 1988; 37:257-259.
211. John T.: Poliovirus vaccine and poliomyelitis control in India. [abstract]1992.New Delhi
212. Varughese P.V., Carter A.O., Acres S.E., et al: Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can J Public Health 1989; 80:363-368.
213. Plotkin S.A.: Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-1065.
214. Stickle G.: Observed and expected poliomyelitis in the United States, 1958–1961. Am J Public Health 1964; 54:222-229.
215. Chin T.D.: Immunity induced by inactivated poliovirus vaccine and excretion of virus. Rev Infect Dis 1984; 6(Suppl. 2):S369-S370.
216. Hofman B.: Poliomyelitis in the Netherlands before and after vaccination with inactivated poliovaccine. J Hyg 1967; 65:547-557.
217. Poliovirus infections. In: Peter G., Hall C., Halsey N., et al ed. Red Book Report of the Committee of Infectious Diseases, 24th ed. Elk Grove, IL: American Academy of Pediatrics; 1997:424-433.
218. Bijkerk H.: Poliomyelitis in the Netherlands. Dev Biol Stand 1981; 47:233-240.
219. Bijkerk H.: Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand 1979; 43:195-206.
220. Oostvogel P.M., van Wijngaarden J.K., van der Avoort H.G., et al: Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–93. Lancet 1994; 344:665-670.[see comments]
221. CDC : Epidemiological notes and reports: follow-up on poliomyelitis-United States, Canada, Netherlands, 1979. MMWR 1979; 28:345.
222. CDC : Lack of evidence for wild poliovirus circulation-United States, 1993. MMWR 1995; 43:957-959.
223. Rumke H.C.: Vaccination against polio. Inactivated polio vaccine used in The Netherlands and Burkina Faso. Trop Geogr Med 1993; 45:202-205.
224. Oostvogel P.M., Rumke H.C., Conyn-Van Spaendonck M.A., et al: Poliovirus circulation among schoolchildren during the early phase of the 1992–1993 poliomyelitis outbreak in The Netherlands. J Infect Dis 2001; 184:1451-1455.
225. Gary H.E., Smith J.B., Jenks J., et al: Failure to detect infection by oral polio vaccine virus following natural exposure among inactivated polio vaccine recipients. Epidemiol Infect 2008; 136:180-183.
226. Mueller J.E., Bessaud M., Huang Q.S., et al: Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Cordoba province, Argentina. Appl Environ Microbiol 2009; 75:1395-1401.

227. Troy S.B., Ferreyra-Reyes L., Huang C.H., et al: Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a Mexican national immunization day. J Clin Microbiol 2011; 49:1777-1783.
227a. Hird T.R., Grassly N.C.: Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLos Pathogens 2012; 8:e1002599.
228. Bottiger M.: Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 1990; 8:443-445.
229. Taranger J., Trollfors B., Knutsson N., et al: Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 2000; 18:884-891.
230. Faden H., Duffy L., Sun M., et al: Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis 1993; 168:452-454.
231. Swartz T.A., Roumiantzeff M., Peyron L., et al: Use of a combined DTP-polio vaccine in a reduced schedule. Dev Biol Stand 1986; 65:159-166.
232. Carlsson R.M., Claesson B.A., Fagerlund E., et al: Antibody persistence in 5 year old children who received a pentavalent vaccine in infancy. Pediatr Infect Dis J 2002; 21:535-541.
233. Black S., Friedland L.R., Ensor K., et al: Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J 2008; 27:341-346.
234. Kitchin N., Southern J., Morris R., et al: Antibody persistence in UK pre-school children who received a primary series of an acellular pertussis-containing pentavalent infant vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 2009; 27:5096-5102.
235. Langue J., Matisse N., Pacoret P., et al: Persistence of antibodies at 5-6 years of age for children who received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 2004; 22:1406-1414.
236. Mallet E., Matisse N., Mathieu N., et al: Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6 year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 2004; 22:1415-1422.
237. Danjou G., Silier T., Dupuy M.: Comparison of DTaP-IPV vaccine with DTP-IPV (Tetracoq) vaccine administered as a second booster at 4 to 7 years of age. 1997.
238. Gajdos V., Soubeyrand B., Vidor E., et al: Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine versus combined diphtheria tetanus and inactivated poliovirus vaccine (REVAXIS®) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio®) given as a booster dose at 6 years of age. Hum Vaccine 2011; 7:1-8.
239. Sanofi Pasteur, Study A3R22. Data in file.
240. Sanofi Pasteur, Study TD517. Data in file.
241. Guerra F., Blatter M.A., Greenberg D., et al: Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a pre-school booster dose: a randomized, clinical trial. Pediatrics 2009; 123:301-312.

242. Zinke M., Disselhoff J., Gartner B., et al: Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin 2010; 6:189-193.
243. Rennels M.B.: Need for polio boosters after two years. Vaccine 2009; 27:179-180.
244. Salk J.: Persistence of immunity after administration of formalin-treated poliovirus vaccine. Lancet 1960; 2:715-723.
245. Salk J.: Are booster doses of poliovirus vaccine necessary?. Vaccine 1990; 8:419-420.
246. Salk D., van Wezel A.L.S.J.: Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 1984.1317-1321.
247. Abbink F., Buisman A.M., Doornbos G., et al: Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005; 191:990-999.
248. Sanofi Pasteur, Regulatory Department. Data in file.
249. Wattigney W.A., Mootrey G.T., Braun M.M., et al: Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001; 107:E83.
250. Reinert P., Boucher J., Pines E., et al: Primary and booster immunization with DTaP-IPV vaccine administered either in combination or in association with a Haemophilus influenzae type b vaccine (Act-HIB): a large scale safety study. 1997.Paris
251. Nathanson N., Langmuir A.D.: The Cutter Incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United states during the spring of 1955. I. Background. Am J Hyg 1963; 78:16-28.
252. Nathanson N., Langmuir A.D.: The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 1995; 142:109-140.
253. Offit P.A.: The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. New Haven, Yale University Press, 2005.
254. Plotkin S.A.: Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 1995; 14:835-839.
255. Butel J.S., Lednicky J.A.: Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 1999; 91:119-134.
256. Vilchez R.A., Madden C.R., Kozinetz C.A., et al: Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 2002; 359:817-823.
257. Shivapurkar N., Harada K., Reddy J., et al: Presence of simian virus 40 DNA sequences in human lymphomas. Lancet 2002; 359:851-852.
258. Dang-Tan T., Mahmud S.M., Puntoni R., et al: Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 2004; 23:6535-6540.
259. Poulin D.L., De Caprio J.A.: Is there a role for SV40 in human cancer?. J Clin Oncol 2006; 24:4356-4365.
260. Schattner A., Ben Chetrit E., Schmilovitz H.: Poliovaccines and the course of systemic lupus erythematosus-a retrospective study of 73 patients. Vaccine 1992; 10:98-100.
261. CDC. Immunization schedules, http://www.cdc.gov/vaccines/recs/schedules/default.htm . (Accessed November 2011)
262. Prevots D.R., Burr R.K., Sutter R.W., et al: Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-22.

263. WHO/UNICEF Joint Reporting Form, http://www.who.int/immunization_monitoring/data/schedule_data.xls . (Accessed November 2011)
264. Plotkin S.A.: Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis. Rev Med Virol 1997; 7:75-81.
265. Centers for Disease Control and Prevention : Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(No. RR-5):
266. Bulletin Épidémilogique Hebdomadaire (BEH). http://www.invs.sante.fr/beh/2010/14_15/beh_14_15.pdf . (Accessed November 2011)
267. Public Health Agency of Canada. http://www.phac-aspc.gc.ca/im/is-cv/index-eng.php#b . (Accessed November 2011)
268. Sutter R.W., Prevots D.R.: Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994; 426:438.
269. Bottiger M.: The elimination of polio in the Scandinavian countries. Public Health Rev 1993; 21:27-33.
270. Bottiger M., Mellin P., Romanus V., et al: Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull World Health Organ 1979; 57:99-103.
271. Hovi T., Cantell K., Huovilainen A., et al: Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986; 1:1427-1432.
272. Lapinleimu K.: Elimination of poliomyelitis in Finland. Rev Infect Dis 1984; 6(Suppl. 2):S457-S460.
273. Magrath D.I., Evans D.M., Ferguson M., et al: Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. J Gen Virol 1986; 67:899-905.
274. Piirainen L., Stenvik M., Roivainen M., et al: Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. Vaccine 1999; 17:1084-1090.
275. von Magnus H., Petersen I.: Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984; 6(Suppl. 2):S471-S474.
276. van Wezel A.L., van Steenis G., van der Marel P., et al: Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 1984; 6(Suppl. 2):S335-S340.
277. Conyn-Van Spaendonck M.A., de Melker H.E., Abbink F., et al: Immunity to poliomyelitis in the Netherlands. Am J Epidemiol 2001; 153:207-214.
278. Malvy D.J., Drucker J.: Elimination of poliomyelitis in France: epidemiology and vaccine status. Public Health Rev 1993; 21:41-49.
279. Roure C., Rebiere I., Aymard M., et al: Surveillance de la poliomyelite en France. Bull Epidemiol Hebd 1993; 15:59-61.
280. Guerin N., Bregere P., Caudrelier P., et al: Neutralizing antibody response to oral poliovirus vaccine after primary immunization with inactivated poliovirus vaccine. Eur J Clin Microbiol Infect 1998; 17:815-816.
281. Drucker J.: Poliomyelitis in France: epidemiology and vaccination status. Pediatr Infect Dis J 1991; 10:967-969.
282. Antona D., Guerin N.: L'éradication de la poliomyelite: ou en est-on en 2010?. Bull Epidemiol Hebd 2010; 48:489-493.
283. Ministry of Health Ontario : Wild-type poliovirus isolated in Hamilton. Public Health Epidemiol Rep 1996; 7:51-52.

284. ACIP : Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine-live attenuated poliovirus vaccine immunization schedules. MMWR 1997; 46:1-25.
285. Strebel P.M., Sutter R.W., Cochi S.L., et al: Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14:568-579.
286. Yogev R., Edwards K.M.: Polio vaccination schedules in the United States: the rationale for change. Sem Ped Infect Dis 1999; 10:249-257.
287. Kolasa M.S., Desai S.N., Bisgard K.M., et al: Impact of the sequential poliovirus immunization schedule: a demonstration project. Am J Prev Med 2000; 18:140-145.
288. Lakhiani C.N., Vivier P.M., Alario A.J., et al: Analysis of the transition from oral polio vaccine to inactivated polio vaccine for primary immunization in a hospital-based primary care practice. Pediatr Infect Dis J 2000; 19:575-576.
289. Lieu T.A., Davis R.L., Capra A.M., et al: Variation in clinician recommendations for multiple injections during adoption of inactivated polio vaccine. Pediatrics 2001; 107:E49.
290. Eskola J., Dagan R.: AvP study PNF35. Data in file2000.
291. Lasch E.E., Abed Y., Abdulla K., et al: Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984; 6(Suppl. 2):S467-S470.
292. Swartz T.A., Ben Porath E., Kanaaneh H., et al: Comparison of inactivated poliovirus vaccine and oral poliovirus vaccine programs in Israel. Rev Infect Dis 1984; 6(Suppl. 2):S556-S561.
293. Linder N., Taushtein I., Handsher R., et al: Placental transfer of maternal poliovirus antibodies in full-term and pre-term infants. Vaccine 1998; 16:236-239.
294. Slater P.E., Orenstein W.A., Morag A., et al: Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990; 335:1192-1195.
295. Fine P.E.: Polio: measuring the protection that matters most. J Infect Dis 2009; 200:673-675.
296. Tucker A.W., Isaacs D., Burgess M.: Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust N Z J Public Health 2001; 25:411-416.
297. Global Post-eradication IPV Supply and Demand Assessment: Integraded Findings, http://www.oliverwyman.com/ow/pdf_files/Post-EradicationIPVSupplyDemandMar09.pdf . (Accessed November 2011)
298. Khan M.M.: Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?. Vaccine 2008; 26:2034-2040.
299. WHO : Meeting of the Strategic Advisory Group of Experts on immunization, April 2011—Conclusions and recommendations. Wkly Epidemiol Rec 2011; 86:205-220.
300. WHO : Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010; 85:213-228.
301. Conclusion and Recommendations of the Polio Research Committee (PRC). November 10–11, 2009. Geneva(Accessed November 2011) www.polioeradication.org/Portals/0/Document/Resources/091111_Recommendation_PRC_v6.pdf
302. Independent Monitoring Board of the Global Polio Eradication Initiative, www.polioeradication.org/Portals/0/Document/Data&Monitoring/IMB_Reports/IMB_Report_April2011.pdf
303. John T.J.: Immunisation against polioviruses in developing countries. Rev Med Virol 1993; 3:149-160.

304. Hull H.F., Aylward R.B.: Ending polio immunization. Science 1997; 277:780.[see comments]
305. John T.J.: Anomalous observations on IPV and OPV vaccination. Dev Biol (Basel) 2001; 105:197-208.
306. The Global Polio Eradication Initiative. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx . (Accessed November 2011)
307. Estevrs K.: Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 1988; 66:739-746.
308. John T.J.: A developing country perspective on vaccine-associated paralytic poliomyelitis. Bull World Health Organ 2004; 82:53-57.
309. McBean A.M., Modlin J.F.: Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 1987; 6:881-887.
310. Hull H.F., Aylward R.B.: Progress towards global polio eradication. Vaccine 2001; 19:4378-4384.
311. Hull H.F., Birmingham M.E., Melgaard B., et al: Progress toward global polio eradication. J Infect Dis 1997; 175(Suppl. 1):S4-S9.
312. Arita I., Nakane M., Fenner F.: Public health: Is polio eradication realistic?. Science 2006; 312:852-854.
313. Aylward R.B., Sutter R.W., Heymann D.L.: Policy. OPV cessation-the final step to a “polio-free” world. Science 2005; 310:625-626.
314. Kew O.M., Sutter R.W., de Gourville E.M., et al: Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635.
315. Bonu S., Rani M., Baker T.D.: The impact of the national polio immunization campaign on levels and equity in immunization coverage: evidence from rural North India. Soc Sci Med 2003; 57:1807-1819.
316. Phadke A., Kale A.: The mirage of polio eradication. Natl Med J India 2004; 17:282.
317. Sharma D.C.: Indian experts favour IPV to eradicate polio. Lancet 2003; 362:1292.
318. Vaccines and biologicals : Report of the interim meeting of the technical consultative group (TCG) on the global eradication of poliomyelitis, Geneva, November 9–11, 2002. Geneva, World Health Organization, 2003.
319. CDC : Brief report: Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication-Geneva, Switzerland, October 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1186-1188.
320. Heymann D.L., Sutter R.W., Aylward R.B.: A global call for new polio vaccines. Nature 2005; 434:699-700.
321. Henderson D.A.: Countering the posteradication threat of smallpox and polio. Clin Infect Dis 2002; 34:79-83.
322. John T.J.: The final stages of the global eradication of polio. N Engl J Med 2000; 343:806-807.
323. WHO. Vaccines and Immunization, http://www.euro.who.int/en/what-we-do/health-topics/diseases-and-conditions/poliomyelitis/publications/2010/who-epidemiological-brief-10-importation-of-wild-poliovirus-and-response-measures-in-the-european-region. (Accessed November 2011)
324. Diamond B.: Global polio campaign doomed to fail, experts warn. Nat Med 2005; 11:1260.
325. Agol V.I., Chumakov K., Ehrenfeld E., et al: Don't drop current vaccine until we have new ones. Nature 2005; 435:881.

326. Georgescu M.M., Delpeyroux F., Tardy-Panit M., et al: High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 1994; 68:8089-8101.
327. Dove A.W., Racaniello V.R.: The polio eradication effort: should vaccine eradication be next?. Science 1997; 277:779-780.[see comments]
328. CDC : Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep 1997; 46:641-643.
329. Guillot S., Caro V., Cuervo N., et al: Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 2000; 74:8434-8443.
330. Kew O., Morris-Glasgow V., Landaverde M., et al: Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-359.
331. Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Committee on Infectious Diseases. American Academy of Pediatrics. Pediatrics 1999; 104:1404-1406.
332. Racaniello V.R.: It is too early to stop polio vaccination. Bull World Health Organ 2000; 78:359-360.
333. Schoub B.D.: The risks of stopping vaccination: perspectives from the developing world. Bull World Health Organ 2000; 78:360-361.
334. Fine P.E.: Gaps in our knowledge about transmission of vaccine-derived polioviruses. Bull World Health Organ 2000; 78:358-359.
335. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec 2003; 78:241-250.
336. Kimman T.Y., Book N.: The polio eradication effort has been a great success—let's finish it and replace it with something even better. Lancet Infect Dis 2006; 6(10):675-678.

HAEMOPHILUS INFLUENZAE TIPA B

1. Watt J.P., Wolfson L.J., O'Brien K.L., et al: Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374:903-911.
2. World Health Organization : WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiological Rec 2006; 81:445-452.
3. Fitzwater S.P., Watt J.P., Levine O.S., et al: Haemophilus influenzae type b conjugate vaccines: Considerations for vaccination schedules and implications for developing countries. Hum Vaccin 2010; 6:810-818.
4. Koch R.: Bericht uber die Thatigkeit der deutschen Cholera-kommission in Aegpytten and Ostindien. Wien Med Wochenschr 1883; 53:1548-1551.
5. Pfieffer R.: Die Aetiologie der Influenzaa. Z Hyg Infect 1893; 13:357-386.
6. Tognotti E.: Scientific triumphalism and learning from facts: bacteriology and the “Spanish flu” challenge of 1918. Soc Hist Med 2003; 16:97-110.
7. Pittman M.: Variation and type specificity in the bacterial species Hemophilus influenzae. J Exp Med 1931; 53:471-492.
8. St Geme III J.: Early events in the pathogenesis of Haemophilus influenzae disease. In: Miller V., Kaper J.B., Portnoy D.A., et al ed. Molecular Genetics of Bacterial Pathogenesis: A Tribute to Stanley Falkow, Washington, DC: American Society for Microbiology; 1994:157-172.
9. Murphy T.F.: Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines 2005; 4:843-853.

10. St Geme III J.W., Falkow S.: Loss of capsule expression by Haemophilus influenzae type b results in enhanced adherence to and invasion of human cells. Infect Immun 1991; 59:1325-1333.
11. van Alphen L.: Molecular epidemiology of Hib strains. In: Ellis R., Granoff D., ed. Development and Clinical Uses of Haemophilus b Conjugate Vaccines, New York, NY: Marcel Dekker, Inc; 1994:129.
12. Fothergill L.D, Wright J.: Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24:273-284.
13. Käyhty H., Makela P., Peltola H.: Immunological basis for PRP vaccines. Development and Clinical Uses of Haemophilus b Conjugate Vaccines, New York, NY: Marcel Dekker, Inc; 1994:1.
14. Peltola H.: Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302-317.
15. Levine O.S., Knoll M.D., Jones A., et al: Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis 2010; 23:236-241.
16. Centers for Disease Control and Prevention : Progress toward introduction of Haemophilus influenzae type b vaccine in low-income countries: worldwide, 2004–2007. MMWR Morb Mortal Wkly Rep 2008; 57:48-151.
17. Tebbutt G.M.: Evaluation of some methods for the laboratory identification of Haemophilus influenzae. J Clin Pathol 1983; 36:991-995.
18. Swift A.J., Moxon E.R., Zwahlen A., et al: Complement-mediated serum activities against genetically defined capsular transformants of Haemophilus influenzae. Microb Pathog 1991; 10:261-269.
19. Lindberg A.A.: Polyosides (encapsulated bacteria). C R Acad Sci III 1999; 322:925-932.
20. Moxon E.R., Vaughn K.A.: The type b capsular polysaccharide as a virulence determinant of Haemophilus influenzae: studies using clinical isolates and laboratory transformants. J Infect Dis 1981; 143:517-524.
21. Moxon E.R., Kroll J.S.: The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol 1990; 150:65-85.
22. Kelly D.F., Moxon E.R., Pollard A.J.: Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113:163-174.
23. Roberts M., Stull T.L., Smith A.L.: Comparative virulence of Haemophilus influenzae with a type b or type d capsule. Infect Immun 1981; 32:518-524.
24. Crisel R.M., Baker R.S., Dorman D.E.: Capsular polymer of Haemophilus influenzae, type b,I: structural characterization of the capsular polymer of strain Eagan. J Biol Chem 1975; 250:4926-4930.
25. Zwahlen A., Kroll J.S., Rubin L.G., et al: The molecular basis of pathogenicity in Haemophilus influenzae: comparative virulence of genetically-related capsular transformants and correlation with changes at the capsulation locus cap. Microb Pathog 1989; 7:225-235.
26. Kroll J.S., Booy R.: Haemophilus influenzae: capsule vaccine and capsulation genetics. Mol Med Today 1996; 2:160-165.
27. Kroll J., Langford P.: Molecular aspects of the pathogenesis of invasive Haemophilus influenzae type b Infections. In: Ellis R., Granoff D., ed. Development and Clinical Uses of Haemophilus b Conjugate Vaccines, New York, NY: Marcel Dekker, Inc; 1994:145.
28. Ueno K., Nishi J., Imuta N., et al: Presence of multiple copies of capsulation loci in invasive Haemophilus influenzae type b (Hib) strains in Japan before introduction of the Hib conjugate vaccine. Microbiol Immunol 2010; 54:160-163.

29. Kroll J.S., Moxon E.R.: Capsulation and gene copy number at the cap locus of Haemophilus influenzae type b. J Bacteriol 1988; 170:859-864.
30. Noel G.J., Brittingham A., Granato A.A., et al: Effect of amplification of the Cap b locus on complement-mediated bacteriolysis and opsonization of type b Haemophilus influenzae. Infect Immun 1996; 64:4769-4775.
31. Ogilvie C., Omikunie A., Wang Y., et al: Capsulation loci of non–serotype b encapsulated Haemophilus influenzae. J Infect Dis 2001; 184:144-149.
32. Kapogiannis B.G., Satola S., Keyserling H.L., et al: Invasive infections with Haemophilus influenzae serotype a containing an IS1016-bexA partial deletion: possible association with virulence. Clin Infect Dis 2005; 41:e97-103.
33. Jarosik G.P., Hansen E.J.: Identification of a new locus involved in expression of Haemophilus influenzae type b lipooligosaccharide. Infect Immun 1994; 62:4861-4867.
34. Johnson A.P., Inzana T.J.: Loss of ciliary activity in organ cultures of rat trachea treated with lipo-oligosaccharide from Haemophilus influenzae. J Med Microbiol 1986; 22:265-268.
35. Williams A.E., Maskell D.J., Moxon E.R.: Relationship between intracellular survival in macrophages and virulence of Haemophilus influenzae type b. J Infect Dis 1991; 163:1366-1369.
36. Mu X.Q., Egelman E.H., Bullitt E.: Structure and function of Hib pili from Haemophilus influenzae type b. J Bacteriol 2002; 184:4868-4874.
37. Guerina N.G., Langermann S., Clegg H.W., et al: Adherence of piliated Haemophilus influenzae type b to human oropharyngeal cells. J Infect Dis 1982; 146:564.
38. Avery O.T., Goebel W.F.: Chemo-immunological studies on conjugated carbohydrate-proteinsV: the immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III Pneumococcus with foreign protein. J Exp Med 1931; 54:437-447.
39. Farley M.M., Stephens D.S., Kaplan S.L., et al: Pilus- and non-pilus-mediated interactions of Haemophilus influenzae type b with human erythrocytes and human nasopharyngeal mucosa. J Infect Dis 1990; 161:274-280.
40. Kaplan S.L., Mason Jr E.O., Wiedermann B.L.: Role of adherence in the pathogenesis of Haemophilus influenzae type b infection in infant rats. Infect Immun 1983; 42:612-617.
41. Käyhty H., Karanko V., Peltola H., et al: Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74:857-865.
42. Santosham M.: Prevention of Haemophilus influenzae type b disease. Vaccine 1993; 11(suppl 1):S52-S57.
43. Murphy T.V., Granoff D., Chrane D.F., et al: Pharyngeal colonization with Haemophilus influenzae type b in children in a day care center without invasive disease. J Pediatr 1985; 106:712-716.
44. Barbour M.L.: Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis 1996; 2:176-182.
45. Michaels R.H., Poziviak C.S., Stonebraker F.E., et al: Factors affecting pharyngeal Haemophilus influenzae type b colonization rates in children. J Clin Microbiol 1976; 4:413-417.
46. Takala A.K., Eskola J., Leinonen M., et al: Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991; 164:982-986.
47. Takala A.K., Santosham M., Almeido-Hill J., et al: Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993; 12:593-599.

48. Adegbola R.A., Secka O., Lahai G., et al: Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005; 366:144-150.
49. Käyhty H.: Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994; 22:397-402.
50. Coulehan J.L., Michaels R.H., Hallowell C., et al: Epidemiology of Haemophilus influenzae type B disease among Navajo Indians. Public Health Rep 1984; 99:404-409.
51. Losonsky G.A., Santosham M., Sehgal V.M., et al: Haemophilus influenzae disease in the White Mountain Apaches: molecular epidemiology of a high risk population. Pediatr Infect Dis 1984; 3:539-547.
52. Olsen S.J., Dejsirilert S., Sangsuk L., et al: Frequent Haemophilus influenzae type B colonization in rural Thailand. Pediatr Infect Dis J 2005; 24:739-742.
53. Gupta M., Kumar R., Deb A.K., et al: Multi-center surveillance for pneumonia & meningitis among children (< 2 yr) for Hib vaccine probe trial preparation in India. Indian J Med Res 2010; 131:649-658.
54. Sung R.Y., Ling J.M., Fung S.M., et al: Carriage of Haemophilus influenzae and Streptococcus pneumoniae in healthy Chinese and Vietnamese children in Hong Kong. Acta Paediatr 1995; 84:1262-1267.
55. Wang S.R., Lo W.T., Chou C.Y., et al: Low rate of nasopharyngeal carriage and high rate of ampicillin resistance for Haemophilus influenzae among healthy children younger than 5 years old in northern Taiwan. J Microbiol Immunol Infect 2008; 41:32-40.
56. Moxon E.R.: The carrier state: Haemophilus influenzae. J Antimicrob Chemother 1986; 18(suppl A):17-24.
57. Ward J.I., Gorman G., Phillips C., et al: Hemophilus influenzae type b disease in a day-care center: report of an outbreak. J Pediatr 1978; 92:713-717.
58. Galil K., Singleton R., Levine O.S., et al: Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999; 179:101-106.
59. Takala A.K., Meuman O., Kleemola M., et al: Preceding respiratory infection predisposing for primary and secondary invasive Haemophilus influenzae type b disease. Pediatr Infect Dis J 1993; 12:189-195.
60. Raza M.W., Ogilvie M.M., Blackwell C.C., et al: Effect of respiratory syncytial virus infection on binding of Neisseria meningitidis and Haemophilus influenzae type b to a human epithelial cell line (HEp-2). Epidemiol Infect 1993; 110:339-347.
61. Myerowitz R.L., Michaels R.H.: Mechanism of potentiation of experimental Haemophilus influenzae type B disease in infant rats by influenza A virus. Lab Invest 1981; 44:434-441.
62. Avadhanula V., Rodriguez C.A., Devincenzo J.P., et al: Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type–dependent manner. J Virol 2006; 80:1629-1636.
63. Nuorti J.P., Butler J.C., Farley M.M.and the Active Bacterial Core Surveillance Team: Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000; 342:681-689.
64. Cartwright K.A., Jones D.M., Smith A.J., et al: Influenza A and meningococcal disease. Lancet 1991; 338:554-557.
65. Rubin L.G., Zwahlen A., Moxon E.R.: Role of intravascular replication in the pathogenesis of experimental bacteremia due to Haemophilus influenzae type b. J Infect Dis 1985; 152:307-314.
66. Scheifele D.W., Daum R.S., Syriopoulou V.P., et al: Haemophilus influenzae bacteremia and meningitis in infant primates. J Lab Clin Med 1980; 95:450-462.

67. La Scolea Jr L.J., Rosales S.V., Welliver R.C., et al: Mechanisms underlying the development of meningitis or epiglottitis in children after Haemophilus influenzae type b bacteremia. J Infect Dis 1985; 151:1162-1165.
68. Santosham M., Moxon E.R.: Detection and quantitation of bacteremia in childhood. J Pediatr 1977; 91:719-721.
69. Kilpatrick M.E., Mikhail I.A., Girgis N.I.: Negative cultures of cerebrospinal fluid in partially treated bacterial meningitis. Trop Geogr Med 1987; 39:345-349.
70. Rådström P., Bäckman A., Qian N., et al: Detection of bacterial DNA in cerebrospinal fluid by an assay for simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and streptococci using a seminested PCR strategy. J Clin Microbiol 1994; 32:2738-2744.
71. Singhi S.C., Mohankumar D., Singhi P.D., et al: Evaluation of polymerase chain reaction (PCR) for diagnosing Haemophilus influenzae b meningitis. Ann Trop Paediatr 2002; 22:347-353.
72. van Ketel R.J., de Wever B., van Alphen L.: Detection of Haemophilus influenzae in cerebrospinal fluids by polymerase chain reaction DNA amplification. J Med Microbiol 1990; 33:271-276.
73. Hoban D.J., Witwicki E., Hammond G.W.: Bacterial antigen detection in cerebrospinal fluid of patients with meningitis. Diagn Microbiol Infect Dis 1985; 3:373-379.
74. Shivaprakash M.R., Rajagopal V., Nagarathna S.: Latex agglutination test in the diagnosis of pyogenic meningitis. J Commun Dis 2004; 36:127-131.
75. Ajello G.W., Bolan G.A., Hayes P.S., et al: Commercial latex agglutination tests for detection of Haemophilus influenzae type b and Streptococcus pneumoniae antigens in patients with bacteremic pneumonia. J Clin Microbiol 1987; 25:1388-1391.
76. Witt C.S., Montgomery J.M., Pomat W., et al: Detection of Streptococcus pneumoniae and Haemophilus influenzae type b antigens in the serum and urine of patients with pneumonia in Papua New Guinea: comparison of latex agglutination and counterimmunoelectrophoresis. Rev Infect Dis 1990; 12(suppl 8):S1001-S1005.
77. Saha S.K., Baqui A.H., Areefin S., et al: Detection of antigenuria for diagnosis of invasive Haemophilus influenzae type b disease. Ann Trop Paediatr 2006; 26:329-336.
78. Manary M.J., Lehmann D., Michael A., et al: Antigenuria in healthy Papua New Guinean children with nasal Haemophilus influenzae type b carriage. Ann Trop Paediatr 1993; 13:385-389.
79. Rubin L.G., Carmody L.: Pneumococcal and Haemophilus influenzae type b antigen detection in children at risk for occult bacteremia. Pediatrics 1987; 80:92-96.
80. Ballard T.L., Roe M.H., Wheeler R.C., et al: Comparison of three latex agglutination kits and counterimmunoelectrophoresis for the detection of bacterial antigens in a pediatric population. Pediatr Infect Dis J 1987; 6:630-634.
81. Counts G.W., Turck M.: Screening for cross-reacting capsular polysaccharide K antigens of Escherichia coli using antiserum agar. J Clin Microbiol 1977; 5:490-491.
82. Rothstein E.P., Madore D.V., Girone J.A., et al: Comparison of antigenuria after immunization with three Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J 1991; 10:311-314.
83. Goepp J.G., Hohenboken M., Almeido-Hill J., et al: Persistent urinary antigen excretion in infants vaccinated with Haemophilus influenzae type b capsular polysaccharide conjugated with outer membrane protein from Neisseria meningitidis. Pediatr Infect Dis J 1992; 11:2-5.
84. Adegbola R.A., Leach A., Mulholland K., et al: Antigenuria in Gambian infants following immunization with a Haemophilus influenzae type b polyribosylribitol phosphate–tetanus toxoid protein conjugate (PRP-T) vaccine. Diagn Microbiol Infect Dis 1998; 32:15-19.

85. Dajani A.S., Asmar B.I., Thirumoorthi M.C.: Systemic Haemophilus influenzae disease: an overview. J Pediatr 1979; 94:355-364.
86. Karma P., Luotonen J., Pukander J., et al: Haemophilus influenzae in acute otitis media. Acta Otolaryngol 1983; 95:105-110.
87. Anderson A.B., Ambrosino D.M., Siber G.R.: Haemophilus influenzae type b unsuspected bacteremia. Pediatr Emerg Care 1987; 3:82-85.
88. Takala A.K., Eskola J., Palmgren J., et al: Risk factors of invasive Haemophilus influenzae type b disease among children in Finland. J Pediatr 1989; 115(5 pt 1):694-701.
89. Rennie R.P., Ibrahim K.H.: Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 2005; 41(suppl 4):S234-S238.
90. Brook I., Foote P.A., Hausfeld J.N.: Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid. Int J Antimicrob Agents 2005; 26:416-419.
91. Simpson G.T., McGill T.I., Healy G.B.: Hemophilus influenzae type B soft tissue infections of the head and neck. Laryngoscope 1981; 91:17-29.
92. Shapiro E.D., Wald E.R., Brozanski B.A.: Periorbital cellulitis and paranasal sinusitis: a reappraisal. Pediatr Infect Dis 1982; 1:91-94.
93. Vuori-Holopainen E., Peltola H.: Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin Infect Dis 2001; 32:715-726.
94. Isaacs D.: Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr Infect Dis J 1989; 8:143-148.
95. Baselski V.S., Wunderink R.G.: Bronchoscopic diagnosis of pneumonia. Clin Microbiol Rev 1994; 7:533-558.
96. Mulholland K., Hilton S., Adegbola R., et al: Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349:1191-1197.
97. Levine O.S., Lagos R., Muñoz A., et al: Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999; 18:1060-1064.
98. Gessner B.D., Sutanto A., Linehan M., et al: Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005; 365:43-52.
99. Baqui A.H., El Arifeen S., Saha S.K., et al: Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J 2007; 26:565-571.
100. de Andrade A.L., de Andrade J.G., Martelli C.M., et al: Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol 2004; 33:173-181.
101. de la Hoz F., Higuera A.B., Di Fabio J.L., et al: Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine 2004; 23:36-42.
102. Smith A., et al: Mechanisms of Haemophilus influenzae type b meningitis. In: Sande M., Smith A., Root R., ed. Bacterial Meningitis, New York, NY: Churchill Livingstone; 1985:11.
103. D'Angio C.T., Froehlke R.G., Plank G.A., et al: Long-term outcome of Haemophilus influenzae meningitis in Navajo Indian children. Arch Pediatr Adolesc Med 1995; 149:1001-1008.

104. Taylor H.G., Michaels R.H., Mazur P.M., et al: Intellectual, neuropsychological, and achievement outcomes in children six to eight years after recovery from Haemophilus influenzae meningitis. Pediatrics 1984; 74:198-205.
105. Edmond K., Clark A., Korczak V.S., et al: Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:317-328.
106. Wenger J.D.: Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 1998; 17(9 suppl):S132-S136.
107. Bijlmer H.A.: World-wide epidemiology of Haemophilus influenzae meningitis: industrialized versus non-industrialized countries. Vaccine 1991; 9(suppl):S5-S9.S25
108. Limcangco M.R., Salole E.G., Armour C.L.: Epidemiology of Haemophilus influenzae type b meningitis in Manila, Philippines, 1994 to 1996. Pediatr Infect Dis J 2000; 19:7-11.
109. Hussain I.H., Sofiah A., Ong L.C., et al: Haemophilus influenzae meningitis in Malaysia. Pediatr Infect Dis J 1998; 17(9 suppl):S189-S190.
110. Ramakrishnan M., Ulland A.J., Steinhardt L.C., et al: Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med 2009; 7:47.doi:10.1186/1741-7015-7-47
111. Kessler A., Wetmore R.F., Marsh R.R.: Childhood epiglottitis in recent years. Int J Pediatr Otorhinolaryngol 1993; 25:155-162.
112. McVernon J., Slack M.P., Ramsay M.E.: Changes in the epidemiology of epiglottitis following introduction of Haemophilus influenzae type b (Hib) conjugate vaccines in England: a comparison of two data sources. Epidemiol Infect 2006; 134:570-572.
113. Garpenholt O., Hugosson S., Fredlund H., et al: Epiglottitis in Sweden before and after introduction of vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999; 18:490-493.
114. Hanna J.: The epidemiology and prevention of Haemophilus influenzae infections in Australian aboriginal children. J Paediatr Child Health 1992; 28:354-361.
115. Ward J.I., Lum M.K., Hall D.B., et al: Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. J Infect Dis 1986; 153:17-26.
116. Ferreccio C., Ortiz E., Astroza L., et al: A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr Infect Dis J 1990; 9:488-494.
117. Wang C.L., Wang S.M., Yang Y.J., et al: Septic arthritis in children: relationship of causative pathogens, complications, and outcome. J Microbiol Immunol Infect 2003; 36:41-46.
118. Goergens E.D., McEvoy A., Watson M., et al: Acute osteomyelitis and septic arthritis in children. J Paediatr Child Health 2005; 41:59-62.
119. Kaplan S.: Pathogenesis and treatment of infants and children. In: Ellis R., Granoff D., ed. Development and Clinical Uses of Haemophilus b Conjugate Vaccines, New York, NY: Marcel Dekker, Inc; 1994:371-388.
120. Howard A.W., Viskontas D., Sabbagh C.: Reduction in osteomyelitis and septic arthritis related to Haemophilus influenzae type B vaccination. J Pediatr Orthop 1999; 19:705-709.
121. Ambati B.K., Ambati J., Azar N., et al: Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology 2000; 107:1450-1453.
122. Smith T.F., O apos D., Wright P.F.: Clinical implications of preseptal (periorbital) cellulitis in childhood. Pediatrics 1978; 62:1006-1009.
123. Schwartz G.R., Wright S.W.: Changing bacteriology of periorbital cellulitis. Ann Emerg Med 1996; 28:617-620.

124. Fisher R.G., Benjamin Jr D.K.: Facial cellulitis in childhood: a changing spectrum. South Med J 2002; 95:672-674.
125. Centers for Disease Control and Prevention : Progress toward eliminating Haemophilus influenzae type b disease among infants and children: United States, 1998–2000. MMWR Morb Mortal Wkly Rep 2002; 51:234-237.
126. Murphy T.F., Brauer A.L., Schiffmacher A.T., et al: Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:266-272.
127. O'Neill J.M., St Geme III J.W., Cutler D., et al: Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas. J Clin Microbio 2003; 41:3064-3069.
128. Faden H., Duffy L., Williams A., et al: Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis 1995; 172:132-135.
129. Klein J.O.: Role of nontypeable Haemophilus influenzae in pediatric respiratory tract infections. Pediatr Infect Dis J 1997; 16(2 suppl):S5-S8.
130. Murphy T.F., Faden H., Bakaletz L.O., et al: Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J 2009; 28:43-48.
131. Falla T.J., Dobson S.R., Crook D.W., et al: Population-based study of non-typable Haemophilus influenzae invasive disease in children and neonates. Lancet 1993; 341:851-854.
132. Faden H.: Meningitis caused by nontypable Haemophilus influenzae in a four-month-old infant. Pediatr Infect Dis J 1991; 10:254-255.
133. Haemophilus influenzae infections. In: Pickering L.K., Baker C.J., Kimberlin D.W., et al ed. 2009 Red Book: Report of the Committee on Infectious Diseases, 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:314-321.
134. World Health Organization : Fever. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Illnesses with Limited Resources, Geneva, Switzerland: WHO Press; 2005:133-172.
135. Ginsburg C.M., McCracken Jr G.H., Rae S., et al: Haemophilus influenzae type b disease: incidence in a day-care center. JAMA 1977; 238:604-607.
136. Andersson von Rosen I., Gotherfors L., Schmeisser S., et al: Outbreak of Haemophilus influenzae type b meningitis in a day care center. Pediatr Infect Dis J 1990; 9:326-332.
137. Makintubee S., Istre G.R., Ward J.I.: Transmission of invasive Haemophilus influenzae type b disease in day care settings. J Pediatr 1987; 111:180-186.
138. Eskola J., Takala A., Käyhty A., et al: Secondary cases of invasive disease caused by spread of Haemophilus influenzae type b. J Infect 1987; 14:233-236.
139. Ward J.I., Fraser D.W., Baraff L.J., et al: Haemophilus influenzae meningitis: a national study of secondary spread in household contacts. N Engl J Med 1979; 301:122-126.
140. Michaels R.H., Norden C.W.: Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. influenzae type b. J Infect Dis 1977; 136:222-228.
141. Jordens J.Z., Slack M.P.: Haemophilus influenzae: then and now. Eur J Clin Microbiol Infect Dis 1995; 14:935-948.
142. Jones M.E., Karlowsky J.A., Blosser-Middleton R., et al: Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents 2002; 19:119-123.
143. Sow S.O., Diallo S., Campbell J.D., et al: Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J 2005; 24:533-537.

144. Kwak Y.H., Jung H.S., Park S.E., et al: Serotypes and antimicrobial susceptibility in clinical isolates of Haemophilus influenzae from Korean children in prevaccination era. J Korean Med Sci 2000; 15:616-622.
145. Rahman M., Hossain S., Baqui A.H., et al: Haemophilus influenzae type-b and non-b-type invasive diseases in urban children (< 5 years) of Bangladesh: implications for therapy and vaccination. J Infect 2008; 56:191-196.
146. Campos J., Hernando M., Román F., et al: Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b. J Clin Microbiol 2004; 42:524-529.
147. Scott J.A., Mwarumba S., Ngetsa C., et al: Progressive increase in antimicrobial resistance among invasive isolates of Haemophilus influenzae obtained from children admitted to a hospital in Kilifi, Kenya, from 1994 to 2002. Antimicrob Agents Chemother 2005; 49:3021-3024.
148. de Andrade A.L., Brandileone M.C., Di Fabio J.L., et al: Haemophilus influenzae resistance in Latin America: systematic review of surveillance data. Microb Drug Resist 2001; 7:403-411.
149. Zanella R.C., Casagrande S.T., Bokermann S., et al: Characterization of Haemophilus influenzae isolated from invasive disease in Brazil from 1990 to 1999. Microb Drug Resist 2002; 8:67-72.
150. Saha S.K., Baqui A.H., Darmstadt G.L., et al: Invasive Haemophilus influenzae type B diseases in Bangladesh, with increased resistance to antibiotics. J Pediatr 2005; 146:227-233.
151. Adams W.G., Deaver K.A., Cochi S.L., et al: Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269:221-226.
152. Bisgard K.M., Kao A., Leake J., et al: Haemophilus influenzae invasive disease in the United States 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998; 4:229-237.
153. Murphy T.V., Osterholm M.T., Pierson L.M., et al: Prospective surveillance of Haemophilus influenzae type b disease in Dallas County, Texas, and in Minnesota. Pediatrics 1987; 79:173-180.
154. Cochi S.L., Broome C.V., Hightower A.W.: Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA 1985; 253:521-529.
155. Watt J.P., Levine O.S., Santosham M.: Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002. J Pediatr 2003; 143(6 suppl):S163-S187.
156. Reinert P., Liwartowski A., Dabernat H., et al: Epidemiology of Haemophilus influenzae type b disease in France. Vaccine 1993; 11(suppl 1):S38-S42.
157. Peltola H., Käyhty H., Virtanen M., et al: Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 310:1561-1566.
158. Yost G.C., Kaplan A.M., Bustamante R., et al: Bacterial meningitis in Arizona American Indian children. Am J Dis Child 1986; 140:943-946.
159. Ward J.I., Margolis H.S., Lum M.K., et al: Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet 1981; 1:1281-1285.
160. Gilbert G.L.: Epidemiology of Haemophilus influenzae type b disease in Australia and New Zealand. Vaccine 1991; 9(suppl):S10-S13.S25
161. Morris S.K., Moss W.J., Halsey N.: Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008; 8:435-443.

162. Russell F.M., Carapetis J.R., Mansoor O., et al: High incidence of Haemophilus influenzae type b infection in children in Pacific island countries. Clin Infect Dis 2003; 37:1593-1599.
163. Ceyhan M., Yildirim I., Balmer P., et al: A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis 2008; 14:1089-1096.
164. Dash N., Panigrahi D., Al Khusalby S., et al: Acute bacterial meningitis among children < 5 years of age in Oman: a retrospective study during 2000–2005. J Infect Dev Ctries 2008; 2:112-115.
165. Review panel on Haemophilus influenzae type b (Hib) disease burden in Bangladesh, Indonesia and other Asian countries, Bangkok, 28–29 January 2004. Wkly Epidemiol Rec 2004; 79:173-175.
166. Shetty S., Cohen A.L., Edmond K., et al: A systematic review and critical evaluation of invasive Haemophilus influenzae type B disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance. Pediatr Infect Dis J 2010; 29:653-661.
167. Broker M.: Burden of invasive disease caused by Haemophilus influenzae type b in Asia. Jpn J Infect Dis 2009; 62:87-92.
168. Batuwanthudawe R., Rajapakse L., Somaratne P., et al: Incidence of childhood Haemophilus influenzae type b meningitis in Sri Lanka. Int J Infect Dis 2010; 14:e372-e376.
169. Minz S., Balraj V., Lalitha M.K., et al: Incidence of Haemophilus influenzae type b meningitis in India. Indian J Med Res 2008; 128:57-64.
170. Peltola H.: Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Pediatr Infect Dis J 1998; 17(9 suppl):S126-S132.
171. Adegbola R.A., Mulholland E.K., Secka O., et al: Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 1998; 177:1758-1761.
172. Fraser D.W., Geil C.C, Feldman R.A.: Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol 1974; 100:29-34.
173. Vadheim C.M., Greenberg D.P., Bordenave N., et al: Risk factors for invasive Haemophilus influenzae type b in Los Angeles County children 18–60 months of age. Am J Epidemiol 1992; 136:221-235.
174. Parke Jr J.C., Schneerson R., Robbins J.B.: The attack rate, age incidence, racial distribution, and case fatality rate of Hemophilus influenzae type b meningitis in Mecklenbury County, North Carolina. J Pediatr 1972; 81:765-769.
175. Cochi S.L., Fleming D.W., Hightower A.W., et al: Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors. J Pediatr 1986; 108:887-896.
176. Granoff D.M., McKinney T., Boles E.G., et al: Haemophilus influenzae type b disease in an Amish population: studies of the effects of genetic factors, immunization, and rifampin prophylaxis on the course of an outbreak. Pediatrics 1986; 77:289-295.
177. Goddard E.A., Beatty D.W., Hoffman E.B.: Immunoglobulin allotypes and genetic susceptibility to invasive Haemophilus influenzae type b and Staphylococcus aureus infections in South African children. Pediatr Infect Dis J 1996; 15:419-424.
178. Petersen G.M., Silimperi D.R., Rotter J.I., et al: Genetic factors in Haemophilus influenzae type b disease susceptibility and antibody acquisition. J Pediatr 1987; 110:228-233.
179. Floyd R.F., Federspiel C.F., Schaffner W.: Bacterial meningitis in urban and rural Tennessee. Am J Epidemiol 1974; 99:395-407.

180. Zielinski A., Kwon C.B., Tomaszunas-Blaszczyk J., et al: Risk of Haemophilus influenzae type b meningitis in Polish children varies directly with number of siblings: possible implications for vaccination strategies. Eur J Epidemiol 2003; 18:917-922.
181. Petersen G.M., Silimperi D.R., Chiu C.Y., et al: Effects of age, breast feeding, and household structure on Haemophilus influenzae type b disease risk and antibody acquisition in Alaskan Eskimos. Am J Epidemiol 1991; 134:1212-1221.
182. Clements D.A., Weigle K.A., Gilbert G.L.: A case-control study examining risk factors for invasive Haemophilus influenzae type b disease in Victoria, Australia 1988–90. J Paediatr Child Health 1995; 31:513-518.
183. Arnold C., Makintube S., Istre G.R.: Day care attendance and other risk factors for invasive Haemophilus influenzae type b disease. Am J Epidemiol 1993; 138:333-340.
184. Jafari H.S., Adams W.G., Robinson K.A., et al: Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations, The Haemophilus influenzae Study Group. Am J Public Health 1999; 89:364-368.
185. Clements D.A., Guise I.A., MacInnes S.J., et al: Haemophilus influenzae type b infections in Victoria, Australia, 1985–1989. J Infect Dis 1992; 165(suppl 1):S33-S34.
186. Istre G.R., Conner J.S., Broome C.V., et al: Risk factors for primary invasive Haemophilus influenzae disease: increased risk from day care attendance and school-aged household members. J Pediatr 1985; 106:190-195.
187. Murphy T.V., Clements J.F., Petroni M., et al: Haemophilus influenzae type b in respiratory secretions. Pediatr Infect Dis J 1989; 8:148-151.
188. Zarkowsky H.S., Gallagher D., Gill F.M., et al: Bacteremia in sickle hemoglobinopathies. J Pediatr 1986; 109:579-585.
189. Winkelstein J.A., Moxon E.R.: The role of complement in the host's defense against Haemophilus influenzae. J Infect Dis 1992; 165(suppl 1):S62-S65.
190. Rosen F.S., Janeway C.A.: Diagnosis and treatment of antibody deficiency syndromes. Postgrad Med 1968; 43:188-194.
191. Chilcote R.R., Baehner R.L., Hammond D.: Septicemia and meningitis in children splenectomized for Hodgkin's disease. N Engl J Med 1976; 295:798-800.
192. Keller D.W., Breiman R.F.: Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21(suppl 1):S77-S83.
193. Casadevall A., Dobroszycki J., Small C., et al: Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med 1992; 92:587-590.
194. Takala A.: Risk factors in transmission of Haemophilus influenzae type b. In: Ellis R., Granoff D., ed. Development and Clinical Uses of Haemophilus b Conjugate Vaccines, New York, NY: Marcel Dekker, Inc; 1994:357-370.
195. Insel R.A., Amstey M., Pichichero M.E.: Postimmunization antibody to the Haemophilus influenzae type b capsule in breast milk. J Infect Dis 1985; 152:407-408.
196. Reid R., Croll J., Santosham M., et al: Bacterial polysaccharide immune globulin. In: Ellis R., Granoff D., ed. Development and Clinical Uses of Haemophilus b Conjugate Vaccines, New York, NY: Marcel Dekker, Inc; 1994:329-338.
197. Santosham M., Reid R., Ambrosino D.M., et al: Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med 1987; 317:923-929.
198. Smith D.H., Peter G., Ingram D.L., et al: Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics 1973; 52:637-644.
199. Käyhty H., Peltola H., Karanko V., et al: The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.

200. Mäkelä P.H., Peltola H., Käyhty H., et al: Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977; 136(suppl):S43-S50.
201. Käyhty H., Peltola H., Eskola J.: Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children. Pediatr Infect Dis J 1988; 7:574-577.
202. Anderson P.: The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149:1034-1035.
203. Daum R., Granoff D.: Lessons learned from the evaluation of immunogenicity. In: Ellis R., Granoff D., ed. Development and Clinical Uses of Haemophilus b Conjugate Vaccines, New York, NY: Marcel Dekker, Inc; 1994:291-312.
204. Ramsey K.P., Popejoy L.A., Jesse S.W., et al: Haemophilus B polysaccharide vaccine: antibody kinetics in 17- to 71-month-old children. Am J Dis Child 1989; 143:28-30.
205. Parke Jr J.C., Schneerson R., Robbins J.B., et al: Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976). J Infect Dis 1977; 136(suppl):S51-S56.
206. Peltola H., Käyhty H., Sivonen A., et al: Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60:730-737.
207. Centers for Disease Control : Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. MMWR Morb Mortal Wkly Rep 1985; 34:201-205.
208. Osterholm M.T., Rambeck J.H., White K.E., et al: Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 1988; 260:1423-1428.
209. Shapiro E.D., Murphy T.V., Wald E.R., et al: The protective efficacy of Haemophilus b polysaccharide vaccine. JAMA 1988; 260:1419-1422.
210. Milstien J.B., Gross T.P., Kuritsky J.N.: Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing. Pediatrics 1987; 80:270-274.
211. Harrison L.H., Broome C.V., Hightower A.W., et al: A day care–based study of the efficacy of Haemophilus b polysaccharide vaccine. JAMA 1988; 260:1413-1418.
212. Ward J.I., Broome C.V., Harrison L.H., et al: Haemophilus influenzae type b vaccines: lessons for the future. Pediatrics 1988; 81:886-893.
213. Black S.B., Shinefield S.R., Hiatt R.A., et al: Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine. Pediatr Infect Dis J 1988; 7:149-156.
214. Granoff D.M., Shackelford P.G., Suarez B.K., et al: Hemophilus influenzae type B disease in children vaccinated with type B polysaccharide vaccine. N Engl J Med 1986; 315:1584-1590.
215. Sood S.K., Daum R.S.: Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation. Pediatrics 1990; 85(4 pt 2):698-704.
216. Berkowitz C.D., Ward J.I., Meier K., et al: Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. J Pediatr 1987; 110:509-514.
217. Lepow M.L., Barkin R.M., Berkowitz C.D., et al: Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infants. J Infect Dis 1987; 156:591-596.
218. Käyhty H., Eskola J., Peltola H., et al: Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J Infect Dis 1987; 155:100-106.

219. Feldman S., Gigliotti F., Shenep J.L., et al: Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990; 161:926-931.
220. Eskola J., Käyhty H., Takala A.K., et al: A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323:1381-1387.
221. Ward J., Brenneman G., Letson G.W., et al: Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990; 323:1393-1401.
222. Turner R.B., Cimino C.O., Sullivan B.J.: Prospective comparison of the immune response of infants to three Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 1991; 10:108-112.
223. Holmes S.J., Murphy T.V., Anderson R.S., et al: Immunogenicity of four Haemophilus influenzae type b conjugate vaccines in 17- to 19-month-old children. J Pediatr 1991; 118:364-371.
224. Decker M.D., Edwards K.M., Bradley R., et al: Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120(2 pt 1):184-189.
225. Granoff D.M., Anderson E.L., Osterholm M.T., et al: Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121:187-194.
226. Bulkow L.R., Wainwright R.B., Letson G.W., et al: Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993; 12:484-492.
227. Schlesinger Y., Granoff D.M.: Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines.The Vaccine Study Group. JAMA 1992; 267:1489-1494.
228. Santosham M., Hill J., Wolff M., et al: Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population. Pediatr Infect Dis J 1991; 10:113-117.
229. Daum R.S., Siber G.R., Ballanco G.A., et al: Serum anticapsular antibody response in the first week after immunization of adults and infants with the Haemophilus influenzae type b–Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Infect Dis 1991; 164:1154-1159.
230. Einhorn M.S., Weinberg G.A., Anderson E.L., et al: Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 1986; 2:299-302.
231. Ambrosino D.M., Sood S.K., Lee M.C., et al: IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in young infants. Pediatr Infect Dis J 1992; 11:855-859.
232. Ahonkhai V.I., Lukacs L.J., Jonas L.C., et al: Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation. Pediatrics 1990; 85(4 pt 2):676-681.
233. Yogev R., Arditi M., Chadwick E.G., et al: Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. Pediatrics 1990; 85(4 pt 2):690-693.
234. Shapiro E.D., Capobianco L.A., Berg A.T., et al: The immunogenicity of Hemophilus influenzae type B polysaccharide–Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children. J Infect Dis 1989; 160:1064-1067.

235. Weinberg G.A., Einhorn M.S., Lenoir A.A., et al: Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide–Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 1987; 111:22-27.
236. Ward J., et al: Immune tolerance and lack of booster responses to Haemophilus influenza (Hib) conjugate vaccination in infants immunized beginning at birth. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992.Anaheim, CA;
237. Kurikka S., Käyhty H., Peltola H., et al: Neonatal immunization: response to Haemophilus influenzae type b–tetanus toxoid conjugate vaccine. Pediatrics 1995; 95:815-822.
238. Millar E.V., O'Brien K.L., Watt J.P., et al: Epidemiology of invasive Haemophilus influenzae type A disease among Navajo and White Mountain Apache children, 1988–2003. Clin Infect Dis 2005; 40:823-830.
239. Siber G.R., Santosham M., Reid G.R., et al: Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 1990; 323:1387-1392.
240. Johns T.L., Hutter G.E.: New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel). Ann Pharmacother 2010; 44:515-523.
241. Zepp F., Schmitt H.J., Cleerbout J., et al: Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009; 8:663-678.
242. Black S., Greenberg D.P.: A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 2005; 4:793-805.
243. Anderson E.L., Decker M.D., Englund J.A., et al: Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA 1995; 273:849-853.
244. Scheifele D., Law B., Mitchell L., et al: Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine 1996; 14:1399-1406.
245. Reid R., Santosham M., Croll J., et al: Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs HbOC vaccine. Pediatr Infect Dis J 1993; 12:812-815.
246. Lise L.D., Mazier D., Jolivet M., et al: Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun 1987; 55:2658-2661.
247. Herzenberg L.A., Tokuhisa T.: Carrier-priming leads to hapten-specific suppression. Nature 1980; 285:664-667.
248. Dagan R., Poolman J., Siegrist C.A.: Glycoconjugate vaccines and immune interference: a review. Vaccine 2010; 28:5513-5523.
249. Granoff D.M., Rathore M.H., Holmes S.J., et al: Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993; 11(suppl 1):S46-S51.
250. Anderson P.: Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 1983; 39:233-238.
251. Schneerson R., Robbins J.B., Chu C., et al: Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and Pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun 1984; 45:582-591.
252. Campagne G., Garba A., Schuchat A., et al: Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey. Niger. Am J Trop Med Hyg 1998; 59:837-842.

253. Guimarães T., Cereda R.F., Bianchin P.J., et al: Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age. Int J Infect Dis 2002; 6:113-117.
254. Castillo de Febres O., Decker M.D., Estopinan M., et al: Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b–tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 1994; 13:635-639.
255. Barington T., Gyhrs A., Kristensen K., et al: Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 1994; 62:9-14.
256. Black S.B., Shinefield H.R., Fireman B., et al: Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10:97-104.
257. Peltola H., Eskola J., Käyhty H., et al: Clinical comparison of the Haemophilus influenzae type B polysaccharide–diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. Arch Pediatr Adolesc Med 1994; 148:620-625.
258. Santosham M., Wolff M., Reid R., et al: The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324:1767-1772.
259. Vadheim C.M., Greenberg D.P., Eriksen E., et al: Eradication of Haemophilus influenzae type b disease in southern California.Kaiser-UCLA Vaccine Study Group. Arch Pediatr Adolesc Med 1994; 148:51-56.
260. Moulton L.H., Chung S., Croll J., et al: Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000; 29:753-756.
261. Horby P., Gilmour R., Wang H., et al: Progress towards eliminating Hib in Australia: an evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Commun Dis Intell 2003; 27:324-341.
262. Gortzak-Uzan L., Fraser D., Dagan R.: Epidemiology of invasive Hemophilus influenzae B infections in Bedouins and Jews: conjugate Hib vaccines [in Hebrew]. Harefuah 1998; 135:175-180.256
263. Booy R., Moxon E.R., MacFarlane J.A., et al: Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet 1992; 340:847.
264. Lagos R., Horwitz I., Toro J., et al: Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996; 15:216-222.
265. Fritzell B., Plotkin S.: Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992; 121:355-362.
266. Peltola H., Kilpi T., Anttila M.: Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340:592-594.
267. Zielen S., Ahrens P., Hofmann D.: Efficacy of Hib vaccine. Lancet 1994; 344:828.
268. Garpenholt O., Silfverdal S.A., Hugosson S., et al: The impact of Haemophilus influenzae type b vaccination in Sweden. Scand J Infect Dis 1996; 28:165-169.
269. Scheifele D.W., Bettinger J.A., Halperin S.A., et al: Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004–2007. Pediatr Infect Dis J 2008; 27:755-757.
270. Gessner B.D.: Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Rev Vaccines 2009; 8:91-102.

271. Lee E.H., Lewis R.F., Makumbi I., et al: Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study. Trop Med Int Health 2008; 13:495-502.
272. Cissé M.F., Breugelmans J.G., Bâ M., et al: The elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 2010; 29:499-503.
273. Sow S.O., Tapia M.D., Diallo S., et al: Haemophilus influenzae type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg 2009; 80:1033-1038.
274. Lagos R., Levine O.S., Avendaño A., et al: The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. Pediatr Infect Dis J 1998; 17(9 suppl):S139-S148.
275. White K.E., Pabst L.J., Cullen K.A.: Up-to-date Haemophilus influenzae type b vaccination coverage during a vaccine shortage. Pediatrics 2011; 127:e707-e712.
276. Gessner B.D., Adegbola R.A.: The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines. Vaccine 2008; 26(suppl 2):B3-B8.
277. Millar E.V., O'Brien K.L., Levine O.S., et al: Toward elimination of Haemophilus influenzae type B carriage and disease among high-risk American Indian children. Am J Public Health 2000; 90:1550-1554.
278. Singleton R., Hammitt L., Hennessey T., et al: The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 2006; 118:e421-e429.
279. Munoz A., Salvador A., Brodsky N.L., et al: Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate–outer membrane protein conjugate vaccine. Pediatrics 1995; 96(2 pt 1):216-219.
280. Washburn L.K., O'Shea T.M., Gillis D.C., et al: Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr 1993; 123:791-794.
281. Heath P.T., Booy R., McVernon J., et al: Hib vaccination in infants born prematurely. Arch Dis Child 2003; 88:206-210.
282. Kristensen K., Gyhrs A., Lausen B., et al: Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J 1996; 15:525-529.
283. D'Angio C.T., Maniscalco W.M., Pichichero M.E.: Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 1995; 96(1 pt 1):18-22.
284. Madhi S.A., Petersen K., Madhi A., et al: Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1–infected children. Clin Infect Dis 2000; 31:170-176.
285. Gibb D., Giacomelli A., Masters J., et al: Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J 1996; 15:1097-1101.
286. Farley M.M., Stephens D.S., Brachman Jr P.S., et al: Invasive Haemophilus influenzae disease in adults: a prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med 1992; 116:806-812.
287. Madhi S.A., Kuwanda L., Saarinen L., et al: Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005; 23:5517-5525.
288. De Sousa dos Santos S., Lopes M.H., Simonsen V., et al: Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 2004; 20:493-496.

289. Chokephaibulkit K., Phongsamart W., Vanprapar N., et al: Catch-up vaccination against Haemophilus influenzae type b in human immunodeficiency virus–infected Thai children older than 2 years old. Vaccine 2004; 22:2018-2022.
290. Mangtani P., Mulholland K., Madhi S.A., et al: Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine 2010; 28:1677-1683.
291. Melvin A.J., Mohan K.M.: Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111(6 pt 1):e641-e644.
292. Madhi S.A., Petersen K., Khoosal M., et al: Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21:315-321.
293. Laube G.F., Berger C., Goetschel P., et al: Immunization in children with chronic renal failure. Pediatr Nephrol 2002; 17:638-642.
294. Sever M.S., Ylidiz A., Eraksoy H., et al: Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron 1999; 81:55-59.
295. Storek J., Viganego F., Dawson M.A., et al: Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 2003; 101:3319-3324.
296. Vance E., George S., Guinan E.C, et al: Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 1998; 22:735-741.
297. Li Volti S., Sciotto A., Fisichella M., et al: Immune responses to administration of a vaccine against Haemophilus influenzae type B in splenectomized and non-splenectomized patients. J Infect 1999; 39:38-41.
298. Newcomer W., Santosham M., Bengston S., et al: Immunogenicity of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer membrane protein complex conjugate vaccine in infants and children with sickle cell disease. Pediatr Infect Dis J 1993; 12:1026-1027.
299. Mäkelä P.H., Käyhty H., Leino T., et al: Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22:287-292.
300. Claesson B.A., Trollfors B., Lagergård T., et al: Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr Infect Dis J 2005; 24:463-464.
301. Scheifele D.W., Halperin S.A., Guasparini R., et al: Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. J Pediatr 1999; 135(2 pt 1):240-245.
302. Trotter C.L., Ramsay M.E., Slack M.P.: Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 2003; 6:55-58.
303. Kelly D.F., Moxon E.R., Yu L.M., et al: Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom. Clin Vaccine Immunol 2009; 16:246-252.
304. Fitzgerald M., Canny M., O'Flanagan D.: Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 2005; 10:E050929.2.

305. Slack M.H., Schapira D., Thwaites R.J., et al: Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed 2004; 89:F269-F271.
306. Nolan T., Altmann A., Skeljo M., et al: Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 2004; 23:14-20.
307. McVernon J., Mitchison N.A., Moxon E.R.: T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis 2004; 4:40-43.
308. McVernon J., Johnson P.D., Pollard A.J., et al: Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 2003; 88:379-383.
309. Eskola J., Olander R.M., Hovi T., et al: Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348:1688-1692.
310. Lee Y.C., Kelly D.F., Yu L.M., et al: Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186-192.
311. Denoël P.A., Goldblatt D., de Vleeschauwer I., et al: Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007; 14:1362-1369.
312. Goldblatt D., Richmond P., Millard E., et al: The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis–containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999; 180:538-541.
313. Trotter C.L., McVernon J., Ramsay M.E., et al: Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008; 26:4434-4445.
314. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42(RR-13):1-15.
315. D'Cruz O.F., Shapiro E.D., Spiegelman K.N., et al: Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome) after immunization with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1989; 115(5 pt 1):743-746.
316. Stratton K.R., Howe C.J., Johnston Jr R.B.: Adverse events associated with childhood vaccines other than pertussis and rubella: summary of a report from the Institute of Medicine. JAMA 1994; 271:1602-1605.
317. Tudor-Williams G., Frankland J., Isaacs D., et al: Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom. Arch Dis Child 1989; 64:520-524.
318. Claesson B.A., et al: Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr 1988; 112:695-702.
319. Centers for Disease Control and Prevention : Recommended Immunization Schedules for Persons Aged 0 Through 18 Years, United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 58:1-4.
320. Global Programme for Vaccines and Immunization (GPV) : The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 1998; 73:64-68.
321. Santosham M., Englund J.A., McInnes P., et al: Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines

given before pregnancy in women of childbearing age and their infants. Pediatr Infect Dis J 2001; 20:931-940.
322. Englund J.A., Glezen W.P., Thompson C., et al: Haemophilus influenzae type b–specific antibody in infants after maternal immunization. Pediatr Infect Dis J 1997; 16:1122-1130.
323. Mulholland K., Suara R.O., Siber G., et al: Maternal immunization with Haemophilus influenzae type b polysaccharide–tetanus protein conjugate vaccine in The Gambia. JAMA 1996; 275:1182-1188.
324. Heath P.T., Booy R., Griffiths H., et al: Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000; 31:973-980.
325. Ladhani S., Heath P.T., Ramsay M.E., et al: Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 2009; 49:372-380.
326. Cerquetti M., Cardines R., Ciofi Degli Atti M.L., et al: Presence of multiple copies of the capsulation b locus in invasive Haemophilus influenzae type b (Hib) strains isolated from children with Hib conjugate vaccine failure. J Infect Dis 2005; 192:819-823.
327. Ferreccio C., Clemens J., Avendano A., et al: The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide–tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1991; 10:764-771.
328. Schmitt H.J., Zepp F., Müschenbom S., et al: Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 1998; 157:208-214.
329. Botet Asensi F.I., Veronese A., Del Carmen Otero M., et al: Immunogenicity and safety in infants of a DTwPHib full liquid vaccine. Acta Paediatr 2003; 92:541-545.
330. Eskola J., Ward J., Dagan R., et al: Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354:2063-2068.
331. Schmitt H.J., von Kries R., Hassenpflug B., et al: Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001; 20:767-774.
332. Kalies H., Verstraeten T., Grote V., et al: Four and one-half-year follow-up of the effectiveness of diphtheria–tetanus toxoids–acellular pertussis/Haemophilus influenzae type b and diphtheria–tetanus toxoids–acellular pertussis–inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J 2004; 23:944-950.
333. Lin T.Y., Wang Y.H., Chang L.Y., et al: Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis–inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. Chang Gung Med J 2003; 26:315-322.
334. West D.J., Rabalais G.P., Watson B., et al: Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b–hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines. BioDrugs 2001; 15:413-418.
335. Greenberg D.P., Wong V.K., Partridge S., et al: Immunogenicity of a Haemophilus influenzae type b–tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus–acellular pertussis–hepatitis B combination vaccine. Pediatr Infect Dis J 2000; 19:1135-1140.
336. Pichichero M.E., Passador S.: Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine

to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis 1997; 25:1378-1384.
337. Zepp F., Knuf M., Heininger U., et al: Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004; 22:2226-2233.
338. Kalies H., Grote V., Siedler A., et al: Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 2008; 26:2545-2552.
339. Fernández J., Balter S., Feris J., et al: Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am J Trop Med Hyg 2000; 62:485-490.
340. Lagos R., Valenzuela M.T., Levine O.S., et al: Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998; 351:1472-1476.
341. Huebner R.E., Nicol M., Mothupi R., et al: Dose response of CRM197 and tetanus toxoid–conjugated Haemophilus influenzae type b vaccines. Vaccine 2004; 23:802-806.
342. Tamm E., Veronese A., Contorni M., et al: Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine 2005; 23:1715-1719.
343. Gallo G., Ciofi degli Atti M.L., Cerquetti M., et al: Impact of a regional Hib vaccination programme in Italy. Vaccine 2002; 20:993-995.
344. Perdue D.G., Bulkow L.R., Gellin B.G., et al: Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. JAMA 2000; 283:3089-3094.
345. Ladhani S., Ramsay M.E., Chandra M., et al: No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine. Lancet Infect Dis 2008; 8:275-276.
346. Gratten M., Morey F., Hanna J., et al: Type, frequency and distribution of Haemophilus influenzae in central Australian aboriginal children with invasive disease. Med J Aust 1994; 160:728-729.
347. Slack M.P., Azzopardi H.J., Hargreaves R.M., et al: Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J 1998; 17(9 suppl):S204-S207.
348. Wenger J.D., Pierce R., Deaver K., et al: Invasive Haemophilus influenzae disease: a population-based evaluation of the role of capsular polysaccharide serotype. Haemophilus influenzae Study Group. J Infect Dis 1992; 165(suppl 1):S34-S35.
349. Heath P.T., Booy R., Azzopardi H.J., et al: Non–type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J 2001; 20:300-305.
350. O'Brien K., et al: Effect of a 7-valent pneumococcal conjugate vaccine on nasopharyngeal (NP) carriage among Navajo and White Mountain Apache (N/WMA) infants. Pediatric Academic Societies' 2001 Annual Meeting, 2001.Baltimore, MD
351. Kyaw M.H., Lynfield R., Schaffner W., et al: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-1463.
352. Hanage W.P., Auranen K., Syrjänen R., et al: Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun 2004; 72:76-81.

353. Lipsitch M.: Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999; 5:336-345.
354. Mitchell V., Walker D., Zuber P., et al: Evidenced-based decision making about Hib vaccination. Lancet 2005; 365:936-937.
355. Feikin D.R., Nelson C.B., Watt J.P., et al: Rapid assessment tool for Haemophilus influenzae type b disease in developing countries. Emerg Infect Dis 2004; 10:1270-1276.
356. Hajjeh R.A., Privor-Dumm L., Edmond K., et al: Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine 2010; 28:7123-7129.
357. Eskola J.: Foresight in medicine: current challenges with Haemophilus influenzae type b conjugate vaccines. J Intern Med 2010; 267:241-250.
358. Verghese V.P., Friberg I.K., Cherian T., et al: Community effect of Haemophilus influenzae type b vaccination in India. Pediatr Infect Dis J 2009; 28:738-740.
359. Shearer J.C., Stack M.L., Richmond M.R., et al: Accelerating policy decisions to adopt Haemophilus influenzae type B vaccine: a global, multivariable analysis. PLoS Med 2010; 7:e1000249.doi:10.1371/journal.pmed.1000249
360. Haemophilus influenzae Type b (Hib): conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiologic Rec 2006; 81:1-12.
361. Hotomi M., Ikeda Y., Suzumoto M., et al: A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine 2005; 23:1294-1300.
362. Kyd J.M., Cripps A.W., Novotny L.A., et al: Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infect Immun 2003; 71:4691-4699.
363. Bertot G.M., Becker P.D., Guzmán C.A., et al: Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 2004; 189:1304-1312.
364. Foxwell A.R., Cripps A.W., Dear K.B.: Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev 2003.CD001958,
365. Gu X.X., Rudy S.F., Chu C., et al: Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine 2003; 21:2107-2114.

HEPATITIS B

2. Ruge H.: Die zusammenhonge zwischen syphilis, salvarsan und der sog: katarrhalischen gelbsucht auf grund von 2500 der marine von 1919–1929 beobachteten follen. Dermatol Wochenschr 1932; 94:278-286.
3. Sofer L.J.: Postarsphenamine jaundice. Am J Syph 1937; 21:309-338.
4. MacCallum F.O.: Jaundice in syphilitics. Br J Vener Dis 1943; 19:63.
5. Murray D.H.: Acriflavine, its use by intravenous injection, in treatment of gonorrhea. J R Army Med Corps 1930; 54:19-27.
6. Flaum A., Malmros H., Persson E.: Eine nosocomiale ikterus epidemic. Acta Med Scand 1926; 16(suppl):544-553.
7. Sherwood P.M.: An outbreak of syringe transmitted hepatitis with jaundice in hospitalized diabetic patients. Ann Intern Med 1950; 33:380-396.
8. Droller H.: Outbreak of Hepatitis in a Diabetic Clinic. Br Med J 1945; 1:623-625.
9. Editorial : Jaundice following yellow fever vaccination. JAMA 1942; 119:1110.

10. Findlay G., MacCallum F.O.: Note on acute hepatitis and yellow fever immunization. Trans R Soc Trop Med Hyg 1937; 51:297-308.
11. Beeson P., Chesney G., McFarlan A.M.: Hepatitis following injection of mumps convalescent plasma, I: use of plasma in the mumps epidemic. Lancet 1944.814-815.
12. McFarlan A., Chesney G.: Hepatitis following injectin of mumps convalescent plasma. II. Epidemiology of the hepatitis. Lancet 1944.816-817.
13. Propert S.: Hepatitis after prophylactic serum. Br Med J 1938; 2:677-678.
14. Beeson P.: Jaundice occurring one to four months after transfusion of blood or plasma: report of seven cases. JAMA 1943; 121:1332-1334.
15. Neefe J.R., Gellis S.S., Stokes Jr J.: Homologous serum hepatitis and infectious (epidemic) hepatitis; studies in volunteers bearing on immunological and other characteristics of the etiological agents. Am J Med 1946; 1:3-22.
16. MacCallum F., Bauer D.J.: Homologous serum jaundice: transmission experiments with human volunteers. Lancet 1944; 1:622-627.
17. Voegt H.: Aetiologie der hepatitis epidemica. MMW Munch Med Wochenschr 1942; 89:76-79.
18. Cameron J.: Infective hepatitis. Q J Med 1943; 12:139-155.
19. Medical Research Council : Infective hepatitis: studies in East Anglia during the period 1943–1947. Special report series no. 273.London, His Majesty's Stationery Office, 1951.
20. Havens Jr W.P.: The etiology of infectious hepatitis. J Am Med Assoc 1947; 134:653-655.discussion, 676–659
21. MacCallum F.O.: Homologous serum hepatitis. Lancet 1947; 2:691-692.
22. Zuckerman A.: The history of viral hepatitis from antiquity to the present. In: Deinhardt F., Deinhardt J., ed. Viral Hepatitis: Laboratory and Clinical Science, New York: Marcel Dekker; 1983:3-32.
23. Krugman S., Giles J.P., Hammond J.: Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967; 200:365-373.
24. Krugman S., Giles J.P.: Viral hepatitis, type B (MS-2-strain): further observations on natural history and prevention. N Engl J Med 1973; 288:755-760.
25. Giles J.P., McCollum R.W., Berndtson Jr L.W., et al: Relation of Australia-SH antigen to the willowbrook MS-2 strain. N Engl J Med 1969; 281:119-122.
26. Seeff L.B., Beebe G.W., Hoofnagle J.H., et al: A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987; 316:965-970.
27. Blumberg B.S., Alter H.J., Visnich S.: A “new” antigen in leukemia sera. JAMA 1965; 191:541-546.
28. Prince A.M.: An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 1968; 60:814-821.
29. Dane D.S., Cameron C.H., Briggs M.: Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1:695-698.
30. Blumberg B.S., Gerstley B.J., Hungerford D.A., et al: A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66:924-931.
31. Krugman S., Giles J.P., Hammond J.: Viral hepatitis, type B (MS-2 strain): studies on active immunization. JAMA 1971; 217:41-45.
32. Hilleman M.R., Buynak E.B., Roehm R.R., et al: Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 1975; 270:401-404.
33. Purcell R.H., Gerin J.L.: Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci 1975; 270:395-399.
34. Zajac B.A., West D.J., McAleer W.J., et al: Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13(suppl A):39-45.

35. Shouval D.: Hepatitis B vaccines. J Hepatol 2003; 39(suppl 1):S70-S76.
36. Beasley R., Hwang L.Y.: Overview of the epidemiology of hepatocellular carcinoma. In: Hollinger F., Lemon S.M., Margolis H.S., ed. Viral Hepatitis and Liver Disease: Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects, Baltimore: Williams & Wilkins; 1991:532-535.
37. Beasley R.P.: Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
38. International Agency for Research on Cancer : IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France, IARC Press, 1994.
39. International Agency for Research on Cancer : Cancer occurrence in developing countries. Lyon, France, IARC Press, 1986.
40. Schafer D.F., Sorrell M.F.: Hepatocellular carcinoma. Lancet 1999; 353:1253-1257.
41. Wright T.L., Lau J.Y.: Clinical aspects of hepatitis B virus infection. Lancet 1993; 342:1340-1344.
42. McMahon B.J.: The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49:S45-S55.
43. Szmaragd C., Foster G.R., Manica A., et al: Genome-wide characterisation of hepatitis B mutations involved in clinical outcome. Heredity 2006; 97:389-397.
44. McMahon B.J., Alward W.L., Hall D.B., et al: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151:599-603.
45. Edmunds W.J., Medley G.F., Nokes D.J., et al: The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993; 253:197-201.
46. Hyams K.C.: Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20:992-1000.
47. Hadler S.C., Judson F.N., O'Malley P.M., et al: Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163:454-459.
48. Polish L.B., Shapiro C.N., Bauer F., et al: Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device. N Engl J Med 1992; 326:721-725.
49. Nikolopoulos G.K., Paraskevis D., Hatzitheodorou E., et al: Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48:1763-1771.
50. Krugman S., Overby L.R., Mushahwar I.K., et al: Viral hepatitis, type B: studies on natural history and prevention re-examined. N Engl J Med 1979; 300:101-106.
51. Hoofnagle J.H., Di Bisceglie A.M.: Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991; 11:73-83.
52. Gilbert R.D., Wiggelinkhuizen J.: The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 1994; 8:11-14.
53. Gianotti F.: Papular acrodermatitis of childhood: an Australia antigen disease. Arch Dis Child 1973; 48:794-799.
54. Caputo R., Gelmetti C., Ermacora E., et al: Gianotti-Crosti syndrome: a retrospective analysis of 308 cases. J Am Acad Dermatol 1992; 26:207-210.
55. McSweeney P.A., Carter J.M., Green G.J., et al: Fatal aplastic anemia associated with hepatitis B viral infection. Am J Med 1988; 85:255-256.
56. Dienstag J.L.: Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infection. Springer Semin Immunopathol 1981; 3:461-472.
57. Centers for Disease Control and Prevention : Surveillance for acute viral hepatitis—United States, 2007. Surveillance Summaries 2009; 58(SS03):1-27.May 22, 2009. MMWR

58. Pappas S.C.: Fulminant viral hepatitis. Gastroenterol Clin North Am 1995; 24:161-173.
59. Hoofnagle J.H., Carithers Jr R.L., Shapiro C., et al: Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240-252.
60. Smedile A., Farci P., Verme G., et al: Influence of delta infection on severity of hepatitis B. Lancet 1982; 2:945-947.
61. Bernuau J., Goudeau A., Poynard T., et al: Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6:648-651.
62. Wai C.T., Fontana R.J., Polson J., et al: Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005; 12:192-198.
63. Steinmuller T., Seehofer D., Rayes N., et al: Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35:1528-1535.
64. Tillmann H.L., Hadem J., Leifeld L., et al: Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13:256-263.
65. Kumar M., Satapathy S., Monga R., et al: A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45:97-101.
66. Hoofnagle J.H.: Chronic hepatitis B. N Engl J Med 1990; 323:337-339.
67. Chan H., Ghany M.G., Lok A.SF.: Hepatitis B. In: Schiff E., Sorrell M.F., Maddrey W.C., ed. Schiff's Diseases of the Liver, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 1999:768.
68. Lok A.S., Lai C.L.: A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8:1130-1133.
69. Hoofnagle J.H., Dusheiko G.M., Seeff L.B., et al: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94:744-748.
70. Milich D.R., Jones J.E., Hughes J.L., et al: Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?. Proc Natl Acad Sci U S A 1990; 87:6599-6603.
71. Bauer T., Sprinzl M., Protzer U.: Immune control of hepatitis B virus. Dig Dis 2011; 29:423-433.
72. Chang M.H., Hwang L.Y., Hsu H.C., et al: Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology 1988; 8:374-377.
73. Liaw Y.F., Chu C.M., Huang M.J., et al: Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. Liver 1984; 4:301-306.
74. Alward W.L., McMahon B.J., Hall D.B., et al: The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985; 151:604-609.
75. Liaw Y.F., Chu C.M., Su I.J., et al: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84:216-219.
76. Lok A.S., Lai C.L., Wu P.C., et al: Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:1839-1843.
77. Bortolotti F., Cadrobbi P., Crivellaro C., et al: Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990; 99:805-810.
78. Sheen I.S., Liaw Y.F., Tai D.I., et al: Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89:732-735.
79. Liaw Y.F., Tai D.I., Chu C.M., et al: Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7:20-23.

80. Lok A.S., Lai C.L.: Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection: incidence, predisposing factors and etiology. J Hepatol 1990; 10:29-34.
81. Fattovich G., Rugge M., Brollo L., et al: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6:167-172.
82. McMahon B.J., Holck P., Bulkow L., et al: Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759-768.
83. Lok A.S., Hadziyannis S.J., Weller I.V., et al: Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25:1283-1287.
84. Brechot C., Degos F., Lugassy C., et al: Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985; 312:270-276.
85. Chung H.T., Lai C.L., Lok A.S.: Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995; 22:25-29.
86. Liaw Y.F., Sheen I.S., Chen T.J., et al: Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13:627-631.
87. Adachi H., Kaneko S., Matsushita E., et al: Clearance of HBsAg in seven patients with chronic hepatitis B. Hepatology 1992; 16:1334-1337.
88. Gandhi M.J., Yang G.G., McMahon B.J., et al: Hepatitis B virions isolated with antibodies to the pre-S1 domain reveal occult viremia by PCR in Alaska Native HBV carriers who have seroconverted. Transfusion 2000; 40:910-916.
89. Lok A.S., Liang R.H., Chiu E.K., et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991; 100:182-188.
90. Lalazar G., Rund D., Shouval D.: Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136:699-712.
91. Hsu Y.S., Chien R.N., Yeh C.T., et al: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-1527.
92. Goldstein S.T., Zhou F., Hadler S.C., et al: A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34:1329-1339.
93. Hsieh C.C., Tzonou A., Zavitsanos X., et al: Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: a birth order study. Am J Epidemiol 1992; 136:1115-1121.
94. Liaw Y.F., Tai D.I., Chu C.M., et al: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493-496.
95. Yu M.W., Hsu F.C., Sheen I.S., et al: Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145:1039-1047.
96. Chevillotte G., Durbec J.P., Gerolami A., et al: Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: an epidemiologic study. Gastroenterology 1983; 85:141-145.
97. Yim H.J., Lok A.S.: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43:S173-S181.
98. Beasley R.P., Hwang L.Y., Lin C.C., et al: Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981; 2:1129-1133.
99. McMahon B.: Hepatocellular carcinoma and viral hepatitis. In: Wilson R., ed. viral hepatitis, New York: Marcel Dekker; 1997:315-330.

100. Fattovich G., Giustina G., Schalm S.W., et al: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21:77-82.
101. Huo T.I., Wu J.C., Lee P.C., et al: Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28:231-236.
102. Seeger C., Mason W.S.: Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68.
103. Neurath A., Thanavala Y.: Hepadnaviruses. In: von Regenmortel M., Neurath A.R., ed. Immunochemistry of Virus, II: The Basis for Serodiagnosis and Vaccines, New York: Elsevier Science; 1990:403-458.
104. Ganem D.: Hepadnaviridae and their replication. In: Fields B., Knipe D.M., Howley P.M., et al ed. Fields Virology, 3 rd ed. Philadelphia: Lippincott-Raven; 1996:2706.
105. Tiollais P., Charnay P., Vyas G.N.: Biology of hepatitis B virus. Science 1981; 213:406-411.
106. Rossner M.T.: Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 1992; 36:101-117.
107. Gerlich W., Bruss V.: Functions of hepatitis B virus proteins and molecular targets for protective immunity. In: Ellis R., ed. Hepatitis B Vaccines in Clinical Practice, New York: Marcel Dekker; 1993:41-82.
108. Neurath A.R., Kent S.B., Strick N., et al: Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986; 46:429-436.
109. Pontisso P., Petit M.A., Bankowski M.J., et al: Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J Virol 1989; 63:1981-1988.
110. Gerlich W.H., Lu X., Heermann K.H.: Studies on the attachment and penetration of hepatitis B virus. J Hepatol 1993; 17(suppl 3):S10-S14.
111. Koziel M.J.: Immunology of viral hepatitis. Am J Med 1996; 100:98-109.
112. Prince A.M., Ikram H., Hopp T.P.: Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A 1982; 79:579-582.
113. Courouce-Pauty A.M., Plancon A., Soulier J.P.: Distribution of HBsAg subtypes in the world. Vox Sang 1983; 44:197-211.
114. Dodd R.Y., Holland P.V., Ni L.Y., et al: Hepatitis B antigen: regional variation in incidence and subtype ratio in the American Red Cross donor population. Am J Epidemiol 1973; 97:111-115.
115. Norder H., Courouce A.M., Coursaget P., et al: Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47:289-309.
116. Liaw Y.F., Chu C.M.: Hepatitis B virus infection. Lancet 2009; 373:582-592.
117. Pujol F.H., Navas M.C., Hainaut P., et al: Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 2009; 286:80-88.
118. Olinger C.M., Jutavijittum P., Hubschen J.M., et al: Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis 2008; 14:1777-1780.
119. Tatematsu K., Tanaka Y., Kurbanov F., et al: A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009; 83:10538-10547.
120. Schaefer S.: Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12:111-124.

121. Erhardt A., Blondin D., Hauck K., et al: Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-1013.
122. Guirgis B.S., Abbas R.O., Azzazy H.M.: Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis 2010; 14:e941-e953.
123. Mushahwar I.K., McGrath L.C., Drnec J., et al: Radioimmunoassay for detection of hepatitis B e antigen and its antibody: results of clinical evaluation. Am J Clin Pathol 1981; 76:692-697.
124. Guidotti L.G., Ishikawa T., Hobbs M.V., et al: Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25-36.
125. Lau J.Y., Wright T.L.: Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342:1335-1340.
126. Butel J.S., Lee T.H., Slagle B.L.: Is the DNA repair system involved in hepatitis-B-virus-mediated hepatocellular carcinogenesis?. Trends Microbiol 1996; 4:119-124.
127. Chang L.J., Hirsch R.C., Ganem D., et al: Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J Virol 1990; 64:5553-5558.
128. Seeger C., Ganem D., Varmus H.E.: Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232:477-484.
129. Hunt C.M., McGill J.M., Allen M.I., et al: Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31:1037-1044.
130. François G., Kew M., Van Damme P., et al: Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications?. Vaccine 2001; 19:3799-3815.
131. Deny P., Zoulim F.: Hepatitis B virus: from diagnosis to treatment. Pathol Biol (Paris) 2010; 58:245-253.
132. Locarnini S.: Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24(suppl 1):3-10.
133. Harrison T.J.: Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 2006; 26:87-96.
134. Locarnini S., Zoulim F.: Molecular genetics of HBV infection. Antivir Ther 2010; 15(suppl 3):3-14.
135. Carman W.F., Jacyna M.R., Hadziyannis S., et al: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588-591.
136. Scaglioni P.P., Melegari M., Wands J.R.: Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233:374-381.
137. Laskus T., Rakela J., Nowicki M.J., et al: Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 1995; 109:1618-1623.
138. Liang T.J., Hasegawa K., Rimon N., et al: A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324:1705-1709.
139. Omata M., Ehata T., Yokosuka O., et al: Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324:1699-1704.
140. Hsu H.Y., Chang M.H., Lee C.Y., et al: Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis 1995; 171:776-781.
141. Liang T.J., Hasegawa K., Munoz S.J., et al: Hepatitis B virus precore mutation and fulminant hepatitis in the United States: a polymerase chain reaction-based assay for the detection of specific mutation. J Clin Invest 1994; 93:550-555.

142. Laskus T., Persing D.H., Nowicki M.J., et al: Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology 1993; 105:1173-1178.
143. Hasegawa K., Huang J., Rogers S.A., et al: Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994; 68:1651-1659.
144. Ling R., Mutimer D., Ahmed M., et al: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-713.
145. Tipples G.A., Ma M.M., Fischer K.P., et al: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in. Hepatology 1996; 24:714-717.
146. Chayama K., Suzuki Y., Kobayashi M., et al: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:1711-1716.
147. Blum H.E., Galun E., Liang T.J., et al: Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 1991; 65:1836-1842.
148. Allen M.I., Deslauriers M., Andrews C.W., et al: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670-1677.
149. Torresi J.: The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25:97-106.
150. Yeh C.T.: Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010; 15:471-475.
151. Locarnini S.A., Yuen L.: Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 2010; 15:451-461.
152. Raimondo G., Costantino L., Caccamo G., et al: Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J Hepatol 2004; 40:515-519.
153. Chen B.F., Liu C.J., Jow G.M., et al: High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130:1153-1168.
154. Howard C., Smith Stirk H.J., Brown S.E., et al: Towards the development of a synthetic hepatitis B vaccine. In: Zuckerman A., ed. Viral Hepatitis and Liver Disease, London: Barbican Centre, Alan R. Liss; 1988:1094-1101.
155. Zanetti A.R., Tanzi E., Manzillo G., et al: Hepatitis B variant in Europe. Lancet 1988; 2:1132-1133.
156. Ogata N., Zanetti A.R., Yu M., et al: Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 1997; 175:511-523.
157. Hsu H.Y., Chang M.H., Ni Y.H., et al: Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26:786-791.
158. Carman W., Thomas H.C., Zuckerman A.J., et al: Molecular variants of hepatitis B virus. In: Zuckerman A., Thomas H.C., ed. Viral Hepatitis, 2nd ed. London: Churchill Livingstone; 1998:141-172.
159. Zuckerman A.J.: Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 2000; 355:1382-1384.
160. Hsu H.Y., Chang M.H., Ni Y.H., et al: Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53:1499-1503.

161. Carman W.F., Korula J., Wallace L., et al: Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345:1406-1407.
162. Jongerius J.M., Wester M., Cuypers H.T., et al: New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998; 38:56-59.
163. Coleman P.F., Chen Y.C., Mushahwar I.K.: Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999; 59:19-24.
164. Mimms L.: Hepatitis B virus escape mutants: "pushing the envelope" of chronic hepatitis B virus infection. Hepatology 1995; 21:884-887.
165. Harrison T.J., Hopes E.A., Oon C.J., et al: Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J Hepatol 1991; 13(suppl 4):S105-S107.
166. Zuckerman A.J., Harrison T.J., Oon C.J.: Mutations in S region of hepatitis B virus. Lancet 1994; 343:737-738.
167. Howard C.R.: The structure of hepatitis B envelope and molecular variants of hepatitis B virus. J Viral Hepat 1995; 2:165-170.
168. Nainan O., Stevens C.E., Taylor P.E., et al: Hepatitis B virus (HBV) antibody resistant mutants among mothers and infants with chronic HBV infection. In: Rizetto M., Purcell R.H., Gerin J.L., et al ed. Viral Hepatitis and Liver Disease. Proceedings of the IXth Triennial Symposium on Viral Hepatitis and Liver Disease, Rome: Edzioni Minerva Medica; 1996:132-143.
169. Ngui S.L., Andrews N.J., Underhill G.S., et al: Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998; 27:100-106.
170. Fortuin M., Karthigesu V., Allison L., et al: Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994; 169:1374-1376.
171. McMahon G., Ehrlich P.H., Moustafa Z.A., et al: Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15:757-766.
172. Ghany M.G., Ayola B., Villamil F.G., et al: Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213-222.
173. Terrault N.A., Zhou S., McCory R.W., et al: Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28:555-561.
174. Chisari F.V., Ferrari C.: Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
175. Di Bisceglie A.M., Rustgi V.K., Hoofnagle J.H., et al: NIH conference: hepatocellular carcinoma. Ann Intern Med 1988; 108:390-401.
176. Biswas R., Tabor E., Hsia C.C., et al: Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43:788-798.
177. Lunn E.R., Hoggarth B.J., Cook W.J.: Prolonged hepatitis B surface antigenemia after vaccination. Pediatrics 2000; 105:E81.
178. Kloster B., Kramer R., Eastlund T., et al: Hepatitis B surface antigenemia in blood donors following vaccination. Transfusion 1995; 35:475-477.
179. Ly D., Yee Jr H.F., Brezina M., et al: Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. Am J Gastroenterol 2002; 97:138-141.

180. Kao J.H., Chen P.J., Lai M.Y., et al: Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. Hepatology 2001; 34:817-823.
181. Silva A.E., McMahon B.J., Parkinson A.J., et al: Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis 1998; 26:895-897.
182. Grob P., Jilg W., Bornhak H., et al: Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000; 62:450-455.
183. Raimondo G., Pollicino T., Cacciola I., et al: Occult hepatitis B virus infection. J Hepatol 2007; 46:160-170.
184. Raimondo G., Allain J.P., Brunetto M.R., et al: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49:652-657.
185. De Feo T.M., Poli F., Mozzi F., et al: Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 2005; 37:1238-1239.
186. Lai C.L., Lau J.Y., Yeoh E.K., et al: Significance of isolated anti-HBc seropositivity by ELISA: implications and the role of radioimmunoassay. J Med Virol 1992; 36:180-183.
187. McMahon B.J., Parkinson A.J., Helminiak C., et al: Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992; 103:590-594.
188. Alter H.J., Seeff L.B., Kaplan P.M., et al: Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976; 295:909-913.
189. Shikata T., Karasawa T., Abe K., et al: Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977; 136:571-576.
190. Brunetto M.R., Stemler M., Schodel F., et al: Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989; 21:151-154.
191. Lok A.S., McMahon B.J.: Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
192. Liaw Y.F., Leung N., Kao J.H., et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
193. European Association for the Study of the Liver : EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
194. Liaw Y.F., Sung J.J., Chow W.C., et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
195. Lok A.S., McMahon B.J.: Chronic hepatitis B: update of recommendations. Hepatology 2004; 39:857-861.
196. Marcellin P., Chang T.T., Lim S.G., et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
197. Lau G.K., Piratvisuth T., Luo K.X., et al: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
198. Dienstag J.L., Schiff E.R., Wright T.L., et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
199. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-807.
200. Lai C.L., Gane E., Liaw Y.F., et al: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
201. Chang T.T., Gish R.G., de Man R., et al: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.

202. Lai C.L., Shouval D., Lok A.S., et al: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
203. Marcellin P., Heathcote E.J., Buti M., et al: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
204. Marcellin P., Lau G.K., Bonino F., et al: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
205. Keeffe E.B., Dieterich D.T., Han S.H., et al: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4:936-962.
206. Hollinger F.B., Lau D.T.: Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin North Am 2006; 35:895-931.
207. Wong S.N., Lok A.S.: Treatment of hepatitis B: who, when, and how?. Arch Intern Med 2006; 166:9-12.
208. Malik A.H., Lee W.M.: Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132:723-731.
209. Lok A.S., McMahon B.J.: Chronic hepatitis B. Hepatology 2007; 45:507-539.
210. Hoofnagle J.H., di Bisceglie A.M.: The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347-356.
211. Locarnini S.: Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25(suppl 1):9-19.
212. Tenney D.J., Levine S.M., Rose R.E., et al: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
213. Snow-Lampart A., Chappell B., Curtis M., et al: No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53:763-773.
214. Kane M.A.: Global status of hepatitis B immunisation. Lancet 1996; 348:696.
215. Lee W.M.: Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
216. Ferlay J., Bray F., Pisani P.: GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide: Version 1. Lyon, France, IARC Press, 2001.
217. Bosch F.X., Ribes J., Borras J.: Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-285.
218. Bosch F.X., Ribes J., Diaz M., et al: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16.
219. Kew M.C.: Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010; 58:273-277.
220. Chen C.J., Yang H.I., Su J., et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
221. Iloeje U.H., Yang H.I., Su J., et al: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686.
222. Yang H.I., Yeh S.H., Chen P.J., et al: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134-1143.
223. Donato F., Boffetta P., Puoti M.: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347-354.

224. Umoh N.J., Lesi O.A., Mendy M., et al: Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in the Gambia. Liver Int 2011; 31:215-221.
225. Gelatti U., Donato F., Tagger A., et al: Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol 2003; 98:907-914.
226. Bosch F.X., Ribes J., Cleries R., et al: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9:191-211.v
227. Wild C.P., Gong Y.Y.: Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010; 31:71-82.
228. Donato F., Tagger A., Gelatti U., et al: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155:323-331.
229. Recommendations of the Immunization Practices Advisory Committee (ACIP) : Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Recomm Rep 1991; 40(RR-13):1-25.
230. McQuillan G.M., Coleman P.J., Kruszon-Moran D., et al: Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89:14-18.
231. Coleman P.J., McQuillan G.M., Moyer L.A., et al: Incidence of hepatitis B virus infection in the United States, 1976–1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998; 178:954-959.
232. Ly K.N., Xing J., Klevens R.M., et al: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156(4):271-278.
233. Ioannou G.N.: Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154:319-328.
234. Weinbaum C.M., Williams I., Mast E.E.Centers for Disease Control and Prevention (CDC): Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57(RR-8):1-20.
235. Cohen C., Evans A.A., London W.T., et al: Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat 2008; 15:12-13.
236. Centers for Disease Control and Prevention : Hepatocellular carcinoma: United States, 2001–2006. MMWR Morb Mortal Wkly Rep 2010; 59:517-520.
237. Hsu C.E., Liu L.C., Juon H.S., et al: Reducing liver cancer disparities: a community-based hepatitis-B prevention program for Asian-American communities. J Natl Med Assoc 2007; 99:900-907.
237a. Ly K.N., Xing J., Klevens R.M., et al: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156(4):271-278.
238. Kim W.R.: Epidemiology of hepatitis B in the United States. Hepatology 2009; 49:S28-S34.
239. Margolis H.S., Coleman P.J., Brown R.E., et al: Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995; 274:1201-1208.
240. Margolis H., Alter M.J., Hadler S.C.: Viral hepatitis. In: Evans A.S., Kaslow R.A., ed. Viral Infections of Humans: Epidemiology and Control, 4th ed. New York: Plenum; 1997:363-418.
241. Martinson F.E., Weigle K.A., Royce R.A., et al: Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol 1998; 147:478-487.
242. Bond W.W., Favero M.S., Petersen N.J., et al: Survival of hepatitis B virus after drying and storage for one week. Lancet 1981; 1:550-551.

243. Petersen N.J., Barrett D.H., Bond W.W., et al: Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976; 32:572-574.
244. Wong V.C., Ip H.M., Reesink H.W., et al: Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: double-blind randomised placebo-controlled study. Lancet 1984; 1:921-926.
245. Stevens C.E., Taylor P.E., Tong M.J., et al: Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257:2612-2616.
246. Poovorawan Y., Sanpavat S., Pongpunlert W., et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261:3278-3281.
247. Lee C.Y., Huang L.M., Chang M.H., et al: The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991; 10:299-303.
248. Beasley R.P., Stevens C.E., Shiao I.S., et al: Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975; 2:740-741.
249. Tong M.J., Thursby M., Rakela J., et al: Studies on the maternal-infant transmission of the viruses which cause acute hepatitis. Gastroenterology 1981; 80:999-1004.
250. Schweitzer I.L., Dunn A.E., Peters R.L., et al: Viral hepatitis B in neonates and infants. Am J Med 1973; 55:762-771.
251. Okada K., Kamiyama I., Inomata M., et al: e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294:746-749.
252. Beasley R.P., Trepo C., Stevens C.E., et al: The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105:94-98.
253. Beasley R.P., Hwang L.Y., Stevens C.E., et al: Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983; 3:135-141.
254. Xu Z.Y., Liu C.B., Francis D.P., et al: Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985; 76:713-718.
255. Stevens C.E., Toy P.T., Tong M.J., et al: Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 1985; 253:1740-1745.
256. Friedman S.M., DeSilva L.P., Fox H.E., et al: Hepatitis B screening in a New York City obstetrics service. Am J Public Health 1988; 78:308-310.
257. Margolis H.S., Alter M.J., Hadler S.C.: Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11:84-92.
258. Beasley R.P., Hwang L.Y.: Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983; 147:185-190.
259. Villarejos V.M., Visona K.A., Gutierrez A., et al: Role of saliva, urine and feces in the transmission of type B hepatitis. N Engl J Med 1974; 291:1375-1378.
260. Cancio-Bello T.P., de Medina M., Shorey J., et al: An institutional outbreak of hepatitis B related to a human biting carrier. J Infect Dis 1982; 146:652-656.
261. Scott R.M., Snitbhan R., Bancroft W.H., et al: Experimental transmission of hepatitis B virus by semen and saliva. J Infect Dis 1980; 142:67-71.
262. Ward R., Borchert P., Wright A., et al: Hepatitis B antigen in saliva and mouth washings. Lancet 1972; 2:726-727.

263. Williams I., Smith M.G., Sinha D., et al: Hepatitis B virus transmission in an elementary school setting. JAMA 1997; 278:2167-2169.
264. Zhang H.W., Yin J.H., Li Y.T., et al: Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008; 57:1713-1720.
265. Bernier R.H., Sampliner R., Gerety R., et al: Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. Am J Epidemiol 1982; 116:199-211.
266. Irwin G.R., Allen A.M., Bancroft W.H., et al: Hepatitis B antigen and antibody: occurrence in families of asymptomatic HB AG carriers. JAMA 1974; 227:1042-1043.
267. Steinberg S.C., Alter H.J., Leventhal B.G.: The risk of hepatitis transmission to family contacts of leukemia patients. J Pediatr 1975; 87:753-756.
268. Nordenfelt E., Dahlquist E.: HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B. Scand J Infect Dis 1978; 10:161-163.
269. Hurie M.B., Mast E.E., Davis J.P.: Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992; 89:269-273.
270. Franks A.L., Berg C.J., Kane M.A., et al: Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med 1989; 321:1301-1305.
271. Mahoney F.J., Lawrence M., Scott C., et al: Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics 1995; 96:1113-1116.
272. Hayashi J., Kashiwagi S., Nomura H., et al: Hepatitis B virus transmission in nursery schools. Am J Epidemiol 1987; 125:492-498.
273. Nigro G., Taliani G.: Nursery-acquired asymptomatic B hepatitis. Lancet 1989; 1:1451-1452.
274. Shapiro C.N., McCaig L.F., Gensheimer K.F., et al: Hepatitis B virus transmission between children in day care. Pediatr Infect Dis J 1989; 8:870-875.
275. Breuer B., Friedman S.M., Millner E.S., et al: Transmission of hepatitis B virus to classroom contacts of mentally retarded carriers. JAMA 1985; 254:3190-3195.
276. David E., McIntosh G., Bek M.D., et al: Molecular evidence of transmission of hepatitis B in a day-care centre. Lancet 1996; 347:118-119.
277. Oleske J., Minnefor A., Cooper Jr R., et al: Transmission of hepatitis B in a classroom setting. J Pediatr 1980; 97:770-772.
278. Goldstein S.T., Alter M.J., Williams I.T., et al: Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. J Infect Dis 2002; 185:713-719.
279. Scognamiglio P., Girardi E., Fusco M., et al: Lack of implementation of hepatitis B virus (HBV) vaccination policy in household contacts of HBV carriers in Italy. BMC Infect Dis 2009; 9:86.
280. Grytdal S.P., Liao Y., Chen R., et al: Hepatitis B testing and vaccination among Vietnamese- and Cambodian-Americans. J Community Health 2009; 34:173-180.
281. Struve J., Giesecke J., Lindh G., et al: Heterosexual contact as a major route for transmission of acute hepatitis B among adults. J Infect 1990; 20:111-121.
282. Francis D.P., Hadler S.C., Thompson S.E., et al: The prevention of hepatitis B with vaccine: report of the Centers for Disease Control Multi-Center Efficacy Trial among Homosexual Men. Ann Intern Med 1982; 97:362-366.
283. Alter M.J., Margolis H.S.: The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990; 74:1529-1541.
284. Szmuness W., Stevens C.E., Zang E.A., et al: A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1:377-385.
285. Szmuness W., Much I., Prince A.M., et al: On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med 1975; 83:489-495.

286. Rantala M., van de Laar M.J.: Surveillance and epidemiology of hepatitis B and C in Europe: a review. Euro Surveill 2008; 13(21):
287. Risbud A., Mehendale S., Basu S., et al: Prevalence and incidence of hepatitis B virus infection in STD clinic attendees in Pune, India. Sex Transm Infect 2002; 78:169-173.
288. Jacobs B., Mayaud P., Changalucha J., et al: Sexual transmission of hepatitis B in Mwanza, Tanzania. Sex Transm Dis 1997; 24:121-126.
289. Ruan Y., Jia Y., Zhang X., et al: Incidence of HIV-1, syphilis, hepatitis B, and hepatitis C virus infections and predictors associated with retention in a 12-month follow-up study among men who have sex with men in Beijing, China. J Acquir Immune Defic Syndr 2009; 52:604-610.
290. Fulford K.W., Dane D.S., Catterall R.D., et al: Australia antigen and antibody among patients attending a clinic for sexually transmitted diseases. Lancet 1973; 1:1470-1473.
291. Jeffries D.J., James W.H., Jefferiss F.J., et al: Australia (hepatitis-associated) antigen in patients attending a venereal disease clinic. Br Med J 1973; 2:455-456.
292. Dietzman D.E., Harnisch J.P., Ray C.G., et al: Hepatitis B surface antigen (HBsAg) and antibody to HBsAg: prevalence in homosexual and heterosexual men. JAMA 1977; 238:2625-2626.
293. Yuan L., Robinson G.: Hepatitis B vaccination and screening for markers at a sexually transmitted disease clinic for men. Can J Public Health 1994; 85:338-341.
294. MacKellar D.A., Valleroy L.A., Secura G.M., et al: Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001; 91:965-971.
295. Gunn R.A., Murray P.J., Ackers M.L., et al: Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis 2001; 28:166-170.
296. Neaigus A., Gyarmathy V.A., Zhao M., et al: Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis 2007; 195:1052-1061.
297. Coutinho R.A., Schut B.J., Albrecht-Van Lent N.A., et al: Hepatitis B among homosexual men in the Netherlands. Sex Transm Dis 1981; 8:333-335.
298. Remis R.S., Dufour A., Alary M., et al: Association of hepatitis B virus infection with other sexually transmitted infections in homosexual men. Omega Study Group. Am J Public Health 2000; 90:1570-1574.
299. Kane A., Lloyd J., Zaffran M., et al: Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999; 77:801-807.
300. Hutin Y.J., Chen R.T.: Injection safety: a global challenge. Bull World Health Organ 1999; 77:787-788.
301. Hutin Y., Stilwell B., Hauri A.M., et al: Transmission of bloodborne pathogens through unsafe injections and proposed approach for the Safe Injection Global Network. In: Margolis H.S., Alter M.J., Liang T.J., et al ed. Viral Hepatitis and Liver Disease, London: International Medical Press; 2002:219-227.
302. Thompson N.D., Perz J.F., Moorman A.C., et al: Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med 2009; 150:33-39.
303. Lanini S., Puro V., Lauria F.N., et al: Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med 2009; 7:15.doi:10.1186/1741-7015-7-15
304. Relation of e antigen to infectivity of HBsAg-positive inoculations among medical personnel. Lancet 1976; 1:492-494.

305. Seeff L.B., Wright E.C., Zimmerman H.J., et al: Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978; 88:285-293.
306. Grady G.F., Lee V.A., Prince A.M., et al: Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978; 138:625-638.
307. Gerberding J.L.: Management of occupational exposures to blood-borne viruses. N Engl J Med 1995; 332:444-451.
308. Centers for Disease Control and Prevention : Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47(RR-19):1-39.
309. Perkins H.A., Busch M.P.: Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010; 50:2080-2099.
310. Zou S., Stramer S.L., Notari E.P., et al: Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49:1609-1620.
311. Committee on International Relations, House of Representatives : Making safe blood available in Africa. 2006. June 27Accessed June 9, 2011 http://commdocs.house.gov/committees/intlrel/hfa28424.000/hfa28424_0f.htm
312. Centers for Disease Control and Prevention : Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence. MMWR Recomm Rep 1991; 40(RR-4):1-17.
313. Tabor E.: The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39:1160-1168.
314. Des Jarlais D.C., Diaz T., Perlis T., et al: Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157:467-471.
315. Garfein R.S., Vlahov D., Galai N., et al: Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-661.
316. Hagan H., McGough J.P., Thiede H., et al: Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149:203-213.
317. Kuo I., Sherman S.G., Thomas D.L., et al: Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend 2004; 73:69-78.
318. Burt R.D., Hagan H., Garfein R.S., et al: Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18–30 years, 1994–2004. J Urban Health 2007; 84:436-454.
319. Levine O.S., Vlahov D., Brookmeyer R., et al: Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users. J Infect Dis 1996; 173:579-583.
320. Neaigus A., Gyarmathy V.A., Miller M., et al: Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend 2007; 89:234-243.
321. Liang X., Bi S., Yang W., et al: Epidemiological serosurvey of hepatitis B in China: declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27:6550-6557.
322. McMahon B.J., Bulkow L.R., Singleton R.J., et al: Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54:801-807.

323. Ni Y.H., Chang M.H., Huang L.M., et al: Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135:796-800.
324. Bialek S.R., Helgenberger L., Fischer G.E., et al: Impact of routine hepatitis B immunization on the prevalence of chronic hepatitis B virus infection in the marshall islands and the federated States of micronesia. Pediatr Infect Dis J 2010; 29:18-22.
325. Hu M.D., Schenzle D., Deinhardt F., et al: Epidemiology of hepatitis A and B in the Shanghai area: prevalence of serum markers. Am J Epidemiol 1984; 120:404-413.
326. Maynard J.E., Kane M.A., Alter M.J., et al: Control of hepatitis B by immunization: global perspectives. In: Vyas G.N., Dienstag J.L., Hoofnagle J.H., ed. Viral Hepatitis and Liver Disease, New York: Grune & Stratton; 1984:967-969.
327. Lingao A.L., Domingo E.O., West S., et al: Seroepidemiology of hepatitis B virus in the Philippines. Am J Epidemiol 1986; 123:473-480.
328. Lee S.D., Lo K.J., Wu J.C., et al: Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 1986; 6:369-373.
329. Whittle H., Inskip H., Bradley A.K., et al: The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis 1990; 161:1112-1115.
330. Toukan A.U., Sharaiha Z.K., Abu-el-Rub O.A., et al: The epidemiology of hepatitis B virus among family members in the Middle East. Am J Epidemiol 1990; 132:220-232.
331. Bensabath G., Hadler S.C., Soares M.C., et al: Epidemiologic and serologic studies of acute viral hepatitis in Brazil's Amazon Basin. Bull Pan Am Health Organ 1987; 21:16-27.
332. Hyams K.C., Osman N.M., Khaled E.M., et al: Maternal-infant transmission of hepatitis B in Egypt. J Med Virol 1988; 24:191-197.
333. Toukan A.: Strategy for the control of hepatitis B virus infection in the Middle East and North Africa. The Middle East Regional Study Group. Vaccine 1990; 8(suppl):S117-S121.discussion, S134–S118
334. Thomas D.L., Cannon R.O., Shapiro C.N., et al: Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994; 169:990-995.
335. Koff R.S., Slavin M.M., Connelly J.D., et al: Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. Gastroenterology 1977; 72:297-300.
336. Redeker A.G., Mosley J.W., Gocke D.J., et al: Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N Engl J Med 1975; 293:1055-1059.
337. Peters C.J., Purcell R.H., Lander J.J., et al: Radioimmunoassay for antibody to hepatitis B surface antigen shows transmission of hepatitis B virus among household contacts. J Infect Dis 1976; 134:218-223.
338. Heathcote J., Gateau P., Sherlock S.: Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus. Lancet 1974; 2:370-371.
339. Armstrong G.L., Mast E.E., Wojczynski M., et al: Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001; 108:1123-1128.
340. Shuler C.M., Fiore A.E., Neeman R., et al: Reduction in hepatitis B virus seroprevalence among U.S.-born children of foreign-born Asian parents: benefit of universal infant hepatitis B vaccination. Vaccine 2009; 27:5942-5947.
341. Burdick R.A., Bragg-Gresham J.L., Woods J.D., et al: Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63:2222-2229.
342. Finelli L., Miller J.T., Tokars J.I., et al: National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52-61.

343. Centers for Disease Control and Prevention : Outbreaks of hepatitis B virus infection among hemodialysis patients: California, Nebraska, and Texas. MMWR Morb Mortal Wkly Rep 1996; 45:285-289.
344. Harzke A.J., Goodman K.J., Mullen P.D., et al: Heterogeneity in hepatitis B virus (HBV) seroprevalence estimates from U.S. adult incarcerated populations. Ann Epidemiol 2009; 19:647-650.
345. Anda R.F., Perlman S.B., D'Alessio D.J., et al: Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination. Am J Public Health 1985; 75:1182-1185.
346. Koplan J.P., Walker J.A., Bryan J.A., et al: Prevalence of hepatitis B surface antigen and antibody at a state prison in Kansas. J Infect Dis 1978; 137:505-506.
347. Decker M.D., Vaughn W.K., Brodie J.S., et al: Seroepidemiology of hepatitis B in Tennessee prisoners. J Infect Dis 1984; 150:450-459.
348. Tucker R.M., Gaffey M.J., Fisch M.J., et al: Seroepidemiology of hepatitis D (delta agent) and hepatitis B among Virginia State prisoners. Clin Ther 1987; 9:622-628.
349. Weinbaum C., Lyerla R., Margolis H.S.Centers for Disease Control and Prevention: Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep 2003; 52(RR-1):1-36.
350. Khan A., Simard E., Wurtzel H., et al: The prevalence, risk factors, and incidence of hepatitis B virus infection among inmates in a state correctional facility [Abstract]. In: 130th Annual Meeting of the American Public Health Association, 2002. Philadelphia, PA
351. Hull H.F., Lyons L.H., Mann J.M., et al: Incidence of hepatitis B in the penitentiary of New Mexico. Am J Public Health 1985; 75:1213-1214.
352. Gupta S., Altice F.L.: Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health 2009; 86:263-279.
353. Macalino G., Salas C.M., Towe C.W., et al: Incidence and community prevalence of HIV and other blood borne pathogens among incarcerated women in Rhode Island [Abstract]. In: National HIV Prevention Conference, Atlanta, GA, US Department of Health and Human Services, CDC, 1999.
354. Morrow K.M.: HIV, STD, and hepatitis risk behaviors of young men before and after incarceration. AIDS Care 2009; 21:235-243.
355. Khan M.R., Doherty I.A., Schoenbach V.J., et al: Incarceration and high-risk sex partnerships among men in the United States. J Urban Health 2009; 86:584-601.
356. Murrill C.S., Weeks H., Castrucci B.C., et al: Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health 2002; 92:385-387.
357. Lopez-Zetina J., Kerndt P., Ford W., et al: Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994–1996. Addiction 2001; 96:589-595.
358. Kunches L.M., Craven D.E., Werner B.G.: Seroprevalence of hepatitis B virus and delta agent in parenteral drug abusers: immunogenicity of hepatitis B vaccine. Am J Med 1986; 81:591-595.
359. Raimondo G., Smedile A., Gallo L., et al: Multicentre study of prevalence of HBV-associated delta infection and liver disease in drug-addicts. Lancet 1982; 1:249-251.
360. Zeldis J.B., Jain S., Kuramoto I.K., et al: Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992; 156:30-35.
361. Mangla J.C., Kim Y.M., Brown M.R., et al: Liver tests, HB-Ag and HB-Ab in asymptomatic drug addicts. Am J Gastroenterol 1976; 65:121-126.

362. Seeff L.B., Zimmerman H.J., Wright E.C., et al: Hepatic disease in asymptomatic parenteral narcotic drug abusers: a Veterans Administration collaborative study. Am J Med Sci 1975; 270:41-47.
363. Cherubin C.E., Schaefer R.A., Rosenthal W.S., et al: The natural history of liver disease in former drug users. Am J Med Sci 1976; 272:244-253.
364. Blanck R.R., Ream N., Conrad M.: Hepatitis B antigen and antibody in heroin users. Am J Gastroenterol 1979; 71:164-167.
365. Kellerman S.E., Hanson D.L., McNaghten A.D., et al: Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:571-577.
366. Kucirka L.M., Farzadegan H., Feld J.J., et al: Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010; 202:845-852.
367. Bialek S.R., Bower W.A., Mottram K., et al: Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health 2005; 82:468-478.
368. Hu Y., Grau L.E., Scott G., et al: Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med 2008; 35:25-32.
369. Averhoff F.M., Moyer L.A., Woodruff B.A., et al: Occupational exposures and risk of hepatitis B virus infection among public safety workers. J Occup Environ Med 2002; 44:591-596.
370. Day C.A., White B., Dore G.J., et al: Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status. Drug Alcohol Depend 2010; 108:134-137.
371. Lum P.J., Hahn J.A., Shafer K.P., et al: Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat 2008; 15:229-236.
372. Segal H.E., Llewellyn C.H., Irwin G., et al: Hepatitis B antigen and antibody in the U.S. Army: prevalence in health care personnel. Am J Public Health 1976; 66:667-671.
373. Pattison C.P., Maynard J.E., Berquist D.R., et al: Epidemiology of hepatitis B in hospital personnel. Am J Epidemiol 1975; 101:59-64.
374. Dienstag J.L., Ryan D.M.: Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization?. Am J Epidemiol 1982; 115:26-39.
375. Smith J.L., Maynard J.E., Berquist K.R., et al: From the Center for Disease Control: comparative risk of hepatitis B amono physicians and dentists. J Infect Dis 1976; 133:705-706.
376. Hadler S.C., Doto I.L., Maynard J.E., et al: Occupational risk of hepatitis B infection in hospital workers. Infect Control 1985; 6:24-31.
377. Hollinger F.B., Grander J.W., Nickel F.R., et al: Hepatitis B prevalence within a dental student population. J Am Dent Assoc 1977; 94:521-527.
378. Simard E.P., Miller J.T., George P.A., et al: Hepatitis B vaccination coverage levels among healthcare workers in the United States, 2002–2003. Infect Control Hosp Epidemiol 2007; 28:783-790.
379. Woodruff B.A., Moyer L.A., O'Rourke K.M., et al: Blood exposure and the risk of hepatitis B virus infection in firefighters. J Occup Med 1993; 35:1048-1054.
380. Werman H.A., Gwinn R.: Seroprevalence of hepatitis B and hepatitis C among rural emergency medical care personnel. Am J Emerg Med 1997; 15:248-251.
381. Spitters C., Zenilman J., Yeargain J., et al: Prevalence of antibodies to hepatitis B and C among fire department personnel prior to implementation of a hepatitis B vaccination program. J Occup Environ Med 1995; 37:663-664.
382. Chaudhary R.K., Perry E., Cleary T.E.: Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. Am J Epidemiol 1977; 105:123-126.

383. Vellinga A., Van Damme P., Meheus A.: Hepatitis B and C in institutions for individuals with intellectual disability. J Intellect Disabil Res 1999; 43(pt 6):445-453.
384. Connor B.A., Jacobs R.J., Meyerhoff A.S.: Hepatitis B risks and immunization coverage among American travelers. J Travel Med 2006; 13:273-280.
385. Zuckerman J.N., Hoet B.: Hepatitis B immunisation in travellers: poor risk perception and inadequate protection. Travel Med Infect Dis 2008; 6:315-320.
386. Leggat P.A., Zwar N.A., Hudson B.J.: Hepatitis B risks and immunisation coverage amongst Australians travelling to Southeast Asia and East Asia. Travel Med Infect Dis 2009; 7:344-349.
387. Harling R., Turbitt D., Millar M., et al: Passage from India: an outbreak of hepatitis B linked to a patient who acquired infection from health care overseas. Public Health 2007; 121:734-741.
388. Herbinger K.H., Nothdurft H.D., Prymula R.: Online survey: knowledge about risks, prevention and consequences of infections with HBV among travellers from four European countries. Curr Med Res Opin 2011; 27:489-496.
389. Namikawa K., Iida T., Ouchi K., et al: Knowledge, attitudes, and practices of Japanese travelers on infectious disease risks and immunization uptake. J Travel Med 2010; 17:171-175.
390. Chen L.H., Wilson M.E., Davis X., et al: Illness in long-term travelers visiting GeoSentinel clinics. Emerg Infect Dis 2009; 15:1773-1782.
391. Sonder G.J., van Rijckevorsel G.G., van den Hoek A.: Risk of hepatitis B for travelers: is vaccination for all travelers really necessary?. J Travel Med 2009; 16:18-22.
392. Steffen R., Rickenbach M., Wilhelm U., et al: Health problems after travel to developing countries. J Infect Dis 1987; 156:84-91.
393. Steffen R.: Risks of hepatitis B for travellers. Vaccine 1990; 8(suppl):S31-S32.discussion, S41–S33
394. Smalligan R.D., Lange W.R., Frame J.D., et al: The risk of viral hepatitis A, B, C, and E among North American missionaries. Am J Trop Med Hyg 1995; 53:233-236.
395. Maynard J.E.: Passive immunization against hepatitis B: a review of recent studies and comment on current aspects of control. Am J Epidemiol 1978; 107:77-86.
396. Terrault N.A., Zhou S., Combs C., et al: Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:1327-1333.
397. Centers for Disease Control and Prevention : Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR Morb Mortal Wkly Rep 1986; 35:231-233.
398. Wells M.A., Wittek A.E., Epstein J.S., et al: Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 1986; 26:210-213.
399. Seeff L.B., Zimmerman H.J., Wright E.C., et al: A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis: a Veterans Administration cooperative study. Gastroenterology 1977; 72:111-121.
400. Palmovic D., Crnjakovic-Palmovic J.: Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules. Infection 1993; 21:42-45.
401. Stevens C.E., Neurath R.A., Beasley R.P., et al: HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979; 3:237-241.
402. Dosik H., Jhaveri R.: Prevention of neonatal hepatitis B infection by high-dose hepatitis B immune globulin. N Engl J Med 1978; 298:602-603.

403. Beckebaum S., Sotiropoulos G.C., Gerken G., et al: Hepatitis B and liver transplantation: 2008 update. Rev Med Virol 2009; 19:7-29.
404. Atkinson W.L., Pickering L.K., Schwartz B., et al: General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002; 51(RR-2):1-35.
405. Samuel D.: The option of liver transplantation for hepatitis B: where are we?. Dig Liver Dis 2009; 41(suppl 2):S185-S189.
406. Francis D.P., Feorino P.M., McDougal S., et al: The safety of the hepatitis B vaccine: inactivation of the AIDS virus during routine vaccine manufacture. JAMA 1986; 256:869-872.
407. Sitrin R.D., Wampler D.E., Ellis R.W.: Survey of licensed hepatitis B vaccines and their production processes. In: Ellis R.W., ed. Hepatitis B Vaccines in Clinical Practice, New York: Marcel Dekker; 1993:83-101.
408. Emini E.A., Ellis R.W., Miller W.J., et al: Production and immunological analysis of recombinant hepatitis B vaccine. J Infect 1986; 13(suppl A):3-9.
409. Stephenne J.: Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990; 8(suppl):S69-S73.discussion, S79–S80
410. Expanded Programme on Immunization : Introduction of hepatitis B vaccine into childhood immunization services: management guidelines, including information for health workers and parents. (WHO.V&B/01.31)Geneva, World Health Organization, 2001.
411. Beran J.: Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8:235-247.
412. Centers for Disease Control and Prevention : Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 1999; 48:563-565.
413. Stratton K., Gable A., McCormick M.C.: Immunization Safety Review. Thimerosal-containing vaccines and neurodevelopmental disorders. In: Board on Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC, National Academy Press, 2001.
414. Zuckerman J.N.: Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006; 78:169-177.
415. Zuckerman J.N., Zuckerman A.J., Symington I., et al: Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 2001; 34:798-802.
416. Rendi-Wagner P., Shouval D., Genton B., et al: Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006; 24:2781-2789.
417. Diez-Delgado J., Dal-Re R., Llorente M., et al: Hepatitis B component does not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants. Vaccine 1997; 15:1418-1422.
418. Bruguera M., Bayas J.M., Vilella A., et al: Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults. Vaccine 1996; 14:1407-1411.
419. West D.J., Hesley T.M., Jonas L.C., et al: Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Hib-HB Vaccine Study Group. Pediatr Infect Dis J 1997; 16:593-599.
420. Melnick J.: Thermostability of poliovirus, measles, and hepatitis B vaccines. Vaccine Res 1995; 4:1-11.

421. Van Damme P., Cramm M., Safary A., et al: Heat stability of a recombinant DNA hepatitis B vaccine. Vaccine 1992; 10:366-367.
422. Otto B.F., Suarnawa I.M., Stewart T., et al: At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine 1999; 18:498-502.
423. Sutanto A., Suarnawa I.M., Nelson C.M., et al: Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Bull World Health Organ 1999; 77:119-126.
424. Hipgrave D.B., Maynard J.E., Biggs B.A.: Improving birth dose coverage of hepatitis B vaccine. Bull World Health Organ 2006; 84:65-71.
425. Levin C.E., Nelson C.M., Widjaya A., et al: The costs of home delivery of a birth dose of hepatitis B vaccine in a prefilled syringe in Indonesia. Bull World Health Organ 2005; 83:456-461.
426. Centers for Disease Control and Prevention : Implementation of newborn hepatitis B vaccination: worldwide, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:1249-1252.
427. Levin A., Levin C., Kristensen D., et al: An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh. Vaccine 2007; 25:6945-6957.
428. McLean A.A., Shaw Jr. R.: Hepatitis B vaccine. Ann Intern Med 1982; 97:451.
429. Hadler S.C., Francis D.P., Maynard J.E., et al: Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-214.
430. Galazka A, Milstien J., Zaffran M.: Thermostability of vaccines. (WHO/GPV/98.07)Geneva, World Health Organization, 1998.
431. Seto D., West D.J., Gilliam R.R., et al: Antibody responses of healthy neonates of two mixed regimens of hepatitis B vaccine. Pediatr Infect Dis J 1999; 18:840-842.
432. Shaw Jr, F.E., Guess H.A., Roets J.M., et al: Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425-430.
433. Redfield R.R., Innis B.L., Scott R.M., et al: Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy. JAMA 1985; 254:3203-3206.
434. Bryan J.P., Sjogren M.H., Perine P.L., et al: Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992; 14:697-707.
435. Sangare L., Manhart L., Zehrung D., et al: Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009; 27:1777-1786.
436. Coursaget P., Relyveld E., Brizard A., et al: Simultaneous injection of hepatitis B vaccine with BCG and killed poliovirus vaccine. Vaccine 1992; 10:319-321.
437. Coursaget P., Yvonnet B., Relyveld E.H., et al: Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen. Infect Immun 1986; 51:784-787.
438. Aristegui J., Muniz J., Perez Legorburu A., et al: Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age. Vaccine 1995; 13:973-977.
439. Giammanco G., Li Volti S., Mauro L., et al: Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine 1991; 9:747-750.
440. Barone P., Mauro L., Leonardi S., et al: Simultaneous administration of HB recombinant vaccine with diphtheria and tetanus toxoid and oral polio vaccine: a pilot study. Acta Paediatr Jpn 1991; 33:455-458.

441. Coursaget P., Fritzell B., Blondeau C., et al: Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines. Vaccine 1995; 13:109-111.
442. Yvonnet B., Coursaget P., Deubel V., et al: Simultaneous administration of hepatitis B and yellow fever vaccines. J Med Virol 1986; 19:307-311.
443. King G.E., Hadler S.C.: Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1994; 13:394-407.
444. Combination vaccines for childhood immunization. MMWR Recomm Rep 1999; 48(RR-5):1-14.
445. Duval B., Deceuninck G.: Seroprotection rates after late doses of hepatitis B vaccine. Pediatrics 2002; 109:350-351.
446. Halsey N.A., Moulton L.H., O'Donovan J.C., et al: Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999; 103:1243-1247.
447. Mangione R., Stroffolini T., Tosti M.E., et al: Delayed third hepatitis B vaccine dose and immune response. Lancet 1995; 345:1111-1112.
448. Keyserling H.L., West D.J., Hesley T.M., et al: Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age. J Pediatr 1994; 125:67-69.
449. Middleman A.B., Kozinetz C.A., Robertson L.M., et al: The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis b immunization among adolescents. Pediatrics 2001; 107:1065-1069.
450. Jackson Y., Chappuis F., Mezger N., et al: High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine 2007; 25:3482-3484.
451. Greenberg D.P., Vadheim C.M., Wong V.K., et al: Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J 1996; 15:590-596.
452. Hadler S.C., Margolis H.S.: Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 1992; 12:282-308.
453. Coursaget P., Kane M.: Overview of clinical studies in developing countries. In: Ellis R.W., ed. Hepatitis B Vaccines in Clinical Practice, New York: Marcel Dekker; 1993:209-228.
454. Da Villa G., Pelliccia M.G., Peluso F., et al: Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol 1997; 148:109-114.
455. Aspinall S., Kocks D.J.: Immunogenicity of a low-cost hepatitis B vaccine in the South African Expanded Programme on Immunisation. S Afr Med J 1998; 88:36-39.
456. Goldfarb J., Baley J., Medendorp S.V., et al: Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994; 13:18-22.
457. Yusuf H.R., Daniels D., Smith P., et al: Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. JAMA 2000; 284:978-983.
458. Jilg W., Schmidt M., Deinhardt F.: Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160:766-769.
459. Thisyakorn U., Montellano M., Lane A.: Routine newborn hepatitis B immunization. Infect Dis Clin Pract 2011; 19:326-331.
460. Clemens R., Sanger R., Kruppenbacher J., et al: Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule: results of a post-marketing surveillance. Vaccine 1997; 15:349-352.

461. Craven D.E., Awdeh Z.L., Kunches L.M., et al: Nonresponsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Ann Intern Med 1986; 105:356-360.
462. Goldwater P.N.: Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15:353-356.
463. Kim M.J., Nafziger A.N., Harro C.D., et al: Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003; 21:1174-1179.
464. Ostrow D.G., Goldsmith J., Kalish S.B., et al: Nonresponse to hepatitis B vaccine in homosexual men. Sex Transm Dis 1987; 14:92-97.
465. Weissman J.Y., Tsuchiyose M.M., Tong M.J., et al: Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988; 260:1734-1738.
466. Alper C.A., Kruskall M.S., Marcus-Bagley D., et al: Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321:708-712.
467. Cooper A., Yusuf H., Rodewald L., et al: Attitudes, practices, and preferences of pediatricians regarding initiation of hepatitis B immunization at birth. Pediatrics 2001; 108:1-7.
467a. Wang Z., Zhang S., Luo C., et al: Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS One 2011; 6(9):e25130.Epub 2011 Sep 22.
468. Merck & Co : Recombivax HB: hepatitis B vaccine (recombinant). Whitehouse Station, NJ, Merck & Co., Inc, 1998.
469. Pichichero M.E., Blatter M.M., Reisinger K.S., et al: Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002; 21:854-859.
470. Lau Y.L., Tam A.Y., Ng K.W., et al: Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121:962-965.
471. Patel D.M., Butler J., Feldman S., et al: Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr 1997; 131:641-643.
472. Kim S.C., Chung E.K., Hodinka R.L., et al: Immunogenicity of hepatitis B vaccine in preterm infants. Pediatrics 1997; 99:534-536.
473. Losonsky G.A., Wasserman S.S., Stephens I., et al: Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103:E14.
474. Freitas da Motta M.S., Mussi-Pinhata M.M., Jorge S.M., et al: Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine 2002; 20:1557-1562.
475. Cassidy W.M., Watson B., Ioli V.A., et al: A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 2001; 107:626-631.
476. Schiff G.M., Sherwood J.R., Zeldis J.B., et al: Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995; 16:12-17.
477. Milne A., Moyes C.D., Allwood G.K., et al: Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children. N Z Med J 1988; 101:67-69.
478. Centers for Disease Control and Prevention : Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11–15 years. MMWR March 31, 2000/; 49(12):261.
479. Marsano L.S., West D.J., Chan I., et al: A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 1998; 16:624-629.

480. Beran J., Kervyn D., Wertzova V., et al: Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine 2010; 28:5993-5997.
481. Van Damme P., Moiseeva A., Marichev I., et al: Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11–15 years: a randomised controlled study. BMC Infect Dis 2010; 10:357.
482. Andre F.E.: Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87:14S-20S.
483. Averhoff F., Mahoney F., Coleman P., et al: Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15:1-8.
484. Collier A.C., Corey L., Murphy V.L., et al: Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988; 109:101-105.
485. Weber D.J., Rutala W.A., Samsa G.P., et al: Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985; 254:3187-3189.
486. Clements M.L., Miskovsky E., Davidson M., et al: Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens. J Infect Dis 1994; 170:510-516.
487. Wood R.C., MacDonald K.L., White K.E., et al: Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993; 270:2935-2939.
488. Treadwell T.L., Keeffe E.B., Lake J., et al: Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 1993; 95:584-588.
489. Roome A.J., Walsh S.J., Cartter M.L., et al: Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993; 270:2931-2934.
490. Winter A.P., Follett E.A., McIntyre J., et al: Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994; 12:771-772.
491. Centers for Disease Control and Prevention. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(50):1709–1711.
492. Bruguera M., Cremades M., Salinas R., et al: Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14:27-30.
493. Zuccotti G.V., Riva E., Flumine P., et al: Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Pediatr 1994; 125:70-72.
494. Zuin G., Principi N., Tornaghi R., et al: Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992; 10:857-860.
495. Diamant E.P., Schechter C., Hodes D.S., et al: Immunogenicity of hepatitis B vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993; 12:877-878.
496. Shouval D., Ilan Y.: Immunization against hepatitis B through adoptive transfer of immunity. Intervirology 1995; 38:41-46.
497. Szmuness W., Stevens C.E., Harley E.J., et al: Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833-841.
498. Centers for Disease Control and Prevention : Update on hepatitis B prevention. MMWR Morb Mortal Wkly Rep 1987; 36:353-360.366
499. Immunisation against hepatitis B. Lancet 1988; 1:875-876.
500. World Health Organization : Informal consultation on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine. Final report. Geneva, WHO, 1992.

501. Jack A.D., Hall A.J., Maine N., et al: What level of hepatitis B antibody is protective?. J Infect Dis 1999; 179:489-492.
502. Coleman P.F.: Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 2006; 12:198-203.
503. Crosnier J., Jungers P., Courouce A.M., et al: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units, II: haemodialysis patients. Lancet 1981; 1:797-800.
504. Szmuness W., Stevens C.E., Harley E.J., et al: Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982; 307:1481-1486.
505. Desmyter J., Colaert J., De Groote G., et al: Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff: double-blind placebo-controlled trial. Lancet 1983; 2:1323-1328.
506. Stevens C.E., Alter H.J., Taylor P.E., et al: Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med 1984; 311:496-501.
507. Beasley R.P., Hwang L.Y., Lee G.C., et al: Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2:1099-1102.
508. Ip H.M., Lelie P.N., Wong V.C., et al: Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989; 1:406-410.
509. Lo K.J., Tsai Y.T., Lee S.D., et al: Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985; 152:817-822.
510. Pongpipat D., Suvatte V., Assateerawatts A.: Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. Asian Pac J Allergy Immunol 1989; 7:37-40.
511. del Canho R., Grosheide P.M., Mazel J.A., et al: Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982–1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15:1624-1630.
512. Poovorawan Y., Sanpavat S., Pongpunglert W., et al: Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992; 11:816-821.
513. Assateerawatt A., Tanphaichitr V.S., Suvatte V., et al: Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high-risk neonates. Asian Pac J Allergy Immunol 1991; 9:89-93.
514. Lee C., Gong Y., Brok J., et al: Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332:328-336.
515. Lolekha S., Warachit B., Hirunyachote A., et al: Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20:3739-3743.
516. Milne A., West D.J., Chinh D.V., et al: Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 2002; 67:327-333.
517. Stevens C.E., Toy P.T., Taylor P.E., et al: Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992; 90:170-173.
518. Assateerawatt A., Tanphaichitr V.S., Suvatte V., et al: Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. Asian Pac J Allergy Immunol 1993; 11:85-91.

519. Poovorawan Y., Sanpavat S., Pongpunlert W., et al: Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990; 8(suppl):S56-S59.discussion, S60-S52
520. Al-Faleh F.Z., Al-Jeffri M., Ramia S., et al: Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect 1999; 38:167-170.
521. Hsu H.M., Chen D.S., Chuang C.H., et al: Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988; 260:2231-2235.
522. Harpaz R., McMahon B.J., Margolis H.S., et al: Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000; 181:413-418.
523. Huang L.M., Chiang B.L., Lee C.Y., et al: Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999; 29:954-959.
524. Resti M., Azzari C., Mannelli F., et al: Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?. Vaccine 1997; 15:1338-1340.
525. Ding L., Zhang M., Wang Y., et al: A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993; 17:475-479.
526. Liao S.S., Li R.C., Li H., et al: Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17:2661-2666.
527. Coursaget P., Leboulleux D., Soumare M., et al: Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994; 21:250-254.
528. Viviani S., Jack A., Hall A.J., et al: Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine 1999; 17:2946-2950.
529. Mintai Z., Kezhou L., Lieming D., et al: Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin Infect Dis 1993; 16:165-167.
530. Hadler S., Coleman P.J., O'Malley P., et al: Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: Hollinger F., Lemon S.M., Margolis H.S., ed. Viral Hepatitis and Liver Disease: Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects, Baltimore: Williams & Wilkins; 1991:776-778.
531. Wainwright R.B., Bulkow L.R., Parkinson A.J., et al: Protection provided by hepatitis B vaccine in a Yupik Eskimo population: results of a 10-year study. J Infect Dis 1997; 175:674-677.
532. Goh K.T., Oon C.J., Heng B.H., et al: Long-term immunogenicity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults. Bull World Health Organ 1995; 73:523-527.
533. Couroucé A., Laplanche A., Benhamou E., et al: Long-term efficacy of hepatitis B vaccination in healthy adults. In: Zuckerman A., ed. Viral Hepatitis and Liver Disease: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease, London, May 1987, New York: Alan R. Liss; 1988:1002-1005.
534. Gibas A., Watkins E., Hinkle C., et al: Long-term persistence of protective antibody after hepatitis B vaccination of healthy adults. In: Zuckerman A., ed. Viral Hepatitis and Liver Disease: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease, London, May 1987, New York: Alan R. Liss; 1988:998-1001.

535. Floreani A., Baldo V., Cristofoletti M., et al: Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004; 22:607-610.
536. Wu Q., Zhuang G.H., Wang X.L., et al: Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011; 29:2302-2307.
537. But D.Y., Lai C.L., Lim W.L., et al: Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26:6587-6591.
538. Poovorawan Y., Chongsrisawat V., Theamboonlers A., et al: Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011; 18:369-375.
539. Roznovsky L., Orsagova I., Kloudova A., et al: Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection 2010; 38:395-400.
540. Bialek S.R., Bower W.A., Novak R., et al: Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881-885.
541. Fitzsimons D., Francois G., Hall A., et al: Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23:4158-4166.
542. Kao J.T., Wang J.H., Hung C.H., et al: Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009; 27:1858-1862.
543. Su F.H., Cheng S.H., Li C.Y., et al: Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25:8085-8090.
544. Hammitt L.L., Hennessy T.W., Fiore A.E., et al: Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-6964.
545. van der Sande M.A., Waight P.A., Mendy M., et al: Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2007; 2:e753.doi:10.1371/journal.pone.0000753
546. van der Sande M.A., Waight P., Mendy M., et al: Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006; 193:1528-1535.
547. Jafarzadeh A., Montazerifar S.J.: Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad 2006; 18:4-9.
548. Alfaleh F., Alshehri S., Alansari S., et al: Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect 2008; 57:404-409.
549. Banatvala J., Van Damme P., Oehen S.: Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19:877-885.
550. Banatvala J.E., Van Damme P.: Hepatitis B vaccine: do we need boosters?. J Viral Hepat 2003; 10:1-6.
551. Jilg W., Schmidt M., Deinhardt F.: Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet 1990; 335:173-174.
552. West D.J., Calandra G.B.: Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14:1019-1027.
553. Hall A.J.: Boosters for hepatitis B vaccination? need for an evidence-based policy. Hepatology 2010; 51:1485-1486.
554. Leuridan E., Van Damme P.: Hepatitis B and the need for a booster dose. Clin Infect Dis 2011; 53:68-75.

555. Jan C.F., Huang K.C., Chien Y.C., et al: Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51:1547-1554.
556. Zanetti A.R., Mariano A., Romano L., et al: Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-1384.
557. Lu C.Y., Chiang B.L., Chi W.K., et al: Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40:1415-1420.
558. Williams I.T., Goldstein S.T., Tufa J., et al: Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003; 22:157-163.
559. Boxall E.H., Sira J.A., El-Shuhkri N., et al: Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004; 190:1264-1269.
560. Gabbuti A., Romano L., Blanc P., et al: Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25:3129-3132.
561. Duval B., Gilca V., Boulianne N., et al: Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005; 24:213-218.
562. Samandari T., Fiore A.E., Negus S., et al: Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120:e373-e381.
563. Lu C.Y., Ni Y.H., Chiang B.L., et al: Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. J Infect Dis 2008; 197:1419-1426.
564. Zinke M., Kappes R., Kindler K., et al: Immune memory to hepatitis B virus in 4–9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009; 5:592-598.
565. Dentinger C.M., McMahon B.J., Butler J.C., et al: Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005; 24:786-792.
566. McMahon B.J., Bruden D.L., Petersen K.M., et al: Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-341.
567. Mele A., Tancredi F., Romano L., et al: Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 2001; 184:905-908.
568. Young B.W., Lee S.S., Lim W.L., et al: The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 2003; 10:23-30.
569. Poovorawan Y., Chongsrisawat V., Theamboonlers A., et al: Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009; 200:33-38.
570. Viviani S., Carrieri P., Bah E., et al: 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:3216-3223.
571. European Consensus Group on Hepatitis B Immunity : Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000; 355:561-565.
572. World Health Organization : Global Advisory Committee on Vaccine Safety: hepatitis B. 2011. July www.who.int/vaccine_safety/topics/hepatitisb/en/index.html

573. Institute of Medicine : Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders. 2002. May www.iom.edu/Reports/2002/Immunization-Safety-Review-Hepatitis-B-Vaccine-and-Demyelinating-Neurological-Disorders.aspx
574. Mikaeloff Y., Caridade G., Assi S., et al: Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 2007; 130:1105-1110.
575. Yu O., Bohlke K., Hanson C.A., et al: Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study. Pharmacoepidemiol Drug Saf 2007; 16:736-745.
576. Duclos P.: Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2003; 2:225-231.
577. Schwalbe J., Ray P., Black S.B., et al: Risk for alopecia after hepatitis B vaccination [Abstract]. Presented at the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September 24–271998.
578. Stratton K., Ford A., Rusch E., et al: Adverse Events of Vaccines: Evidence and Causality. Washington, DC, The National Academies Press, 2011.
579. World Health Organization : Hepatitis B vaccines. Wkly Epidemiol Rec 2009; 84:405-419.
580. World Health Organization : 2010.May http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R18-en.pdf
581. Centers for Disease Control and Prevention (CDC) : Implementation of newborn hepatitis B vaccination: worldwide, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:1249-1252.
582. Saari T.N.: Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 2003; 112:193-198.
583. World Health Organization : Workers' health: global plan of action. In: Sixtieth World Health Assembly, 2007. May www.who.int/gb/ebwha/pdf_files/WHA60/A60_R26-en.pdf
584. World Health Organization : Vaccine-preventable diseases and vaccines. International Travel and Health, Geneva: World Health Organization; 2009:106-107.www.who.int/ith/ITH2009Chapter6.pdf
585. Fonseca M.O., Pang L.W., de Paula Cavalheiro N., et al: Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23:2902-2908.
586. Kaplan J.E., Benson C., Holmes K.H.Centers for Disease Control and Prevention: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58(RR-4):1-207.
587. Schroth R.J., Hitchon C.A., Uhanova J., et al: Hepatitis B vaccination for patients with chronic renal failure. Cochrane Database Syst Rev 2004.CD003775
588. Kong N.C., Beran J., Kee S.A., et al: A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008; 73:856-862.
589. Kundi M.: New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6:133-140.
590. Andre F.E., Zuckerman A.J.: Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994; 44:144-151.
591. Roumeliotou-Karayannis A., Papaevangelou G., Tassopoulos N., et al: Post-exposure active immunoprophylaxis of spouses of acute viral hepatitis B patients. Vaccine 1985; 3:31-34.

592. Papaevangelou G., Roumeliotou-Karayannis A., Richardson S.C., et al: Postexposure immunoprophylaxis of spouses of patients with acute viral hepatitis B. In: Zuckerman A., ed. Viral Hepatitis and Liver Disease, New York: Alan R. Liss; 1988:992-994.
593. Mitsui T., Iwano K., Suzuki S., et al: Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology 1989; 10:324-327.
594. Grady G.: Viral hepatitis: passive prophylaxis with globulins-state of the art in 1978. In: Vyas G., Cohen S.N., Schmid R., ed. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis, and Prevention, Philadelphia, PA: Franklin Institute Press; 1978:467-476.
595. Beasley R., Stevens C.E.: Vertical transmission of HBV and interruption with globulin. In: Vyas G., Cohen S.N., Schmid R., ed. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis, and Prevention, Philadelphia, PA: Franklin Institute Press; 1978:333-345.
596. Mast E.E., Weinbaum C.M., Fiore A.E., et al: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP): part 2: immunization of adults. MMWR Recomm Rep 2006; 55(RR-16):1-25.
597. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1997; 46(RR-18):1-42.
598. Recommendations of the International Task for Disease Eradication. MMWR Recomm Rep 1993; 42(RR-16):1-38.
599. Ghendon Y.: WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990; 8(suppl):S129-S133.discussion, S134-S138
600. Centers for Disease Control and Prevention : Global disease elimination and eradication as public health strategies. Proceedings of a conference. Atlanta, Georgia, USA. 23–25 February 1998. MMWR Morb Mortal Wkly Rep 1999; 48(suppl):1-208.
601. Centers for Disease Control and Prevention : Update: International Task Force for Disease Eradication, 1990 and 1991. MMWR Morb Mortal Wkly Rep 1992; 41(40–42):
602. Chen D.S.: Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50:805-816.
603. Van Damme P., Kane M., Meheus A.: Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ 1997; 314:1033-1036.
604. Van Damme P., Van Herck K., Leuridan E., et al: Introducting universal hepatitis B vaccination in Europe: differences still remain between countries. Euro Surveill 2004; 9:67-68.
605. Shepard C.W., Simard E.P., Finelli L., et al: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28:112-125.
606. Ni Y.H., Huang L.M., Chang M.H., et al: Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007; 132:1287-1293.
607. Chen H.L., Chang M.H., Ni Y.H., et al: Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276:906-908.
608. Chang M.H., Chen C.J., Lai M.S., et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855-1859.

609. Chang M.H., You S.L., Chen C.J., et al: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348-1355.
610. Whittle H., Jaffar S., Wansbrough M., et al: Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325:569.
611. Ng K.P., Saw T.L., Baki A., et al: Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 2005; 194:163-168.
612. Tsebe K.V., Burnett R.J., Hlungwani N.P., et al: The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001; 19:3919-3926.
613. Perz J.F., Elm Jr J.L., Fiore A.E., et al: Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination. Pediatrics 2006; 118:1403-1408.
614. McMahon B.J., Dentinger C.M., Bruden D., et al: Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-1396.
615. Piazza M., Da Villa G., Picciotto L., et al: Mass vaccination against hepatitis B in infants in Italy. Lancet 1988; 2:1132.
616. Zanetti A.R., Tanzi E., Romano L., et al: Vaccination against hepatitis B: the Italian strategy. Vaccine 1993; 11:521-524.
617. Bonanni P., Pesavento G., Bechini A., et al: Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21:685-691.
618. Mele A., Tosti M.E., Mariano A., et al: Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clin Infect Dis 2008; 46:868-875.
619. Romano L., Paladini S., Van Damme P., et al: The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011; 43(suppl 1):S2-S7.
620. Lee C.L., Ko Y.C.: Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997; 99:351-353.
621. Chen S.M., Kung C.M., Yang W.J., et al: Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. J Clin Virol 2011; 52:11-16.
622. Miller M.A., McCann L.: Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000; 9:19-35.
623. Beutels P., Edmunds W.J., Antonanzas F., et al: Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20:1-7.
624. Tu H.A., Woerdenbag H.J., Kane S., et al: Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines 2009; 8:907-920.
625. Kane M.A.: Status of hepatitis B immunization programmes in 1998. Vaccine 1998; 16(suppl):S104-S108.
626. World Health Organization : Expanded programme on immunization. Global Advisory Group: pt I. Wkly Epidemiol Rec 1992; 67:11-15.
627. Beeching N.J., Hepatitis B.: infections. BMJ 2004; 329:1059-1060.
628. Grundy G., Beeching N.: Understanding social stigma in women with hepatitis C. Nurs Stand 2004; 19:35-39.
629. Beeching N.J., Clarke P.D., Kitchin N.R., et al: Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 2004; 23:29-35.

630. Azam S.N., Beadsworth M.B., Jenkins N.E., et al: Adrenoleukodystrophy: a trap for the physician. Hosp Med 2004; 65:502-503.
631. Kolas A.: GAVI and hepatitis B immunisation in India. Glob Public Health 2011; 6:28-40.
632. Busteed S., Beeching N.J., Nye F.J., et al: Tuberculous osteomyelitis: chasing the elusive tubercle. Hosp Med 2004; 65:438-439.
633. Centers for Disease Control and Prevention : National, state, and local area vaccination coverage among children aged 19–35 months: United States. MMWR Morb Mortal Wkly Rep 2010; 59:1171-1177.
634. Mast E.E., Margolis H.S., Fiore A.E.Centers for Disease Control and Prevention: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54(RR-16):1-33.
635. Creati M., Saleh A., Ruff T.A., et al: Implementing the birth dose of hepatitis B vaccine in rural Indonesia. Vaccine 2007; 25:5985-5993.
636. Lawson L.L., Bailey J.W., Beeching N.J., et al: The stool examination reports amoeba cysts: should you treat in the face of over diagnosis and lack of specificity of light microscopy?. Trop Doct 2004; 34:28-30.
637. Harling R., Crook P., Lewthwaite P., et al: Burden and cost of imported infections admitted to infectious diseases units in England and Wales in 1998 and 1999. J Infect 2004; 48:139-144.
638. Kilvington S., Gray T., Dart J., et al: Acanthamoeba keratitis: the role of domestic tap water contamination in the United Kingdom. Invest Ophthalmol Vis Sci 2004; 45:165-169.
639. Houweling H., Spaendonck M.C., Paulussen T., et al: Preparing for the next public debate: Universal vaccination against hepatitis B. Vaccine 2011; 29:8960-8964.
640. Freedman LP, Graham WJ, Brazier E, et al. Practical lessons from global safe motherhood initiatives: time for a new focus on implementation. Lancet. 2007 Oct 13;370(9595):1383-91.
641. Rani M., Yang B., Nesbit R.: Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications. Bull World Health Organ 2009; 87:707-713.
642. Progress towards meeting the 2012 hepatitis B control milestone: Western Pacific Region. Wkly Epidemiol Rec 2011; 86(180–188):
643. United Nations. Report of the Secretary-General: prevention and control of non-communicable diseases. www.un.org/en/ga/president/65/issues/ncdiseases.shtml . Accessed 19 May 2011.
644. United Nations. UN General Assembly Political Declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS. Sixty-fifth session; Agenda item 10. http://daccess-dds-ny.un.org/doc/UNDOC/LTD/N11/367/84/PDF/N1136784.pdf?OpenElement . Accessed 8 June 2011.
645. Shi Z., Yang Y., Ma L., et al: Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010; 116:147-159.
646. Bzowej N.H., Hepatitis B.: therapy in pregnancy. Curr Hepat Rep 2010; 9:197-204.
647. Rottinghaus S.T., Poland G.A., Jacobson R.M., et al: Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003; 21:4604-4608.
648. Jacques P., Moens G., Desombere I., et al: The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20:3644-3649.

649. Cooper C., Mackie D.: Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 2011; 10:417-427.
650. Shapira M.Y., Zeira E., Adler R., et al: Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001; 34:123-127.
651. Michel M.L., Mancini-Bourgine M.: Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005; 34(suppl 1):S108-S114.
652. Streatfield S.J.: Oral hepatitis B vaccine candidates produced and delivered in plant material. Immunol Cell Biol 2005; 83:257-262.
653. Rajkannan R., Dhanaraju M.D., Gopinath D., et al: Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles. Vaccine 2006; 24:5149-5157.
654. Coffman R.L., Sher A., Seder R.A.: Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503.

OSPICE

1. Abu Becr M.: A Discourse on the Smallpox and Measles. [Mead R, English Trans.].London, J Brindley, 1748.
2. Black F.L.: Measles. In: Evans A.S., ed. Viral Infections of Humans: Epidemiology and Control, 3rd ed. New York: Plenum; 1989:451-465.
3. Wilson G.S.: Measles as a universal disease. Am J Dis Child 1962; 103:219-223.
4. Sydenham T.: The Works of Thomas Sydenham, vol. 2. London: Sydenham Society; 1922:250-251.
5. Enders J.F.: Francis Home and his experimental approach to medicine. Bull Hist Med 1964; 38:101-112.
6. Panum P.L.: Observation made during the epidemic of measles on the Faroe Islands in the year 1846. Med Classics 1939; 3:839-886.
7. Goldberger J., Anderson J.F.: An experimental demonstration of the presence of the virus of measles in the mixed buccal and nasal secretions. J Am Med Assoc 1911; 57:476-478.
8. Enders J.F., Peebles T.C.: Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954; 86:277-286.
9. Milovanovic M.V., Enders J.F., Mitus A.: Cultivation of measles virus in human amnion cells and developing chick embryo. Proc Soc Exp Biol Med 1957; 95:120-127.
10. Katz S.L., Milovanovic M.V., Enders J.F.: Propagation of measles virus in cultures of chick embryo cells. Proc Soc Exp Biol Med 1958; 97:23-29.
11. Katz S.L., Enders J.F.: Immunization of children with a live attenuated measles virus. Am J Dis Child 1959; 98:605-607.
12. Enders J.F., Katz S.L., Milovanovic M.V., et al: Studies on an attenuated measles-virus vaccine. I. Development and preparation of the vaccine: techniques for assay of effects of vaccination. N Engl J Med 1960; 263:153-159.
13. Katz S.L., Enders J.F., Holloway A.: Studies on an attenuated measles-virus vaccine. II. Clinical, virologic and immunologic effects of vaccine in institutionalized children. N Engl J Med 1960; 263:159-161.
14. Kempe C.H., Ott E.W., St Vincent L., et al: Studies on an attenuated measles-virus vaccine. III. Clinical and antigenic effects of vaccine in institutionalized children. N Engl J Med 1960; 263:162-165.
15. Black F.L., Sheridan S.R.: Studies on an attenuated measles-virus vaccine. IV. Administration of vaccine by several routes. N Engl J Med 1960; 263:165-169.
16. Lepow M.L., Gray N., Robbins F.C.: Studies on an attenuated measles-virus vaccine. V. Clinical, antigenic and prophylactic effects of vaccine in institutionalized and home-dwelling children. N Engl J Med 1960; 263:170-173.

17. Krugman S.L., Giles J.P., Jacobs A.M.: Studies on an attenuated measles-virus vaccine. VI. Clinical, antigenic and prophylactic effects of vaccine in institutionalized children. N Engl J Med 1960; 263:174-177.
18. Katz S.L., Kempe H.C., Black F.L., et al: Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccination. N Engl J Med 1960; 263:180-184.
19. Enders J.F.: Measles virus: historical review, isolation and behavior in various systems. Am J Dis Child 1962; 103:282-287.
20. Enders J.F., Katz S.L., Holloway A.: Development of attenuated measles-virus vaccines: a summary of recent investigation. Am J Dis Child 1962; 103:335-340.
21. Seminar on the Epidemiology and Prevention of Measles and Rubella. Arch Virusforsch 1965; 16:1-551.
22. Centers for Disease Control (CDC) : Goal to eliminate measles from the United States. MMWR Morb Mortal Wkly Rep 1978; 41:391.
23. Hinman A.R., Brandling-Bennett A.D., Nieberg P.I.: The opportunity and obligation to eliminate measles from the United States. JAMA 1979; 242:1157-1162.
24. Hinman A.R., Orenstein W.A., Bloch A.B., et al: Impact of measles in the United States. Rev Infect Dis 1983; 5:439-444.
25. Markowitz L.E., Preblud S.R., Orenstein W.A., et al: Patterns of transmission in measles outbreaks in the United States, 1985–1986. N Engl J Med 1989; 320:75-81.
26. Katz S.L., Hinman A.R.: Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis 2004; 189(Suppl. 1):S43-S47.
27. Centers for Disease Control and Prevention (CDC) : Measles: United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1348-1351.
28. King A., Varughese P., De Serres G., et al: Measles elimination in Canada. J Infect Dis 2004; 189(Suppl. 1):S236-S242.
29. de Quadros C.A., Izurieta H., Venczel L., et al: Measles eradication in the Americas: progress to date. J Infect Dis 2004; 189(Suppl. 1):S227-S235.
30. Strebel P.M., Henao-Restrepo A.M., Hoekstra E., et al: Global measles elimination efforts: the significance of measles elimination in the United States. J Infect Dis 2004; 189(Suppl. 1):S251-S257.
31. Rabo E., Taranger J.: Scandinavian model for eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1984; 289:1402-1404.
32. Bottiger M., Christenson B., Romanus V., et al: Swedish experience of two-dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1987; 295:1264-1267.
33. Peltola H., Kurki T., Virtanen M., et al: Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet 1986; 1:137-139.
34. Peltola H., Jokinen S., Paunio M., et al: Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008; 8:796-803.
35. Khalil M.K.M., Al Mazrou Y.Y., Al Howasi M.N., et al: Measles in Saudi Arabia: from control to elimination. Ann Saudi Med 2005; 25:324-328.
36. Chao M, An Z, Lixin H, et al. Progress towards measles elimination in the People's Republic of China: 2000–2009. J Infect Dis 204(Suppl. 1): S447–54.
37. van Druten J.A.M., de Boo T., Plantinga A.D.: Measles, mumps, and rubella control by vaccination. Dev Biol Stand 1986; 65:53-63.
38. Henderson R.H., Keja J., Hayden G., et al: Immunizing the children of the world: progress and prospects. Bull World Health Organ 1988; 66:535-543.
39. Cliff A., Haggett P., Smallman-Raynor M.: Measles: An Historical Geography of a Major Human Viral Disease. Cambridge, MA, Blackwell Scientific, 1993.

40. Hersh B.S., Tambina G., Nogueira C., et al: Review of regional measles surveillance data in the Americas, 1996-1999. Lancet 2000; 355:1943-1948.
41. Otten M., Kezaala R., Fall A., et al: Public health impact of accelerated measles control in the WHO African Region 2000-03. Lancet 2005; 366:832-839.
42. Hopkins D.R., Hinman A.R., Koplan J.P., et al: The case for global measles eradication. Lancet 1982; 1:1396-1398.
43. Hinman A.R., Bart K.J., Hopkins D.R.: Costs of not eradicating measles. Am J Public Health 1985; 75:713-715.
44. de Quadros C.A.: Global eradication of poliomyelitis and measles: another quiet revolution. Ann Intern Med 1997; 127:156-158.
45. Centers for Disease Control and Prevention (CDC) : Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR Recomm Rep 1997; 46(RR-11):1-20.
46. Orenstein W.A., Strebel P.M., Papania M., et al: Measles eradication: is it in our future?. Am J Public Health 2000; 90:1521-1525.
47. World Health Organization : Proceedings of the global technical consultation to assess the feasibility of measles eradication, 28-230 July 2010. J Infect Dis 2011; 204(Suppl. 1):4-13.
48. Lessler J., Brookmeyer R., Reich N.G., et al: Identifying the probable timing and setting of respiratory virus infections. Infect Control Hosp Epidemiol 2010; 31:809-815.
49. Robbins F.C.: Measles: clinical features. Pathogenesis, pathology, and complications. Am J Dis Child 1962; 103:266-273.
50. Katz S.L., Enders J.F., Holloway A.: Use of Edmonston attenuated measles strain: a summary of three years' experience. Am J Dis Child 1962; 103:340-344.
51. Kempe C.H., Fulginiti V.A.: The pathogenesis of measles virus infection. Arch Gesamte Virusforsch 1965; 16:103-128.
52. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises. Case 34-1988. Progressive pulmonary consolidations in a 10-year-old boy with Evans' syndrome. N Engl J Med 1988; 319:495-509.
53. Moss W.J., Griffin D.E.: Measles. Lancet 2012; 379:153-164.Epub August 18, 2011 .doi: 10.1016/S0140-6736(10)62352-5
54. Koplik H.: The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal mucous membrane. Arch Pediatr 1896; 13:918-922.
55. Gresser I., Chany C.: Isolation of measles virus from the washed leukocyte fraction of blood. Proc Soc Exp Biol Med 1963; 113:695-698.
56. Gresser I., Katz S.L.: Isolation of measles virus from urine. N Engl J Med 1960; 263:452-454.
57. Ruckle G.: Rogers KD. Studies with measles virus. II. Isolation of virus and immunologic studies in persons who have had natural disease. J Immunol 1957; 78:341-355.
58. Griffin D.E., Ward B.J., Jauregui E., et al: Immune activation in measles. N Engl J Med 1989; 320:1667-1672.
59. McChesney M.B., Oldstone B.A.: Virus-induced immunosuppression: infections with measles virus and human immunodeficiency virus. Adv Immunol 1989; 45:335-380.
60. Griffin D.E.: Immune responses during measles virus infection. Curr Top Microbiol Immunol 1995; 191:117-134.
61. Moss W.J., Polack F.P.: Immune responses to measles and measles vaccine: challenges for measles control. Viral Immunol 2001; 14:297-309.
62. Atabani S.F., Byrnes A.A., Jaye A., et al: Natural measles causes prolonged suppression of interleukin-12 production. J Infect Dis 2001; 184:1-9.
63. Okada H., Kobune F., Sato T.A., et al: Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch Virol 2000; 145:905-920.

64. Bech V.: Studies on the development of complement fixing antibodies in measles patients: observations during a measles epidemic in Greenland. J Immunol 1959; 83:267-275.
65. Stokes Jr. J., Reilly C.M., Buynak E.B., et al: Immunologic studies of measles. Am J Hyg 1961; 74:293-303.
66. Enders-Ruckle G.: Methods of determining immunity, duration, and character of immunity resulting from measles. Arch Gesamte Virusforsch 1965; 16:182-207.
67. Krugman S., Giles J.P., Friedman H., et al: Studies on immunity to measles. J Pediatr 1965; 66:471-488.
68. Norrby E., Gollmar Y.: Appearance and persistence of antibodies against different virus components of regular measles infections. Infect Immun 1972; 6:240-247.
69. Kibler R., ter Meulen V.: Antibody-mediated cytotoxicity after measles virus infection. J Immunol 1975; 114:93-98.
70. Bellanti J.A., Sanga R.L., Klutinis B., et al: Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines. N Engl J Med 1969; 280:628-633.
71. Polna I., Aleksandrowicz J., Krawczynski K., et al: Measles antibodies in nasal secretions and sera of children with measles. Acta Virol 1977; 21:331-337.
72. Friedman M., Hadari I., Goldstein V., et al: Virus-specific secretory IgA antibodies as a means of rapid diagnosis of measles and mumps infection. Isr J Med Sci 1983; 19:881-884.
73. Ruckdeschel J.C., Graziano K.D., Mardiney Jr M.R.: Additional evidence that the cell-associated system is the primary host defense against measles (rubeola). Cell Immunol 1975; 17:11-18.
74. Graziano K.D., Ruckdeschel J.C., Mardiney Jr M.R.: Cell-associated immunity to measles (rubeola): the demonstration of in vitro lymphocyte tritiated thymidine incorporation in response to measles complement fixation antigen. Cell Immunol 1975; 15:347-359.
75. Krause P.J., Cherry J.D., Naiditch M.J., et al: Revaccination of previous recipients of killed measles vaccine: clinical and immunologic studies. J Pediatr 1978; 93:565-571.
76. Krause P.J., Cherry J.D., Carney J.M., et al: Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories. Am J Dis Child 1980; 134:567-571.
77. Whittle H.C., Werblinska J.: Cellular cytotoxicity to measles virus during natural measles infection. Clin Exp Immunol 1980; 42:136-143.
78. Gallagher M.R., Welliver R., Yamanaka T., et al: Cell-mediated immune responsiveness to measles: its occurrence as a result of naturally acquired or vaccine-induced infection and in infants of immune mothers. Am J Dis Child 1981; 135:48-51.
79. Sissons J.G.P., Colby S.D., Harrison W.O., et al: Cytotoxic lymphocytes generated in vitro with acute measles virus infection. Clin Immunol Immunopathol 1985; 34:60-68.
80. Black F.L., Rosen L.: Patterns of measles antibodies in residents of Tahiti and their stability in the absence of re-exposure. J Immunol 1962; 88:725-731.
81. Krugman S., Katz S.L., Gershon A.A., et al: Measles. In: Krugman S., ed. Infectious Diseases of Children, 8th ed. St. Louis: CV Mosby; 1985:152-166.
82. Cherry J.D.: Measles. In: Feigen R.D., Cherry J.D., ed. Textbook of Pediatric Infectious Diseases, 2nd ed. Philadelphia: WB Saunders; 1987:1607-1628.
83. Hilleman M.R.: Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2002; 20:651-665.
84. Appelbaum E., Dolgopol V.B., Dolgin J.: Measles encephalitis. Am J Dis Child 1949; 77:25-48.
85. Christensen P.E., Schmidt H., Bang H.O., et al: An epidemic of measles in southern Greenland, 1951. Measles in virgin soil. II. The epidemic proper. Acta Med Scand 1953; 144:430-449.

86. Peart A.FW., Nagler F.P.: Measles in the Canadian Arctic, 1952. Can J Public Health 1954; 45:146-156.
87. Miller H.G., Stanton J.B., Gibbons J.L.: Para-infectious encephalomyelitis and related syndromes: a critical review of the neurologic complications of certain specific fevers. Q J Med 1956; 25:247-505.
88. Miller D.L.: Frequency of complication of measles, 1963: report on a national inquiry by the Public Health Laboratory Service in collaboration with the Society of Medical Officers of Health. Br Med J 1964; 2:75-78.
89. Bech V.: The measles epidemic in Greenland in 1962. Arch Gesamte Virusforsch 1965; 16:53-56.
90. Littauer J., Sorensen K.: The measles epidemic at Umanak in Greenland in 1962. Dan Med J 1965; 12:43-50.
91. McLean D.M., Best J.M., Smith P.A., et al: Viral infections of Toronto children during 1965. II. Measles encephalitis and other complications. Can Med Assoc J 1966; 94:906-910.
92. Barkin R.M.: Measles mortality: a retrospective look at the vaccine era. Am J Epidemiol 1975; 102:341-349.
93. Barkin R.M.: Measles mortality: analysis of the primary cause of death. JAMA 1975; 129:307-309.
94. Modlin J.F., Jabbour J.T., Witte J.J., et al: Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics 1977; 59:505-512.
95. Modlin J.F., Halsey N.A., Eddins D.L., et al: Epidemiology of subacute sclerosing panencephalitis. J Pediatr 1979; 94:231-236.
96. Becroft D.M.O., Osborne D.R.S.: The lungs in fatal measles infection in childhood: pathological, radiological and immunological correlations. Histopathology 1980; 4:401-412.
97. Englehandt S.F., Halsey N.A., Eddins D.L., et al: Measles mortality in the United States 1971-1975. Am J Public Health 1980; 70:1166-1169.
98. Johnson R.T., Griffin D.E., Hirsch R.L., et al: Measles encephalomyelitis-clinical and immunologic studies. N Engl J Med 1984; 310:137-141.
99. Centers for Disease Control (CDC) : Subacute sclerosing panencephalitis surveillance: United States. MMWR Morb Mortal Wkly Rep 1982; 31:585-588.
100. Atkinson W.L., Markowitz L.E.: Measles and measles vaccine. Semin Pediatr Infect Dis 1991; 2:100-107.
101. Greenberg B.L., Sack R.B., Salazar-Lindo E., et al: Measles associated diarrhea in hospitalized children in Lima, Peru: pathogenic agents and impact on growth. J Infect Dis 1991; 164:495-502.
102. Perry R.T., Halsey N.A.: The clinical significance of measles. J Infect Dis 2004; 189(Suppl. 1):S4-16.
103. von Pirquet C.E.: Das Verhalten der kutanen Tuberkulinreaktion wahrend der Masern. Dtsch Med Wochenschr 1908; 34:1297-1300.
104. Flick J.A.: Does measles really predispose to tuberculosis?. Am Rev Respir Dis 1976; 114:257-265.
105. Morley D., Woodland M., Martin W.J.: Measles in Nigerian children: a study of the disease in West Africa, and its manifestations in England and other countries during difficult epochs. J Hyg (Camb) 1963; 61:115-134.
106. Morley D.: Severe measles in the tropics. Br Med J 1969; 1:297-300.363–5
107. Scheifele D.W., Forbes C.E.: The biology of measles in African children. East Afr Med J 1973; 50:169-173.
108. Assaad F.: Measles: summary of worldwide impact. Rev Infect Dis 1983; 5:452-459.
109. Borgono J.M.: Current impact of measles in Latin America. Rev Infect Dis 1983; 5:417-421.

110. Hull H.F., Williams P.J., Oldfield F.: Measles mortality and vaccine efficacy in rural West Africa. Lancet 1983; 1:972-975.
111. Loening U.E., Coovadia H.M.: Age-specific occurrence rates of measles in urban, periurban, and rural environments and implication for time of vaccination. Lancet 1983; 2:324-326.
112. Nieberg P., Dibley M.J.: Risk factors for fatal measles infections. Int J Epidemiol 1986; 15:309-311.
113. Porter J.D.H., Gastellu-Etchegorry M., Navarre I., et al: Measles outbreaks in the Mozambican refugee camps in Malawi: the continued need for an effective vaccine. Int J Epidemiol 1989; 19:1072-1077.
114. Narain J.P., Khare S., Rana S.R.S., et al: Epidemic measles in an isolated unvaccinated population, India. Int J Epidemiol 1989; 18:952-958.
115. The Kasongo Project Team : Influence of measles vaccination on survival pattern of 7-35-month-old children in Kasongo, Zaire. Lancet 1981; 1:764-767.
116. Foster S.O., McFarland D.A., John M.A.: Health sector priorities review, measles. In: Jamison D.T., Mosley W.H., ed. Evolving Health Sector Priorities in Developing Countries, Washington, DC: The World Bank; 1993:161-183.
117. Singh J., Sharma R.S., Verghese T.: Measles mortality in India: a review of community-based studies. J Commun Dis 1994; 26:203-214.
118. Mgone J.M., Mgone C.S., Duke T., et al: Control measures and the outcome of the measles epidemic of 1999 in the Eastern Highlands Province. P N G Med J 2000; 43:91-97.
119. Nandy R., Handzel T., Zaneidou , et al: Case-fatality rate during a measles outbreak in Niger in 2003. Clin Infect Dis 2006; 42:322-328.
120. Hussey G.D., Clements C.J.: Clinical problems in measles case management. Ann Trop Paediatr 1996; 16:307-317.
121. Markowitz L.E., Neiburg P.: The burden of acute respiratory infection due to measles in developing countries and the potential impact of measles vaccine. Rev Infect Dis 1991; 13(Suppl. 6):S555-S561.
122. Koster F., Curlin G., Aziz K.M.A., et al: Synergistic impact of measles and diarrheoa in nutrition and mortality in Bangladesh. Bull World Health Organ 1981; 59:901-908.
123. Sarker S.A., Wahed M.A., Rahaman M.M., et al: Persistent protein losing enteropathy in post measles diarrhea. Arch Dis Child 1986; 61:739-743.
124. Expanded Programme on Immunisation, Programme for the Prevention of Blindness Nutrition : Joint WHO/UNICEF statement on vitamin A for measles. Wkly Epidemiol Rec 1987; 62:133-134.
125. Gilbert C.E., Wood M., Waddel K., et al: Causes of childhood blindness in east Africa: results in 491 pupils attending 17 schools for the blind in Malawi, Kenya, and Uganda. Ophthalmic Epidemiol 1995; 2:77-84.
126. Foster A., Sommer A.: Corneal ulceration, measles, and childhood blindness in Tanzania. Br J Ophthalmol 1987; 71:331-343.
127. Gershon A.A., Krugman S.: Measles Virus. In: Lennette E.H., Schmidt N.S., ed. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 5th ed. Washington, DC: American Public Health Association; 1979:665-669.
128. Rima B.K.: The pathogenesis of subacute sclerosing panencephalitis. Rev Med Virol 1994; 4:81-90.
129. Jin L., Beard S., Hunjan R., et al: Characterization of measles virus strains causing SSPE: a study of 11 cases. J Neurovirol 2002; 8:335-344.
130. Bellini W.J., Rota J.S., Lowe L.E., et al: Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686-1693.

131. Dyken P.R.: Neuroprogressive disease of post-infectious origin: a review of a resurging subacute sclerosing panencephalitis (SSPE). Ment Retard Dev Disabil Res Rev 2001; 7:217-225.
132. Horta-Barbosa L., Fuccillo D.A., Sever J., et al: Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy. Nature 1969; 221:974.
133. Halsey N.A., Modlin J.F., Jabbour J.T., et al: Risk factors in subacute sclerosing panencephalitis: a case control study. Am J Epidemiol 1980; 3:415-420.
134. Billeter M.A., Cattaneo R., Spielhofer P., et al: Generation and properties of measles virus mutations typically associated with subacute sclerosing panencephalitis. Ann N Y Acad Sci 1994; 724:367-377.
135. Ebkom A., Wakefield A.J., Zack M., et al: Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344:508-510.
136. Wakefield A.J., Ekbom A., Dhillon A.P., et al: Crohn's disease: pathogenesis and persistent measles virus infection. Gastroenterology 1995; 108:991-996.
137. Thompson N.P., Montgomery S.M., Pounder R.E., et al: Is measles vaccination a risk factor for inflammatory bowel disease?. Lancet 1995; 345:1071-1074.
138. Wakefield A.J., Montgomery S.M.: Measles virus a risk factor for inflammatory bowel disease: an unusually tolerant approach. Am J Gastroenterol 2000; 95:1389-1392.
139. Uhlmann V., Martin C.M., Sheils O., et al: Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002; 55:84-90.
140. Iizuka M., Nakagomi O., Chiba M., et al: Absence of measles virus in Crohn's disease [letter]. Lancet 1995; 345:199.
141. Afzal M.A., Armitage E., Ghosh S., et al: Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. J Med Virol 2000; 62:377-382.
142. Feeney M., Clegg A., Winwood P., et al: A case-control study of measles vaccination and inflammatory bowel disease. Lancet 1997; 350:764-766.
143. Davis R.L., Kramarz P., Bohlke K., et al: Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease. Arch Pediatr Adolesc Med 2001; 155:354-359.
144. Taylor B., Miller E., Lingam R., et al: Measles, mumps, rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324:393-396.
145. Madsen K.M., Hviid A., Vestergaard M., et al: A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347:1477-1482.
146. Straton K., Gable A., Shetty P., et al: Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC, National Academy Press, 2001.
147. Editors of The Lancet : Retraction: ileal lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010; 375:445.
148. Deer B.: How the case against the MMR vaccine was fixed. BMJ 2011; 342:77-82.
149. Niedermeyer H.P., Arnold W., Neubert W.J., et al: Persistent measles virus infection as a possible cause of otosclerosis: state of the art. Ear Nose Throat J 2000; 79:552-554.556, 558 passim
150. Reddy S.V., Menaa C., Singer F.R., et al: Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Exp Hematol 1999; 27:1528-1532.
151. Ohara Y.: Multiple sclerosis and measles virus. Jpn J Infect Dis 1999; 52:198-200.
152. Atmar R.L., Englund J.A., Hammill H.: Complications of measles in pregnancy. Clin Infect Dis 1992; 14:217-226.

153. Eberhart-Phillips J.E., Frederick P.D., Baron R.C., et al: Measles in pregnancy: a descriptive study of 58 cases. Obstet Gynecol 1993; 82:797-801.
154. Siegel M.: Congenital malformations following chickenpox, measles, mumps, and hepatitis: results of a cohort study. JAMA 1973; 226:1521-1524.
155. Jesperson C.S., Littover J., Saglid V.: Measles as a cause of fetal defects: a retrospective study of ten measles epidemics in Greenland. Acta Paediatr Scand 1977; 66:367-376.
156. Siegel M., Fuerst H.T., Peress N.S.: Comparative fetal mortality in maternal virus diseases: a prospective study on rubella, measles, mumps, chicken pox, and hepatitis. N Engl J Med 1966; 274:768-771.
157. Stokes Jr J., Maris E.P., Gellis S.S.: Chemical, clinical and immunologic studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prevention and attenuation of measles. J Clin Invest 1944; 23:531-540.
158. Janeway C.A.: Use of concentrated human serum γ-globulin in the prevention and attenuation of measles. Bull N Y Acad Med 1945; 21:202-222.
159. Brody J.A., Bridenbraugh E.: Prophylactic γ-globulin and live measles vaccine in an island epidemic of measles. Lancet 1964; 2:811-813.
160. Stiehm E.R.: Standard and special human immune serum globulins as therapeutic agents. Pediatrics 1979; 63:301-319.
161. Krugman S., Giles J.P., Jacobs A.M., et al: Studies with live attenuated measles-virus vaccine. Am J Dis Child 1962; 103:353-363.
162. Karlitz S., Markham F.S.: Immunity after modified measles. Am J Dis Child 1962; 103:682-687.
163. Linnemann Jr C.C.: Measles vaccine: immunity, reinfection, and revaccination. Am J Epidemiol 1973; 97:365-371.
164. Schaffner W., Schluederberg A.ES., Byrne E.B.: Clinical epidemiology of sporadic measles in a highly immunized population. N Engl J Med 1968; 279:783-789.
165. Cherry J.D., Feigen R.D., Lobes Jr J.A., et al: Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study. J Pediatr 1972; 81:217-230.
166. Linnemann C.C., Hegg M.E., Rotte T.C., et al: Measles IgM response during reinfection of previously vaccinated children. J Pediatr 1973; 82:798-801.
167. Schluederberg A., Lamm S.H., Landrigan P.J., et al: Measles immunity in children vaccinated before one year of age. Am J Epidemiol 1973; 97:402-409.
168. Smith F.R., Curran A.S., Raciti A., et al: Reported measles in persons immunologically primed by prior vaccination. J Pediatr 1982; 101:391-393.
169. Nagy G., Kosa S., Takatsy S., et al: The use of IgM tests for analysis of the causes of measles vaccine failures: experience gained in an epidemic in Hungary in 1980 and 1981. J Med Virol 1984; 13:93-103.
170. Mathias R., Meekison J., Arcand T., et al: The role of secondary vaccine failures in measles outbreaks. Am J Public Health 1989; 79:475-478.
171. Edmonson M.B., Addiss D.G., McPherson J.T., et al: Mild measles and secondary vaccine failure during sustained outbreak in a highly vaccinated population. JAMA 1990; 263:2467-2471.
172. Reyes M.A., Franky De Borrero M., Roa J., et al: Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 1987; 6:848-851.
173. Dai B., Chen Z.H., Liu Q.C., et al: Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull World Health Organ 1991; 69:415-423.

174. Ishiwada N., Addae M.M., Tetteh J.K., et al: Vaccine-modified measles in previously immunized children in Accra, Ghana: clinical, virological and serological parameters. Trop Med Int Health 2001; 6:694-698.
175. Mitus A., Enders J.F., Craig J.M., et al: Persistence of measles virus and depression of antibody formation in patients with giant cell pneumonia after measles. N Engl J Med 1959; 261:882-889.
176. Mitus A., Enders J.F., Edsall G., et al: Measles in children with malignancy: problems and prevention. Arch Gesamte Virusforsch 1965; 16:331-337.
177. Siegel M.M., Walter T.K., Ablin A.R.: Measles pneumonia in childhood leukemia. Pediatrics 1977; 60:38-40.
178. Krasinski K., Borkowsky W.: Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989; 261:2512-2516.
179. Gray M.M., Hann I.M., Glass S., et al: Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective review. Br Med J (Clin Res Ed) 1987; 295:19-22.
180. Kaplan L.J., Daum R.S., Smaron M., et al: Severe measles in immunocompromised patients. JAMA 1992; 267:1237-1241.
181. Markowitz L.E., Chandler F.W., Roldan E.O., et al: Fatal measles pneumonia without rash in a child with AIDS. J Infect Dis 1988; 158:480-483.
182. Nahmias A.J., Griffith D., Salsbury C., et al: Thymic aplasia and lymphopenia, plasma cells and normal immunoglobulins: relation to measles virus infection. JAMA 1967; 201:729-734.
183. Good R.A., Zak S.J.: Disturbances in gamma globulin synthesis as ‘experiments of nature’. Pediatrics 1956; 18:109-149.
184. Burnet F.M.: Measles as an index of immunological function. Lancet 1968; 2:610-613.
185. Coovadia H.M., Brain P., Hallett A.F., et al: Immunoparesis and outcome in measles. Lancet 1977; 1:619-621.
186. Aicardi J., Goutiere S.F., Arsenio-Nunes M.L., et al: Acute measles encephalitis in children with immunosuppression. Pediatrics 1977; 59:232-239.
187. Roos R.P., Graves M.C., Wollmann R.L., et al: Immunologic and virologic studies of measles inclusion body encephalitis: the relationship to subacute sclerosing panencephalitis. Neurology 1981; 31:1263-1270.
188. Enders J.F., McCarthy K., Mitus A., et al: Isolation of measles virus at autopsy in cases of giant-cell pneumonia without rash. N Engl J Med 1959; 261:875-881.
189. Palumbo P., Hoyt L., Demasio K., et al: Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11:1008-1014.
190. Rauh L.W., Schmidt R.: Measles immunization with killed virus vaccine: serum antibody titers and experience with exposure to measles epidemic. Am J Dis Child 1965; 109:232-237.
191. Fulginiti V.A., Eller J.J., Downie A.W., et al: Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967; 202:1075-1080.
192. Nader P.R., Horowitz M.S., Rousseau J.: Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J Pediatr 1968; 72:22-28.
193. Gokiert J.G., Beamish W.E.: Altered reactivity to measles virus in previously vaccinated children. Can Med Assoc J 1970; 103:724-727.
194. Buser F., Montagnon B.: Severe illness in children exposed to natural measles after prior vaccination against the disease. Scand J Infect Dis 1970; 2:157-160.

195. O'Neil A.E.: The measles epidemic in Calgary 1969-1970: the protective effect of vaccination for the individual and the community. Can Med Assoc J 1971; 105:819-825.
196. Welliver R.C., Cherry J.D., Holtzman A.E.: Typical, modified, and atypical measles: an emerging problem in the adolescent and adult. Arch Intern Med 1977; 137:39-41.
197. Weiner L.B., Corwin R.M., Nieberg P.I., et al: A measles outbreak among adolescents. J Pediatr 1977; 90:17-20.
198. Chatterji M., Mankad V.: Failure of attenuated viral vaccine in prevention of atypical measles. JAMA 1977; 238:2635.
199. Hall W.W., Breese Hall C.: Atypical measles in adolescents: evaluation of clinical and pulmonary function. Ann Intern Med 1979; 90:882-886.
200. Martin D.B., Weiner L.B., Nieberg P.I., et al: Atypical measles in adolescents and young adults. Ann Intern Med 1979; 90:877-881.
201. Fulginiti V.A., Helfer R.E.: Atypical measles in adolescent siblings 16 years after killed measles virus vaccine. JAMA 1980; 244:804-806.
202. Annuziato D., Kaplan M.H., Hull W.W., et al: Atypical measles syndrome: pathologic and serologic findings. Pediatrics 1982; 70:203-209.
203. Griffin D.: Measles virus. In: Knipe D.M., Howley P.M., ed. Fields Virology, 4th ed. Philadelphia: Lippincott–Raven; 2001:1401-1441.
204. Lennon R.G., Isacson P., Rosales T., et al: Skin tests with measles and poliomyelitis vaccines in recipients of inactivated measles virus vaccine. JAMA 1967; 200:275-280.
205. Polack F.P., Auwerter P.G., Lee S.H., et al: Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 1999; 5:629-634.
206. Polack F.P., Hoffman S.J., Crujeiras G., et al: A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003; 9:1209-1213.
207. Laptook A., Wind A., Nussbaum M., et al: Pulmonary lesions in atypical measles. Pediatrics 1978; 62:42-46.
208. Centers for Disease Control (CDC) : Death from measles, possibly atypical: Michigan. MMWR Morb Mortal Wkly Rep 1979; 28:298-299.
209. Cherry J.D., Feigen R.D., Lobes L.A., et al: Atypical measles in children previously immunized with attenuated measles virus vaccines. Pediatrics 1972; 50:712-717.
210. St. Geme Jr J.W., Bush B.M., George B.L.: Exaggerated natural measles following attenuated virus immunization: a refraction-toxic shock syndrome [letter]. Pediatrics 1981; 67:942.
211. American Academy of Pediatrics : Measles. In: Pickering L.K., ed. 2009 Red Book: Report of the Committee on Infectious Diseases, . Elk Grove Village, IL: American Academy of Pediatrics; 2009:444-455.28th ed
212. Centers for Disease Control and Prevention (CDC) : Recommendations of the Advisory Committee on Immunization Practices (ACIP): measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. MMWR Recomm Rep 1998; 47(RR-8):1-57.
213. Waterson A.P.: Measles virus. Arch Gesamte Virusforsch 1965; 16:57-80.
214. Bostock C.J., Barrett T., Crowther J.R.: Characterization of the European seal morbillivirus. Vet Microbiol 1990; 23:351-360.
215. Imagawa D.T.: Relationships among measles, canine distemper, and rinderpest viruses. Prog Med Virol 1968; 10:160-193.
216. Furuse Y., Suzuki A., Oshitani H.: Origin of measles virus: divergence from rinderpest virus between the 11th and 12th centuries. Virol J 2010; 7:52.

217. Dhiman N., Jacobson R.M., Poland G.A.: measles virus receptors: SLAM and CD46. Rev Med Virol 2004; 14:217-229.
218. Watanabe A., Yoneda M., Ikeda F., et al: CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J Virol 2010; 84:4183-4193.
219. Crowley J.C., Dowling P.C., Menonna J., et al: Sequence variability and function of measles virus 3′ and 5′ ends and intercistronic regions. Virology 1988; 164:498-506.
220. Parks C.L., Lerch R.A., Walpita P., et al: Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage. J Virol 2001; 75:921-933.
221. Parks C.L., Lerch R.A., Walpita P., et al: Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol 2001; 75:910-920.
222. Takeda M., Kato A., Kobune F., et al: Measles virus attenuation associated with transcriptional impediment and a few amino acid changes in the polymerase and accessory proteins. J Virol 1998; 72:8690-8696.
223. Takeuchi K., Miyajima N., Kobune F., et al: Comparative nucleotide sequence analyses of the entire genomes of B95a cell-isolated and Vero cell-isolated measles viruses from the same patient. Virus Genes 2000; 20:253-257.
224. Baricevic M., Forcic D., Santak M., et al: A comparison of complete untranslated regions of measles virus genomes derived from wild-type viruses and SSPE brain tissues. Virus Genes 2007; 35:17-27.
225. Giraudon P., Jacquier M.F., Wild T.F.: Antigenic analysis of African measles virus field isolates: identification and localization of one conserved and two variable epitope sites on the NP protein. Virus Res 1988; 10:137-152.
226. Baczko D., Brinckmann U., Padowitz I., et al: Nucleotide sequence of the genes encoding the matrix protein of two wild-type measles virus strains. J Gen Virol 1991; 72:2279-2282.
227. Taylor M.J., Godfrey E., Baczko K., et al: Identification of several different lineages of measles virus. J Gen Virol 1991; 72:83-88.
228. Rota J.S., Hummel K.B., Rota P.A., et al: Genetic variability of the glycoprotein genes of current wildtype measles isolates. J Virol 1992; 188:135-142.
229. Rota P.A., Bloom A.E., Vanchiere J.A., et al: Evolution of the nucleoprotein and matrix genes of wild-type strains of measles virus isolated from recent epidemics. Virology 1994; 198:724-730.
230. Rota J.S., Wang Z.D., Rota P.A., et al: Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 1994; 31:317-330.
231. Mulders M.N., Truong A.T., Muller C.P.: Monitoring of measles elimination using molecular epidemiology. Vaccine 2001; 19:2245-2249.
232. Rota J.S., Bellini W.J., Rota P.A.: Measles. In: Thompson R.C.A., ed. Molecular Epidemiology of Infectious Diseases, London: Kluwer Academic & Lippincott-Raven; 2000:168-180.
233. Rota J.S., Heath J.L., Rota P.A., et al: Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J Infect Dis 1996; 173:32-37.
234. Rota P.A., Rota J.S., Redd S.B., et al: Genetic analysis of measles viruses isolated in the United States between 1989 and 2001: absence of an endemic genotype since 1994. J Infect Dis 2004; 189(Suppl. 1):S160-S164.
235. World Health Organization : Standardization of the nomenclature for describing the genetic characteristics of wild-type measles viruses. Wkly Epidemiol Rec 1998; 73:265-272.
236. World Health Organization : Measles virus nomenclature update: 2012. Wkly Epidemiol Rec 2012; 87:73-80.

237. Featherstone D.A., Brown D.W.G., Sanders R.: Development of the global measles laboratory network. J Infect Dis 2003; 187:S264-S269.
238. Rota P.A., Brown K., Mankertz A., et al: Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis 2011; 204(Suppl. 1):S514-S523.
239. Ono N., Tatsuo H., Hidaka Y., et al: Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 2001; 75:4399-4401.
240. Kouomou D.W., Wild T.F.: Adaptation of wild-type measles virus to tissue culture. J Virol 2002; 76:1505-1509.
241. Enders J.F., Katz S.L., Grogran E.: Markers for Edmonston measles virus. Am J Dis Child 1962; 103:473-474.
242. McCarthy K.: Measles in laboratory hosts and tissue culture systems. Am J Dis Child 1962; 103:314-319.
243. Suringa D.W.R., Bank L.J., Ackerman A.B.: Role of measles virus in skin lesions and Koplik's spots. N Engl J Med 1970; 283:1139-1142.
244. Buynak E.B., Peck J.M., Creamer A.A., et al: Differentiation of virulent from avirulent measles strains. Am J Dis Child 1962; 103:460-473.
245. DeMaeyer E., Enders J.F.: Growth characteristics, interferon production and plaque formation with different lines of Edmonston measles virus. Arch Gesamte Virusforsch 1965; 16:151-160.
246. Katz S.L.: Immunization with live attenuated measles virus vaccines: five years' experience. Arch Virusforsch 1965; 16:222-230.
247. Papp K.: Experiences prouvant que la voie d'infection de la rougeole est la contamination de la muqueuse conjunctival. Rev Immunol Ther Antimicrob 1956; 20:27-36.
248. Fenner F.: The pathogenesis of the acute exanthems. Lancet 1948; 2:915-920.
249. Moench T.R., Griffin D.E., Obriecht C.R., et al: Acute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA. J Infect Dis 1988; 158:433-442.
250. Lemon K., de Vries R.D., Mesman A.W., et al: 2011 Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog 2011; 7:e1001263.
251. Ogra P.L., Fishaut M., Gallagher M.R.: Viral vaccination via mucosal routes. Rev Infect Dis 1980; 2:352-369.
252. Thomas H.I., Barret E., Hesketh L.M., et al: Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19, rubella infection. J Clin Virol 1999; 14:107-118.
253. Oliveira M.I., Curti S.P., Figueiredo C.A., et al: Rash after measles vaccination: laboratory analysis of cases reported in Saõ Paulo, Brazil. Rev Saude Publica 2002; 36:155-159.
254. Ramsay M., Reacher M., O'Flynn C., et al: Causes of morbilliform rash in a highly immunized English population. Arch Dis Child 2002; 87:202-206.
255. Llanes-Rodas R., Liu C.: Rapid diagnosis of measles from urinary sediments stained with fluorescent antibody. N Engl J Med 1966; 275:515-523.
256. Lightwood R., Nolan R., Franco M., et al: Epithelial giant cells in measles as an aid in diagnosis. J Pediatr 1970; 77:59-64.
257. Fulton R.E., Middleton P.J.: Immunofluorescence in diagnosis of measles infection in children. J Pediatr 1975; 86:17-22.
258. Olding-Stenkvist E., Bjorvatn B.: Rapid detection of measles virus in skin rashes by immunofluorescence. J Infect Dis 1976; 134:463-469.

259. Nommensen F.E., Dekkers N.W.: Detection of measles antigen in conjunctival epithelial lesions staining by lissamine green during measles virus infection. J Med Virol 1981; 7:157-162.
260. Boyd J.F.: A fourteen year study to identify measles antigen in urine specimens by fluorescent-antibody methods. J Infect 1983; 6:163-170.
261. Jin L., Richards A., Brown D.W.: Development of a dual target-PCR for detection and characterization of measles virus in clinical specimens. Mol Cell Probes 1996; 10:191-200.
262. Rota P.A., Khan A.S., Durigon E., et al: Detection of measles virus RNA in urine specimens from vaccine recipients. J Clin Microbiol 1995; 33:2485-2488.
263. Riddell M.A., Chibo D., Kelly H.A., et al: Investigation of optimal specimen type and sampling time for detection of measles virus RNA during a measles epidemic. J Clin Microbiol 2001; 39:375-376.
264. Ramsay M., Brugha R., Brown D.: Surveillance of measles in England and Wales: implications of a national saliva testing programme. Bull World Health Organ 1997; 75:515-521.
265. Wassilak S.GF., Bernier R.H., Herrmann K.L., et al: Measles seroconfirmation using dried capillary blood specimens in filter paper. Pediatr Infect Dis 1984; 3:117-121.
266. Krugman S., Giles J.P., Jacobs A.M., et al: Studies with a further attenuated live measles-virus vaccine. Pediatrics 1963; 31:919-928.
267. Krugman S.: Present status of measles and rubella immunization in the United States: a medical progress report. J Pediatr 1977; 90:1-12.
268. Krugman S.: Further-attenuated measles vaccine: characteristics and use. Rev Infect Dis 1983; 5:477-481.
269. Schluederberg A.: Immune globulins in human viral infections. Nature 1965; 205:1232-1233.
270. Heffner Jr R.R., Schluederberg A.: Specificity of the primary and secondary antibody responses to myxoviruses. J Immunol 1967; 98:668-672.
271. Polna I., Aleksandrowicz J., Roszkowska K.: Localization of measles antibody and inhibitor activity in fractions of human sera at different stages of the disease, and sera of animals immunized with measles virus. I. Dynamics of increase in measles antibody activity and its localization in children sera after natural infection. Acta Microbiol Pol A 1973; 5:131-138.
272. Aleksandrowicz J., Polna I.: Sadowski W. II. Primary and secondary immunological response of experimental animals to attenuated and nonattenuated measles virus. Acta Microbiol Pol A 1973; 5:139-145.
273. Friedman M.G., Philip M., Dagan R.: Virus-specific IgA in serum, saliva, and tears of children with measles. Clin Exp Immunol 1989; 75:58-64.
274. Erdman D.D., Anderson L.J., Adams D.R., et al: Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus. J Clin Microbiol 1991; 29:1466-1471.
275. Erdman D.D., Heath J.L., Watson J.C., et al: Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection. J Med Virol 1993; 41:44-48.
276. Cutchins E.C.: A comparison of the hemagglutination-inhibition, neutralization and complement fixation tests in the assay of antibody to measles. J Immunol 1962; 88:788-795.
277. Albrecht P., Herrmann K., Burns G.R.: Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3:251-260.
278. Roesing T.G., Meeker J., Garfinkle B., et al: Determination of antibody to measles virus by a fluoroimmunoassay (FIAX). J Biol Stand 1981; 9:401-407.

279. Forghani B., Schmidt N.J.: Antigen requirements, sensitivity, and specificity of enzyme immunoassays for measles and rubella viral antibodies. J Clin Microbiol 1979; 9:657-664.
280. Kleiman M.B., Blackburn C.KL., Zimmerman S.E., et al: Comparison of enzyme-linked immunosorbent assay for acute measles with hemagglutination inhibition, complement fixation, and fluorescent-antibody methods. J Clin Microbiol 1981; 14:147-152.
281. Neumann P.W., Weber J.M., Jessamine A.G., et al: Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol 1985; 22:296-298.
282. Weigle K.A., Murphy M.D., Brunell P.A.: Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. J Clin Microbiol 1984; 19:376-379.
283. Hummel K.B., Erdman D.D., Heath J., et al: Baculovirus expression of the nucleoprotein gene of measles virus and the utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol 1992; 30:2874-2880.
284. Rossier E., Miller H., McCulloch B., et al: Comparison of immunofluorescence and enzyme immunoassay for detection of measles-specific immunoglobulin M antibody. J Clin Microbiol 1991; 29:1069-1071.
285. Mayo D.R., Brennan T., Cormier D.P., et al: Evaluation of a commercial measles virus immunoglobulin M enzyme immunoassay. J Clin Microbiol 1991; 29:2865-2867.
286. Black F.L.: Measles active and passive immunity in a worldwide perspective. Prog Med Virol 1989; 36:1-33.
287. Ratnam S., Gadag V., West R., et al: Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995; 33:811-815.
288. Bellini W.J., Helfand R.F.: Current challenges in the laboratory diagnosis of measles infections. J Infect Dis 2003; 187(Suppl. 1):S283-S290.
289. Ratnam S., Tipples G., Head C., et al: Performance of indirect immunoglobulin M (IgM) serology tests and IgM capture assays for laboratory diagnosis of measles. J Clin Microbiol 2000; 38:99-104.
290. Jenkerson S.A., Beller M., Middaugh J.P., et al: False positive rubeola IgM tests. N Engl J Med 1995; 332:1103-1104.
291. Helfand R.F., Heath J.L., Anderson L.J., et al: Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset. J Infect Dis 1997; 175:195-199.
292. Brown D.W., Ramsay M.E., Richards A.F., et al: Salivary diagnosis of measles: a study of notified cases in the United Kingdom, 1991–1993. BMJ 1994; 308:1015-1017.
293. Samuel D., Sasnauskas K., Jin L., et al: Development of a measles specific IgM ELISA for use with serum and oral fluid samples using recombinant measles nucleoprotein produced in Saccharomyces cerevisiae. J Clin Virol 2003; 28:121-129.
294. Condorelli F., Scalia G., Stivala A., et al: Detection of immunoglobulin G to measles virus, rubella virus, and mumps virus in serum samples and in microquantities of whole blood dried on filter paper. J Virol Methods 1994; 49:25-36.
295. Helfand R.F., Keyserling H.L., Williams I., et al: Comparative detection of measles and rubella IgM and IgG derived from filter paper blood and serum samples. J Med Virol 2001; 65:751-757.
296. De Swart R.L., Nur Y., Abdallah A., et al: Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnosis and epidemiological studies of measles. J Clin Microbiol 2001; 39:270-273.

297. Mercader S., Featherstone D., Bellini W.J.: Comparison of available methods to elute serum from dried blood spot samples for measles serology. J Virol Methods 2006; 137:140-149.
298. Olding-Stenkvist E., Forsgren M., Henley D., et al: Measles encephalopathy during immunosuppression: failure of treatment. Scand J Infect Dis 1982; 14:1-4.
299. Simpson R., Eden O.B.: Possible interferon response in a child with measles encephalitis during immunosuppression. Scand J Infect Dis 1984; 16:315-319.
300. Beatty D.W., Handzel Z.T., Pecht M., et al: A controlled trial of treatment of acquired immunodeficiency in severe measles with thymic humoral factor. Clin Exp Immunol 1984; 56:479-485.
301. Tovo P.A., Pugliese A., Palomba E., et al: Thymostimulin therapy in patients with measles meningoencephalitis. Thymus 1986; 8:91-94.
302. Wesley A.G., Coovadia H.M., Kiepiela P.: Levamisole therapy in children at risk from severe measles. Ann Trop Paediatr 1982; 2:23-29.
303. Banks G., Fernandez H.: Clinical use of ribavirin in measles: a summarized review. In: Smith R.A., Knight V., Smith J.A.D., ed. Clinical Applications of Ribavirin, New York: Academic Press; 1984:203-209.
304. Ross L.A., Kim K.S., Mason W.H., et al: Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am J Med 1990; 88:313-314.
305. Hussey G.D., Klein M.: A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323:160-164.
306. Barclay A.J.G., Foster A., Sommer A.: Vitamin A supplements and mortality related to measles: a randomized clinical trial. Br Med J (Clin Res Ed) 1987; 294:294-296.
307. D'Souza R., D'Souza R.: Vitamin A for preventing secondary infections in children with measles-a systematic review. J Trop Pediatr 2002; 48:72-77.
308. Sudfeld C.R., Navar A.M., Halsey N.A.: Effectiveness of measles vaccination and vitamin A treatment. Int J Epidemiol 2010; 39(Suppl. 1):i48-i55.
309. World Health Organization and United Nations Children's Fund : Measles mortality reduction and regional elimination: strategic plan, 2001-2005. (WHO/V&B/01.13)Geneva, World Health Organization, 2001.
310. Butler J.C., Havens P.L., Sowell A.L., et al: Measles severity and serum retinol (vitamin A) concentration among children in the United States. Pediatrics 1993; 91:1176-1181.
311. Frieden T.R., Sowell A.L., Henning K.J., et al: Vitamin A levels and severity of measles: New York City. Am J Dis Child 1992; 146:182-186.
312. Arrieta A.C., Zaleska M., Stutman H.R., et al: Vitamin A levels in children with measles in Long Beach, California. J Pediatr 1992; 121:75-78.
313. Huiming Y., Chaomin W., Meng M.: Vitamin A for treatming measles in children. Cochrane Database Syst Rev 2005; 4:CD001479.
314. Shann F.: Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence. BMJ 1997; 314:334-336.
315. Garly M.L., Bale C., Martins C.L., et al: Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomized double-blind placebo controlled trial in Guinea Bissau. Br Med J 2006; 333:1245.
316. Freeman J.M.: Treatment for subacute sclerosing panencephalitis with 5-bromo-2-deoxyuridine and Pyran copolymer. Neurology 1968; 18(pt 2):176-192.
317. Steiner I., Wirguin I., Morag A., et al: Intraventricular alpha interferon for subacute sclerosing panencephalitis. J Child Neurol 1989; 4:20-23.
318. Gascon G.G., Yamani S., Cafege A.: Treatment of subacute sclerosing panencephalitis with alpha interferon. Ann Neurol 1991; 30:227-228.

319. DuRant R.H., Dyken P.R., Swift A.V.: The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis. J Pediatr 1982; 101:288-293.
320. Anlar B., Yalaz K., Kose G., et al: Beta-interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis. J Child Neurol 1998; 13:557-559.
321. Yazaki M., Yamazaki M., Urasawa N., et al: Successful treatment with alpha-interferon of a patient with chronic measles infection of the brain and parkinsonism. Eur Neurol 2000; 44:184-186.
322. Langmuir A.D.: Medical importance of measles. Am J Dis Child 1962; 103:224-226.
323. Black F.L.: Measles antibody prevalence in diverse populations. Am J Dis Child 1962; 103:242-249.
324. Preblud S.R., Gross F., Halsey N.A., et al: Assessment of susceptibility to measles and rubella. JAMA 1982; 247:1134-1137.
325. deJong J.G.: The survival of measles virus in air, in relation to the epidemiology of measles. Arch Gesamte Virusforsch 1965; 16:97-102.
326. Riley R.C., Murphy G., Riley R.L.: Airborne spread of measles in a suburban elementary school. Am J Epidemiol 1978; 107:421-432.
327. Bloch A.B., Orenstein W.A., Ewing W.M., et al: Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75:676-683.
328. Ehresmann K.R., Hedberg C.W., Grimm M.B., et al: An outbreak of measles at an international sporting event with airborne transmission in a domed stadium. J Infect Dis 1995; 171:679-683.
329. Top F.H.: Measles in Detroit, 1935. I. Factors influencing the secondary attack rate among susceptibles at risk. Am J Public Health 1938; 28:935-943.
330. Hope-Simpson R.E.: Infectiousness of communicable diseases in the household. Lancet 1952; 2:549-554.
331. Sutter R.W., Markowitz L.E., Bennetch J.M., et al: Measles among the Amish: a comparative study of measles severity in primary and secondary cases in households. J Infect Dis 1991; 163:12-16.
332. Brandling-Bennett A.D., Landrigan P.J., Baker E.L.: Failure of vaccinated children to transmit measles. JAMA 1973; 224:616-618.
333. Lievano F., Papania M., Helfand R., et al: Lack of evidence of measles virus shedding in people with inapparent measles infections. J Infect Dis 2004; 189(Suppl. 1):S165-S170.
334. Hedrich A.W.: The corrected average attack rate from measles among city children. Am J Hyg 1930; 11:576-600.
335. London W.P., Yorke J.A.: Recurrent outbreaks of measles, chickenpox, and mumps. I. Seasonal variation in contact rates. Am J Epidemiol 1973; 98:453-468.
336. Yorke J.A., London W.P.: Recurrent outbreaks of measles, chickenpox, and mumps. II. Systematic differences in contact rates and stochastic effects. Am J Epidemiol 1973; 98:469-482.
337. Crawford G.E., Gremillion D.H.: Epidemic measles and rubella in Air Force recruits: impact of immunization. J Infect Dis 1981; 144:403-410.
338. Chen R.T., Goldbaum G.M., Wassilak S.G.F., et al: An explosive point-source outbreak in a highly vaccinated population. Am J Epidemiol 1989; 129:173-182.
339. Centers for Disease Control and Prevention (CDC) : Measles outbreak among school-aged children: Juneau, Alaska, 1996. MMWR Morb Mortal Wkly Rep 1996; 45:777-780.
340. Hennessy K.A., Ion-Nedelcu N., Craciun M., et al: Measles epidemic in Romania, 1996–1998: assessment of vaccine effectiveness by case-control and cohort studies. Am J Epidemiol 1999; 150:1250-1257.

341. Lambert S.B., Morgan M.L., Riddel M.A., et al: Measles outbreak in young adults in Victoria, 1999. Med J Aust 2000; 173:467-471.
342. Collaborative study by Ministry of Health of Kenya and World Health Organization: measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children. Bull World Health Organ 1977; 55:21-31.
343. Ministries of Health of Brazil, Chile, Costa Rica, and Ecuador and the Pan American Health Organization : Seroconversion rates and measles antibody titers induced by measles vaccination in Latin American children 6 to 12 months of age. Rev Infect Dis 1983; 5:596-605.
344. Halsey N.A.: The optimal age for administering measles vaccine in developing countries. In: Halsey N.A., de Quadros C.A., ed. Recent Advances in Immunization: A Bibliographic Review. (Publication No. 451), . Washington, DC: Pan American Health Organization; 1983:4-17.
345. Halsey N.A., Boulos R., Mode F., et al: Responses to measles vaccine in Haitian infants 6 to 12 months old: influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med 1985; 313:544-549.
346. Black F.L., Berman L.L., Borgono J.M., et al: Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am J Epidemiol 1986; 124:442-452.
347. Whittle H.C., Mee J., Werblinska J., et al: Immunity to measles in malnourished children. Clin Exp Immunol 1980; 42:144-151.
348. Aaby P., Bukh J., Hoff G., et al: High measles mortality in infancy related to intensity of exposure. J Pediatr 1986; 109:40-44.
349. Morley D.C., Aaby P.: Managing measles: size of infecting dose may be important [letter]. BMJ 1997; 314:1692.
350. Paunio M., Peltola H., Valle M., et al: Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees. Am J Epidemiol 1998; 148:1103-1110.
351. Centers for Disease Control and Prevention (CDC) : Progress toward global measles control and regional elimination, 1990–1997. MMWR Morb Mortal Wkly Rep 1998; 47:1049-1054.
352. World Health Organization. Measles. doc340. www.who.int/mediacentre/factsheets/fs286/en/ . Accessed 28 June 2012
353. Simons E., Ferrari M., Fricks J., et al: Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 2012; 9:2173-2178.379(9832)
354. Bloch A.B., Orenstein W.A., Stetler H.C., et al: Health impact of measles vaccination in the United States. Pediatrics 1985; 76:524-532.
354a. Centers for Disease Control and Prevention (CDC) : Global measles mortality, 2000–2008. MMWR Morb Mortal Wkly Rep 2009; 58:1321-1326.
355. Hatziandreu E.J., Brown R.E., Halpern M.T.: A Cost-Benefit Analysis of Measles-Mumps-Rubella Vaccine: Final Report. Arlington, VA, Battelle, 1994.
356. Zhou F., Reef S., Massoudi M., et al: An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis 2004; 189(Suppl. 1):S131-S145.
357. Mandomando I.M., Naniche D., Pasetti M.F., et al: Measles-specific neutralizing antibodies in rural Mozambique: seroprevalence and presence in breast milk. Am J Trop Med Hyg 2008; 79:787-792.
358. Oyedele O.O., Odemuyiwa S.O., Ammerlaan W., et al: Passive immunity to measles in the breastmilk and cord blood of some Nigerian subjects. J Trop Pediatr 2005; 51:45-48.

359. Lepage P., Munyakazi C., Hennart P.: Breastfeeding and hospital mortality in children in Rwanda. Lancet 1981; 2:409-411.
360. Aaby P., Bukh J., Lisse I.M., et al: Breastfeeding and measles mortality in Guinea-Bissau. Lancet 1981; 2:1231.
361. Zingher A.: Convalescent whole blood, plasma and serum in the prophylaxis of measles. JAMA 12 April 1926; 12:1180-1187.Reprinted inRev Med Vir 2005; 15:407-421.
362. Endo A., Izumi H., Miyashita M., et al: Current efficacy of postexposure prophylaxis against measles with immunoglobulin. J Pediatr 2001; 138:926-928.
363. Audet S., Virata-Theimer M.L., Beeler J.A., et al: Measles-virus-neutralizing antibodies in intravenous immunoglobulins. J Infect Dis 2006; 194:781-789.
364. Department of Health and Human Services, Food and Drug Administration : Additional Standards for Human Blood and Blood Products (21 CFR Part 640, Subpart J): Immune Globulin (Human). Code of Federal Regulations, Title 21 2005; vol. 7:revised April 1[accessed 01.05.06]
365. Department of Health and Human Services, Food and Drug Administration, Blood Products Advisory Committee Meeting Minutes August 16, 2007. Measles Antibody Levels in U.S. Immune Globulin Products. www.fda.gov/ohrms/dockets/ac/07/minutes/2007–4317M.htm ; [accessed 28.04.11].
366. Okuno Y., Takahashi M., Toyoshima K., et al: Studies on the prophylaxis of measles with attenuated living virus. III. Inoculation tests in man and monkey with chick embryo passage measles virus. Biken J 1960; 3:115-122.
367. Katz S.L., Morley D.C., Krugman S.: Attenuated measles vaccine in Nigerian children. Am J Dis Child 1962; 103:402-405.
368. Smorodinstev A.A., Boychuk L.M., Shikina E.S., et al: Further experiences with live measles vaccines in U.S.S.R. Am J Dis Child 1962; 103:384-386.
369. Report of a WHO Scientific Group : measles vaccine. World Health Organ Tech:Rep Ser 1963; 263:5-37.
370. Medical Research Council : Vaccination against measles: a study of clinical reactions and serological response of young children. Br Med J 1965; 1:817-823.
371. Medical Research Council : Vaccination against measles: a clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Br Med J 1966; 1:441-446.
372. Bolotovskij V.M., Nefedova L.A., Gelikman B.G., et al: Comparative studies of measles vaccine in a controlled trial in the USSR. Bull World Health Organ 1966; 34:859-864.
373. Cockburn W.C., Pecenka J., Sundaresan T.: WHO supported comparative studies of attenuated live measles vaccines. Bull World Health Organ 1966; 34:223-231.
374. Swartz T., Klingberg W., Nishmi M., et al: A comparative study of four live measles vaccines in Israel. Bull World Health Organ 1968; 39:285-292.
375. Ikic D., Juzasic M., Beck M., et al: Attenuation and characterization of Edmonston-Zagreb measles virus. Ann Immunol Hung 1972; 16:175-181.
376. Peradze T.V., Smorodintsev A.A.: Epidemiology and specific prophylaxis of measles. Rev Infect Dis 1983; 5:487-490.
377. Mirchamsy H.: Measles immunization in Iran. Rev Infect Dis 1983; 5:491-494.
378. Clements C.J., Milstein J.B., Grabowsky M., et al: Research into Alternative Measles Vaccines in the 1990s. (EPI/Gen/88.11 Rev 1)Geneva, World Health Organization, 1988.
379. Hirayama M.: Measles vaccine used in Japan. Rev Infect Dis 1983; 5:495-503.
380. Makino S.: Development and characteristics of live AIK-C measles virus vaccine: a brief report. Rev Infect Dis 1983; 5:504-505.
381. Jianzhi X., Zhihui C.: Measles vaccine in the People's Republic of China. Rev Infect Dis 1983; 5:506-510.

382. Mirchamsy H., Bahrami S., Shafyi A., et al: The isolation and characterization of a human diploid cell strain and its use in production of measles vaccine. J Biol Stand 1986; 14:75-79.
383. Okuno Y., Ueda S., Kurimura T., et al: Studies on further attenuated live measles vaccine. VII. Development and evaluation of CAM-70 measles virus vaccine. Biken J 1971; 14:253-258.
384. McCrumb F.R., Kress S., Saunders E., et al: Studies with live attenuated measles-virus vaccine. I. Clinical and immunologic responses in institutionalized children. Am J Dis Child 1961; 101:689-700.
385. Kress S.: Schluederberg AE, Hornick RB, et al. Studies with live attenuated measles-virus vaccine. II. Clinical and immunologic response of children in an open community. Am J Dis Child 1961; 101:701-707.
386. Hornick R.B., Schluederberg A.E., McCrumb Jr F.R.: Vaccination with live attenuated measles virus. Am J Dis Child 1962; 103:344-347.
387. Stokes Jr J., Hilleman M.R., Weibel R.E., et al: Efficacy of live attenuated measles-virus vaccine given with human immune globulin. N Engl J Med 1961; 265:507-513.
388. Weibel R., Halenda R., Stokes Jr J., et al: Administration of Enders' live measles virus vaccine with immune globulin. JAMA 1962; 180:1086-1094.
389. Morley D., Katz S.L., Krugman S.: The clinical reaction of Nigerian children to measles vaccine with and without gamma globulin. J Hyg (Camb) 1963; 61:135-141.
390. Benson P.F., Butler N.R., Goeffe A.P., et al: Vaccination of infants with living attenuated measles vaccine (Edmonston strain) with and without gamma-globulin. Br Med J 1964; 2:851-853.
391. Weibel R.E., Stokes Jr J., Halenda R., et al: Durable immunity two years after administration of Enders' live measles-virus vaccine with immune globulin. N Engl J Med 1964; 270:172-175.
392. Warren R.J., Nader P.R., Levine R.H.: Measles immune globulin: proposed standard dose given with live attenuated measles virus vaccine. JAMA 1968; 203:186-188.
393. Warren J., Gallian M.J.: Concentrated inactivated measles-virus vaccine: preparation and antigenic potency. Am J Dis Child 1962; 103:418-423.
394. Feldman H.A.: Protective value of inactivated measles vaccine. Am J Dis Child 1962; 103:423-424.
395. Karzon D.T., Winkelstein Jr W., Jenss R., et al: Field trial of inactivated measles vaccine. Am J Dis Child 1962; 103:425-426.
396. Karlitz S., Berliner B.C., Orange M., et al: Inactivated measles virus vaccine: subsequent challenge with attenuated live virus vaccine. JAMA 1963; 184:673-679.
397. Fulginiti V.A., Kempe C.H.: Measles exposure among vaccine recipients. Am J Dis Child 1963; 106:450-461.
398. Krugman S., Stone S., Hu R., et al: Measles immunization incorporated in the routine schedule for infants: efficacy of a combined inactivated-live vaccination regimen. Pediatrics 1964; 34:795-797.
399. Karzon D.T., Rush D., Winkelstein W.: Immunization with inactivated measles virus vaccine: effect of booster dose and response to natural challenge. Pediatrics 1965; 36:40-50.
400. Guinee V.F., Henderson D.A., Casey H.L., et al: Cooperative measles vaccine field trial. I. Clinical efficacy. II. Serologic studies. Pediatrics 1966; 37:649-665.
401. Centers for Disease Control (CDC) : Recommendations of the Public Health Service Advisory Committee on Immunization Practice: measles vaccines. MMWR Morb Mortal Wkly Rep 1967; 16:269-271.
402. Orenstein W.A., Halsey N.A., Hayden G.F., et al: Current status of measles in the United States, 1973–1977. J Infect Dis 1978; 137:847-853.

403. Suzuki K., Morita M., Katoh M., et al: Development and evaluation of the TD97 measles virus vaccine. J Med Virol 1990; 32:194-901.
404. Mann G.F., Allison L.M.C., Copeland J.A., et al: A simplified plaque assay system for measles virus. J Biol Stand 1980; 8:219-225.
405. Bellocq C., Roux L.: Wide occurrence of measles virus subgenomic RNAs in attenuated live-virus vaccines. Biologicals 1990; 18:337-343.
406. Mori T., Sasaki K., Hashimoto H., et al: Molecular cloning and complete sequence of genomic RNA of the AIK-C strain of attenuated measles virus. Virus Genes 1993; 7:67-81.
407. Valsamakis A., Kaneshima H., Griffin D.E.: Strains of measles vaccine and their ability to replicate in and damage human thymus. J Infect Dis 2001; 183:498-502.
408. Bankamp B., Takeda M., Zhang Y., et al: Genetic characterization of measles vaccine strains. J Infect Dis 2011; 204(Suppl. 1):S533-S548.
409. Lecouturier V., Fayolle J., Caballero M., et al: Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J Virol 1996; 70:4200-4204.
410. Liu X., Bankamp B., Xu W., et al: The genomic termini of wild type and vaccine strains of measles virus. Virus Res 2006; 122:78-84.
411. Andelman S.L., Schwarz A., Andelman M.B., et al: Experimental vaccination against measles: clinical evaluation of a highly attenuated live measles vaccine. JAMA 1963; 184:721-723.
412. Schwarz A.J.: Immunization against measles: development and evaluation of a highly attenuated live measles vaccine. Ann Paediatr 1964; 202:241-252.
413. Schwarz A.J.F., Anderson J.T.: Immunization with a further attenuated live measles vaccine. Arch Virusforsch 1965; 16:273-278.
414. Schwarz A.J.F., Anderson J.T., Ramos-Alvarez M., et al: Extensive clinical evaluations of a highly attenuated live measles vaccine. JAMA 1967; 199:84-88.
415. Hilleman M.R., Buynak E.B., Weibel R.E., et al: Development and evaluation of the Moraten measles virus vaccine. JAMA 1968; 206:587-590.
416. Krugman S., Constantinidis P., Medovy H., et al: Comparison of two further attenuated live measles-virus vaccines. Am J Dis Child 1969; 117:137-138.
417. Centers for Disease Control (CDC) : Recommendations of the Public Health Service Advisory Committee on Immunization Practice. MMWR Morb Mortal Wkly Rep 1965; 14:64-67.
418. Potency test. Code of Federal Regulations Title 21, Sec. 630.34. April 1, 1996
419. Sassani A., Mirchamsy H., Shafyi A., et al: Excessive attenuation of measles virus as a possible cause of failure in measles immunization. Ann Inst Pasteur Virol 1987; 138:491-501.
420. Makino S., Sasaki K., Nakayama T., et al: A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain) and rubella (Takahashi strain) vaccine. Am J Dis Child 1990; 144:905-910.
421. McAleer W.J., Markus H.Z., McLean A.A., et al: The stability on storage at various temperatures of the live measles, mumps, and rubella virus vaccines in a new stabilizer. J Biol Stand 1980; 8:281-287.
422. Wallace R.B., Landrigan P.J., Smith A., et al: Trial of a reduced dose of measles vaccine in Nigerian children. Bull World Health Organ 1976; 53:361-364.
423. McGraw T.T.: Reimmunization following early immunization with measles vaccine: a prospective study. Pediatrics 1986; 77:45-48.
424. Lee G.C-Y.: Intranasal vaccination with attenuated measles virus. Proc Soc Exp Biol Med 1963; 112:656-658.

425. Kok P.W., Kenya P.R., Ensering H.: Measles immunization with further attenuated heat-stable measles vaccine using five different methods of administration. Trans R Soc Trop Med Hyg 1983; 77:171-176.
426. Sabin A.B.: Immunization against measles by aerosol. Rev Infect Dis 1983; 5:514-523.
427. Sabin A.B., Arechiga A.F., Fernandez de Castro J., et al: Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 1983; 240:2651-2652.
428. Sabin A.B., Arechiga A.F., Fernandez de Castro J., et al: Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984; 251:2363-2371.
429. Whittle H.C., Rowland M.G., Mann G.F., et al: Immunization of 4–6-month-old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 1984; 2:834-837.
430. Khanum S., Garelick H., Uddin N., et al: Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet 1987; 1:150-153.
431. Ekunwe E.O.: Immunization by inhalation of aerosolized measles vaccine. Ann Trop Paediatr 1990; 10:145-149.
432. Cutts F.T., Clements C.J., Bennett J.V.: Alternative routes of measles immunization: a review. Biologicals 1997; 25:323-338.
433. Dilraj A., Cutts F., de Castro J., et al: Response to different measles vaccines strains given by aerosol and subcutaneous routes to schoolchildren: a randomized trial. Lancet 2000; 355:798-803.
434. Sepulveda-Amor J., Valdespino-Gomez J.L., Garcia-Garcia Mde L., et al: A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002; 20:2790-2795.
435. Wong-Chew R.M., Islas-Romero R., Garcia-Garcia Mde L., et al: Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 2006; 24:683-690.
436. Centers for Disease Control and Prevention (CDC). : Notice to readers: licensure of a combined live attenuated measles, mumps, rubella and varicella vaccine. MMWR Morb Mortal Wkly Rep 2006; 54:1212-1214.(Errata: MMWR Morb Mortal Wkly Rep 2006;54:1237).
437. Peltola H., Heinonen O.P.: Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo-controlled trial in twins. Lancet 1986; 1:939-942.
438. Isozaki M., Kuno-Sakai H., Hoshi N., et al: Effects and side effects of a new trivalent combined measles-mumps-rubella (MMR) vaccine. Tokai J Exp Clin Med 1982; 7:547-550.
439. Beck M., Smerdel S., Dedic I., et al: Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine. Dev Biol Stand 1986; 65:95-100.
440. Just M., Berger R., Glueck R., et al: Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Dev Biol Stand 1986; 65:25-27.
441. Buynak E.B., Weibel R.E., Whitman Jr J.E., et al: Combined live measles-mumps-rubella virus vaccines: findings in clinical-laboratory studies. JAMA 1969; 207:2259-2262.
442. Smorodintsev A.A., Nasibov M.N., Jakovleva N.V.: Experience with live rubella virus vaccine combined with live vaccines against measles and mumps. Bull World Health Organ 1970; 42:283-289.
443. Krugman S., Muriel G., Fontana V.J.: Combined live measles, mumps, rubella vaccine: immunological response. Am J Dis Child 1971; 121:380-381.
444. Stokes Jr J., Weibel R.E., Vallarejos V.M., et al: Trivalent combined measles-mumps-rubella vaccine: findings in clinical-laboratory studies. JAMA 1971; 218:57-61.

445. Karchmer A.W., Friedman J.P., Casey H.L., et al: Simultaneous administration of live virus vaccines: measles, mumps, poliomyelitis, and smallpox. Am J Dis Child 1971; 121:382-388.
446. Landrigan P.J., Murphy K.B., Meyer Jr H.M., et al: Combined measles-rubella vaccines: virus dose and serologic response. Am J Dis Child 1973; 125:65-67.
447. Schwarz A.J.F., Jackson J.E., Ehrenkranz N.J., et al: Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. Am J Dis Child 1975; 129:1408-1412.
448. Krugman R.D., Witte J.J., Parkman P.D., et al: Combined administration of measles, mumps, rubella, and trivalent poliovirus vaccines. Public Health Rep 1977; 92:220-222.
449. Weibel R.E., Carlson Jr A.J., Villarejos V.M., et al: Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus (40979). Proc Soc Exp Biol Med 1980; 165:323-326.
450. Lerman S.J., Bollinger M., Brunken J.M.: Clinical and serologic evaluation of measles, mumps and rubella (HPV-77:DE5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics 1981; 68:18-22.
451. Sugiura A., Ohtawara M., Hayami M., et al: Field trial of trivalent measles-rubella-mumps vaccine in Japan. J Infect Dis 1982; 146:709.
452. Parkman P.D., Hopps H.E., Albrecht P., et al: Simultaneous administration of vaccines. (Publication No. 451) In: Halsey N.A., de Quadros C.A., ed. Recent Advances in Immunization: A Bibliographic Review, Washington, DC: Pan American Health Organization; 1983:65-80.
453. Brunell P.A., Weigle K., Murphy M.D.: Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA 1983; 250:1409-1412.
454. Orenstein W.A., Herrmann K.L., Albrecht P., et al: Immunity against measles and rubella in Massachusetts school children. Dev Biol Stand 1986; 65:75-83.
455. Knuf M., Habermehl P., Zepp F., et al: Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006; 25:12-18.
456. Shinefeld H., Black S., Thear M., et al: Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type B conjugate hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J 2006; 25:287-292.
457. Lieberman J.M., Williams W.R., Miller J.M., et al: The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 2006; 25:615-622.
458. Klein N.P., Fireman B., Yih W.K., et al: Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1-e8.
459. Jacobsen S.J., Ackerson B.K., Sy L.S., et al: Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656-4661.
460. Elliott A.Y.: Manufacture and testing of measles, mumps and rubella vaccine. Proceedings of the 19th Immunization Conference, 1984:79-86.Boston; May 21–24
461. Böni J., Stadler J., Reigel F., et al: Detection of reverse transcriptase activity in live attenuated virus vaccines. Clin Diagn Virol 1996; 5:43-53.
462. Mahy B.WJ., Hadler S.C.: Detection of an RNA-dependent DNA polymerase activity. Comment: Clin Diagn Virol 1996;5:43–53. Clin Diagn Virol 1996; 5:1-2.
463. Weissmahr R.N., Schüpbach J., Böni J.: Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J Virol 1997; 71:3005-3012.

464. Johnson J.A., Heneine W.: Characterization of endogenous avian leucosis viruses in chicken embryonic fibroblast substrates used in production of measles and mumps vaccines. J Virol 2001; 75:3605-3612.
465. Hussain A.I., Shanmugam V., Switzer W.M., et al: Lack of evidence of endogenous avian leucosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients. Emerg Infect Dis 2001; 7:66-72.
466. Waters T.D., Anderson P.S., Beebe G.W., et al: Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 1972; 177:76-77.
467. Peetermans J., Colinet G., Stephenne J., et al: Stability of freeze-dried and reconstituted measles vaccines. Dev Biol Stand 1978; 41:259-264.
468. Heyman D.L., Smith E.L., Nakano J.H., et al: Further field testing of the more heat-stable measles vaccines in Cameroon. Br Med J (Clin Res Ed) 1982; 285:531-533.
469. WHO Expert Committee on Biological Standardization. : Requirements for measles, mumps, and rubella vaccines and combined vaccines (live). World Health Organ Tech Rep Ser 1994; 840(annex 3):100-201.
470. Petralli J.K., Merigan T.C., Wilbur J.C.: Action of endogenous interferon against vaccinia infection in children. Lancet 1965; 2:401-405.
471. Trubina L.M., Yakovenko Z.F., Itkis S.N., et al: Interferon formation induced by various viruses in cultures of leukocytes from children vaccinated against measles. Acta Virol 1972; 16:446.
472. Nakayama T., Urano T., Osano M., et al: Long-term regulation of interferon production by lymphocytes from children inoculated with live measles virus vaccine. J Infect Dis 1988; 158:1386-1390.
473. Kalis J.M., Quie P.G., Balfour Jr H.H.: Measles (rubeola) susceptibility among elementary schoolchildren. Am J Epidemiol 1975; 101:527-531.
474. Bass J.W., Halstead S.B., Fischer G.W., et al: Booster vaccination with further live attenuated measles vaccine. JAMA 1976; 235:31-34.
475. Albrecht P., Ennis F.A., Saltzman E.J., et al: Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977; 91:715-718.
476. Krugman R.D., Rosenberg R., McIntosh K., et al: Further attenuated live measles vaccine: the need for revised recommendations. J Pediatr 1977; 91:766-767.
477. Balfour H.H., Amren D.D.: Rubella, measles, and mumps antibodies following vaccination of children: a potential rubella problem. Am J Dis Child 1978; 132:573-577.
478. Wilkins J., Wehrle P.F.: Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. J Pediatr 1979; 94:865-869.
479. Sato H., Albrecht P., Reynolds D.W., et al: Transfer of measles, mumps, and rubella antibodies from mother to infant: its effect on measles, mumps, and rubella immunization. Am J Dis Child 1979; 133:1240-1243.
480. Orenstein W.A., Albrecht P., Herrman K.L., et al: Evaluation of low levels of measles antibody: the plaque neutralization test as a measure of prior exposure to measles virus. J Infect Dis 1986; 155:146-149.
481. Stetler H.C., Orenstein W.A., Bernier R.H., et al: Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 1986; 77:471-476.
482. Pedersen I.R., Mordhorst C.H., Ewald T., et al: Long-term antibody response after measles vaccination in an isolated arctic society in Greenland. Vaccine 1986; 4:173-178.
483. Helfand R.F., Kebede S., Gary H.E., et al: Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clin Diagn Lab Immunol 1999; 6:178-180.

484. Brown P., Gajdusek C., Tasi T.: Persistence of measles antibody in the absence of circulating natural virus five years after immunization of an isolated virgin population with Edmonston B vaccine. Am J Epidemiol 1969; 90:514-518.
485. Weibel R.E., Buynak E.B., McLean A.A., et al: Persistence of antibody in human subjects 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines (40967). Proc Soc Exp Biol Med 1980; 165:260-263.
486. Isomura S., Morishima T., Nishikawa K., et al: A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine. Biken J 1986; 29:19-26.
487. Linnemann C.C., Dine M.S., Bloom J.E., et al: Measles antibody in previously vaccinated children: the need for revaccination. Am J Dis Child 1972; 124:53-57.
488. Arbeter A.M., Arthur J.H., Blakeman G.J., et al: Measles immunity: reimmunization of children who previously received live measles vaccine and gamma globulin. J Pediatr 1972; 81:737-741.
489. Mossong J., O'Callaghan C.J., Ratnam S.: Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 2000; 19:523-529.
490. LeBaron C.W., Beeler J., Sullivan B.J., et al: Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294-301.
491. LeBaron C.W., Beeler J., Sullivan B.J., et al: Persistance of measles antibody after 2 doses of measles vaccine in a post-elimination environment. Arch Pediatr Adolesc Med 2007; 161:294-301.
492. Ward B.J., Griffin D.E.: Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin Immunol Immunopathol 1993; 67:171-177.
493. Pabst H.F., Spady D.W., Marusyk R.G., et al: Reduced measles immunity in infants in a well vaccinated population. Pediatr Infect Dis J 1992; 11:525-529.
494. Bautista-Lopez N.L., Vaisberg A., Kanashiro R., et al: Immune response to measles vaccine in Peruvian children. Bull World Health Organ 2001; 79:1038-1046.
495. Gans H., Yasukawa L., Rinki M., et al: Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-826.
496. Judelsohn R.G., Fleissner M.L., O'Mara D.J.: School-based measles outbreaks: correlation of age at immunization with risk of disease. Am J Public Health 1980; 70:1162-1165.
497. Faust H.S., Thompson F.E.: Age at and time since vaccination during a measles outbreak in a rural community. Am J Dis Child 1983; 137:977-980.
498. Shelton J.D., Jacobson J.E., Orenstein W.A., et al: Measles vaccine efficacy: influence of age at vaccination vs duration of time since vaccination. Pediatrics 1978; 62:961-964.
499. Hull H.F., Montes J.D., Hays P.C., et al: Risk factors for measles vaccine failure among immunized students. Pediatrics 1985; 76:518-523.
500. Ward B.J., Boulianne N., Ratnam S., et al: Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995; 172:1591-1595.
501. Starr S., Berkowitz S.: Effects of measles, gamma-globulin modified measles and vaccine measles on the tuberculin test. N Engl J Med 1964; 270:386-391.
502. Fireman P., Friday G., Kumate J.: Effect of measles vaccine on immunologic responsiveness. Pediatrics 1969; 43:264-272.

503. Zweiman B., Pappagianis D., Maibach H., et al: Effect of measles immunization on tuberculin hypersensitivity and in vitro lymphocyte reactivity. Int Arch Allergy 1971; 40:834-841.
504. Arneborn P., Biberfeld G.: T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella. Infect Immun 1983; 39:29-37.
505. Griffin D.E., Moench T.R., Johnson R.T., et al: Peripheral blood mononuclear cells during natural measles virus infection: cell surface phenotypes and evidence for activation. Clin Immunol Immunopathol 1986; 40:305-312.
506. Schnorr J.J., Cutts F.T., Wheeler J.G., et al: Immune modulation after measles vaccination of 6-9-months-old Bangladeshi infants. Vaccine 2001; 19:1503-1510.
507. Karp C.L., Wysocka M., Wahl L.M., et al: Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996; 273:228-231.
508. Kempe C.H.: Measles vaccine in children with asthma and tuberculosis. Am J Dis Child 1962; 103:409.
509. Berkovich S., Starr S.: Use of live-measles-virus vaccine to abort an expected outbreak of measles within a closed population. N Engl J Med 1963; 269:75-77.
510. van Binnendijk R.S., Poelen M.C., van Amerongen G., et al: Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis 1997; 175:524-532.
511. Morfin F., Beguin A., Lina B., et al: Detection of measles vaccine in the throat of a vaccinated child. Vaccine 2002; 20:1541-1543.
512. Wittler R.R., Veit B.C., Mcintyre S., et al: Measles revaccination response in a school-age population. Pediatrics 1991; 88:1024-1030.
513. Christenson B., Bottiger M.: Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994; 12:129-133.
514. Deseda-Tous J., Cherry J.D., Spencer M.J., et al: Measles revaccination: persistence and degree of antibody titer by type of immune response. Am J Dis Child 1978; 132:287-290.
515. Markowitz L.E., Albrecht P., Orenstein W.A., et al: Persistence of measles antibody after revaccination. J Infect Dis 1992; 166:205-208.
516. Bartoloni A., Cutts F.T., Guglielmetti P., et al: Response to measles revaccination among Bolivian school-aged children. Trans R Soc Trop Med Hyg 1997; 91:716-718.
517. Watson J.C., Pearson J.A., Markowitz L.E., et al: An evaluation of measles revaccination among school-entry-aged children. Pediatrics 1996; 97:613-618.
518. Poland G.A., Jacobson R.M., Thampy A.M., et al: Measles reimmunization in children seronegative after initial immunization. JAMA 1997; 277:1156-1158.
519. Cote T.R., Sivertson D., Horan J.M., et al: Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes. Public Health Rep 1993; 108:431-435.
520. Zhu Y.D., Heath J., Collins J., et al: Experimental measles. II. Infection and immunity in the rhesus macaque. Virology 1997; 233:85-92.
521. Wyde P.R., Stittelaar K.J., Osterhaus A.D., et al: Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine 2000; 19:42-53.
522. Zhu Y., Rota P., Wyatt L., et al: Evaluation of recombinant vaccinia virus measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 2000; 276:202-213.
523. Chen R.T., Markowitz L.E., Albrecht P., et al: Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-1042.

524. Black F.L., Berman L.L., Libel M., et al: Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull World Health Organ 1984; 62:315-319.
525. Lampe R.M., Weir M.R., Scott R.MC., et al: Measles reimmunization in children immunized before 1 year of age. Am J Dis Child 1985; 139:33-35.
526. Orenstein W.A., Bernier R.H., Dondero T.J., et al: Field evaluation of vaccine efficacy. Bull World Health Organ 1985; 63:1055-1068.
527. Marks J.S., Hayden G.F., Orenstein W.A.: Methodologic issues in the evaluation of vaccine effectiveness: measles vaccine at 12 vs. 15 months. Am J Epidemiol 1982; 116:510-523.
528. Wyll S.A., Witte J.J.: Measles in previously vaccinated children: an epidemiological study. JAMA 1971; 216:1306-1310.
529. Landrigan P.J.: Epidemic measles in a divided city. JAMA 1972; 221:567-570.
530. King G.E., Markowitz L.E., Patriarca P.A., et al: Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991; 10:883-887.
531. Baba R., Yabuuchi H., Takahashi M., et al: Seroepidemiologic behavior of varicella zoster virus infection in a semiclosed community after introduction of VZV vaccine. J Pediatr 1984; 105:712-716.
532. Gay N.J.: The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 2004; 189(Suppl. 1):S27-S35.
533. De Serres G., Gay N.J., Farrington C.P.: Epidemiology of transmissible diseases after elimination. Am J Epidemiol 2000; 151:1039-1048.
534. Wallinga J., Levy-Bruhl D., Gay N.J., et al: Estimation of measles reproduction ratios and prospects for elimination of measles by vaccination in some Western European countries. Epidemiol Infect 2001; 127:281-295.
535. Hutchins S.S., Redd S.C., Schrag S., et al: National serologic survey of measles immunity among persons 6 years of age and older, 1988–1994. Medscape Gen Med 2001; 3:Accessed 28 June 2012.
536. McQuillan G.M., Kruszon-Moran D., Hyde T.B., et al: Seroprevalence of measles antibody in the US population, 1999–2004. J Infect Dis 2007; 196:1459-1464.
537. Janaszek W., Gut W., Gay N.J.: The epidemiology of measles in Poland: prevalence of measles virus antibodies in the population. Epidemiol Infect 2000; 125:385-392.
538. Kelly H.A., Gidding H.F., Karapanagiotidis T., et al: Residual susceptibility to measles among young adults in Victoria. Australia following a national targeted measles-mumps-rubella vaccination campaign. BMC Public Health 2007; 7:99.
539. Tapia M.D., Sow S.O., Medina-Moreno S., et al: A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali. Am J Trop Med Hyg 2005; 73:26-31.
540. Osborne K., Gay N., Hesketh L., et al: Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol 2000; 29:362-368.
541. de Melker H., Pebody R.G., Edmunds W.J., et al: The seroepidemiology of measles in Western Europe. Epidemiol Infect 2001; 126:249-259.
542. Hutse V., Van Hecke K., De Bruyn R., et al: Oral fluid for the serological and molecular diagnosis of measles. Int J Infect Dis 2010; 14:e991-e997.
543. Nokes D.J., Enquselassie F., Nigatu W., et al: Has oral fluid the potential to replace serum for the evaluation of population immunity levels? A study of measles, rubella and hepatitis B in rural Ethiopia. Bull World Health Organ 2001; 79:588-595.
544. Nigatu W., Samuel D., Cohen B., et al: Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys. Vaccine 2008; 26:4769-4774.

545. Ohuma E.O., Okiro E.A., Bett A., et al: Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models. Epidemiol Infect 2009; 137:227-233.
546. Vyse A.J., Gay N.J., Hesketh L.M., et al: Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiol Infect 2006; 134:1303-1312.
547. Choi Y.H., Gay N., Fraser G., et al: The potential for measles transmission in England. BMC Public Health 2008; 8:338.
548. Chen S.C., Chang C.F., Jou L.J., et al: Modelling vaccination programmes against measles in Taiwan. Epidemiol Infect 2007; 135:775-786.
549. Hayden G.F.: Measles vaccine failure: a survey of causes and means of prevention. Clin Pediatr 1979; 18:1555-1567.
550. Orenstein W.A., Markowitz L., Preblud S.R., et al: Appropriate age for measles vaccination in the United States. Dev Biol Stand 1986; 65:13-21.
551. Caceras V.M., Strebel P.M., Sutter R.W.: Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 2000; 31:110-119.
552. Leuridan E., Van Damme P.: Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 2007; 25:6296-6304.
553. Reilly C.M., Stokes Jr J., Buynak E.B., et al: Living attenuated measles-virus vaccine in early infancy: studies of the role of passive antibody in immunization. N Engl J Med 1961; 265:165-169.
554. American Academy of Pediatrics : Report of the Committee on the Control of Infectious Diseases, Evanston, IL: American Academy of Pediatrics; 1964:8.
555. Shasby D.M., Shope T.C., Downs H., et al: Epidemic measles in a highly vaccinated population. N Engl J Med 1977; 296:585-589.
556. Nkowane B.M., Bart S.W., Orenstein W.A., et al: Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. Am J Public Health 1987; 77:434-438.
557. Reynolds D.W., Start A.: Immunity to measles in children vaccinated before and after one year of age. Am J Dis Child 1972; 124:848-849.
558. Marks J.S., Halpin T.J., Orenstein W.A.: Measles vaccine efficacy in children previously vaccinated at 12 months of age. Pediatrics 1978; 62:955-960.
559. Krugman S.: Present status of measles and rubella immunization in the United States: a medical progress report. J Pediatr 1971; 78:1-16.
560. Davis R.M., Whitman E.D., Orenstein W.A., et al: A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol 1987; 126:438-449.
561. Linnemann Jr C.C., Dine M.S., Rosella G.A., et al: Measles immunity after revaccination: results in children vaccinated before 10 months of age. Pediatrics 1982; 69:332-335.
562. Murphy M.D., Brunell P.A., Lievens A.W., et al: Effect of early immunization on antibody response to reimmunization with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA). Pediatrics 1984; 74:90-93.
563. Hutchins S.S., Dezayas A., Le Blond K., et al: Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol 2001; 154:1064-1071.
564. Yeager A.S., Davis J.H., Ross L.A., et al: Measles immunization: successes and failures. JAMA 1977; 237:347-351.
565. Wilkins J., Wehrle P.F.: Evidence for reinstatement of infants 12 to 14 months of age into routine measles immunization programs. Am J Dis Child 1978; 132:164-166.

566. Yeager A.S., Harvey B., Crosson Jr F.J., et al: Need for measles revaccination in adolescents: correlation with birth date prior to 1972. J Pediatr 1983; 102:191-195.
567. Maldonado Y.A., Lawrence E.C., DeHovitz R., et al: Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 1995; 96:447-450.
568. Redd S.C., King G.E., Heath J.L., et al: Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis 2004; 189(Suppl. 1):S116-S122.
569. Markowitz L.E., Albrecht P., Rhodes P., et al: Changing levels of measles antibody titers in women and children in the United States: impact on response to revaccination. Pediatrics 1996; 97:53-58.
570. Gagneur A., Pinquier D., Aubert M., et al: Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006. Clin Vaccine Immunol 2008; 15:1845-1850.
571. Hamilton B.E., Martin J.A., Ventura S.J.: Births: preliminary data for 2009. Natl Vital Stat Rep 2010; 29:3.[accessed 30.04.11].
572. Papania M.J., Baughman A.L., Lee S., et al: Increased susceptibility to measles in infants in the United States. Pediatrics 1999; 104:e59.Accessed 28 June 2012
573. Linder N., Tallen-Gozani E., German B., et al: Placental transfer of measles antibodies: effect of gestational age and maternal vaccination status. Vaccine 2004; 22:1509-1514.
574. Scott S., Cumberland P., Shulman C.E., et al: Neonatal measles in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis 2005; 191:1854-1860.
575. de Moraes-Pinto M.I., Verhoff F., Chimsuku L., et al: Placental antibody transfer: influence of maternal HIV infection and placental malaria. Arch Dis Child Fetal Neonatal Ed 1998; 79:F202-F205.
576. World Health Organization : Measles Vaccine, WHO position paper. Wkly Epidemiol Rec 2009; 84:349-350.
577. Kumar M.L., Johnson C.E., Chui L.W., et al: Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. Vaccine 1998; 16:2047-2051.
578. Gans H.A., Arvin A.M., Galinus J., et al: Deficiency of the humoral immune response to measles vaccine in infants immunized at 6 months. JAMA 1998; 280:527-532.
579. Wheelock E.F., Larke R.PB., Caroline N.L.: Interference in human viral infections: present status and prospects for the future. Prog Med Virol 1968; 10:286-347.
580. Ndikuyeze A., Munoz A., Stewart J., et al: Immunogenicity and safety of measles vaccine in ill African children. Int J Epidemiol 1988; 17:448-455.
581. Krober M.S., Stracener C.E., Bass J.W.: Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. JAMA 1991; 265:2095-2096.
582. Dennehy P.H., Saracen C.L., Peter G.: Seroconversion rates to combined measles-mumps-rubella-varicella (MMRV) vaccine of children with upper respiratory tract infection. Pediatrics 1994; 94:514-516.
583. Ratman S., West R., Gadag V.: Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. J Pediatr 1995; 127:432-434.
584. King G.E., Markowitz L.E., Heath J., et al: Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996; 275:704-707.
585. Edmonson M.B., Davis J.P., Hopfensperger D.J., et al: Measles vaccination during the respiratory virus season and risk of vaccine failure. Pediatrics 1996; 98:905-910.
586. Simasathien S., Migasena S., Bellini W., et al: Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections. Vaccine 1997; 15:329-334.

587. Peter G.: Measles immunization: recommendations, challenges, and more information. JAMA 1991; 265:2111-2112.
588. McMurray D.N., Loomis A.S., Cassazza L.J., et al: Influence of moderate malnutrition on morbidity and antibody response following vaccination with live, further attenuated measles virus vaccine. Bull Pan Am Health Organ 1979; 13:52-57.
589. Ifekwunigwe A.E., Grasset N., Glass R., et al: Immune response to measles and smallpox vaccinations in malnourished children. Am J Clin Nutr 1980; 33:621-624.
590. Rudy B.J., Rutstein R.M., Pinto-Martin J.P.: Responses to measles immunization in children infected with human immunodeficiency virus. J Pediatr 1994; 25:72-74.
591. al-Attar I., Reisman J., Muehlmann M., et al: Decline of measles antibody titers after immunization in human immunodeficiency virus infected children. Pediatr Infect Dis J 1995; 14:149-151.
592. Hilgartner M.W., Maeder M.A., Mahoney E.M., et al: Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Am J Hematol 2001; 66:92-98.
593. Oxtoby M.J., Ryder R., Mvula M., et al: Patterns of immunity to measles among African children infected with human immunodeficiency virus [abstract]. Proceedings of the 38th Epidemic Intelligence Service Conference, 1989.Atlanta, GA; April 3–7,
594. Lepage P., Dabis F., Msellati P., et al: Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. Am J Dis Child 1992; 146:550-555.
595. Cutts F.T., Mandala K., St Louis M., et al: Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasa, Zaire. J Infect Dis 1993; 167:1418-1421.
596. Thaithumyanon P., Punnahitananda S., Thisyakorn U., et al: Immune responses to measles immunization and the impact on HIV-infected children. Southeast Asian J Trop Med Public Health 2000; 31:658-662.
597. Moss W.S., Scott S., Mugala N., et al: Immunogenicity of standard-titre measles vaccine in HIV-I infected and uninfected Zambian children: an observational study. J Infect Dis 2007; 196:347-355.
598. Arpadi S.M., Markowitz L.E., Baughman A.L., et al: Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996; 97:653-657.
599. Goon P., Cohen B., Jin L., et al: MMR vaccine in HIV-infected children-potential hazard?. Vaccine 2001; 19:3816-3819.
600. Zolopa A.B., Kemper C.A., Shiboski S., et al: Progressive immunodeficiency due to infection with human immunodeficiency virus does not lead to waning immunity to measles in a cohort of homosexual men. Clin Infect Dis 1994; 18:636-638.
601. Belaunzarán-Zamudio P.F., García-León M.L., Wong-Chew R.M., et al: Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine 2009; 27:7059-7064.
602. Semba R.D., Munasir Z., Beeler J., et al: Reduced seroconversion to measles in infants given vitamin A with measles vaccination. Lancet 1995; 345:1330-1332.
603. Benn C.S., Aaby P., Baleá C., et al: Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. Lancet 1997; 350:101-105.
604. Bahl R., Kumar R., Bhandari N., et al: Vitamin A administered with measles vaccine to nine-month-old infants does not reduce vaccine immunogenicity. J Nutr 1999; 129:1569-1573.
605. Semba R.D., Akib A., Beeler J., et al: Effect of vitamin A supplementation on measles vaccination in nine-month-old infants. Public Health 1997; 111:245-247.

606. Randomized trial to assess benefits and safety of vitamin A supplementation linked to immunization in early infancy. WHO/CHD Immunization-Linked Vitamin A Supplementation Study Group. Lancet 1998; 352:1257-1263.
607. Ross D.A., Cutts F.T.: Vindication of policy of vitamin A with measles vaccination. Lancet 1997; 350:81-82.
608. Poland G.A., Jacobson R.M., Schaid D., et al: The association between HLA class I alleles and measles vaccine-induced antibody response: evidence for a significant association. Vaccine 1998; 16:1869-1871.
609. Jacobson R.M., Poland G.A.: The genetic basis for measles vaccine failure. Acta Paediatr Suppl 2004; 93:43-46.
610. St Sauver J.L., Dhiman N., Ovsyannikova I.G., et al: Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine. Hum Immunol 2005; 66:788-798.
611. Whittle H.C., Mann G., Eccles M., et al: Effects of dose and strain of vaccine on success of measles vaccination in infants aged 4-5 months. Lancet 1988; 1:963-966.
612. Markowitz L.E., Sepulveda J., Diaz-Ortega J.L., et al: Immunization of six-month old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 1990; 322:580-587.
613. Tidjani O., Grunitsky B., Guerin N., et al: Serological effects of Edmonston-Zagreb, Schwarz and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet 1989; 2:1357-1360.
614. Kiepiela P., Coovadia H.M., Loening W.EK., et al: Lack of efficacy of the live standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants. Bull World Health Organ 1991; 69:221-227.
615. Job J.S., Halsey N.A., Boulos R., et al: Successful immunization of infants at 6 months of age with high dose Edmonston-Zagreb measles vaccine. Pediatr Infect Dis J 1991; 10:303-311.
616. Dabis F., Sow A., Waldman R., et al: The epidemiology of measles in a partially vaccinated African city: implications for immunization programmes. Am J Epidemiol 1988; 127:171-178.
617. Kambarami R.A., Nathoo K.J., Nkrumah F.K., et al: Measles epidemic in Harare, Zimbabwe, despite high measles immunization coverage rates. Bull World Health Organ 1991; 69:213-219.
618. Tsai H.Y., Huang L.M., Shih Y.T., et al: Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants. Viral Immunol 1999; 12:343-348.
619. Nkrumah F.K., Osei-Kwasi M., Dunyo S.K., et al: Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana. Bull World Health Organ 1998; 76:353-359.
620. Pabst H.F., Spady D.W., Carson M.M., et al: Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6-month-old infants. Vaccine 1999; 17:1910-1918.
621. World Health Organization. Expanded Programme on Immunization. Global Advisory Group. Part I. Wkly Epidemiol Rec 1990; 65:5-12.
622. Holt E.A., Moulton L.H., Siberry G.K., et al: Differential mortality by measles vaccine titer and sex. J Infect Dis 1993; 168:1087-1097.
623. Garenne M., Leroy O., Beau F.P., et al: Child mortality after high titer measles vaccines: prospective study in Senegal. Lancet 1991; 338:903-907.
624. Aaby P., Samb B., Simondon F., et al: Divergent mortality for male and female recipients of low-titre and high-titre measles vaccines in rural Senegal. Am J Epidemiol 1993; 138:756-765.

625. Libman M.D., Ibrahim S.A., Omer M.I., et al: No evidence for short- or long-term morbidity after increased titer measles vaccination in Sudan. Pediatr Infect Dis J 2002; 21:112-119.
626. World Health Organization. Expanded Programme on Immunization : Safety of high-titre measles vaccines. Wkly Epidemiol Rec 1992; 67:357-361.
627. Krugman R.D., Meyer B.C., Parkman P.D., et al: Impotency of vaccines as a result of improper handling in clinical practice. J Pediatr 1972; 85:512-514.
628. Lerman S.J., Gold E.: Measles in children previously vaccinated against measles. JAMA 1971; 216:1311-1314.
629. Markowitz L.E., Preblud S.R., Fine P.E., et al: Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 1990; 9:101-109.
630. Miller C.: Live measles vaccine: a 21-year follow-up. Br Med J (Clin Res Ed) 1987; 295:22-24.
631. Dine M.S., Hutchins S.S., Thomas A., et al: Persistence of vaccine-induced antibody to measles 26–33 years after vaccination. J Infect Dis 2004; 189(Suppl. 1):S123-S130.
632. Hirose M., Hidaka Y., Miyazaki C., et al: Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination. Scand J Infect Dis 1997; 29:187-190.
633. Hutchins S.S., Markowitz L.E., Mead P., et al: School-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. Am J Epidemiol 1990; 132:157-168.
634. Lynn T.V., Beller M., Funk E.A., et al: Incremental effectiveness of 2 doses of measles-containing vaccine compared with 1 dose among high school students during an outbreak. J Infect Dis 2004; 189(Suppl. 1):S86-S90.
635. Guris D., McCready J., Watson J.C., et al: Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr Infect Dis J 1996; 15:1082-1086.
636. Ramsay M.E., Moffatt D., O'Connor M.: Measles vaccine: a 27-year follow-up. Epidemiol Infect 1994; 112:409-412.
637. Anders J.F., Jacobson R.M., Poland G.A., et al: Secondary failure rates of measles vaccines: a meta-analysis of published studies. Pediatr Infect Dis J 1996; 15:62-66.
638. Meyer Jr H.M.: Field experience with combined live measles, smallpox, and yellow fever vaccines. Arch Gesamte Virusforsch 1965; 16:366-374.
639. Sherman R.M., Hendrickse R.G., Montifiore D.: Simultaneous administration of live measles virus vaccine and smallpox vaccine. Br Med J 1967; 2:672-676.
640. Weibel R.E., Stokes Jr J., Buynak E.B., et al: Clinical laboratory experiences with a more attenuated Enders measles virus vaccine (Moraten) combined with smallpox vaccine. Pediatrics 1969; 43:567-572.
641. Ruben F.L., Smith E.A., Foster S.O., et al: Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children. Bull World Health Organ 1973; 48:175-181.
642. Lapeyssonnie L., Omer I.A., Nicolas A., et al: A study of the serological response of Sudanese children to three associated immunizations (measles, tetanus, meningococcal A meningitis). Med Trop (Mars) 1979; 39:71-79.
643. Ajjan N., Fayet M.T., Biron G., et al: Combination of attenuated measles vaccine (Schwarz) with meningococcus A and A + C vaccine. Dev Biol Stand 1978; 41:209-216.
644. Deforest A., Long S.S., Lischner H.W., et al: Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and oral poliovirus vaccines. Pediatrics 1988; 81:237-246.

645. Huang L., Lee C., Hsu C., et al: Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Pediatr Infect Dis J 1990; 9:461-465.
646. Lhuillier M., Mazzariol M.J., Zadi S., et al: Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand 1989; 17:9-15.
647. Adu F.D., Omotade O.O., Oyedele O.I., et al: Field trial of combined yellow fever and measles vaccines among children in Nigeria. East Afr Med J 1996; 73:579-582.
648. Centers for Disease Control (CDC) : Recommendations of the Immunization Practices Advisory Committee (ACIP): new recommended schedule for active immunization of normal infants and children. MMWR Morb Mortal Wkly Rep 1986; 35:577-579.
649. King G.E., Hadler S.C.: Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1994; 13:394-407.
650. Giammanco G., Li Volti S., Salemi I., et al: Immune response to simultaneous administration of a combined measles, mumps, and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine. Eur J Epidemiol 1993; 9:199-202.
651. Centers for Disease Control (CDC) : Adverse Events Following Immunization Surveillance Report No. 3, 1985–1986. Atlanta, GA, Centers for Disease Control, 1989.
652. John T.J., Selvakumar R., Balrai V., et al: Antibody response to measles vaccine with DTPP [letter]. Am J Dis Child 1987; 141:14.
653. Chen R.T., Haber P., Mullen J.R.: Surveillance of the safety of simultaneous administration of vaccines. The Centers for Disease Control and Prevention experience. Ann N Y Acad Sci 1995; 754:309-320.
654. Englund J.A., Swarez C.S., Kelly J., et al: Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr 1989; 114:37-44.
655. Watson B.M., Laufer D.S., Kuter B.J., et al: Safety and immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine (MMRIIV) in healthy children. J Infect Dis 1996; 173:731-734.
656. Ruuskanen O., Salmi T.T., Halonen P.: Measles vaccination after exposure to natural measles. J Pediatr 1978; 93:43-46.
657. Dayan G.H., Panero M.S., Urquiza A., et al: Rubella and measles seroprevalence among women of childbearing age, Argentina, 2002. Epidemiol Infect 2005; 133:861-869.
658. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Pediatric AIDS : Measles immunization in HIV-infected children. Pediatrics 1999; 103(pt 1):1057-1060.
659. Centers for Disease Control and Prevention (CDC) : Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 1999; 48(RR-5):1-15.
660. Byrne E.B., Rosenstein B.J., Jaworski A.A., et al: A statewide mass measles immunization program. JAMA 1967; 199:619-623.
661. Chen R.T., Moses J.M., Markowitz L.E., et al: Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine 1991; 9:297-299.
662. LeBaron C.W., Bi D., Sullivan B.J., et al: Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics 2006; 118:1422-1430.
663. Griffin M.R., Ray W.A., Mortimer E.A., et al: Risk of seizures after measles-mumps-rubella immunization. Pediatrics 1991; 88:881-885.

664. Harris R.W., Isacson P., Karzon D.T.: Vaccine-induced hypersensitivity: reactions to live measles and mumps vaccine in prior recipients of inactivated measles vaccine. J Pediatr 1969; 74:552-563.
665. Stetler H.C., Gens R.D., Seastrom G.R.: Severe local reactions to live measles virus vaccine following an immunization program. Am J Public Health 1983; 73:899-900.
666. Landrigan P.J., Witte J.J.: Neurologic disorders following live measles-virus vaccination. JAMA 1973; 223:1459-1462.
667. Abe T., Nonaka C., Hiraiwa M., et al: Acute and delayed neurologic reaction to inoculation with attenuated live measles virus. Brain Dev 1985; 7:421-423.
668. Davis R.L., Marcuse E., Black S., et al: MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink (VSD) project. Pediatrics 1997; 100:767-771.
669. Barlow W.E., Davis R.L., Glasser J.W., et al: The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656-661.
670. Czajka H., Schuster V., Zepp F., et al: A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 2009; 27:6504-6511.
671. Halperin S.A., Ferrera G., Scheifele D., et al: Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine 2009; 27:2701-2706.
672. Shinefield H., Black S., Digilio L., et al: Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005; 24:665-669.
673. Kuter B.J., Brown M.L., Hartzel J., et al: Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin 2006; 2:205-214.
674. Institute of Medicine : Measles and mumps vaccine. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality, Washington, DC: National Academy Press; 1994:130.
675. Mantadakis E., Farmaki E., Buchanan G.R.: Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010; 156:623-628.
676. France E.K., Glanz J., Xu S., et al: Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121:e687-e692.
677. Carapetis J.R., Curtis N., Royle J.: MMR immunisation: true anaphylaxis to MMR vaccine is extremely rare. BMJ 2001; 323:869.
678. Bohlke K., Davis R.L., Marcy S.M., et al: Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112:815-820.doi:10.1542:peds.112.4.815
679. Yavuz S.T., Sahiner U.M., Sekerel B.E., et al: Anaphylactic reactions to measles-mumps-rubella vaccine in three children with allergies to hen's egg and cow's milk. Acta Paediatr 2011; 100:e94-e96.
680. James J.M., Burks A.W., Roberson P.K., et al: Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262-1266.
681. Pool V., Braun M.M., Kelso J.M., et al: Prevalence of anti-gelatin Ig E antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 2002; 110:e71.
682. Duclos P., Ward B.J.: Measles vaccines: a review of adverse events. Drug Saf 1998; 6:435-454.
683. Forman M.L., Cherry J.D.: Isolation of measles virus from the cerebrospinal fluid of a child with encephalitis following measles vaccination. Proceedings of the 77th Annual Meeting of the American Pediatric Society, April 26–29, 1967.Atlantic City, NJ; Abstract 13

684. Bino S., Kakarriqi E., Xibinaku M., et al: Measles-rubella mass immunization campaign in Albania, November 2000. J Infect Dis 2003; 187(Suppl. 1):S223-S229.
685. Bloch A.B., Orenstein W.A., Wassilak S.G., et al: Epidemiology of measles and its complications. In: Gruenberg E.M., Lewis C., Goldston S.E., ed. Vaccinating against Brain Syndromes: The Campaign against Measles and Rubella; Monographs in Epidemiology and Biostatistics, vol. 9. New York: Oxford University Press; 1986:5-20.
686. Mäkelä A., Nuorti J.P., Peltola H.: Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110:957-963.
687. Ray P., Hayward J., Michelson D., et al: Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J 2006; 25:768-773.
688. Miller D., Wadsworth J., Diamond J.: Measles vaccination and neurological events. Lancet 1997; 349:730-731.
689. Weibel R.E., Caserta V., Benor D.E.: Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics 1998; 101(pt 1):383-387.
690. Morens D.M., Halsey N.A., Schoenberger L.B., et al: Reye syndrome associated with vaccination with live virus vaccines: an exploration of possible etiologic relationships. Clin Pediatr 1979; 18:42-44.
691. Chan C.C., Sogg R.L., Steinman L.: Isolated oculomotor palsy after measles immunization. Am J Ophthalmol 1980; 89:446-448.
692. Karzarian E.L., Gager W.E.: Optic neuritis complicating measles, mumps, and rubella vaccination. Am J Ophthalmol 1978; 86:544-547.
693. Marshall G.S., Wright P.F., Fenichel G.M., et al: Diffuse retinopathy following measles, mumps, and rubella vaccination. Pediatrics 1985; 76:989-991.
694. Brodsky L., Stanievich J.: Sensorineural hearing loss following live measles virus vaccination. Int J Pediatr Otorhinolaryngol 1985; 10:159-163.
695. Trump R.C., White T.R.: Cerebellar ataxia presumed due to live, attenuated measles virus vaccine. JAMA 1967; 199:165-166.
696. Glenn M.P., McKendrick D.W.: Varicella bullosa associated with measles vaccine. Br J Dermatol 1970; 83:595-596.
697. Shoss R.G., Rayhanzadeh S.: Toxic epidermal necrolysis following measles vaccination. Arch Dermatol 1974; 110:766-770.
698. Buntain W.L., Missall S.R.: Local subcutaneous atrophy following measles, mumps, and rubella vaccination [letter]. Am J Dis Child 1976; 130:335.
699. Buck B.E., Yang L.C., Caleb M.H., et al: Measles virus panniculitis subsequent to vaccine administration. J Pediatr 1982; 101:366-373.
700. da Silveira C.M., Salisbury D.M., de Quadros C.A.: Measles vaccination and Guillain-Barré syndrome. Lancet 1997; 349:14-16.
701. Patja A., Paunio M., Kinnunen E., et al: Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination. J Pediatr 2001; 138:250-254.
702. DeStefano F., Gu D., Kramarz P., et al: Childhood vaccinations and risk of asthma. Pediatr Infect Dis J 2002; 21:498-504.
703. Campbell H., Andrews N., Brown K.E., et al: Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 2007; 36:1334-1348.
704. Rima B.K., Duprex W.P.: Molecular mechanisms of measles virus persistence. Virus Res 2005; 111:132-147.
705. http://www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx

706. Bellini W.J., Rota J.S., Lowe L.E., et al: Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686-1693.
707. Miki K., Komase K., Mgone C.S., et al: Molecular analysis of measles virus genome derived from SSPE and acute measles patients in Papua, New Guinea. J Med Virol 2002; 68:105-112.
708. Jin L., Beard S., Hunjan R., et al: Characterization of measles virus strains causing SSPE: a study of 11 cases. J Neurovirol 2002; 8:335-344.
709. Sonoda S., Nakayama T.: Detection of measles virus genome in lymphocytes from asymptomatic healthy children. J Med Virol 2001; 65:381-387.
710. Katayama Y., Kohso K., Nishimura A., et al: Detection of measles virus mRNA from autopsied human tissues. J Clin Microbiol 1998; 36:299-301.
711. Park D.W., Boldt H.C., Massicotte S.J., et al: Subacute sclerosing panencephalitis manifesting as viral retinitis: clinical and histopathologic findings. Am J Ophthalmol 1997; 123:533-542.
712. Koppel B.S., Poon T.P., Khandji A., et al: Subacute sclerosing panencephalitis and acquired immunodeficiency syndrome: role of electroencephalography and magnetic resonance imaging. J Neuroimaging 1996; 6:122-125.
713. Budka H., Urbanits S., Liberski P.P., et al: Subacute measles virus encephalitis: a new and fatal opportunistic infection in a patient with AIDS. Neurology 1996; 46:586-587.
714. Bitnun A., Shannon P., Durward A., et al: Measles inclusion body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855-861.
715. Adverse Effects of Vaccines Evidence and Causality. A Brief Report, August 2011. Bethesda, MD: Institute of Medicine; 2011:2-3.Accessed 28 June 2012. www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx
716. Monafo W.J., Haslam D.B., Roberts R.L., et al: Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 1994; 124:273-276.
717. Centers for Disease Control and Prevention (CDC) : Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection. MMWR Morb Mortal Wkly Rep 1996; 45:603-606.
718. Moss W.J., Monze M., Ryon J.J., et al: Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 2002; 35:189-196.
719. Moss W.J., Clements C.J., Halsey N.A.: Immunization of children at risk for infection with the human immunodeficiency virus. Bull World Health Organ 2003; 81:61-70.
720. Angel J.B., Walpita P., Lerch R.A., et al: Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998; 129:104-106.
721. Centers for Disease Control and Prevention (CDC) : 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR Recomm Rep 1994; 43(RR-12):1-19.
722. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Pediatric AIDS : Measles immunization in HIV-infected children. Pediatrics 1999; 103(pt 1):1057-1060.
723. Machado C.M., de Souza V.A., Sumita L.M., et al: Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant 2005; 35:787-791.
724. Kurihara N., Reddy S.V., Menaa C., et al: Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 2000; 105:607-614.
725. Wakefield A.J., Murch S.H., Anthony A.: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637-641.

726. Halsey N.A., Hyman S.L.: Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, IL, June 12–13, 2000. Pediatrics 2001; 107:E84.
727. D'Souza Y., Fombonne E., Ward B.J.: No evidence of persisting measles virus in peripheral blood mononlcear cells from children with autism spectrum disorder. Pediatrics 2006; 118:1664-1675.
728. Wakefield A.J., Montgomery S.M.: Measles, mumps, rubella vaccine: through a glass, darkly. Adverse Drug React 2000; 19:1-19.
729. Wakefield A.J., Anthony A., Murch S.H.: Enterocolitis in children with developmental disorders. Am J Gastroenterol 2000; 95:2285-2295.
730. Deer B.: How the case against the MMR vaccine was fixed. BMJ 2011; 342:c5347.
731. Retraction: ileal lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010; 375:445.
732. Demicheli V., Jefferson T., Rivetti A., et al: Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2005; 4:CD004407
733. World Health Organization : WHO position on measles vaccines. Vaccine 2009; 27:7219-7221.
734. de Quadros C.A., Olivé J.M., Hersh B.S., et al: Measles elimination in the Americas: evolving strategies. JAMA 1996; 275:224-229.
735. Centers for Disease Control and Prevention (CDC) : General recommendations on immunization: recommendations of the Advisory Committee on Immunization. MMWR Recomm Rep 2011; 60(RR-2):1-64.
736. Centers for Disease Control and Prevention (CDC) : Notice to readers: licensure of a combined live attenuated measles, mumps, rubella and varicella vaccine. MMWR Morb Mortal Wkly Rep 2006; 54:1212-1214.Errata:MMWR Morb Mortal Wkly Rep 2006; 54:1237.
737. Centers for Disease Control and Prevention (CDC) : Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4):1-40.
738. Centers for Disease Control and Prevention (CDC) : Use of combination measles,mumps, rubella and varicella vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-3):1-12.
739. Nolan T., Bernstein D.I., Block S.L., et al: Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008; 121:508-516.
740. Centers for Disease Control and Prevention. Immunization of Health-Care Personnel. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Recommendations and Reports November 25, 2011 / 60(RR07);1-45. Accessed on 28 June 2012 at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm
740a. Centers for Disease Control and Prevention : Measles - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 20(61):253-257.
741. Centers for Disease Control and Prevention (CDC). Childcare and school immunization requirements: measles 2nd dose. www2a.cdc.gov/nip/schoolsurv/irMeasles2.htm; [accessed 09.05.11].
741a. Centers for Disease Control and Prevention (CDC). School vaccination coverage reports. Coverage estimates for school entry vaccinations. 2009-2010. http://www2.cdc.gov/nip/schoolsurv/nationalavg.asp
742. Centers for Disease Control and Prevention (CDC). Morb Mortal Wkly Rep. MMWR. 2011;60(21);700–704. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a4.htm . (Accessed 28 June 2012)

743. Baughman A.L., Williams W.W., Atkinson W.L., et al: The impact of college pre-matriculation requirements on risk for measles outbreaks. JAMA 1994; 255:1127-1132.
744. Atkinson W.L., Markowitz L.E., Adams N.C., et al: Transmission of measles in medical settings, 1985-1989. Am J Med 1991; 91(Suppl. 3B):320S-324S.
745. Yip F.Y., Papania M.J., Redd S.B.: Measles outbreak epidemiology in the United States, 1993-2001. J Infect Dis 2004; 189(Suppl. 1):S54-S60.
746. Parker Fiebelkorn A., Redd S.B., Gallagher K., et al: Measles in the United States during the postelimination era. J Infect Dis 2010; 202:1520-1528.
748. Subbarao E.K., Amin S., Kumar M.L.: Prevaccination serologic screening for measles in health care workers. J Infect Dis 1991; 163:876-878.
749. Grabowsky M., Markowitz L.: Serologic screening, mass immunization and implications for immunization programs. J Infect Dis 1991; 164:1237-1238.(Accessed on JID website on 28 June 2012.)
750. McLaughlin M., Thomas P., Onorato I., et al: Live viral vaccines in human immunodeficiency virus infected children: a retrospective survey. Pediatrics 1988; 82:229-233.
751. Centers for Disease Control and Prevention (CDC) : Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Recomm Rep 1993; 42(RR-4):1-18.
752. Tomblyn M., Chiller T., Einsele H., et al: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143-1238.
753. Henning K.J., White M.H., Sepkowitz K.A., et al: A national survey of immunization practices following allogenic bone marrow transplantation. JAMA 1997; 277:1148-1151.
754. Ljungman P., Aschan J., Barkholt L., et al: Measles immunity after allogenic stem cell transplantation; influence of donor type, graft type, intensity of conditioning and graft-versus-host disease. Bone Marrow Transplant 2004; 34:589-593.
755. Machado C.M.: Reimmunization after haematopoietic stem cell transplantation. Expert Rev Vaccines 2005; 4:219-228.
756. Scott T.FM., Bonanno D.E.: Reactions to live-measles-virus vaccine in children previously vaccinated with killed-virus vaccine. N Engl J Med 1967; 277:248-250.Accessed 28 June 2012 at
757. Stowe J., Kafatos G., Andrews N., et al: Idiopathic thrombocytopenic purpura and the second dose of MMR. Arch Dis Child 2008; 93:182-183.
758. Centers for Disease Control and Prevention (CDC) : Guidelines for preventing opportunistic infections amng haematopoietic stem cell transplant recipients. Recommendations of the CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplant. MMWR Recomm Rep 2000; 49(RR-10):1-147.
759. Lee C.H., Lee E.G., Lee J.Y., et al: The incidence of tuberculosis after a measles outbreak. Clin Infect Dis 2008; 46:902-904.
760. Starr S., Berkovich S.: The effect of measles, gamma globulin modified measles, and attenuated measles vaccine on the course of treated tuberculosis in children. Pediatrics 1965; 35:97-102.
761. Bellini W.J., Rota J.S., Greer P.W., et al: Measles vaccination death in a child with severe combined immunodeficiency: report of a case [abstract]. Presented at the Annual Meeting of Laboratory Investigation, 1992.
762. Moss W.J., Cutts F., Griffin D.E.: Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 1999; 29:106-112.

763. Shu M., Liu Q., Wang J., et al: Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008. Vaccine 2011; 29:3507-3510.
764. Wood R.A., Berger M., Dreskin S.C., et al: An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008; 122:e771-e777.
765. Pool V., Braun M.M., Celso J.M., et al: Prevalence of anti-IgE antibodies in persons with anaphylaxis following measles-mumps-rubella vaccination in the United States. Pediatrics 2002; 110:e71.
766. Sakaguchi M., Ogura H., Inouye S.: IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995; 96:563-565.
767. Sakaguchi M., Nakayama T., Inouye S.: Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996; 98:1058-1061.
768. Patja A., Makinen-Kiljunen S., Davidkin I., et al: Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 2001; 107:e27.doi:10.1542/peds.107.2.e27.
769. Fasano M.B., Wood R.A., Cooke S.K., et al: Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr 1992; 120:878-881.
770. Herman J.J., Radin R., Schneiderman R.: Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. J Pediatr 1983; 102:196-199.
771. American Academy of Pediatrics : Active immunization. In: Peter G., ed. 1988 Red Book: Report of the Committee on Infectious Diseases, 21st ed. Elk Grove Village, IL: American Academy of Pediatrics; 1998:5-28.
772. Kemp A., Van Asperen P., Mukhi A.: Measles immunization in children with clinical reactions to egg protein. Am J Dis Child 1990; 144:33-35.
773. James J.M., Burks A.W., Roberson P.K., et al: Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262-1266.
774. Siber G.R., Werner B.G., Halsey N.A., et al: Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122:204-211.
775. Oski F.A., Naiman J.L.: Effect of live measles vaccine on the platelet count. N Engl J Med 1966; 275:352-356.
776. Miller E., Waight P., Farrington C.P., et al: Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227-229.
777. Nieminen U., Peltola H., Syrjälä M.T., et al: Acute thrombocytopenic purpura following measles, mumps, and rubella vaccination: a report on 23 patients. Acta Pediatr 1993; 82:267-270.
778. Vlacha V., Forman E.N., Miron D., et al: Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996; 97:738-739.
779. Beeler J., Varricchio F., Wise R.: Thrombocytopenia after immunization with measles vaccines: review of the Vaccine Adverse Event Reporting System (1990 to 1994). Pediatr Infect Dis J 1996; 15:88-90.
780. Drachtman R.A., Murphy S., Ettinger L.J.: Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148:326-327.
781. Centers for Disease Control (CDC) : Adverse Events Following Immunization (Surveillance Report No. 3, 1985–1986). Atlanta, GA, Centers for Disease Control, 1989.
782. Putz M.M., Bouche F.B., de Swart R.L., et al: Experimental vaccines against measles in a world of changing epidemiology. Int J Parasitol 2003; 33:525-545.
783. Pan C.H., Valsamakis A., Colella T., et al: Inaugural article: modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 2005; 102:11581-11588.

784. Pasetti M.F., Barry E.M., Losonsky G., et al: Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J Virol 2003; 77:5209-5217.
785. Capozzo A.V., Ramirez K., Polo J.M., et al: Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol 2006; 176:5671-5681.
786. Song M.K., Vindurampulle C.J., Capozzo A.V., et al: Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol 2005; 79:9854-9861.
787. Stittelaar K.J., de Swart R.L., Vos H.W., et al: Enteric administration of a live attenuated measles vaccine does not induce protective immunity in a macaque model. Vaccine 2002; 20:2906-2912.
788. Conacher M., Alexander J., Brewer J.M.: Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 2001; 19:2965-2974.
789. Sharpe S., Fooks A., Lee J., et al: Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology 2002; 293:210-216.
790. Omer S.B., Hiremath G.S., Halsey N.A.: Respiratory administration of measles vaccine. Lancet 2010; 375:706-708.
791. Higginson D., Theodoratou E., Nair H., et al: An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children. BMC Public Health 2010; 11(Suppl. 3):S31.
792. Bellanti J.A., Zeligs B.J., Mendez-Inocenio J., et al: Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 2004; 22:1214-1220.
793. Hiremath G.S., Omer S.B.: A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccin 2005; 1:30-36.
794. Henao-Restrepo A.M., Greco M., Laurie X., et al: Measles aerosol vaccine project. Procedia in Vaccinology 2 2010.147-150.
795. Cutts F.T., Markowitz L.E.: Successes and failures in measles control. J Infect Dis 1994; 170(Suppl. 1):S32-S41.
796. Black F.L.: Measles endemicity in insular populations: community size and its evolutionary implication. J Theor Biol 1966; 11:207-211.
797. Grenfell B.T., Bjornstad O.N., Kappey J.: Travelling waves of measles and spatial hierarchies in measles epidemics. Nature 2001; 414:716-723.
798. Anderson R.M., May R.M.: Vaccination and herd immunity to infectious diseases. Nature 1985; 318:323-329.
799. Nokes D.J., Williams J.R., Butler A.R.: Towards eradication of measles virus: global progress and strategy evaluation. Vet Microbiol 1995; 44:333-350.
800. Mclean A.R., Anderson R.M.: Measles in developing countries. Part II. The predicted impact of mass immunization. Epidemiol Infect 1988; 100:419-442.
801. Chen R.T., Weierbach R., Bisoffi Z., et al: A ‘post-honeymoon period’ measles outbreak in Muyinga sector, Burundi. Int J Epidemiol 1994; 23:185-193.
802. Agocs M.M., Markowitz L.E., Straub I., et al: The 1988-1989 measles epidemic in Hungary: assessment of vaccine failure. Int J Epidemiol 1992; 21:1007-1013.
803. Thacker S.B., Millar D.J.: Mathematical modeling and attempts to eliminate measles: a tribute to the late professor George Macdonald. Am J Epidemiol 1991; 133:517-525.

804. Conrad J.L., Wallace R., Witte J.J.: The epidemiologic rationale for the failure to eradicate measles in the United States. Am J Public Health 1971; 61:2304-2310.
805. Fine P.E.M.: Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15:265-302.
806. Hethcote H.W.: Measles and rubella in the United States. Am J Epidemiol 1983; 117:2-13.
807. De Serres G., Gay N.J., Farrington C.P.: Epidemiology of transmissible diseases after elimination. Am J Epidemiol 2000; 151:1039-1048.
808. Cutts F.T., Henderson R.H., Clements C.J., et al: Principles of measles control. Bull World Health Organ 1991; 69:1-7.
809. Cutts F.T., Grabowsky M., Markowitz L.E.: The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 1995; 23:95-106.
810. Clemens J.D., Stanton B., Chakraborty J., et al: Measles vaccination and childhood mortality in rural Bangladesh. Am J Epidemiol 1988; 128:1330-1339.
811. Holt E.A., Boulos R., Halsey N.A., et al: Childhood survival in Haiti: protective effect of measles vaccination. Pediatrics 1990; 85:188-194.
812. Aaby P., Pedersen I.R., Knudsen K., et al: Child mortality related to seroconversion or lack of seroconversion after measles vaccination. Pediatr Infect Dis J 1989; 8:197-200.
813. Kabir Z., Long J., Reddaiah V.P., et al: Non-specific effect of measles vaccination on overall child mortality in an area of rural India with high vaccination coverage: a population-based case-control study. Bull World Health Organ 2003; 81:244-250.
814. van den Ent M.V.X., Brown D.W., Hoekstra E.J., et al: Measles mortality reduction contributes substantially to reduction of all cause mortality among children less than five years of age, 1990-2008. J Infect Dis 2011; 204(Suppl. 1):S18-S23.
815. Centers for Disease Control and Prevention (CDC) : Measles: United States, 1996 and the interruption of indigenous transmission. MMWR Morb Mortal Wkly Rep 1997; 46:242-246.
816. Ramsay M.E., Li J., White J., et al: The elimination of indigenous measles transmission in England and Wales. J Infect Dis 2003; 187(Suppl. 1):S198-S207.
817. Duclos P., Redd S.C., Varughese P., et al: Measles in adults in Canada and the United States: implications for measles elimination and eradication. Int J Epidemiol 1999; 28:141-146.
818. King A., Varughese P., De Serres G., et al: Measles elimination in Canada. J Infect Dis 2004; 189(Suppl. 1):S236-S242.
819. Pelletier L., Chung P., Duclos P., et al: A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine 1998; 9:989-996.
820. Hinman A.R., Orenstein W.A., Papania M.J.: Evolution of measles elimination strategies in the United States. J Infect Dis 2004; 189(Suppl. 1):S17-S22.
821. Hersh B.S., Markowitz L.E., Maes E.F., et al: The geography of measles in the United States, 1980-1989. JAMA 1992; 267:1936-1941.
822. Gustafson T.L., Lievens A.W., Brunell P.A., et al: Measles outbreak in a fully immunized secondary school population. N Engl J Med 1987; 316:771-774.
823. Atkinson W.L., Orenstein W.A., Krugman S.: The resurgence of measles in the United States, 1989-1990. Annu Rev Med 1992; 43:451-463.
823a. European Centre for Disease Prevention and Control. Surveillance report: European monthly measles monitoring, 21 February 2012. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2012. Available at http://ecdc.europa.eu/en/publications/publications/sur_emmo_european-monthly-measles-monitoring-february-2012.pdf . Accessed July 3, 2012.

824. Gindler J.S., Atkinson W.L., Markowitz L.E., et al: The epidemiology of measles in the United States in 1989 and 1990. Pediatr Infect Dis J 1992; 11:841-846.
825. National Vaccine Advisory Committee : The measles epidemic: the problems, barriers, and recommendations. JAMA 1991; 266:1547-1552.
826. Centers for Disease Control and Prevention (CDC) : Measles vaccination levels among selected groups of preschool-aged children-United States. MMWR Morb Mortal Wkly Rep 1990; 40:36-39.
827. Centers for Disease Control and Prevention (CDC) : Vaccination coverage of 2-year-old children-United States, 1991-1992. MMWR Morb Mortal Wkly Rep 1993; 42:985-988.
828. Zell E.R., Dietz V., Stevenson J., et al: Low vaccination levels of US preschool and school-age children: retrospective assessments of vaccination coverage, 1991-1992. JAMA 1994; 271:833-839.
829. Papania M.J., Seward J.F., Redd S.B., et al: Epidemiology of measles in the United States, 1997-2001. J Infect Dis 2004; 189(Suppl. 1):S61-S68.
830. Oster N.V., Harpaz R., Redd S.B., et al: International importation of measles virus-United States, 1993-2001. J Infect Dis 2004; 189(Suppl. 1):S48-S53.
831. Hutchins S.S., Bellini W.J., Coronado V., et al: Population immunity to measles in the United States, 1999. J Infect Dis 2004; 189(Suppl. 1):S91-S97.
832. Orenstein W.A.: The role of measles elimination in development of a national immunization program. Pediatr Infect Dis J 2006; 25:1093-1101.
833. Gay N.J., Pelletier L., Duclos P.: Modelling the incidence of measles in Canada: an assessment of the options for vaccination policy. Vaccine 1998; 16:794-801.
834. Dallaire F., De Serres G., Tremblay F.W., et al: Long-Lasting Measles outbreak affecting several unrelated networks of unvaccinated persons. J Infect Dis 2009; 200:1602-1605.
835. Tipples G.A., Gray M., Garbutt M., et al: Genotyping of measles virus in Canada: 1979-2002. J Infect Dis 2004; 189(Suppl. 1):S171-S176.
836. Jansen V.A.A., Stollenwerk N., Jensen H.J., et al: Measles outbreaks in a population with declining vaccine uptake. Science 2003; 301:804.
837. Mankertz A., Mulders M., Shulga S., et al: Molecular genotyping and epidemiology of measles virus transmission in the World Health Organization European Region, 2007-2009. J Infect Dis 2011; 204(Suppl. 1):S335-S342.
838. Mankertz A., et al: Spread of measles virus D-4 Hamburg, Europe, 2008–2011. Emerg Infect Dis. 2011 Au; 17(8):1396-1401.
839. Peltola H., Davidkin I., Paunio M., et al: Mumps and rubella eliminated from Finland. JAMA 2000; 284:2643-2647.
840. Gidding H.F., Riddell M.A., McIntyre P.B., et al: Elimination of endemic measles transmission in Australia. Bull World Health Organ 2009; 87:64-71.Epub November 4, 2008
841. Centers for Disease Control and Prevention (CDC) : Elimination of measles: South Korea, 2001-2006. MMWR Morb Mortal Wkly Rep 2007; 56:304-307.
842. Ciofi Degli Atti M.L., Filia A., et al: Assessment of measles incidence, measles-related complications and hospitalizations during an outbreak in a southern Italian region. Vaccine 2006; 24:1332-1338.
843. Wichmann O., Siedler A., Sagebiel D., et al: Further efforts needed to achieve measles elimination in Germany: results of an outbreak investigation. Bull World Health Organ 2009; 87:108-115.
844. Delaporte E., Richard J.L., Wyler Lazarevic C.A., et al: Ongoing measles outbreak Geneva, Switzerland, January to March 2011. Euro Surveill. 2011; Mar 10; 16(10):pii: 19815.(Accessed 28 June 2012)
845. Siedler A., Tischer A., et al: Progress towards measles elimination in Germany. J Infect Dis 2003; 187(Suppl. 1):S208-S216.

846. Martin R., Wassilak S., Emiroglu N., et al: What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003-2009 and essential accelerated actions. J Infect Dis 2011; 204(Suppl. 1):S325-S334.
847. Onishchenko G., Ezhlova E., Gerasimova A., et al: Progress toward measles elimination in the Russian Federation, 2003-2009. J Infect Dis 2011; 204(Suppl. 1):S366-S372.
848. Khetsuriani N., Deshevoi S., Goel A., et al: Supplementary immunization activities to achieve measles elimination: experience of the European Region. J Infect Dis 2011; 204(Suppl. 1):S343-S352.
849. Spika J.S., Aidyralieva C., Mukharskaya L., et al: Measles outbreak in the Ukraine. Euro Surveill 2006; 11:E060309.1.
850. Marinova L., Muscat M., Mihneva Z., et al: An update on an ongoing measles outbreak in Bulgaria. Euro Surveill 2009; 14:pii=19442.
851. World Health Organization : Outbreak news. Measles outbreaks in Europe. Wkly Epidemiol Rec 2011; 86:173-174.
852. Cutts F.T., Olive J.-M.: Vaccination programs in developing countries. In: Plotkin S.A., Orenstein W.A., ed. Vaccines, 3rd ed. Philadelphia: WB Saunders; 1999:1047-1073.
853. Molinert H.T., Rodriguez R., Galindo M.: Principales Aspectos del Programa Nacional de Immunizacion de la Republica de Cuba. Havana, Cuba, Ministry of Health, 1993.
854. Martin R., Wassilak S., Emiroglu N., et al: What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003-2009 and essential accelerated actions. J Infect Dis 2011; 204(Suppl. 1):S325-S334.
855. Prevots D.R., Parise M.S., Segatto T.CV., et al: Interruption of measles transmission in Brazil, 2000. J Infect Dis 2003; 187(Suppl. 1):S111-S120.
856. Rota P.A., Bellini W.J.: Update on global distribution of wild-type measles viruses. J Infect Dis 2003; 187(Suppl. 1):S270-S276.
857. Castillo-Solorzano C., Ruiz Matus C., Flannery B., et al: The Americas: paving the road toward global measles eradication. J Infect Dis 2011; 204(Suppl. 1):S270-S278.
858. Pan American Health Organization : Measles elimination in Mexico. EPI Newslett 2004; 26:4-6.
859. Pan American Health Organization : Measles outbreak reported in Venezuela. Immunization Newslett 2006; 28:1-2.
860. Parker A.A., Staggs W., Dayan G.H., et al: Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006; 355:447-455.
861. Chen S.Y., Anderson S., Kutty P.K., et al: Healthcare-associated measles outbreak in the U.S. after an importation: challenges and economic impact. J Infect Dis 2011; 203:1517-1525.
862. Sugerman D.E., Barskey A.E., Delea M.G., et al: Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 2010; 125:747-755.
863. Biellik R., Madema S., Taole A., et al: First 5 years of measles elimination in southern Africa: 1996-2000. Lancet 2002; 359:1564-1568.
864. World Health Organization : Measles outbreaks and progress towards meeting measles pre-elimination goals: WHO African Region, 2009-2010. Wkly Epidemiol Rec 2011; 86:129-136.
865. www.measlesinitiative.org
866. Wolfson L.J., Strebel P.M., Gacic-Dobo M., et al: Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007; 369:191-200.
867. Cutts F.T., Henao-Restrepo A.-M., Olive J.-M.: Measles elimination: progress and challenges. Vaccine 1999; 17:S47-S52.

868. Olive J.-M., Aylward B.R., Melgaard B.: Disease eradication as a public health strategy: is measles next?. World Health Stat Q 1997; 50:185-187.
869. Meissner H.C., Strebel P.M., Orenstein W.A.: Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 2004; 114:1065-1069.
870. Keegan R., Dabbagh A., Strebel P.M., et al: Comparing measles with previous eradication programs: enabling and constraining factors. J Infect Dis 2011; 204(Suppl. 1):S54-S61.
871. Strebel P.M., Cochi S.L., Hoekstra E., et al: Commentary: a world without measles. J Infect Dis 2011; 204(Suppl. 1):S1-S3.
872. Levin A., Burgess C., Garrison L.P., et al: Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis 2011; 204(Suppl. 1):S98-106.
873. World Health Organization : Meeting of the Strategic Advisory Group of Experts on Immunization, November 2010: summary, conclusions and recommendations. Wkly Epidemiol Rec 2011; 86:1-16.
874. The Bill and Melinda Gates Foundation : Measles: closing the window of vulnerability for children. www.gatesfoundation.org/storygallery/measles.htm;
875. Robertson S.E., Markowitz L.E., Berry D.A., et al: A million dollar measles outbreak: epidemiology, risk factors and a selective re-vaccination strategy. Public Health Rep 1992; 107:24-31.

ZAUŠNJACI

1. Hamilton R.: An account of a distemper by the common people of England vulgarly called the mumps. Transactions of the Royal Society of Edinburgh 1790; 2:59-72.
2. Gordon J.E., Heeren R.H.: The epidemiology of mumps. Am J Med Sci 1940; 200:338-359.
3. Hirsch A.: Handbook of Geographical and Historical Pathology. Volume I: Acute Infective Diseases. 2nd ed. London, England, Sydenham Society, 1883.
4. Penttinen K., Cantell K., Somer P., et al: Mumps vaccination in the Finnish defense forces. Am J Epidemiol 1968; 88:234-244.
5. Gordon J., Kilham L.: Ten years in the epidemiology of mumps. Am J Med Sci 1949; 218:338-359.
6. Postovit V.A.: Epidemic parotitis in adults [in Russian]. Voen Med Zh March 1983.38-41.
7. Arday D.R., Kanjarpane D.D., Kelley P.W.: Mumps in the US Army 1980-86: should recruits be immunized?. Am J Public Health 1989; 79:471-474.
8. Kuhlman J.C.: Mumps outbreak aboard the USS Reuben James. Mil Med 1994; 159:255-257.
9. Granata S.: Sulla etiologia degli orecchioni da virus filtrable. Med Ital 1908; 6:647-649.
10. Nicolle C., Conseil E.: Essai de reproduction experimentale des oreillons chez le singe. Compt Rend Soc de Biol 1913; 75:217.
11. Gordon M.H.: Report of the Medical Officer. Great Britain Local Gov Public Health and Medical Subjects 1914.96.
12. Johnson C.D., Goodpasture E.W.: The etiology of mumps. Am J Hyg 1935; 21:46-57.
13. Habel K.: Cultivation of mumps virus in the developing chick embryo and its application to studies of immunity to mumps in man. Public Health Rep 1945; 60:201-212.
14. Enders J.F., Levens J.H.: Attenuation of virulence with retention of antigenicity of mumps virus after passage in the embryonated egg. J Immunol 1946; 54:283-291.
15. Habel K.: Preparation of mumps vaccine and immunization of monkeys against experimental mumps infection. Public Health Rep 1946; 61:1655-1664.

16. Habel K.: Vaccination of human beings against mumps; vaccine administered at the start of an epidemic, I: incidence and severity of mumps in vaccinated and control groups. Am J Hyg 1951; 54:295-311.
17. Habel K.: Immunity response in mumps with complications. J Lab Clin Med 1952; 39:785-790.
18. Smorodintsev A.A., Luzyanina T.Y., Mikutskaya B.A.: Data on the efficiency of live mumps vaccine from chick embryo cell cultures. Acta Virol 1965; 62:240-247.
19. Weibel R.E., Stokes Jr J., Buynak E.B., et al: Live attenuated mumps-virus vaccine, 3: clinical and serologic aspects in a field evaluation. N Engl J Med 1967; 276:245-251.
20. Reed D., Brown G., Merrick R.: A mumps epidemic on St. George Island, Alaska. JAMA 1967; 199:113-117.
21. Philip R.N., Reinhard K.P., Lachman D.B.: Observations on a mumps epidemic in a "virgin" population. Am J Hyg 1959; 69:91-111.
22. Brunell P.A., Brickman A., O'Hare D., et al: Ineffectiveness of isolation of patients as a method of preventing the spread of mumps: failure of the mumps skin-test antigen to predict immune status. N Engl J Med 1968; 279:1357-1361.
23. Falk W.A., Buchan K., Dow M., et al: The epidemiology of mumps in southern Alberta 1980-1982. Am J Epidemiol 1989; 130:736-749.
24. Cooney M.K., Fox J.P., Hall C.E.: The Seattle Virus Watch, VI: observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol 1975; 101:532-551.
25. Henle G., Henle W., Wendell K., et al: Isolation of mumps virus from human beings with induced apparent or inapparent infections. J Exp Med 1948; 88:223-232.
26. Koskiniemi M., Vaheri A.: Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet 1989; 1:31-34.
27. Koskiniemi M., Donner M., Pettay O.: Clinical appearance and outcome in mumps encephalitis in children. Acta Paediatr Scand 1983; 72:603-609.
28. Leboreiro-Fernandez A., Moura-Ribeiro M.V., Leboreiro I.E., et al: Mumps meningoencephalitis: an epidemiological approach. Arq Neuropsiquiatr 1997; 55:12-15.
29. Cox M.J., Anderson R.M., Bundy D.A.: Seroepidemiological study of the transmission of the mumps virus in St. Lucia, West Indies. Epidemiol Infect 1989; 102:147-160.
30. Hope-Simpson R.E.: Infectiousness of comminicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952; 2:549-554.
31. McGuiness A.C., Gall E.A.: Mumps at army camps in 1943. War Med 1944; 5:95-104.
32. Schwarz N.G., Bernard H., Melnic A., et al: Mumps outbreak in the Republic of Moldova, 2007-2008. Pediatr Infect Dis J 2010; 29:703-706.
33. Bjorvatn B.: Mumps virus recovered from testicles by fine-needle aspiration biopsy in cases of mumps orchitis. Scand J Infect Dis 1973; 5:3-5.
34. Dejucq N., Jegou B.: Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev 2001; 65:208-231.
35. Beard C.M., Benson R.C., Kelalis P.P., et al: The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clin Proc 1977; 52:3-7.
36. Swerdlow A.J., Huttly S.R., Smith P.G.: Testicular cancer and antecedent diseases. Br J Cancer 1987; 55:97-103.
37. Brown L.M., Pottern L.M., Hoover R.N.: Testicular cancer in young men: the search for causes of the epidemic increase in the United States. J Epidemiol Community Health 1987; 41:349-354.
38. Dayan G.H., Quinlisk M.P., Parker A.A., et al: Recent resurgence of mumps in the United States. N Engl J Med 2008; 358:1580-1589.

39. Maynard J.E., Shramek G., Noble G.R.: Use of attenuated live mumps virus vaccine during a “virgin soil” epidemic of mumps on St. Paul Island, Alaska. Am J Epidemiol 1970; 92:301-306.
40. Prinz W., Taubert H.D.: Mumps in pubescent females and its effect on later reproductive function. Gynaecologia 1969; 167:23-27.
41. Kurtz J.B., Tomlinson A.H., Pearson J.: Mumps virus isolated from a fetus. Br Med J (Clin Res Ed) 1982; 284:471.
42. Jones J.F., Ray C.G., Fulginiti V.A.: Perinatal mumps infection. J Pediatr 1980; 96:912-914.
43. Siegel M., Fuerst H.T., Peress N.S.: Comparative fetal mortaltiy in matenal virus diseases: a prospective study on rubella, measles, mumps, chickenpox, and hepatitis. N Engl J Med 1966; 274:768-771.
44. Siegel M.: Congenital malformations following chickenpox, measles, mumps, and hepatitis: results of a cohort study. JAMA 1973; 226:1521-1524.
45. Sterner G., Grandien M.: Mumps in pregnancy at term. Scand J Infect Dis Suppl 1990; 71:36-38.
46. Groenendaal F., Rothbarth P.H., van den Anker J.N., et al: Congenital mumps pneumonia: a rare cause of neonatal respiratory distress. Acta Paediatr Scand 1990; 79:1252-1254.
47. Lacour M., Maherzi M., Vienny H., et al: Thrombocytopenia in a case of neonatal mumps infection: evidence for further clinical presentations. Eur J Pediatr 1993; 152:739-741.
48. Reman O., Freymuth F., Laloum D., et al: Neonatal respiratory distress due to mumps. Arch Dis Child 1986; 61:80-81.
49. Nishino H., Engel A.G., Rima B.K.: Inclusion body myositis: the mumps virus hypothesis. Ann Neurol 1989; 25:260-264.
50. Boxall N., Kubinyiova M., Prikazsky V.: An increase in the number of mumps cases in the Czech Republic, 2005-2006. Euro Surveill 2008; 13(16):
51. Dacou-Voutetakis C., Constantinidis M., Moschos A., et al: Diabetes mellitus following mumps: insulin reserve. Am J Dis Child 1974; 127:890-891.
52. Hyoty H., Leinikki P., Reunanen A., et al: Mumps infections in the etiology of type 1 (insulin-dependent) diabetes. Diabetes Res 1988; 9:111-116.
53. Sultz H.A., Hart B.A., Zielezny M., et al: Is mumps virus an etiologic factor in juvenile diabetes mellitus. J Pediatr 1975; 86:654-656.
54. Otten A., Helmke K., Stief T.: Mumps, mumps vaccination, islet cell antibodies and the first manifestation of diabetes mellitus type I. Behring Inst Mitt July 1984.83-88.
55. Goto A., Takahashi Y., Kishimoto M., et al: A case of fulminant type 1 diabetes associated with significant elevation of mumps titers. Endocr J 2008; 55:561-564.
56. Russell R.R., Donald J.C.: The neurological complications of mumps. Br Med J 1958; 30:27-30.
57. Bang H.O., Bang J.: Involvement of the central nervous system in mumps. Acta Med Scand 1943; 113:487-505.
58. Bruyn H.B., Sexton H.M., Brainerd H.D.: Mumps meningoencephalitis: a clinical review of 119 cases with one death. Calif Med 1957; 86:153-160.
59. Brown J.W., Kirkland H.B., Hein G.E.: Central nervous system involvement during mumps. Am J Med Sci 1948; 215:434-441.
60. Bennett A.D., Modlin J., Orenstein W.A., et al: Current status of mumps in the United States. J Infect Dis 1975; 132:106-109.
61. Wagenvoort J.H., Harmsen M., Boutahar-Trouw B.J.: Epidemiology of mumps in the Netherlands. J Hyg (Lond) 1980; 85:313-326.
62. Cohen H.A., Ashkenazi A., Nussinovitch M., et al: Mumps-associated acute cerebellar ataxia. Am J Dis Child 1992; 146:930-931.

63. Nussinovitch M., Prais D., Volovitz B.: Post-infectious acute cerebellar ataxia in children. Clin Pediatr (Phila) 2003; 42:581-584.
64. Bansal R., Kalita J., Misra U.K., et al: Myelitis: a rare presentation of mumps. Pediatr Neurosurg 1998; 28:204-206.
65. Gibbons J.L., Miller H.G., Stanton J.B.: Para-infectious encephalomyelitis and related syndromes; a critical review of the neurological complications of certain specific fevers. Q J Med 1956; 25:427-505.
66. Kilham L., Levens J., Enders J.F.: Nonparalytic poliomyelitis and mumps meningoencephalitis: differential diagnosis. J Am Med Assoc 1949; 140:934-936.
67. Johnstone J.A., Ross C.A., Dunn M.: Meningitis and encephalitis associated with mumps infection: a 10-year survey. Arch Dis Child 1972; 47:647-651.
68. Ogata H., Oka K., Mitsudome A.: Hydrocephalus due to acute aqueductal stenosis following mumps infection: report of a case and review of the literature. Brain Dev 1992; 14:417-419.
69. Timmons G.D., Johnson K.P.: Aqueductal stenosis and hydrocephalus after mumps encephalitis. N Engl J Med 1970; 283:1505-1507.
70. Witte J.J., Karchmer A.W.: Surveillance of mumps in the United States as background for use of vaccine. Public Health Rep 1968; 83:5-100.
71. Association for the Study of Infectious Disease : A retrospective survey of the complications of mumps. J R Coll Gen Pract 1974; 24:552-556.
72. Carr M.J., Moss E., Waters A., et al: Molecular epidemiological evaluation of the recent resurgence in mumps virus infections in Ireland. J Clin Microbiol 2010; 48:3288-3294.
73. Noren G.R., Adams Jr P., Anderson R.C.: Positive skin reactivity to mumps virus antigen in endocardial fibroelastosis. J Pediatr 1963; 62:604-606.
74. Ni J., Bowles N.E., Kim Y.H., et al: Viral infection of the myocardium in endocardial fibroelastosis: molecular evidence for the role of mumps virus as an etiologic agent. Circulation 1997; 95:133-139.
75. Rosenberg D.H.: Electrocardiographic changes in epidemic parotitis (mumps). Proc Soc Exp Biol Med 1945; 58:9-11.
76. Roberts W.C., Fox III S.M.: Mumps of the heart: clinical and pathologic features. Circulation 1965; 32:342-345.
77. Chaudary S., Jaski B.E.: Fulminant mumps myocarditis. Ann Intern Med 1989; 110:569-570.
78. Arita M., Ueno Y., Masuyama Y.: Complete heart block in mumps myocarditis. Br Heart J 1981; 46:342-344.
79. Leff R.L., Love L.A., Miller F.W., et al: Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992; 339:1192-1195.
80. Fox S.A., Ward B.K., Robbins P.D., et al: Inclusion body myositis: investigation of the mumps virus hypothesis by polymerase chain reaction. Muscle Nerve 1996; 19:23-28.
81. Enders J.F.: Techniques of laboratory diagnosis, tests for susceptibility, and experiments on specific prophylaxis. J Pediatr 1946; 29:129-142.
82. Utz J.P., Houk V.N., Alling D.W.: Clinical and laboratory studies of mumps, IV: viruria and abnormal renal function. N Engl J Med 1964; 270:1283-1286.
83. Lin C.Y., Chen W.P., Chiang H.: Mumps associated with nephritis. Child Nephrol Urol 1990; 10:68-71.
84. Utz J.P., Szwed C.F., Kasel J.A.: Clinical and laboratory studies of mumps, II: detection and duration of excretion of virus in urine. Proc Soc Exp Biol Med 1958; 99:259-261.
85. Hall R., Richards H.: Hearing loss due to mumps. Arch Dis Child 1987; 62:189-191.
86. Vuori M., Lahikainen E.A., Peltonen T.: Perceptive deafness in connection with mumps: a study of 298 servicemen suffering from mumps. Acta Otolaryngol 1962; 55:231-236.

87. Okamoto M., Shitara T., Nakayama M., et al: Sudden deafness accompanied by asymptomatic mumps. Acta Otolaryngol Suppl 1994; 514:45-48.
88. Bitnun S., Rakover Y., Rosen G.: Acute bilateral total deafness complicating mumps. J Laryngol Otol 1986; 100:943-945.
89. Hashimoto H., Fujioka M., Kinumaki H.: An office-based prospective study of deafness in mumps. Pediatr Infect Dis J 2009; 28:173-175.
90. Gordon S.C., Lauter C.B.: Mumps arthritis: a review of the literature. Rev Infect Dis 1984; 6:338-344.
91. Harel L., Amir J., Reish O., et al: Mumps arthritis in children. Pediatr Infect Dis J 1990; 9:928-929.
92. Mulaosmanović V., Sakić M., Ferhatović M.: Secondary autoimmune hemolytic anemia caused by epidemic parotitis virus [in Croatian]. Med Arh 2002; 56(3 suppl 1):46-47.
93. O'Brien P.K., Smith D.S., Galpin O.P.: Acute pancreatitis and haemolytic anaemia associated with mumps-virus infection. Br Med J 1965; 2:1529.
94. Eylan E., Zmucky R., Sheba C.: Mumps virus and subacute thyroiditis: evidence of a causal association. Lancet 1957; 272:1062-1063.
95. Parmar R.C., Bavdekar S.B., Sahu D.R., et al: Thyroiditis as a presenting feature of mumps. Pediatr Infect Dis J 2001; 20:637-638.
96. Famma P.G., Paton W.B., Bostock M.I.: Thrombocytopenic purpura complicating mumps. Br Med J 1964; 2:1244.
97. Nasab A.R.: Thrombocytopenic purpura as a complication of mumps. Clin Pediatr (Phila) 1971; 10:420-421.
98. Okazaki K., Tanabayashi K., Takeuchi K., et al: Molecular cloning and sequence analysis of the mumps virus gene encoding the L protein and the trailer sequence. Virology 1992; 188:926-930.
99. Elango N., Varsanyi T.M., Kovamees J., et al: Molecular cloning and characterization of six genes, determination of gene order and intergenic sequences and leader sequence of mumps virus. J Gen Virol 1988; 69(pt 11):2893-2900.
100. Elliott G.D., Yeo R.P., Afzal M.A., et al: Strain-variable editing during transcription of the P gene of mumps virus may lead to the generation of non-structural proteins NS1 (V) and NS2. J Gen Virol 1990; 71(pt 7):1555-1560.
101. Paterson R.G., Lamb R.A.: RNA editing by G-nucleotide insertion in mumps virus P-gene mRNA transcripts. J Virol 1990; 64:4137-4145.
102. Lamb R.A., Paterson R.G., Jardetzky T.S.: Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology 2006; 344:30-37.
103. Curran J., Kolakofsky D.: Replication of paramyxoviruses. Adv Virus Res 1999; 54:403-422.
104. Bankamp B., Horikami S.M., Thompson P.D., et al: Domains of the measles virus N protein required for binding to P protein and self-assembly. Virology 1996; 216:272-277.
105. Houben K., Marion D., Tarbouriech N., et al: Interaction of the C-terminal domains of Sendai virus N and P proteins: comparison of polymerase-nucleocapsid interactions within the paramyxovirus family. J Virol 2007; 81:6807-6816.
106. Harrison M.S., Sakaguchi T., Schmitt A.P.: Paramyxovirus assembly and budding: building particles that transmit infections. Int J Biochem Cell Biol 2010; 42:1416-1429.
107. Takimoto T., Portner A.: Molecular mechanism of paramyxovirus budding. Virus Res 2004; 106:133-145.
108. Merz D.C., Wolinsky J.S.: Biochemical features of mumps virus neuraminadases and their relative relationship with pathogenicity. Virology 1981; 114:218-227.
109. Jensik S.C., Silver S.: Polypeptides of mumps virus. J Virol 1976; 17:363-373.

110. Malik T.H., Wolbert C., Mauldin J., et al: Functional consequences of attenuating mutations in the haemagglutinin neuraminidase, fusion and polymerase proteins of a wild-type mumps virus strain. J Gen Virol 2007; 88(pt 9):2533-2541.
111. Fujii N., Yokosawa N., Shirakawa S.: Suppression of interferon response gene expression in cells persistently infected with mumps virus, and restoration from its suppression by treatment with ribavirin. Virus Res 1999; 65:175-185.
112. Kubota T., Yokosawa N., Yokota S., et al: C terminal CYS-RICH region of mumps virus structural V protein correlates with block of interferon alpha and gamma signal transduction pathway through decrease of STAT 1-alpha. Biochem Biophys Res Commun 2001; 283:255-259.
113. Nishio M., Garcin D., Simonet V., et al: The carboxyl segment of the mumps virus V protein associates with Stat proteins in via a tryptophan-rich motif. Virology 2002; 300:92-99.
114. Wilson R.L., Fuentes S.M., Wang P., et al: Function of small hydrophobic proteins of paramyxovirus. J Virol 2006; 80:1700-1709.
115. Liang Y., Ma S., Yang Z., et al: Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine 2008; 26:4276-4283.
116. Somboonthum P., Yoshii H., Okamoto S., et al: Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. Vaccine 2007; 25:8741-8755.
117. Houard S., Varsanyi T.M., Milican F., et al: Protection of hamsters against experimental mumps virus (MuV) infection by antibodies raised against the MuV surface glycoproteins expressed from recombinant vaccinia virus vectors. J Gen Virol 1995; 76(pt 2):421-423.
118. Love A., Rydbeck R., Utter G., et al: Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis. J Virol 1986; 58:220-222.
119. Lemon K., Rima B.K., McQuaid S., et al: The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence. J Virol 2007; 81:8293-8302.
120. Malik T.H., Wolbert C., Nerret L., et al: Single amino acid changes in the mumps virus HN and L proteins are associated with neuroattenuation. J Gen Virol 2009; 90:1741-1747.
121. Rydbeck R., Love A., Orvell C., et al: Antigenic variation of envelope and internal proteins of mumps virus strains detected with monoclonal antibodies. J Gen Virol 1986; 67(pt 2):281-287.
122. Orvell C.: The reactions of monoclonal antibodies with structural proteins of mumps virus. J Immunol 1984; 132:2622-2629.
123. Jin L., Rima B., Brown D., et al: Proposal for genetic characterisation of wild-type mumps strains: preliminary standardisation of the nomenclature. Arch Virol 2005; 150:1903-1909.
124. Palacios G., Jabado O., Cisterna D., et al: Molecular identification of mumps virus genotypes from clinical samples: standardized method of analysis. J Clin Microbiol 2005; 43:1869-1878.
125. Kunkel U., Driesel G., Henning U., et al: Differentiation of vaccine and wild mumps viruses by polymerase chain reaction and nucleotide sequencing of the SH gene: brief report. J Med Virol 1995; 45:121-126.
126. Santos C.L., Ishida M.A., Foster P.G., et al: Detection of a new mumps virus genotype during parotitis epidemic of 2006-2007 in the State of Sao Paulo. Brazil. J Med Virol 2008; 80:323-329.
127. Mühlemann K.: The molecular epidemiology of mumps virus. Infect Genet Evol 2004; 4:215-219.

128. Johansson B., Tecle T., Orvell C.: Proposed criteria for classification of new genotypes of mumps virus. Scand J Infect Dis 2002; 34:355-357.
129. Ivancic-Jelecki J., Santak M., Forcic D.: Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains. Infect Genet Evol 2008; 8:603-613.
130. Yamada A., Takeuchi K., Tanabayashi K., et al: Sequence variation of the P gene among mumps virus strains. Virology 1989; 172:374-376.
131. Saito H., Takahashi Y., Harata S., et al: Isolation and characterization of mumps virus strains in a mumps outbreak with a high incidence of aseptic meningitis. Microbiol Immunol 1996; 40:271-275.
132. Forsey T., Mawn J.A., Yates P.J., et al: Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxynucleotide sequencing. J Gen Virol 1990; 71(pt 4):987-990.
133. Tecle T., Johansson B., Yun Z., et al: Antigenic and genetic characterization of the fusion (F) protein of mumps virus strains. Arch Virol 2000; 145:1199-1210.
134. Uchida K., Shinohara M., Shimada S., et al: Characterization of the F gene of contemporary mumps virus strains isolated in Japan. Microbiol Immunol 2003; 47:167-172.
135. Yates P.J., Afzal M.A., Minor P.D.: Antigenic and genetic variation of the HN protein of mumps virus strains. J Gen Virol 1996; 77(pt 10):2491-2497.
136. Lee J.Y., Kim Y.Y., Shin G.C., et al: Molecular characterization of two genotypes of mumps virus circulated in Korea during 1998-2001. Virus Res 2003; 97:111-116.
137. Rubin S.A., Mauldin J., Chumakov K., et al: Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine 2005; 24:2668.
138. Amexis G., Rubin S., Chatterjee N., et al: Identification of a new genotype H wild-type mumps virus strain and its molecular relatedness to other virulent and attenuated strains. J Med Virol 2003; 70:284-286.
139. Ivancic J., Gulija T.K., Forcic D., et al: Genetic characterization of L-Zagreb mumps vaccine strain. Virus Res 2005; 109:95-105.
140. Sauder C.J., Zhang C.X., Link M.A., et al: Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence. Vaccine 2009; 27:5822-5829.
141. Rafiefard F., Johansson B., Tecle T., et al: Characterization of mumps virus strains with varying neurovirulence. Scand J Infect Dis 2005; 37:330-337.
142. Tecle T., Johansson B., Jejcic A., et al: Characterization of three co-circulating genotypes of the small hydrophobic protein gene of mumps virus. J Gen Virol 1998; 79(pt 12):2929-2937.
143. Tecle T., Mickiene A., Johansson B., et al: Molecular characterisation of two mumps virus genotypes circulating during an epidemic in Lithuania from 1998 to 2000. Arch Virol 2002; 147:243-253.
144. Gut J.P., Lablache C., Behr S., et al: Symptomatic mumps virus reinfections. J Med Virol 1995; 45:17-23.
145. Nojd J., Tecle T., Samuelsson A., et al: Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 2001; 19:1727-1731.
146. Montes M., Cilla G., Artieda J., et al: Mumps outbreak in vaccinated children in Gipuzkoa (Basque Country). Spain. Epidemiol Infect 2002; 129:551-556.
147. Server A.C., Merz D.C., Waxham M.N., et al: Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun 1982; 35:179-186.
148. Foy H.M., Cooney M.K., Hall C.E., et al: Isolation of mumps virus from children with acute lower respiratory tract disease. Am J Epidemiol 1971; 94:467-472.

149. Meyer M.B.: An epidemiologic study of mumps: its spread in schools and families. Am J Hyg 1962; 75:259-281.
150. Wolinsky J.S., Klassen T., Baringer J.R.: Persistance of neuroadapted mumps virus in brains of newborn hamsters after intraperitoneal inoculation. J Infect Dis 1976; 133:260-267.
151. Fleischer B., Kreth H.W.: Mumps virus replication in human lymphoid cell lines and in peripheral blood lymphocytes: preference for T cells. Infect Immun 1982; 35:25-31.
152. Ukkonen P., Granstrom M.L., Penttinen K.: Mumps-specific immunoglobulin M and G antibodies in natural mumps infection as measured by enzyme-linked immunosorbent assay. J Med Virol 1981; 8:131-142.
153. Overman J.R.: Viremia in human mumps virus infections. Arch Intern Med 1958; 102:354-356.
154. Ennis F.A., Jackson D.: Isolation of virus during the incubation period of mumps infection. J Pediatr 1968; 72:536-537.
155. Utz J.P., Kasel J.A., Cramblett H.G., et al: Clinical and laboratory studies of mumps, I: laboratory diagnosis by tissue-culture techniques. N Engl J Med 1957; 257:497-502.
156. Leymaster O.R., Ward T.G.: Direct isolation of mumps virus in chick embryos. Proc Soc Exp Biol Med 1947; 65:346-348.
157. Polgreen P.M., Bohnett L.C., Cavanaugh J.E., et al: The duration of mumps virus shedding after the onset of symptoms. Clin Infect Dis 2008; 46:1447-1449.
158. Kutty P.K., Kyaw M.H., Dayan G.H., et al: Guidance for isolation precautions for mumps in the United States: a review of the scientific basis for policy change. Clin Infect Dis 2010; 50:1619-1628.
159. Jalal H., Bahadur G., Knowles W., et al: Mumps epididymo-orchitis with prolonged detection of virus in semen and the development of anti-sperm antibodies. J Med Virol 2004; 73:147-150.
160. Ternavasio-de la Vega H.G., Boronat M., Ojeda A., et al: Mumps orchitis in the post-vaccine era (1967-2009): a single-center series of 67 patients and review of clinical outcome and trends. Medicine (Baltimore) 2010; 89:96-116.
161. Le G.R., Mouchel T., Ruffault A., et al: Mumps virus decreases testosterone production and gamma interferon–induced protein 10 secretion by human Leydig cells. J Virol 2003; 77:3297-3300.
162. Clifford V., Wadsley J., Jenner B., et al: Mumps vaccine associated orchitis: evidence supporting a potential immune-mediated mechanism. Vaccine 2010; 28:2671-2673.
163. Johnson R.T., Johnson K.P.: Myxoviruses and infections of the nervous system. Neurology 1968; 18(1 pt 2):101-103.
164. Johnson R.T., Mims G.A.: Pathogenesis for viral infections of the nervous system. N Engl J Med 1968; 278:84-92.
165. Yamauchi T., Wilson C., St Geme Jr J.W.: Transmission of live, attenuated mumps virus to the human placenta. N Engl J Med 1974; 290:710-712.
166. Kabakus N., Aydinoglu H., Yekeler H., et al: Fatal mumps nephritis and myocarditis. J Trop Pediatr 1999; 45:358-360.
167. Kabakus N., Aydinoglu H., Bakkaloglu S.A., et al: Mumps interstitial nephritis: a case report. Pediatr Nephrol 1999; 13:930-931.
168. Hughes W.T., Steigman A.J., Delong H.F.: Some implications of fatal nephritis associated with mumps. Am J Dis Child 1966; 111:297-301.
169. Dastur F.: Mumps and acute tubular necrosis. Practitioner 1968; 201:796-797.
170. Lemoine G.H., Lapasset F.: A case of mumps pancreatitis with autopsy. Bull et Mem Soc Med d hop de Paris 1905; 22:640-647.
171. Dopter G., Repaci G.: Contribution a l'etude anatomo-pathologique des oreillons. Arch de Med Exper et d'anat Path 1909; 21:533-545.

172. Huppertz H.I., Chantler J.K.: Restricted mumps virus infection of cells derived from normal human joint tissue. J Gen Virol 1991; 72(pt 2):339-347.
173. Huppertz H.I., Niki N.P., Chantler J.K.: Susceptibility of normal human joint tissue to viruses. J Rheumatol 1991; 18:699-704.
174. Westmore G.A., Pickard B.H., Stern H.: Isolation of mumps virus from the inner ear after sudden deafness. Br Med J 1979; 1:14-15.
175. Mizushima N., Murakami Y.: Deafness following mumps: the possible pathogenesis and incidence of deafness. Auris Nasus Larynx 1986; 13(suppl 1):S55-S57.
176. Lindsay J.R., Davey P.R., Ward P.H.: Inner ear pathology in deafness due to mumps. Ann Otol Rhinol Laryngol 1960; 69:918-935.
177. Unal M., Katircioglu S., Karatay M.C., et al: Sudden total bilateral deafness due to asymptomatic mumps infection. Int J Pediatr Otorhinolaryngol 1998; 45:167-169.
178. Tanaka K., Fukuda S., Suenaga T., et al: Experimental mumps virus–induced labyrinthitis. Immunohistochemical and ultrastructural studies. Acta Otolaryngol Suppl 1988; 456:98-105.
179. Bjorvatn B.: Incidence and persistence of mumps-specific IgM and IgA in the sera of mumps patients. Scand J Infect Dis 1974; 6:125-129.
180. Brown G.C., Baublis J.V., O'Leary T.P.: Development and duration of mumps fluorescent antibodies in various immunoglobulin fractions of human serum. J Immunol 1970; 104:86-94.
181. Friedman M.G.: Salivary IgA antibodies to mumps virus during and after mumps. J Infect Dis 1981; 143:617.
182. van der Logt J.T., Heessen F.W., van Loon A.M., et al: Hemadsorption immunosorbent technique for determination of mumps immunoglobulin M antibody. J Clin Microbiol 1982; 15:82-86.
183. Narita M., Matsuzono Y., Takekoshi Y., et al: Analysis of mumps vaccine failure by means of avidity testing for mumps virus–specific immunoglobulin G. Clin Diagn Lab Immunol 1998; 5:799-803.
184. Gotlieb T., Bashe Jr. W.J., Henle G., et al: Studies on the prevention of mumps, V: the development of a neutralization test and its application to convalescent sera. J Immunol 1953; 71:66-75.
185. Amanna I.J., Carlson N.E., Slifka M.K.: Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357:1903-1915.
186. Tsutsumi H., Chiba Y., Abo W., et al: T-cell–mediated cytotoxic response to mumps virus in humans. Infect Immun 1980; 30:129-134.
187. Burgess D.C., Burgess M.A., Leask J.: The MMR vaccination and autism controversy in United Kingdom 1998-2005: inevitable community outrage or a failure of risk communication?. Vaccine 2006; 24:3921-3928.
188. Hanna-Wakim R., Yasukawa L.L., Sung P., et al: Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis 2008; 197:1669-1675.
189. Chiba Y., Dzierba J.L., Morag A., et al: Cell-mediated immune response to mumps virus infection in man. J Immunol 1976; 116:12-15.
190. Rola-Pleszczynski M., Vincent M.M., Hensen S.A., et al: 51Chromium-release microassay technique for cell-mediated immunity to mumps virus: correlation with humoral and delayed-type skin hypersensitivity responses. J Infect Dis 1976; 134:546-551.
191. Ichiyama T., Maeba S., Suenaga N., et al: Analysis of cytokine levels in cerebrospinal fluid in mumps meningitis: comparison with echovirus type 30 meningitis. Cytokine 2005; 30:243-247.
192. Jokinen S., Osterlund P., Julkunen I., et al: Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis 2007; 196:861-867.

193. Martin R., Vallbracht A., Kreth H.W.: Interferon-gamma secretion by in activated cytotoxic T lymphocytes from the blood and cerebrospinal fluid during mumps meningitis. J Neuroimmunol 1991; 33:191-198.
194. Morishima T., Miyazu M., Ozaki T., et al: Local immunity in mumps meningitis. Am J Dis Child 1980; 134:1060-1064.
195. Larke R.P.: Interferon in the cerebrospinal fluid of children with central nervous system disorders. Can Med Assoc J 1967; 96:21-32.
196. Waddell D.J., Wilbur J.R., Merigan T.C.: Interferon production in human mumps infections. Proc Soc Exp Biol Med 1968; 127:320-324.
197. Nagai H., Morishima T., Morishima Y., et al: Local T cell subsets in mumps meningitis. Arch Dis Child 1983; 58:927-928.
198. de Boer A.W., de Vaan G.A.: Mild course of mumps in patients with acute lymphoblastic leukaemia. Eur J Pediatr 1989; 148:618-619.
199. Meyer M.B., Stifler W.C., Joseph J.M.: Evaluation of mumps vaccine given after exposure to mumps, with special reference to the exposed adult. Pediatrics 1966; 37:304-315.
200. Meurman O., Vainionpaa R., Rossi T., et al: Viral etiology of parotitis. Scand J Infect Dis 1983; 15:145-148.
201. Andersson J., Sterner G.: A 16-month-old boy with infectious mononucleosis, parotitis and Bell's palsy. Acta Paediatr Scand 1985; 74:629-632.
202. Battle S., Laudenbach J., Maguire J.H.: Influenza parotitis: a case from the 2004 to 2005 vaccine shortage. Am J Med Sci 2007; 333:215-217.
203. Lee A.C., Lim W.L., So K.T.: Epstein-Barr virus associated parotitis. J Paediatr Child Health 1997; 33:177-178.
204. Davidkin I., Jokinen S., Paananen A., et al: Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis 2005; 191:719-723.
205. Hatchette T.F., Mahony J.B., Chong S., et al: Difficulty with mumps diagnosis: what is the contribution of mumps mimickers?. J Clin Virol 2009; 46:381-383.
206. Gaulin C., DeSerres G.: Need for a specific definition of mumps in a highly immunized population. Can Commun Dis Rep 1997; 23:14-16.
207. Centers for Disease Control and Prevention : Manual for the Surveillance of Vaccine-Preventable Diseases. Atlanta, GA, CDC, 1997.
208. Gay N., Miller E., Hesketh L., et al: Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Commun Dis Rep CDR Rev 1997; 7:R21-R26.
209. Gut J.P., Spiess C., Schmitt S., et al: Rapid diagnosis of acute mumps infection by a direct immunoglobulin M antibody capture enzyme immunoassay with labeled antigen. J Clin Microbiol 1985; 21:346-352.
210. Blomberg J., Nilsson I., Andersson M.: Viral antibody screening system that uses a standardized single dilution immunoglobulin G enzyme immunoassay with multiple antigens. J Clin Microbiol 1983; 17:1081-1091.
211. Pipkin P.A., Afzal M.A., Heath A.B., et al: Assay of humoral immunity to mumps virus. J Virol Methods 1999; 79:219-225.
212. Christenson B., Bottiger M.: Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. Biologicals 1990; 18:213-219.
213. Fedova D., Bruckova M., Plesnik V., et al: Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test. J Hyg Epidemiol Microbiol Immunol 1987; 31:409-422.
214. Guy R.J., Andrews R.M., Kelly H.A., et al: Mumps and rubella: a year of enhanced surveillance and laboratory testing. Epidemiol Infect 2004; 132:391-398.

215. Pelosi J., Meyer P.A., Schluter W.W.: Mumps surveillance: results of improved case investigation and serologic testing of suspected cases, Texas, 1995-1996. J Public Health Manag Pract 2001; 7:69-74.
216. Sanz J.C., Mosquera M.M., Echevarria J.E., et al: Sensitivity and specificity of immunoglobulin G titer for the diagnosis of mumps virus in infected patients depending on vaccination status. APMIS 2006; 114:788-794.
217. Hatchette T., Davidson R., Clay S., et al: Laboratory diagnosis of mumps in a partially immunized population: the Nova Scotia experience. Can J Infect Dis Med Microbiol 2009; 20:e157-e162.
218. Bringuier J.P., Andre J., Sohier R.: The use of IgM antibody responses in the diagnosis of primary infections to measles, rubella, mumps, and M. parainfluenzae viruses. Med Microbiol Immunol 1978; 164:299-305.
219. Nicolai-Scholten M.E., Ziegelmaier R., Behrens F., et al: The enzyme-linked immunosorbent assay (ELISA) for determination of IgG and IgM antibodies after infection with mumps virus. Med Microbiol Immunol 1980; 168:81-90.
220. Meurman O., Hanninen P., Krishna R.V., et al: Determination of IgG- and IgM-class antibodies to mumps virus by solid-phase enzyme immunoassay. J Virol Methods 1982; 4:249-256.
221. Briss P.A., Fehrs L.J., Parker R.A., et al: Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994; 169:77-82.
222. Wehner H., Morris R., Logan M., et al: A secondary school outbreak of mumps following the childhood immunization programme in England and Wales. Epidemiol Infect 2000; 124:131-136.
223. Lee J.Y., Na B.K., Kim J.H., et al: Regional outbreak of mumps due to genotype H in Korea in 1999. J Med Virol 2004; 73:85-90.
224. Rota J.S., Turner J.C., Yost-Daljev M.K., et al: Investigation of a mumps outbreak among university students with two measles-mumps-rubella (MMR) vaccinations, Virginia, September-December 2006. J Med Virol 2009; 81:1819-1825.
225. Bitsko R.H., Cortese M.M., Dayan G.H., et al: Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage. J Clin Microbiol 2008; 46:1101-1103.
226. Cunningham C., Faherty C., Cormican M., et al: Importance of clinical features in diagnosis of mumps during a community outbreak. Ir Med J 2006; 99:171-173.
227. Krause C.H., Molyneaux P.J., Ho-Yen D.O., et al: Comparison of mumps-IgM ELISAs in acute infection. J Clin Virol 2007; 38:153-156.
228. Warrener L., Samuel D.: Evaluation of a commercial assay for the detection of mumps specific IgM antibodies in oral fluid and serum specimens. J Clin Virol 2006; 35:130-134.
229. Sanz-Moreno J.C., Limia-Sanchez A., Garcia-Comas L., et al: Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine 2005; 23:4921-4925.
230. Afzal M.A., Dussupt V., Minor P.D., et al: Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations. J Virol Methods 2005; 126:149-156.
231. Knowles W.A., Cohen B.J.: Efficient isolation of mumps virus from a community outbreak using the marmoset lymphoblastoid cell line B95a. J Virol Methods 2001; 96:93-96.
232. Kilham L.: Isolation of mumps virus from the blood of a patient. Proc Soc Exp Biol Med 1948; 69:99-100.
233. Jin L., Feng Y., Parry R., et al: Real-time PCR and its application to mumps rapid diagnosis. J Med Virol 2007; 79:1761-1767.

234. Boddicker J.D., Rota P.A., Kreman T., et al: Real-time reverse transcription–PCR assay for detection of mumps virus RNA in clinical specimens. J Clin Microbiol 2007; 45:2902-2908.
235. Krause C.H., Eastick K., Real-time Ogilvie M.M: Real-time PCR for mumps diagnosis on clinical specimens: comparison with results of conventional methods of virus detection and nested PCR. J Clin Virol 2006; 37:184-189.
236. Cusi M.G., Bianchi S., Valassina M., et al: Rapid detection and typing of circulating mumps virus by reverse transcription/polymerase chain reaction. Res Virol 1996; 147:227-232.
237. Afzal M.A., Buchanan J., Dias J.A., et al: RT-PCR based diagnosis and molecular characterisation of mumps viruses derived from clinical specimens collected during the 1996 mumps outbreak in Portugal. J Med Virol 1997; 52:349-353.
238. World Health Organization : Mumps virus vaccines: WHO position paper. Wkly Epidemiol Rec 2007; 82:49-60.
239. Uchida K., Shinohara M., Shimada S., et al: Rapid and sensitive detection of mumps virus RNA directly from clinical samples by real-time PCR. J Med Virol 2005; 75:470-474.
240. Poggio G.P., Rodriguez C., Cisterna D., et al: Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases. J Clin Microbiol 2000; 38:274-278.
241. Date A.A., Kyaw M.H., Rue A.M., et al: Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008; 197:1662-1668.
242. Anderson L.J., Seward J.F.: Mumps epidemiology and immunity: the anatomy of a modern epidemic. Pediatr Infect Dis J 2008; 27(10 suppl):S75-S79.
243. DeFranco A.L.: Molecular aspects of B-lymphocyte activation. Annu Rev Cell Biol 1987; 3:143-178.
244. Slifka M.K., Ahmed R.: Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection. Ann N Y Acad Sci 1996; 797:166-176.
245. Latner D.R., McGrew M., Williams N., et al: Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol 2011; 18:35-42.
246. Brickman A., Brunell P.A.: Susceptibility of medical students to mumps: comparison of serum neutralizing antibody and skin test. Pediatrics 1971; 48:447-450.
247. Ennis F.A.: Immunity to mumps in an institutional epidemic: correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies. J Infect Dis 1969; 119:654-657.
248. Bashe Jr W.J., Gotlieb T., Henle G., et al: Studies on the prevention of mumps, VI: the relationship of neutralizing antibodies to the determination of susceptibility and to the evaluation of immunization procedures. J Immunol 1953; 71:76-85.
249. Weibel R.E., Buynak E.B., McLean A.A., et al: Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 1975; 56:380-387.
250. Weibel R.E., Buynak E.B., Stokes Jr J., et al: Persistence of immunity four years following Jeryl Lynn strain live mumps virus vaccine. Pediatrics 1970; 45:821-826.
251. Cortese M.M., Barskey A.E., Tegtmeier G.E., et al: Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis 2011; 204:1413-1422.
252. Orvell C., Tecle T., Johansson B., et al: Antigenic relationships between six genotypes of the small hydrophobic protein gene of mumps virus. J Gen Virol 2002; 83(pt 10):2489-2496.

253. Rubin S.A., Qi L., Audet S.A., et al: Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 2008; 198:508-515.
253a. Allwinn R., Zeidler B., Steinhagen K., et al: Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity?. Eur J Clin Microbiol Infect Dis 2011; 30:1223-1228.
254. Vandermeulen C., Clement F., Roelants M., et al: Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination. J Infect Dis 2009; 199:1457-1460.
255. Collins S.D.: Age incidence of the common communicable diseases of children. Public Health Rep 1929; 44:763-826.
256. US Department of Health Education and Welfare : Mumps surveillance, Report No. 1. 1. Atlanta, GA, US Dept of Health, 1968.
257. Brooks H.: Epidemic parotitis as a military disease. Med Clin North Am 1918; 2:493-505.
258. Black F.L.: Nationwide serum survey of United States military recruits, 1962, 3: measles and mumps antibodies. Am J Hyg 1964; 80:304-307.
259. Kelley P.W., Petruccelli B.P., Stehr-Green P., et al: The susceptibility of young adult Americans to vaccine-preventable infections: a national serosurvey of US Army recruits. JAMA 1991; 266:2724-2729.
260. Seroepidemiology of measles, mumps and rubella. Wkly Epidemiol Rec 1992; 67:231-233.
261. Aksit S., Egemen A., Ozacar T., et al: Mumps seroprevalence in an unvaccinated population in Izmir. Turkey. Acta Paediatr 2000; 89:370-371.
262. Narayan K.M., Moffat M.A.: Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland. Health Bull (Edinb) 1992; 50:47-53.
263. Anderson R.M., Crombie J.A., Grenfell B.T.: The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidemiol Infect 1987; 99:65-84.
264. Nokes D.J., Wright J., Morgan-Capner P., et al: Serological study of the epidemiology of mumps virus infection in north-west England. Epidemiol Infect 1990; 105:175-195.
265. Arroyo M., Alia J.M., Mateos M.L., et al: Natural immunity to measles, rubella and mumps among Spanish children in the pre-vaccination era. Int J Epidemiol 1986; 15:95-100.
266. Galazka A.M., Robertson S.E., Kraigher A.: Mumps and mumps vaccine: a global review. Bull World Health Organ 1999; 77:3-14.
267. Levitt L.P., Mahoney D.H., Casey H.L., et al: Mumps in a general population: a sero-epidemiologic study. Am J Dis Child 1970; 120:134-138.
268. Research Unit of the Royal College of General Practitioners : The incidence and complications of mumps. J R Coll Gen Pract 1974; 24:545-551.
269. Nardone A., Pebody R.G., van den Hof S., et al: Sero-epidemiology of mumps in western Europe. Epidemiol Infect 2003; 131:691-701.
270. Janaszek-Seydlitz W., Bucholc B., Gorska P., et al: Mumps in Poland since 1990 to 2003: epidemiology and antibody prevalence. Vaccine 2005; 23:2711-2716.
271. Afzal M.A., Marsden S., Hull R.M., et al: Evaluation of the neurovirulence test for mumps vaccines. Biologicals 1999; 27:43-49.
272. Barskey A.E., Glasser J.W., LeBaron C.W.: Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine 2009; 27:6186-6195.
273. Centers for Disease Control and Prevention : Measles prevention. MMWR 1989; 38(suppl 9):1-18.

274. Copelovici Y., Strulovici D., Cristea A.L., et al: Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications. Virologie 1979; 30:171-177.
275. Gellis S.S., McGuiness A.C., Peters M.: A study of the prevention of mumps orchitis by gammaglobulin. Am J Med Sci 1945; 210:661-664.
276. Hodes D., Brunell P.A.: Mumps antibody: placental transfer and disappearance during the first year of life. Pediatrics 1970; 45:99-101.
277. Centers for Disease Control and Prevention : Mumps prevention. MMWR 1989; 38:388-400.
278. Utz J.P.: Viruria in man, an update. Prog Med Virol 1974; 17:77-90.
279. Plotkin S.A., Rubin S.A.: Mumps vaccine. In: Plotkin S.A., Orenstein W.A., Offit P.A., ed. Vaccines, 5th ed.. Philadelphia, PA: Saunders Elsevier; 2008:435-465.
280. Leineweber B., Grote V., Schaad U.B., et al: Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J 2004; 23:361-363.
281. Desgrandchamps D., Schaad U.B., Glaus J., et al: Seroprevalence of IgG antibodies against measles, mumps and rubella in Swiss children during the first 16 months of life [in German]. Schweiz Med Wochenschr 2000; 130:1479-1486.
282. Nicoara C., Zach K., Trachsel D., et al: Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses. Clin Diagn Lab Immunol 1999; 6:868-871.
283. Hilleman M.R.: Past, present, and future of measles, mumps, and rubella virus vaccines. Pediatrics 1992; 90:149-153.
284. Hilleman M.R.: The development of live attenuated mumps virus vaccine in historic perspective and its role in the evolution of combined measles-mumps-rubella. In: Plotkin S.A., Fantini B., ed. Vaccinia, Vaccination, Vaccinology: Jenner, Pasteur, and Their Successors, Paris, France: Elsevier; 1996:283-292.
285. Smorodintsev A.A., Klyatchko N.S.: Live anti-mumps vaccine, I: results of tests of the immunogenic properties of live vaccine when administered intradermally to susceptible children. Acta Virol 1958; 2:137-144.
286. Beck M., Welsz-Malecek R., Mesko-Prejac M., et al: Mumps vaccine L-Zagreb, prepared in chick fibroblasts, I: production and field trials. J Biol Stand 1989; 17:85-90.
287. Buynak E.B., Hilleman M.R.: Live attenuated mumps virus vaccine, 1: vaccine development. Proc Soc Exp Biol Med 1966; 123:768-775.
288. Afzal M.A., Pickford A.R., Forsey T., et al: The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol 1993; 74(pt 5):917-920.
289. Amexis G., Rubin S.A., Chizhikov V., et al: Sequence diversity of Jeryl Lynn strain of mumps virus: quantitative mutant analysis for vaccine quality control. Virology 2002; 300:171-179.
290. Tillieux S.L., Halsey W.S., Sathe G.M., et al: Comparative analysis of the complete nucleotide sequences of measles, mumps, and rubella strain genomes contained in Priorix-Tetra and ProQuad live attenuated combined vaccines. Vaccine 2009; 27:2265-2273.
291. Usonis V., Bakasenas V., Chitour K., et al: Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Infection 1998; 26:222-226.
292. Miller E., Andrews N., Stowe J., et al: Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol 2007; 165:704-779.
293. Cruz R.C., Rodriguez I.M., Olvera J., et al: Study of the immune response engendered by differents combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 2003; 22:280-286.

294. Lee C.Y., Tang R.B., Huang F.Y., et al: A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Int J Infect Dis 2002; 6:202-209.
295. Kanra G., Ceyhan M., Ozmert E.: Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT. 4385 mumps virus strain in healthy Turkish children. Turk J Pediatr 2000; 42:275-277.
296. Crovari P., Gabutti G., Giammanco G., et al: Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. the Cooperative Group for the Study of MMR vaccines. Vaccine 2000; 18:2796-2803.
297. Gatchalian S., Cordero-Yap L., Lu-Fong M., et al: A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Southeast Asian J Trop Med Public Health 1999; 30:511-517.
298. Domingo E., Martinez-Salas E., Sobrino F., et al: The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance: a review. Gene 1985; 40:1-8.
299. Amexis G., Fineschi N., Chumakov K.: Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain. Virology 2001; 287:234-241.
300. Brown E.G., Dimock K., Wright K.E.: The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. J Infect Dis 1996; 174:619-622.
301. Kosutic-Gulija T., Forcic D., Santak M., et al: Genetic heterogeneity of L-Zagreb mumps virus vaccine strain. Virol J 2008; 5:79.
302. Boriskin Y.S., Yamada A., Kaptsova T.I., et al: Genetic evidence for variant selection in the course of dilute passaging of mumps vaccine virus. Res Virol 1992; 143:279-283.
303. Boriskin Y.S., Kaptsova T.I., Booth J.C.: Mumps virus variants in heterogeneous mumps vaccine. Lancet 1993; 341:318-319.
304. Yamanishi K., Hosai H., Ueda S., et al: Studies on live attenuated mumps virus vaccine, II: biological characteristics of the strains adapted to the amniotic and chorioallantoic cavity of developing chick embryos. Biken J 1970; 13:127-132.
305. Yamanishi K., Takahashi M., Ueda S., et al: Studies on live mumps virus vaccine, V: development of a new mumps vaccine “AM 9” by plaque cloning. Biken J 1973; 16:161-166.
306. Gluck R., Hoskins J.M., Wegmann A., et al: Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells. Dev Biol Stand 1986; 65:29-35.
307. Rubin S.A., Snoy P.J., Wright K.E., et al: The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains. J Infect Dis 1999; 180:521-525.
308. Rubin S.A., Afzal M.A., Powell C.L., et al: The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis 2005; 191:1123-1128.
309. Saika S., Kidokoro M., Aoki A., et al: Neurovirulence of mumps virus: intraspinal inoculation test in marmosets. Biologicals 2004; 32:147-152.
310. Saika S., Kidokoro M., Kubonoya H., et al: Development and biological properties of a new live attenuated mumps vaccine. Comp Immunol Microbiol Infect Dis 2006; 29:89-99.
311. Shah D., Vidal S., Link M.A., et al: Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus. J Med Virol 2009; 81:130-138.
312. Afzal M.A., Yates P.J., Minor P.D.: Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. J Infect Dis 1998; 177:265-266.

313. Sauder C.J., Vandenburgh K., Iskow R.C., et al: Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 2006; 350:48-57.
314. Sauder C.J., Zhang C.X., Ngo L., et al: Gene-specific contributions to mumps virus neurovirulence and neuroattenuation. J Virol 2011; 85:7059-7069.
315. Makino S., Sasaki K., Nakayama T., et al: A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine: findings in clinical and laboratory studies. Am J Dis Child 1990; 144:905-910.
316. Knuf M., Zepp F., Meyer C.U., et al: Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. Eur J Pediatr 2010; 169:925-933.
317. Gillet Y., Habermehl P., Thomas S., et al: Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Med 2009; 7:16.doi:10.1186/1741-7015-7-16
318. Cusi M.G., Correale P., Valassina M., et al: Comparative study of the immune response in mice immunized with four live attenuated strains of mumps virus by intranasal or intramuscular route. Arch Virol 2001; 146:1241-1248.
319. Castro J.F., Bennett J.V., Rincon H.G., et al: Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine 2005; 23:1079-1084.
320. Bennett J.V., Fernandez de Castro J., Poblete R.M., et al: A new, rapid, and promising approach to aerosol immunization: inflatable bags and valved masks. Vaccine 2009; 27:4571-4575.
321. Buynak E.B., Hilleman M.R., Leagus M.B., et al: Jeryl Lynn strain live attenuated mumps virus vaccine: influence of age, virus dose, lot, and gammaglobulin administration on response. JAMA 1968; 203:9-13.
322. Feiterna-Sperling C., Bronnimann R., Tischer A., et al: Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. Pediatr Infect Dis J 2005; 24:1083-1088.
323. Goh P., Lim F.S., Han H.H., et al: Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 2007; 35:326-333.
324. Czajka H., Schuster V., Zepp F., et al: A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 2009; 27:6504-6511.
325. Shinefield H., Black S., Digilio L., et al: Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005; 24:665-669.
326. Lieberman J.M., Williams W.R., Miller J.M., et al: The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 2006; 25:615-622.
327. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR 2008; 57:258-260.
328. Marin M., Broder K.R., Temte J.L.: Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-3):1-12.
329. American Academy of Pediatrics Committee on Infectious Diseases : Policy statement: prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011; 128:630-632.doi:10.1542/peds.2011-1968

330. Weibel R.E., Buynak E.B., Stokes Jr. J., et al: Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines. Pediatrics 1973; 51:467-475.
331. LeBaron C.W., Forghani B., Beck C., et al: Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199:552-560.
332. Centers for Disease Control and Prevention : Status report on the Childhood Immunization Initiative: national, state, and urban area vaccination coverage levels among children aged 19-35 months: United States, 1996. MMWR 1997; 46:657-664.
333. Centers for Disease Control and Prevention : National, state, and urban area vaccination coverage among children aged 19-35 months: United States, 2005. MMWR 2006; 55:988-993.
334. Centers for Disease Control and Prevention : National, state, and local area vaccination coverage among children aged 19-35 months: United States, 2009. MMWR 2010; 59:1171-1177.
335. Centers for Disease Control and Prevention : National, state, and local area vaccination coverage among adolescents aged 13-17 years: United States, 2009. MMWR 2010; 59:1018-1023.
335a. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years– United States, 2010 : MMWR 2011; 60:1117-1123.
336. Davidkin I., Kontio M., Paunio M., et al: MMR vaccination and disease elimination: the Finnish experience. Expert Rev Vaccines 2010; 9:1045-1053.
337. Theeten H., Hutse V., Hens N., et al: Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. Epidemiol Infect 2011; 139:494-504.
338. Bottiger M., Christenson B., Romanus V.: Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1987; 295:1264-1267.
339. Muhsen K., Aboudy Y., Mendelson E., et al: Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease. Epidemiol Infect 2008; 136:688-693.
340. Ringler M., Gobel G., Most J., et al: Fully vaccinated children are rare: immunization coverage and seroprevalence in Austrian school children. Eur J Epidemiol 2003; 18:161-170.
341. Mossong J., Putz L., Schneider F.: Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study. Epidemiol Infect 2004; 132:11-18.
342. Vicens C.N., Nobrega F.T., Joseph J.M., et al: Evaluation of tests for the measurement of previous mumps infection and analysis of mumps experience by blood group. Am J Epidemiol 1966; 84:371-381.
343. Henle W., Crawford M.N., Henle G., et al: Studies on the prevention of mumps, VII: evaluation of dosage schedules for inactivated mumps vaccine. J Immunol 1959; 83:17-28.
344. Bottiger M., Christenson B., Taranger J., et al: Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of schoolchildren. Vaccine 1985; 3:113-116.
345. Sullivan K.M., Halpin T.J., Marks J.S., et al: Effectiveness of mumps vaccine in a school outbreak. Am J Dis Child 1985; 139:909-912.
346. Roth A.: Immunization with live attenuated mumps virus vaccine in Honolulu: a field trial. Am J Dis Child 1968; 115:459-460.
347. Stokes Jr. J., Weibel R.E., Buynak E.B., et al: Live attenuated mumps virus vaccine, II: early clinical studies. Pediatrics 1967; 39:363-371.

348. Sugg W.C., Finger J.A., Levine R.H., et al: Field evaluation of live virus mumps vaccine. J Pediatr 1968; 72:461-466.
349. Young M.L., Dickstein B., Weibel R.E., et al: Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic. Pediatrics 1967; 40:798-803.
350. Ehrengut W., Georges A.M., Andre F.E.: The reactogenicity and immunogenicity of the Urabe Am 9 live mumps vaccine and persistence of vaccine induced antibodies in healthy young children. J Biol Stand 1983; 11:105-113.
351. Vesikari T., Andre F.E., Simoen E., et al: Evaluation in young children of the Urabe Am 9 strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain. Acta Paediatr Scand 1983; 72:37-40.
352. Christenson B., Heller L., Bottiger M.: The immunizing effect and reactogenicity of two live attenuated mumps virus vaccines in Swedish schoolchildren. J Biol Stand 1983; 11:323-331.
353. Popow-Kraupp T., Kundi M., Ambrosch F., et al: A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children. J Med Virol 1986; 18:69-79.
354. Lerman S.J., Bollinger M., Brunken J.M.: Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics 1981; 68:18-22.
355. Brunell P.A., Weigle K., Murphy M.D., et al: Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA 1983; 250:1409-1412.
356. Edees S., Pullan C.R., Hull D.: A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health 1991; 105:91-97.
357. Forleo-Neto E., Carvalho E.S., Fuentes I.C., et al: Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months. Vaccine 1997; 15:1898-1901.
358. Wellington K., Goa K.L.: Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 2003; 63:2107-2126.
359. Usonis V., Bakasenas V., Denis M.: Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385. Infection 2001; 29:159-162.
360. Usonis V., Bakasenas V., Kaufhold A., et al: Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18:42-48.
361. Nakayama T., Urano T., Osano M., et al: Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response. Microbiol Immunol 1990; 34:497-508.
362. Bhargava I., Chhaparwal B.C., Phadke M.A., et al: Immunogenicity and reactogenicity of indigenously produced MMR vaccine. Indian Pediatr 1995; 32:983-988.
363. Garaseferian M.G., Bolotovskii V.M., Shatrova L.P.: Prevention of mumps in preschool institutions using a live mumps vaccine made from strain L-3 [in Russian]. Zh Mikrobiol Epidemiol Immunobiol April 1988.39-42.
364. Just M., Berger R., Gluck R., et al: Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Dev Biol Stand 1986; 65:25-27.
365. Tischer A., Gerike E.: Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000; 18:1382-1392.
366. Dhiman N., Ovsyannikova I.G., Jacobson R.M., et al: Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clin Immunol 2005; 115:154-161.

367. Gans H., Yasukawa L., Rinki M., et al: Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-826.
368. Schwarzer S., Reibel S., Lang A.B., et al: Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 1998; 16:298-304.
369. King G.E., Markowitz L.E., Heath J., et al: Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996; 275:704-707.
370. Redd S.C., King G.E., Heath J.L., et al: Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis 2004; 189(suppl 1):S116-S122.
371. Schoub B.D., Johnson S., McAnerney J.M., et al: Measles, mumps and rubella immunization at nine months in a developing country. Pediatr Infect Dis J 1990; 9:263-267.
372. Gans H., DeHovitz R., Forghani B., et al: Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003; 21:3398-3405.
373. Davidson W.L., Buynak E.B., Leagus M.B., et al: Vaccination of adults with live attenuated mumps virus vaccine. JAMA 1967; 201:995-998.
374. Christenson B., Böttiger M.: Vaccination against measles, mumps and rubella (MMR): a comparison between the antibody responses at the ages of 18 months and 12 years and between different methods of antibody titration. J Biol Stand 1985; 13:167-172.
375. Dayan G.H., Rubin S.: Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clin Infect Dis 2008; 47:1458-1467.
376. Kuno-Sakai H., Ozaki K., Kimura M.: Two doses of measles mumps rubella (MMR) vaccine. Acta Paediatr Jpn 1989; 31:690-697.
377. Davidkin I., Valle M., Julkunen I.: Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination: a nine-year follow-up. Vaccine 1995; 13:1617-1622.
378. Jacobson R.M., Poland G.A.: The genetic basis for measles vaccine failure. Acta Paediatr Suppl 2004; 93:43-46.
379. Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., et al: Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 2006; 193:655-663.
380. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., et al: HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 2007; 25:3090-3100.
381. Weibel R.E., Buynak E.B., McLean A.A., et al: Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps, and rubella virus vaccines. Proc Soc Exp Biol Med 1979; 162:328-332.
382. Weibel R.E., Buynak E.B., McLean A.A., et al: Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. Pediatrics 1978; 61:5-11.
383. Weibel R.E., Buynak E.B., McLean A.A., et al: Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines. Proc Soc Exp Biol Med 1980; 165:260-263.
384. Miller E., Hill A., Morgan-Capner P., et al: Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995; 13:799-802.
385. Boulianne N., De Serres G., Ratnam S., et al: Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 1995; 13:1611-1616.

386. Broliden K., Abreu E.R., Arneborn M., et al: Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 1998; 16:323-327.
387. Davidkin I., Jokinen S., Broman M., et al: Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197:950-956.
388. Zignol M., Peracchi M., Tridello G., et al: Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004; 101:635-641.
389. Cheng F.W., Leung T.F., Chan P.K., et al: Recovery of humoral and cellular immunities to vaccine-preventable infectious diseases in pediatric oncology patients. Pediatr Hematol Oncol 2010; 27:195-204.
390. Kano H., Mizuta K., Sakakihara Y., et al: Efficacy and safety of immunization for pre- and post- liver transplant children. Transplantation 2002; 74:543-550.
391. Spoulou V., Giannaki M., Vounatsou M., et al: Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 2004; 33:1187-1190.
392. Ljungman P., Fridell E., Lonnqvist B., et al: Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159:610-615.
393. King S.M., Saunders E.F., Petric M., et al: Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:633-636.
394. Schulman S.L., Deforest A., Kaiser B.A., et al: Response to measles-mumps-rubella vaccine in children on dialysis. Pediatr Nephrol 1992; 6:187-189.
395. Centers for Disease Control and Prevention. Guide to vaccine contraindications and precautions. February 10, 2010 http://www.cdc.gov/vaccines/recs/vac-admin/downloads/contraindications-guide-508.pdf . Accessed January 20, 2011.
396. McFarland E.: Immunizations for the immunocompromised child. Pediatr Ann 1999; 28:487-496.
397. Aurpibul L., Puthanakit T., Sirisanthana T., et al: Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637-642.
398. Frenkel L.M., Nielsen K., Garakian A., et al: A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med 1994; 148:57-60.
399. Hilleman M.R., Weibel R.E., Buynak E.B., et al: Live attenuated mumps-virus vaccine, IV: protective efficacy as measured in a field evaluation. N Engl J Med 1967; 276:252-258.
400. Smorodintsev A.A., Nasibov M.N., Jakovleva N.V.: Experience with live rubella virus vaccine combined with live vaccines against measles and mumps. Bull World Health Organ 1970; 42:283-289.
401. Kim-Farley R., Bart S., Stetler H., et al: Clinical mumps vaccine efficacy. Am J Epidemiol 1985; 121:593-597.
402. Wharton M., Cochi S.L., Hutcheson R.H., et al: A large outbreak of mumps in the postvaccine era. J Infect Dis 1988; 158:1253-1260.
403. Lewis J.E., Chernesky M.A., Rawls M.L., et al: Epidemic of mumps in a partially immune population. Can Med Assoc J 1979; 121:751-754.
404. Orenstein W.A., Bernier R.H., Dondero T.J., et al: Field evaluation of vaccine efficacy. Bull World Health Organ 1985; 63:1055-1068.

405. Cortese M.M., Jordan H.T., Curns A.T., et al: Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 2008; 46:1172-1180.
406. Marin M., Quinlisk P., Shimabukuro T., et al: Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students: Iowa, 2006. Vaccine 2008; 26:3601-3607.
407. Bangor-Jones R.D., Dowse G.K., Giele C.M., et al: A prolonged mumps outbreak among highly vaccinated aboriginal people in the Kimberley region of Western Australia. Med J Aust 2009; 191:398-401.
408. Roberts C., Porter-Jones G., Crocker J.: Mumps outbreak on the island of Anglesey, North Wales, December 2008-January 2009. Euro Surveill 2009; 14(5):
409. Centers for Disease Control and Prevention : Update: mumps outbreak: New York and New Jersey, June 2009–January 2010. MMWR 2010; 59:125-129.
410. Schaffzin J.K., Pollock L., Schulte C., et al: Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics 2007; 120:e862-e868.
410a. Yung C.F., Andrews N., Bukasa A., et al: Mumps complications and effects of mumps vaccination, England and Wales, 2002–2006. Emerg Infect Dis 2011; 17:661-667.
410b. Demicheli V., Rivetti A., Debalini M.G.: Vaccines for measles, mumps and rubella in children (Review). Cochrane Database Syst Rev. 2:CD004407. 2012.
411. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. The Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases. Vaccine 1998; 16:818-822.
412. Mora J.L., Lopez T.M., Camacho J.C.: Efectividad communitaria de las vacunas frente a la paratiditis infecciosa estudio de casos. Rev Esp Salud Publica 1999; 73:455-464.
413. Paccaud M.F., Hazeghi P., Bourquin M., et al: A look back at 2 mumps outbreaks [in German]. Soz Praventivmed 1995; 40:72-79.
414. Ortuondo E.M., Sancristobal I.G., Soria L.L., et al: Outbreak of viral parotiditis in a school in Bizkaia, Spain, in 2006 [in Spanish]. Rev Esp Salud Publica 2007; 81:33-42.
415. Ong G., Goh K.T., Ma S., et al: Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect 2005; 51:294-298.
416. Richard J.L., Zwahlen M., Feuz M., et al: Comparison of the effectiveness of two mumps vaccines during an outbreak in Switzerland in 1999 and 2000: a case-cohort study. Eur J Epidemiol 2003; 18:569-577.
417. Pons C., Pelayo T., Pachon I., et al: Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy. Euro Surveill 2000; 5:80-84.
418. Efficacy of mumps vaccine: Ohio. MMWR 1983; 32:391-398.
419. Hersh B.S., Fine P.E., Kent W.K., et al: Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119:187-193.
420. Vandermeulen C., Roelants M., Vermoere M., et al: Outbreak of mumps in a vaccinated child population: a question of vaccine failure?. Vaccine 2004; 22:2713-2716.
421. Castilla J., Garcia C.M., Arriazu M., et al: Effectiveness of Jeryl Lynn–containing vaccine in Spanish children. Vaccine 2009; 27:2089-2093.
422. Cohen C., White J.M., Savage E.J., et al: Vaccine effectiveness estimates, 2004-2005 mumps outbreak. England. Emerg Infect Dis 2007; 13:12-17.
423. Cheek J.E., Baron R., Atlas H., et al: Mumps outbreak in a highly vaccinated school population. Arch Pediatr Adolesc Med 1995; 149:774-778.
424. Dominguez A., Oviedo M., Torner N., et al: Mumps: a year of enhanced surveillance in Catalonia, Spain. Vaccine 2009; 27:3492-3495.
425. Kaaijk P., van der Zeijst B., Boog M., et al: Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill 2008; 13(26):

426. Centers for Disease Control and Prevention : Mumps epidemic: United Kingdom, 2004-2005. MMWR 2006; 55:173-175.
427. Centers for Disease Control and Prevention : Brief report: update: mumps activity: United States, January 1-October 7, 2006. MMWR 2006; 55:1152-1153.
428. Mossong J., Bonert C., Weicherding P., et al: Mumps outbreak among the military in Luxembourg in 2008: epidemiology and evaluation of control measures. Euro Surveill 2009; 14(7):pii=19121.
429. Brockhoff H.J., Mollema L., Sonder G.J., et al: Mumps outbreak in a highly vaccinated student population, the Netherlands, 2004. Vaccine 2010; 28:2932-2936.
430. Otto W., Mankertz A., Santibanez S.: Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Euro Surveill 2010; 15(50):
431. Public Health Agency of Canada. Update on Mumps Outbreak in the Maritimes: National Summary, October 26, 2007. 2007 http://www.phac-aspcgcca/mumps-oreillons/prof_ehtml . Accessed January 21, 2011.
432. Watson-Creed G., Saunders A., Scott J., et al: Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults. CMAJ 2006; 175:483-488.
433. Stein-Zamir C., Shoob H., Abramson N.: Mumps outbreak in Jerusalem affecting mainly male adolescents. Euro Surveill 2009; 14(50):
434. Whelan J., van Binnendijk R., Greenland K.: Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands, 2010. Euro Surveill 2010; 15(17):
435. Savage E., Ramsay M., White J., et al: Mumps outbreaks across England and Wales in 2004: observational study. BMJ 2005; 330:1119-1120.
436. Patch J.R., Han Z., McCarthy S.E., et al: The YPLGVG sequence of the Nipah virus matrix protein is required for budding. Virol J 2008; 5:137-149.
437. Akcali A., Yilmaz N., Uyar Y., et al: Genotyping of mumps virus circulating in Turkey in the 2006-2007 winter season. Arch Virol 2009; 154:1807-1812.
438. Hindiyeh M.Y., Aboudy Y., Wohoush M., et al: Characterization of large mumps outbreak among vaccinated Palestinian refugees. J Clin Microbiol 2009; 47:560-565.
438a. Rubin S.A., Link M.A., Sauder C.J., et al: Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol 2012; 86:615-620.
439. Peltola H., Davidkin I., Paunio M., et al: Mumps and rubella eliminated from Finland. JAMA 2000; 284:2643-2647.
440. Slater P.E., Anis E., Leventhal A.: The control of mumps in Israel. Eur J Epidemiol 1999; 15:765-767.
441. Watson J.C., Hadler S.C., Dykewicz C.A.: Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47(RR-8):1-57.
442. Fescharek R., Quast U., Maass G., et al: Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use, II: tolerability and analysis of spontaneously reported side effects. Vaccine 1990; 8:446-456.
443. Miller C., Miller E., Rowe K., et al: Surveillance of symptoms following MMR vaccine in children. Practitioner 1989; 233:69-73.
444. Dos Santos B.A., Ranieri T.S., Bercini M., et al: An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Rev Panam Salud Publica 2002; 12:240-246.
445. Nagai T., Nakayama T.: Mumps vaccine virus genome is present in throat swabs obtained from uncomplicated healthy recipients. Vaccine 2001; 19:1353-1355.
446. Sawada H., Yano S., Oka Y., et al: Transmission of Urabe mumps vaccine between siblings. Lancet 1993; 342:371.

447. Nakayama T., Oka S., Komase K., et al: The relationship between the mumps vaccine strain and parotitis after vaccination. J Infect Dis 1992; 165:186-187.
448. Atrasheuskaya A.V., Neverov A.A., Rubin S., et al: Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine 2006; 24:1530-1536.
449. Kaic B., Gjenero-Margan I., Aleraj B., et al: Transmission of the L-Zagreb mumps vaccine virus, Croatia, 2005-2008. Euro Surveill 2008; 13(16):
450. Vukic B.T., Pavic I., Milotic I., et al: Aseptic meningitis after transmission of the Leningrad-Zagreb mumps vaccine from vaccinee to susceptible contact. Vaccine 2008; 26:4879.
451. Tesovic G., Poljak M., Lunar M.M., et al: Horizontal transmission of the Leningrad-Zagreb mumps vaccine strain: a report of three cases. Vaccine 2008; 26:1922-1925.
452. Plans P.: Prevalence of antibodies associated with herd immunity: a new indicator to evaluate the establishment of herd immunity and to decide immunization strategies. Med Decis Making 2010; 30:438-443.
453. Centers for Disease Control and Prevention : Summary of Notifiable Diseases: United States, 2007. MMWR 2009; 56:1-94.
454. Rothstein E.P., Bernstein H.H., Glode M.P., et al: Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. Am J Dis Child 1993; 147:854-857.
455. Dashefsky B., Wald E., Guerra N., et al: Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Pediatrics 1990; 85(4 pt 2):682-689.
456. Huang L.M., Lee C.Y., Hsu C.Y., et al: Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Pediatr Infect Dis J 1990; 9:461-465.
457. King G.E., Hadler S.C.: Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1994; 13:394-407.
458. Arbeter A.M., Baker L., Starr S.E., et al: Combination measles, mumps, rubella and varicella vaccine. Pediatrics 1986; 78(4 pt 2):742-747.
459. Arbeter A.M., Baker L., Starr S.E., et al: The combination measles, mumps, rubella and varicella vaccine in healthy children. Dev Biol Stand 1986; 65:89-93.
460. Englund J.A., Suarez C.S., Kelly J., et al: Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr 1989; 114:37-44.
461. Cohen B.J., Jin L., Brown D.W., et al: Infection with wild-type mumps virus in army recruits temporally associated with MMR vaccine. Epidemiol Infect 1999; 123:251-255.
462. Kuczyk M.A., Denil J., Thon W.F., et al: Orchitis following mumps vaccination in an adult. Urol Int 1994; 53:179-180.
463. Abdelbaky A.M., Channappa D.B., Islam S.: Unilateral epididymo-orchitis: a rare complication of MMR vaccine. Ann R Coll Surg Engl 2008; 90:336-337.
464. Feldman G., Zer M.: Infantile acute pancreatitis after mumps vaccination simulating an acute abdomen. Pediatr Surg Int 2000; 16:488-489.
465. Toovey S., Jamieson A.: Pancreatitis complicating adult immunisation with a combined mumps measles rubella vaccine: a case report and literature review. Travel Med Infect Dis 2003; 1:189-192.
466. Asatryan A., Pool V., Chen R.T., et al: Live attenuated measles and mumps viral strain–containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990-2003. Vaccine 2008; 26:1166-1172.

467. DeStefano F., Verstraeten T., Jackson L.A., et al: Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60:504-509.
468. Patja A., Mäkinen-Kiljunen S., Davidkin I., et al: Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 2001; 107:E27.doi:10.1542/peds.107.2.e27
469. Griffin M.R., Ray W.A., Mortimer E.A., et al: Risk of seizures after measles-mumps-rubella immunization. Pediatrics 1991; 88:881-885.
470. Marshall G.S., Wright P.F., Fenichel G.M., et al: Diffuse retinopathy following measles, mumps, and rubella vaccination. Pediatrics 1985; 76:989-991.
471. Plesner A.M., Hansen F.J., Taudorf K., et al: Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study. Acta Paediatr 2000; 89:58-63.
472. Drachtman R.A., Murphy S., Ettinger L.J.: Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148:326-327.
473. Jonville-Bera A.P., Autret E., Galy-Eyraud C., et al: Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-merieux serums et vaccins. Pediatr Infect Dis J 1996; 15:44-48.
474. Nieminen U., Peltola H., Syrjala M.T., et al: Acute thrombocytopenic purpura following measles, mumps and rubella vaccination: a report on 23 patients. Acta Paediatr 1993; 82:267-270.
475. Hilleman M.R., Buynak E.B., Whitman Jr. J.E., et al: Live attenuated rubella virus vaccines: experiences with duck embryo cell preparations. Am J Dis Child 1969; 118:166-171.
476. Heisler M.B., Richmond J.B.: Lessons from Finland's successful immunization program. N Engl J Med 1994; 331:1446-1447.
477. Johnson J.A., Heneine W.: Characterization of endogenous avian leukosis viruses in chicken embryonic fibroblast substrates used in production of measles and mumps vaccines. J Virol 2001; 75:3605-3612.
478. Shahabuddin M., Sears J.F., Khan A.S.: No evidence of infectious retroviruses in measles virus vaccines produced in chicken embryo cell cultures. J Clin Microbiol 2001; 39:675-684.
479. da Silveira C.M., Kmetzsch C.I., Mohrdieck R., et al: The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol 2002; 31:978-982.
480. da Cunha S.S., Rodrigues L.C., Barreto M.L., et al: Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 2002; 20:1106-1112.
481. Tesovic G., Lesnikar V.: Aseptic meningitis after vaccination with L-Zagreb mumps strain: virologically confirmed cases. Vaccine 2006; 24:6371-6373.
482. Phadke M.A., Patki P.S., Kulkarni P.S., et al: Pharmacovigilance on MMR vaccine containing L-Zagreb mumps strain. Vaccine 2004; 22:4135-4136.
483. Pan American Health Organization PAHO : Special Program for Vaccines and Immunization. Evaluation of the Bahamas' MMR campaign. EPI Newsl 1999; 21:4-5.February
484. Sharma H.J., Oun S.A., Bakr S.S., et al: No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clin Microbiol Infect 2010; 16:347-352.

485. Nagai T., Okafuji T., Miyazaki C., et al: A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine 2007; 25:2742-2747.
486. Baba K., Okuno Y., Tanaka-Taya K., et al: Immunization coverage and natural infection rates of vaccine-preventable diseases among children by questionnaire survey in 2005 in Japan. Vaccine 2011; 29:3089-3092.
487. Santos-Lopez G., Cruz C., Pazos N., et al: Two clones obtained from Urabe AM9 mumps virus vaccine differ in their replicative efficiency in neuroblastoma cells. Microbes Infect 2006; 8:332-339.
488. Nalin D.R.: Evaluating mumps vaccines. Lancet 1992; 339:305.
489. Nalin D.R.: Mumps vaccine complications: which strain?. Lancet 1989; 2:1396.
490. Black S., Shinefield H., Ray P., et al: Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997; 16:500-503.
491. Schlipkoter U., Muhlberger N., von K.R., Weil J.: Surveillance of measles-mumps-rubella vaccine–associated aseptic meningitis in Germany. Infection 2002; 30:351-355.
492. Colville A., Pugh M.: Mumps meningitis and measles, mumps and rubella vaccine. Lancet 1992; 340:786.
493. Miller E., Goldacre M., Pugh S., et al: Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993; 341:979-982.
494. Ehrengut W., Zastrow K.: Complications after preventive mumps vaccination in West Germany (including multiple preventive vaccinations) [in German]. Monatsschr Kinderheilkd 1989; 137:398-402.
495. Kimura M., Kuno-Sakai H., Yamazaki S., et al: Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn 1996; 38:205-211.
496. Ki M., Park T., Yi S.G., et al: Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Am J Epidemiol 2003; 157:158-165.
497. Ueda K., Miyazaki C., Hidaka Y., et al: Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet 1995; 346:701-702.
498. Maruyama H., Tomizawa I.: Reports on aseptic meningitis after MMR vaccination. Clin Virol 1994; 22:77-82.
499. Hrynash Y., Nadraga A., Dasho M.: Effectiveness of a vaccination program against mumps in Ukraine. Eur J Clin Microbiol Infect Dis 2008; 27:1171-1176.
500. Cizman M., Mozetic M., Radescek-Rakar R., et al: Aseptic meningitis after vaccination against measles and mumps. Pediatr Infect Dis J 1989; 8:302-308.
501. Odisseev H., Gacheva N.: Vaccinoprophylaxis of mumps using mumps vaccine, strain Sofia 6, in Bulgaria. Vaccine 1994; 12:1251-1254.
502. Enders J.F.: Viral and rickettsial infections of man. 3 rd ed. Philadelphia, PA, J. B. Lippincott Company, 1959.
503. Peltola H.: Mumps vaccination and meningitis. Lancet 1993; 341:994-995.
504. Fullerton K.E., Reef S.E.: Commentary: ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control. Int J Epidemiol 2002; 31:983-984.
505. World Health Organization : Mumps virus vaccines: WHO position paper. Wkly Epidemiol Rec 2001; 76:346-355.
506. Bonnet M.C., Dutta A., Weinberger C., et al: Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006; 24:7037-7045.

507. Advisory Committee on Immunization Practices. ACIP Provisional Recommendations for Measles-Mumps-Rubella (MMR): Evidence of Immunity Requirements for Healthcare Personnel. 2009 ***http://www.immunizeorg/acip/acip_vaxasp . Accessed January 21, 2011.
508. Fasano M.B., Wood R.A., Cooke S.K., et al: Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr 1992; 120:878-881.
509. James J.M., Burks A.W., Roberson P.K., et al: Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262-1266.
510. Beck S.A., Williams L.W., Shirrell M.A., et al: Egg hypersensitivity and measles-mumps-rubella vaccine administration. Pediatrics 1991; 88:913-917.
511. Trotter A.C., Stone B.D., Laszlo D.J., et al: Measles, mumps, rubella vaccine administration in egg-sensitive children: systemic reactions during vaccine desensitization. Ann Allergy 1994; 72:25-28.
512. National Advisory Committee on Immunization (NACI) : Supplementary statement MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens. Can Commun Dis Rep 1996; 22:113-115.
513. Danerseau A.M., Robinson J.L.: Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr 2008; 4:254-258.
514. Visser L.E., Gonzalez Perez K.C., Ramos T.J.: An outbreak of mumps in the Province of Leon Spain 1995-1996. Euro Surveill 1998; 3(14–18):14-18.
515. Hatziandreau E.J., Brown R.E., Halpern M.T.: A cost benefit analysis of the measles-mumps-rubella (MMR) vaccine: final report. Arlington,VA, Battelle, Medical Technology Assessment and Research Program, Centers for Public Research and Evaluation, 1994. Report 447
516. van Loon F.P., Holmes S.J., Sirotkin B.I., et al: Mumps surveillance: United States, 1988-1993. MMWR CDC Surveill Summ 1995; 44:1-14.
517. Sosin D.M., Cochi S.L., Gunn R.A., et al: Changing epidemiology of mumps and its impact on university campuses. Pediatrics 1989; 84:779-784.
518. Kaplan K.M., Marder D.C., Cochi S.L., et al: Mumps in the workplace: further evidence of the changing epidemiology of a childhood vaccine-preventable disease. JAMA 1988; 260:1434-1438.
519. McNabb S.J., Jajosky R.A., Hall-Baker P.A., et al: Summary of notifiable diseases: United States, 2005. MMWR 2007; 54:1-92.
520. McNabb S.J., Jajosky R.A., Hall-Baker P.A., et al: Summary of notifiable diseases: United States, 2006. MMWR 2008; 55:1-92.
521. Centers for Disease Control and Prevention : Summary of notifiable diseases: United States, 2008. MMWR 2009; 57:1-94.
522. Cochi S.L., Preblud S.R., Orenstein W.A.: Perspectives on the relative resurgence of mumps in the United States. Am J Dis Child 1988; 142:499-507.
523. Jajosky R.A., Hall P.A., Adams D.A., et al: Summary of notifiable diseases: United States, 2004. MMWR 2006; 53:1-79.
524. Rantala H., Uhari M.: Occurrence of childhood encephalitis: a population-based study. Pediatr Infect Dis J 1989; 8:426-430.
525. Centers for Disease Control and Prevention : Update: multistate outbreak of mumps: United States, January 1-May 2, 2006. MMWR 2006; 55:559-563.
526. Koplan J.P., Preblud S.R.: A benefit-cost analysis of mumps vaccine. Am J Dis Child 1982; 136:362-364.
527. White C.C., Koplan J.P., Orenstein W.A.: Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985; 75:739-744.

528. Zhou F., Reef S., Massoudi M., et al: An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis 2004; 189(suppl 1):S131-S145.
529. Ciofi Degli Atti M.L., Rota M.C., Bella A.: Do changes in policy affect vaccine coverage levels? Results of a national study to evaluate childhood vaccination coverage and reasons for missed vaccination in Italy. Vaccine 2004; 22:4351-4357.
530. Eradication of measles, rubella and routine mumps in Cuba: report of a technical advisory group. Washington, DC, Pan American Health Organization, 1989.
531. Slater P.E., Roitman M., Costin C.: Mumps incidence in Israel: impact of MMR vaccine. Public Health Rev 1990; 18:88-93.
532. Statement on Mumps Vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007; 33(ACS-8):1-10.
533. Schmid D., Holzmann H., Alfery C.: Mumps outbreak in young adults following a festival in Austria, 2006. Euro Surveill 2008; 13(7):
534. Kuzmanovska G., Polozhani A., Mikik V., et al: Mumps outbreak in the former Yugoslav Republic of Macedonia, January 2008–June 2009: epidemiology and control measures. Euro Surveill 2010; 15(23):
535. Mrazova M., Smelhausova M., Sestakova Z., et al: The 2001 serological survey in the Czech Republic: mumps. Cent Eur J Public Health 2003; 11(suppl):S50-S53.
536. Huerta M., Davidovitch N., Aboudy Y., et al: Declining population immunity to mumps among Israeli military recruits. Vaccine 2006; 24:6300-6303.
537. Jones A.G., White J.M., Begg N.T.: The impact of MMR vaccine on mumps infection in England and Wales. CDR (Lond Engl Rev) 1991; 1:R93-R96.
538. Vaccination coverage statistics for children up to two years of age in the United Kingdom. Commun Dis Rep CDR Wkly 1996; 6:262.
539. Donaghy M., Cameron J.C., Friederichs V.: Increasing incidence of mumps in Scotland: options for reducing transmission. J Clin Virol 2006; 35:121-129.
540. Gupta R.K., Best J., MacMahon E.: Mumps and the UK epidemic 2005. BMJ 2005; 330:1132-1135.
541. Health Protection Agency. Confirmed Cases of Measles, Mumps and Rubella 1996–2009. 2011 http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733833790 . Accessed January 25, 2011.
542. Wakefield A.J., Murch S.H., Anthony A., et al: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637-641.
543. Dyer C.: Lancet retracts Wakefield's MMR paper. BMJ 2010; 340:c696.doi:10.1136/bmj.c696
544. Hendrickson B.A., Turner J.R.: MMR vaccination, ileal lymphoid nodular hyperplasia, and pervasive developmental disorder. Lancet 2002; 359:2051-2052.
545. Maldonado Y.A.: Current controversies in vaccination: vaccine safety. JAMA 2002; 288:3155-3158.
546. Wilson K., Mills E., Ross C., et al: Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 2003; 157:628-634.
547. DeStefano F., Thompson W.W.: MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines 2004; 3:19-22.
548. Mrozek-Budzyn D., Kieltyka A., Majewska R.: Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J 2010; 29:397-400.

549. Wright J.A., Polack C.: Understanding variation in measles-mumps-rubella immunization coverage: a population-based study. Eur J Public Health 2006; 16:137-142.
550. Health Protection Agency. Quarterly Vaccine Coverage Data Tables. 2011 http://www.hpaorguk http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1211441442288 . Accessed February 14, 2012.
551. Paunio M., Virtanen M., Peltola H., et al: Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland. Am J Epidemiol 1991; 133:1152-1160.
552. Peltola H., Heinonen O.P., Valle M., et al: The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331:1397-1402.
553. Hyoty H., Hiltunen M., Reunanen A., et al: Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Childhood Diabetes in Finland Study Group. Diabetologia 1993; 36:1303-1308.
554. Dias J.A., Cordeiro M., Afzal M.A., et al: Mumps epidemic in Portugal despite high vaccine coverage: preliminary report. Euro Surveill 1996; 1:25-28.
555. Amela C., Pachon I., de Ory F.: Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. Eur J Epidemiol 2003; 18:71-79.
556. Matter H.C., Cloetta J., Zimmermann H.: Measles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft. J Epidemiol Community Health 1995; 49(suppl 1):4-8.
557. Matter L., Germann D., Bally F., et al: Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Eur J Epidemiol 1997; 13:61-66.
558. World Health Organization. WHO vaccine-preventable diseases: monitoring system 2011 global summary. 2011 http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tsincidencemum.htm . Accessed February 14, 2012.
559. Eick A.A., Hu Z., Wang Z., et al: Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000-2004. Vaccine 2008; 26:494-501.
560. Mancuso J.D., Krauss M.R., Audet S., et al: ELISA underestimates measles antibody seroprevalence in US military recruits. Vaccine 2008; 26:4877-4878.
561. Clardy W.F.: Susceptibility in USAF recruits to vaccine-preventable diseases. Vaccine 1993; 11:573-575.
562. Department of the Air Force. Vaccine policy and guidance for adults and accessions. June 7 http://www.vaccines.mil/documents/951AFSGOJune2006.pdf . Accessed January 25, 2011.
563. Broder K.R., Cortese M.M., Iskander J.K.: Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-3):1-34.
564. Recommendations of the International Task Force for Disease Eradication. MMWR Rep Recomm Rep 1993; 42(RR-16):1-38.
565. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR Recomm Rep 1997; 46(RR-11):1-20.

566. Buxton J., Craig C., Daly P., et al: An outbreak of mumps among young adults in Vancouver, British Columbia, associated with “rave” parties. Can J Public Health 1999; 90:160-163.
567. Centers for Disease Control and Prevention : Mumps epidemic: Iowa, 2006. MMWR 2006; 55:366-368.
568. Spanaki A., Hajiioannou J., Varkarakis G., et al: Mumps epidemic among young British citizens on the island of Crete. Infection 2007; 35:104-106.
569. Castilla J., Garcia C.M., Barricarte A., et al: Mumps outbreak in Navarre region, Spain, 2006-2007. Euro Surveill 2007; 12:E070215.
570. Sartorius B., Penttinen P., Nilsson J., et al: An outbreak of mumps in Sweden, February-April 2004. Euro Surveill 2005; 10:191-193.
571. Whyte D., O'Dea F., McDonnell C., et al: Mumps epidemiology in the Mid-West of Ireland 2004-2008: increasing disease burden in the university/college setting. Euro Surveill 2009; 14(16):
572. Laurence D., McGavin D.: The complications of mumps. Br Med J 1948; 1:94-97.
573. Centers for Disease Control and Prevention : Mumps outbreaks on university campuses: Illinois, Wisconsin, South Dakota. MMWR 1987; 36:496.495
574. Eurosentinel : Surveillance of measles and mumps by sentinel networks of general practitioners. Wkly Epidemiol Rec 1991; 66:297-300.
575. Sullivan K.M., Halpin T.J., Kim-Farley R., et al: Mumps disease and its health impact: an outbreak-based report. Pediatrics 1985; 76:533-536.
576. Fuller I.C.: Mumps and its complications: an example of the utilization of disease indices. J R Coll Gen Pract 1968; 16:494-496.
577. Humphries J.: Complications of mumps. Am J Med Sci 1947; 213:354-357.
578. Palihawadana P., Jayaratne I.L., Wijemunige N.: An outbreak of mumps in Dompe. Ceylon Med J 2007; 52:35-36.
579. Levine M.I.: A sponsored epidemic of mumps in a private school. Am J Public Health Nations Health 1944; 34:1274-1276.
580. Oda K., Kato H., Konishi A.: The outbreak of mumps in a small island in Japan. Acta Paediatr Jpn 1996; 38:224-228.
581. Eagles A.Y.: Analysis of a four year epidemic of mumps. Arch Med Interna 1947; 80:374-387.
582. Robert Koch-Institut : Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut Stand: Juli 2005. Epidemiol Bull 2005; 30:257-272.
583. Gee S., O'Flanagan D., Fitzgerald M., et al: Mumps in Ireland, 2004-2008. Euro Surveill 2008; 13(18):
584. Ministero della Sanità: Italia. Decreto. Nuovo calendario delle vaccinazioni obbligatorie e raccomandate per l'età evolutiva. Gazzetta Ufficiale 1999; 87:
585. Bernard H., Schwarz N.G., Melnic A., et al: Mumps outbreak ongoing since October 2007 in the Republic of Moldova. Euro Surveill 2008; 13(13):
586. van den H.S., Beaumont M.T., Berbers G.A., et al: Antibodies against mumps in the Netherlands as assessed by indirect ELISA and virus neutralization assay. Epidemiol Infect 2003; 131:703-709.
587. Follin P., Dotevall L., Jertborn M., et al: Effective control measures limited measles outbreak after extensive nosocomial exposures in January-February 2008 in Gothenburg, Sweden. Euro Surveill 2008; 13(30):
588. Vesikari T., Andre F.E., Simoen E., et al: Comparison of the Urabe Am 9-Schwarz and Jeryl Lynn–Moraten combinations of mumps-measles vaccines in young children. Acta Paediatr Scand 1983; 72:41-46.

589. Vesikari T., Ala-Laurila E.L., Heikkinen A., et al: Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children. Am J Dis Child 1984.843-847.
590. Centers for Disease Control and Prevention : Mumps in an elementary school: New York. MMWR 1973; 22:185-186.
591. Dasovic T., Kovacic V., Vodopija I., et al: The effect of the live attenuated parotitis vaccine on the course of parotitis epidemic in school children [author's transl). Lijec Vjesn 1976; 98:231-233.
592. Chaiken B.P., Williams N.M., Preblud S.R., et al: The effect of a school entry law on mumps activity in a school district. JAMA 1987; 257:2455-2458.
593. Pena A.A., Pitarch S.M., Adsuara L.S.: Epidemia de paratiditis in una poblacion escolar y eficacia de la vacunacion antiparotiditis. Med Clin (Barc) 1989; 93:607-610.
594. Guimbao Bescós J., Moreno Marin M.P., Gutiérrez Colás V., et al: Parotiditis in postvaccination period: epidemiologic pattern and vaccine effectiveness in an epidemic outbreak [in Spanish]. Med Clin (Barc) 1992; 99:281-285.
595. Chamot E., Toscani L., Egger P., et al: Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland) [in French]. Rev Epidemiol Sante Publique 1998; 46:100-107.
596. Toscani L., Batou M., Bouvier P., et al: Comparison of the efficacy of various strains of mumps vaccine: a school survey [in French]. Soz Praventivmed 1996; 41:341-347.
597. Baron S., Guibert M., Soltysiak M., et al: Une epidemie d'oreillons a Millau (Aveyron): estimation de l'efficacite vaccinale de la souche Urabe. Bulletin Epidemiologique Hebdomadaire 1997; 39:177-178.
598. Goncalves G., De Araujo A., Monteiro Cardoso M.L.: Outbreak of mumps associated with poor vaccine efficacy: Oporto Portugal 1996. Euro Surveill 1998; 3:119-121.
599. Bell A., Fyfe M., Bigham M., et al: Outbreak of mumps among young adults: Vancouver, British Columbia. Can Commun Dis Rep 1997; 23:169-172.
600. Whitman C.: Mumps outbreak in a highly vaccinated population. New York City VacScene 1999; 1:1-3.
601. Schlegel M., Osterwalder J.J., Galeazzi R.L., et al: Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ 1999; 319:352.
602. Goh K.T.: Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet 1999; 354:1355-1356.
603. Harling R., White J.M., Ramsay M.E., et al: The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005; 23:4070-4074.
604. Fu C., Liang J., Wang M.: Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps. Clin Vaccine Immunol 2008; 15:1425-1428.
605. Dominguez A., Torner N., Castilla J., et al: Mumps vaccine effectiveness in highly immunized populations. Vaccine 2010; 28:3567-3570.
606. Rebiere I., Galy-Eyraud C.: Estimation of the risk of aseptic meningitis associated with mumps vaccination, France, 1991-1993. Int J Epidemiol 1995; 24:1223-1227.
607. Jonville-Bera A.P., Autret E., Galy-Eyraud C., et al: Aseptic meningitis following mumps vaccine: a retrospective survey by the French Regional Pharmacovigilance centres and by Pasteur-Merieux Serums & Vaccins. Pharmacoepidemiol Drug Saf 1996; 5:33-37.
608. Furesz J., Contreras G.: Vaccine-related mumps meningitis: Canada. Can Dis Wkly Rep 1990; 16:253-254.
609. Dourado I., Cunha S., Teixeira M.G., et al: Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol 2000; 151:524-530.

610. Farrington P., Pugh S., Colville A., et al: A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345:567-569.
611. Fujinaga T., Motegi Y., Tamura H., et al: A prefecture-wide survey of mumps meningitis associated with measles, mumps and rubella vaccine. Pediatr Infect Dis J 1991; 10:204-209.
612. Sugiura A., Yamada A.: Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 1991; 10:209-213.
613. Maguire H.C., Begg N.T., Handford S.G.: Meningoencephalitis associated with MMR vaccine. CDR (Lond Engl Rev) 1991; 1:R60-R61.
614. Al Mazrou Y., Tumsah S., Khalil M.: Safety evaluation of MMR vaccine during a primary school campaign in Saudi Arabia. J Trop Pediatr 2002; 48:354-358.

RUBELA

1. O'Reilly M.: Falling on deaf ears. Perspect Biol Med 1992; 39:204.
2. Smith J.L.: Rotheln (epidemic roseola-German measles-hybrid measles, etc.). Arch Dermatol 1875; 1:1-13.
3. Veale H.: History of an epidemic of rotheln, with observation on its pathology. Edinburgh Med J 1866; 12:404-414.
4. Gregg N.M.: Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941; 3:35-346.
5. Burgess M.A.: Gregg's rubella legacy 1941-1991. Med J Aust 1991; 155:355-357.
6. Pitt D., Keir E.H.: Results of rubella in pregnancy. Med J Aust 1965; 2:647-651.
7. Lundstrom R.: Rubella during pregnancy: a follow-up study of children born after an epidemic of rubella in Sweden, 1951, with additional investigations on proplylaxis and treatment of maternal rubella. Acta Paediatr Scand 1962; 133(Suppl):1-110.
8. Greenberg M., Pellitteri O., Barton J.: Frequency of defects in infants whose mothers had rubella during pregnancy. JAMA 1957; 165:675-678.
9. Manson M.M., Logan W.P.D., Loy R.M.: Rubella and other virus infections during pregnancy. (Report on Public Health and Mechanical Subjects, No. 101.)London, Her Royal Majesty's Stationery Office, 1960.
10. Weller T.H., Neva F.A.: Propagation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc Soc Exp Biol Med 1962; 111:215-225.
11. Parkman P.D., Buescher E.L., Artenstein M.S.: Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med 1962; 111:225-230.
12. Witte J.J., Karchmer A.W.: Epidemiology of rubella. Am J Dis Child 1969; 118:107-112.
13. Rubella surveillance. Bethesda, MD, National Communicable Disease Center, United States Department of Health, Education and Welfare, 1969. p. 1
14. Plotkin S.A., Oski F.A., Hartnett E.M., et al: Some recently recognized manifestations of the rubella syndrome. J Pediatr 1965; 67:182-191.
15. Meyer H.M., Parkman P.D., Hobbins T.E., et al: Attenuated rubella viruses: laboratory and clinical characteristics. Am J Dis Child 1969; 118:155-169.
16. Prinzie A., Huygelen C., Gold J., et al: Experimental live attenuated rubella virus vaccine: Clinical evaluation of Cendehill strain. Am J Dis Child 1969; 118:172-177.
17. Plotkin S.A., Farquhar J., Katz M., et al: Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child 1969; 118:178-185.
18. Heggie A.D., Robbins F.C.: Natural rubella acquired after birth. Am J Dis Child 1969; 118:12-17.

19. Plotkin S.A.: Rubella viruses. In: Lennette E.H., Schmidt N.J., ed. Diagnostic Procedures for Viral and Rickettsial Infections, 4th ed. Washington, DC: American Public Health Association; 1969:364-413.
20. Kanto T.G., Tanner M.: Rubella arthritis and rheumatoid arthritis. Arthritis Rheum 1962; 5:378-383.
21. Fraser F.R.E., Cunningham A., Hayes K., et al: Rubella arthritis in adults. Isolation of virus, cytology and other aspects of infection. Clin Exp Rheumatol 1983; 1:287-293.
22. Smith C.A., Petty R.E., Tingle A.J.: Rubella virus and arthritis. Rheum Dis Clin North Am 1987; 13:265-274.
23. Bosma T.J., Etherington J., O'Shea S., et al: Rubella virus and chronic joint disease: is there an association?. J Clin Microbiol 1998; 36:3524-3526.
24. Morse E.E., Zinkham W.H., Jackson D.P.: Thrombocytopenic purpura following rubella infection in children and adults. Arch Intern Med 1966; 117:573-579.
25. Sherman F.E., Michaels R.H., Kenny F.M.: Acute encephalopathy (encephalitis) complicating rubella: Reports of cases with virologic studies, cortisol-production determinations and observations at autopsy. JAMA 1965; 192:675-681.
26. Pisternick D., Hopps J., Dannecker G.E., et al: Fulminant verlaufende Rotelnenzephalitis mit latalem Ausgang. Monatsschr Kinderheilkd 1997; 145:105-108.
27. Katz M., Plotkin S.A.: Parainfectious encephalopathies associated with measles, mumps, chickenpox and German measles. In: Goldensohn E.S., Appel S.H., ed. Scientific Approaches to Clinical Neurology, vol. 1. Philadelphia: Lea & Febiger; 1977:405-425.
28. Moriuchi H., Yamasaki S., Mori K., et al: A rubella epidemic in Sasebo, Japan in 1987, with various complications. Acta Paediatr Jpn 1990; 32:67-75.
29. Ruben A.: Rubella-associated encephalitis in Tonga, 2002. 2006.
30. Townsend J.J., Baringer J.R., Wolinsky J.S., et al: Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med 1975; 292:990-993.
31. Weil M.L., Itabashi H., Cremer N.E., et al: Chronic progressive panencephalitis due to rubella virus simulating subacute sclerosing panencephalitis. N Engl J Med 1975; 292:994-998.
32. Yaginuma Y., Kawamura M., Ishikawa M.: Landry-Guillain-Barré-Strohl syndrome in pregnancy. J Obstet Gynaecol Res 1996; 22:47-49.
33. Kalvenes M.B., Kalland K.H., Haukenes G.: Radioimmunoprecipitation and immunoblot studies of antibodies to rubella virus in patients with chronic liver disease. Arch Virol 1994; 136:73-85.
34. Rothova A.: The riddle of fuchs heterochromic uveitis. Am J Ophthalmol 2007; 144:447-448.
35. Quentin C.D., Reiber H.: Fuch's heterochromic cyclitis [in German]. Ophthalmologe 2006; 103:347-348.
36. Birnbaum A.D., Tessler H.H., Schultz K.L., et al: Epidemiologic relationship between fuchs heterochromic iridocyclitis and the United States rubella vaccination program. Am J Ophthalmol 2007; 144:424-428.
37. Cooper L., Preblud S.R., Alford C.A.: Rubella. In: Remington J.S., Klein J.O., ed. Infectious Diseases of the Fetus and Newborn Infant, 4th ed. Philadelphia: WB Saunders; 1995:268-311.
38. Cosachow J., Frieri M.: Hyper-IgM syndrome with congenital rubella. Pediatr Asthma Allergy Immunol 1995; 9:79-85.
39. O'Neill J.F.: The ocular manifestations of congenital infection: a study of the early effect and long-term outcome of maternally transmitted rubella and toxoplasmosis. Trans Am Ophthalmol Soc 1998; 96:813-879.
40. Dusak R.S.: Congenital rubella syndrome-major review. Optometry 2009; 80:36-43.

41. Oster M.E., Riehle-Colarusso T., Correa A.: An update on cardiovascular malformations in congenital rubella syndrome. Birth Defects Res A Clin Mol Teratol 2010; 88:1-8.
42. Reef S.E., Plotkin S., Cordero J.F., et al: Preparing for elimination of congenital rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85-95.
43. deVisser L., Braakenburg A., Rothova A., et al: Rubella virus-associated uvelitis: clinical manifestations and visual prognosis. Am J Ophthalmol 2008; 148:292-297.
44. Siegel M., Fuerst H.T., Peress N.S.: Fetal mortality in maternal rubella. Results of a prospective study from 1957 to 1964. Am J Obstet Gynecol 1966; 96:247-253.
45. Miller E., Cradock-Watson J.E., Pollock T.M.: Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982; 2:781-784.
46. South M.A., Sever J.L.: Teratogen update: the congenital rubella syndrome. Teratology 1985; 31:297-307.
47. Ingalls T.H.: German measles and German measles in pregnancy. Am J Dis Child 1957; 93:555-558.
48. Grillner L., Forsgren M., Barr B., et al: Outcome of rubella during pregnancy with special reference to the 17th-24th weeks of gestation. Scand J Infect Dis 1983; 15:321-325.
49. Sheridan M.D.: Final report of a prospective study of children whose mothers had rubella in early pregnancy. Br Med J 1964; 2:536-539.
50. Rawls W.E., Desmyter J., Melnick J.L.: Serologic diagnosis and fetal involvement in maternal rubella. Criteria for abortion. JAMA 1968; 203:627-631.
51. Thompson K.M., Tobin J.O.: Isolation of rubella virus from abortion material. Br Med J 1970; 1:264-266.
52. Cradock-Watson J.E., Bourne M.S., Vandervelde E.M.: IgG, IgA and IgM responses in acute rubella determined by the immunofluorescent technique. J Hyg (Lond) 1972; 70:473-485.
53. Enders G., Nickerl-Pacher U., Miller E., et al: Outcome of confirmed periconceptional maternal rubella. Lancet 1988; 1:1445-1447.
54. Katow S.: Rubella virus genome diagnosis during pregnancy and mechanism of congenital rubella. Intervirology 1998; 41:163-169.
55. Connolly J.H., Nevin N.C., Simpson D.M., et al: Outcome of pregnancy in a rubella outbreak in Northern Ireland 1978-1979. Ulster Med J 1984; 53:65-73.
56. Kono R., Hayakawa Y., Hibi M., et al: Experimental vertical transmission of rubella virus in rabbits. Lancet 1969; 1:343-347.
57. O'Donnell N.: History of congenital rubella syndrome. J Vocational Rehabil 1996; 6:149-157.
58. Tomer Y., Davies T.F.: Infection, thyroid disease, and autoimmunity. Endocr Rev 1993; 14:107-120.
59. Ginsberg-Fellner F., Witt M.E., Yagihashi S., et al: Congenital rubella syndrome as a model for type 1 (insulin-dependent) diabetes mellitus: increased prevalence of islet cell surface antibodies. Diabetologia 1984; 27(Suppl.):87-89.
60. Burgess M.A., Forrest J.M.: Congenital rubella and diabetes mellitus. Diabetologia 2009; 52:369-370.
61. Takasu N., Ikema T., Komiya I., et al: Forty-year observation of 280 Japanese patients with congenital rubella syndrome. Diabetes Care 2005; 28:2331-2332.
62. Viskari H., Paronen J., Keskinen P., et al: Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome. Clin Exp Immunol 2003; 133:378-383.
63. Frey T.K.: Molecular biology of rubella virus. Adv Virus Res 1994; 44:69-160.

64. Pettersson R.F., Oker-Blom C., Kalkkinen N., et al: Molecular and antigenic characteristics and synthesis of rubella virus structural proteins. Rev Infect Dis 1985; 7(Suppl. 1):S140-S149.
65. Oker-Blom C., Ulmanen I., Kaariainen L., et al: Rubella virus 40S genome RNA specifies a 24S subgenomic mRNA that codes for a precursor to structural proteins. J Virol 1984; 49:403-408.
66. Oker-Blom C., Kalkkinen N., Kaariainen L., et al: Rubella virus contains one capsid protein and three envelope glycoproteins, E1, E2a, and E2b. J Virol 1983; 46:964-973.
67. Waxham M.N., Wolinsky J.S.: A model of the structural organization of rubella virions. Rev Infect Dis 1985; 7(Suppl. 1):S133-S139.
68. Hovi T., Vaheri A.: Infectivity and some physicochemical characteristics of rubella virus ribonucleic acid. Virology 1970; 42:1-8.
69. Sedwick W.D., Sokol F.: Nucleic acid of rubella virus and its replication in hamster kidney cells. J Virol 1970; 5:478-489.
70. Forng R.Y., Frey T.K.: Identification of the rubella virus nonstructural proteins. Virology 1995; 206:843-853.
71. Ilkow C.S., Weckbecker D., Cho W.J., et al: The rubella virus capsid protein inhibits mitochondrial import. J Virol 2010; 84:119-130.
72. Londesborough P., Ho-Terry L., Terry G.: Sequence variation and biological activity of rubella virus isolates. Arch Virol 1995; 140:563-570.
73. Bosma T.J., Best J.M., Corbett K.M., et al: Nucleotide sequence analysis of a major antigenic domain of the E1 glycoprotein of 22 rubella virus isolates. J Gen Virol 1996; 77(pt 10):2523-2530.
74. Zheng D.P., Frey T.K., Icenogle J., et al: Global distribution of rubella virus genotypes. Emerg Infect Dis 2003; 9:1523-1530.
75. Abernathy E.S., Hübschen J.M., Muller C.P., et al: Status of global virologic surveillance for rubella viruses. J Infect Dis 2011; 204(Suppl. 1):S524-S532.
76. Zhu Z., Abernathy E., Cui A., et al: Rubella virus genotypes in the People's Republic of China between 1979 and 2007: a shift in endemic viruses during the 2001 rubella epidemic. J Clin Microbiol 2010; 48:1775-1781.
77. Vauloup-Fellous C., Hübschen J.M., Abernathy E.S., et al: Phylogenetic analysis of rubella viruses involved in congenital rubella infections in France between 1995 and 2009. J Clin Microbiol 2010; 48:2530-2535.
78. Rajasundari T.A., Sundaresan P., Vijayalakshmi P., et al: Laboratory confirmation of congenital rubella syndrome in infants: an eye hospital based investigation. J Med Virol 2008; 80:536-546.
79. Song K.J., Baek L.H., Kim J.H., et al: Analysis of genotype-specific sequences in E1, E2, and C genes of rubella virus [abstract]. American Society for Virology, 19th Annual Meeting, 2000. Fort Collins, CO:
80. Katow S.: Surveillance of congenital rubella syndrome in Japan, 1978-2002: effect of revision of the immunization law. Vaccine 2004; 22:4084-4091.
81. Zheng D.P., Zhu H., Revello M.G., et al: Phylogenetic analysis of rubella virus isolated during a period of epidemic transmission in Italy, 1991-1997. J Infect Dis 2003; 187:1587-1597.
82. Katow S.: Molecular epidemiology of rubella virus in Asia: utility for reduction in the burden of diseases due to congenital rubella syndrome. Pediatr Int 2004; 46:207-213.
83. Papa A., Gioula G., Antoniadis A., et al: Rubella epidemic strain, Greece, 1999. Emerg Infect Dis 2004; 10:1696-1697.
84. World Health Organization : Global measles and rubella laboratory network: update [in English, French]. Wkly Epidemiol Rec 2005; 80:384-388.

85. Derdeyn C.A., Frey T.K.: Characterization of defective-interfering RNAs of rubella virus generated during serial undiluted passage. Virology 1995; 206:216-226.
86. Herrmann K.L.: Rubella virus. In: Lennette E.H., Schmidt N.J., ed. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 5th ed. Washington, DC: American Public Health Association; 1979:725-766.
87. Alford C.A., Neva F.A., Weller T.H.: Virologic and serologic studies on human products of conception after maternal rubella. N Engl J Med 1964; 271:1275-1281.
88. Plotkin S.A., Boué A., Boué J.G.: The in vitro growth of rubella virus in human embryo cells. Am J Epidemiol 1965; 81:71-85.
89. Rawls W.E., Melnick J.L.: Rubella virus carrier cultures derived from congenitally infected infants. J Exp Med 1966; 123:795-816.
90. Naeye R.L., Blanc W.: Pathogenesis of congenital rubella. JAMA 1965; 194:1277-1283.
91. Plotkin S.A., Vaheri A.: Human fibroblasts infected with rubella virus produce a growth inhibitor. Science 1967; 156:659-661.
92. Megyeri K., Berencsi K., Halazonetis T.D., et al: Involvement of a p53-dependent pathway in rubella virus-induced apoptosis. Virology 1999; 259:74-84.
93. Pugachev K.V., Frey T.K.: Rubella virus induces apoptosis in culture cells. Virology 1998; 250:359-370.
94. Hofmann J., Pletz M.W., Liebert U.G.: Rubella virus-induced cytopathic effect in vitro is caused by apoptosis. J Gen Virol 1999; 80(pt 7):1657-1664.
95. Duncan R.J., Muller N., Lee N., et al: Rubella virus-induced apoptosis varies among cell lines and is modulated by bcl-Xl, and caspase inhibitors. Virology 1999; 255:117-128.
96. Adamo P., Asis L., Silveyra P., et al: Rubella virus does not induce apoptosis in primary human embryo fibroblast cultures: a possible way of viral persistence in congenital infection. Viral Immunol 2004; 17:87-100.
97. Tondury G., Smith D.W.: Fetal rubella pathology. J Pediatr 1965; 68:867-879.
98. Lee J.Y., Bowden D.S.: Rubella virus replication and links to teratogenicity. Clin Microbiol Rev 2000; 13:571-587.
99. Atreya C.D., Mohan K.V., Kulkarni S.: Rubella virus and birth defects: molecular insights into the viral teratogenesis at the cellular level. Birth Defects Res A Clin Mol Teratol 2004; 70:431-437.
100. Adamo M.P., Zapata M., Frey T.K.: Analysis of gene expression in fetal and adult cells infected with rubella virus. Virology 2008; 370:1-11.
101. Webster W.S.: Teratogen update: congenital rubella. Teratology 1998; 58:13-23.
102. Best J.M., Enders G.: Laboratory diagnosis of rubella and congenital rubella. In: Banatvala J., Peckham C., ed. Rubella Viruses, London: Elsevier; 2007:39-77.
103. Ho-Terry L., Terry G.M., Londesborough P.: Diagnosis of foetal rubella virus infection by polymerase chain reaction. J Gen Virol 1990; 71:1607-1611.
104. Bosma T.J., Corbett K.M., O'Shea S., et al: PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol 1995; 33:1075-1079.
105. Tanemura M., Suzumori K., Yagami Y., et al: Diagnosis of fetal rubella infection with reverse transcription and nested polymerase chain reaction: a study of 34 cases diagnosed in fetuses. Am J Obstet Gynecol 1996; 174:578-582.
106. Mace M., Cointe D., Six C., et al: Diagnostic value of reverse transcription-PCR of amniotic fluid for prenatal diagnosis of congenital rubella infection in pregnant women with confirmed primary rubella infection. J Clin Microbiol 2004; 42:4818-4820.
107. Bosma T.J., Corbett K.M., Eckstein M.B., et al: Use of PCR for prenatal and postnatal diagnosis of congenital rubella. J Clin Microbiol 1995; 33:2881-2887.

108. Abernathy E., Cabezas C., Sun H., et al: Confirmation of rubella within 4 days of rash onset: comparison of rubella virus RNA detection in oral fluid with immunoglobulin M detection in serum or oral fluid. J Clin Microbiol 2009; 47:182-188.
109. Hübschen J.M., Kremer J.R., De L.S., et al: A multiplex TaqMan PCR assay for the detection of measles and rubella virus. J Virol Methods 2008; 149:246-250.
110. Stewart G.L., Parkman P.D., Hopps H.E., et al: Rubella-virus hemagglutination-inhibition test. N Engl J Med 1967; 276:554-557.
111. Herrmann K.L.: Available rubella serologic tests. Rev Infect Dis 1985; 7(Suppl. 1):S108-S112.
112. Akingbade D., Cohen B.J., Brown D.W.: Detection of low-avidity immunoglobulin G in oral fluid samples: new approach for rubella diagnosis and surveillance. Clin Diagn Lab Immunol 2003; 10:189-190.
113. Assaad F., Ljungars-Esteves K.: Rubella-world impact. Rev Infect Dis 1985; 7(Suppl. 1):S29-S36.
114. Vyse A.J., Brown D.W., Cohen B.J., et al: Detection of rubella virus-specific immunoglobulin G in saliva by an amplification-based enzyme-linked immunosorbent assay using monoclonal antibody to fluorescein isothiocyanate. J Clin Microbiol 1999; 37:391-395.
115. Takahashi S., Machikawa F., Noda A., et al: Detection of immunoglobulin G and A antibodies to rubella virus in urine and antibody responses to vaccine-induced infection. Clin Diagn Lab Immunol 1998; 5:24-27.
116. Terada K., Niizuma T., Kataoka N., et al: Testing for rubella-specific IgG antibody in urine. Pediatr Infect Dis J 2000; 19:104-108.
117. Manikkavasagan G., Bukasa A., Brown K.E., et al: Oral fluid testing during 10 years of rubella elimination, England and Wales. Emerg Infect Dis 2010; 16:1532-1538.
118. Granberg C., Meurman O.: Performance of two new enzyme immunoassays for the detection of IgM and IgG antibodies to rubella. Eur J Clin Microbiol Infect Dis 1994; 13:512-515.
119. Skendzel L.P.: Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 1996; 106:170-174.
120. Meitsch K., Enders G., Wolinsky J.S., et al: The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods. J Med Virol 1997; 51:280-283.
121. Vauloup-Fellous C., Ursulet-Diser J., Grangeot-Keros L.: Development of a rapid and convenient method for determination of rubella virus-specific immunoglobulin G avidity. Clin Vaccine Immunol 2007; 14:1416-1419.
122. Wilson K.M., Di Camillo C., Doughty L., et al: Humoral immune response to primary rubella virus infection. Clin Vaccine Immunol 2006; 13:380-386.
123. Pustowoit B., Liebert U.G.: Predictive value of serological tests in rubella virus infection during pregnancy. Intervirology 1998; 41:170-177.
124. Hofmann J., Liebert U.G.: Significance of avidity and immunoblot analysis for rubella IgM-positive serum samples in pregnant women. J Virol Methods 2005; 130:66-71.
125. The immunological basis for immunization series. Module 11: rubella. Geneva, World Health Organization, 2008. [accessed 1, June 2011] http://whqlibdoc.who.int/publications/2008/9789241596848_eng.pdf
126. Khoury M.J., Adams M.M., Rhodes P., et al: Monitoring for multiple malformations in the detection of epidemics of birth defects. Teratology 1987; 36:345-353.
127. Mauracher C.A., Mitchell L.A., Tingle A.J.: Selective tolerance to the E1 protein of rubella virus in congenital rubella syndrome. J Immunol 1993; 15:2041-2049.
128. Menser M.A., Harley J.D., Hertzberg R., et al: Persistence of virus in lens for three years after prenatal rubella. Lancet 1967; 2:387-388.

129. Cooper L.Z., Green R.H., Krugman S., et al: Neonatal thrombocytopenic purpura and other manifestations of rubella contracted in utero. Am J Dis Child 1965; 110:416-427.
130. Scheie H.G., Schaffer D.B., Plotkin S.A., et al: Congenital rubella cataracts. Surgical results and virus recovery from intraocular tissue. Arch Ophthalmol 1967; 77:440-444.
131. Plotkin S.A., Cochran W., Lindquist J.M., et al: Congenital rubella syndrome in late infancy. JAMA 1967; 200:435-441.
132. Holt S., Hudgins D., Krishnan K.R., et al: Diffuse myelitis associated with rubella vaccination. Br Med J 1976; 2:1037-1038.
133. Forrest J.M., Turnbull F.M., Sholler G.F., et al: Gregg's congenital rubella patients 60 years later. Med J Aust 2002; 177:664-667.
134. O'Shea S., Best J., Banatvala J.E.: A lymphocyte transformation assay for the diagnosis of congenital rubella. J Virol Methods 1992; 37:139-148.
135. Shyamala G., Sowmya P., Madhavan H.N., et al: Relative efficiency of polymerase chain reaction and enzyme-linked immunosorbant assay in determination of viral etiology in congenital cataract in infants. J Postgrad Med 2008; 54:17-20.
136. Cockburn W.C.: World aspects of the epidemiology of rubella. Am J Dis Child 1969; 118:112-122.
137. Castillo-Solórzano C., Marsigli C., Bravo-Alcántara P., et al: Elimination of rubella and congenital rubella syndrome in the Americas. J Infect Dis 2011; 204(Suppl. 2):S571-S578.
138. Halstead S.B., Diwan A.R., Oda A.I.: Susceptibility of rubella among adolescents and adults in Hawaii. JAMA 1969; 210:1881-1883.
139. Anderson R.M., May R.M.: Infectious diseases of humans: dynamics and control. Oxford, UK, Oxford University Press, 1992.
140. Cutts F.T., Abebe A., Messele T., et al: Sero-epidemiology of rubella in the urban population of Addis Ababa, Ethiopia. Epidemiol Infect 2000; 124:467-479.
141. Edmunds W.J., Gay N.J., Kretzschmar M., et al: The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect 2000; 125:635-650.
142. Metcalf C.J., Bjornstad O.N., Ferrari M.J., et al: The epidemiology of rubella in Mexico: seasonality, stochasticity and regional variation. Epidemiol Infect 2010; 15:1-10.
143. Ingalls T.H., Plotkin S.A., Meyer Jr H.M.: Rubella: epidemiology, virology, and immunology. Am J Med Sci 1967; 253:349-373.
144. Kouadio I.K., Koffi A.K., Attoh-Toure H., et al: Outbreak of measles and rubella in refugee transit camps. Epidemiol Infect 2009; 137:1593-1601.
145. Bisno A.L., Spence L.P., Stewart J.A., et al: Rubella in Trinidad: sero-epidemiologic studies of an institutional outbreak. Am J Epidemiol 1969; 89:74-81.
146. Brody J.A.: The infectiousness of rubella and the possibility of reinfection. Am J Public Health Nations Health 1966; 56:1082-1087.
147. Grayston J.T., Gale J.L., Watten R.H.: The epidemiology of rubella on Taiwan. I. Introduction and description of the 1957-1958 epidemic. Int J Epidemiol 1972; 1:245-252.
148. Fogel A., Gerichter C.B., Rannon L., et al: Serologic studies in 11,460 pregnant women during the 1972 rubella epidemic in Israel. Am J Epidemiol 1976; 103:51-59.
149. Hatakeyama S., Moriya K., Itoyama S., et al: Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan. Infect Control Hosp Epidemiol 2004; 25:591-594.
150. de Azevedo Neto R.S., Silveira A.S.B., Nokes D.J., et al: Rubella seroepidemiology in a non-immunized population of Saõ Paulo State, Brazil. Epidemiol Infect 1994; 113:161-173.
151. Yamamoto L., Mejía E., López R.M., et al: Susceptibility to rubella infection in females at high risk. Immune protection associated to population density. Trop Geogr Med 1995; 47:235-238.

152. Cutts F.T., Robertson S.E., Diaz-Ortega J.L., et al: Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bull World Health Organ 1997; 75:55-68.
153. Bamgboye A.E., Afolabi K.A., Esumeh F.I., et al: Prevalence of rubella antibody in pregnant women in Ibadan, Nigeria. West Afr J Med 2004; 23:245-248.
154. Boonruang S., Buppasiri P.: Rubella antibodies in normal pregnant women at Srinagarind Hospital, Khon Kaen, Thailand. J Med Assoc Thai 2005; 88:455-459.
155. Onyenekwe C.C., Kehinde-Agbeyangi T.A., Ofor U.S., et al: Prevalence of rubella-IgG antibody in women of childbearing age in Lagos, Nigeria. West Afr J Med 2000; 19:23-26.
156. Aksit S., Egemen A., Ozacar T., et al: Rubella seroprevalence in an unvaccinated population in Izmir: recommendations for rubella vaccination in Turkey. Pediatr Infect Dis J 1999; 18:577-580.
157. Desinor O.Y., Anselme R.J., Laender F., et al: Seroprevalence of antibodies against rubella virus in pregnant women in Haiti. Rev Panam Salud Publica 2004; 15:147-150.
158. Dayan G.H., Zimmerman L., Shteinke L., et al: Investigation of a rubella outbreak in Kyrgyzstan in 2001: implications for an integrated approach to measles elimination and prevention of congenital rubella syndrome. J Infect Dis 2003; 187(Suppl. 1):S235-S240.
159. Karakoc G.B., Altintas D.U., Kilinc B., et al: Seroprevalence of rubella in school girls and pregnant women. Eur J Epidemiol 2003; 18:81-84.
160. Wysokinska T., Janaszek W., Bucholc B., et al: The prevalence of anti-rubella antibodies in women of childbearing age in Poland. Vaccine 2004; 22:1899-1902.
161. Bartoloni A., Bartalesi F., Roselli M., et al: Seroprevalence of varicella zoster and rubella antibodies among rural populations of the Chaco region, south-eastern Bolivia. Trop Med Int Health 2002; 7:512-517.
162. Malakmadze N., Zimmerman L.A., Uzicanin A., et al: Development of a rubella vaccination strategy: contribution of a rubella susceptibility study of women of childbearing age in Kyrgyzstan, 2001. Clin Infect Dis 2004; 38:1780-1783.
163. Dromigny J.A., Nabeth P., Perrier Gros Claude J.D.: Evaluation of the seroprevalence of rubella in the region of Dakar (Senegal). Trop Med Int Health 2003; 8:740-743.
164. Ki M., Kim M.H., Choi B.Y., et al: Rubella antibody loss rates in Korean children. Epidemiol Infect 2002; 129:557-564.
165. Palihawadana P., Wickremasinghe A.R., Perera J.: Seroprevalence of rubella antibodies among pregnant females in Sri Lanka. Southeast Asian J Trop Med Public Health 2003; 34:398-404.
166. Vijayalakshmi P., Anuradha R., Prakash K., et al: Rubella serosurveys at three Aravind Eye Hospitals in Tamil Nadu, India. Bull World Health Organ 2004; 82:259-264.
167. Lindquist J.M., Plotkin S.A., Shaw L., et al: Congenital rubella syndrome as a systemic infection. Studies of affected infants born in Philadelphia, U.S.A. Br Med J 1965; 2:1401-1406.
168. Williams N.M., Preblud S.R.: Rubella and congenital rubella surveillance, 1983. MMWR CDC Surveill Summ 1984; 33:1SS-110.
169. Centers for Disease Control and Prevention (CDC) : Elimination of rubella and congenital rubella syndrome: United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279-282.
170. Peckham C.: Congenital rubella in the United Kingdom before 1970: the prevaccine era. Rev Infect Dis 1985; 7(Suppl. 1):S11-S16.
171. Zimmerman L.A., Muscat M., Jankovic D., et al: Status of rubella and congenital rubella syndrome surveillance, 2005-2009, the World Health Organization European Region. J Infect Dis 2011; 203:S381-S388.

172. Mellinger A.K., Cragan J.D., Atkinson W.L., et al: High incidence of congenital rubella syndrome after a rubella outbreak. Pediatr Infect Dis J 1995; 14:573-578.
173. Hahné S., Macey J., van Binnendijk R., et al: Rubella outbreak in the Netherlands, 2004-2005: high burden of congenital infection and spread to Canada. Pediatr Infect Dis J 2009; 28:795-800.
174. Seth P., Manjunath N., Balaya S.: Rubella infection: the Indian scene. Rev Infect Dis 1985; 7(Suppl. 1):S64-S67.
175. Mingle J.A.: Frequency of rubella antibodies in the population of some tropical African countries. Rev Infect Dis 1985; 7(Suppl. 1):S68-S71.
176. Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses. Wkly Epidemiol Rec 2005; 80:126-132.
177. Thant K.Z., Oo W.M., Myint T.T., et al: Active surveillance for congenital rubella syndrome in Yangon, Myanmar. Bull World Health Organ 2006; 84:12-20.
178. Andrade J.Q., Bunduki V., Curti S.P., et al: Rubella in pregnancy: intrauterine transmission and perinatal outcome during a Brazilian epidemic. J Clin Virol 2006; 35:285-291.
179. Broor S., Kapil A., Kishore J., et al: Prevalence of rubella virus and cytomegalovirus infections in suspected cases of congenital infections. Indian J Pediatr 1991; 58:75-78.
180. Eckstein M., Vijayalakshmi P., Killedar M., et al: Aetiology of childhood cataract in south India. Br J Ophthalmol 1996; 80:628-632.
181. Ballal M., Shivananda P.G.: Prevalence of rubella virus in suspected cases of congenital infections. Indian J Pediatr 1997; 64:231-235.
182. Johar S.-R., Savalia N.-K., Vasavada A.R., et al: Epidemiology based etiological study of pediatric cataract in western India. Indian J Med Sci 2004; 58:115-121.
183. Chandy S., Abraham A.M., Jana A.K., et al: Congenital rubella syndrome and rubella in Vellore, South India. Epidemiol Infect 2011; 139:1-5.
184. Mahalakshmi B., Therese K.L., Devipriya U., et al: Infectious aetiology of congenital cataract based on TORCHES screening in a tertiary eye hospital in Chennai, Tamil Nadu, India. Indian J Med Res 2010; 131:559-564.
185. Rahman M.M., Khan A.M., Hafiz M.M., et al: Congenital hearing impairment associated with rubella: lessons from Bangladesh. Southeast Asian J Trop Med Public Health 2002; 33:811-817.
186. Lawn J.E., Reef S., Baffoe-Bonnie B., et al: Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana. Am J Public Health 2000; 90:1555-1561.
187. Upreti S.R., Thapa K., Pradhan Y.V., et al: Developing rubella vaccination policy in Nepal: results from rubella surveillance and seroprevalence and congenital rubella syndrome studies. J Infect Dis 2011; 203:S435-S440.
188. Mou J., Griffiths S.M., Fong H.F., et al: Seroprevalence of rubella in female migrant factory workers in Shenzhen, China. Vaccine 2010; 28:7844-7851.
189. Goodson J.L., Masresha B., Dosseh A., et al: Rubella epidemiology in Africa in the prevaccine era, 2002-2009. J Infect Dis 2011; 203:S215-S225.
190. Bloom S., Rguig A., Berraho A., et al: Congenital rubella syndrome burden in Morocco: a rapid retrospective assessment. Lancet 2005; 365:135-141.
191. Lanzieri T.M., Parise M.S., Siqueira M.M., et al: Incidence, clinical features and estimated costs of congenital rubella syndrome after a large rubella outbreak in Recife, Brazil, 1999-2000. Pediatr Infect Dis J 2004; 23:1116-1122.
192. Khandekar R., Al Awaidy S., Ganesh A., et al: An epidemiological and clinical study of ocular manifestations of congenital rubella syndrome in Omani children. Arch Ophthalmol 2004; 122:541-545.

193. Sadighi J., Eftekhar H., Mohammad K.: Congenital rubella syndrome in Iran. BMC Infect Dis 2005; 5:44.
194. Reef S.E., Frey T.K., Theall K., et al: The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 2002; 287:464-472.
195. Kono R., Hirayama M., Sugishita C., et al: Epidemiology of rubella and congenital rubella infection in Japan. Rev Infect Dis 1985; 7(Suppl. 1):S56-S63.
196. Ueda K., Nishida Y., Oshima K., et al: An explanation for the high incidence of congenital rubella syndrome in Ryukyu. Am J Epidemiol 1978; 107:344-351.
197. Cooper L.Z.: Birth defects. Original article series: rubella, a preventable cause of birth defects. Natl Found March of Dimes 1968; 4:23-35.
198. Horstmann D.M.: Rubella: the challenge of its control. J Infect Dis 1971; 123:640-654.
199. Horstmann D.M.: Viral vaccines and their ways. Rev Infect Dis 1979; 1:502-516.
200. Menser M.A., Hudson J.R., Murphy A.M., et al: Epidemiology of congenital rubella and results of rubella vaccination in Australia. Rev Infect Dis 1985; 7(Suppl. 1):S37-S41.
201. Swartz T.A., Hornstein L., Epstein I.: Epidemiology of rubella and congenital rubella infection in Israel, a country with a selective immunization program. Rev Infect Dis 1985; 7(Suppl. 1):S42-S46.
202. Celers J., Aymard M., Feingold J., et al: Rubella and congenital cataracts [in French]. Arch Fr Pediatr 1983; 40:391-395.
203. Zgorniak-Nowosielska I., Zawilinska B., Szostek S.: Rubella infection during pregnancy in the 1985-86 epidemic: follow-up after seven years. Eur J Epidemiol 1996; 12:303-308.
204. Miller C.L.: Rubella in the developing world. Epidemiol Infect 1991; 107:63-68.
205. Gale J.L., Detels R., Kim K.S., et al: Epidemiology of rubella on Taiwan. Am J Dis Child 1969; 118:143-145.
206. Gomwalk N.E., Ahmad A.A.: Prevalence of rubella antibodies on the African continent. Rev Infect Dis 1989; 11:116-121.
207. Owens C.S., Espino R.T.: Rubella in Panama: still a problem. Pediatr Infect Dis J 1989; 8:110-115.
208. Kishore J., Broor S., Seth P.: Acute rubella infection in pregnant women in Delhi. Indian J Med Res 1990; 91:245-246.
209. Cutts F.T., Vynnycky E.: Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 1999; 28:1176-1184.
210. Vynnycky E., Adams E.: unpublished data2011.
211. Millian S.J., Kogon A., Klein S.: Rubella antibody levels in commercial gamma globulin preparations. Am J Public Health 1971; 61:353-358.
212. Siber G.R., Werner B.G., Halsey N., et al: Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122:204-211.
213. Brody J.A., Sever J.L., Schiff G.M.: Prevention of rubella by gamma-blobulin during an epidemic in Barrow, Alaska in 1964. N Engl J Med 1965; 272:127-129.
214. McDonald J.C., Peckham C.S.: Gammaglobulin in prevention of rubella and congenital defect: a study of 30,000 pregnancies. Br Med J 1967; 3:633-637.
215. Public Health Laboratory Service Working Party on Rubella : Studies of the effect of immunoglobulin on rubella in pregnancy. Br Med J 1970; 3:633-637.
216. Martin du Pan R., Koechli B., Douath A.: Protection of nonimmune volunteers against rubella by intravenous administration of normal human gamma globulin. J Infect Dis 1972; 126:341-344.
217. Schiff G.M.: Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. Am J Dis Child 1969; 118:322-327.

218. Doege T.C., Kim K.S.: Studies of rubella and its prevention with immune globulin. JAMA 1967; 200:584-590.
219. Cooper L., Giles J.P., Florman A.: Protective effect of antirubella human immunoglobulin [abstract]. Abstracts of Society for Pediatric Research, 1971:79.
220. Clarke D.M., Loo T.W., McDonald H., et al: Expression of rubella virus cDNA coding for the structural proteins. Gene 1988; 65:23-30.
221. Frey T.K., Marr L.D., Hemphill M.L., et al: Molecular cloning and sequencing of the region of the rubella virus genome coding for glycoprotein E1. Virology 1986; 154:228-232.
222. Terry G.M., Ho-Terry L., Londesborough P., et al: Localization of the rubella E1 epitopes. Arch Virol 1988; 98:189-197.
223. Chaye H.H., Chong P., Tripet B., et al: Localization of the virus neutralizing and hemagglutinin epitopes of e1 glycoprotein of rubella virus. Virology 1992; 189:483-492.
224. Hobman T.C., Qiu Z.Y., Chaye H., et al: Analysis of rubella virus E1 glycosylation mutants expressed in COS cells. Virology 1991; 181:768-772.
225. Wolinsky J.S., McCarthy M., Allen-Cannady O., et al: Monoclonal antibody-defined epitope map of expressed rubella virus protein domains. J Virol 1991; 65:3986-3994.
226. Ilonen J., Seppänen H., Närvänen A., et al: Recognition of synthetic peptides with sequences of rubella virus E1 polypeptide by antibodies and T lymphocytes. Viral Immunol 1992; 5:221-228.
227. Lovett A.E., McCarthy M., Wolinsky J.S.: Mapping cell-mediated immunodominant domains of the rubella virus structural proteins using recombinant proteins and synthetic peptides. J Gen Virol 1993; 74:445-452.
228. Marttila J., Ilonen J., Lehtinen M., et al: Definition of three minimal T helper cell epitopes of rubella virus E1 glycoprotein. Clin Exp Immunol 1996; 104:394-397.
229. Mitchell L.A., Décarie D., Tingle A.J., et al: Use of synthetic peptides to map regions of rubella virus capsid protein recognized by human T lymphocytes. Vaccine 1994; 12:639-645.
230. Seto N.O.L., Gillam S.: Expression and characterization of a soluble rubella virus E1 envelope protein. J Med Virol 1994; 44:192-199.
231. Johansson T., Enestam A., Kronqvist R., et al: Synthesis of soluble rubella virus spike proteins in two lepidopteran insect cell lines: large scale production of the E1 protein. J Biotechnol 1996; 50:171-180.
232. Terry G.M., Ho-Terry L., Londesborough P., et al: A bio-engineered rubella E1 antigen. Arch Virol 1989; 104:63-75.
233. Seppanen H., Huhtala M.L., Vaheri A.: Diagnostic potential of baculovirus-expressed rubella virus envelope proteins. J Clin Microbiol 1991; 29:1877-1882.
234. Perrenoud G., Messerli F., Thierry A.C., et al: A recombinant rubella virus E1 glycoprotein as a rubella vaccine candidate. Vaccine 2004; 23:480-488.
235. Trudel M., Nadon F., Seguin C., et al: Neutralizing response of rabbits to an experimental rubella subunit vaccine made from immunostimulating complexes. Can J Microbiol 1988; 34:1351-1354.
236. Robinson K., Mostratos A., Grencis R.K.: Generation of rubella virus-neutralising antibodies by vaccination with synthetic peptides. FEMS Immunol Med Microbiol 1995; 10:191-198.
237. Qiu Z., Ou D., Hobman T.C., et al: Expression and characterization of virus-like particles containing rubella virus structural proteins. J Virol 1994; 68:4086-4091.
238. Hobman T.C., Lundstrom M.L., Mauracher C.A., et al: Assembly of rubella virus structural proteins into virus-like particles in transfected cells. Virology 1994; 202:574-585.
239. Pougatcheva S.O., Abernathy E.S., Vzorov A.N., et al: Development of a rubella virus DNA vaccine. Vaccine 1999; 17:2104-2112.

240. Plotkin S.A.: History of rubella and the recent history of cell culture. In: Plotkin S., Fantini B., ed. Vaccinia, Vaccination, Vaccinology: Jenner, Pasteur, and Their Successors, Paris: Elsevier; 1996:271-282.
241. Hilleman M.R., Buynak E.B., Whitman Jr J.E., et al: Live attenuated rubella virus vaccines. Experiences with duck embryo cell preparations. Am J Dis Child 1969; 118:166-171.
242. Preblud S.R., Serdula M.K., Frank Jr J.A., et al: Rubella vaccination in the United States: a ten-year review. Epidemiol Rev 1980; 2:171-194.
243. McCollum R.W., Randolph M.F., Byrne E.B., et al: Rubella virus vaccine (HPV-77-DE 5). Antigenic and protective efficacy in a community trial. Am J Dis Child 1969; 118:186-189.
244. Davis W.J., Larson H.E., Simsarian J.P., et al: A study of rubella immunity and resistance to infection. JAMA 1971; 215:600-608.
245. Wallace R.B., Isacson P.: Comparative trial of HPV-77, DE-5 and RA 27-3 live-attenuated rubella vaccines. Am J Dis Child 1972; 124:536-538.
246. Gershon A.A., Frey H.M., Borkowsky W., et al: Live attenuated rubella virus vaccine: comparison of responses to HPV-77-DE5 and RA 27/3 strains. Am J Med Sci 1980; 279:95-97.
247. Balfour Jr H.H., Amren D.P.: Rubella vaccine (HPV-77 DE5 strain) fails to sustain antibody titres. Lancet 1977; 2:1130-1131.
248. Wilkins J., Leedom J.M., Portnoy B., et al: Reinfection with rubella virus despite live vaccine induced immunity. Trials of HPV-77 and HPV-80 live rubella virus vaccines and subsequent artificial and natural challenge studies. Am J Dis Child 1969; 118:275-294.
249. Fogel A., Gerichter C.B., Barena B., et al: Response to experimental challenge in persons immunized with different rubella vaccines. J Pediatr 1978; 92:26-29.
250. Klock L.E., Rachelefsky G.S.: Failure of rubella herd immunity during an epidemic. N Engl J Med 1973; 288:69-72.
251. Spruance S.L., Smith C.B.: Joint complications associated with derivatives of HPV-77 rubella virus vaccine. Am J Dis Child 1971; 122:105-111.
252. Perkins F.T.: Licensed vaccines. Rev Infect Dis 1985; 7(Suppl. 1):S73-S76.
253. Plotkin S.A., Farquhar J.D., Ogra P.L.: Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States. JAMA 1973; 225:585-590.
254. Plotkin S.A., Cornfeld D., Ingalls T.H.: Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus. Am J Dis Child 1965; 110:381-389.
255. Plotkin S.A., Farquhar J., Katz M., et al: A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am J Epidemiol 1967; 86:468-477.
256. Plotkin S.A., Buser F.: History of RA27/3 rubella vaccine. Rev Infect Dis 1985; 7(Suppl. 1):S77-S78.
257. Nakhasi H.L., Thomas D., Zheng D., et al: Nucleotide sequence of capsid, E2 and E1 protein genes of rubella virus vaccine strain RA27/3. Nucl Acids Res 1989; 17:4393-4394.
258. Zheng D.X., Dickens L., Liu T.Y., et al: Nucleotide sequence of the 24S subgenomic messenger RNA of a vaccine strain (HPV77) of rubella virus: comparison with a wild- type strain (M33). Gene 1989; 82:343-349.
259. Frey T.K., Abernathy E.S.: Identification of strain-specific nucleotide sequences in RA 27/3 rubella virus vaccine. J Infect Dis 1993; 168:854-864.
260. Londesborough P., Terry G., Ho-Terry L.: Reactivity of a recombinant rubella E1 antigen expressed in E. coli. Arch Virol 1992; 122:391-397.

261. Best J.M., Thomson A., Nores J.R., et al: Rubella virus strains show no major antigenic differences. Intervirology 1992; 34:164-168.
262. Ueda K.: Development of the rubella vaccine and vaccination strategy in Japan. Vaccine 2009; 27:3232-3233.
263. National Institutes of Health of Japan : Rubella vaccine. Vaccine Handbook. Tokyo: Maruzen; 2000:127-137.
264. Kakizawa J., Nitta Y., Yamashita T., et al: Mutations of rubella virus vaccine TO-336 strain occurred in the attenuation process of wild progenitor virus. Vaccine 2001; 19:2793-2802.
265. Skata M., Nakayama T.: Protease and helicase domains are related to the temperature sensitivity of wild-type rubella viruses. Vaccine 2011; 29:1107-1113.
266. Otsuki N., Abo H., Kubota T., et al: Elucidation of the full genetic information of Japanese rubella vaccines and the genetic changes associated with in vitro vaccine virus phenotypes. Vaccine 2011; 29:1863-1873.
267. Tillieux S.L., Halsey W.S., Sathe G.M., et al: Comparative analysis of the complete nucleotide sequences of measles, mumps, and rubella strain genomes contained in Priorix-Tetra and ProQuad live attenuated combined vaccines. Vaccine 2009; 27:2265-2273.
268. Zealley H., Morrison A.M., Freestone D.S.: Dose response studies with Wistar RA 27/3 strain live attenuated rubella vaccine. J Biol Stand 1974; 2:111-119.
269. Plotkin S.A., Ingalls T.H., Farquhar J.D., et al: Intranasally administered rubella vaccine. Lancet 1968; 2:934-936.
270. Puschak R., Young M., McKee T.V., et al: Intranasal vaccination with RA 27-3 attenuated rubella virus. J Pediatr 1971; 79:55-60.
271. Ingalls T.H., Horne Jr H.W.: Immunisation of women with rubella (RA27-3) vaccine administered intranasally. Lancet 1971; 1:830-832.
272. Hillary I.B.: Trials of intranasally administered rubella vaccine. J Hyg (Lond) 1971; 69:547-552.
273. Ganguly R., Durrer B., Waldman R.H.: Rubella virus immunization of preschool children via the respiratory tract. Am J Dis Child 1974; 128:821-823.
274. Midulla M., Assensio A.M., Balducci L., et al: Intranasal versus subcutaneous rubella vaccination in schoolgirls. Dev Biol Stand 1976; 33:241-248.
275. Freestone D.S.: Clinical trials carried out to assess non-parenteral routes for administration of Wistar RA 27/3 strain live attenuated rubella vaccine. Dev Biol Stand 1976; 33:237-240.
276. Ganguly R., Ogra P.L., Regas S., et al: Rubella immunization of volunteers via the respiratory tract. Infect Immun 1973; 8:497-502.
277. Paradise J.E., Nemorofsky D., Huggins G.R., et al: Intranasal administration of RA 27/3 rubella virus vaccine. A clinical trial in young adults. J Adolesc Health Care 1984; 5:75-78.
278. Sepúlveda-Amor J., Valdespino-Gómez J.L., García-García Mde L., et al: A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002; 20:2790-2795.
279. Castro J.F., Bennett J.V., Rincon H.G., et al: Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine 2005; 23:1079-1084.
280. Diaz-Ortega J.L., Bennett J.V., Castaneda D., et al: Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR. Vaccine 2010; 28:692-698.
281. Plotkin S.A., Beale A.J.: Production of RA27/3 rubella vaccine and clinical results with the vaccine. Dev Biol Stand 1976; 37:291-296.

282. Elliott A.Y.: Manufacture and Testing of Measles, Mumps, and Rubella Vaccine. Atlanta, GA: Centers for Disease Control, Public Health Service; 1984:79-84.
283. McAleer W.J., Markus H.Z., McLean A.A., et al: Stability on storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabilizer. J Biol Stand 1980; 8:281-287.
284. Hillary I.B., Meenan P.N., Griffith A.H., et al: Rubella vaccine trial in children. Br Med J 1969; 2:531-532.
285. Berger R., Just M., Gluck R.: Interference between strains in live virus vaccines, I: combined vaccination with measles, mumps and rubella vaccine. J Biol Stand 1988; 16:269-273.
286. Vaananen P., Makela P., Vaheri A.: Effect of low level immunity on response to live rubella virus vaccine. Vaccine 1986; 4:5-8.
287. Freestone D.S., Reynolds G.M., McKinnon J.A., et al: Vaccination of schoolgirls against rubella. Assessment of serological status and a comparative trial of Wistar RA 27/3 and Cendehill strain live attenuated rubella vaccines in 13-year-old schoolgirls in Dudley. Br J Prev Soc Med 1975; 29:258-261.
288. Bottiger M., Heller L.: Experiences from vaccination and revaccination of teenage girls with three different rubella vaccines. J Biol Stand 1976; 4:107-114.
289. Grillner L.: Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines. Scand J Infect Dis 1975; 7:169-172.
290. Menser M.A., Forrest J.M., Bransby R.D.: Rubella vaccination in Australia: 1. A five-year follow-up of vaccinated schoolgirls. Med J Aust 1978; 2:83-85.
291. Weibel R.E., Carlson Jr A.J., Villarejos V.M., et al: Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 Rubella virus (40979). Proc Soc Exp Biol Med 1980; 165:323-326.
292. Best J.M., Banatvala J.E., Bowen J.M.: New Japanese rubella vaccine: comparative trials. Br Med J 1974; 3:221-224.
293. Wang S.S., Han Y.R., Su W.N., et al: Studies on the reactogenicity and immunogenicity of the BRD-2 and RA27/3 live attenuated rubella vaccines. Vaccine 1984; 2:277-280.
294. Le Bouvier G.L., Plotkin S.A.: Precipitin responses to rubella vaccine RA 27-3. J Infect Dis 1971; 123:220-223.
295. Nedeljkovic J., Jovanovic T., Oker-Blom C.: Maturation of IgG avidity to individual rubella virus structural proteins. J Clin Virol 2001; 22:47-54.
296. Cusi M.G., Metelli R., Valensin P.E.: Immune responses to wild and vaccine rubella viruses after rubella vaccination. Arch Virol 1989; 106:63-72.
297. Ogra P.L., Kerr-Grani D., Umana G., et al: Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus. N Engl J Med 1971; 285:1333-1339.
298. Cradock-Watson J.E., Ridehalgh M.K., Bourne M.S., et al: Nasal immunoglobulin responses in acute rubella determined by the immunofluorescent technique. J Hyg (Lond) 1973; 71:603-617.
299. Cradock-Watson J.E., Macdonald H., Ridehalgh M.K., et al: Specific immunoglobulin responses in serum and nasal secretions after the administration of attenuated rubella vaccine. J Hyg (Lond) 1974; 73:127-141.
300. O'Shea S., Best J.M., Banatvala J.E., et al: Development and persistence of class-specific antibodies in the serum and nasopharyngeal washings of rubella vaccinees. J Infect Dis 1985; 151:89-98.
301. Banatvala J.E., Druce A., Best J., et al: Specific IgM responses after rubella vaccination; potential application following inadvertent vaccination during pregnancy. Br Med J 1977; 2:1263-1264.

302. Meegan J.M., Evans B.K., Horstmann D.M.: Use of enzyme immunoassays and the latex agglutination test to measure the temporal appearance of immunoglobulin G and M antibodies after natural infection or immunization with rubella virus. J Clin Microbiol 1983; 18:745-748.
303. O'Shea S., Best J.M., Banatvala J.E., et al: Development and persistence of class-specific antibodies in the serum and nasopharyngeal washings of rubella vaccines. J Infect Dis 1985; 151:89-98.
304. Lalla M., Vesikari T., Virolainen M.: Lymphoblast proliferation and humoral antibody response after rubella vaccination. Clin Exp Immunol 1973; 15:193-202.
305. Honeyman M.C., Forrest J.M., Dorman D.C.: Cell-mediated immune response following natural rubella and rubella vaccination. Clin Exp Immunol 1974; 17:665-671.
306. Vesikari T., Buimovici-Klein E.: Lymphocyte responses to rubella antigen and phytohemagglutinin after administration of the RA 27/3 strain of live attenuated rubella vaccine. Infect Immun 1975; 11:748-753.
307. Heigl Z., Wasserman J., Forsgren M.: In vitro lymphocyte reactivity to rubella antigen following vaccination. Scand J Infect Dis 1980; 12:13-20.
308. Dhiman N., Ovsyannikova I.G., Jacobson R.M., et al: Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clin Immunol 2005; 115:154-161.
309. Steele R.W., Hensen S.A., Vincent M.M., et al: Development of specific cellular and humoral immune responses in children immunized with live rubella virus vaccine. J Infect Dis 1974; 130:449-453.
310. Morag A., Morag B., Bernstein J.M., et al: In vitro correlates of cell-mediated immunity in human tonsils after natural or induced Rubella virus infection. J Infect Dis 1975; 131:409-416.
311. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., et al: The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 2004; 65:1506-1515.
312. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., et al: Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J Infect Dis 2005; 191:515-519.
313. Pukhalsky A.L., Shmarina G.V., Bliacher M.S., et al: Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination. Mediators Inflamm 2003; 12:203-207.
314. Rager-Zisman B., Bazarsky E., Skibin A., et al: The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine 2003; 21:2580-2588.
315. Dhiman N., Haralambieva I.H., Kennedy R.B., et al: SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics 2010; 62:197-210.
316. Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., et al: Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. PLoS One 2010; 5:e11806.doi:10.1371/journal.pone.0011806
317. Pankratz V.S., Vierkant R.A., O'Byrne M.M., et al: Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol 2010; 11:48.
318. Balfour Jr H.H., Groth K.E., Edelman C.K., et al: Rubella viraemia and antibody responses after rubella vaccination and reimmunization. Lancet 1981; 1:1078-1080.

319. Detels R., Kim K.S., Gale J.L., et al: Viral shedding in Chinese children following vaccination with HPV-77 and Cendehill-51 live attenuated rubella vaccines. Am J Epidemiol 1971; 94:473-478.
320. Marshall W.C., Peckham C.S., Darby C.P., et al: Further studies with rubella vaccines in adults and children. Practitioner 1971; 207:632-638.
321. Veronelli J.A.: An open community trial of live rubella vaccines. Study of vaccine virus transmissibility and antigenic efficacy of three HPV-77 derivatives. JAMA 1970; 213:1829-1836.
322. Meyer Jr H.M., Parkman P.D.: Rubella vaccination. A review of practical experience. JAMA 1971; 215:613-619.
323. Mogabgab W.J., Stowe Jr F.R.: Evaluation of attenuated rubella virus vaccine in families. Am J Dis Child 1971; 122:122-128.
324. Scott H.D., Byrne E.B.: Exposure of susceptible pregnant women to rubella vaccinees. Serologic findings during the Rhode Island immunization campaign. JAMA 1971; 215:609-612.
325. Halstead S.B., Diwan A.R.: Failure to transmit rubella virus vaccine. A close-contact study in adults. JAMA 1971; 215:634-636.
326. Fleet Jr W.F., Schaffner W., Lefkowitz Jr L.B., et al: Exposure of susceptible teachers to rubella vaccinees. Am J Dis Child 1972; 123:28-30.
327. Fleet W.F., Vaughn W., Lefkowitz Jr L.B., et al: Gestational exposure to rubella vaccinees: a population surveillance study. Am J Epidemiol 1975; 101:220-230.
328. Wolf J.E., Eisen J.E., Fraimow H.S.: Symptomatic rubella reinfection in an immune contact of a rubella vaccine recipient. South Med J 1993; 86:91-93.
329. Schiff G.M., Bloom J.E.: Evaluation of rubella vaccination in a large school system. J Pediatr 1971; 78:211-219.
330. Lipman R.P., Bethel M.B., Wooten J.H., et al: Attenuated rubella vaccine (HPV-77): evaluation in a large controlled trial. Am J Public Health 1971; 61:1392-1402.
331. Linnemann Jr C.C., Hutchinson L., Rotte T.C., et al: Stability of the rabbit immunogenic marker of RA 27-3 rubella vaccine virus after human passage. Infect Immun 1974; 9:547-549.
332. Lerman S.J., Bollinger M., Brunken J.M.: Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics 1981; 68:18-22.
333. Brunell P.A., Weigle K., Murphy M.D., et al: Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA 1983; 250:1409-1412.
334. Klinge J., Lugauer S., Korn K., et al: Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine 2000; 18:3134-3140.
335. Tischer A., Gerike E.: Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000; 18:1382-1392.
336. Bar-Oz B., Levichek Z., Moretti M.E., et al: Pregnancy outcome following rubella vaccination: a prospective controlled study. Am J Med Genet A 2004; 130:52-54.
337. Usonis V., Bakasenas V., Kaufhold A., et al: Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18:42-48.
338. Gothefors L., Bergstrom E., Backman M.: Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis 2001; 33:545-549.

339. Cruz Rojo C., Rodriguez , Iglesias M., Olvera J., et al: Study of the immune response engendered by differents combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 2003; 22:280-286.
340. Furesz J.: Antibody response of school children to live attenuated rubella virus vaccines as measured with various serologic methods. Am J Epidemiol 1972; 95:536-541.
341. Leuridan E., Hens N., Hutse V.: Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine 2011; 29:2222-2226.
342. Schoub B.D., Johnson S., McAnerney J.M., et al: Measles, mumps, and rubella immunization at nine months in a developing country. Pediatr Infect Dis J 1990; 9:263-267.
343. Goh P., Lim F.S., Han H.H., et al: Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella (MMRV) vaccine in healthy children from 9 months of age. Infection 2007; 35:326-333.
344. Zignol M., Peracchi M., Tridello G., et al: Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004; 101:635-641.
345. Borte S., Liebert U.G., Borte M., et al: Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009; 48:144-148.
346. Spoulou V., Giannaki M., Vounatsou M., et al: Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 2004; 33:1187-1190.
347. Azzari C., Gambineri E., Resti M., et al: Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome). Vaccine 2005; 23:1668-1671.
348. Grayston J.T., Detels R., Chen K.P., et al: Field trial of live attenuated rubella virus vaccine during an epidemic on Taiwan. Preliminary report of efficacy of three HPV-77 strain vaccines in the prevention of clinical rubella. JAMA 1969; 207:1107-1110.
349. Chang T.W., DesRosiers S., Weinstein L.: Clinical and serologic studies of an outbreak of rubella in a vaccinated population. N Engl J Med 1970; 283:246-248.
350. Furukawa T., Miyata T., Kondo K., et al: Rubella vaccination during an epidemic. JAMA 1970; 213:987-990.
351. Beasley R.P., Detels R., Kim K.S., et al: Prevention of rubella during an epidemic on Taiwan. HPV-77 and RA 27-3 rubella vaccines administered subcutaneoulsly and intranasally HPV 77 vaccine mixed with mumps and-or measles vaccines. Am J Dis Child 1969; 118:301-306.
352. de Valk H.M., Garde X., Cohen B., et al: Clinical efficacy of rubella vaccine determined during an outbreak of rubella in a primary school, France, 1997. JET 1997; 213:987-990.
353. D'Amelio R., Biselli R., Fascia G., et al: Measles-mumps-rubella vaccine in the Italian armed forces. JAMA 2000; 284:2059.
354. Landrigan P.J., Stoffels M.A., Anderson E., et al: Epidemic rubella in adolescent boys. Clinical features and results of vaccination. JAMA 1974; 227:1283-1287.
355. Crawford G.E., Gremillion D.H.: Epidemic measles and rubella in air force recruits: impact of immunization. J Infect Dis 1981; 144:403-410.
356. Greaves W.L., Orenstein W.A., Hinman A.R., et al: Clinical efficacy of rubella vaccine. Pediatr Infect Dis 1983; 2:284-286.
357. Koskiniemi M., Vaheri A.: Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet 1989; 1:31-34.
358. Plotkin S.A.: Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75.

359. O'Shea S., Best J., Banatvala J.E.: Viremia, virus excretion, and antibody responses after challenge to volunteers with low levels of antibody to rubella virus. J Infect Dis 1983; 148:639-647.
360. Matter L., Kogelschatz K., Germann D.: Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis 1997; 175:749-755.
361. Best J.: Personal communication to Plotkin SA2001.
362. Harcourt G.C., Best J.M., Banatvala J.E.: Rubella-specific serum and nasopharyngeal antibodies in volunteers with naturally acquired and vaccine-induced immunity after intranasal challenge. J Infect Dis 1980; 142:145-155.
363. Schiff G.M., Donath R., Rotte T.: Experimental rubella studies. I. Clinical and laboratory features of infection caused by the Brown strain rubella virus. II. Artificial challenge studies of adult rubella vaccinees. Am J Dis Child 1969; 118:269-274.
364. Naficy K., Nategh R., Ahangary S., et al: Artificial challenge studies in rubella. Utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children. Am J Dis Child 1970; 120:520-523.
365. Horstmann D.M., Liebhaber H., Le Bouvier G.L., et al: Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med 1970; 283:771-778.
366. Lehane D.E., Newberg N., Beam Jr W.E.: Evaluation of rubella herd immunity during an epidemic. JAMA 1970; 213:2236-2239.
367. Judelsohn R.G., Wyll S.A.: Rubella in Bermuda. Termination of an epidemic by mass vaccination. JAMA 1973; 223:401-406.
368. Klock L.E., Rachelefsky G.S.: Failure of rubella herd immunity during an epidemic. N Engl J Med 1973; 288:69-72.
369. Rachelefsky G.S., Herrmann K.L.: Congenital rubella surveillance following epidemic rubella in a partially vaccinated community. J Pediatr 1974; 84:474-478.
370. Banatvala J.E., Best J.M., O'Shea S., et al: Persistence of rubella antibodies after vaccination: detection after experimental challenge. Rev Infect Dis 1985; 7(Suppl. 1):S86-S90.
371. Cusi M.G., Rossolini G.M., Valensin P.E., et al: Serological evidence of reinfection among vaccinees during rubella outbreak [letter]. Lancet 1990; 336:1071.
372. Scott R.M., Schydlower M., Lampe R.M., et al: The immunoglobulin response to reimmunization with rubella vaccine. J Pediatr 1981; 99:531-534.
373. Morgan-Capner P., Hodgson J., Hambling M.H., et al: Detection of rubella-specific IgM in subclinical rubella reinfection in pregnancy. Lancet 1985; 1:244-246.
374. Forsgren M., Soren L.: Subclinical rubella reinfection in vaccinated women with rubella-specific IgM response during pregnancy and transmission of virus to the fetus. Scand J Infect Dis 1985; 17:337-341.
375. Hamkar R., Jalilvand S., Abdolbaghi M.H., et al: Inadvertent rubella vaccination of pregnant women: evaluation of possible transplacental infection with rubella vaccine. Vaccine 2006; 24:3558-3563.
376. Forrest J.M., Menser M.A., Honeyman M.C., et al: Clinical rubella eleven months after vaccination. Lancet 1972; 2:399-400.
377. Andrews J., Tang J.W., Hesketh L., et al: Symptomatic rubella re-infection in pregnancy with no evidence of fetal infection. Prenat Diagn 2004; 24:227-228.
378. Northrop R.L., Gardner W.M., et al: Rubella reinfection during early pregnancy: a case report. Obstet Gynecol 1972; 39:524-526.

379. Morgan-Capner P., Burgess C., Ireland R.M., et al: Clinically apparent rubella reinfection with a detectable rubella specific IgM response. Br Med J (Clin Res Ed) 1983; 286:1616.
380. Eilard T., Strannegard O.: Rubella reinfection in pregnancy followed by transmission to the fetus. J Infect Dis 1974; 129:594-596.
381. Das B.D., Lakhani P., Kurtz J.B., et al: Congenital rubella after previous maternal immunity. Arch Dis Child 1990; 65:545-546.
382. Keith C.G.: Congenital rubella infection from reinfection of previously immunised mothers. Aust N Z J Ophthalmol 1991; 19:291-293.
383. Weber B., Enders G., Schlösser R., et al: Congenital rubella syndrome after maternal reinfection. Infection 1993; 21:118-121.
384. Robinson J., Lemay M., Vaudry W.L.: Congenital rubella after anticipated maternal immunity: two cases and a review of the literature. Pediatr Infect Dis J 1994; 13:812-815.
385. Paludetto R., van den Heuvel J., Stagni A., et al: Rubella embryopathy after maternal reinfection. Biol Neonat 1994; 65:340-341.
386. Braun C., Kampa D., Fressle R., et al: Congenital rubella syndrome despite repeated vaccination of the mother: a coincidence of vaccine failure with failure to vaccinate. Acta Paediatr 1994; 83:674-677.
387. Fogel A., Handsher R., Barnea B.: Subclinical rubella in pregnancy-occurrence and outcome. Isr J Med Sci 1985; 21:133-138.
388. Bott L.M., Eizenberg D.H.: Congenital rubella after successful vaccination. Med J Aust 1982; 1:514-515.
389. Enders G., Calm A., Schaub J.: Rubella embryopathy after previous maternal rubella vaccination. Infection 1984; 12:96-98.
390. Forsgren M., Carlstrom G., Strangert K.: Congenital rubella after maternal reinfection. Scand J Infect Dis 1979; 11:81-83.
391. Levine J.B., Berkowitz C.D., St.Geme J.W.: Rubella virus reinfection during pregnancy leading to late-onset congenital rubella syndrome. J Pediatr 1982; 100:589-591.
392. Schoub B.D., Blackburn N.K., O'Connell K., et al: Symptomatic rubella re-infection in early pregnancy and subsequent delivery of an infected but minimally involved infant. S Afr Med J 1990; 78:484-485.
393. Gilbert J., Kudesia G.: Fetal infection after maternal reinfection with rubella. BMJ 1989; 299:1217.
394. Bullens D., Smets K., Vanhaesebrouck P.: Congenital rubella syndrome after maternal reinfection. Clin Pediatr (Phila) 2000; 39:113-116.
395. Banerji A., Ford-Jones E.L., Kelly E., et al: Congenital rubella syndrome despite maternal antibodies. CMAJ 2005; 172:1678-1679.
396. Ushida M., Katow S., Furukawa S.: Congenital rubella syndrome due to infection after maternal antibody conversion with vaccine. Jpn J Infect Dis 2003; 56:68-69.
397. Morgan-Capner P., Miller E., Vurdien J.E.: Outcome of pregnancy after maternal reinfection with rubella. CDR (Lond Engl Rev) 1991; 1:R57-R59.
398. O'Shea S., Corbett K.M., Barrow S.M., et al: Rubella reinfection; role of neutralising antibodies and cell-mediated immunity. Clin Diagn Virol 1994; 2:349-358.
399. Mitchell L.A., Ho M.K., Rogers J.E., et al: Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals. J Clin Microbiol 1996; 34:2210-2218.
400. Liebhaber H., Ingalls T.H., Le Bouvier G.L., et al: Vaccination with RA 27-3 rubella vaccine. Persistence of immunity and resistance to challenge after two years. Am J Dis Child 1972; 123:133-136.

401. Black F.L., Lamm S.H., Emmons J.E., et al: Reactions to rubella vaccine and persistence of antibody in virgin-soil populations after vaccination and wild-virus-induced immunization. J Infect Dis 1976; 133:393-398.
402. Balfour Jr H.H., Groth K.E., Edelman C.K.: RA27/3 rubella vaccine. A four-year follow-up. Am J Dis Child 1980; 134:350-353.
403. Zealley H., Edmond E.: Rubella screening and immunisation of schoolgirls: results six to seven years after vaccination. Br Med J (Clin Res Ed) 1982; 284:382-384.
404. Hillary I.B., Griffith A.H.: Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 1984; 2:274-276.
405. O'Shea S., Woodward S., Best J.M., et al: Rubella vaccination: persistence of antibodies for 10-21 years. Lancet 1988; 2:909.
406. King Jr J.C., Lichenstein R., Feigelman S., et al: Measles, mumps, and rubella antibodies in vaccinated Baltimore children. Am J Dis Child 1993; 147:558-560.
407. Miller E., Hill A., Morgan-Capner P., et al: Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995; 13:799-802.
408. Boulianne N., De Serres G., Ratnam S., et al: Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 1995; 13:1611-1616.
409. Bottiger M.: Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine 1995; 13:1759-1762.
410. Christenson B., Bottiger M.: Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994; 12:41-45.
411. Hyde T.B., Kruszon-Moran D., McQuillan G.M., et al: Rubella immunity levels in the United States population: has the threshold of viral elimination been reached?. Clin Infect Dis 2006; 43(Suppl. 3):S146-S150.
412. Johnson C.E., Kumar M.L., Whitwell J.K., et al: Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996; 15:687-692.
413. Ratnam S., West R., Gadag V.: Rubella antibody levels in school aged children in Newfoundland: implications for a two-dose rubella vaccination strategy. Can J Infect Dis 1997; 8:85-88.
414. Mitchell L.A., Tingle A.J., Decarie D., et al: Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27/3 vaccine: associations with boost in neutralizing antibody titer. Vaccine 1999; 17:2356-2365.
415. LeBaron C.W., Forghani B., Matter L., et al: Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 200:888-899.
416. de Haas R., van den Hof S., Berbers G.A., et al: A. Prevalence of antibodies against rubella virus in the Netherlands 9 years after changing from selective to mass vaccination. Epidemiol Infect 1999; 123:263-270.
417. Vandermeulen C., Mathieu R., Geert L.R., et al: Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 2007; 25:6672-6676.
418. Davidkin I., Peltola H., Leinikki P., et al: Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 2000; 18:3106-3112.
419. Davidkin I., Jokinen S., Broman M., et al: Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197:950-956.

420. Kakoulidou M., Forsgren M., Lewensohn-Fuchs I., et al: Serum levels of rubella-specific antibodies in Swedish women following three decades of vaccination programmes. Vaccine 2010; 28:1002-1007.
421. Mossong J., Putz L., Schneider F.: Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study. Epidemiol Infect 2004; 132:11-18.
422. Al Mazrou Y.Y., Khalil M.K., Tischer A., et al: Serosurvey of measles, mumps and rubella antibodies in Saudi children. Saudi Med J 2005; 26:1551-1554.
423. Zanetta D.M., Cabrera E.M., Azevedo R.S., et al: Seroprevalence of rubella antibodies in the State of Saõ Paulo, Brazil, 8 years after the introduction of vaccine. Vaccine 2003; 21:3795-3800.
424. Kremer J.R., Schneider F., Muller C.P.: Waning antibodies in measles and rubella vaccinees: a longitudinal study. Vaccine 2006; 24:2594-2601.
424a. Lin C.C., Yang C.Y., Shih Y.L., et al: Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA27/3 in junior high school. Clin Vacc Imm 2011; 19:1-4.
425. Best J.M.: Rubella vaccines: past, present and future. Epidemiol Infect 1991; 107:17-30.
426. Strassburg M.A., Greenland S., Stephenson T.G., et al: Clinical effectiveness of rubella vaccine in a college population. Vaccine 1985; 3:109-112.
427. Forrest J.M., Slinn R.F., Nowak M.J., et al: Duration of immunity to rubella. Lancet 1971; 1:1013.
428. Hoshino M., Oka Y., Deguchi M., et al: The ten-year follow-up of the persistence of humoral antibody to rubella virus acquired by vaccination with the Japanese To-336 vaccine. J Biol Stand 1982; 10:213-219.
429. Ueda K., Yoshikawa H., Ohashi K., et al: Clinical experience with a live attenuated rubella virus vaccine, Matsuba strain GMK3SK6ORK6, in special reference to 6-year follow-up of rubella antibodies to prevention of rubella infection during an epidemic. J Pediatr 1978; 20:481-484.
430. Asahi T., Ueda K., Hidaka Y., et al: Twenty-three-year follow-up study of rubella antibodies after immunization in a closed population, and serological response to revaccination. Vaccine 1997; 15:1791-1795.
431. Toyoda M., Ihara T., Nakano T., et al: Expression of interleukin-2 receptor alpha and CD45RO antigen on T lymphocytes cultured with rubella virus antigen, compared with humoral immunity in rubella vaccinees. Vaccine 1999; 17:2051-2058.
432. Latner D.R., McGrew M., Williams N., et al: Enzyme-linked immunospot assay detection of mumps-specific antibody-screening B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol 2011; 18:35-42.
433. Balfour Jr H.H.: Rubella reimmunization now. Am J Dis Child 1979; 133:1231-1233.
434. Lawless M.R., Abramson J.S., Harlan J.E., et al: Rubella susceptibility in sixth graders: effectiveness of current immunization practice. Pediatrics 1980; 65:1086-1089.
435. Brandling-Bennett A.D., Jackson R.S., Halstead S.B., et al: Serologic response to revaccination with two rubella vaccines. Am J Dis Child 1976; 130:1081-1084.
436. Serdula M.K., Halstead S.B., Wiebenga N.H., et al: Serological response to rubella revaccination. JAMA 1984; 251:1974-1977.
437. Robinson R.G., Dudenhoeffer F.E., Holroyd H.J., et al: Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those unimmunized. J Pediatr 1982; 101:188-191.
438. Fitzpatrick S.B., Anthony R., Heald F.: Serological response to rubella revaccination in adolescent females. J Adolesc Health Care 1983; 4:168-170.

439. Pebody R.G., Edmunds W.J., Conyn-van Spaendonck M., et al: The seroepidemiology of rubella in western Europe. Epidemiol Infect 2000; 125:347-357.
440. Forrest J.M., Honeyman M.C., Menser M.A.: Immunity after congenital rubella. Lancet 1972; 1:1075-1076.
441. Becker N.G., Rouderfer V.: Simultaneous control of measles and rubella by multidose vaccination schedules. Math Biosci 1996; 131:81-102.
442. Schell K., Kenny M.T., Jackson J.E.: Serological evaluation of measles virus (Schwarz strain), mumps virus (Jeryl Lynn strain) and rubella virus (Cendehill strain) combination vaccines. J Biol Stand 1975; 3:231-239.
443. Deforest A., Long S.S., Lischner H.W., et al: Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 1988; 81:237-246.
444. Watson B.M., Laufer D.S., Kuter B.J., et al: Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis 1996; 173:731-734.[published erratum appears in J Infect Dis 1996;173:1529]
445. Freestone D.S., Prydie J., Smith S.G., et al: Vaccination of adults with Wistar RA 27/3 rubella vaccine. J Hyg (Lond) 1971; 69:471-477.
446. Fogel A., Moshkowitz A., Rannon L., et al: Comparative trials of RA 27-3 and Cendehill rubella vaccines in adult and adolescent females. Am J Epidemiol 1971; 93:392-398.
447. Peltola H., Heinonen O.P.: Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1986; 1:939-942.
448. Virtanen M., Peltola H., Paunio M., et al: Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 2000; 106:E62.doi:1542/peds.106.5.e62
449. Edees S., Pullan C.R., Hull D.: A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health 1991; 105:91-97.
450. Shohat T., Green M.S., Nakar O., et al: Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Isr Med Assoc J 2000; 2:192-195.
451. LeBaron C.W., Bi D., Sullivan B.J., et al: Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics 2006; 118:1422-1430.
452. Vesikari T., Baer M., Willems P.: Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J 2007; 26:153-158.
453. Howson C.P., Howe C.J., Fineberg H.V.: Chronic arthritis. In: Howson C.P., Howe C.J., Fineberg H.V., ed. Adverse Effects of Pertussis and Rubella Vaccines, Washington, DC: National Academy Press; 1991:196..Institute of Medicine
454. IOM (Institute of Medicine) : Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: National Academics Press; 2011:89-210.574–6
455. Epidemiologic report: adverse events temporally associated with immunizing agents: 1989 report. Can Med Assoc J 1991; 145:1269-1275.
456. Dudgeon J.A., Marshall W.C., Peckham C.S., et al: Clinical and laboratory studies with rubella vaccines in adults. Br Med J 1969; 1:271-276.
457. Barnes E.K., Altman R., Austin S.M., et al: Joint reactions in children vaccinated against rubella. II. Comparison of three vaccines. Am J Epidemiol 1972; 95:59-66.
458. Kilroy A.W., Schaffner W., Fleet Jr W.F., et al: Two syndromes following rubella immunization. Clinical observations and epidemiological studies. JAMA 1970; 214:2287-2292.M.

459. Thompson G.R., Weiss J.J., Shillis J.L., et al: Intermittent arthritis following rubella vaccination. A three-year follow-up. Am J Dis Child 1973; 125:526-530.
460. Spruance S.L., Klock Jr L.E., Bailey A., et al: Recurrent joint symptoms in children vaccinated with HPV-77DK12 rubella vaccine. J Pediatr 1972; 80:413-417.
461. Gilmartin Jr R.C., Jabbour J.T., Duenas D.A.: Rubella vaccine myeloradiculoneuritis. J Pediatr 1972; 80:406-412.
462. Swartz T.A., Klingberg W., Goldwasser R.A., et al: Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine. Am J Epidemiol 1971; 94:246-251.
463. Weibel R.E., Stokes Jr J., Buynak E.B., et al: Influence of age on clinical response to HPV-77 duck rubella vaccine. JAMA 1972; 222:805-807.
464. Lerman S.J., Nankervis G.A., Heggie A.D., et al: Immunologic response, virus excretion, and joint reactions with rubella vaccine. A study of adolescent girls and young women given live attenuated virus vaccine (HPV-77:DE-5). Ann Intern Med 1971; 74:67-73.
465. Horstmann D.M., Liebhaber H., Kohorn E.I.: Post-partum vaccination of rubella-susceptible women. Lancet 1970; 2:1003-1006.
466. Fox J.P., Rainey H.S., Hall C.E., et al: Rubella vaccine in postpubertal women. Experience in Western Washington State. JAMA 1976; 236:837-843.
467. Rowlands D.F., Freestone D.S.: Vaccination against rubella of susceptible schoolgirls in Reading. J Hyg (Lond) 1971; 69:579-586.
468. Polk B.F., Modlin J.F., White J.A., et al: PCA controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 1982; 115:19-25.
469. Ogra P.L., Chiba Y., Ogra S.S., et al: Rubella-virus infection in juvenile rheumatoid arthritis. Lancet 1975; 1:1157-1161.
470. Ogra P.L., Herd J.K.: Arthritis associated with induced rubella infection. J Immunol 1971; 107:810-813.
471. Nepom G.T., Ou D., Lybrand T.P., et al: Recognition of altered self major histocompatibility complex molecules modulated by specific peptide interactions. Eur J Immunol 1996; 26:949-952.
472. Pogue G.P., Hofmann J., Duncan R., et al: Autoantigens interact with cis-acting elements of rubella virus RNA. J Virol 1996; 70:6269-6277.
473. Mitchell L.A., Tingle A.J., MacWilliam L., et al: HLA-DR class II associations with rubella vaccine-induced joint manifestations. J Infect Dis 1998; 177:5-12.
474. Miki N.P., Chantler J.K.: Differential ability of wild-type and vaccine strains of rubella virus to replicate and persist in human joint tissue. Clin Exp Rheumatol 1992; 10:3-12.
475. Lund K.D., Chantler J.K.: Mapping of genetic determinants of rubella virus associated with growth in joint tissue. J Virology 2000; 74:796-804.
476. Tingle A.J., Kettyls G.D., Ford D.K.: Studies on vaccine-induced rubella arthritis. Serologic findings before and after immunization. Arthritis Rheum 1979; 22:400-402.
477. Tingle A.J., Allen M., Petty R.E., et al: Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann Rheum Dis 1986; 45:110-114.
478. Singh V.K., Tingle A.J., Schulzer M.: Rubella-associated arthritis. II. Relationship between circulating immune complex levels and joint manifestations. Ann Rheum Dis 1986; 45:115-119.
479. Howson C.P., Katz M., Johnston Jr R.B., et al: Chronic arthritis after rubella vaccination. Clin Infect Dis 1992; 15:307-312.
480. Phillips P.E., Doughtery R.M., Mican J.M.: Failure to isolate rubella virus (RV) from blood of adults after vaccination. Arthritis Rheum 1989; 113:427.

481. Frenkel L., Garakian A., Cherry J.D.: Rubella virus (RV): no evidence of persistent infection following immunization with RA27/3 or wild type infection. Abstracts of 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991:1294.Chicago
482. Nielsen K., Garakian A., Frenkel L.M., et al: The in vitro growth and serial passage of RA 27/3 rubella vaccine virus in cord blood mononuclear leukocytes from normal babies. Pediatr Res 1995; 37:623-625.
483. Zhang D., Nikkari S., Vainionpaa R., et al: Detection of rubella, mumps, and measles virus genomic RNA in cells from synovial fluid and peripheral blood in early rheumatoid arthritis. J Rheumatol 1997; 24:1260-1265.
484. Slater P.E., Ben-Zvi T., Fogel A., et al: Absence of an association between rubella vaccination and arthritis in underimmune postpartum women. Vaccine 1995; 13:1529-1532.
485. Ray P., Black S., Shinefield H., et al: Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team [see comments]. JAMA 1997; 278:551-556.
486. Tingle A.J., Mitchell L.A., Grace M., et al: Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet 1997; 349:1277-1281.
487. Mitchell L.A., Tingle A.J., Grace M., et al: Rubella virus vaccine associated arthropathy in postpartum immunized women: influence of preimmunization serologic status on development of joint manifestations. J Rheumatol 2000; 27:418-423.
488. Rubella vaccines. WHO position paper. Wkly Epidemiol Rec 2011; 86:301-316.
489. Weibel R.E., Benor D.E.: Chronic arthropathy and musculoskeletal symptoms associated with rubella vaccines. A review of 124 claims submitted to the National Vaccine Injury Compensation Program. Arthritis Rheum 1996; 39:1529-1534.[published erratum appears in Arthritis Rheum 1996;39:1930]
490. Chiba Y., Sadeghi E., Ogra P.L.: Abnormalities of cellular immune response in arthritis induced by rubella vaccination. J Immunol 1976; 117(5 pt 1):1684-1687.
491. Coyle P.K., Wolinsky J.S., Buimovici-Klein E., et al: Rubella-specific immune complexes after congenital infection and vaccination. Infect Immun 1982; 36:498-503.
492. Centers for Disease Control and Prevention (CDC) : Adverse events following immunization. Report no. 1, 1979-1982.Atlanta, GA, Department of Health and Human Services, Public Health Service, 1984.
493. Schaffner W., Fleet W.F., Kilroy A.W., et al: Polyneuropathy following rubella immunization. A follow-up study and review of the problem. Am J Dis Child 1974; 127:684-688.
494. Cusi M.G., Bianchi S., Santini L., et al: Peripheral neuropathy associated with anti-myelin basic protein antibodies in a woman vaccinated with rubella virus vaccine. J Neurovirol 1999; 5:209-214.
495. Kazarian E.L., Gager W.E.: Optic neuritis complicating measles, mumps, and rubella vaccination. Am J Ophthalmol 1978; 86:544-547.
496. Kline L.B., Margulies S.L., Oh S.J.: Optic neuritis and myelitis following rubella vaccination. Arch Neurol 1982; 39:443-444.
497. Islam S.M., El Sheikh H.F., Tabbara K.F.: Anterior uveitis following combined vaccination for measles, mumps and rubella (MMR): a report of two cases. Acta Ophthalmol Scand 2000; 78:590-592.
498. Centers for Disease Control and Prevention (CDC) : Rubella surveillance. Report no. 2. Atlanta, GA:Department of Health and Human Services, Public Health Service, 1970.
499. Behan P.O.: Diffuse myelitis associated with rubella vaccination. Br Med J 1977; 1:166.
500. Joyce K.A., Rees J.: Transverse myelitis after measles, mumps, and rubella vaccine. BMJ 1997; 311:422.

501. Lim S., Park S.M., Choi H.S., et al: Transverse myelitis after measles and rubella vaccination. J Paediatr Child Health 2004; 40:583-584.
502. Cizman M., Pokorn M., Osredkar D.: Re: transverse myelitis after measles and rubella vaccination. J Paediatr Child Health 2005; 41:460.
503. Morton-Kute L.: Rubella vaccine and facial paresthesias. Ann Intern Med 1985; 102:563.
504. Tsuru T., Mizuguchi M., Ohkubo Y., et al: Acute disseminated encephalomyelitis after live rubella vaccination. Brain Dev 2000; 22:259-261.
505. Gunderman J.R.: Guillain-Barré syndrome. Occurrence following combined mumps-rubella vaccine. Am J Dis Child 1973; 125:834-835.
506. Rees J., Hughes R.: Guillain-Barré syndrome after measles, mumps, and rubella vaccine. Lancet 1994; 343:733.
507. Hughes R.: Vaccines and Guillain-Barré syndrome. BMJ 1996; 312:1475-1476.
508. Patja A., Paunio M., Kinnunen E., et al: Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination. J Pediatr 2001; 138:250-254.
509. Makela A., Nuorti J.P., Peltola H.: Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110:957-963.
510. Chantler J.K., Smyrnis L., Tai G.: Selective infection of astrocytes in human glial cell cultures by rubella virus. Lab Invest 1995; 72:334-340.
511. Shin S.Y., Lee S.W., Cho Y.H., et al: Blood-borne transmission of the measles, mumps, and rubella vaccine virus. Transfusion 2011; 51:663-664.
512. Peters M.E., Horowitz S.: Bone changes after rubella vaccination. AJR Am J Roentgenol 1984; 143:27-28.
513. Zeffer K.B., Sauer M.V.: Orchitis after a rubella vaccination. A case report. J Reprod Med 1988; 33:80-81.
514. Sharma O.N.: Thrombocytopenia following measles-mumps-rubella vaccination in a one-year-old infant. Clin Pediatr (Phila) 1973; 12:315.
515. Neiderud J.: Thrombocytopenic purpura after a combined vaccine against morbilli, parotitis and rubella. Acta Paediatr Scand 1983; 72:613-614.
516. Erlewyn-Lajeunesse M., Manek R., Lingam R., et al: Anaphylaxis following single component measles and rubella immunisation. Arch Dis Child 2008; 93:974-975.
517. Nieminen U., Peltola H., Syrjälä M.T., et al: Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993; 82:267-270.
518. Chang S.K., Farrell D.L., Dougan K., et al: Acute idiopathic thrombocytopenic purpura following combined vaccination against measles, mumps, and rubella. J Am Board Fam Pract 1996; 9:53-55.
519. Bayer W.L., Sherman F.E., Michaels R.H., et al: Purpura in congenital and acquired rubella. N Engl J Med 1965; 273:1362-1366.
520. Autret E., Jonville-Bera A.P., Galy-Eyraud C., et al: Thrombocytopenic purpura after isolated or combined vaccination against measles, mumps and rubella[in French]. Thérapie 1996; 51:677-680.
521. Okazaki N., Takeguchi M., Sonoda K., et al: Detection of platelet-binding anti-measles and anti-rubella virus IgG antibodies in infants with vaccine-induced thrombocytopenic purpa. Vaccine 2011; 29:4878-4880.
522. Drachtman R.A., Murphy S., Ettinger L.J.: Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148:326-327.
523. Vlacha V., Forman E.N., Miron D., et al: Recurrent thrombocytopenic purpura after repeated measles-mumps- rubella vaccination. Pediatr Infect Dis J 1996; 97:738-739.

524. Miller E., Waight P., Farrington C.P., et al: Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227-229.
524a. Andrews N., Stowe J., Miller E., et al: A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine 2012; 30:3042-3046.
525. France E.K., Glanz J., Xu S., et al: Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121:e687-e692.doi:1542/peds.2007-1578
526. Mantadakis E., Farmaki E., Buchanan G.R.: Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010; 156:623-628.
527. Bibby A.C., Farrell A., Cummins M., et al: Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?. Arch Dis Child 2008; 93:354-355.
528. Advisory Committee on Immunization Practices (ACIP) : Update: vaccine side effects, adverse reactions, contraindications, and precautions. MMWR Recomm Rep 1996; 45(RR-12):1-35.
529. Pool V., Chen R., Rhodes P.: Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura. Pediatr Infect Dis J 1997; 16:423-424.
530. Lindberg B., Ahlfors K., Carlsson A., et al: Previous exposure to measles, mumps, and rubella—but not vaccination during adolescence—correlates to the prevalence of pancreatic and thyroid autoantibodies. Pediatrics 1999; 104:e12.doi:1542/peds. 104.e12
531. Midulla M., Businco L., Moschini L.: Some effects of rubella vaccination of immunologic responsiveness. Acta Paediatr Scand 1972; 61:609-611.
532. Ganguly R., Cusumano C.L., Waldman R.H.: Suppression of cell-mediated immunity after infection with attenuated rubella virus. Infect Immun 1976; 13:464-469.
533. Arneborn P., Biberfeld G., Wasserman J.: Immunosuppression and alterations of T-lymphocyte subpopulations after rubella vaccination. Infect Immun 1980; 29:36-41.
534. Munyer T.P., Mangi R.J., Dolan T., et al: Depressed lymphocyte function after measles-mumps-rubella vaccination. J Infect Dis 1975; 132:75-78.
535. Mellor J.A., Langford D.T., Zealley H., et al: A survey of cancer morbidity and mortality in vaccinees seven to 12 years after the administration of live vaccine propagated in human diploid cells. J Biol Stand 1983; 11:221-225.
536. Nicoara C., Zach K., Trachsel D., et al: Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses. Clin Diagn Lab Immunol 1999; 6:868-871.
537. Doroudchi M., Samsami Dehaghani A., Emad K., et al: Placental transfer of rubella-specific IgG in fullterm and preterm newborns. Int J Gynaecol Obstet 2003; 81:157-162.
538. Leineweber B., Grote V., Schaad U.B., et al: Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J 2004; 23:361-363.
539. Herrmann K.L., Wende R.D., Witte J.J.: Rubella immunization with HPV-77 DE5 vaccine during infancy. Am J Dis Child 1971; 121:474-476.
540. Wilkins J., Wehrle P.F.: Further evaluation of the optimum age for rubella vaccine administration. Am J Dis Child 1979; 133:1237-1239.
541. Schoub B.D., Johnson S., McAnerney J.M., et al: Measles, mumps and rubella immunization at nine months in a developing country. Pediatr Infect Dis J 1990; 9:263-267.
542. Volti S.L., Giammanco-Bilancia G., Grassi M., et al: Duration of the immune response to MMR Vaccine in children of two age-different groups. Eur J Epidemiol 1993; 9:311-314.
543. Singh R., John T.J., Cherian T., et al: Immune response to measles, mumps and rubella vaccine at 9, 12 and 15 months of age. Indian J Med Res 1994; 100:155-159.

544. Ratnam S., Chandra R., Gadag V.: Maternal measles and rubella antibody levels and serologic response in infants immunized with MMR II vaccine at 12 months of age. J Infect Dis 1993; 168:1596-1598.
545. Rubella prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1990; 39(RR-15):1-18.
546. Dennehy P.H., Saracen C.L., Peter G.: Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994; 94:514-516.
547. Ratnam S., West R., Gadag V.: Measles and rubella anatibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. J Pediatr 1995; 127:432-434.
548. Cilla G., Pena B., Marimon J.M., et al: Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection. Vaccine 1996; 14:492-494.
549. Schiff G.M., Linnemann Jr C.C., Rotte T., et al: Rubella surveillance and immunization. Susceptibility in nonurban adolescents. JAMA 1973; 226:554-556.
550. Rauh J.L., Schiff G.M., Johnson L.B.: Rubella surveillance and immunization among adolescent girls in Cincinnati. Am J Dis Child 1972; 124:71-75.
551. Mann J.M., Montes J.M., Hull H.F., et al: Risk of pregnancy among adolescent schoolgirls participating in a measles mass immunization program. Am J Public Health 1983; 73:527-529.
552. Lerman S.J., Lerman L.M., Nankervis G.A., et al: Accuracy of rubella history. Ann Intern Med 1971; 74:97-98.
553. Tattersall J.M., Freestone D.S.: Rubella vaccination in young women attending a family planning clinic. Practitioner 1973; 211:769-772.
554. Halstead E., Halstead S.B., Jackson R.S., et al: Rubella vaccination: fertility control in a large-scale vaccination program for postpubertal women. Am J Obstet Gynecol 1975; 121:1089-1094.
555. Gringras M., Reisler R., Caisley J., et al: Vaccination of rubella-susceptible women during oral contraceptive care in general practice. Br Med J 1977; 2:245-246.
556. Rowlands S., Bethel R.G.: Contraceptive cover for rubella vaccination. Practitioner 1982; 226:1155-1156.
557. Schiff G.M., Young B.C., Stefanovic G.M., et al: Challenge with rubella virus after loss of detectable vaccine-induced antibody. Rev Infect Dis 1985; 7(Suppl. 1):S157-S163.
558. Kelly C.S., Gibson J.L., Williams C.S., et al: Postpartum rubella immunization. Results with the HPV-77 strain. Obstet Gynecol 1971; 37:338-342.
559. Tobin J.O.: Rubella vaccination of postpartum women and of adolescents in the Northwest of England. Can J Public Health 1971; 62:634-667.
560. Beazley J.M., Hurley R., Middlebrook C., et al: Rubella vaccination in the puerperium. Br J Prev Soc Med 1971; 25:140-143.
561. Grillner L., Hedstrom C.E., Bergstrom H., et al: Vaccination against rubella of newly delivered women. Scand J Infect Dis 1973; 5:237-241.
562. Cheldelin L.V., Francis D.P., Tilson H.: Postpartum rubella vaccination. A survey of private physicians in Oregon. JAMA 1973; 225:158-159.
563. Griffiths P.D., Baboonian C.: Is post partum rubella vaccination worthwhile?. J Clin Pathol 1982; 35:1340-1344.
564. Black N.A., Parsons A., Kurtz J.B., et al: Post-partum rubella immunisation: a controlled trial of two vaccines. Lancet 1983; 2:990-992.
565. Marshall W.C., Peckham C.S., Dudgeon J.A., et al: A. Parity of women contracting rubella in pregnancy. Implications with respect to rubella vaccination. Lancet 1976; 1:1231-1233.

566. Edmond E., Zealley H.: The impact of a rubella prevention policy on the outcome of rubella in pregnancy. Br J Obstet Gynaecol 1986; 93:563-567.
567. Baldwin J.A., Freestone D.S.: Risk of early post-partum pregnancy in context of post-partum vaccination against rubella. Lancet 1971; 2:366-367.
568. Sharp D.S., Macdonald H.: Use of medroxyprogesterone acetate as a contraceptive in conjunction with early postpartum rubella vaccination. Br Med J 1973; 4:443-446.
569. Bolognese R.J., Corson S.L., Fuccillo D.A., et al: The susceptibility of the postpartum and postabortal cervix and uterine cavity to infection with attenuated rubella virus. Am J Obstet Gynecol 1976; 125:525-527.
570. Buimovici-Klein E., Hite R.L., Byrne T., et al: Isolation of rubella virus in milk after postpartum immunization. J Pediatr 1977; 91:939-941.
571. Landes R.D., Bass J.W., Millunchick E.W., et al: Neonatal rubella following postpartum maternal immunization. J Pediatr 1980; 97:465-467.
572. Losonsky G.A., Fishaut J.M., Strussenberg J., et al: Effect of immunization against rubella on lactation products. I. Development and characterization of specific immunologic reactivity in breast milk. J Infect Dis 1982; 145:654-660.
573. Losonsky G.A., Fishaut J.M., Strussenberg J., et al: Effect of immunization against rubella on lactation products. II. Maternal-neonatal interactions. J Infect Dis 1982; 145:661-666.
574. Perez-Trallero E., Cilla G., Urbieta M.: Rubella immunisation of men: advantages of herd immunity. Lancet 1996; 348:413.
575. Bakasun V., Suzanic-Karnincic S.A.: Rubella outbreak in the region of Rijeka, Croatia. Int J Epidemiol 1995; 24:453-456.
576. Lim M.K., Fong Y.F., Soh C.S.: Rubella seroprevalence in the Singapore Armed Forces (SAF) and the changing need of the SAF rubella immunisation programme. Ann Acad Med Singapore 1997; 26:37-39.
577. Adams M.S., Croft A.M., Winfield D.A., et al: An outbreak of rubella in British troops in Bosnia. Epidemiol Infect 1997; 118:253-257.
578. Migliani R., Renaudat-Olivaud A., Barneche J.P., et al: Epidémie de rubéole en 1996 dans un centre d'instruction militarie dans le centre de la France. Bull Epidémiol Hebd 1996; 28:124-125.
579. Weiss K.E., Falvo C.E., Buimovici-Klein E., et al: Evaluation of an employee health service as a setting for a rubella screening and immunization program. Am J Public Health 1979; 69:281-283.
580. Polk B.F., White J.A., DeGirolami P.C., et al: An outbreak of rubella among hospital personnel. N Engl J Med 1980; 303:541-545.
581. Centers for Disease Control and Prevention (CDC) : Nosocomial rubella infection: North Dakota, Alabama, Ohio. MMWR Morb Mortal Wkly Rep 1981; 29:630-631.
582. Centers for Disease Control and Prevention (CDC) : Rubella in hospitals: California. MMWR Morb Mortal Wkly Rep 1983; 32:37-39.
583. Greaves W.L., Orenstein W.A., Stetler H.C., et al: Prevention of rubella transmission in medical facilities. JAMA 1982; 248:861-864.
584. Heseltine P.N., Ripper M., Wohlford P.: Nosocomial rubella-consequences of an outbreak and efficacy of a mandatory immunization program. Infect Control 1985; 6:371-374.
585. Weber D.J., Rutala W.A., Orenstein W.A.: Prevention of mumps, measles, and rubella among hospital personnel. J Pediatr 1991; 119:322-326.
586. Geiger R., Fink F.M., Sölder B., et al: Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission. J Med Virol 1995; 47:442-444.

587. Ljungman P., Fridell E., Lonnqvist B., et al: Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159:610-615.
588. King S.M., Saunders E.F., Petric M., et al: Response to measles, mumps, and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:633-636.
589. Flynn J.T., Frisch K., Kershaw D.B., et al: Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999; 15:269-272.
590. Kwitten P.L., Rosen S., Sweinberg S.K.: MMR vaccine and neomycin allergy. Pediatric Forum 1993; 147:128-129.
591. Brena A.E., Cooper E.R., Cabral H.J., et al: Antibody response to measles and rubella vaccine by children with HIV infection. J Acquir Immune Defic Syndr 1993; 6:1125-1129.
592. Aurpibul L., Puthanakit T., Sirisanthana T., et al: Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1415-1418.
593. Lima M., Succi R.C., Nunes A.M., et al: Rubella immunization in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2004; 23:604-607.
594. Stermole B.M., Grandits G.A., Roediger M., et al: Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults. Vaccine 2011; 29:2874-2880.
595. Floridia M., Pinnetti C., Ravizzza M., et al: Rubella susceptibility profile in pregnant women with HIV. Clin Infect Dis 2011; 52:960-961.
596. Frenkel L.M., Nielsen K., Garakian A., et al: A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med 1994; 148:57-60.
597. Lima M., Menezes Succi R.C., Nunes Dos Santos A.M., et al: Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J 2004; 23:604-607.
598. Fleet Jr W.F., Benz Jr E.W., Karzon D.T., et al: Fetal consequences of maternal rubella immunization. JAMA 1974; 227:621-627.
599. Araujo P.R., Albertoni G., Arnoni C., et al: Rubella vaccination and transitory false-positive test results for human immunodeficiency virus Type 1 in blood donors. Transfusion 2009; 49:2516-2517.
600. Heijstek M.W., Pileggi G.C., Zonneveld-Huijssoon E., et al: Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66:1384-1387.
601. Borte S., Liebert U.G., Borte M., et al: Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009; 48:144-148.
602. Korematsu S., Miyahara H., Kawano T., et al: A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine 2004; 27:5041-5042.2009
603. Aytac S., Yalcin S.S., Cetin M., et al: Measles, mumps and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol 2010; 27:333-343.
604. Centers for Disease Control and Prevention (CDC) : Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:1117.
605. Rubella vaccination during pregnancy-United States, 1971-1983. MMWR Morb Mortal Wkly Rep 1984; 33:365-368.373

606. Bart S.W., Stetler H.C., Preblud S.R., et al: Fetal risk associated with rubella vaccine: an update. Rev Infect Dis 1985; 7(Suppl. 1):S95-102.
607. Enders G.: Rubella antibody titers in vaccinated and nonvaccinated women and results of vaccination during pregnancy. Rev Infect Dis 1985; 7(Suppl. 1):S103-S107.
608. Hofmann J., Kortung M., Pustowoit B., et al: Persistent fetal rubella vaccine virus infection following inadvertent vaccination during early pregnancy. J Med Virol 2000; 61:155-158.
609. Enders G.: Personal communication: Plotkin SA,2006.
610. Reyna J., Herbas I., Gómez M., et al: Perinatal outcome of inadvertent immunization with the measles-rubella vaccine in pregnant Mexican women during the campaign for the eradication of congenital rubella in 2008. World J Vaccines 2011; 1:1-4.
611. Castillo-Solórzano C., Reef S.E., Morice A., et al: Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001-2008. J Infect Dis 2011; 204(Suppl. 2):S713-S717.
612. Soares R.C., Siqueira M.M., Toscano C.M., et al: Follow-up study of unknowingly pregnant women vaccinated against rubella in Brazil, 2001-2002. J Infect Dis 2011; 204(Suppl. 2):S729-S736.
613. Ivankovich G., Rodriguez G., Morice A., et al: Congenital rubella syndrome or infections due to rubella vaccinal virus. Washington, DC;Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004;.6504:246, 2004
614. da Silva e Sa G.R., Camacho L.A., Siqueira M.M., et al: Seroepidemiological profile of pregnant women after inadvertent rubella vaccination in the state of Rio de Janeiro, Brazil, 2001-2002. Rev Panam Salud Publica 2006; 19:371-378.
615. Badilla X., Morice A., Vila-Aguero M.L., et al: Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J 2007; 26:830-835.2007
616. Namaei M.H., Ziaee M., Naseh N.: Congenital rubella syndrome in infants of women vaccinated during or just before pregnancy with measles-rubella vaccine. Indian J Med Res 2008; 127:551-554.
617. Nasiri R., Yoseffi J., Khajedaloe M., et al: Congenital rubella syndrome after rubella vaccination in 1-4 weeks periconceptional period. Indian J Pediatr 2009; 76:279-282.
618. Rubella vaccination during pregnancy: United States, 1971-1986. MMWR Morb Mortal Wkly Rep 1987; 36:457-461.
619. Sheppard S., Smithells R.W., Dickson A., et al: Rubella vaccination and pregnancy: preliminary report of a national survey. Br Med J (Clin Res Ed) 1986; 292:727.
620. Romualdo J., Silva N., Camacho L.A., et al: Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29:6327-6334.
621. Cooper L.Z., Florman A.L., Ziring P.R., et al: Loss of rubella hemagglutination inhibition antibody in congenital rubella. Failure of seronegative children with congenital rubella to respond to HPV-77 rubella vaccine. Am J Dis Child 1971; 122:397-403.
622. Ingalls T.H., Plotkin S.A., Philbrook F.R., et al: Immunisation of schoolchildren with rubella (RA27-3) vaccine. Intranasal and subcutaneous administration. Lancet 1970; 1:99-101.
623. World Health Organization : Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2000; 75:161-169.
624. World Health Organization (WHO) : Report of a meeting on preventing congenital rubella syndrome: immunization strategies, surveillance needs. vol. 10Geneva, WHO Departments of Vaccines and Biologicals, 2000. p. 1–77

625. World Health Organization (WHO) : Percentage of member states, by WHO region, with routine rubella vaccination nationwide, 1996 versus 2004. WHO/IVB database, 2005. WHO Bulletin Report, March 2000, WHO/VB/000
626. Strebel P.M., Gacic-Dobo M., Reef S., et al: Global use of rubella vaccines, 1980-2009. J Infect Dis 2011; 204(Suppl. 2):S579-S584.
627. Weinstein L., Chang T.W.: Rubella immunization. N Engl J Med 1973; 288:100-101.
628. Farquhar J.D.: Experience with rubella and rubella immunization in institutionalized children. J Pediatr 1973; 83:51-56.
629. Schoenbaum S.C., Biano S., Mack T.: Epidemiology of congenital rubella syndrome. The role of maternal parity. JAMA 1975; 233:151-155.
630. Centers for Disease Control and Prevention (CDC) : Increase in rubella and congenital rubella syndrome: United States, 1988-1990. MMWR Morb Mortal Wkly Rep 1991; 40:93-99.
631. Dykewicz C.A., Kruszon-Moran D., McQuillan G.M., et al: Rubella seropositivity in the United States, 1988-1994. Clin Infect Dis 2001; 33:1279-1286.
632. Danovaro-Holliday M.C., LeBaron C.W., Allensworth C., et al: A large rubella outbreak with spread from the workplace to the community. JAMA 2000; 284:2733-2739.
633. Centers for Disease Control and Prevention (CDC) : Brief report: imported case of congenital rubella syndrome: New Hampshire, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1160-1161.
634. Reef S.E., Redd S.B., Abernathy E., et al: Evidence used to support the achievement and maintenance of elimination of rubella and congenital rubella syndrome in the United States. J Infect Dis 2011; 204(Suppl. 2):S593-S597.
635. White C.C., Koplan J.P., Orenstein W.A.: Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985; 75:739-744.
636. Centers for Disease Control Prevention (CDC) : Measles prevention. MMWR Morb Mortal Wkly Rep 1989; 38:1-18.
637. American Academy of Pediatrics Committee on Infectious Diseases : Measles: reassessment of the current immunization policy. Pediatrics 1989; 84:1110-1113.
638. Zhou F., Reef S., Massoudi M., et al: An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis 2004; 189(Suppl. 1):S131-S145.
639. Furesz J., Varughese P., Acres S.E., et al: Rubella immunization strategies in Canada. Rev Infect Dis 1985; 7(Suppl. 1):S191-S193.
640. Macey J, Lipskie T, Tam T, et al. Rubella elimination, the Canadian experience. J Infect Dis 204(Suppl. 2):S585–92.
641. Centers for Disease Control Prevention (CDC) : Progress toward elimination of measles and prevention of congenital rubella infection: European region, 1990-2004. MMWR Morb Mortal Wkly Rep 2006; 54:175-178.
642. Best J.M., Castillo-Solórzano C., Spika J.S., et al: Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee on Research Related to Measles and Rubella Vaccines and Vaccination, June 2004. J Infect Dis 2005; 192:1890-1897.
643. Zimmerman L., Rogalska J., Wannemuehler K.A., et al: Toward rubella elimination in Poland: need for supplemental immunization activities, enhanced surveillance, and further integration with measles elimination efforts. J Infect Dis 2011; 203:S389-S395.
644. Reef S.E., Strebel P., Dabbagh A., et al: Progress toward control of rubella and prevention of congenital rubella syndrome-worldwide, 2009. J Infect Dis 2011; 203:S24-S27.

645. Spika J.S., Wassilak S., Pebody R., et al: Measles and rubella in the World Health Organization European region: diversity creates challenges. J Infect Dis 2003; 187(Suppl. 1):S191-S197.
645a. Usonis V., Anca I., André F., et al: Rubella revisited: where are we on the road to disease elimination in Central Europe?. Vaccine 2011; 29:9141-9147.
645b. Derrough T., Bacci S., Lopalco P.L.: Letter to the editor: commitment needed for the prevention of congenital rubella syndrome in Europe. Euro Surveill 2012; 17(10):pii20106
646. Dudgeon J.A.: Selective immunization: protection of the individual. Rev Infect Dis 1985; 7(Suppl. 1):S185-S190.
647. Smithells R.W., Sheppard S., Marshall W.C., et al: National Congenital Rubella Surveillance Programme 1971-81. Br Med J (Clin Res Ed) 1982; 285:1363.
648. Peckham C.S., Marshall W.C., Dudgeon J.A.: Rubella vaccination of schoolgirls: factors affecting vaccine uptake. Br Med J 1977; 1:760-761.
649. Noah N.D., Fowle S.E.: Immunity to rubella in women of childbearing age in the United Kingdom. Br Med J 1988; 297:1301-1304.
650. Goldwater P.N., Quiney J.R., Banatvala J.E.: Maternal rubella at St. Thomas' Hospital: is there a need to change British vaccination policy?. Lancet 1978; 2:1298-1300.
651. Freestone D.S.: Vaccination against rubella in Britain: benefits and risks. Dev Biol Stand 1979; 43:339-348.
652. Hambling M.H.: Changes in the distribution of rubella antibodies in women of childbearing age during the first eight years of a rubella vaccination programme. J Infect 1980; 2:341-346.
653. Clarke M., Seagroatt V., Schild G.C., et al: Surveys of rubella antibodies in young adults and children. Lancet 1983; 1(Pt 1):667-669.
654. Gilmore D., Robinson E.T., Gilmour W.H., et al: Effect of rubella vaccination programme in schools on rubella immunity in a general practice population. Br Med J (Clin Res Ed) 1982; 284:628-630.
655. MIller C.L., Miller E., Sequeira P.J., et al: Effect of selective vaccination on rubella susceptibility and infection in pregnancy. Br Med J (Clin Res Ed) 1985; 291:1398-1401.
656. Anderson R.M., Grenfell B.T.: Control of congenital rubella syndrome by mass vaccination. Lancet 1985; 2:827-828.
657. Anderson R.M., Grenfell B.T.: Quantitative investigations of different vaccination policies for the control of congenital rubella syndrome (CRS) in the United Kingdom. J Hyg (Lond) 1986; 96:305-333.
658. Walker D., Carter H., Jones I.G.: Measles, mumps, and rubella: the need for a change in immunisation policy. Br Med J (Clin Res Ed) 1986; 292:1501-1502.
659. Hutchinson A.: Rubella prevention-a new era?. J R Coll Gen Pract 1988; 38:193-194.
660. Miller E.: Rubella in the United Kingdom. Epidemiol Infect 1991; 107:31-42.
661. Miller E., Tookey P., Morgan-Capner P., et al: Rubella surveillance to June 1994: third joint report from the PHLS and the National Congenital Rubella Surveillance Programme. CDR Rev 1994; 4:R146-R152.
662. Miller E., Waight P., Gay N., et al: The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. CDR Rev 1997; 7:R26-R32.
663. Sheridan E., Aitken C., Jeffries D., et al: Congenital rubella syndrome: a risk in immigrant populations. Lancet 2002; 359:674-675.
663a. Byrne L., Brant L., Reynolds C., et al: Seroprevalence of low rubella IgG antibody levels among antenatal women in England by NHS Blood and Transplant: 2004–2005. Vaccine 2012; 30:161-167.Is rubella susceptibility increasing?

664. MMR vaccine coverage at 24 months stabilises in the UK. Commun Dis Rep CDR Wkly 1999; 9:113.116
665. Tookey P.: Rubella in England, Scotland and Wales. Euro Surveill 2004; 9:21-23.
666. Christenson B., Bottiger M., Heller L.: Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience. Br Med J (Clin Res Ed) 1983; 287:389-391.
667. Rabo E., Taranger J.: Scandinavian model for eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1984; 289:1402-1404.
668. Bottiger M., Christenson B., Taranger J., et al: Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of schoolchildren. Vaccine 1985; 3:113-116.
669. Christenson B., Bottiger M.: Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Vaccine 1991; 9:326-329.
670. Bottiger M., Forsgren M.: Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine 1997; 15:1538-1544.
671. Dannetun E., Tegnell A., Hermansson G., et al: Timeliness of MMR vaccination-influence on vaccination coverage. Vaccine 2004; 22:4228-4232.
672. Glismann S.: Rubella in Denmark. Euro Surveill 2004; 9:12-13.
673. Haargaard B., Wohlfahrt J., Fledelius H.C., et al: A nationwide Danish study of 1027 cases of congenital/infantile cataracts: etiological and clinical classifications. Ophthalmology 2004; 111:2292-2298.
674. Peltola H., Kurki T., Virtanen M., et al: Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet 1986; 1:137-139.
675. Peltola H., Heinonen O.P., Valle M., et al: The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331:1397-1402.
676. Ukkonen P.: Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979-1992. Scand J Infect Dis 1996; 28:31-35.
677. Davidkin I., Peltola H., Leinikki P.: Epidemiology of rubella in Finland. Euro Surveill 2004; 9:13-14.
678. Peltola H., Jokinen S., Paunio M., et al: Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008; 8:796-803.
679. Marret H., Golfier F., Di Maio M., et al: Rubella in pregnancy. Management and prevention [in French]. Presse Med 1999; 28:2117-2122.
680. Antona D., Guerin N.: Couverture vaccinale rougeole-rubéole-oreillons en France en 1998: première et deuxième doses. Bull Epidémiol Hebd 1999; 19:74-75.
681. Levy-Bruhl D., Six C., Parent I.: Rubella control in France. Euro Surveill 2004; 9:15-16.
682. Che D., Baron S., Levy-Bruhl D.: Epidemiology of rubella in France, 20 years after the advent of vaccination [in French]. Rev Prat 2000; 50:1629-1631.
683. de Melker H.E., van den Hof S., et al: Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine 2003; 21:716-720.
684. Van Doornum G.J.: Personal Communication2005.
685. van der Heijden O.G., Conyn-van Spaendonck M.A., Plantinga A.D., et al: A model-based evaluation of the national immunization programme against rubella infection and congenital rubella syndrome in the Netherlands. Epidemiol Infect 1998; 121:653-671.
686. Hahné S., Macey J., Tipples G., et al: Rubella outbreak in an unvaccinated religious community in the Netherlands spreads to Canada. Euro Surveill 2005; 10:125-126.

687. Gabutti G., Rota M.C., Salmaso S., et al: Epidemiology of measles, mumps and rubella in Italy. Epidemiol Infect 2002; 129:543-550.
688. Anonymous : Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines. Vaccine 2007; 25:1-9.
689. Revello M.G., Gorini G., Zavattoni M., et al: Congenital rubella infection following rubella outbreak in northern Italy, 2002: need for an effective vaccination programme. Eur J Clin Microbiol Infect Dis 2004; 23:780-783.
689a. Muscat M., Zimmerman L., Bacci S., et al: Toward rubella elimination in Europe: an epidemiological assessment. Vaccine 2012; 30:199-207.
689b. Calimeri S., Capus A., LaFauci V., et al: Prevalence of serum anti-rubella virus antibodies among pregnant women in southern Italy. Int. J. Gynaecol Obstet 2012; 116:211-213.
690. Amela C., Pachón I., de Ory F.: Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. Eur J Epidemiol 2003; 18:71-79.
691. Bloom S., Trepka M.J., Becerra M.A., et al: Low rates of postpartum vaccination in a high-risk population, Miami-Dade County, Florida. Abstracts of the 42nd Annual Meeting of the Infectious Disease Society of America, vol. 1060. September 30-October 3, 2004:236.Boston, MA
692. Lemos C., Ramirez R., Ordobas M., et al: New features of rubella in Spain: the evidence of an outbreak. Euro Surveill 2004; 9:9-11.
693. Sanz J.C., de Ory F.: Rubella: a new scenario for an old disease [in Spanish]. Enferm Infecc Microbiol Clin 2006; 24:36-44.
693a. Martinez d.e., Aragón M.V., Pena-Rey I., et al: Situation of Rubella in Spain in the elimination phase. Rubella and Congenital Rubella Syndrome, 1997–2007. The Open Vaccine Journal 2010; 3:55-59.
694. Dominguez A., Torner N., Martinez A., et al: Rubella elimination programme strengthened through measles elimination programme in Catalonia. Vaccine 2006; 24:1433-1437.
695. Panagiotopoulos T., Georgakopoulou T.: Epidemiology of rubella and congenital rubella syndrome in Greece, 1994-2003. Euro Surveill 2004; 9:17-19.
696. Matter L., Bally F., Germann D., et al: The incidence of rubella virus infections in Switzerland after the introduction of the MMR mass vaccination programme. Eur J Epidemiol 1995; 11:305-310.
697. Rafila A., Marin M., Pistol A., et al: A large rubella outbreak, Romania-2003. Euro Surveill 2004; 9:7-9.
698. Kasper S., Allerberger F., Aberle S., et al: Rubella in Austria, 2008-2009. Pediatr Infect Dis J 2010; 29:448-452.
699. Bino S., Kakarriqi E., Xibinaku M., et al: Measles-rubella mass immunization campaign in Albania, November 2000. J Infect Dis 2003; 187(Suppl. 1):S223-S229.
700. Berger S.A., Ginsberg G.M., Slater P.E.: Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants. Isr J Med Sci 1990; 26:74-80.
701. Huerta M., Davidovitch N., Ankol O.E., et al: Declining seroprevalence of rubella antibodies among young Israeli adults: a 12-year comparison. Prev Med 2004; 39:1223-1226.
702. Cohen D., Muhsen K., Aboudy Y., et al: Use of rubella seroepidemiological data for assessment of previous vaccination policy and for decision making in response to epidemics in Israel. Vaccine 2006; 24:5604-5608.
703. Slater P.: Personal communication,2006.

704. Fogel A., Barnea B.S., Aboudy Y., et al: Rubella in pregnancy in Israel: 15 years of follow-up and remaining problems. Isr J Med Sci 1996; 32:300-305.
705. Slater P.E., Roitman M., Leventhal A., et al: Control of rubella in Israel: progress and challenge. Public Health Rev 1996; 24:183-192.
706. Semerikov V.V., Lavrentyeva I.N., Popov V.F., et al: Rubella in the Russian Federation: epidemiological features and control measures to prevent the congenital rubella syndrome. Epidemiol Infect 2000; 125:359-366.
707. Anonymous : SVI Technical Advisory Group meets. EPI Newslett 1997; 37:1-4.
708. Gallegos D., Olea A., Sotomayor V., et al: Rubella outbreaks following virus importations: the experience of Chile. J Infect Dis 2011; 204(Suppl. 2):S669-S674.
709. Castillo-Solórzano C., Reef S.E., Morice A., et al: Guidelines for the documentation and verification of measles, rubella, and congenital rubella syndrome elimination in the region of the Americas. J Infect Dis 2011; 204(Suppl. 2):S683-S689.
710. Morice A., Avila-Aguero M.L., Salas-Peraza D., et al: Approach to verify the status of measles, rubella, and congenital rubella syndrome elimination in Costa Rica. J Infect Dis 2011; 204(Suppl. 2):S690-S697.
711. Castillo-Solórzano C., Carrasco P., Tambini G., et al: New horizons in the control of rubella and prevention of congenital rubella syndrome in the Americas. J Infect Dis 2003; 187(Suppl. 1):S146-S152.
712. Centers for Disease Control and Prevention (CDC) : Nationwide campaign for vaccination of adults against rubella and measles: Costa Rica, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:976-979.
713. Morice A., Carvajal X., Leon M., et al: Accelerated rubella control and congenital rubella syndrome prevention strengthen measles eradication: the Costa Rican experience. J Infect Dis 2003; 187(Suppl. 1):S158-S163.
714. Massad E., Nascimento Burattini M., de Azevedo Neto R.S., et al: A model-based design of a vaccination strategy against rubella in a non-immunized community of Saõ Paulo state, Brazil. Epidemiol Infect 1994; 112:579-594.
715. Massad E., Azevedo Neto R.S., et al: Assessing the efficacy of a mixed vaccination strategy against rubella in Saõ Paulo, Brazil. Int J Epidemiol 1995; 24:842-850.
716. Dinelli M.I., Fisberg M., Moraes-Pinto M.I.: Rubella susceptibility in adolescents and immunization. International Congress of Infectious Disease (ICID) Abstracts, March 4-7, 2004:S222.Cancun, Mexico
717. PAHO : Brazil accelerates control of rubella and prevention of congenital rubella syndrome. EPI Newslett 2002; 24:1-8.
718. Cunha S.C., Dourado I.: MMR mass vaccination campaigns, vaccine-related adverse events, and the limits of the decision making process, in Brazil. Health Policy 2004; 67:323-328.
718a. Menegolla I.A., Bercini M.A., Schermann M.T., et al: Outbreak of rubella after mass vaccination of children and adult women: challenges for rubella elimination strategies. Rev Panam Salud Publica 2011; 29:243-251.
719. Pan American Health Organization : Brazil: vaccination campaign to eliminate rubella. Immunization Newslett 2009; 31:1-4.
720. Pan American Health Organization : Rubella campaign in Chile. EPI Newslett 1999; 21:3-4.
721. Centers for Disease Control and Prevention (CDC) : Progress toward elimination of rubella and congenital rubella syndrome: the Americas, 2003-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1176-1179.

722. Francis B.H., Thomas A.K., McCarty C.A.: The impact of rubella immunization on the serological status of women of childbearing age: a retrospective longitudinal study in Melbourne, Australia. Am J Public Health 2003; 93:1274-1276.
723. Coulter C., Wood R., Robson J.: Rubella infection in pregnancy. Commun Dis Intell 1999; 23:93-96.
724. Causer J., Mira M., Karr M., et al: Serological survey of measles and rubella immunity in Sydney preschool children. J Paediatr Child Health 2000; 36:418-421.
725. Cheah D., Hall R., Mead C., et al: The effectiveness of rubella vaccine. Med J Aust 1993; 158:434-435.
726. Burgess M.: Personal communication2006.
727. Guy R.J., Andrews R.M., Robinson P.M., et al: Mumps and rubella surveillance in Victoria, 1993 to 2000. Commun Dis Intell 2003; 27:94-99.
728. Brotherton J., McIntyre P., Puech M., et al: Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun Dis Intell 2004; 28(Suppl. 2):vii-116.
729. Song N., Gao Z., Wood J.G., et al: Current epidemiology of rubella and congenital rubella syndrome in Australia: progress towards elimination. Vaccine 2012.4073-4078.
730. Su S.B., Guo H.R.: Seroprevalence of rubella among women of childbearing age in Taiwan after nationwide vaccination. Am J Trop Med Hyg 2002; 67:549-553.
731. Tseng H.F., Chang C.K., Tan H.F., et al: Seroepidemiology study of rubella antibodies among pregnant women from seven Asian countries: evaluation of the rubella vaccination program in Taiwan. Vaccine 2006; 24:5772-5777.
732. Terada K.: Rubella and congenital rubella syndrome in Japan: epidemiological problems. Jpn J Infect Dis 2003; 56:81-87.
733. Robertson S.E., Cutts F.T., Samuel R., et al: Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 2: vaccination against rubella. Bull World Health Organ 1997; 75:69-80.
734. Narimah A.: Rubella immunization in Malaysia: 20 years on, and the challenges ahead. Med J Malaysia 2005; 60:267-268.
735. Park K.S., Kim H.S.: Seroprevalence of rubella antibodies and effects of vaccination among healthy university women students in Korea. Yonsei Med J 1996; 37:420-426.
735a. Dewan P., Gupta P.: Burden of congenital rubella syndrome (CRS) in India: a systematic review. Indian Pediatr 2012; 49:377-399.
736. Gao L., Hethcote H.: Simulations of rubella vaccination strategies in China. Math Biosci 2006; 202:371-385.
737. Hamkar R., Jalilvand S., Mokhtari-Azad T., et al: Evaluation of immunity against rubella in Iranian after mass campaign for measles-rubella vaccination on December 2003. Am J Infect Control 2006; 34:588-592.
738. El Sayed N., Kandeel N., Moussa I., et al: Progress toward measles and rubella elimination in Egypt. 2011. 203, S318–S324
739. Lin C.C., Yang C.Y., Shih Y.L., et al: Rubella seroepidemiology and estimations of the catch-up immunisation rate and persistence of antibody titers in pregnant women in Taiwan. Br J Obstet Gynaecol 2011; 118:706-712.
740. Soleimanjahi H., Bamdad T., Fotouhi F., et al: Prevalence of HI antibody titer against rubella virus to determine the effect of mass vaccination in Tehran. J Clin Virol 2005; 34:153-154.
741. Hinman A.R., Irons B., Lewis M., et al: Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ 2002; 80:264-270.
742. Bart K.J., Orenstein W.A., Preblud S.R., et al: Universal immunization to interrupt rubella. Rev Infect Dis 1985; 7(Suppl. 1):S177-S184.

743. Haas D.M., Flowers C.A., Congdon C.L.: Rubella, rubeola, and mumps in pregnant women: susceptibilities and strategies for testing and vaccinating. Obstet Gynecol 2005; 106:295-300.
744. Vyse A.J., Gay N.J., White J.M., et al: Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiol Rev 2002; 24:125-136.
745. Knox E.G.: Epidemiology of prenatal infections: an extension of the congenital rubella model. Stat Med 1983; 2:1-12.
746. Anderson R.M., May R.M.: Vaccination against rubella and measles: quantitative investigations of different policies. J Hyg (Lond) 1983; 90:259-325.
747. Gay N.J., Valambia S., Galasko D., et al: Selective rubella vaccination programmes: a survey of districts in England and Wales. Rev Med Virol 1994; 4:261-277.
748. Vynnycky E., Gay N.J., Cutts F.T.: The predicted impact of private sector MMR vaccination on the burden of congenital rubella syndrome. Vaccine 2003; 21:2708-2719.
749. Panagiotopoulos T., Antoniadou I., Valassi-Adam E.: Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999; 319:1462-1467.
750. Lanzieri T.M., Segatto T.C., Siqueira M.M., et al: Burden of congenital rubella syndrome after a community-wide rubella outbreak, Rio Branco, Acre, Brazil, 2000 to 2001. Pediatr Infect Dis J 2003; 22:323-329.
751. Gay N. Modeling the impact of strategy options. [unpublished document, 2002].
752. Vasconez N., Rodriguez R., Pinos J., et al: Vaccination of adults to sustain the interruption of measles transmission and to eliminate rubella and congenital rubella syndrome in Ecuador. EPI Newslett 2004; 26:1-3.
753. Robinson J.L., Lee B.E., Preiksaitis J.K., et al: Prevention of congenital rubella syndrome-what makes sense in 2006?. Epidemiol Rev 2006; 28:81-87.
754. Perrenoud G., Messerli F., Thierry A.C., et al: A recombinant rubella virus E1 glycoprotein as a rubella vaccine candidate. Vaccine 2004; 23:480-488.
755. Fenner F.: Candidate viral diseases for elimination or eradication. Bull World Health Organ 1998; 76(Suppl. 2):68-70.
756. Plotkin S.A., Katz M., Cordero J.F.: The eradication of rubella. JAMA 1999; 281:561-562.
757. Plotkin S.A.: Rubella eradication. Vaccine 2001; 19:3311-3319.
758. Robertson S.E., Featherstone D.A., Gacic-Dobo M., et al: Rubella and congenital rubella syndrome: global update. Rev Panam Salud Publica 2003; 14:306-315.
759. Plotkin S.A.: Birth and death of congenital rubella syndrome. JAMA 1984; 251:2003-2004.
760. Orenstein W.A., Bart K.J., Hinman A.R., et al: The opportunity and obligation to eliminate rubella from the United States. JAMA 1984; 251:1988-1994.

RAZNO:

Ikić D, Jančikić B, Hrabar A, Borčić B. Epidemiological evaluation of live measles vaccine prepared from further attenuiated vaccinal strain Edmonston-Zagreb. Procesedings. Symposium on stability and effectiveness of measles, poliomyelitis and pertussis vaccines JAZu. Zagreb 1976:137-145.
Borčić B. Utjecaj obaveznog cijepljenja na kretanje pobola od nekih zaraznih bolesti u SR Hrvatskoj. Zbornik radova. Simpozij "Imunologija i imunološki preparati". Savez farmaceutskih tehničara Jugoslavije. Opatija, 1976.
Borčić B, Aleraj B, Hreljac-Hibšer Lj, Hibšer M, Golac V. Ocjena zaštitne vrijednosti vakcine protiv ospica. Lij vjes 1979;101:464

Borčić B. Evaluacija utjecaja obaveznih vakcinacija na pobol od nekih zaraznih bolesti u SR Hrvatskoj. Materia socio-medica iugoslavica 1982;5(2-4):755-758.
Borčić B. Tetanus: Liječiti ili cijepiti? Jedna "cost-benefit" analiza. Zdravstvo 1983,25:435¬
Mišić-Majerus Lj, Borčić B, Punda V, Bujiš N, Toth D. Prvi rezultati ispitivanja FSME--IMMUN inject vakcine u zaštiti ljudi od krpeljnog meningoencefalitisa na Kalničko¬-Panonskom području 1980-1981 godine. Zbornik radova. IV Kongres infektologa Jugoslavije. Beograd, l984:133-6.
Borčić B, Majerus-Mišić Lj, Raos B, Punda V, Bujuć N, Toth D. Ispitivanje reaktogenosti i imunogenosti "FSME-IMMUN" vakcine protiv krpeljnog meningoencefalitisa. Lij vjes 1984;106:425-8.
Delimar N, Borčić B. Evaluacija efikasnosti vakcine protiv morbila na terenu. Zbornik radova. I Kongres epidemiologa Jugoslavije. Zadar 1986:30-2.
Beck M, Smerdel S, Dedić I, Delimar N, Rajninger-Miholić M, Juzbašić M, Manhalter T, Borčić B, Mihajić Z. Immune response to Edmonston-Zagreb measles virus strain on monovalent and combined MMR vaccine. Develop biol Standard 1986;65:95-100.
Borčić B, Smerdel S, Eldan JA, Kolić J, Ferdebar M. O efikasnosti domaće kombinirane vakcine protiv ospica, zaušnjaka i cr1jenke. Arhiv ZMD 1988;32:85-92.
Borčić B, Aleraj B. Analiza stanja i kretanja morbila u SR Hrvatskoj s prijedlogom mjera za njihovu što bržu eliminaciju. Rad JAZU No 430 (Medicinske znanosti). Knjiga XXII. Zagreb 1988:31-9.
Borčić B, Smerdel S, Abu Eldan J, Kolić J, Ferdebar M, Kordić D, Mohaček M. Stvaranje i trajanje imunosti u djece cijepljene protiv ospica vakcinom Edmonston-Zagreb. Lij vjes 1989;111:131-4.
Borčić B, Gašparović V, Mihaljević I, Aleraj B, Gjenero-Margan I. Ispitivanje reaktogenosti i imunogenosti rekombinantne DNA vakcine protiv hepatitisa B "Engerix-B". Acta med iug 1989;43:247-54.
Borčić B, Abu Eldan J, Rajninger-Miholić M. Imunost na ospice cijepljenih prije 18-19 godina. Medicina 1990;26:67-70.
Borčić B, Ferdebar M, Rajninger-Miholić M. Imuni odgovor na revakcinaciju protiv rubeole 13 godina nakon primovakcinacije. Arhiv ZMD 1991;35:167-72.
Abu Eldan J, Borčić B, Smerdel S. Persistence of immunity against measles in persons immunized with Edmonston-Zagreb vaccine. Acta med Croat 1991;45:297-304.
Borčić B. An assessment of the epidemiological situation for EPI taget diseases. WHO Reg Off for Europe. Doc ICP/EPI 033/13. Milan 1992. (nema).
Gašparović V, Puljević D, Gjurašin M, Delimar N, Borčić B, Gašparović H, Mihaljević I. The significance of immunocompromised condition in the prophylaxis of hepatitis B in chronic renal insufficiency. Acta med Croat 1993;47:61-5.
Borčić B, Kružić V., Dobrovšak-Šourek V. Poliomijelitis u Hrvatskoj: 10 godina od zadnje epidemije ili dokle smo stigli s eradikacijom. Paediatr Croat 1993;37:109-13.
Anonimno. Expanded programms on immunization. Epidemiological situation of vaccine¬preventable diseases. Croatia. WHO. Wkly Epidem Rec 1994;69:163-4.
Borčić B, Dobrovšak-Šourek V. Utjecaj obaveznih cijepljenja na pobol od određenih zaraznih bolesti. Imunoprofilaksa. Hrvatski liječnički zbor. Zagreb 1994:27-32.
Borčić B, Dobrovšak-Šourek V. Utjecaj obveznih cijepljenja na pobol od određenih zaraznih bolesti. Zbornik radova. Vakcinologija danas i sutra. Hrvatsko mikrobiološko društvo. Zagreb: 1995:42-7.
Borčić B, Kovač Š, Mihaljević I, Dobrovšak-Šourek V, Ljubičić M. Reaktogenost i imunogenost "Havrix 360" vakcine protiv hepatitisa A. Liječ vjesn 1996;118:162-4.

Borčić B, Sindik-Milošević T, Džepina-Mlinarić A, Dobrovšak-Šourek V, Ljubičić M, Gotovac P. Imunost hrvatskog pučanstva na difteriju 1994. godine. Liječ vjes 1996;118:227¬9.
Borčić B. Imunoprofilaksa. U: Vrhovac B i sur. Interna medicina. Naprijed. Zagreb 1997:1567-9.
Borčić B, Dobrovšak-Šourek V. Utjecaj obveznog cijepljenja na pobol od određenih zaraznih bolesti. Paediatr Croat 1998;42(supl 1):1-3.
Borčić B, Dobrovšak-Šourek V, Kaić B, Ljubičić M. A comparative study of reactogenicity and immunogenicity of an oral and an inactivated polio vaccine. Acta med Croat 1998;52:155-8.
Borčić B, Kružić V, Kaić B, Ljubin-Sternak S, Ljubičić M, Dobrovšak-Šourek V. Immunity of the Croatian population to poliomyelitis - a serosurvey. Acta med Croat 1998;52:229-33.
Kaić B, Borčić B, Ljubičić M, Brkić I, Mihaljević I. Hepatitis A control in refugee camp by active immunization. Vaccine 2001;19:3615-9.
Kaic B. Impact of vaccination on vaccine-preventable disease burden in Croatia. Periodicum biologorum. VOL. 114, No 2, 141-147, 2012.
Kaic B, Gjenero-Margan I, Aleraj B, Vilibic-Cavlek T, Santak M, Cvitković A, Nemeth-Blazic T, Ivic Hofman I. Spotlight on measles 2010: Excretion of vaccine strain measles virus in urine and pharyngeal secretions of a child with vaccine associated febrile rash illness, Croatia, March 2010. Euro Surveill. 2010;15(35):pii=19652
Kosor Krnic E, Gagro A, Drazenovic V, Kuzman I, Jeren T, Cecuk-Jelicic E, Kerhin-Brkljacic V, Gjenero-Margan I, Kaic B, Rakusic S, Sabioncello A, Markotic A, Rabatic S, Mlinaric-Galinovic G, Dekaris D. Enumeration of haemagglutinin-specific CD8+ T cells after influenza vaccination using MHC class I peptide tetramers. Scand J Immunol. 2008 Jan;67(1):86-94.
Kaic B, Gjenero-Margan I, Aleraj B, Ljubin-Sternak S, Vilibic-Cavlek T, Kilvain S, Pavic I, Stojanovic D, Ilic A. Transmission of the L-Zagreb mumps vaccine virus, Croatia, 2005-2008. Euro Surveill. 2008 Apr 17;13(16). pii: 18843
Bernard Kaić, Ira Gjenero-Margan, Tatjana-Nemeth-Blažić. Cijepljenje protiv bolesti uzrokovanih HPV tipovima 6, 11, 16 i 18. HČJZ Vol 4, Broj 13, 7. siječanj 2008.
Kaic B. Aseptic meningitis after vaccination with L-Zagreb mumps strain-virologically confirmed cases Faulty calculation of rates. Vaccine. 2007 Jan 26;25(7):1159-60. Epub 2006 Oct 25.
Cavlek TV, Sternak SL, Kaic B, Zarkovic M, Marina BM, Sojat LC, Basnec A, Galinovic, GM. Subacute sclerosing panencephalitis in Croatia 1994-2004. Acta Microbiologica et Immunologica Hungarica. 2007;54 (1):57-63.
Kosor KE, Gagro A, Kozaric KD, Vilibic M, Grubisic IM, Folnegovic SV, Drazenovic V, Cecuk JE, Gjenero MI, Kuzman I, Jeren T, Sabioncello A, Kerhin BV, Kaic B, Markotic A, Gotovac K, Rabatic S, Mlinaric GG, Dekaris D. Outcome of influenza vaccination in combat-related post-traumatic stress disorder (PTSD) patients. Clin Exp Immunol. 2007 Aug;149(2):303-10. Epub 2007 May 18.
Kosor E, Gagro A, Drazenovic V, Kuzman I, Jeren T, Rakusic S, Rabatic S, Markotic A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacic V, Gjenero-Margan I, Kaic B, Mlinaric-Galinovic G, Kastelan A, Dekaris D. [MHC tetramers: tracking specific immunity] Acta Med Croatica. 2003;57(4):255-9.